<SEC-DOCUMENT>0001171843-24-006599.txt : 20241126
<SEC-HEADER>0001171843-24-006599.hdr.sgml : 20241126
<ACCEPTANCE-DATETIME>20241126161517
ACCESSION NUMBER:		0001171843-24-006599
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241126
DATE AS OF CHANGE:		20241126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PORTAGE BIOTECH INC.
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40086
		FILM NUMBER:		241503967

	BUSINESS ADDRESS:	
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110
		BUSINESS PHONE:		416-737-7600

	MAIL ADDRESS:	
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DEALCHECK COM INC
		DATE OF NAME CHANGE:	19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_112624.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:ptgef="http://portagebiotech.com/20240930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_IFRS%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_ptgef_portagebiotech.com_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_045_20240401_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wMy0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DDocumentFiscalYearFocus_2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001095435 -->
<!-- Field: Set; Name: xdx; ID: xdx_078_XDX_F%2D%2D\Lakshmipathi\November 2024\Portage bio update\exh__991.embedded.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_F%2D%2D\Lakshmipathi\November 2024\Portage bio update\exh__991.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">



<p style="margin: 0; font-size: 10pt; text-align: center"><b>UNITED STATES</b></p>

<p style="margin: 0; font-size: 10pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"><b>FORM <span id="xdx_900_edei--DocumentType_c20240401__20240930_z16jbI1Fe4T1"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000018" name="dei:DocumentType">6-K</ix:nonNumeric></span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</b></p>

<p style="margin: 0; font-size: 10pt; text-align: center"><b>UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"><b>For the month of November 2024</b></p>

<p style="margin: 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: center">Commission File Number: <span id="xdx_909_edei--EntityFileNumber_c20240401__20240930_zoFDZeUku8ob"><b><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000019" name="dei:EntityFileNumber">001-40086</ix:nonNumeric></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityRegistrantName_c20240401__20240930_zUYHyi8KHw47"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000020" name="dei:EntityRegistrantName">Portage Biotech Inc.</ix:nonNumeric></span></span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: center">(Translation of registrant&#8217;s name into English)</p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20240401__20240930_zRFt9Px3mom4" style="text-decoration: underline"><b><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000021" name="dei:EntityAddressAddressLine1">Clarence
Thomas Building</ix:nonNumeric></b></span><b><span style="text-decoration: underline">, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20240401__20240930_zXAnMZwla9a3"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000022" name="dei:EntityAddressAddressLine2">P.O.
Box 4649</ix:nonNumeric></span></span></b><b><span style="text-decoration: underline">, <span id="xdx_901_edei--EntityAddressAddressLine3_c20240401__20240930_z9d9RUIG9rO2"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000023" name="dei:EntityAddressAddressLine3">Road
Town</ix:nonNumeric></span></span></b><b><span style="text-decoration: underline">, <span id="xdx_905_edei--EntityAddressCityOrTown_c20240401__20240930_z6Y4G1KnF7n1"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000024" name="dei:EntityAddressCityOrTown">Tortola</ix:nonNumeric></span></span></b><b><span style="text-decoration: underline">, <span id="xdx_904_edei--EntityAddressCountry_c20240401__20240930_zwtbTl25Xdgh"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" format="ixt-sec:countrynameen" id="Fact000025" name="dei:EntityAddressCountry">British Virgin Islands</ix:nonNumeric></span></span></b><b><span style="text-decoration: underline">, <span id="xdx_905_edei--EntityAddressPostalZipCode_c20240401__20240930_zDDrd4tf6FAh"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000026" name="dei:EntityAddressPostalZipCode">VG1110</ix:nonNumeric></span></span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: center">(Address of principal executive offices)</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; background-color: white">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</p>

<p style="margin: 0; font-size: 10pt; background-color: white">Form 20-F&#160;&#9746;&#160;Form 40-F &#9744;</p>

<p style="margin: 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0; font-size: 10pt; background-color: white">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center; background-color: white"><b>INCORPORATION BY REFERENCE</b></p>

<p style="margin: 0; font-size: 10pt; background-color: white"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; background-color: white">This report on Form 6-K (including the exhibits attached
hereto) shall be deemed to be incorporated by reference into the registration statement on Form S-8 (File No. 333-275842) of Portage
Biotech Inc. (including any prospectuses forming a part of such registration statement) and to be a part thereof from the date on which
this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; background-color: white">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; font-size: 10pt; text-align: center"><b>EXHIBITS</b></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 10pt">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><b>Exhibit No.</b></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 89%"><b>Exhibit</b></td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><b><a href="exh_991.htm">99.1</a></b></td>
    <td>&#160;</td>
    <td style="padding-left: 1.45pt"><a href="exh_991.htm">Unaudited Condensed Consolidated Interim Financial Statements for the three
    and six months ended September 30, 2024. Unaudited - Prepared by Management as of November 26, 2024.</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b><a href="exh_992.htm">99.2</a></b></td>
    <td>&#160;</td>
    <td style="padding-left: 1.45pt"><a href="exh_992.htm">Management&#8217;s Discussion and Analysis for the three and six months ended
    September 30, 2024.</a></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><b>101.INS</b></td>
    <td>&#160;</td>
    <td style="padding-left: 1.45pt">Inline XBRL Instance Document.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b>101.SCH</b></td>
    <td>&#160;</td>
    <td style="padding-left: 1.45pt">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><b>101.CAL</b></td>
    <td>&#160;</td>
    <td style="padding-left: 1.45pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b>101.DEF</b></td>
    <td>&#160;</td>
    <td style="padding-left: 1.45pt">Inline XBRL Taxonomy Definition Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><b>101.LAB</b></td>
    <td>&#160;</td>
    <td style="padding-left: 1.45pt">Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b>101.PRE</b></td>
    <td>&#160;</td>
    <td style="padding-left: 1.45pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><b>104</b></td>
    <td>&#160;</td>
    <td style="padding-left: 1.45pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</td></tr>
  </table>
<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; font-size: 10pt; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; background-color: white">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; background-color: white">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="margin: 0; font-size: 10pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 100%">Date:&#160;&#160;November 26, 2024</td></tr>
  </table>
<p style="margin: 0; font-size: 10pt; background-color: white">&#160;</p>

<p style="margin: 0; font-size: 10pt; background-color: white"><b>PORTAGE BIOTECH INC.</b></p>

<p style="margin: 0; font-size: 10pt; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font-size: 10pt; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 2%; font-size: 10pt">By:</td>
    <td style="border-bottom: Black 1pt solid; width: 38%; font-size: 10pt"><i>/s/ Andrea Park</i></td>
    <td style="width: 60%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt">Andrea Park</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt">Chief Financial Officer</td>
    <td>&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:ptgef="http://portagebiotech.com/20240930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_IFRS%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_ptgef_portagebiotech.com_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_045_20240401_20240930 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wMy0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DDocumentFiscalYearFocus_2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DDocumentType_6%2DK -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DEntityCentralIndexKey_0001095435 -->
<!-- Field: Set; Name: xdx; ID: xdx_078_XDX_F%2D%2D\Lakshmipathi\November 2024\Portage bio update\exh__991.embedded.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_07B_SO_F%2D%2D\Lakshmipathi\November 2024\Portage bio update\exh__991.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_071_CP_F%2D%2D\Lakshmipathi\November 2024\Portage bio update\f6k__112624.htm -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_060_EURPShares_0_iso4217%2D%2DEUR_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--03-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000005" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000006" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000007" name="dei:DocumentType">6-K</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000008" name="dei:EntityCentralIndexKey">0001095435</ix:nonNumeric>
  <ix:nonFraction name="ifrs-full:OtherAssets" contextRef="AsOf2024-09-30" id="xdx2ixbrl0051" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:OtherCurrentLiabilities" contextRef="AsOf2024-09-30" id="xdx2ixbrl0072" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2024-09-30" id="xdx2ixbrl0081" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:CommitmentsAndContingentLiabilities" contextRef="AsOf2024-09-30" id="xdx2ixbrl0117" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantsLiability" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0141" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantsLiability" contextRef="From2023-04-012023-09-30" id="xdx2ixbrl0143" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0145" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0147" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0151" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2023-04-012023-09-30" id="xdx2ixbrl0153" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0157" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0180" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestments" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0195" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestments" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0197" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-03-31_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedForRestrictedStockUnitsNet" contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedForRestrictedStockUnitsNet" contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedForRestrictedStockUnitsNet" contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedForRestrictedStockUnitsNet" contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-03-31_custom_StockOptionReserveMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-03-31_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0376" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-03-31_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0424" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestment" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestment" contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestment" contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestment" contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantsLiability" contextRef="From2023-04-012023-09-30" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2023-04-012023-09-30" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:IncreaseDecreaseInShareOfLossInAssociate" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:FairValueOfSharesIssuedForServices" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" contextRef="From2023-04-012023-09-30" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ProceedsFromExerciseOfPrefundedWarrants" contextRef="From2023-04-012023-09-30" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:RightToUseAssetAcquired" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:LeaseLiabilityIncurred" contextRef="From2024-04-01to2024-09-30" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:CurrentReceivablesFromSaleOfProperties" contextRef="AsOf2024-09-30" id="xdx2ixbrl0623" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:CurrentReceivablesFromRentalOfProperties" contextRef="AsOf2024-03-31" id="xdx2ixbrl0627" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:SecurityDepositOnOfficeLease" contextRef="AsOf2024-03-31" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:WarrantLiabilityExercisePrice" contextRef="AsOf2023-03-31" id="xdx2ixbrl0667" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="ptgef:WarrantsLiabilityShares" contextRef="AsOf2023-03-31" id="xdx2ixbrl0669" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ptgef:WarrantsLiabilityFairValue" contextRef="AsOf2023-03-31" id="xdx2ixbrl0671" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiability" contextRef="From2023-04-012024-03-31" id="xdx2ixbrl0691" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiability" contextRef="From2024-04-012024-06-30" id="xdx2ixbrl0699" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiability" contextRef="From2024-07-012024-09-30" id="xdx2ixbrl0707" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember" id="xdx2ixbrl0819" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember" id="xdx2ixbrl0821" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember" id="xdx2ixbrl0849" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember" id="xdx2ixbrl0851" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember" id="xdx2ixbrl0879" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember" id="xdx2ixbrl0881" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesAWarrantsMember" id="xdx2ixbrl1001" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember" id="xdx2ixbrl1047" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2023-09-30_ifrs-full_WarrantsMember" id="xdx2ixbrl1158" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-09-30_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1246" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl1247" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1249" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl1250" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2024-09-30_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1253" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl1254" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2024-03-31_custom_FairValueToOtherComprehensiveIncomeMember" id="xdx2ixbrl1256" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl1257" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl1265" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember" id="xdx2ixbrl1267" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2024-09-30_custom_AmortizedCostMember" id="xdx2ixbrl1269" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2024-03-31_custom_AmortizedCostMember" id="xdx2ixbrl1271" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ptgef-20240930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-04-01to2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-07-012024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-07-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_AccumulatedOtherComprehensiveLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_AccumulatedOtherComprehensiveLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_AccumulatedOtherComprehensiveLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_StockOptionReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_AccumulatedOtherComprehensiveLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_ifrs-full_NoncontrollingInterestsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_ifrs-full_BottomOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-09-012021-09-30_ifrs-full_TopOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_CountryOfBritishVirginIslandsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ptgef:CountryOfBritishVirginIslandsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_CountryOfDelawareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ptgef:CountryOfDelawareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ParexelInternationalLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:ParexelInternationalLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_ParexelInternationalLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:ParexelInternationalLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ClassBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:ClassBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_ClassCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:ClassCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-282023-09-29_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-28</xbrli:startDate>
        <xbrli:endDate>2023-09-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-282023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-28</xbrli:startDate>
        <xbrli:endDate>2023-09-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-26_custom_PlacementAgentWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-25</xbrli:startDate>
        <xbrli:endDate>2023-08-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-282024-05-29_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-28</xbrli:startDate>
        <xbrli:endDate>2024-05-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-29_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_custom_SeriesBWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_ifrs-full_TopOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_ifrs-full_BottomOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-052022-07-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-05</xbrli:startDate>
        <xbrli:endDate>2022-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_ATMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ATMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_ATMMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ATMMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsAndPreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-03_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_custom_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_ifrs-full_RestrictedShareUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_PBI2021EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_ifrs-full_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_RestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-282023-03-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-28</xbrli:startDate>
        <xbrli:endDate>2023-03-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-252022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-25</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_AmortizedCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_FairValueToOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_AmortizedCostMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-09-30_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_SaugatuckMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095435</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EURPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:EUR</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>














































<p style="margin: 0; text-align: right"><b>Exhibit 99.1</b></p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0 0 0 1in; font-size: 10pt"><b><span id="xdx_90B_edei--EntityRegistrantName_c20240401__20240930_zXD0IBxua9fj"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000027" name="dei:EntityRegistrantName">Portage Biotech Inc.</ix:nonNumeric></span></b></p>

<p style="margin: 0 0 0 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0 0 0 1in; font-size: 10pt"><b>Condensed Consolidated Interim Financial Statements</b></p>

<p style="margin: 0 0 0 1in; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0 0 0 1in; font-size: 10pt"><b>For the Three and Six Months Ended <span id="xdx_90A_edei--DocumentPeriodEndDate_c20240401__20240930_zXZ2HyfTxHXj"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" format="ixt:datemonthdayyearen" id="Fact000028" name="dei:DocumentPeriodEndDate">September 30, 2024</ix:nonNumeric></span> and 2023</b></p>

<p style="margin: 0 0 0 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0 0 0 1in; font-size: 10pt"><b>(Unaudited &#8211; Prepared by Management as of November 26,
2024)</b></p>

<p style="margin: 0 0 0 1in; font-size: 10pt">&#160;</p>

<p style="margin: 0 0 0 1in; font-size: 10pt"><b>(Expressed in U.S. Dollars)</b></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; font-size: 10pt"><b>Portage Biotech Inc.</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Financial Statements</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1pt; width: 88%; text-align: center"><b>TABLE OF CONTENTS</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 11%; text-align: center"><b>Page No.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="#a_001">Notice to Reader</a></td>
    <td>&#160;</td>
    <td style="text-align: center"><a href="#a_001">F-1</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="#a_002">Condensed Consolidated Interim Statements of Financial Position</a></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><a href="#a_002">As of September 30, 2024 and March 31, 2024 (Unaudited)</a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><a href="#a_002">F-2</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="#a_003">Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)</a></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="#a_003">Three and six months ended September 30, 2024 and 2023</a></td>
    <td>&#160;</td>
    <td style="text-align: center"><a href="#a_003">F-3</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="#a_004">Condensed Consolidated Interim Statements of Changes in Shareholders&#8217; Equity (Unaudited)</a></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="#a_004">Six months ended September 30, 2024 and 2023</a></td>
    <td>&#160;</td>
    <td style="text-align: center"><a href="#a_004">F-4</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="#a_005">Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</a></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="#a_005">Six months ended September 30, 2024 and 2023</a></td>
    <td>&#160;</td>
    <td style="text-align: center"><a href="#a_005">F-5</a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><a href="#a_006">Notes to Condensed Consolidated Interim Financial Statements (Unaudited)</a></td>
    <td>&#160;</td>
    <td style="text-align: center"><a href="#a_006">F-6 to F-29</a></td></tr>
  </table>
<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; font-size: 10pt; text-align: center"><span id="a_001"></span><b>NOTICE TO READER OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</b></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify">The condensed consolidated interim financial statements of Portage Biotech
Inc. are comprised of the condensed consolidated interim statements of financial position as of September 30, 2024 and March 31, 2024, the condensed consolidated interim statements of operations and other comprehensive
income (loss) for the three and six months ended September 30, 2024 and 2023 and the condensed consolidated interim statements of changes
in shareholders&#8217; equity and the condensed consolidated interim statements of cash flows for the six months ended September 30, 2024
and 2023, and are the responsibility of Portage Biotech Inc.&#8217;s management.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify">The condensed consolidated interim financial statements of Portage Biotech
Inc. have been prepared by Portage Biotech Inc.&#8217;s management and include the selection of appropriate accounting principles, judgments
and estimates necessary to prepare these condensed consolidated interim financial statements in accordance with International Financial
Reporting Standards.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
  <tr style="vertical-align: top">
    <td style="width: 45%; text-align: center"><i>/s/ Andrea Park</i></td>
    <td style="width: 55%; text-align: center"><i>/s/ Ian Walters</i></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">Andrea Park, Chief Financial Officer</td>
    <td style="text-align: center">Ian Walters, MD, Chairman of the Board and Chief Executive Officer</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">DATE:&#160;&#160;November 26, 2024</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table>
<p style="margin: 0; font-size: 10pt; text-align: center"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; font-size: 10pt"><b></b></p>

<p style="margin: 0; font-size: 10pt"><b><span id="a_002"></span>PORTAGE BIOTECH INC.</b></p>

<p style="margin: 0; font-size: 10pt"><b>Condensed Consolidated Interim Statements of Financial Position</b></p>

<p style="margin: 0; font-size: 10pt"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0; font-size: 10pt"><b>(Unaudited &#8211; see Notice to Reader dated November 26,
2024)</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_pn3n3_zlGlcMBVex45" summary="xdx: Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20240930_zaBHFA4A5nh8" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_498_20240331_z7XAGln9AsU3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">Notes</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, <br/>2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, <br/>2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--AssetsAbstract_iB_zPZoItlfiiYb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--CurrentAssetsAbstract_i01B_zrsQfPolWCO4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CashAndCashEquivalents_i02I_maCzrp1_zAl0FnN8KDhe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left; width: 63%">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: center">14</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-09-30" id="Fact000036" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,764</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000037" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,028</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--TradeAndOtherCurrentReceivables_i02I_maCzrp1_zsYFGKmINiM8" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">5</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2024-09-30" id="Fact000039" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">922</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2024-03-31" id="Fact000040" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,667</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentAssets_i02TI_mtCzrp1_maCzj39_zmNHCEeBBoY3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2024-09-30" id="Fact000042" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,686</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2024-03-31" id="Fact000043" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,695</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--NoncurrentAssetsAbstract_i02B_zqBYCR657jJl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-current assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--RightofuseAssets_i02I_maCzpdI_zLTi9AJlQYZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Right to use asset</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-09-30" id="Fact000048" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2024-03-31" id="Fact000049" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--OtherAssets_i02I_maCzpdI_z2E0JuIcYjR8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Other assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0051">-</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherAssets" contextRef="AsOf2024-03-31" id="Fact000052" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--NoncurrentAssets_i02TI_mtCzpdI_maCzj39_zkFBU5o5uv7k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total non-current assets</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2024-09-30" id="Fact000054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2024-03-31" id="Fact000055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--Assets_i01TI_mtCzj39_zqxVAXBSNRXb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2024-09-30" id="Fact000057" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,706</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2024-03-31" id="Fact000058" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,779</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--EquityAndLiabilitiesAbstract_iB_zpWzh3Lmvqse" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities and Equity</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--CurrentLiabilitiesAbstract_i01B_zcJYIwneEKt2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Current liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherCurrentPayables_i02I_maCz9Nm_z5dHgZNJwYJ" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Accounts payable and accrued liabilities</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">7</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2024-09-30" id="Fact000066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2024-03-31" id="Fact000067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,836</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--CurrentLeaseLiabilities_i02I_maCz9Nm_zvbXpWcaoR4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Lease liability - current, including interest</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2024-09-30" id="Fact000069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2024-03-31" id="Fact000070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--OtherCurrentLiabilities_i02I_maCz9Nm_zjnFheSR2P58" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Other current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0072">-</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentLiabilities" contextRef="AsOf2024-03-31" id="Fact000073" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentLiabilities_i02TI_mtCz9Nm_maCz2kE_zzeWzFgMKtla" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2024-09-30" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">873</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2024-03-31" id="Fact000076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,879</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--NoncurrentLiabilitiesAbstract_i01B_zvEddtSs8Qp7" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Non-current liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--NoncurrentLeaseLiabilities_i02I_maCzGfX_z8KiCmhNuwSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left">Lease liability - non-current</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0081">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2024-03-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilityNonCurrent_i02I_maCzGfX_zEn4eylZ7Urb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">6</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantLiabilityNonCurrent" contextRef="AsOf2024-09-30" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,138</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:WarrantLiabilityNonCurrent" contextRef="AsOf2024-03-31" id="Fact000085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,564</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--NoncurrentLiabilities_i02TI_mtCzGfX_maCz2kE_zLM1xXapE4P5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total non-current liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2024-09-30" id="Fact000087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,138</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLiabilities" contextRef="AsOf2024-03-31" id="Fact000088" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,571</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--Liabilities_i02TI_mtCz2kE_maCzGx6_zcxCMDabd5sh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2024-09-30" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,011</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2024-03-31" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,450</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--EquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Shareholders&#8217; Equity</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IssuedCapital_i02I_maCz3w7_zMfv5dRr2te4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Capital stock</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">9</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2024-09-30" id="Fact000096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219,606</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IssuedCapital" contextRef="AsOf2024-03-31" id="Fact000097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219,499</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--OtherReserves_i02I_maCz3w7_zDUd9IBCOyKi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 9pt">Stock option reserve</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">10</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2024-09-30" id="Fact000099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,126</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherReserves" contextRef="AsOf2024-03-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,841</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--RetainedEarnings_i02I_maCz3w7_zcvqCpkWMVy8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Accumulated deficit</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2024-09-30" id="Fact000102" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">242,334</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2024-03-31" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">239,318</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eifrs-full--EquityAttributableToOwnersOfParent_i02TI_mtCz3w7_maCzR92_zIpfG1ppZvxd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Total equity attributable to owners of the Company</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2024-09-30" id="Fact000105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,398</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:EquityAttributableToOwnersOfParent" contextRef="AsOf2024-03-31" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,022</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--NoncontrollingInterests_i02I_maCzR92_zj8gTyj4s1Ce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">16</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2024-09-30" id="Fact000108" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">703</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2024-03-31" id="Fact000109" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">693</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--Equity_i02TI_mtCzR92_maCzGx6_zuHnoaVU7Zyd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total equity</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-09-30" id="Fact000111" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">695</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2024-03-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,329</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--EquityAndLiabilities_i01TI_mtCzGx6_zZ1JtRS6hzsc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and equity</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2024-09-30" id="Fact000114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,706</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2024-03-31" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,779</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--CommitmentsAndContingentLiabilities_iI_zIYVXao8IgV2" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Commitments and Contingent Liabilities (Note 12)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0117">&#8211;</span></b></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center">The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; font-size: 10pt"><b><span id="a_003"></span>PORTAGE BIOTECH INC.</b></p>

<p style="margin: 0; font-size: 10pt"><b>Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss)</b></p>

<p style="margin: 0; font-size: 10pt"><b>(U.S. Dollars in thousands, except per share amounts)</b></p>

<p style="margin: 0; font-size: 10pt"><b>(Unaudited &#8211; see Notice to Reader dated November 26,
2024)</b></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_113_pn3n3_zERkVQjrX8ze" summary="xdx: Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_499_20240701__20240930_zf1swSBqICGc" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49E_20230701__20230930_zaOoqJwDjwbl" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_491_20240401__20240930_zyqZ0XIu7HAf" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49D_20230401__20230930_zJv4hHwYg7o7" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">Note</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended<br/> September 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended<br/> September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2023</td></tr>
  <tr id="xdx_402_eifrs-full--ProfitLossAbstract_iB_z77onBA2AGVk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--ResearchAndDevelopmentExpense_i01_msPLFOAzaj2_z7lkLowQC6ig" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left; width: 37%">Research and development</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 10%; font-size: 10pt; text-align: center">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2024-07-012024-09-30" id="Fact000125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">723</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" id="Fact000126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,237</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2024-04-01to2024-09-30" id="Fact000127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,028</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2023-04-012023-09-30" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,865</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--GeneralAndAdministrativeExpense_i01_msPLFOAzaj2_zygSRH3qQw4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">General and administrative expenses</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2024-07-012024-09-30" id="Fact000130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">881</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" id="Fact000131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,693</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2024-04-01to2024-09-30" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,415</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GeneralAndAdministrativeExpense" contextRef="From2023-04-012023-09-30" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,062</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--ProfitLossFromOperatingActivities_i01T_mtPLFOAzaj2_maPLBTzGdG_z6P7noT7xpU6" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss from operations</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2024-07-012024-09-30" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,604</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2023-07-012023-09-30" id="Fact000136" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,930</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2024-04-01to2024-09-30" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,443</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossFromOperatingActivities" contextRef="From2023-04-012023-09-30" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,927</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--ChangeInFairValueOfWarrantsLiability_i01N_di_msPLBTzGdG_zfEAUbByjv4j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">6</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantsLiability" contextRef="From2024-07-012024-09-30" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">716</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0141">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantsLiability" contextRef="From2024-04-01to2024-09-30" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">426</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0143">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_i01_maPLBTzGdG_zU9x9rQ8ydN1" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Change in fair value of deferred purchase price payable &#150; Tarus and deferred obligation &#150; iOx milestone</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0145">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2023-07-012023-09-30" id="Fact000146" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">113</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0147">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2023-04-012023-09-30" id="Fact000148" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,224</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--GainOnSettlementWithParexelIoxCro_i01N_di_msPLBTzGdG_zyTLA7F3W2Cd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Gain on settlement with Parexel &#8211; iOx CRO</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">12</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2024-07-012024-09-30" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">946</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0151">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2024-04-01to2024-09-30" id="Fact000152" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">946</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0153">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_i01_maPLBTzGdG_zi1srpdJ3N21" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Share of loss in associate accounted for using equity method</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0155">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2023-07-012023-09-30" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">40</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0157">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" contextRef="From2023-04-012023-09-30" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eifrs-full--DepreciationAndAmortisationExpense_i01N_di_msPLBTzGdG_zmA3Z8epgcM" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Depreciation expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2024-07-012024-09-30" id="Fact000160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2023-07-012023-09-30" id="Fact000161" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2024-04-01to2024-09-30" id="Fact000162" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2023-04-012023-09-30" id="Fact000163" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eifrs-full--GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_i01_maPLBTzGdG_zYu947GKECr6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Foreign exchange transaction (loss) gain</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="From2024-07-012024-09-30" id="Fact000165" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="From2023-07-012023-09-30" id="Fact000166" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="From2024-04-01to2024-09-30" id="Fact000167" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" contextRef="From2023-04-012023-09-30" id="Fact000168" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--RevenueFromInterest_i01_maPLBTzGdG_z370lQcAt6Zc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Interest income, net</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2024-07-012024-09-30" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2023-07-012023-09-30" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2024-04-01to2024-09-30" id="Fact000172" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">69</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2023-04-012023-09-30" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--ProfitLossBeforeTax_i01T_mtPLBTzGdG_maNLzvQz_zrInUkTV8Nx8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Loss before benefit for income taxes</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-07-012024-09-30" id="Fact000175" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,362</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2023-07-012023-09-30" id="Fact000176" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,072</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-04-01to2024-09-30" id="Fact000177" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,024</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2023-04-012023-09-30" id="Fact000178" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,143</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eifrs-full--IncomeTaxExpenseContinuingOperations_i01N_di_msNLzvQz_zDjnbvbFg2Eb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Income tax benefit (expense)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">8</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0180">-</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2023-07-012023-09-30" id="Fact000181" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">907</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2024-04-01to2024-09-30" id="Fact000182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2023-04-012023-09-30" id="Fact000183" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,052</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NetLoss_i01T_mtNLzvQz_maCIzRNg_zXRtvCM9W8Yi" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetLoss" contextRef="From2024-07-012024-09-30" id="Fact000185" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,362</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetLoss" contextRef="From2023-07-012023-09-30" id="Fact000186" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,165</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetLoss" contextRef="From2024-04-01to2024-09-30" id="Fact000187" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,026</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetLoss" contextRef="From2023-04-012023-09-30" id="Fact000188" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,091</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eifrs-full--OtherComprehensiveIncomeAbstract_i01B_zU4v0HdKtSk6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other comprehensive income (loss)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NetUnrealizedGainOnInvestments_i01_maCIzRNg_zgAmlAz9dWYf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Net unrealized (loss) gain on investments</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0195">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestments" contextRef="From2023-07-012023-09-30" id="Fact000196" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,300</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0197">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestments" contextRef="From2023-04-012023-09-30" id="Fact000198" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">469</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ComprehensiveLossForPeriod_i01T_mtCIzRNg_zIYgcnz0rUI9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ComprehensiveLossForPeriod" contextRef="From2024-07-012024-09-30" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,362</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ComprehensiveLossForPeriod" contextRef="From2023-07-012023-09-30" id="Fact000201" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,465</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ComprehensiveLossForPeriod" contextRef="From2024-04-01to2024-09-30" id="Fact000202" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,026</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ComprehensiveLossForPeriod" contextRef="From2023-04-012023-09-30" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,622</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--ProfitLossAttributableToAbstract_iB_z9ya5wJed3uj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Net loss attributable to:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_maPLz6vW_zPGJYqoZ9uzf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left"><b>Owners of the Company</b></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2024-07-012024-09-30" id="Fact000210" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,360</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2023-07-012023-09-30" id="Fact000211" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,158</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2024-04-01to2024-09-30" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,016</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2023-04-012023-09-30" id="Fact000213" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,077</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eifrs-full--ProfitLossAttributableToNoncontrollingInterests_i01_maPLz6vW_ziYbmHLzXTp6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left"><b>Non-controlling interest</b></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">16</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2024-07-012024-09-30" id="Fact000215" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2023-07-012023-09-30" id="Fact000216" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2024-04-01to2024-09-30" id="Fact000217" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToNoncontrollingInterests" contextRef="From2023-04-012023-09-30" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eifrs-full--ProfitLoss_i01T_mtPLz6vW_zLkaVX15pt5c" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-07-012024-09-30" id="Fact000220" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,362</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-07-012023-09-30" id="Fact000221" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,165</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-01to2024-09-30" id="Fact000222" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,026</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012023-09-30" id="Fact000223" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,091</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--ComprehensiveIncomeAttributableToAbstract_iB_zNzdzgzNju51" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Comprehensive loss attributable to:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_i01_maCIzstI_zpiLqsHEy1ph" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left"><b>Owners of the Company</b></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" contextRef="From2024-07-012024-09-30" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,360</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" contextRef="From2023-07-012023-09-30" id="Fact000231" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,458</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" contextRef="From2024-04-01to2024-09-30" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,016</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" contextRef="From2023-04-012023-09-30" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,608</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eifrs-full--ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_i01_maCIzstI_zqIkc1XCg4Jh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left"><b>Non-controlling interest</b></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">16</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="From2024-07-012024-09-30" id="Fact000235" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="From2023-07-012023-09-30" id="Fact000236" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="From2024-04-01to2024-09-30" id="Fact000237" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" contextRef="From2023-04-012023-09-30" id="Fact000238" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--ComprehensiveIncomeAttributableToOwnerOfParent_i01T_mtCIzstI_z8KJxqZruQZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ComprehensiveIncomeAttributableToOwnerOfParent" contextRef="From2024-07-012024-09-30" id="Fact000240" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,362</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ComprehensiveIncomeAttributableToOwnerOfParent" contextRef="From2023-07-012023-09-30" id="Fact000241" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,465</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ComprehensiveIncomeAttributableToOwnerOfParent" contextRef="From2024-04-01to2024-09-30" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,026</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ComprehensiveIncomeAttributableToOwnerOfParent" contextRef="From2023-04-012023-09-30" id="Fact000243" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10,622</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--EarningsPerShareAbstract_iB_zf6uHudlAe6f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold">Loss per share</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">11</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Basic and diluted</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--BasicEarningsLossPerShare_pip0_c20240701__20240930_zquPDeSnDGPg" title="Loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><span id="xdx_908_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240701__20240930_ztoNYWXRAIAa" title="Loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2024-07-012024-09-30" id="Fact000250" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2024-07-012024-09-30" id="Fact000252" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">1.26</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90C_eifrs-full--BasicEarningsLossPerShare_pip0_c20230701__20230930_zjUtbKYEgX8l" title="Loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><span id="xdx_905_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230701__20230930_zl0NAHUZJKXj" title="Loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2023-07-012023-09-30" id="Fact000254" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2023-07-012023-09-30" id="Fact000256" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">5.80</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--BasicEarningsLossPerShare_pip0_c20240401__20240930_zPHJPQbYWjI1" title="Loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><span id="xdx_904_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240401__20240930_zolGNuNyntu6" title="Loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2024-04-01to2024-09-30" id="Fact000258" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2024-04-01to2024-09-30" id="Fact000260" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">2.84</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--BasicEarningsLossPerShare_pip0_c20230401__20230930_ztXhz4phWx16" title="Loss per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90E_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230401__20230930_zRnr1GwtuV06" title="Loss per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2023-04-012023-09-30" id="Fact000262" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2023-04-012023-09-30" id="Fact000264" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">12.47</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_iB_z3Vje7XLzgQ1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Weighted average shares outstanding</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">11</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 8.9pt">Basic and diluted</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--WeightedAverageShares_pn3n3_c20240701__20240930_z5J2XPq1jZ6h" title="Weighted average shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><span id="xdx_900_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240701__20240930_zgT5LEMUYwS" title="Weighted average shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2024-07-012024-09-30" id="Fact000271" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2024-07-012024-09-30" id="Fact000273" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,076</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eifrs-full--WeightedAverageShares_pn3n3_c20230701__20230930_zkheDF6Ziug4" title="Weighted average shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><span id="xdx_900_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230701__20230930_zWcVpeHMr4Ui" title="Weighted average shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2023-07-012023-09-30" id="Fact000275" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2023-07-012023-09-30" id="Fact000277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">890</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_903_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_z71waEUYUnOk" title="Weighted average shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><span id="xdx_904_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240401__20240930_zHC0WRH5a78b" title="Weighted average shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2024-04-01to2024-09-30" id="Fact000279" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2024-04-01to2024-09-30" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,063</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eifrs-full--WeightedAverageShares_pn3n3_c20230401__20230930_zEOj5AvjX5lj" title="Weighted average shares outstanding, basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><span id="xdx_90D_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20230930_z2BpoEg5giS2" title="Weighted average shares outstanding, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uZGVuc2VkIENvbnNvbGlkYXRlZCBJbnRlcmltIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgT3RoZXIgQ29tcHJlaGVuc2l2ZSBJbmNvbWUgKExvc3MpIChVbmF1ZGl0ZWQpAA__"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2023-04-012023-09-30" id="Fact000283" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2023-04-012023-09-30" id="Fact000285" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">888</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center">The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><span id="a_004"></span>PORTAGE BIOTECH INC.</b></p>

<p style="margin: 0; font-size: 10pt"><b>Condensed Consolidated Interim Statements of Changes in Shareholders&#8217; Equity</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>For the Six Months Ended September 30, 2024 and 2023</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated November 26,
2024)</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)" id="xdx_308_114_pn3n3_zGBC5v9gaxIg" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-left: 9pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B5_ifrs-full--ComponentsOfEquityAxis_ifrs-full--IssuedCapitalMember_zmVDeJnKXEPh" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B0_ifrs-full--ComponentsOfEquityAxis_custom--StockOptionReserveMember_zPT1X9ZYX4F2" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B3_ifrs-full--ComponentsOfEquityAxis_custom--AccumulatedOtherComprehensiveLossMember_zUIAebysKQCf" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4BD_ifrs-full--ComponentsOfEquityAxis_ifrs-full--RetainedEarningsMember_zXdJiLFPixz1" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B8_ifrs-full--ComponentsOfEquityAxis_ifrs-full--EquityAttributableToOwnersOfParentMember_zxbzTwDg7VKc" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4B6_ifrs-full--ComponentsOfEquityAxis_ifrs-full--NoncontrollingInterestsMember_zU9xW6Or6qQ9" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_4BE_zgSkZ0ftAAIf" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Accumulated</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Equity</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Number</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Stock</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Other</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Attributable</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Non-</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">of</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Capital</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Option</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Comprehensive</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">(Accumulated</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">to Owners</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Controlling</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Reserve</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Loss</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Deficit)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">of Company</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Equity</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-size: 10pt; padding-left: 9pt">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>In 000&#8217;</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr id="xdx_432_c20240401__20240930_ecustom--EquityPreSplit_iS_pn3n3_zATAlFRYbWad" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt; width: 44%">Balance, April 1, 2024 (Pre-Split)</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfSharesOutstanding_iS_pn3n3_c20240401__20240930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zH8JKcctMJf8" title="Beginning balance, shares" style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2024-03-31_ifrs-full_IssuedCapitalMember" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">19,784</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right">&#160;</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ReverseStockSplitValue_pn3n3_zh0NMLdzqBAa" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Balance, April 1, 2024 (After 1-for-20 reverse stock split)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ReverseStockSplitShares_pn3n3_c20240401__20240930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zH7zBuZFKUza" title="After 1-for-20 reverse stock split, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitShares" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000305" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">989</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219,499</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,841</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">239,318</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000301" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,022</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000302" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">693</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2024-04-01to2024-09-30" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,329</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_pn3n3_zvXRVW78lO23" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">285</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">285</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2024-04-01to2024-09-30" id="Fact000313" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">285</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--PrefundedWarrantsExercised_pn3n3_zMD5DfzYsFkd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Pre-Funded warrants exercised</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--PrefundedWarrantsExercisedShares_pn3n3_c20240401__20240930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zjTjcthDBuz1" title="Pre-Funded warrants exercised, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PrefundedWarrantsExercisedShares" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000323" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">60</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000315" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PrefundedWarrantsExercised" contextRef="From2024-04-01to2024-09-30" id="Fact000321" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_pn3n3_zgp8U28931Q2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td title="Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split, shares" id="xdx_988_ecustom--AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_pn3n3_c20240401__20240930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z0UDsvwUUPEl" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000333" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">52</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--SharesIssuedForAccruedBonuses_pn3n3_zPcENdev6dp8" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued for accrued bonuses </td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedForAccruedBonusesShares_pn3n3_c20240401__20240930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zhHab155Vj89" title="Shares issued for accrued bonuses, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForAccruedBonusesShares" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000343" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">14</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000339" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0340">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForAccruedBonuses" contextRef="From2024-04-01to2024-09-30" id="Fact000341" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--SharesIssuedForRestrictedStockUnitsNet_pn3n3_zpxb6UdpC04b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued for restricted
    stock units, net</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_981_ecustom--SharesIssuedForRestrictedStockUnitsNetShares_pn3n3_c20240401__20240930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zmahdv7u9qjl" title="Shares issued for restricted stock units, net, shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForRestrictedStockUnitsNetShares" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000353" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForRestrictedStockUnitsNet" contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000345" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">-</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForRestrictedStockUnitsNet" contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000349" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedForRestrictedStockUnitsNet" contextRef="From2024-04-01to2024-09-30" id="Fact000351" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ProfitLoss_pn3n3_zoEWKJkZAbul" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Net loss for period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&#8211;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember" id="Fact000358" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,016</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000359" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,016</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000360" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-01to2024-09-30" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,026</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_439_c20240401__20240930_ecustom--EquityPreSplit_iE_pn3n3_zpt2nIv7Xku7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, September 30, 2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfSharesOutstanding_iE_pn3n3_c20240401__20240930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zJy3JJZfrU" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000371" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,116</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-09-30_ifrs-full_IssuedCapitalMember" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219,606</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-09-30_custom_StockOptionReserveMember" id="Fact000364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,126</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-09-30_ifrs-full_RetainedEarningsMember" id="Fact000366" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">242,334</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000367" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,398</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-09-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">703</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2024-09-30" id="Fact000369" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">695</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr id="xdx_430_c20230401__20230930_ecustom--EquityPreSplit_iS_pn3n3_zdFIOWlB2q2h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; width: 44%">Balance, April 1, 2023 (Pre-Split)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfSharesOutstanding_iS_pn3n3_c20230401__20230930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z7iYe7YrY721" title="Beginning balance, shares" style="width: 4%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2023-03-31_ifrs-full_IssuedCapitalMember" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">17,606</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0376">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8211;</span></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 4%; font-size: 10pt; text-align: right"><b></b></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ReverseStockSplitValue_pn3n3_z9mJckoWeC46" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Balance, April 1, 2023 (After 1-for-20 reverse stock split)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_981_ecustom--ReverseStockSplitShares_pn3n3_c20230401__20230930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z9GPS7Pf3T7k" title="After 1-for-20 reverse stock split, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitShares" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="Fact000391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">880</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="Fact000383" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">218,782</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,204</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="Fact000385" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,325</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember" id="Fact000386" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">159,616</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000387" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">76,045</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000388" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">650</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ReverseStockSplitValue" contextRef="From2023-04-012023-09-30" id="Fact000389" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75,395</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_pn3n3_zGO1T60Yixl2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember" id="Fact000394" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,512</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000397" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,512</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" contextRef="From2023-04-012023-09-30" id="Fact000399" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,512</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--SharesIssuedUnderAtm_iP3ifrs-full--IncreaseDecreaseThroughSharebasedPaymentTransactions_pn3n3_z9G8BqAsnPSk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shares issued under ATM</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharesIssuedUnderAtmShares_iP3custom--SharesIssuedUnderAtm_pn3n3_c20230401__20230930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z12V9oGEfVyc" title="Shares issued under ATM, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtmShares" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="Fact000409" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">9</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">682</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000405" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">682</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedUnderAtm" contextRef="From2023-04-012023-09-30" id="Fact000407" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">682</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--ShareIssueRelatedCost_iNP3custom--SharesIssuedUnderAtmShares_pn3n3_di_zUKW16mwXfO3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Share issuance costs</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="Fact000411" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000415" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ShareIssueRelatedCost" contextRef="From2023-04-012023-09-30" id="Fact000417" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedOrAccruedForServices_iP3ifrs-full--ShareIssueRelatedCost_zbZ05b7p5i31" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Shares issued or accrued for services</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharesIssuedOrAccruedForServicesShares_iP3custom--SharesIssuedOrAccruedForServices_pn3n3_c20230401__20230930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zbEULrSRjqs3" title="Shares issued or accrued for services, shares" style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServicesShares" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="Fact000427" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember" id="Fact000419" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000423" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:SharesIssuedOrAccruedForServices" contextRef="From2023-04-012023-09-30" id="Fact000425" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NetUnrealizedGainOnInvestment_iP3custom--SharesIssuedOrAccruedForServicesShares_pn3n3_zPgwksDzfVI8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Net unrealized gain on investments</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#8211;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestment" contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="Fact000431" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">469</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0432">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestment" contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">469</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NetUnrealizedGainOnInvestment" contextRef="From2023-04-012023-09-30" id="Fact000435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">469</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--ProfitLoss_pn3n3_zsMEm1GBGiQk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss for period</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&#8211;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember" id="Fact000440" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,077</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,077</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000442" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012023-09-30" id="Fact000443" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,091</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_435_c20230401__20230930_ecustom--EquityPreSplit_iE_pn3n3_zw8Hzn63a7F1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance, September 30, 2023</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfSharesOutstanding_iE_pn3n3_c20230401__20230930__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z4a4rVxvrsO3" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2023-09-30_ifrs-full_IssuedCapitalMember" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">890</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-09-30_ifrs-full_IssuedCapitalMember" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">219,494</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-09-30_custom_StockOptionReserveMember" id="Fact000446" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,716</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-09-30_custom_AccumulatedOtherComprehensiveLossMember" id="Fact000447" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,856</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-09-30_ifrs-full_RetainedEarningsMember" id="Fact000448" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">170,693</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember" id="Fact000449" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67,661</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-09-30_ifrs-full_NoncontrollingInterestsMember" id="Fact000450" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">664</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:EquityPreSplit" contextRef="AsOf2023-09-30" id="Fact000451" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66,997</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center">The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0; font-size: 10pt"><b></b></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; font-size: 10pt"><b><span id="a_005"></span>PORTAGE BIOTECH INC.</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Condensed Consolidated Interim Statements of Cash Flows</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>For the Six Months Ended September 30, 2024 and 2023</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars in thousands)</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>(Unaudited &#8211; see Notice to Reader dated November 26,
2024)</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_112_pn3n3_zdPpNVrRPrH" summary="xdx: Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_491_20240401__20240930_zsyDvbvIxsqc" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_494_20230401__20230930_zomo6BQKd2D5" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_400_eifrs-full--CashFlowsFromUsedInOperatingActivitiesAbstract_iB_zPPvFbCbcQqc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from operating activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--ProfitLoss_i01_maAFIDIzlCI_zfF3Yd3kulP3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left; width: 74%">Net loss for the period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2024-04-01to2024-09-30" id="Fact000458" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,026</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2023-04-012023-09-30" id="Fact000459" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,091</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eifrs-full--AdjustmentsForReconcileProfitLossAbstract_i01B_z71hvq85ZRN1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Adjustments for non-cash items:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eifrs-full--AdjustmentsForSharebasedPayments_i01_maAFIDIzlCI_z0rPJZGZ0xGh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2024-04-01to2024-09-30" id="Fact000464" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">285</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2023-04-012023-09-30" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,512</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ChangeInFairValueOfWarrantsLiability_i01_maAFIDIzlCI_zVK4eTK8rsE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantsLiability" contextRef="From2024-04-01to2024-09-30" id="Fact000467" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">426</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--GainOnSettlementWithParexelIoxCro_i01_maAFIDIzlCI_z2Tq5nNo1oNi" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Gain on settlement with Parexel &#8211; iOx CRO</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:GainOnSettlementWithParexelIoxCro" contextRef="From2024-04-01to2024-09-30" id="Fact000470" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">946</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_i01N_di_msAFIDIzlCI_zZMn05pFLWcd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Change in fair value of deferred purchase price payable &#8211; Tarus and deferred obligation &#8211; iOx milestone</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" contextRef="From2023-04-012023-09-30" id="Fact000474" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,224</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--IncreaseDecreaseInDeferredTaxLiabilityAsset_i01N_di_msAFIDIzlCI_zhmubAktW3f6" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Decrease in deferred tax liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset" contextRef="From2023-04-012023-09-30" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,063</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--IncreaseDecreaseInShareOfLossInAssociate_i01N_di_msAFIDIzlCI_zmYtjdgq3f67" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Share of loss in associate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IncreaseDecreaseInShareOfLossInAssociate" contextRef="From2023-04-012023-09-30" id="Fact000480" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">90</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--FairValueOfSharesIssuedForServices_i01_maAFIDIzlCI_zmVzNVyYvsRb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Fair value of shares issued for services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:FairValueOfSharesIssuedForServices" contextRef="From2023-04-012023-09-30" id="Fact000483" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--AdjustmentsForDepreciationAndAmortisationExpense_i01_maAFIDIzlCI_znMQz8hNhmci" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Depreciation</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="From2024-04-01to2024-09-30" id="Fact000485" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" contextRef="From2023-04-012023-09-30" id="Fact000486" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ChangesInOperatingWorkingCapitalAbstract_i01B_zGu8T9qxxkv9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Changes in operating working capital:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--AdjustmentsForDecreaseIncreaseInPrepaidExpenses_i02_maAFIDIzlCI_zxcXsp8UYRpb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" contextRef="From2024-04-01to2024-09-30" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,216</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" contextRef="From2023-04-012023-09-30" id="Fact000492" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">286</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--AdjustmentsForDecreaseIncreaseInOtherAssets_i02_maAFIDIzlCI_z1aGWeiXAQG4" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Other assets</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2024-04-01to2024-09-30" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" contextRef="From2023-04-012023-09-30" id="Fact000495" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAccountPayable_i02_maAFIDIzlCI_zmQPnPtZbFnl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Accounts payable and accrued liabilities</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2024-04-01to2024-09-30" id="Fact000497" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">399</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" contextRef="From2023-04-012023-09-30" id="Fact000498" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,224</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--AdjustmentsForIncreaseDecreaseInOtherLiabilities_i02_maAFIDIzlCI_zSNE5hdCv47a" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Other</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" contextRef="From2024-04-01to2024-09-30" id="Fact000500" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--CashFlowsFromUsedInOperatingActivities_iT_mtAFIDIzlCI_maIDICAz1Pk_zBWq1gtwB6l5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20.15pt">Net cash used in operating activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2024-04-01to2024-09-30" id="Fact000503" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,246</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2023-04-012023-09-30" id="Fact000504" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,745</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CashFlowsFromUsedInInvestingActivitiesAbstract_iB_zAbZaPU9O1rb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Cash flows from financing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ProceedsFromExerciseOfPrefundedWarrants_i01_maCFFUIzUuH_zlKN88sG1vpc" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Proceeds from the&#160;exercise of Pre-Funded Warrants</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromExerciseOfPrefundedWarrants" contextRef="From2024-04-01to2024-09-30" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement_i01_maCFFUIzUuH_ziqhrQSeAJfb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Proceeds from shares issued under ATM and Committed Purchase Agreement</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" contextRef="From2023-04-012023-09-30" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">682</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--PaymentsForShareIssueCosts_i01N_di_msCFFUIzUuH_zrevBcp9iyR4" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Share issuance costs</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:PaymentsForShareIssueCosts" contextRef="From2023-04-012023-09-30" id="Fact000516" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--RepaymentOfLeaseLiability_i01N_di_msCFFUIzUuH_zLizQP4cXa3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Repayment of lease liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:RepaymentOfLeaseLiability" contextRef="From2024-04-01to2024-09-30" id="Fact000518" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:RepaymentOfLeaseLiability" contextRef="From2023-04-012023-09-30" id="Fact000519" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eifrs-full--CashFlowsFromUsedInFinancingActivities_iT_maIDICAz1Pk_mtCFFUIzUuH_zjjaFTBsvbwb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20.15pt">Net cash (used in) provided by financing activities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2024-04-01to2024-09-30" id="Fact000521" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2023-04-012023-09-30" id="Fact000522" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">645</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--IncreaseDecreaseInCashAndCashEquivalents_iT_mtIDICAz1Pk_zZWmUTVx7UNl" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Decrease in cash and cash equivalents during the period</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2024-04-01to2024-09-30" id="Fact000524" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,264</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2023-04-012023-09-30" id="Fact000525" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,100</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eifrs-full--CashAndCashEquivalents_iS_zIA3OdUGmp12" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and cash equivalents at beginning of the period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000527" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,028</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2023-03-31" id="Fact000528" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,545</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CashAndCashEquivalents_iE_zOYsuI3UP4l9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of the period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-09-30" id="Fact000530" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,764</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2023-09-30" id="Fact000531" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,445</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--SupplementalDisclosureOfCashFlowInformationAbstract_iB_zqGxtpw2hHP9" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--CashPaidForInterest_i01_zfhOj0gat2e8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Cash paid for interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:CashPaidForInterest" contextRef="From2024-04-01to2024-09-30" id="Fact000536" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:CashPaidForInterest" contextRef="From2023-04-012023-09-30" id="Fact000537" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract_iB_zEwiQnb7ds8l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--RightToUseAssetAcquired_i01I_zOXm2AZZGDng" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Right to use asset acquired</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:RightToUseAssetAcquired" contextRef="From2023-04-012023-09-30" id="Fact000543" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">303</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LeaseLiabilityIncurred_i01_zsfwTykKtJz5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 20pt; font-size: 10pt; text-align: left">Lease liability incurred</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:LeaseLiabilityIncurred" contextRef="From2023-04-012023-09-30" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">303</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center">The accompanying notes are an integral part of these condensed consolidated
interim financial statements.</p>

<p style="margin: 0; font-size: 10pt; text-align: center">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: center"></p>

<p style="margin: 0; font-size: 10pt"><b></b></p>

<p style="margin: 0; font-size: 10pt"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0; font-size: 10pt"><b><span id="a_006"></span>PORTAGE BIOTECH INC.</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p>

<p style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000548" name="ptgef:NatureOfOperationsExplanatory"><p id="xdx_802_ecustom--NatureOfOperationsExplanatory_zcLRZdXnyXV5" style="margin: 0; font-size: 10pt"><b>NOTE 1. <span id="xdx_823_zDHRMIATIQv">NATURE OF OPERATIONS</span></b></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Portage Biotech Inc. (the &#8220;Company&#8221; or &#8220;Portage&#8221;)
is incorporated in the British Virgin Islands (&#8220;BVI&#8221;) with its registered office located at Clarence Thomas Building, P.O.
Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services Inc. (&#8220;PDS&#8221;), is located at 59 Wilton Road,
Westport, CT, 06880, USA.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company is a foreign private issuer under the Securities
and Exchange Commission (the &#8220;SEC&#8221;) rules. It is also a reporting issuer under the securities legislation of the provinces
of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&#8220;CSE&#8221;) under the symbol
&#8220;PBT.U&#8221;. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
under the symbol &#8220;PRTG&#8221;. As the principal market for the Company&#8217;s ordinary shares is Nasdaq, the Company voluntarily
delisted from the CSE on April 23, 2021.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Portage is a clinical-stage immuno-oncology company advancing
treatments the Company believes will be first-in class therapies that target known checkpoint resistance pathways to improve long-term
treatment response and quality of life in patients with invasive cancers. Portage&#8217;s access to next-generation technologies coupled
with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies
that accelerate these medicines through the translational pipeline. After a review of the Company&#8217;s future funding needs for clinical
development of its programs as well as the current capital raising market for biotechnology companies, the Company made the decision to
discontinue the Company sponsored trial for the invariant natural killer T-cell (&#8220;iNKT&#8221;) program and pause further patient
accrual to the Company sponsored adenosine trial for both PORT-6 and PORT-7. The Company is exploring strategic alternatives, which may
include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings, both in and out of court, a
company wind down, further financing efforts or other strategic action.</p>


<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"><b><i>Reverse Stock Split</i></b></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;)
approved a reverse stock split of its ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024,
the Company&#8217;s ordinary shares began trading on Nasdaq on a split-adjusted basis under the existing trading symbol &#8220;PRTG&#8221;.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The reverse stock split was implemented to increase the
per share trading price of the Company&#8217;s ordinary shares for the purpose of ensuring a share price high enough to comply with the
minimum $1.00 bid price requirement for continued listing on Nasdaq. The Company received notice from Nasdaq on August 30, 2024 informing
the Company that it had regained compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As a result of the reverse stock split,
every twenty (20) pre-split ordinary shares were converted into one (1) post-split ordinary share. Any fractional shares resulting from
the reverse stock split were rounded up to the nearest whole post-split ordinary share. The reverse stock split affected all shareholders
uniformly and did not alter any shareholder&#8217;s percentage interest in the Company&#8217;s ordinary shares, except for adjustments
that may result from the treatment of fractional shares. All outstanding options and warrants entitling their holders to purchase the
Company&#8217;s ordinary shares were adjusted as a result of the reverse stock split, in accordance with the terms of each such security.
In addition, the number of ordinary shares reserved for future issuance pursuant to the Company&#8217;s equity incentive plans were also
appropriately adjusted. The number of authorized ordinary shares was not proportionately reduced because the Company has an unlimited
number of authorized ordinary shares available for issuance, as permitted under the laws of the British Virgin Islands.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">All share and per share information
included in the condensed consolidated interim financial statements have been retroactively adjusted to reflect the impact of the reverse
stock split as if the stock split occurred at the beginning of the periods presented. The shares of ordinary shares authorized remained
at an unlimited number of ordinary shares without par value.</p>
<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>


<ix:exclude><p id="xdx_237_zSB0Crj8mZB9" style="margin: 0">&#160;</p></ix:exclude>
<ix:exclude><p id="xdx_23C_z1uFkcLWNth3" style="margin: 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><p id="xdx_234_zjFPDhlmiZjj" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_z0mYqAB0lQJb" style="margin: 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 8 -->
    <div id="xdx_23A_zgSBe3AT1orc" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zzKv7zLGQBn4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_z0aOXwNdEANc" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zlS4R9iEWDI6" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zyRICl2RVS08" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zvVGVEZb7hR6" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zFMVxXPdm2xl" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000559" name="ifrs-full:DisclosureOfGoingConcernExplanatory"><p id="xdx_808_eifrs-full--DisclosureOfGoingConcernExplanatory_zhrrssrqEuh8" style="margin: 0; font-size: 10pt"><b>NOTE 2. <span id="xdx_828_zGZQ0eWndc82">GOING CONCERN</span></b></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As of September 30, 2024, the Company had cash and cash
equivalents of approximately $<span id="xdx_90A_eifrs-full--Cash_iI_pn5n6_c20240930_zZB5ujfHhFxb"><ix:nonFraction name="ifrs-full:Cash" contextRef="AsOf2024-09-30" id="Fact000560" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.8</ix:nonFraction>
</span>million and total current liabilities of approximately $<span id="xdx_906_ecustom--TotalCurrentLiabilities_iI_pn5n6_c20240930_zdtpdfN5W0Dg" title="Total current liabilities"><ix:nonFraction name="ptgef:TotalCurrentLiabilities" contextRef="AsOf2024-09-30" id="Fact000562" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction>
</span>million. For the six months ended September 30, 2024, the Company is reporting a net loss of approximately $<span id="xdx_907_ecustom--NetLossIncome_pn6n6_c20240401__20240930_ztJx0YCAe7M" title="Net loss"><ix:nonFraction name="ptgef:NetLossIncome" contextRef="From2024-04-01to2024-09-30" id="Fact000564" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">3</ix:nonFraction></span>.0
million, and cash used in operating activities of approximately $<span id="xdx_90D_ecustom--CashUsedInOperatingActivities_pn5n6_c20240401__20240930_zqHk0zQFjwf1" title="Cash used in operating activities"><ix:nonFraction name="ptgef:CashUsedInOperatingActivities" contextRef="From2024-04-01to2024-09-30" id="Fact000566" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.3</ix:nonFraction>
</span>million. As of November 25, 2024, the Company had approximately $<span id="xdx_901_eifrs-full--CashOnHand_iI_pn5n6_c20241125_zGLAOvpN5gtj" title="Cash and cash equivalents on hand"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2024-11-25" id="Fact000568" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction>
</span>million of cash and cash equivalents on hand.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s cash and cash equivalents balance
is decreasing, and the Company did not generate positive cash flows from operations for the six months ended September 30, 2024 and fiscal
year ended March 31, 2024 (&#8220;Fiscal 2024&#8221;).</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">In late Fiscal 2024, because of continued liquidity
constraints, the Company made the decision to discontinue further clinical development of its iNKT sponsored trial and pause further
patient accrual to its sponsored adenosine program for both PORT-6 and PORT-7. The Company is exploring strategic alternatives,
which may include finding a partner for one or more of its assets, a sale of our company, a merger, restructurings, both in and out
of court, company wind down, further financing efforts or other strategic action. These factors raise significant doubt about the
Company&#8217;s ability to continue as a going concern within one year after the date of the condensed consolidated interim
statement of financial position.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company has incurred significant operating losses
since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable.
The losses result primarily from its conduct of research and development activities. As previously discussed, the Company has discontinued
its iNKT sponsored trial and paused further patient accrual to the Company sponsored adenosine program in order to preserve cash resources.
Additionally, during the fourth quarter of Fiscal 2024, the Company sold its shares in Intensity on Nasdaq.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company historically has funded its operations principally
from proceeds from issuances of equity and debt securities. The Company will require significant additional capital to make the investments
it needs to execute its longer-term business plan, beyond the potential proceeds that could be reasonably generated from its &#8220;at-the-market&#8221;
(&#8220;ATM&#8221;) program and Committed Purchase Agreement (as defined below) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln&#8221;)
given the Company&#8217;s current trading volume on Nasdaq. The Company&#8217;s ability to successfully raise sufficient funds through
the sale of debt or equity securities when needed is subject to many risks and uncertainties and, future equity issuances would result
in dilution to existing shareholders and any future debt securities may contain covenants that limit the Company's operations or ability
to enter into certain transactions. See Note 9, &#8220;Capital Stock and Reserves,&#8221; for a further discussion.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">There can be no assurance that the Company&#8217;s evaluation
of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be
successful or on attractive terms. Any potential transaction would be dependent on a number of factors that may be beyond the Company&#8217;s
control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction
with the Company and the availability of financing to the Company or third parties in a potential transaction with the Company on reasonable
terms. The process of reviewing strategic alternatives may require the Company to incur additional costs and expenses. It could negatively
impact the Company&#8217;s ability to attract, retain and motivate key employees, and expose the Company to potential litigation in connection
with this process or any resulting transaction. If the Company is unable to effectively manage the process, the Company&#8217;s financial
condition and results of operations could be adversely affected. In addition, any strategic alternative that may be pursued and completed
ultimately may not deliver the anticipated benefits or enhance shareholder value. There can be no guarantee that the process of evaluating
strategic alternatives will result in the Company entering into or completing a potential transaction within the anticipated timing or
at all. There is no set timetable for this evaluation and the Company does not intend to disclose developments with respect to this evaluation
unless and until the Company determines that further disclosure is appropriate or legally required. As of November 25, 2024, the Company
had approximately $<span id="xdx_901_eifrs-full--CashOnHand_iI_pn5n6_c20241125_zGg95JAYe3f6" title="Cash and cash equivalents on hand"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2024-11-25" id="Fact000570" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million of cash and cash equivalents on hand, which the Company expects is only sufficient to cover its operating
needs through January 2025. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within
one year after the date of the condensed consolidated interim statement of financial position. There were no adjustments made to reflect
the effect of this doubt.</p>

<p style="margin: 0; font-size: 10pt"><b></b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<ix:exclude><p id="xdx_230_zMKtrzfeezj2" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div id="xdx_23F_zg9Yh3zxRjB7" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_z7JZWvkZh6r3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zzYVTQpybHlj" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zxLhFyTgcwyk" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_z3BcBtMDWGGf" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zaGamScd2hEb" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zAy45BO3lu51" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000578" name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory"><p id="xdx_80D_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zWrQ2fFpRgRj" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 3. <span id="xdx_82C_zEKCtndpCue">BASIS OF PRESENTATION</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Statement of Compliance and Basis of Presentation</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">These condensed consolidated interim financial statements
have been prepared in accordance with the International Financial Reporting Standards (&#8220;IFRS&#8221;) issued by the International
Accounting Standards Board (&#8220;IASB&#8221;), International Accounting Standards (&#8220;IAS&#8221;) 34 <i>Interim Financial Reporting</i>
and interpretations of the International Financial Reporting Interpretations Committee. These condensed consolidated interim financial
statements do not include all of the information required for full annual financial statements and should be read in conjunction with
the audited consolidated financial statements of the Company for the year ended March 31, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">These condensed consolidated interim financial statements
have been prepared on an historical cost basis except for items disclosed herein at fair value (see Note 14, &#8220;Financial Instruments
and Risk Management&#8221;). In addition, these condensed consolidated interim financial statements have been prepared using the accrual
basis of accounting, except for cash flow information.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company has only one reportable operating segment.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">These condensed consolidated interim financial statements
were approved and authorized for issuance by the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board on November 26<span style="font-size: 10pt"></span>,
2024.</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Consolidation</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The consolidated financial statements include the accounts
of the Company and:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(a)</td><td style="text-align: justify">SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(b)</td><td style="text-align: justify">iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company,
through SalvaRx, exchanged certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing <span id="xdx_902_ecustom--PercentageOfOutstandingShares_pip0_dp_c20210901__20210930_z3jGGTP0zKH6" title="Percentage of outstanding shares"><ix:nonFraction name="ptgef:PercentageOfOutstandingShares" contextRef="From2021-09-012021-09-30" id="Fact000580" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17.83</ix:nonFraction></span>%
of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from <span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zkvoRLUhY2me" title="Percentage of ownership subsidiary"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-09-012021-09-30_ifrs-full_BottomOfRangeMember" id="Fact000582" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.49</ix:nonFraction></span>%
to <span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_z2LJjqTSDy73" title="Percentage of ownership subsidiary"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2021-09-012021-09-30_ifrs-full_TopOfRangeMember" id="Fact000584" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">78.32</ix:nonFraction></span>%. On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. The Company&#8217;s 44% interest in
Stimunity S.A. (&#8220;Stimunity&#8221;) was transferred from Portage to iOx in December 2023 and was increased to 48.9% upon the conversion
of the convertible note to equity;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(c)</td><td style="text-align: justify">Saugatuck, a <span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20240401__20240930__ifrs-full--SegmentsAxis__custom--CountryOfBritishVirginIslandsMember_zM93r3Py7XJ7" title="Percentage of ownership subsidiary"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-04-012024-09-30_custom_CountryOfBritishVirginIslandsMember" id="Fact000586" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">70</ix:nonFraction></span>% owned subsidiary incorporated in the British Virgin Islands;</td></tr></table>

<p style="margin: 0 0 0 0.5in; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(d)</td><td style="text-align: justify">Tarus Therapeutic Holdings Ltd., a wholly-owned subsidiary incorporated in the British Virgin Islands;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(e)</td><td style="text-align: justify">PDS, a <span id="xdx_904_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20240401__20240930__ifrs-full--SegmentsAxis__custom--CountryOfDelawareMember_zyTeJulxTnie" title="Percentage of ownership subsidiary"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" contextRef="From2024-04-012024-09-30_custom_CountryOfDelawareMember" id="Fact000588" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% owned subsidiary incorporated in Delaware, which provides human resources, and other services
to each operating subsidiary via a shared services agreement;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(f)</td><td style="text-align: justify">SalvaRx LLC, a wholly-owned subsidiary through SalvaRx incorporated in Delaware;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(g)</td><td style="text-align: justify">Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck incorporated in Delaware; and</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(h)</td><td style="text-align: justify">Tarus Therapeutics, LLC (&#8220;Tarus&#8221;), a wholly-owned subsidiary of Portage incorporated in Delaware.</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">All inter-company balances and transactions have been
eliminated in consolidation.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Non-controlling interest in the equity of a subsidiary
is accounted for and reported as a component of shareholders&#8217; equity. As of September 30, 2024 and March 31, 2024, non-controlling
interest represents the <span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4CVFbjn51Ri" title="Non-controlling interest"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zaIaAAHFedtl" title="Non-controlling interest"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" contextRef="From2024-04-012024-09-30_custom_SaugatuckMember" id="Fact000590" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" contextRef="From2023-04-012024-03-31_custom_SaugatuckMember" id="Fact000592" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></ix:nonFraction></span></span>% shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div id="xdx_233_z9naJn3jl7wk" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zxRPJnEgyzBh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_235_zMdVtju2P4cd" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify"></p>
<ix:exclude><p id="xdx_238_zW1oYSqmAlbj" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zaaQfbdKr0k9" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zkVjgr9hgdY" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zxuhEiriwbm8" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zeLhY8N91Iya" style="margin: 0; font-size: 10pt; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zHSKDo0nyd4c" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 3. BASIS OF PRESENTATION <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zzB7j2qpBSVa" style="margin: 0; font-size: 10pt; text-align: justify">&#160;</p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Functional and Presentation Currency</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s functional and presentation currency
is the U.S. Dollar.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Use of Estimates and Judgments</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The preparation of the condensed consolidated interim
financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application
of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Estimates and underlying assumptions are reviewed on
an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future
periods affected.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Significant areas where estimates are
made include valuation of financial instruments, deferred tax assets and liabilities, warrant liabilities, research and development costs,
contingent consideration assumed and measurement of share-based compensation. Significant areas where critical judgments are applied include
in-process research and development and warrant liabilities.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Reclassifications</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Certain prior year amounts between
accounts payable and accrued liabilities have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23A_zeCSsy1BeFjk" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div id="xdx_23B_zQAxGI1UhoT8" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_zUuekm60snN5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zhbWruODOf0f" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zdxU7ipNJIGj" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zow00sY8rAK1" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zf0ThfUXIqIc" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zueOL4MgBba5" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>


</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000607" name="ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"><p id="xdx_805_ecustom--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_z1D0ZVDdE39c" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 4.</b>&#160; <b><span id="xdx_823_zMSJ5cvJNbh6">SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The accounting policies are set out in Note 4 to the
Company&#8217;s audited consolidated financial statements for Fiscal 2024. These policies have been applied consistently to all periods
presented in these condensed consolidated interim financial statements.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000609" name="ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory"><p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zKaYTrbq7im9" style="margin: 0; font-size: 10pt; text-align: justify"><b><span id="xdx_864_zMXSuqmHhCh8">Recent Accounting Pronouncements</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>IFRS Pronouncements Issued</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Impact of Adoption of Significant New IFRS Standards in Fiscal 2025</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>



<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(a)</b></td><td style="text-align: justify"><b>Amendments to IAS 1: Non-current Liabilities with Covenants</b></td></tr></table>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The amendments to IAS 1, &#8220;Presentation of Financial
Statements,&#8221; clarify how conditions with which an entity must comply within twelve months after the reporting period affect the
classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these
conditions.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The amendments to IFRS 16 and IAS 1 were effective for
annual periods beginning on or after January 1, 2024. The adoption of these amendments did not have a material effect on the Company&#8217;s
annual consolidated financial statements or the condensed consolidated interim financial statements for the three and six months ended
September 30, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 23.05pt"><b>(b)</b></td><td style="text-align: justify"><b>Amendments to IAS 7 and IFRS 7: Supplier Finance</b></td></tr></table>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The amendments to IAS 7 and IFRS 7, &#8220;Statement
of Cash Flows,&#8221; require disclosures to enhance the transparency of supplier finance arrangements and their effects on an entity&#8217;s
liabilities, cash flows and exposure to liquidity risk. The amendments to IAS 7 and IFRS 7 were effective for annual periods beginning
on or after January 1, 2024 (with transitional reliefs in the first year). The adoption of these amendments did not have a material effect
on the Company&#8217;s annual consolidated financial statements or the condensed consolidated interim financial statements for the three
and six months ended September 30, 2024.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_237_zD3eBc56roWk" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 12 -->
    <div id="xdx_231_z5oYrqkAiXB7" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zlYXxCDTvULa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_z5KAwCMmTp0i" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zxoGcFSJbuJ9" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zZdRj8o1tydd" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zqPJm5hIWcIf" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zYDkBbXUY2sh" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_z8ezIZZvOFck" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 4.</b>&#160; <b>SIGNIFICANT ACCOUNTING POLICIES <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zSwKsdYNs2Ng" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>New Accounting Standards, Interpretations and Amendments</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Standards issued but not yet effective up to the date
of issuance of the Company&#8217;s condensed consolidated interim financial statements is listed below. This is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes
effective.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Amendments to IAS 21 &#8211; Lack of Exchangeability</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">An entity is impacted by the amendments to IAS 21, &#8220;The
Effects of Changes in Foreign Exchange Rates,&#8221; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The Company is evaluating whether the adoption of the amendments to IAS 21 would have a material effect
on the Company&#8217;s annual consolidated financial statements or its condensed consolidated interim financial statements.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000619" name="ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory"><p id="xdx_804_ecustom--DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory_zguFcxKP0HM2" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 5. <span id="xdx_822_zSnXhVx0Zcsj">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">At September 30, 2024 and March 31, 2024, prepaid expenses
and other receivables were comprised of the following (in thousands):</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000621" name="ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z0jPJYwGU6vd" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zpQkJ8fMrDwd" style="display: none">Schedule of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20240930_zzEU0woN1Sx6" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20240331_zdxu0LM7fXZf" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_maCPzKMQ_zzk7XYFBfK4b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left">Prepaid clinical research costs</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentReceivablesFromSaleOfProperties" contextRef="AsOf2024-03-31" id="Fact000624" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,924</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CurrentReceivablesFromRentalOfProperties_iI_maCPzKMQ_zJRDfyKZ9e1e" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Refund from Parexel</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentReceivablesFromRentalOfProperties" contextRef="AsOf2024-09-30" id="Fact000626" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">552</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzKMQ_zku20B74vfyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid insurance</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="AsOf2024-09-30" id="Fact000629" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">249</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentAdvancesToSuppliers" contextRef="AsOf2024-03-31" id="Fact000630" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">575</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--TaxDeposits_iI_maCPzKMQ_zntCDP3FnKKk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax deposits</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:TaxDeposits" contextRef="AsOf2024-09-30" id="Fact000632" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">63</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:TaxDeposits" contextRef="AsOf2024-03-31" id="Fact000633" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">64</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzKMQ_zRUK8u0x0R9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other prepaid expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="AsOf2024-09-30" id="Fact000635" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepaidExpenses" contextRef="AsOf2024-03-31" id="Fact000636" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">65</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzKMQ_zLhyFgKfzFP1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2024-09-30" id="Fact000638" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2024-03-31" id="Fact000639" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SecurityDepositOnOfficeLease_iI_pn3n3_maCPzKMQ_zJHqSHVHSNb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Security deposit on office lease expiring in May 2025</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:SecurityDepositOnOfficeLease" contextRef="AsOf2024-09-30" id="Fact000641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzKMQ_zYSZF37e1hja" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepayments" contextRef="AsOf2024-09-30" id="Fact000644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">922</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CurrentPrepayments" contextRef="AsOf2024-03-31" id="Fact000645" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,667</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The decrease in prepaid expenses and other receivables
<span style="background-color: white">from $<span id="xdx_906_ecustom--PrepaidExpensesAndOtherReceivablesNoncurrent_iI_pn5n6_c20240331__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_zuLd0xoFWpIa" title="Prepaid expenses and other receivables"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivablesNoncurrent" contextRef="AsOf2024-03-31_custom_ParexelInternationalLimitedMember" id="Fact000647" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million as of March 31, 2024 to $<span id="xdx_904_ecustom--PrepaidExpensesAndOtherReceivablesNoncurrent_iI_pn5n6_c20240930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_zmG51KSG5s5h" title="Prepaid expenses and other receivables"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivablesNoncurrent" contextRef="AsOf2024-09-30_custom_ParexelInternationalLimitedMember" id="Fact000649" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.9</ix:nonFraction></span> million as of September 30, 2024 </span>is primarily
attributable to periodic amortization of prepaid clinical research costs and insurance premiums and the write-off of $<span id="xdx_905_ecustom--WriteoffOfAdvances_iI_pn5n6_c20240930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_z33LJpUCH5n5" title="Write-off of advances"><ix:nonFraction name="ptgef:WriteoffOfAdvances" contextRef="AsOf2024-09-30_custom_ParexelInternationalLimitedMember" id="Fact000651" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million of advances
to Parexel <span style="color: #212529; background-color: white">International (IRL) Limited (&#8220;Parexel&#8221;)</span>, partially
offset by a $<span id="xdx_903_ecustom--RefundReceivables_iI_pn5n6_c20240930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_zNn9ilJYcPE2" title="Refund receivables"><ix:nonFraction name="ptgef:RefundReceivables" contextRef="AsOf2024-09-30_custom_ParexelInternationalLimitedMember" id="Fact000653" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million refund receivable from Paraxel as of September 30, 2024. Refer to the &#8220;iOx &#8211; Parexel Master Services
Agreement&#8221; section of Note 12, &#8220;Commitments and Contingent Liabilities&#8221; for further discussion regarding this matter.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_231_z6JPEp0kcZV8" style="margin: 0; font-size: 10pt; text-align: center"></p></ix:exclude>

<ix:exclude><p id="xdx_237_z5Z86b5fn672" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zwdBlZwJieB2" style="margin: 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 13 -->
    <div id="xdx_231_zfN0ktf9m7C1" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zDVMaRcPqA77" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zlvRlh3kYkik" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zflJm5tNyzD" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zj6PLVQKXVE5" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zO5SfnfrZoqj" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_z6RRsaqVbsuj" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000663" name="ptgef:WarrantLiabilityTextBlock"><p id="xdx_80B_ecustom--WarrantLiabilityTextBlock_zP3234WjSSre" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 6. <span id="xdx_826_zKWV27FunZtf">WARRANT LIABILITY</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On August 15, 2024, the Company effected
a reverse stock split of its ordinary shares at a ratio of 1-for-20. The number of warrants and exercise price information herein have
been retroactively adjusted to reflect the impact of the reverse stock split. See Note 1 &#8220;Nature of Operations&#8221; and Note 9,
&#8220;Capital Stock and Reserves&#8221; for further discussion on the reverse stock split.</p>

<p style="margin: 0pt 0 0pt 26.7pt; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following table summarizes the changes in the warrant
liability during the three and six months ended September 30, 2024:</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000665" name="ptgef:ScheduleOfWarrantLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zwLAxhHXwtPd" summary="xdx: Disclosure - WARRANT LIABILITY (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BC_zXWGbAfywazb" style="display: none">Schedule of changes in the warrant
liability</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Warrants</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value Balance</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Warrant liability as of April 1, 2023</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--WarrantLiabilityExercisePrice_iI_pip0_c20230331_zR8JQdLDTJE6" title="Warrants liability exercise price" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_ecustom--WarrantsLiabilityShares_iS_pip0_c20230401__20240331_z2Pq7GJJQzp4" title="Warrants liability, shares at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0669">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20230401__20240331_z4pZHKZA9HW2" title="Warrants liability, fair value at beginning" style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold">Fair value of warrants at issuance on October 3, 2023:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 61%; font-size: 10pt; font-weight: bold; text-align: left">Class B Warrants</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zSmJyE5hKpw1" title="Fair value of warrants at issuance exercise price" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsAtIssuanceExercisePrice" contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember" id="Fact000673" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zZN73Kn7CPZf" title="Fair value of warrants shares" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsShares" contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember" id="Fact000675" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">157,895</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zrfqAQ46ti9k" title="Fair value of warrants amount"><ix:nonFraction name="ptgef:FairValueOfWarrantsAmount" contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember" id="Fact000677" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,537</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Class C Warrants</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zznyU7KV5Fqc" title="Fair value of warrants at issuance exercise price" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsAtIssuanceExercisePrice" contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember" id="Fact000679" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_z0lkrOfzaO8j" title="Fair value of warrants shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsShares" contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember" id="Fact000681" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">157,895</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zlWO6Pqg7OG9" title="Fair value of warrants amount"><ix:nonFraction name="ptgef:FairValueOfWarrantsAmount" contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember" id="Fact000683" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,663</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Placement Agent Warrants</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMBu6zY15JVh" title="Fair value of warrants at issuance exercise price" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsAtIssuanceExercisePrice" contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember" id="Fact000685" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">47.50</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw6ax8GTFgHa" title="Fair value of warrants shares" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:FairValueOfWarrantsShares" contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember" id="Fact000687" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">7,896</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_znbVJV9Zf6qc" title="Fair value of warrants amount"><ix:nonFraction name="ptgef:FairValueOfWarrantsAmount" contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember" id="Fact000689" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">232</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b><span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20230401__20240331_zvJwJGOMsKQl" title="Change in fair value of warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0691">&#8211;</span></span></b></span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_ziR3u6w2Has9" title="Change in fair value of warrant liability, amount" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiabilityAmount" contextRef="From2023-04-012024-03-31" id="Fact000693" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,868</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Warrant liability as of March 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><b style="display: none">&#8211;</b></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20240630_zUGjw8zX5Eoc" title="Warrants liability, shares at beginning" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityShares" contextRef="AsOf2024-03-31" id="Fact000695" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">323,686</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20240630_zZfOIdB69ecb" title="Warrants liability, fair value at beginning"><ix:nonFraction name="ptgef:WarrantsLiabilityFairValue" contextRef="AsOf2024-03-31" id="Fact000697" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,564</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--ChangeInFairValueOfWarrantLiability_c20240401__20240630_zDW06zxkz7Cg" title="Change in fair value of warrant liability, shares"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20240630_zDVOnoY49hl4" title="Change in fair value of warrant liability, amount" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiabilityAmount" contextRef="From2024-04-012024-06-30" id="Fact000701" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,142</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Warrant liability as of June 30, 2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td title="Change in fair value of warrant liability exercise price" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WarrantsLiabilityShares_iS_pip0_c20240701__20240930_zlmlvAwiTZu" title="Warrants liability, shares at beginning" style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityShares" contextRef="AsOf2024-06-30" id="Fact000703" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">323,686</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td title="Change in fair value of warrant liability, amount" style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_903_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240701__20240930_zEk1ELkUSKIh" title="Warrants liability, fair value at beginning"><ix:nonFraction name="ptgef:WarrantsLiabilityFairValue" contextRef="AsOf2024-06-30" id="Fact000705" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">422</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td title="Change in fair value of warrant liability exercise price" style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20240701__20240930_zTjtO1x8Yx34" title="Change in fair value of warrant liability, shares"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td title="Change in fair value of warrant liability, amount" id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240701__20240930_zh6K6ejO8LFc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiabilityAmount" contextRef="From2024-07-012024-09-30" id="Fact000709" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">716</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrant liability as of September 30, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><b style="display: none">&#8211;</b></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantsLiabilityShares_iE_pip0_c20240701__20240930_zf2cT80Wi85i" title="Warrants liability, shares at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityShares" contextRef="AsOf2024-09-30" id="Fact000711" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">323,686</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20240401__20240930_zksU6cTyeeUk" title="Warrants liability, fair value at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:WarrantsLiabilityFairValue" contextRef="AsOf2024-09-30" id="Fact000713" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,138</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zD5WVRGnzKJ3" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On September 29, 2023, the Company entered into a securities
purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional and accredited investor in connection with a registered
direct offering (the &#8220;the Registered Direct Offering&#8221;) and a concurrent private placement (the &#8220;Private Placement&#8221;)
and together with the Registered Direct Offering, the &#8220;Offerings&#8221;). The Offerings closed on October 3, 2023.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Pursuant to the Purchase Agreement, in the Registered
Direct Offering, the Company sold (i) <span id="xdx_905_ecustom--OrdinaryNumberOfStockSold_pip0_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember_zpdKRLglN3xd" title="Number of stock sold"><ix:nonFraction name="ptgef:OrdinaryNumberOfStockSold" contextRef="From2023-09-282023-09-29_custom_PurchaseAgreementMember" id="Fact000715" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">98,500</ix:nonFraction></span> shares of the Company&#8217;s ordinary shares at a purchase price of $<span id="xdx_907_ecustom--PurchasePriceOfPerShare_pip0_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember_znPswoVGxSOd" title="Purchase price of per share"><ix:nonFraction name="ptgef:PurchasePriceOfPerShare" contextRef="From2023-09-282023-09-29_custom_PurchaseAgreementMember" id="Fact000717" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">38.00</ix:nonFraction></span> per share and
(ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <span id="xdx_90E_ecustom--PurchaseWarrants_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zxUUrqu08mm7" title="Purchase ordinary shares"><ix:nonFraction name="ptgef:PurchaseWarrants" contextRef="From2023-09-282023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000719" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,395</ix:nonFraction></span> ordinary shares, at a purchase price of $<span id="xdx_905_ecustom--PurchasePriceOfPerShare_pip0_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zmJvp56kFvsi" title="Purchase price of per share"><ix:nonFraction name="ptgef:PurchasePriceOfPerShare" contextRef="From2023-09-282023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000721" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">37.98</ix:nonFraction></span>
per Pre-Funded Warrant. All Pre-Funded Warrants, which were exercisable for one ordinary share at an exercise price of $<span id="xdx_904_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_z3Vq45dso3me" title="Exercise price"><ix:nonFraction name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" contextRef="AsOf2023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember" id="Fact000723" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.02</ix:nonFraction></span> per share,
were exercised in full on May 29, 2024.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_232_zqyqnROScNHh" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 14 -->
    <div id="xdx_23A_z7kGdxilMnSc" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_z6ULk4XpMDXk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_z0N89MNl1NDi" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zmWJPVQMZWf" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zI3n2DxwZla4" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zRnj7edjc4W5" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zDRVcqvMSTkd" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zXtAaxPcyBsi" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 6. WARRANT LIABILITY <span style="letter-spacing: -0.1pt"><i>(Cont&#8217;d)</i></span></b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zPUrw2fEj8dk" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">In the Private Placement, the Company issued to such
institutional and accredited investor unregistered warrants to purchase up to <span id="xdx_904_ecustom--OrdinarySharesPurchase_pip0_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zVBxxJfTju7e" title="Ordinary shares purchase"><ix:nonFraction name="ptgef:OrdinarySharesPurchase" contextRef="From2024-04-012024-09-30_custom_SeriesAWarrantsMember" id="Fact000733" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">157,895</ix:nonFraction></span> ordinary shares (the &#8220;Series A Warrants&#8221;),
unregistered warrants to purchase up to <span id="xdx_909_ecustom--OrdinarySharesPurchase_pip0_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zN9z4HPJKg54" title="Ordinary shares purchase"><ix:nonFraction name="ptgef:OrdinarySharesPurchase" contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember" id="Fact000735" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">157,895</ix:nonFraction></span> ordinary shares (the &#8220;Series B Warrants&#8221;), and unregistered warrants to purchase
up to <span id="xdx_909_ecustom--OrdinarySharesPurchase_pip0_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zFDAjV7yrEWa" title="Ordinary shares purchase"><ix:nonFraction name="ptgef:OrdinarySharesPurchase" contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember" id="Fact000737" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">157,895</ix:nonFraction></span> ordinary shares (the &#8220;Series C Warrants,&#8221; together with the Series A Warrants and the Series B Warrants, the
&#8220;Private Warrants&#8221;), together exercisable for an aggregate of up to 473,685 ordinary shares (the &#8220;Private Warrant Shares&#8221;).
Pursuant to the terms of the Purchase Agreement, for each ordinary share and Pre-Funded Warrant issued in the Registered Direct Offering,
an accompanying Series A Warrant, Series B Warrant and Series C Warrant were issued to such institutional and accredited investor. Each
Series A Warrant is exercisable for one Private Warrant Share at an exercise price of $<span id="xdx_90E_ecustom--ExercisePriceOfOutstandingWarrant_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zNYddc7uzvB7" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceOfOutstandingWarrant" contextRef="AsOf2024-09-30_custom_SeriesAWarrantsMember" id="Fact000739" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">38.00</ix:nonFraction></span> per share, is immediately exercisable and
will expire 18 months from the date of issuance. Each Series B Warrant is exercisable for one Private Warrant Share at an exercise price
of $<span id="xdx_902_ecustom--ExercisePriceOfOutstandingWarrant_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zkft17r0YC3" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceOfOutstandingWarrant" contextRef="AsOf2024-09-30_custom_SeriesBWarrantsMember" id="Fact000741" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">45.20</ix:nonFraction></span> per share, is immediately exercisable and will expire three years from the date of issuance. Each Series C Warrant is exercisable
for one Private Warrant Share at an exercise price of $<span id="xdx_90D_ecustom--ExercisePriceOfOutstandingWarrant_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zYNNQjPqLqh2" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceOfOutstandingWarrant" contextRef="AsOf2024-09-30_custom_SeriesCWarrantsMember" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">45.20</ix:nonFraction></span> per share, is immediately exercisable and will expire five years from the
date of issuance. The net proceeds to the Company from the Offerings were approximately $<span id="xdx_905_eifrs-full--ProceedsFromIssuingShares_pn5n6_c20240401__20240930_zUlWBPmonRe" title="Net proceeds warrants"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2024-04-01to2024-09-30" id="Fact000745" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.3</ix:nonFraction></span> million, after deducting placement agent&#8217;s
fees and estimated offering expenses of approximately $<span id="xdx_903_eifrs-full--ProfessionalFeesExpense_pn5n6_c20240401__20240930_zhQcuCpYQjQ9" title="Estimated offering expenses"><ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2024-04-01to2024-09-30" id="Fact000747" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Pursuant to an engagement letter, dated as of August
26, 2023, between the Company and H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;), the Company paid the Placement Agent
a total cash fee equal to <span id="xdx_909_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pip0_dp_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zvIxA30N6SP2" title="Interest rate"><ix:nonFraction name="ifrs-full:PercentageOfVotingEquityInterestsAcquired" contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction></span>% of the aggregate gross proceeds received in the Offerings, or $<span id="xdx_901_ecustom--AggregateGrossProceeds_iI_pn4n6_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zvIahjQjvEdd" title="Aggregate gross proceeds"><ix:nonFraction name="ptgef:AggregateGrossProceeds" contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember" id="Fact000751" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.36</ix:nonFraction></span> million. The Company also paid the
Placement Agent in connection with the Offerings a management fee equal to <span id="xdx_908_ecustom--ManagementFeePercentage_iI_pip0_dp_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zPv7Ahyo4DEj" title="Management fee percentage"><ix:nonFraction name="ptgef:ManagementFeePercentage" contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember" id="Fact000753" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span>% of the aggregate gross proceeds raised in the Offerings
($<span id="xdx_903_ecustom--AggregateGrossProceedsIncrease_iI_pn4n6_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zQE0hB2Tpb6b" title="Aggregate gross proceeds increase"><ix:nonFraction name="ptgef:AggregateGrossProceedsIncrease" contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember" id="Fact000755" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.06</ix:nonFraction></span> million), $<span id="xdx_904_eifrs-full--AdministrativeExpense_pp0p0_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zGtei3LASj6a" title="Non-accountable expenses"><ix:nonFraction name="ifrs-full:AdministrativeExpense" contextRef="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember" id="Fact000757" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000</ix:nonFraction></span> for non-accountable expenses and $<span id="xdx_906_eifrs-full--FeeAndCommissionExpense_pp0p0_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_z8Nc31kqmmd5" title="Clearing fees"><ix:nonFraction name="ifrs-full:FeeAndCommissionExpense" contextRef="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember" id="Fact000759" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,950</ix:nonFraction></span> for clearing fees. In addition, the Company issued to the Placement
Agent, or its designees, warrants to purchase up to <span id="xdx_90D_ecustom--PurchaseOfWarrants_pip0_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zl1DS9IdLlF7" title="Purchase warrants"><ix:nonFraction name="ptgef:PurchaseOfWarrants" contextRef="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">7,896</ix:nonFraction></span> ordinary shares (the &#8220;Placement Agent Warrants,&#8221; and together with
the Pre-Funded Warrants and the Private Warrants, the &#8220;Warrants&#8221;), which represented <span id="xdx_90B_ecustom--SaleOfWarrantPercentage_iI_pip0_dp_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zs5qq6BDiy42" title="Sale of warrant percentage"><ix:nonFraction name="ptgef:SaleOfWarrantPercentage" contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember" id="Fact000763" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% of the aggregate number of ordinary
shares and Pre-Funded Warrants sold in the Registered Direct Offering. The Placement Agent Warrants have substantially the same terms
as the Series B Warrants and the Series C Warrants, except that the Placement Agent Warrants have an exercise price equal to $<span id="xdx_905_ecustom--ExercisePriceWarrantPerShare_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zv3QADJWK9T4" title="Exercise price warrant per share"><ix:nonFraction name="ptgef:ExercisePriceWarrantPerShare" contextRef="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember" id="Fact000765" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">47.50</ix:nonFraction></span>, or
125% of the offering price per ordinary share sold in the Registered Direct Offering and will be exercisable for five years from the commencement
of the sales pursuant to the Offerings. The Private Warrants, Private Warrant Shares, Placement Agent Warrants and ordinary shares underlying
the Placement Agent Warrants were registered for resale under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)
pursuant to a registration statement on Form F-1 that was declared effective by the SEC on November 7, 2023 (the &#8220;Resale Registration
Statement&#8221;).</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Series B Warrants, the Series C Warrants and the
Placement Agent Warrants include the obligation, in the event of a Fundamental Transaction, as defined in the Series B Warrants, the Series
C Warrants and the Placement Agent Warrants, for the Company or the successor entity to purchase the warrants from the holder at the discretion
of the holder and at the Black-Scholes value, as defined in the warrant agreements. As a result, management concluded that, in line with
IAS 9, &#8220;Financial Instruments&#8221; and IAS 32, &#8220;Financial Instruments: Presentation,&#8221; such warrants will be accounted
for as financial liabilities on the condensed consolidated interim statement of financial position with the changes in fair value recognized
in the condensed consolidated interim statement of operations and other comprehensive income (loss). The Company allocated the net proceeds
of $<span id="xdx_906_ecustom--NetProceedsWarrantLiability_iI_pn5n6_c20240930_z8vpMxqyudA8" title="Net proceeds warrant liability"><ix:nonFraction name="ptgef:NetProceedsWarrantLiability" contextRef="AsOf2024-09-30" id="Fact000767" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.3</ix:nonFraction></span> million for the Registered Direct Offering to the warrant liability and recognized the excess of the fair value of the warrant
liabilities at inception of $<span id="xdx_90C_eifrs-full--IncreaseDecreaseInFairValueMeasurementLiabilities_pn5n6_c20240401__20240930_zR1EVBlH8jd3" title="Excess of the fair value of the warrant liabilities"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities" contextRef="From2024-04-01to2024-09-30" id="Fact000769" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million as a loss on the Registered Direct Offering of $<span id="xdx_903_ecustom--LossOnWarrantLiabilities_iI_pn5n6_c20240930_z9G45oNC0Ntf" title="Loss on warrant liabilities"><ix:nonFraction name="ptgef:LossOnWarrantLiabilities" contextRef="AsOf2024-09-30" id="Fact000771" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.4</ix:nonFraction></span> million and offering expenses of $<span id="xdx_903_ecustom--OfferingExpenses_iI_pn5n6_c20240930_zG5ZGJiEQa5l" title="Offering expenses"><ix:nonFraction name="ptgef:OfferingExpenses" contextRef="AsOf2024-09-30" id="Fact000773" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million.
The Company also recorded a loss of $<span id="xdx_904_ecustom--ChangeInFairValueOfWarrantLiabilities_pn5n6_di_c20240701__20240930_zg9yKQjDxfm5" title="Gain (loss) in the fair value of the warrant liabilities"><ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiabilities" contextRef="From2024-07-012024-09-30" id="Fact000775" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="USD">0.7</ix:nonFraction></span> million and a gain of $<span id="xdx_909_ecustom--ChangeInFairValueOfWarrantLiabilities_pn5n6_c20240401__20240930_zHY7z150roQb" title="Gain (loss) in the fair value of the warrant liabilities"><ix:nonFraction name="ptgef:ChangeInFairValueOfWarrantLiabilities" contextRef="From2024-04-01to2024-09-30" id="Fact000777" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million from the change in the fair value of the warrant liabilities
for the three and six months ended September 30, 2024, respectively, resulting in a warrant liability balance of $<span id="xdx_908_ecustom--WarrantLiabilityBalance_iI_pn5n6_c20240930_zcsWGGnhrep4" title="Warrant liability balance"><ix:nonFraction name="ptgef:WarrantLiabilityBalance" contextRef="AsOf2024-09-30" id="Fact000779" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million at September
30, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company filed the Resale Registration Statement to
register for the resale of the Private Warrant Shares and the ordinary shares issuable upon the exercise of the Placement Agent Warrants,
which was declared effective by the SEC on November 7, 2023. Pursuant to the terms of the Purchase Agreement, the Company is obligated
to use its commercially reasonable efforts to keep the Resale Registration Statement effective at all times until such institutional and
accredited investor (and its successors and assigns) no longer owns any Private Warrants or ordinary shares issuable upon exercise thereof.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23F_z43bmxiEZq0d" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div id="xdx_23C_zqfHPgEOTY9j" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_z3g7NpdtJ41g" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zSfoVJcOtceh" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zBKJw7xOzsG6" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zMXO5SV7bm6c" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zVEMz9GUyVOc" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zRgoEEboQ7ch" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zNhvo79RyfB8" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 6. WARRANT LIABILITY <span style="letter-spacing: -0.1pt"><i>(Cont&#8217;d)</i></span></b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zJXG5Hexm3Pa" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On May 29, 2024, Armistice Capital Master Fund Ltd. exercised
its Pre-Funded Warrants at an exercise price of $<span id="xdx_908_ecustom--ExercisePrice_c20240528__20240529__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zbLgFRaPDsBj" title="Warrants exercise price"><ix:nonFraction name="ptgef:ExercisePrice" contextRef="From2024-05-282024-05-29_custom_PreFundedWarrantsMember" id="Fact000789" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.02</ix:nonFraction></span> per share increasing the Company&#8217;s total shares outstanding to <span id="xdx_902_eifrs-full--NumberOfSharesOutstanding_iI_pip0_c20240529__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zbvt7TxVkKPc" title="Total shares outstanding"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2024-05-29_custom_PreFundedWarrantsMember" id="Fact000791" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,048,765</ix:nonFraction></span>.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The accounting for the Series A Warrants and the Pre-Funded
Warrants is detailed below in Note 9, &#8220;Capital Stock and Reserves.&#8221;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Series B Warrants</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">A fair value of
$<span id="xdx_90D_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zkWQFTq02GUe" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember" id="Fact000793" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.40</ix:nonFraction></span> per each Series B Warrant was identified at the issue date of October 3, 2023. A fair value of $<span id="xdx_903_ecustom--FairValueOfWarrantPerShare_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zDDzBoB8w0w" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2024-09-30_custom_SeriesBWarrantsMember" id="Fact000795" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.05</ix:nonFraction></span> per each warrant has been
identified as of September 30, 2024.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">The inputs associated
with calculating the fair value are reflected below.</span></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember" escape="true" id="Fact000797" name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEkrm5UZJBGe" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BD_zREPodEHY8ti" style="display: none">Schedule of fair value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90D_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zZTmCC7cclRi" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember" id="Fact000799" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJ19voToTy92" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2024-09-30_custom_SeriesBWarrantsMember" id="Fact000801" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zt6hxDAGNJv9" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember" id="Fact000803" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">39.40</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJBVKTZ9m2e5" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2024-09-30_custom_SeriesBWarrantsMember" id="Fact000805" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.65</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z84uGXOtPsna" title="Expected life"><ix:nonNumeric contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember" format="ixt-sec:duryear" id="Fact000807" name="ptgef:OptionLifeShareOptions">3.01</ix:nonNumeric></span> years</b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z4gqsqiIR7S9" title="Expected life"><ix:nonNumeric contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember" format="ixt-sec:duryear" id="Fact000809" name="ptgef:OptionLifeShareOptions">2.01</ix:nonNumeric></span> years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zT5LiGEXS3T6" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember" id="Fact000811" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">90.4</ix:nonFraction></span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zHsOvAIO55m3" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember" id="Fact000813" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">159.22</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zoT9D9Wc3gF4" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember" id="Fact000815" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.95</ix:nonFraction></span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrBMzoUezxPj" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember" id="Fact000817" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.66</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z04kXw66MSIk" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zP1oUWszKJwc" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0821">&#8211;</span></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zeA6l8wF3ev1" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Series C Warrants</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">A fair value of
$<span id="xdx_909_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zHyusLZVIfCl" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember" id="Fact000823" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.60</ix:nonFraction></span> per each Series C Warrant was identified at the issue date of October 3, 2023. A fair value of $<span id="xdx_902_ecustom--FairValueOfWarrantPerShare_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zZgoxflsyTHf" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2024-09-30_custom_SeriesCWarrantsMember" id="Fact000825" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.91</ix:nonFraction></span> per each warrant has been
identified as of September 30, 2024.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">The inputs associated
with calculating the fair value are reflected below.</span></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember" escape="true" id="Fact000827" name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_897_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zNo8g7HfVAx" summary="xdx: Disclosure -  WARRANT LIABILITY (Details 2)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BE_z5i9uOgWjsI7" style="display: none">Schedule of fair value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z3J6gnWUkU4f" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember" id="Fact000829" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zsCGSLy6od" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2024-09-30_custom_SeriesCWarrantsMember" id="Fact000831" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">45.20</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90F_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4NWSvRDipa5" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember" id="Fact000833" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">39.40</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zoSDcNdfzyrc" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2024-09-30_custom_SeriesCWarrantsMember" id="Fact000835" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.65</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zffuAbj4Gna4" title="Expected life"><ix:nonNumeric contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" id="Fact000837" name="ptgef:OptionLifeShareOptions">5.00</ix:nonNumeric></span> years</b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zR2vvuZGlCek" title="Expected life"><ix:nonNumeric contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" id="Fact000839" name="ptgef:OptionLifeShareOptions">4.01</ix:nonNumeric></span> years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_905_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7sKqapVVSzf" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember" id="Fact000841" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.7</ix:nonFraction></span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4bXOJnQUMn4" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember" id="Fact000843" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">129.26</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zi1Ht5zQ8sg8" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember" id="Fact000845" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.80</ix:nonFraction></span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_903_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zxeevLgY5d83" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember" id="Fact000847" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.58</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zw0kH9IKVOXk" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0849">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zIS5SgmE9Kth" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8211;</span></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z8iBtJ6ERVXi" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Placement Agent Warrants</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">A fair value of
$<span id="xdx_905_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zWHqKMbmVl39" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember" id="Fact000853" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.40</ix:nonFraction></span> per each Placement Agent Warrant was identified at the issue date of October 3, 2023. A fair value of $<span id="xdx_906_ecustom--FairValueOfWarrantPerShare_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zFPY4u3vSlUj" title="Fair value of warrant per share"><ix:nonFraction name="ptgef:FairValueOfWarrantPerShare" contextRef="AsOf2024-09-30_custom_PlacementAgentWarrantsMember" id="Fact000855" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.86</ix:nonFraction></span> per each warrant has
been identified as of September 30, 2024.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">The inputs associated
with calculating the fair value are reflected below.</span></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember" escape="true" id="Fact000857" name="ifrs-full:DisclosureOfFairValueMeasurementExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNqJsTXTy39d" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B6_zizEuT02aYM2" style="display: none">Schedule of fair value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90A_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcEOVuZQcbE9" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember" id="Fact000859" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">47.60</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHmGOB1v5pgi" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2024-09-30_custom_PlacementAgentWarrantsMember" id="Fact000861" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">47.50</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_901_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGzHzT9ujqM8" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember" id="Fact000863" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">39.40</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z7MOsQV6Uzx4" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2024-09-30_custom_PlacementAgentWarrantsMember" id="Fact000865" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">6.65</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zAO26TCEDHFe" title="Expected life"><ix:nonNumeric contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact000867" name="ptgef:OptionLifeShareOptions">4.99</ix:nonNumeric></span> years</b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9gSMGkD40b" title="Expected life"><ix:nonNumeric contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact000869" name="ptgef:OptionLifeShareOptions">4.01</ix:nonNumeric></span> years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zFEYBL2WEmq7" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember" id="Fact000871" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100.7</ix:nonFraction></span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKmBRjn0xTG7" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember" id="Fact000873" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">129.26</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90C_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNXdKGvaccSl" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember" id="Fact000875" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.80</ix:nonFraction></span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zo9o1tyDYZMe" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember" id="Fact000877" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.58</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_906_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zfPd7mIQxc12" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0879">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z45tug4uPhn6" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8211;</span></span></td></tr>
  </table>


<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_238_z53R2K5hz0Mj" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 16 -->
    <div id="xdx_237_zY8fDOFoJuKj" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zHVZ3CF808O5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zQfVPz4sqYGl" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zl0qcdVxc2Fl" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zcknSx28IK31" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zJpVrBeI7Fi6" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_z6gLdqNcyzOi" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000889" name="ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock"><p id="xdx_80B_ecustom--AccountsPayableAndAccruedLiabilitiesTextBlock_zrKjZ7frTjSj" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 7.&#160; <span id="xdx_826_z5qymSj23Dc8">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">At September 30, 2024 and March 31, 2024, accounts payable
and accrued liabilities were comprised of the following (in thousands):</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000891" name="ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_ztM36cLVhTV3" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span><span id="xdx_8BF_zIgoWOD3J5p8" style="display: none">Schedule of accounts payable and accrued liabilities</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20240930_zwsLYUqXcj0b" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20240331_zEoKifOeHuyk" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr id="xdx_409_ecustom--AccountsPayableAndAmountsAccruedToCro_iI_zGrnUPIAEMl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and amounts accrued to CRO</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAmountsAccruedToCro" contextRef="AsOf2024-09-30" id="Fact000893" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">49</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAmountsAccruedToCro" contextRef="AsOf2024-03-31" id="Fact000894" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,413</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_zU2Hkru1iIgb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued bonuses and other payroll-related expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses" contextRef="AsOf2024-09-30" id="Fact000896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">371</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses" contextRef="AsOf2024-03-31" id="Fact000897" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">525</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zaFtbYZIToK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued accounting and auditing fees</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccruedAccountingAndAuditingFees" contextRef="AsOf2024-09-30" id="Fact000899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">127</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedAccountingAndAuditingFees" contextRef="AsOf2024-03-31" id="Fact000900" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedLegalFees_iI_zSo5RglA1PIh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued legal fees</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccruedLegalFees" contextRef="AsOf2024-09-30" id="Fact000902" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedLegalFees" contextRef="AsOf2024-03-31" id="Fact000903" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedOtherProfessionalFees_iI_z9yIRqvCxyjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued other professional fees</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccruedOtherProfessionalFees" contextRef="AsOf2024-09-30" id="Fact000905" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedOtherProfessionalFees" contextRef="AsOf2024-03-31" id="Fact000906" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">157</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--OtherAccountsPayable_iI_zUfZuBt5BYoc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other accounts payable</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:OtherAccountsPayable" contextRef="AsOf2024-09-30" id="Fact000908" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">172</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherAccountsPayable" contextRef="AsOf2024-03-31" id="Fact000909" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedClinicalAndRdServices_iI_zWuKHzGuHyRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued clinical and R&amp;D services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccruedClinicalAndRdServices" contextRef="AsOf2024-09-30" id="Fact000911" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccruedClinicalAndRdServices" contextRef="AsOf2024-03-31" id="Fact000912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">179</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OtherAccruedExpenses_iI_pn3n3_zbcoTDtytPE" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:OtherAccruedExpenses" contextRef="AsOf2024-09-30" id="Fact000914" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:OtherAccruedExpenses" contextRef="AsOf2024-03-31" id="Fact000915" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_pn3n3_zO9lOvxYHt3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilityNet" contextRef="AsOf2024-09-30" id="Fact000917" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilityNet" contextRef="AsOf2024-03-31" id="Fact000918" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,836</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The decrease in <span style="background-color: white">accounts
payable and accrued liabilities from $<span id="xdx_907_eifrs-full--OtherPayables_iI_pn5n6_c20240331_zDMnyuOpAtBj" title="Accounts payable and accrued liabilities"><ix:nonFraction name="ifrs-full:OtherPayables" contextRef="AsOf2024-03-31" id="Fact000920" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million as of March 31, 2024 to $<span id="xdx_905_eifrs-full--OtherPayables_iI_pn5n6_c20240930_zJSurSXSL56g" title="Accounts payable and accrued liabilities"><ix:nonFraction name="ifrs-full:OtherPayables" contextRef="AsOf2024-09-30" id="Fact000922" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million as of September 30, 2024 is primarily attributable
to the write-off of $<span id="xdx_907_eifrs-full--DecreaseThroughWriteoffFinancialAssets_pn3n6_c20240401__20240930_zRa7xwbQvYq5" title="Accounts payable and accrued liabilities write-off"><ix:nonFraction name="ifrs-full:DecreaseThroughWriteoffFinancialAssets" contextRef="From2024-04-01to2024-09-30" id="Fact000924" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.486</ix:nonFraction></span> million in connection with the settlement with Parexel. </span>Refer to the &#8220;iOx &#8211; Parexel Master
Services Agreement&#8221; section of Note 12, &#8220;Commitments and Contingent Liabilities&#8221; for further discussion regarding this
matter.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000926" name="ifrs-full:DisclosureOfIncomeTaxExplanatory"><p id="xdx_80A_eifrs-full--DisclosureOfIncomeTaxExplanatory_zakDMfsPx0ti" style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b>NOTE 8. <span id="xdx_825_zkwSv8g53iMj">INCOME TAXES</span></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company is a BVI business company. The BVI government
does not, under existing legislation, impose any income or corporate tax on corporations.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">PDS is a U.S. corporation and is subject to U.S. federal,
state and local income taxes, as applicable.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">iOx is subject to U.K. taxes.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following is a reconciliation of the U.S. taxes to
the effective income tax rates for the six months ended September 30, 2024 and 2023 (in thousands, except percentages):</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000928" name="ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z9rHamzxYfn7" summary="xdx: Disclosure - INCOME TAXES (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B2_zGEeeJFpITia" style="display: none">Schedule of effective income tax rates</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20240401__20240930_zHJnklBFtjE9" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20230401__20230930_zMcz3nbMzRJi" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_iN_di_znGvqV0P44Zk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Loss before income taxes</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2024-04-01to2024-09-30" id="Fact000930" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,024</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2023-04-012023-09-30" id="Fact000931" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">12,143</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncomeTaxExpenseContinuingOperation_iN_di_zLFaFRaXIb27" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income tax benefit</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:IncomeTaxExpenseContinuingOperation" contextRef="From2024-04-01to2024-09-30" id="Fact000933" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:IncomeTaxExpenseContinuingOperation" contextRef="From2023-04-012023-09-30" id="Fact000934" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,052</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_zVO4lrL8mbV1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Effective tax rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:TaxRateEffectOfTaxLosses" contextRef="From2024-04-01to2024-09-30" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.10</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:TaxRateEffectOfTaxLosses" contextRef="From2023-04-012023-09-30" id="Fact000937" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.66</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">%</td></tr>
  </table></ix:nonNumeric>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s effective tax rates were <span id="xdx_90F_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_c20240401__20240930_zYtaw09zcZ35"><ix:nonFraction name="ifrs-full:TaxRateEffectOfTaxLosses" contextRef="From2024-04-01to2024-09-30" id="Fact000938" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.10</ix:nonFraction></span>% and
<span id="xdx_900_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_c20230401__20230930_zTtntrt8wp5g"><ix:nonFraction name="ifrs-full:TaxRateEffectOfTaxLosses" contextRef="From2023-04-012023-09-30" id="Fact000939" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.66</ix:nonFraction></span>% for the six months ended September 30, 2024 and 2023, respectively. The decrease in the effective tax rate was primarily due to
a change in the mix of income and losses in the various tax jurisdiction in which the Company operates.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23C_z4c8jrQJPrXi" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 17 -->
    <div id="xdx_23D_ztHhQhdx9d5e" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zLqohHsWh5l6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zo4W2ij14qP6" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zi8zfCDiZai6" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zdBzdGDjrKlk" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zs7J9RWwtOyb" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zsSRVDccljch" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000947" name="ptgef:CapitalStockAndReservesTextBlock"><p id="xdx_805_ecustom--CapitalStockAndReservesTextBlock_z6hY6CoqtJv7" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 9. <span id="xdx_825_zZF4TiVfWu9k">CAPITAL STOCK AND RESERVES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Authorized ordinary shares<b>: </b>Unlimited number of
Portage ordinary shares without par value.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. The reverse stock split decreased the number of ordinary shares
outstanding as of September 30, 2023, from <span id="xdx_90C_ecustom--NumberOfOrdinarySharesOutstandingDecrease_c20230401__20230930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zDavpgghJ9hc" title="Number of ordinary shares outstanding, decrease"><ix:nonFraction name="ptgef:NumberOfOrdinarySharesOutstandingDecrease" contextRef="From2023-04-012023-09-30_ifrs-full_TopOfRangeMember" id="Fact000949" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,808,225</ix:nonFraction></span>
to <span id="xdx_900_ecustom--NumberOfOrdinarySharesOutstandingDecrease_c20230401__20230930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zY7parI27pqc" title="Number of ordinary shares outstanding, decrease"><ix:nonFraction name="ptgef:NumberOfOrdinarySharesOutstandingDecrease" contextRef="From2023-04-012023-09-30_ifrs-full_BottomOfRangeMember" id="Fact000951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">890,412</ix:nonFraction></span>.
All share and per share information included in the condensed consolidated interim financial statements and in the Notes to the
condensed consolidated interim financial statements have been retroactively adjusted to reflect the impact of the reverse stock
split unless otherwise noted. The number of ordinary shares authorized remained at an unlimited number of common shares without par value.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Any fractional shares resulting from the reverse
stock split were rounded up to the nearest whole post-split ordinary share. As a result of this round up provision, the Company
issued an additional 52,254 shares.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0pt 5.6pt 0pt 8.25pt; font-size: 10pt; text-align: justify; text-indent: 18.4pt">Portage filed a shelf registration
statement with the SEC in order to sell ordinary shares, debt securities, warrants and units in one or more offerings from time to time,
which became effective on March 8, 2021 (&#8220;March 2021 Registration Statement&#8221;). In connection with the March 2021 Registration
Statement, Portage has filed with the SEC:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"/><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a base prospectus, which covered the offering, issuance and sale by Portage of up
to $200 million in the aggregate of the securities identified above from time to time in one or more offerings;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"/><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a prospectus supplement, which covered the offer, issuance and sale by Portage in
its ATM offering of up to a maximum aggregate offering price of $50 million of Portage&#8217;s ordinary shares that may be issued and
sold from time to time under a Controlled Equity Offering Sales Agreement, dated February 24, 2021 (the &#8220;Sales Agreement&#8221;),
with Cantor Fitzgerald &amp; Co., the sales agent (&#8220;Cantor Fitzgerald&#8221;);</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"/><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by
Portage of 57,500 ordinary shares for gross proceeds of approximately $26.5 million in a firm commitment underwritten public offering
with Cantor Fitzgerald;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"/><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a prospectus supplement dated August 19, 2022, for the resale of up to $30 million
in ordinary shares that Portage may sell from time to time to Lincoln and an additional 4,726 shares that were issued to Lincoln; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"/><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a prospectus supplement dated September 29, 2023 for the offer, issuance and
                                                                                                             sale by Portage in a registered direct public offering through H.C. Wainwright &amp; Co., the placement agent, to an institutional
                                                                                                             and accredited investor of (i) 98,500 ordinary shares at a purchase price of $38.00 per share; and (ii) Pre-Funded Warrants to
                                                                                                             purchase up to 59,395 ordinary shares, at a purchase price of $37.98 per Pre-Funded Warrant Shares, for aggregate gross proceeds of
                                                                                                             approximately $6 million. All Pre-Funded Warrants, which were exercisable
for one ordinary share at an exercise price of $0.02 per share, were exercised in full on May 29, 2024.</td></tr></table>

<p style="margin: 0pt 5.6pt 0pt 41.1pt; font-size: 10pt; text-align: justify"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 5.6pt 0pt 8.25pt; font-size: 10pt; text-align: justify; text-indent: 18.4pt"><span id="xdx_900_ecustom--CashFundDescription_c20240401__20240930_z8Be9MvaAbb2" title="Cash fund, description"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact000953" name="ptgef:CashFundDescription">The Sales Agreement permits the Company
to sell in an ATM program up to $50 million of ordinary shares from time to time. Through September 30, 2024, the Company raised approximately $4.2 million in gross proceeds through the sale of shares of common shares
under the ATM program. Any sales under the prospectus will be deemed to be
made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act.</ix:nonNumeric></span></p>

<ix:exclude><p id="xdx_234_zomtmdH1Jvc9" style="margin: 0pt 5.6pt 0pt 8.25pt; font-size: 10pt; text-align: justify; text-indent: 18.4pt">&#160;</p></ix:exclude>



<ix:exclude><p id="xdx_234_z60B0cnTJeNe" style="margin: 0; font-size: 10pt">&#160;</p></ix:exclude>


<p id="xdx_8A8_znBKDu1SwIc1" style="margin: 0; font-size: 10pt; text-align: left">&#160;</p>

<ix:exclude><p id="xdx_23E_z9knXPHjAYc1" style="margin: 0; font-size: 10pt; text-align: center"></p></ix:exclude>

<ix:exclude><p id="xdx_232_z44GA7R37l26" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 18 -->
    <div id="xdx_237_zCTVgWotKoHg" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zsSAS0NLuER" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zfe9C7PVXQuj" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>


<ix:exclude><p id="xdx_23E_zntAreu4OMyi" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zTeX1aYtslW2" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zOpBHuowC2Cf" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zMb9mMi1xzqb" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zP5ZUkL0Fz9k" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zjFXKPwOxplk" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 9. CAPITAL STOCK AND RESERVES <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zktXXuS1Tsw6" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On July 6, 2022, the Company entered into a Purchase
Agreement (the &#8220;Committed Purchase Agreement&#8221;) with Lincoln, under which it may require Lincoln to purchase ordinary shares
of the Company having an aggregate value of up to $30 million (the &#8220;Purchase Shares&#8221;) over a period of 36 months. Upon execution
of the Committed Purchase Agreement, the Company issued to Lincoln <span id="xdx_905_ecustom--NumberOfOrdinaryShareIssued_pip0_c20220705__20220706_zuopKK3mm7le" title="Number of ordinary share issued"><ix:nonFraction name="ptgef:NumberOfOrdinaryShareIssued" contextRef="From2022-07-052022-07-06" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">4,726</ix:nonFraction></span> ordinary shares, representing a 3% commitment fee. Pursuant to
the Committed Purchase Agreement, Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based
on various market criteria and share amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason,
effective upon one business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The
requirement that Lincoln must make a purchase will be suspended based on various criteria such as there not being an effective registration
statement for Lincoln to be able to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing
to be Depository Trust Company eligible, among other things. The Committed Purchase Agreement does not impose any financial or business
covenants on the Company, and there are no limitations on the use of proceeds. The Company may raise capital from other sources in its
sole discretion; provided, however, that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like
securities until the three-year anniversary of the date of the Committed Purchase Agreement, excluding, however, an ATM transaction with
a registered broker-dealer, which includes any sales under the Sales Agreement with Cantor Fitzgerald.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">During the six months ended September 30, 2023, the
Company sold <span id="xdx_90F_ecustom--NumberOfSharesSold_c20230401__20230930__ifrs-full--CounterpartiesAxis__custom--ATMMember_z1hfipEjBD86" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2023-04-012023-09-30_custom_ATMMember" id="Fact000969" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,331</ix:nonFraction></span>
ordinary shares under the ATM program, generating net proceeds of approximately $<span id="xdx_900_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn5n6_c20230401__20230930__ifrs-full--CounterpartiesAxis__custom--ATMMember_z6UKGwIpC6Kd" title="Net proceeds from sale"><ix:nonFraction name="ifrs-full:ProceedsFromSalesOfBiologicalAssets" contextRef="From2023-04-012023-09-30_custom_ATMMember" id="Fact000971" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million. There were <span id="xdx_900_ecustom--NumberOfSharesSold_do_c20240401__20240930__ifrs-full--CounterpartiesAxis__custom--ATMMember_zfrdouh2idIb" title="Number of shares sold"><ix:nonFraction name="ptgef:NumberOfSharesSold" contextRef="From2024-04-012024-09-30_custom_ATMMember" id="Fact000973" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> shares sold under the ATM program during the six months ended September 30, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s March 2021 Registration Statement
expired on March 8, 2024. In order to issue additional shares under its ATM program or the Committed Purchase Agreement in the future,
the Company would be required to file a new registration statement, which must be declared effective by the SEC prior to use, and to file
a prospectus supplement related to the ATM program and the Committed Purchase Agreement, as the case may be.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Furthermore, the ATM program and the Committed Purchase
Agreement with Lincoln are generally limited based on, among other things, the Company&#8217;s Nasdaq trading volume. Under General Instruction
I.B.5 to Form F-3 (the &#8220;Baby Shelf Rule&#8221;), the amount of funds the Company can raise through primary public offerings of securities
in any 12-month period using a registration statement on Form F-3 is limited to one-third of the aggregate market value of the ordinary
shares held by the Company&#8217;s non-affiliates, which limitation may change over time based on its stock price, number of ordinary
shares outstanding and the percentage of ordinary shares held by non-affiliates. Accordingly, the Company is limited by the Baby Shelf
Rule as of the filing of this Form 6-K, until such time as its non-affiliate public float exceeds $<span id="xdx_906_ecustom--PublicFloat_iI_pn6n6_c20240930_zHnFS1RHMCUg" title="Public float"><ix:nonFraction name="ptgef:PublicFloat" contextRef="AsOf2024-09-30" id="Fact000975" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">75</ix:nonFraction></span> million.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On September 29, 2023, the Company entered into the Purchase
Agreement with an institutional and accredited investor in connection with the Registered Direct Offering and the Private Placement. The
Offerings closed on October 3, 2023.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_236_z0u0UzGNjb3i" style="margin: 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 19 -->
    <div id="xdx_236_zDagEwaGCr4j" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zS9Yev0vPDka" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zZ52p53GIJ76" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zVmsr366vls3" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zH4jlKlHSlR7" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zckJBcVSTYi" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_z3IMJ140o9na" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zvTEMxPMDqB5" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 9. CAPITAL STOCK AND RESERVES <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z2L6GRcu89Vi" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company filed the Resale Registration Statement to
register for resale the Private Warrant Shares and the ordinary shares issuable upon the exercise of Placement Agent Warrants, which was
declared effective by the SEC on November 7, 2023. Pursuant to the terms of the Purchase Agreement, the Company is obligated to use its
commercially reasonable efforts to keep the Resale Registration Statement effective at all times until such institutional and accredited
investor (and its successors and assigns) no longer owns any Private Warrants or ordinary shares issuable upon exercise thereof.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">If a Fundamental Transaction (as defined in the Warrants)
occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the
Company may exercise and will assume all of the Company&#8217;s obligations under the Warrants with the same effect as if such successor
entity had been named in the Warrants themselves. If holders of ordinary shares are given a choice as to the securities, cash or property
to be received in such a Fundamental Transaction, then the holders of the Warrants shall be given the same choice as to the consideration
they would receive upon any exercise of the Warrants following such a Fundamental Transaction. Additionally, as more fully described in
the Series B Warrants, Series C Warrants and Placement Agent Warrants, in the event of certain Fundamental Transactions, the holders of
the Series B Warrants, Series C Warrants and Placement Agent Warrants will be entitled to receive cash consideration in an amount equal
to the Black-Scholes value of the Series B Warrants, Series C Warrants and Placement Agent Warrants, as the case may be, upon the consummation
of such Fundamental Transaction.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">See Note 6, &#8220;Warrant Liability,&#8221; for a discussion
of the Registered Direct Offering.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Series A Warrants and Pre-Funded Warrants </i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Series A Warrants and the Pre-Funded Warrants are
classified as a component of equity because they are freestanding financial instruments that are legally detachable and separately exercisable
from the ordinary shares with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase
its shares, and permit the holders to receive a fixed number of ordinary shares upon exercise. In addition, the Series A Warrants and
the Pre-Funded Warrants do not provide any guarantee of value or return.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="color: windowtext">On the October 3, 2023
issue date, the calculated fair value of the Series A Warrants and the Pre-Funded Warrants as of March 31, 2024 was $<span id="xdx_90B_ecustom--FairValueOfWarrants_iI_pn3n6_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsAndPreFundedWarrantsMember_zsnz1VqMKrPj" title="Fair value of warrants"><ix:nonFraction name="ptgef:FairValueOfWarrants" contextRef="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember" id="Fact000985" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">2.968</ix:nonFraction></span> million ($<span id="xdx_904_ecustom--WarrantsPerShare_iI_pn3n6_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsAndPreFundedWarrantsMember_zn86iHt8DMVf" title="Warrants per share"><ix:nonFraction name="ptgef:WarrantsPerShare" contextRef="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember" id="Fact000987" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USDPShares">0.94</ix:nonFraction></span>
per such warrant). </span>Because the fair value of the warrants accounted for as liabilities exceeded the net proceeds from the Registered
Direct Offering, the proceeds allocated to the Common Shares, the Pre-Funded Warrants and the Series A warrants was zero.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Series A Warrants</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">The inputs associated
with calculating the fair value are reflected below.</span></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact000989" name="ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_z20IHUyfJbLg" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details 1)" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B4_zspI3QY90L7f" style="display: none">Schedule of fair value</span> </td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 14%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zH37deVPzwX9" title="Exercise price"><ix:nonFraction name="ptgef:ExercisePriceFairValue" contextRef="AsOf2023-10-03_custom_SeriesAWarrantsMember" id="Fact000991" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">38.00</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zmDA5IRvLmz4" title="Share price"><ix:nonFraction name="ptgef:SharePriceFairvalue" contextRef="AsOf2023-10-03_custom_SeriesAWarrantsMember" id="Fact000993" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">39.40</ix:nonFraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930_zlmOM0oEsudd" title="Expected life"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" format="ixt-sec:duryear" id="Fact000995" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">1.50</ix:nonNumeric></span> years</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zuPPX2xvmPu3" title="Expected volatility"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesAWarrantsMember" id="Fact000997" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">96.0</ix:nonFraction></span>%</td><td style="font-size: 10pt; font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zQa0R0ELaN2a" title="Risk free interest rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2023-10-012023-10-03_custom_SeriesAWarrantsMember" id="Fact000999" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.32</ix:nonFraction></span>%</td><td style="font-size: 10pt; font-weight: bold; text-align: center"/></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zflUNZxJi4Bj" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zJYipCh3Scf5" style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_234_z792DT4l3fA4" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 20 -->
    <div id="xdx_237_zhbASGZNBxX2" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_z5ZIARvQombb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_z4aOJDusHsCh" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_z1VvsCRoCcwg" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zfVAaQKljI22" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zZZagT7h1Idg" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zJn4zXOgWtK7" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zb26RpN7zJd4" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 9. CAPITAL STOCK AND RESERVES <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zXkaB4jAyb43" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Nature and Purpose of Reserves</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Stock Option Reserve</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The stock option reserve reflects the reserve of compensation
expense recognized over the vesting period based upon the grant date fair value of the Company&#8217;s equity settled grants calculated
in accordance with IFRS 2, &#8220;Share-based Payment&#8221;. See Note 10, &#8220;Stock Option Reserve,&#8221; below for a further discussion.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001011" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory"><p id="xdx_80A_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zD9QWzPtTB1" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 10. <span id="xdx_827_z5B3wAAgASVe">STOCK OPTION RESERVE</span></b></p>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Amended and Restated 2021 Equity Incentive
Plan and Grants of Stock Options and Restricted Stock Units</p>
<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following table provides the activity for the Company&#8217;s
stock option reserve for the six months ended September 30, 2024 and 2023 (in thousands):</p>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001013" name="ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_zlDP52wSZwp4" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_zXqKGpNgflDk" style="display: none">Schedule of stock options</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><b>2023</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20240930_zcynfXm3Vdud" title="Balance, beginning of period" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2024-03-31" id="Fact001015" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,841</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionReserve_iS_pn3n3_c20230401__20230930_za8ZZf6KiUrk" title="Balance, beginning of period" style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2023-03-31" id="Fact001017" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,204</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20240401__20240930_z1JrgPkKhPUa" title="Share-based compensation expense" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AdjustmentsForSharebasedPayment" contextRef="From2024-04-01to2024-09-30" id="Fact001019" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">285</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20230401__20230930_z0CTjzMn5oVb" title="Share-based compensation expense" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AdjustmentsForSharebasedPayment" contextRef="From2023-04-012023-09-30" id="Fact001021" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,512</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20240930_ztXuuyhXTpPc" title="Balance, end of period" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2024-09-30" id="Fact001023" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,126</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20230401__20230930_z0YKUYL3SMV" title="Balance, end of period" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:StockOptionReserve" contextRef="AsOf2023-09-30" id="Fact001025" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,716</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zhgDDc5pxfR" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On August 15, 2024, the Company effected
a reverse stock split of its ordinary shares at a ratio of 1-for-20. All share and per share information have been retroactively adjusted
to reflect the impact of the reverse stock split unless otherwise noted. See Note 1 &#8220;Nature of Operations&#8221; and Note 9, &#8220;Capital
Stock and Reserves&#8221; for further discussion on the reverse stock split.</p>
<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_237_zCQrKtegUSkd" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 21 -->
    <div id="xdx_23B_zyfBImh8Mozh" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_z8B19y3k6G4l" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_z7TW6iyhJyXi" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zMaC5u69YZFd" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zwY5vSePoad4" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z7O1E0ZKrJbh" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zkwJY9dIqwh4" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zqwLfdZawj6g" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 10. STOCK OPTION RESERVE <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_z0u36hCNkL0d" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As of September 30, 2024, <span id="xdx_903_ecustom--SharesReservedForAwardsGranted_iI_c20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zk9Gf5vWrHg2" title="Shares reserved for awards granted"><ix:nonFraction name="ptgef:SharesReservedForAwardsGranted" contextRef="AsOf2024-09-30_custom_PBI2021EquityIncentivePlanMember" id="Fact001035" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">82,429</ix:nonFraction></span> shares were reserved
for awards previously granted and <span id="xdx_908_ecustom--SharesAvailableForFutureAwards_iI_c20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zBqzzZ9B8jR9" title="Shares available for future awards"><ix:nonFraction name="ptgef:SharesAvailableForFutureAwards" contextRef="AsOf2024-09-30_custom_PBI2021EquityIncentivePlanMember" id="Fact001037" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,997</ix:nonFraction></span> shares were available for future awards under the Amended and Restated 2021 Equity Incentive
Plan.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The changes in the number of stock options issued and
outstanding for the six months ended September 30, 2024 and 2023 were as follows:</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001039" name="ptgef:ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock_zhlxz0fEpE59" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zASsIQifpgfg" style="display: none">Schedule of changes in the number of stock options</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zdJTBHDonrOe" title="Balance, beginning of period" style="width: 14%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2024-03-31_custom_PBI2021EquityIncentivePlanMember" id="Fact001041" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">90,281</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z7Bt2VuZdvvb" title="Balance, beginning of period" style="width: 14%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2023-03-31_custom_PBI2021EquityIncentivePlanMember" id="Fact001043" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">98,171</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Expired or forfeited</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zb6m9yGQ2Do2" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" contextRef="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember" id="Fact001045" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="Shares">25,167</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z4jvdcexEGR6" title="Expired or forfeited" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z9TE6YjSFTM5" title="Balance, end of period" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2024-09-30_custom_PBI2021EquityIncentivePlanMember" id="Fact001049" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">65,114</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjbjLpw8Dipa" title="Balance, end of period" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfOutstandingShareOption" contextRef="AsOf2023-09-30_custom_PBI2021EquityIncentivePlanMember" id="Fact001051" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">98,171</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Exercisable, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zvcXdnReWvjg" title="Exercisable, end of period" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember" id="Fact001053" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">43,723</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zo0jcoERTe0d" title="Exercisable, end of period" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" contextRef="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember" id="Fact001055" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">38,461</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z8WxKp5AbF1h" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The table above does not include fully vested
restricted stock units (&#8220;RSUs&#8221;) granted to certain executives in January 2021 and January 2022. In January 2024, the
company issued <span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zadjl6G7IP42" title="Shares issued"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">308</ix:nonFraction></span>
shares for the exercise of <span id="xdx_902_ecustom--NumberOfSharesExercise_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zF1SrRFGo6n5" title="Number of shares exercise"><ix:nonFraction name="ptgef:NumberOfSharesExercise" contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember" id="Fact001059" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">470</ix:nonFraction></span>
RSUs net of <span id="xdx_909_ecustom--SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zFu4KXD559t2" title="Shares repurchased into treasury employee payroll taxes"><ix:nonFraction name="ptgef:SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember" id="Fact001061" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">162</ix:nonFraction></span>
shares repurchased into treasury to pay for an employee&#8217;s payroll taxes. In September 2024, the company issued <span id="xdx_902_eifrs-full--NumberOfSharesIssued_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zHWgHTQ46Itf" title="Shares issued"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember" id="Fact001063" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">882</ix:nonFraction></span>
shares for the exercise of <span id="xdx_90C_ecustom--NumberOfSharesExercise_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zyCbWHWrnIJ5" title="Number of shares exercise"><ix:nonFraction name="ptgef:NumberOfSharesExercise" contextRef="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember" id="Fact001065" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,152</ix:nonFraction></span>
RSUs net of <span id="xdx_90E_ecustom--SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z4dvcK388up" title="Shares repurchased into treasury employee payroll taxes"><ix:nonFraction name="ptgef:SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" contextRef="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember" id="Fact001067" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">270</ix:nonFraction></span>
shares  repurchased into treasury  to pay for an employee&#8217;s payroll taxes. As September 30, 2024, there were <span id="xdx_907_ecustom--NumberOfSharesGranted_pip0_c20240401__20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zznLHxRGwHI8" title="Number of shares granted"><ix:nonFraction name="ptgef:NumberOfSharesGranted" contextRef="From2024-04-012024-09-30_ifrs-full_RestrictedShareUnitsMember" id="Fact001069" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">17,315</ix:nonFraction></span>
RSUs granted and outstanding of which <span id="xdx_906_ecustom--NumberOfShareOutstanding_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z3sxeMw7LBnc" title="Number of shares outstanding"><ix:nonFraction name="ptgef:NumberOfShareOutstanding" contextRef="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember" id="Fact001071" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">12,150</ix:nonFraction></span> <span id="xdx_90E_ecustom--DescriptionOfRestrictedStockUnitsExpire_c20240401__20240930_zZGlaE6iKlAh" title="Description of share expire"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact001073" name="ptgef:DescriptionOfRestrictedStockUnitsExpire">RSUs
expire in January 2031 and 5,165 expire in January 2032.</ix:nonNumeric></span></p>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following is the weighted average exercise price
and the remaining contractual life for outstanding options as of September 30,
2024 and 2023:</p>

<p style="margin: 0; font-size: 10pt; text-indent: 0.3in">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001075" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"><table cellpadding="0" cellspacing="0" id="xdx_89A_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zFxw5TIRItd7" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B4_zTv7Hv0vlj5b" style="display: none">Schedule of weighted average exercise price
and the remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br/>2021 Equity Incentive Plan</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIad7SwwqsBi" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember" id="Fact001077" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">205.18</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zGh48cZLymy7" title="Weighted average exercise price" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember" id="Fact001079" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">210.60</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life (in years)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOcegh40ODz6" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001081" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">7.39</ix:nonNumeric></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zuR9VcEmIVQj" title="Weighted average remaining contractual life (in years)"><ix:nonNumeric contextRef="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact001083" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">8.36</ix:nonNumeric></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zfQrITqf0kAf" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The vested options can be exercised at any time in accordance
with the applicable option agreement. The exercise price was greater than the market price for all options outstanding as of September
30, 2024 and March 31, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company recorded approximately $<span id="xdx_905_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20240701__20240930_znWb3L5xML2g" title="Share based compensation expense"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="From2024-07-012024-09-30" id="Fact001085" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.141</ix:nonFraction></span> million and
$<span id="xdx_900_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20230701__20230930_zZ7Z5Qx3oO59" title="Share based compensation expense"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="From2023-07-012023-09-30" id="Fact001087" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.743</ix:nonFraction></span> million of share-based compensation expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the three months
ended September 30, 2024 and 2023, respectively. The Company recorded approximately $<span id="xdx_903_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20240401__20240930_z8Gjyqsj9yj" title="Share based compensation expense"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="From2024-04-01to2024-09-30" id="Fact001089" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.285</ix:nonFraction></span> million and $<span id="xdx_90A_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20230401__20230930_zAzU6wtcKWx8" title="Share based compensation expense"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="From2023-04-012023-09-30" id="Fact001091" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.512</ix:nonFraction></span> million of share-based compensation
expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the six months ended September 30, 2024 and 2023, respectively.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_238_z1oi0IgPBPAe" style="margin: 0; font-size: 10pt; text-align: center"></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zxCQxQkoLhU5" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 22 -->
    <div id="xdx_232_zSyn9GVFP6V8" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zqSMPMLO3bcf" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zLLhEtEXdUJi" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z6UJF8xjn6mc" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zTW4omdyxu29" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zyWwJgTrBnki" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_z0R7UibVlLdc" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001100" name="ifrs-full:EarningsPerShareExplanatory"><p id="xdx_806_eifrs-full--EarningsPerShareExplanatory_zpLiKB3awY4d" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 11. <span id="xdx_829_zx33HBxwzOHa">LOSS PER SHARE</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">Basic earnings per
share (&#8220;EPS&#8221;) is calculated by dividing the net loss attributable to ordinary equity holders of the Company by the weighted
average number of ordinary shares outstanding during the period.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">&#160;</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">Diluted EPS is calculated
by dividing the net loss attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding
during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential
ordinary shares into ordinary shares. Shares issuable under Pre-Funded Warrants are considered outstanding for this purpose.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">&#160;</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">The calculation
of Basic and Diluted EPS reflects the Pre-Funded Warrants as outstanding shares.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following table reflects the loss and share data
used in the basic and diluted EPS calculations (in thousands, except per share amounts):</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001102" name="ptgef:ScheduleOfEarningsPerShareTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zXTd7XlTdbZc" summary="xdx: Disclosure - LOSS PER SHARE (Details)" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B7_zYcLtYyttqYj" style="display: none">Schedule of basic and diluted EPS calculations</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_499_20240701__20240930_zAJGlILzTB61" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20230701__20230930_z7vdwkfL0og" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20240401__20240930_z8AXReKtALwg" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49E_20230401__20230930_zgmBPTleEXE" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2023</td></tr>
  <tr id="xdx_400_ecustom--NumeratorAbstract_iB_zADINWgftxda" style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">Numerator</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to owners of the Company</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240701__20240930_zYHxLZsDXOZ8" title="Net loss attributable to owners of the Company">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2024-07-012024-09-30" id="Fact001109" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,360</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230701__20230930_zssZdyWUmkh3" title="Net loss attributable to owners of the Company">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2023-07-012023-09-30" id="Fact001111" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,158</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240401__20240930_zBqeRPFoc1Mj" title="Net loss attributable to owners of the Company">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2024-04-01to2024-09-30" id="Fact001113" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,016</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_903_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230401__20230930_z7NAZGiabPOe" title="Net loss attributable to owners of the Company">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOwnersOfParent" contextRef="From2023-04-012023-09-30" id="Fact001115" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">11,077</ix:nonFraction></span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--DenominatorAbstract_iB_z3zN9tjnO8Gd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">Denominator</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average number of shares &#8211; Basic and Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--WeightedAverageShares_pn3n3_c20240701__20240930_zu8R0HbBwaE5" title="Weighted average number of shares - Basic"><span id="xdx_90C_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240701__20240930_zt0TQCMPITMj" title="Weighted average number of shares - Diluted"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2024-07-012024-09-30" id="Fact001122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2024-07-012024-09-30" id="Fact001124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,076</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eifrs-full--WeightedAverageShares_pn3n3_c20230701__20230930_zwRLbr6xxxy5" title="Weighted average number of shares - Basic"><span id="xdx_90B_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230701__20230930_zqmy5lItQT59" title="Weighted average number of shares - Diluted"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2023-07-012023-09-30" id="Fact001126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2023-07-012023-09-30" id="Fact001128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">890</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zwhs1VqvnI4h" title="Weighted average number of shares - Basic"><span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zEvvP0JpaQwk" title="Weighted average number of shares - Basic"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2024-04-01to2024-09-30" id="Fact001130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2024-04-01to2024-09-30" id="Fact001132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,063</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_908_eifrs-full--WeightedAverageShares_pn3n3_c20230401__20230930_zFwbdmWEq71k" title="Weighted average number of shares - Basic"><span id="xdx_902_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20230930_zNj4OJX6lFad" title="Weighted average number of shares - Diluted"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2023-04-012023-09-30" id="Fact001134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="ifrs-full:AdjustedWeightedAverageShares" contextRef="From2023-04-012023-09-30" id="Fact001136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">888</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--BasicEarningsLossPerShare_pip0_c20240701__20240930_zzFRLyefpNY" title="Basic loss per share"><span id="xdx_903_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240701__20240930_zwYCQ8ByZGH5" title="Diluted loss per share">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2024-07-012024-09-30" id="Fact001138" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2024-07-012024-09-30" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">1.26</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_906_eifrs-full--BasicEarningsLossPerShare_pip0_c20230701__20230930_zhj9JnRkGi35" title="Basic loss per share"><span id="xdx_90E_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230701__20230930_zQvzHStWWph2" title="Diluted loss per share">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2023-07-012023-09-30" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2023-07-012023-09-30" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">5.80</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--BasicEarningsLossPerShare_pip0_c20240401__20240930_zFRXdXFQAi2e" title="Basic loss per share"><span id="xdx_901_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240401__20240930_zJxTh14EJkTk" title="Diluted loss per share">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2024-04-01to2024-09-30" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2024-04-01to2024-09-30" id="Fact001148" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">2.84</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eifrs-full--BasicEarningsLossPerShare_pip0_c20230401__20230930_z3P9w4RcoqO9" title="Basic loss per share"><span id="xdx_900_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230401__20230930_zsggS3zYyMub" title="Diluted loss per share">(<ix:nonFraction name="ifrs-full:BasicEarningsLossPerShare" contextRef="From2023-04-012023-09-30" id="Fact001150" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="ifrs-full:DilutedEarningsLossPerShare" contextRef="From2023-04-012023-09-30" id="Fact001152" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">12.47</ix:nonFraction></ix:nonFraction></span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zqob4TeieqF7" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Number of ordinary shares are retroactively adjusted
to reflect the impact of the 1-for-20 reverse stock split on August 15, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The inclusion of the Company&#8217;s share purchase warrants
(other than Pre-Funded Warrants, as described above), stock options and RSUs in the computation of diluted loss per share would have an
anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between basic
loss per share and diluted loss per share for the three and six months ended September 30, 2024 and 2023. The following table reflects
the Company&#8217;s outstanding securities by year that would have an anti-dilutive effect on loss per share and, accordingly, were excluded
from the calculation.</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001154" name="ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_ztTT3dH923Ie" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BF_zKm91mX0YDh4" style="display: none">Schedule of anti-dilutive effect on loss per share</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zs2EOIpMcTnk" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2024-09-30_ifrs-full_WarrantsMember" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">481,581</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zV7L6EwwhOMi" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1158">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Stock options</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_z2g5zf249sl7" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2024-09-30_custom_StockOptionsMember" id="Fact001160" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">65,114</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zmmhajLnAo8b" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2023-09-30_custom_StockOptionsMember" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">98,171</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zIpnXQz6Gysi" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2024-09-30_custom_RestrictedStockUnitsMember" id="Fact001164" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">17,315</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zk0cmB2yQvf1" title="Anti-dilutive effect on loss per share" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AntidilutiveEffectOnLossPerShare" contextRef="AsOf2023-09-30_custom_RestrictedStockUnitsMember" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">18,937</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_znGgcpzkWanb" style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23F_zYAiqjnZkyS" style="margin: 0; font-size: 10pt; text-align: center"></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zUdQVZIXD9p" style="margin: 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 23 -->
    <div id="xdx_233_zMsEwUAEGtgi" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zAej8s09huo1" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zfYyTcbjbJ7f" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zYHy53IXNh8a" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zbZCh47garS4" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zDS0QW7Wg113" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_zZ5X98lTP8ef" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001175" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"><p id="xdx_801_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zaSVebmzPC8b" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 12. <span id="xdx_82E_zEWuSuG9kS4l">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>iOx &#8211; Parexel Master Services Agreement</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Effective March 15, 2022, iOx entered into a Master Services
Agreement (the &#8220;MSA&#8221;) with Parexel under which Parexel agreed to act as
a&#160;clinical service provider (&#8220;CRO&#8221;) pursuant to a work order (&#8220;Work Order&#8221;) effective June 1, 2022. Under such Work Order,
Parexel planned to operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer. The MSA provided
for a five-year term, and the Work Order provided for a term to end upon the completion of the services required. The budget provided
for service fees and pass-through expenses and clinical sites totaling $11.5 million. During the year ended March 31, 2023 (&#8220;Fiscal
2023&#8221;), the Company executed two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs. As
a result of the Company&#8217;s decision to discontinue the development with respect to this program, on December 20, 2023, the Company
provided Parexel notice of termination of the contract, with a planned termination date of April 18, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As the ongoing CRO services were wound down, the Company
noticed that expenses incurred under the CRO agreement were higher than originally budgeted. Parexel agreed to refund the Company $<span id="xdx_906_ecustom--RetainageDeposits_iI_pn3n6_c20240930_zdfCaXvFoLOi" title="Release liability amount"><ix:nonFraction name="ptgef:RetainageDeposits" contextRef="AsOf2024-09-30" id="Fact001177" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.552</ix:nonFraction></span>
million and release the liability for amounts invoiced and unbilled services totaling $<span id="xdx_90D_ecustom--UnbilledContractsReceivables_iI_pn3n6_c20240930_zwKJ8lUkOHbg" title="Unbilled services"><ix:nonFraction name="ptgef:UnbilledContractsReceivables" contextRef="AsOf2024-09-30" id="Fact001179" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.486</ix:nonFraction></span> million, and the Company forfeited advanced
payments of $<span id="xdx_90C_ecustom--ForfeitedAdvancedPayments_iI_pn3n6_c20240930_zHjWAsx1jD47" title="Forfeited advanced payments"><ix:nonFraction name="ptgef:ForfeitedAdvancedPayments" contextRef="AsOf2024-09-30" id="Fact001181" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.091</ix:nonFraction></span> million. As a result, the Company recognized a net gain of $<span id="xdx_900_ecustom--GainOnLiability_iI_pn3n6_c20240930_zsb7jbSfKln4" title="Gain on liability"><ix:nonFraction name="ptgef:GainOnLiability" contextRef="AsOf2024-09-30" id="Fact001183" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.946</ix:nonFraction></span> million as of September 30, 2024. As of March 31,
2024, the Company reflected $<span id="xdx_906_ecustom--PayablesToParexelInAccountsPayableAndAccruedLiabilities_iI_pn3n6_c20240331_zZ3q2LZu92s1" title="Payables to parexel in accounts payable and accrued liabilities"><ix:nonFraction name="ptgef:PayablesToParexelInAccountsPayableAndAccruedLiabilities" contextRef="AsOf2024-03-31" id="Fact001185" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.414</ix:nonFraction></span> million of payables to Parexel in accounts payable and accrued liabilities and $<span id="xdx_90A_eifrs-full--CurrentTradeReceivables_iI_pn3n6_c20240331_zCUA7G1aDRAj" title="Prepaid expenses and other receivables"><ix:nonFraction name="ifrs-full:CurrentTradeReceivables" contextRef="AsOf2024-03-31" id="Fact001187" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.277</ix:nonFraction></span> million in prepaid
expenses and other receivables in the consolidated <span style="background-color: white">statement of financial position. </span>The Company
received the refund from Parexel on October 3, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Tarus &#8211; Fortrea Clinical Service Agreement</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On March 1, 2023, Tarus entered into a clinical service
agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier
of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services
to be provided is approximately $<span id="xdx_904_ecustom--BudgetedCosts_pn5n6_c20230228__20230302_z3PBzWsaxNEg" title="Budgeted costs"><ix:nonFraction name="ptgef:BudgetedCosts" contextRef="From2023-02-282023-03-02" id="Fact001189" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">12.1</ix:nonFraction></span> million. Because of the Company&#8217;s decision to discontinue and pause further accrual of all
clinical studies, the Company is negotiating a revision to the services required under the change in circumstances.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23F_zH79wjYO1Iv4" style="margin: 0; font-size: 10pt; text-align: center"></p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b></b></p>

<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_23B_zwlfS6RBmEoc" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23D_znoY8cdPqnw8" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zK4sffhTQKgk" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zRAiwMIyiI6b" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_z5lavqnHCJd4" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_238_zCm05meoT6Y8" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zMYpar9BW2Y9" style="margin: 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001197" name="ifrs-full:DisclosureOfRelatedPartyExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfRelatedPartyExplanatory_z2MlVwRVOZid" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 13. <span id="xdx_827_z6qCF7b6FdH3">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>SalvaRx Acquisition</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Two of the Company&#8217;s directors are also directors
of SalvaRx Group plc, a company which owns approximately 4.1% of the Company&#8217;s issued and outstanding ordinary shares as of September
30, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Investments</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company has entered into related party transactions
and certain services agreements with its investees.&#160;Key management personnel of the Company have also entered into related party
transactions with investees. Key management personnel are those people who have the authority and responsibility for planning, directing
and controlling the activities of the Company, including directors and senior management of the Company.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following subsidiaries and associates are considered
related parties:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(a)</td><td style="text-align: justify"><b>Stimunity</b>. The Chief Executive Officer (&#8220;CEO&#8221;) of Portage is one of three members of
the board of directors of Stimunity. The Company wrote-off its investment in Stimunity to nil in the Fiscal 2024 period.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(b)</td><td style="text-align: justify"><b>iOx</b>. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Portage director resigned
from the iOx board leaving two Portage insiders as directors. The CEO of Portage is also the CEO of iOx, and the management team of Portage
comprises the management team of iOx.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(c)</td><td style="text-align: justify"><b>Saugatuck</b>. The Chairman and CEO of the Company is the sole director of Saugatuck. Saugatuck is
70% owned by the Company and is controlled by Portage.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(d)</td><td style="text-align: justify"><b>Intensity</b>. The CEO of Portage previously served as a part-time officer of Intensity until becoming
a consultant in 2023. Additionally, Intensity provided services (primarily rent) to Portage through April 2023. For the six months ended
September 30, 2023, the Company paid $<span id="xdx_90C_ecustom--PortagePaidIntensity_pn4n6_c20230401__20230930_zsnMSyIT9kWa" title="Portage paid intensity"><ix:nonFraction name="ptgef:PortagePaidIntensity" contextRef="From2023-04-012023-09-30" id="Fact001199" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">0.01</ix:nonFraction></span> million. No such services were provided subsequent to April 2023.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt">(e)</td><td style="text-align: justify"><b>Portage Development Services Inc</b>. PDS provides human resources and other services to each operating
subsidiary of Portage through shared services agreements.</td></tr></table>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Transactions between the parent company and its subsidiaries,
which are related parties, have been eliminated in consolidation and are not disclosed in this note.</p>

<p style="margin: 0pt 0 0pt 8.25pt; font-size: 10pt; font-style: italic; font-weight: bold">&#160;</p>

<p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Board Resignations and Appointments</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On April 25, 2024, Mark Simon resigned
all of his positions on the Board of Directors, and on April 26, 2024, Linda Kozick and Dr. Robert Glassman resigned all of their positions
on the Board of Directors. On April 30, 2024, Dr. Jean -Christophe Renondin and Dr. Justin Stebbing were elected to the Board.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23A_zAiJRmlAeBAe" style="margin: 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 25 -->
    <div id="xdx_233_zSYhZNEOpbb3" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zBtpvzWGXfkc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>


<ix:exclude><p id="xdx_234_zrv4TDCuf2w7" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zWC549r1sjk" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_z6PV4bxk2f9a" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zHB7tHCw0lob" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_z4U7hMRzyPRd" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_z6wr2IKzhech" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 13. RELATED PARTY TRANSACTIONS <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zG0ueVI0ZnYh" style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p></ix:exclude>



<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Bonuses &amp; Board Compensation
Arrangements</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">In December 2022,
the Board approved executive performance bonuses, as recommended by the Compensation Committee, totaling $<span id="xdx_902_ecustom--CompensationCommittee_pn5n6_c20221225__20221231_zLQstJ33N2Q6" title="Compensation committee"><ix:nonFraction name="ptgef:CompensationCommittee" contextRef="From2022-12-252022-12-31" id="Fact001209" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.6</ix:nonFraction></span> million, which is equivalent
to <span id="xdx_906_ecustom--OriginalAnnualTargetsPercentage_pip0_dp_c20221225__20221231_zMkIZECjpry1" title="Original annual targets percentage"><ix:nonFraction name="ptgef:OriginalAnnualTargetsPercentage" contextRef="From2022-12-252022-12-31" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">73.5</ix:nonFraction></span>% of original annual targets established by the Board in December 2021. The bonuses were approved based upon the original performance
targets established. The Board further approved a payment structure of 25% of approved bonuses, which were paid in January 2023, with
the balance of amounts due payable upon a new financing. The accrued, unpaid amount of approximately $<span id="xdx_90D_ecustom--AccountsPayableAndAccruedExpenses_iI_pn5n6_c20240930_zBBCadOexkY1" title="Accounts payable and accrued expenses"><span id="xdx_903_ecustom--AccountsPayableAndAccruedExpenses_iI_pn5n6_c20240331_zyV0TT2vtQz3" title="Accounts payable and accrued expenses"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedExpenses" contextRef="AsOf2024-09-30" id="Fact001213" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedExpenses" contextRef="AsOf2024-03-31" id="Fact001215" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></ix:nonFraction></span></span> million is included in accounts
payable and accrued liabilities in the condensed consolidated interim statements of financial position as of each of September 30, 2024
and March 31, 2024. </span>No executive performance bonus has been approved by the Compensation Committee or the Board for Fiscal Year
2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Effective January 1, 2022, each non-employee Board
member is entitled to receive cash Board fees of $40,000 per annum, payable quarterly in arrears. Additionally, each non-employee
Board member is entitled to an annual grant of 345 options to purchase Portage ordinary shares, which would vest the first annual
anniversary of the grant date. The Company incurred Board fees totaling nil <span id="xdx_909_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20240701__20240930_zYQHGHEiv2Xh" title="Incurred Board fees total" style="display: none"><ix:nonFraction name="ifrs-full:OtherFeeAndCommissionExpense" contextRef="From2024-07-012024-09-30" id="Fact001217" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90D_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20230701__20230930_z6mORYUKJgmk" title="Incurred Board fees total"><ix:nonFraction name="ifrs-full:OtherFeeAndCommissionExpense" contextRef="From2023-07-012023-09-30" id="Fact001219" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">82,500</ix:nonFraction></span> during the three months ended September
30, 2024 and 2023, respectively, and $<span id="xdx_909_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20240401__20240930_zg6GQV4VlG06" title="Incurred Board fees total"><ix:nonFraction name="ifrs-full:OtherFeeAndCommissionExpense" contextRef="From2024-04-01to2024-09-30" id="Fact001221" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,205</ix:nonFraction></span> and $<span id="xdx_90D_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20230401__20230930_zswv0CoB7D6f" title="Incurred Board fees total"><ix:nonFraction name="ifrs-full:OtherFeeAndCommissionExpense" contextRef="From2023-04-012023-09-30" id="Fact001223" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,000</ix:nonFraction></span> during the six months ended September 30, 2024 and 2023, respectively.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Non-employee Board chairpersons are entitled to an annual
cash fee of $30,000, payable quarterly in arrears. In lieu of a non-executive chairperson, the lead director is entitled to an annual
cash fee of $20,000 per annum paid quarterly in arrears. <span id="xdx_900_ecustom--AnnualFeesdescription_c20240401__20240930_zjbJT72xnatl" title="Annual fees description"><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" id="Fact001225" name="ptgef:AnnualFeesdescription">Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nominating Committee of the Board is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears.
Members of those committees are entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears. All
non-executive board members waived their right to board fees for the six months ended September 30, 2024, except for the non-executive
board members who resigned in late April 2024.</ix:nonNumeric></span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Retention Agreements and General Releases</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On July 22, 2024, the Company and Portage
Development Services, Inc. entered into a Retention Agreement and General Release (&#8220;Retention Agreement&#8221;) with each of Allan
Shaw (&#8220;Employee&#8221;) and Joseph Ciavarella (&#8220;Consultant&#8221;). Under the terms of each of the Retention Agreements, Employee&#8217;s
current employment agreement and Consultant&#8217;s current consulting agreement both terminated on July 22, 2024, except with respect
to certain provisions. In return for continuing to provide services to the Company and its affiliates and completing certain Applicable
Retention Events, as defined in the respective Retention Agreements, the Company paid an aggregate $0.2 million (the &#8220;Retention
Amount&#8221;) to Employee and Consultant, in addition to their monthly pay through September 30, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company accrued the Retention
Amount, as well as the monthly pay totaling $0.2 million through September 30, 2024, in the condensed consolidated interim financial statements
for the three months ended June 30, 2024, as the material terms of the Retention Agreements were known and agreed upon at June 30, 2024.
In accordance with the terms of the Retention Agreements, the Company paid in full the Retention Amount and issued 14,348 ordinary shares
to the Employee and Consultant in lieu of cash bonuses accrued in Fiscal 2023 totaling $0.1 million by September 30, 2024, the date on
which the Employee&#8217;s employment and the Consultant&#8217;s consulting relationship with the Company and its affiliates ended.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_23D_zaiZ8Ht9H3yg" style="margin: 0; font-size: 10pt; text-align: center"></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zxkj9RTefG4g" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 26 -->
    <div id="xdx_234_zLnJIDmsAUT9" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zATaLCUSh97e" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zydOUDx63Dti" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_z59PuUDtjbIa" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_236_zljr1jiH8F94" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zqWW2lbtyFd4" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z2MsA8I7PFD8" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001234" name="ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory"><p id="xdx_808_ecustom--DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_zMrid2zf3ou9" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 14. <span id="xdx_821_zH24xjfeYjT1">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s financial instruments recognized
in the Company&#8217;s condensed consolidated interim statements of financial position consist of the following:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Fair value estimates are made at a specific point in
time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties
and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could
significantly affect these estimates.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following table summarizes the Company&#8217;s financial
instruments as of September 30, 2024 and March 31, 2024 (in thousands):</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001236" name="ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_zipsfya99PV7" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span><span id="xdx_8B9_zasVIPpgU6Pb" style="display: none">Schedule of financial instruments</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zUu1WWqUfH05" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49F_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zGD22lNC0Jyj" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_492_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z6u5FHh8ORl5" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zd0m5ib0Z01l" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49A_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z7D1v6pnwLp2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zk8qvAhQiIs5" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--CashAndCashEquivalents_i01I_zGv0ysjUwoB4" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-09-30_custom_AmortizedCostMember" id="Fact001245" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,764</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2024-03-31_custom_AmortizedCostMember" id="Fact001248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,028</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1249">&#8211;</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">&#8211;</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PrepaidExpensesAndOtherReceivable_i01I_zpddYPigyQo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2024-09-30_custom_AmortizedCostMember" id="Fact001252" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">922</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1253">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:PrepaidExpensesAndOtherReceivable" contextRef="AsOf2024-03-31_custom_AmortizedCostMember" id="Fact001255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,667</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_498_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zLF7FLIsvTo6" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_491_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z4xznnO58W4k" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zbNO4yhYYBr3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zgZQzdvHCrMb" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AccountsPayableAndAccruedLiabilities_i01I_zgWgFVr1Z5Qg" style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2024-09-30_custom_AmortizedCostMember" id="Fact001264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">845</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><ix:nonFraction name="ptgef:AccountsPayableAndAccruedLiabilities" contextRef="AsOf2024-03-31_custom_AmortizedCostMember" id="Fact001266" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,836</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1267">&#8211;</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--WarrantLiability_i01I_za1ckSSwfoH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1269">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember" id="Fact001270" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,138</ix:nonFraction></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WarrantLiability" contextRef="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember" id="Fact001272" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,564</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>






</ix:nonNumeric><p id="xdx_8AE_zQcuP6MGdeIb" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0; font-size: 10pt">&#160;</p>

<ix:exclude><p id="xdx_234_zOemoUlEkTeb" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 27 -->
    <div id="xdx_239_zeWVT8spmEae" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zMjuCHpceOkb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zLIAEAznGZ24" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zDBc3zihDIQf" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zdd9KiQQwDXk" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_231_z1cbccieb5c1" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zxOtoIHhmdK4" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zuvBQKKYKfii" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 14. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont&#8217;d)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zQXU6orve3V5" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">A summary of the Company&#8217;s risk exposures as it
relates to financial instruments are reflected below.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>
<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Fair value of Financial Instruments</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s financial assets and liabilities
are comprised of cash and cash equivalents, receivables and investments in equities and public entities, accounts payable and accrued
liabilities, lease liability, and warrant liability.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company classifies the fair value of these transactions
according to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Level 1 &#8211; Values are based on unadjusted quoted prices available in active markets for identical
assets or liabilities as of the reporting date.</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Level 2 &#8211; Values are based on inputs, including quoted forward prices for commodities, time value
and volatility factors, which can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly
or indirectly observable as of the reporting date.</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Level 3 &#8211; Values are based on prices or valuation techniques that are not based on observable market
data. Investments are classified as Level 3 financial instrument.</td></tr></table>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Assessment of the significance of a particular input
to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Management has assessed that the fair values of cash
and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities
of these instruments.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following methods and assumptions were used to estimate
their fair values:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>Warrant Liability</b>: The fair value is estimated
using a Black-Scholes model and in certain cases, a Monte Carlo simulation (Level 3) (see Note 6, &#8220;Warrant Liability&#8221;).</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<ix:exclude><p id="xdx_23B_zFjWS0QeQta7" style="margin: 0; font-size: 10pt"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 28 -->
    <div id="xdx_234_zGI35fzC0sB9" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zas6rPVt7xe3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zyRL8CB9Emda" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_z6zuvabFgghd" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zD1wYKQCrSgf" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zC0ddHILh7y5" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_znyZc57eLYP2" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_z0dR8dSXnIpc" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 14. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont'd)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zv4EBmDgHkh8" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>


<p style="margin: 0pt; font-size: 10pt; text-align: justify"><b>Credit Risk, Liquidity Risk and Foreign Currency Risk</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Our financial instruments are exposed to certain financial risks: Credit Risk, Liquidity
Risk and Foreign Currency Risk.</p>
<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Credit Risk</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Credit risk is the risk of loss associated with a counterparty&#8217;s
inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#8217;s condensed consolidated interim statements of financial position.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>Cash and cash equivalents: </b>Cash and cash equivalents
comprise cash on hand and amounts invested in underlying treasury and money market funds that are readily convertible to a known amount
of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. <span style="background-color: white">As
of September 30, 2024 and March 31, 2024, cash equivalents was comprised of a money market account with maturities less than 90 days from
the date of purchase. </span>Cash and cash equivalents are held with major international financial institutions and therefore the risk
of loss is minimal.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Liquidity Risk</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Liquidity risk is the risk that the Company will encounter
difficulty in satisfying financial obligations as they become due.</p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<ix:exclude><p id="xdx_234_za6HqjZfgMB" style="margin: 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 29 -->
    <div id="xdx_23C_zMmIvQE301J7" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zpU2wphomk4d" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zZyzKAvNCbA6" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zk9Y5sGUB889" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zisoz74aZU6l" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zX7PNdwbcVrd" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zriVjEcNGk7h" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zawThNd2bfx" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 14. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT <i>(Cont'd)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zKAkRgVEY7gb" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p></ix:exclude>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s approach to managing liquidity is
to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed
conditions without incurring unacceptable losses or risking harm to the Company&#8217;s reputation. The Company holds sufficient cash
and cash equivalents to satisfy current obligations under accounts payable and accruals.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company monitors its liquidity position regularly
to assess whether it has the funds necessary to meet its operating needs and needs for investing in new projects.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As a biotech company at an early stage of development
and without significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional
financing may not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty
in global capital markets could have an impact on the Company&#8217;s future ability to access capital on terms that are acceptable to
the Company. There can be no assurance that required financing will be available to the Company. See Note 9, &#8220;Capital Stock and
Reserves,&#8221; for a discussion of the Company&#8217;s share offering.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Foreign Currency Risk</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">While the Company operates in various jurisdictions,
substantially all of the Company&#8217;s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K.
settleable in British pound sterling.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001298" name="ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock"><p id="xdx_80A_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zoSDgN6DUI5i" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 15. <span id="xdx_82A_zNYXymQWUoTl">CAPITAL MANAGEMENT</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company considers the items included in shareholders&#8217;
equity as capital. The Company had accounts payable and accrued liabilities of approximately $<span id="xdx_902_ecustom--PayablesAndAccruedExpense_iI_pn5n6_c20240930_zn2oiL8OuuH2" title="Accounts payables and accrued liabilities"><ix:nonFraction name="ptgef:PayablesAndAccruedExpense" contextRef="AsOf2024-09-30" id="Fact001300" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.8</ix:nonFraction></span> million and lease liability - current
of $<span id="xdx_909_eifrs-full--CurrentLeaseLiabilities_iI_pn3n6_c20240930_zg1qvRXs3s66" title="Lease liability - current"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2024-09-30" id="Fact001302" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.028</ix:nonFraction></span> million as of September 30, 2024 (accounts payable and accrued liabilities of approximately $<span id="xdx_908_ecustom--PayablesAndAccruedExpense_iI_pn5n6_c20240331_zGUvAivGNgra" title="Accounts payables and accrued liabilities"><ix:nonFraction name="ptgef:PayablesAndAccruedExpense" contextRef="AsOf2024-03-31" id="Fact001304" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million as of March 31, 2024
and lease liability - current of $<span id="xdx_90E_eifrs-full--CurrentLeaseLiabilities_iI_pn3n6_c20240331_zZVLZwTzbbXa" title="Lease liability - current"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2024-03-31" id="Fact001306" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">0.040</ix:nonFraction></span> million as of March 31, 2024) and current assets of approximately $<span id="xdx_905_ecustom--CurrentAsset_iI_pn5n6_c20240930_zYs3sRCBSb91" title="Current assets"><ix:nonFraction name="ptgef:CurrentAsset" contextRef="AsOf2024-09-30" id="Fact001308" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.7</ix:nonFraction></span> million as of September
30, 2024 (approximately $<span id="xdx_902_ecustom--CurrentAsset_iI_pn5n6_c20240331_zU02m2gRLXIf" title="Current assets"><ix:nonFraction name="ptgef:CurrentAsset" contextRef="AsOf2024-03-31" id="Fact001310" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">7.7</ix:nonFraction></span> million as of March 31, 2024). The Company&#8217;s objectives when managing capital are to safeguard the
Company&#8217;s ability to continue as a going concern in order to pursue new business opportunities and to maintain a flexible capital
structure, which optimizes the costs of capital at an acceptable risk.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company manages the capital structure and makes adjustments
to it in light of changes in economic conditions and the risk characteristics of the underlying assets.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Nasdaq Listing Rule 5550(b)(1) requires companies listed
on the Nasdaq Capital Market to maintain shareholders&#8217; equity of at least $<span id="xdx_907_ecustom--ShareholdersEquity_iI_pn5n6_c20240930_zr1rzwizPlu3" title="Shareholders' equity"><ix:nonFraction name="ptgef:ShareholdersEquity" contextRef="AsOf2024-09-30" id="Fact001312" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million for continued listing. As of September 30,
2024, shareholders&#8217; equity attributable to the owners of the Company was approximately $<span id="xdx_90F_ecustom--ShareholdersEquityAttributableToOwners_iI_pn5n6_c20240930_zQzidMNFTqq" title="Shareholders' equity attributable to owners"><ix:nonFraction name="ptgef:ShareholdersEquityAttributableToOwners" contextRef="AsOf2024-09-30" id="Fact001314" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million (approximately $<span id="xdx_904_ecustom--ShareholdersEquityAttributableToOwners_iI_pn6n6_c20240331_zEJj6L0HfXX5" title="Shareholders' equity attributable to owners"><ix:nonFraction name="ptgef:ShareholdersEquityAttributableToOwners" contextRef="AsOf2024-03-31" id="Fact001316" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">4</ix:nonFraction></span>.0 million
as of March 31, 2024). As a result, the Company is not currently in compliance with Nasdaq Listing Rule 5550(b)(1). Accordingly, the Company
expects Nasdaq to notify it of such non-compliance. The Company does not anticipate that the notification will have an immediate effect
on the listing of the Company&#8217;s ordinary shares on the Nasdaq Capital Market. In accordance with the Nasdaq Listing Rules, the Company
expects to have 45 calendar days from the date of the notification to submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1).
If the Company&#8217;s compliance plan is accepted, it may be granted up to 180 calendar days from the date of the initial notification
to evidence compliance. If the compliance plan is not accepted or the Company is otherwise unable to provide evidence of compliance within
Nasdaq&#8217;s allotted timeframe, Nasdaq may take steps to delist the Company&#8217;s ordinary shares. There can be no assurance that
the Company will be able to increase its shareholders&#8217; equity in the future.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company is not subject to any externally imposed
capital requirements and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the
Company&#8217;s approach to capital management during the six months ended September 30, 2024 and 2023.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_zTl3DM5NLE56" style="margin: 0; font-size: 10pt"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 30 -->
    <div id="xdx_230_zdM8dnOQPXBb" style="border-bottom: Black 4pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_z6DkugjkPOLh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zgLyICYQScI" style="margin: 0; font-size: 10pt"><b>PORTAGE BIOTECH INC.</b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zCj9leFDDTg2" style="margin: 0; font-size: 10pt; text-align: justify"><b>Notes to Condensed Consolidated Interim Financial Statements</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_zmHnR6t4SFDf" style="margin: 0; font-size: 10pt; text-align: justify"><b>(U.S. Dollars)</b></p></ix:exclude>

<ix:exclude><p id="xdx_232_z5Tr5uH737Yi" style="border-bottom: black 1.5pt solid; margin: 0; font-size: 10pt"><b>(Unaudited &#8211; See Notice to Reader dated November 26,
2024)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zcWGAGoj0mbk" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001324" name="ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory"><p id="xdx_80D_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zagSiQPRFyH3" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 16. <span id="xdx_823_zxQw7jhdOjS5">NON-CONTROLLING INTEREST</span></b></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">The details of non-controlling interest for the six months ended September
30, 2024 and 2023 are as follows (in thousands):</p>

<ix:nonNumeric contextRef="From2024-04-01to2024-09-30" escape="true" id="Fact001326" name="ptgef:ScheduleOfNoncontrollingInterestTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_zYOORpqQXiKk" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span><b><span id="xdx_8B0_zJGkj4De6xA2" style="display: none">Schedule of non-controlling interest</span></b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Saugatuck <br/>and subsidiary</b></span></td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2024</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4udUogfx4D6" title="Non-controlling interest, at beginning" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2024-03-31_custom_SaugatuckMember" id="Fact001328" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">693</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zes1DKm0cNcg" title="Net loss attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2024-04-012024-09-30_custom_SaugatuckMember" id="Fact001330" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">10</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of September 30, 2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zJJ9t8JEgnWf" title="Non-controlling interest, at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2024-09-30_custom_SaugatuckMember" id="Fact001332" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">703</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Saugatuck <br/>and subsidiary</b></span></td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font-size: 10pt">Non-controlling interest as of April 1, 2023</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zRW5e9EgMf2i" title="Non-controlling interest, at beginning" style="width: 10%; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2023-03-31_custom_SaugatuckMember" id="Fact001334" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">650</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z26eLOAlmNya" title="Net loss attributable to non-controlling interest" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ptgef:NetLossAttributableToNoncontrollingInterest" contextRef="From2023-04-012023-09-30_custom_SaugatuckMember" id="Fact001336" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Non-controlling interest as of September 30, 2023</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zm290RE9uf95" title="Non-controlling interest, at ending" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NoncontrollingInterests" contextRef="AsOf2023-09-30_custom_SaugatuckMember" id="Fact001338" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">664</ix:nonFraction></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z4SLhKrYuxxb" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Saugatuck and subsidiary includes Saugatuck and its wholly-owned
subsidiary, Saugatuck Rx LLC.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>



</ix:nonNumeric><p id="xdx_81C_zWPiJcvnGeul" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="border-bottom: Black 4pt solid; text-align: center; margin-top: 0; margin-bottom: 0; font-size: 10pt">F-29</p>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exh_992.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">Exhibit <FONT STYLE="letter-spacing: -0.2pt">99.2</FONT></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0"><B>&#160;</B></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0"><B>&#160;</B></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0"><B>&#160;</B></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 9.45pt 0 0"><B>&#160;</B></P>

<P STYLE="font: bold 16pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 3.1pt; text-align: center">PORTAGE BIOTECH <FONT STYLE="letter-spacing: -0.2pt">INC.</FONT></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 0.1pt 0 0"><B>&#160;</B></P>

<P STYLE="font: bold 9pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 3.1pt; text-align: center">THREE <FONT STYLE="letter-spacing: -0.25pt">AND
SIX </FONT>MONTHS ENDED SEPTEMBER 30, <FONT STYLE="letter-spacing: -0.2pt">2024</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>&#160;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>&#160;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>&#160;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"><B>&#160;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 9.65pt 0 0"><B>&#160;</B></P>

<P STYLE="font: bold 16pt Times New Roman, Times, Serif; margin: 0 0.7pt 0 3.1pt; text-align: center">MANAGEMENT&#8217;S DISCUSSION AND
<FONT STYLE="letter-spacing: -0.1pt">ANALYSIS</FONT></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 18.05pt 0.7pt 0 3.1pt; text-align: center">Prepared as of November 26, <FONT STYLE="letter-spacing: -0.2pt">2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 11.35pt 0 0"><BR STYLE="clear: both"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&#160;</FONT></P>

<P STYLE="text-align: center; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt; color: Black"><B>TABLE
OF <FONT STYLE="letter-spacing: -0.1pt">CONTENTS</FONT></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 9.3pt"><FONT STYLE="font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.7pt"><FONT STYLE="font-size: 10pt"><B>Page
    No.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 9.3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.3pt; width: 93%"><FONT STYLE="font-size: 10pt"><A HREF="#FLS">Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.7pt; width: 7%"><FONT STYLE="font-size: 10pt; letter-spacing: -0.5pt"><A HREF="#FLS">3</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.3pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.7pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#Natureofoperations">Nature of Operations and Overview</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.5pt"><A HREF="#Natureofoperations">3</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt"><A HREF="#summary">Summary of Results</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.5pt"><A HREF="#summary">6</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#numberordinaryshares">Number of Ordinary Shares</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.5pt"><A HREF="#numberordinaryshares">7</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#businessenvironment">Business Environment &#8211; Risk Factors</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.5pt"><A HREF="#businessenvironment">7</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#ourprogramsandtech">Our Programs and Technology &#8211; Recent
    Developments</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.5pt"><A HREF="#ourprogramsandtech">8</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#resultsoperations">Results of Operations</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#resultsoperations">12</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#liquidity">Liquidity and Capital Resources</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#liquidity">16</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.1pt"><A HREF="#keycontractualobligations">Key Contractual
    Obligations</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#keycontractualobligations">18</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#offbalancesheetarrangements">Off-balance Sheet Arrangements</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#offbalancesheetarrangements">19</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#transactions">Transactions with Related Parties</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#transactions">19</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#financialandderivative">Financial and Derivative Instruments</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#financialandderivative">19</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#useofestimates">Use of Estimates and Judgments</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#useofestimates">22</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#newaccountingstandards">New Accounting Standards, Interpretations
    and Amendments</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#newaccountingstandards">22</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt"><A HREF="#internalcontrol">Internal Control over Financial Reporting</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#internalcontrol">22</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.8pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 9.05pt"><FONT STYLE="font-size: 10pt"><A HREF="#publicsecurities">Public Securities Filings</A></FONT></TD>
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; text-align: center; line-height: 9.05pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.25pt"><A HREF="#publicsecurities">22</A></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.05pt 0 0 3.1pt; text-align: center"><BR STYLE="clear: both"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.7pt 0.1in 0 8.35pt; text-align: justify">Management Discussion and
<FONT STYLE="letter-spacing: -0.1pt">Analysis</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The following
discussion and analysis by management of the financial condition and financial results for Portage Biotech Inc. for the three and six
months ended September 30, 2024, should be read in conjunction with the unaudited condensed consolidated interim financial statements
for the three and six months ended September 30, 2024, together with the related Management&#8217;s Discussion and Analysis and audited
consolidated financial statements for the year ended March 31, 2024, and the annual report on Form 20-F (our &#8220;Annual Report&#8221;)
for the fiscal year ended March 31, 2024 (&#8220;Fiscal 2024&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><FONT STYLE="letter-spacing: -0.1pt"><A NAME="FLS"></A>Forward-Looking
Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">This document
includes &#8220;forward-looking statements.&#8221; All statements, other than statements of historical facts, included herein or incorporated
by reference herein, including without limitation, statements regarding our business strategy, plans and objectives of management for
future operations and those statements preceded by, followed by or that otherwise include the words &#8220;believe,&#8221; &#8220;expects,&#8221;
&#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;should,&#8221;
&#8220;could,&#8221; &#8220;targets,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221;
or &#8220;continue,&#8221; or similar expressions or variations on such expressions are forward-looking statements. We can give no assurances
that such forward-looking statements will prove to be correct.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Each forward-looking
statement reflects our current view of future events and is subject to risks, uncertainties and other factors that could cause actual
results to differ materially from any results expressed or implied by our forward-looking statements.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We have
made the decision to discontinue our sponsored trial for the invariant natural killer T-cell (&#8220;iNKT&#8221;) program and pause further
patient accrual to our sponsored adenosine program for both PORT-6 and PORT-7. In the event that we resume these clinical trials and
further development of our programs, our risks and uncertainties include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">our plans and ability to develop and commercialize
    product candidates and the timing of these development <FONT STYLE="letter-spacing: -0.1pt">programs;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt">&#8226;</TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">clinical development of our product candidates,
    including the timing for availability and release of results of current and future clinical <FONT STYLE="letter-spacing: -0.1pt">trials;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt">&#8226;</TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">our expectations regarding regulatory communications,
    submissions or <FONT STYLE="letter-spacing: -0.1pt">approvals;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt">&#8226;</TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">the potential functionality, capabilities, benefits
    and risks of our product candidates as compared to <FONT STYLE="letter-spacing: -0.1pt">others;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">our maintenance and establishment of intellectual
    property rights in our product <FONT STYLE="letter-spacing: -0.1pt">candidates;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt">&#8226;</TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">our need for financing and our estimates regarding
    our capital requirements and future revenues and <FONT STYLE="letter-spacing: -0.1pt">profitability;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt">&#8226;</TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">our estimates of the size of the potential markets
    for our product candidates; <FONT STYLE="letter-spacing: -0.25pt">and</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt">&#8226;</TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">our selection and licensing of product <FONT STYLE="letter-spacing: -0.1pt">candidates</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our business
focus has been that of a pharmaceutical development business subject to all of the risks of a pharmaceutical development business. In
the event that we resume enrollment in the clinical trials and further development of our programs, we do not anticipate directly engaging
in the commercialization of the product candidates we develop.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><FONT STYLE="font-size: 10pt; line-height: 104%">These
statements are based on assumptions and analyses made by us in light of our experience and our perception of historical trends, current
conditions and expected future developments based on the focus of our business activities on biotechnology, as well as other factors
we believe are appropriate in particular circumstances. However, whether actual results and developments will meet our expectations and
predictions depends on a number of risks and uncertainties, which could cause actual results to differ materially from our expectations,
including the risks set forth </FONT>under the heading &#8220;Business Environment &#8211; Risk Factors&#8221; below and <FONT STYLE="font-size: 10pt; line-height: 104%">in
Item 3 &#8220;Key Information &#8211; Risk Factors&#8221; in our Annual Report on Form 20-F for the year ended March 31, 2024.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Consequently,
all of the forward-looking statements made in this Management&#8217;s Discussion and Analysis are qualified by these cautionary statements.
We cannot assure you that the actual results or developments anticipated by us will be realized or, even if substantially realized, that
they will have the expected effect on us or our business or operations.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Unless the
context indicates otherwise the terms &#8220;Portage Biotech Inc.,&#8221; &#8220;the Company,&#8221; &#8220;our Company,&#8221; &#8220;Portage,&#8221;
&#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; are used interchangeably in this Management&#8217;s Discussion and Analysis and
mean Portage Biotech Inc. and its subsidiaries. Capitalized terms used but not defined herein have the meaning ascribed to such terms
in our unaudited condensed consolidated interim financial statements for the three <FONT STYLE="letter-spacing: -0.05pt">and six </FONT>months
ended September 30, <FONT STYLE="letter-spacing: -0.1pt">2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify"><A NAME="Natureofoperations"></A>Nature
of Operations and <FONT STYLE="letter-spacing: -0.1pt">Overview</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Due to our
future funding needs for clinical development of our programs as well as the current capital raising market for biotechnology companies,
we made the decision to discontinue the IMPORT-201 trial (PORT-2) and to pause further patient accrual to the ADPORT-601 trial (PORT-6
and PORT-7). The PORT-3 investigator trial is continuing, and all existing patients in the ADPORT-601 study will continue until disease
progression. We are continuing to collect and analyze data from these patients. We replaced a patient who withdrew and is unevaluable
for the 28-day dose limiting toxicity (&#8220;DLT&#8221;) period. We are exploring strategic alternatives, which may include finding
a partner for one or more of our assets, a sale of our company, a merger, restructurings, both in and out of court, company winddown,
further financing efforts or other strategic action. The following discussion reflects our operations in the event we are able to raise
additional capital to fund the clinical development of our programs.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify"></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We are a
clinical stage immuno-oncology company that advances treatments, in which we believe will be first-in-class therapies that target known
checkpoint resistant pathways, to improve long-term treatment response and the quality of life in patients with invasive cancers.&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our access
to next-generation technologies has provided us the capability to identify and understand biological mechanisms, clinical therapies and
product development strategies that have supported our programs through the translational pipeline and into the clinic.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We have
sourced and developed early- to mid-stage treatments that we believe will be first-in-class therapies for a variety of cancers, by funding,
implementing viable, cost-effective product development strategies, clinical counsel/trial design, shared services, financial and project
management to enable efficient, turnkey execution of commercially informed development plans. Our drug development pipeline portfolio
continues to encompass product candidates or technologies based on biology addressing known resistance pathways/mechanisms of current
checkpoint inhibitors with established scientific rationales.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our Board
of Directors approved a reverse stock split of our ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August
15, 2024, our ordinary shares began trading on Nasdaq on a split-adjusted basis under the existing trading symbol &#8220;PRTG&#8221;.
The reverse stock split was implemented to increase the per share trading price of our ordinary shares for the purpose of ensuring a
share price high enough to comply with the minimum $1.00 bid price requirement for continued listing on Nasdaq. We received notice from
Nasdaq on August 30, 2024 informing us that we had regained compliance with the minimum $1.00 bid price requirement for continued listing
on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">The Portage <FONT STYLE="letter-spacing: -0.1pt">Approach</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our mission
has been to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused
on overcoming immune resistance and expanding the addressable patient population. Given these foundations, we have managed capital allocation
and risk as much as we have overseen drug development. By focusing our efforts on translational medicine and pipeline diversification,
we have sought to mitigate overall exposure to many of the inherent risks of drug development.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our approach
has been guided by the following core <FONT STYLE="letter-spacing: -0.1pt">elements:</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Portfolio diversification to mitigate risk and
    maximize <FONT STYLE="letter-spacing: -0.1pt">optionality;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Capital allocation based on risk-adjusted potential,
    including staged funding to pre-specified scientific and clinical <FONT STYLE="letter-spacing: -0.1pt">results;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Virtual infrastructure and key external relationships
    to maintain a lean operating <FONT STYLE="letter-spacing: -0.1pt">base;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Internal development capabilities complemented
    by external business <FONT STYLE="letter-spacing: -0.1pt">development;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Rigorous asset selection for broad targets with
    disciplined ongoing <FONT STYLE="letter-spacing: -0.1pt">evaluation;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Focus on translational medicine and therapeutic
    candidates with single agent <FONT STYLE="letter-spacing: -0.1pt">activity;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Conduct randomized trials early and test non-overlapping
    mechanisms of action; <FONT STYLE="letter-spacing: -0.25pt">and</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Improve potential outcomes for patients with
    invasive <FONT STYLE="letter-spacing: -0.1pt">cancers.</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We have
executed such approach through our internal core team and our network of experts, contract labs and academic <FONT STYLE="letter-spacing: -0.1pt">partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify">Our Science <FONT STYLE="letter-spacing: -0.1pt">Strategy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Prior to
our decision to discontinue our iNKT IMPORT-201 sponsored trial and pause further patient accrual in the adenosine program, our goal
has been to develop immuno-oncology therapeutics that will dramatically improve the standard-of-care for patients with cancer. The key
elements of our scientific strategy have been to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Build a pipeline of differentiated oncology therapeutic
    candidates that are diversified by mechanism, broad targets, therapeutic approach, modality, stage of development, leading to a variety
    of deal types that can be executed with partners;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Expand our pipeline through research collaborations,
    business development and internally designed <FONT STYLE="letter-spacing: -0.1pt">programs;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Continue to advance and evolve our pipeline;
    <FONT STYLE="letter-spacing: -0.25pt">and</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Evaluate strategic opportunities to accelerate
    development timelines and maximize the value of our <FONT STYLE="letter-spacing: -0.1pt">portfolio.</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify">Our <FONT STYLE="letter-spacing: -0.1pt">Pipeline</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We have
built a strong portfolio of immuno-oncology therapeutic candidates and programs that are diversified by mechanism, therapeutic approach,
modality and stage of development. Prior to our decision to discontinue further development of our iNKT sponsored trial and pause further
patient accrual to our sponsored adenosine program, we rigorously assessed each of our programs on an ongoing basis using internally
defined success criteria to justify continued investment and determine proper capital allocation. When certain programs do not meet our
de-risking criteria for advancement, we look to monetize or terminate those programs and preserve our capital and resources to invest
in programs with greater potential.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The charts
set forth below, illustrate the state of our immuno-oncology therapeutic product candidates and programs before development activities
were discontinued and/or paused. At this time PORT-3 is the only candidate currently actively recruiting and being evaluated as part
of an investigator sponsored study without funding from us. Additionally, notwithstanding our decision to pause further development of
PORT-2 and PORT-7 both INDs continue to remain active and the clinical trial for PORT-6 remains open, with further enrollment into additional
cohorts still on pause. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. Before you make an investment decision regarding us, you should make your own
analysis of forward-looking statements and our projections about candidate and program development and results.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="novelpipeline.jpg" ALT="">&#160;</P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify; text-indent: 20.7pt">&#160;</P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="engagerplatform.jpg" ALT="">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 19.2pt"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.35pt 0 0"><BR STYLE="clear: both"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.7pt 0.1in 0 8.35pt; text-align: justify">Our Business <FONT STYLE="letter-spacing: -0.1pt">Model</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We are a
development organization that is structured to facilitate flexibility in financing and ease of partnering, licensing, and merger/acquisition
of individual assets and or technology platforms. The intellectual property (&#8220;IP&#8221;) for each platform is held in separate
private entities. Our employees and consultants work across the pipeline of assets and we believe that this can (i) enhance operational
efficiency, (ii) maintain an optimal cost structure, (iii) attract leading collaborators, and (iv) promote asset flexibility, as further
described below. If we were to resume enrollment in our clinical programs, we believe our experience and approach would continue to leverage
the operating and cost structures that are further described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.65pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/104% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.8pt"></TD>
    <TD STYLE="width: 16.55pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt"><I>Enhance operational efficiency</I>: We allocate
    resources while empowering managers to make program-level decisions in order to increase productivity and speed. We believe this
    model enables a flexible organizational structure that can achieve scale through the addition of programs without increasing burdensome
    bureaucracy or redundant infrastructure.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt"><I>Maintain an optimal cost structure</I>: We
    have a relatively small number of employees and have partnered with a number of service providers to leverage their infrastructure
    and expertise as needed instead of embarking on capital-intensive lab, manufacturing, and equipment expenditures. By reducing overhead
    costs, we believe we can increase the likelihood that we can generate a return on invested capital.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt"><I>Attract leading collaborators and licensors</I>:
    Our pipeline is comprised of therapies we believe will be first-in-class therapies for a variety of cancers sourced via our industry
    contacts and relationships (including academia and pharmaceutical industry executives). On preclinical programs/technology, we initially
    established development structures enabling us to keep licensors economically incentivized at the program level. We believe that
    our experienced drug development leadership team and approach to resource allocation differentiate us from other potential <FONT STYLE="letter-spacing: -0.1pt">licensees.</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt"><I>Leverage the commoditized checkpoint marketplace
    and explore the potential to further enhance long-term clinical benefits for patients with cancer and also expand the eligible population
    to include those who do not currently receive anti-PD-1 therapy</I>: Presently there are multiple approved checkpoint therapeutics
    that lack differentiation, resulting in a competitive market dynamic, which will favor combination therapy. There remains opportunity
    for potential expansion in the PD-1 market with our adenosine antagonists. Studies show that 70-80% of patients do not respond or
    have a limited response to existing monotherapies, such as PD-1 checkpoint inhibitors. We see potential for our unique approach of
    using adenosine antagonists to initiate an immune response in tumors that have become refractory to checkpoint therapy or to increase
    the number of front-line patients achieving more durable responses. Combinations can improve this but often come at the cost of significant
    additional toxicity. The market is saturated with at least 14 approved PD-1 antibodies, and every major pharmaceutical company competes
    in this space. Extending the use of PD-1 antibodies could still provide a significant potential upside for companies competing for
    market share.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.8pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/104% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.8pt"></TD>
    <TD STYLE="width: 16.55pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt"><I>Promote asset flexibility</I>: Our structure
    is designed to maximize flexibility and cost efficiency. This allows us to efficiently pursue various subsidiary-level transactions,
    such as stock or asset sales, licensing transactions, strategic partnerships and/or co-development arrangements. It also provides
    us with the flexibility to terminate programs with minimal costs if results do not meet our de-risking criteria for advancement.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We are a
BVI business company incorporated under the BVI Business Companies Act (Revised Edition 2020, as amended) with our registered office
located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110. Our U.S. agent, Portage Development
Services Inc., is located at 59 Wilton Road, Westport, CT 06880.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><FONT STYLE="font-size: 10pt; line-height: 104%">We
currently are a foreign private issuer under SEC rules. We are also a reporting issuer under the securities legislation of the provinces
of Ontario and British Columbia. Our ordinary shares were listed on the CSE under the symbol &#8220;PBT.U&#8221;. On February 25, 2021,
our ordinary shares began trading on the Nasdaq Capital Market under the symbol &#8220;PRTG&#8221;. As the principal market for our ordinary
shares is Nasdaq, we voluntarily delisted from the CSE on April 23, 2021</FONT>.</P>

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.7pt 0 0 8.35pt"><A NAME="summary"></A>Summary of <FONT STYLE="letter-spacing: -0.1pt">Results</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0 0"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The following
table summarizes financial information for the quarter ended September 30, 2024, and the preceding eight quarters (in thousands except
net loss per share). All share and per share amounts reflect the 1-for-20 reverse stock split effected August 15, <FONT STYLE="letter-spacing: -0.1pt">2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0.05pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 9pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">Quarter Ended</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 2.85pt; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 2.85pt; text-align: center"><B>Sept. <FONT STYLE="letter-spacing: -0.25pt">30,</FONT></B></P>
        <P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 3.75pt 0 2.85pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>2024</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 3.75pt 0 2.85pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 2.85pt; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 3.75pt 0 2.85pt; text-align: center"><B>June <FONT STYLE="letter-spacing: -0.25pt">30,</FONT></B></P>
        <P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 3.45pt 0 2.15pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>2024</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 3.45pt 0 2.15pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 3.45pt 0 2.15pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 3.45pt 0 2.15pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>Mar.
        </B></FONT><B><FONT STYLE="letter-spacing: -0.25pt">31,</FONT></B></P>
        <P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 3.45pt 0 2.5pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>2024</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 3.45pt 0 2.5pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 3.5pt 0 2.5pt; text-align: center">&#160;</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 3.5pt 0 2.5pt; text-align: center"><B>Dec. <FONT STYLE="letter-spacing: -0.25pt">31,</FONT></B></P>
        <P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 0.05pt 0 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>2023</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 0.05pt 0 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 0.05pt 0 0; text-align: center"><B>Sept. <FONT STYLE="letter-spacing: -0.25pt">30,</FONT></B></P>
        <P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 0 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>2023</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 0 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>June <FONT STYLE="letter-spacing: -0.25pt">30,</FONT></B></P>
        <P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 0.95pt 0 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>2023</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 0.95pt 0 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 0.95pt 0 0; text-align: center">&#160;</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 0.95pt 0 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>Mar.
        </B></FONT><B><FONT STYLE="letter-spacing: -0.25pt">31,</FONT></B></P>
        <P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 2pt 0 0.05pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>2023</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 2pt 0 0.05pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 2pt 0 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 2pt 0 0; text-align: center"><B>Dec. <FONT STYLE="letter-spacing: -0.25pt">31,</FONT></B></P>
        <P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 1.4pt 0 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>2022</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 1.4pt 0 0; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 1.4pt 0 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/9.95pt Times New Roman, Times, Serif; margin: 0 1.4pt 0 0; text-align: center"><B>Sept. <FONT STYLE="letter-spacing: -0.25pt">30</FONT></B></P>
        <P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 0 0 2.2pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>2022</B></FONT></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 9pt/10.05pt Times New Roman, Times, Serif; margin: 1.8pt 0 0 2.2pt; text-align: center"><FONT STYLE="letter-spacing: -0.2pt"><B>&#160;</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0pt">Net loss attributable to owners of
    the Company</TD>
    <TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(1,360</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(1,656</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(24,889</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(39,373</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(5,158</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(5,919</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(94,448</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(7,485</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 2%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(949</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0pt">Comprehensive loss attributable to the owners of the Company</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1,360</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1,656</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(28,371</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(36,398</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(6,458</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(4,150</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(95,714</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(11,502</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(949</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 9pt"><B>Working capital</B></FONT><B> <FONT STYLE="font-size: 7.5pt">(1)</FONT></B></TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">1,813</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">2,191</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">4,816</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">4,808</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">3,131</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">8,254</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">11,811</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">13,110</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">15,737</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Equity attributable to owners of the Company</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">1,398</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">2,511</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">4,022</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">31,999</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">67,661</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">73,307</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">76,045</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">168,945</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">178,434</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Net loss per share - Basic</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1.26</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1.58</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(23.74</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(37.68</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(5.79</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(6.68</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(108.81</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(8.79</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1.13</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Net loss per share - Diluted</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1.26</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1.58</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(23.74</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(37.68</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(5.79</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 9pt; letter-spacing: -0.1pt">(6.68</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(108.81</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(8.79</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1.13</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"></TD>
    <TD STYLE="text-align: left; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in; width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2022 working capital is net of warrant liability of $8 settleable on a non-cash <FONT STYLE="letter-spacing: -0.1pt">basis.</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.35pt; text-align: justify"><A NAME="numberordinaryshares"></A>Number
of Ordinary <FONT STYLE="letter-spacing: -0.1pt">Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The following
table summarizes the number of our ordinary shares issued and outstanding at September 30, 2024 and November 26, <FONT STYLE="letter-spacing: -0.1pt">2024:</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><FONT STYLE="letter-spacing: -0.1pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 11pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">November 26, 2024</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 69%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Shares issued (a) </FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,116,681</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,123,757</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Shares outstanding (a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">1,116,249</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">1,121,059</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; letter-spacing: -0.05pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
    amounts exclude an aggregate of 12,150 restricted stock units granted to our executive chairman and an employee on January 13, 2021,
    which vested immediately on the date of grant and are subject to certain restrictions for the settlement and delivery of the ordinary
    shares underlying the restricted stock units and 5,165 restricted stock units granted to employees (one of whom is executive chairman)
    on January 19, 2022, which vested immediately on the date of grant and are subject to certain restrictions for the settlement and
    delivery of the ordinary shares underlying the restricted stock units. In January 2024, we issued 308 shares for the exercise of
    470 RSUs net of 162 shares repurchased into treasury to pay for an employee&#8217;s payroll taxes. In September 2024, we issued 882
    shares for the exercise of 1,152 RSUs net of 270 shares repurchased into treasury to pay for an employee&#8217;s payroll taxes.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 9pt/103% Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.7pt 0 0 8.35pt; text-align: justify"><A NAME="businessenvironment"></A>Business
Environment &#8211; Risk <FONT STYLE="letter-spacing: -0.1pt">Factors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Please refer
to the Annual Report for Fiscal 2024 <FONT STYLE="letter-spacing: -0.1pt">on Form 20-F as filed with the Securities and Exchange Commission
on August 14, 2024, </FONT>for detailed information as the economic and industry factors are substantially unchanged as of the date hereof
other than as described below.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><B><I>We
may not be able to regain, or maintain, compliance with the continued listing requirements of The Nasdaq Capital Market.</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify; text-indent: 23.05pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our ordinary
shares are listed on the Nasdaq Capital Market, and we are therefore subject to its continued listing requirements, including requirements
with respect to the market value of our publicly-held shares, market value of our listed shares, minimum bid price per share, and minimum
shareholders&#8217; equity, among others. If we fail to satisfy one or more of the requirements, we may be delisted from the Nasdaq Capital
Market.</P>

<P STYLE="font: 11pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Nasdaq Listing
Rule 5550(b)(1) requires companies listed on the Nasdaq Capital Market to maintain shareholders&#8217; equity of at least $2.5 million
for continued listing. As of September 30, 2024, our shareholders&#8217; equity was $1.398 million and, as a result, we are not currently
in compliance with Nasdaq Listing Rule 5550(b)(1). Accordingly, we expect Nasdaq to notify us of such non-compliance. We do not anticipate
that the notification will have an immediate effect on the listing of our ordinary shares on the Nasdaq Capital Market. In accordance
with the Nasdaq Listing Rules, we expect that we will have 45 calendar days from the date of the notification to submit a plan to regain
compliance with Nasdaq Listing Rule 5550(b)(1). If our compliance plan is accepted, we may be granted up to 180 calendar days from the
date of the initial notification to evidence compliance. If our compliance plan is not accepted or we are otherwise unable to evidence
compliance within Nasdaq&#8217;s allotted timeframe, Nasdaq may take steps to delist our ordinary shares. There can be no assurance that
we will be able to increase our shareholders&#8217; equity in the future.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Delisting
from the Nasdaq Capital Market may adversely affect our ability to raise additional financing through the public or private sale of equity
securities, may significantly affect the ability of investors to trade our securities and may negatively affect the value and liquidity
of our ordinary shares. Delisting also could have other negative results, including the potential loss of employee confidence, the loss
of institutional investors or interest in business development opportunities.</P>

<P STYLE="font: 11pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">If we are
delisted from Nasdaq and we are not able to list our ordinary shares on another exchange, our ordinary shares could be quoted on the
OTC Bulletin Board or in the &#8220;pink sheets.&#8221; As a result, we could face significant adverse consequences including, among
others:</P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/104% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.8pt"></TD>
    <TD STYLE="width: 16.55pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">a limited availability of market quotations for
    our securities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 45.35pt; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/104% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.8pt"></TD>
    <TD STYLE="width: 16.55pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">a determination that our shares are a &#8220;penny
    stock&#8221; which will require brokers trading in our ordinary shares to adhere to more stringent rules and possibly result in a
    reduced level of trading activity in the secondary trading market for our securities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/104% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.8pt"></TD>
    <TD STYLE="width: 16.55pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">a limited amount of news and little or no analyst
    coverage for us;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 45.35pt; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/104% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.8pt"></TD>
    <TD STYLE="width: 16.55pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">we would no longer qualify for exemptions from
    state securities registration requirements, which may require us to comply with applicable state securities laws; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/104% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.8pt"></TD>
    <TD STYLE="width: 16.55pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">a decreased ability to issue additional securities
    (including pursuant to short-form Registration Statements on Form F-3) due to the Baby Shelf Rule or obtain additional financing
    in the future.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><A NAME="ourprogramsandtech"></A>Our
Programs and Technology &#8211; Recent <FONT STYLE="letter-spacing: -0.1pt">Developments</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">After a
review of our future funding needs for clinical development of our programs as well as the current capital raising market for biotechnology
companies, we made the decision to discontinue our iNKT sponsored trial (the investigator sponsored trial of PORT-3 is ongoing without
financial support from us) and pause further patient accrual in our sponsored adenosine program. We are exploring strategic alternatives,
which may include finding a partner for one or more of our assets, a sale of our company, a merger, restructurings, both in and out of
court, a company wind down, further financing efforts or other strategic action. Below is a discussion of our clinical programs and the
status of such programs prior to our decision to discontinue our iNKT sponsored trial and pause further patient accrual to our sponsored
studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.65pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Adenosine Receptor Antagonist
<FONT STYLE="letter-spacing: -0.1pt">Platform</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">A critical
mechanism of cancer immune evasion is the generation of high levels of immunosuppressive adenosine within the tumor microenvironment
(&#8220;TME&#8221;). Research suggests that the TME has significantly elevated concentrations of extracellular adenosine. Engagement
with adenosine receptors type 2A (&#8220;A2A&#8221;) and type 2B (&#8220;A2B&#8221;) triggers a dampening effect on the immune response,
suppressing effector cell function and stabilizing immunosuppressive regulatory cells. Over-expression of the A2A and A2B receptors leads
to a poor prognosis in multiple cancers, including prostate cancer, colorectal cancer and lung adenocarcinoma, driven by a reduced ability
to generate an immune response against the tumor.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">These findings
have made A2A and A2B high-priority targets for immunotherapeutic intervention. Before pausing, we were advancing four adenosine antagonists
that we believe to be first-in-class, which together represent a broad suite of adenosine-targeting approaches and were expected to enable
a comprehensive exploration of how targeting the adenosine pathway could potentially improve response in multiple cancer and non-cancer
indications. By modulating the adenosine pathway in four different ways, we expected to determine the optimal approach to maximize the
impact of the mechanism of action on different tumors.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We have
designed the ADPORT-601 clinical trial to evaluate the activity and safety of PORT-6 and PORT-7 alone and in combination. If we resume
accrual, we would expect this trial to adapt over time and also include safety cohorts for these two agents with other immune activating
agents including others from our internal pipeline. Depending on the data, it can be expanded to evaluate either agent as monotherapy
or a randomized comparison of either agent plus standard of care versus standard of care alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><FONT STYLE="letter-spacing: -0.2pt">PORT-6
(TT-</FONT><FONT STYLE="letter-spacing: -0.25pt">10)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">PORT-6 is
an A2A antagonist being studied for the treatment of A2A expressing solid tumors. We believe PORT-6 is more potent, more durable and
more selective than other clinical stage A2A agents.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Prior to
pausing patient enrollment in the clinical study, the ADPORT-601 Phase 1a trial for PORT-6 dosed its first patient in June 2023. There
have been a total of 12 patients dosed to date, with one patient continuing to receive treatment and the first two dose escalation cohorts
being completed. The third cohort has been fully enrolled, with only one patient experienced a serious adverse event (blurry vision and
stroke) that the investigator initially determined could possibly be related to PORT-6. With further follow-up, this event was classified
as unrelated to treatment. We remain encouraged by the two patients (discontinued) who received six or more lines of prior therapy and
experienced prolonged stable disease for more than eight months. After the study was put on hold, we made the decision to replace a patient
that withdrew treatment due to and unrelated adverse event prior to DLT assessment and that patient remains in the trial with stable
disease. Further recruitment remains on pause, with three investigator sites still open, while we explore strategic alternatives.</P>



<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 3.7pt 0.1in 0 8.35pt; text-align: justify"><FONT STYLE="letter-spacing: -0.2pt">PORT-7
(TT-</FONT><FONT STYLE="letter-spacing: -0.25pt">4)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">PORT-7 is
an A2B antagonist for the treatment of solid tumors. PORT-7 has a very selective profile that focuses on A2B. PORT-7 is in Phase 1a from
an IND perspective, though we have not commenced dosing patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><FONT STYLE="letter-spacing: -0.2pt">PORT-8
(TT-</FONT><FONT STYLE="letter-spacing: -0.25pt">53)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">PORT-8 is
a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid <FONT STYLE="letter-spacing: -0.1pt">tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><FONT STYLE="letter-spacing: -0.2pt">PORT-9
(TT-</FONT><FONT STYLE="letter-spacing: -0.25pt">3)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">PORT-9 is
an A2B antagonist designed to treat colorectal and gastrointestinal cancers. The PORT-9 program is a pre-clinical stage <FONT STYLE="letter-spacing: -0.1pt">program.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">In connection
with the adenosine program, we will focus on solid tumor types with high adenosine expression of receptors A2A and A2B and enrich for
patients that have high adenosine expression and therefore have potential to benefit most from treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0pt 8.35pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Pipeline and Investee <FONT STYLE="letter-spacing: -0.1pt">Programs</FONT></I></B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Prior to
our decision to discontinue our iNKT sponsored trial and pause further development of our adenosine program, we were focused on delivering
clinical data with the adenosine program described above and prioritizing the allocation of financial resources to that program. Developmental
work continued on some of the other developmental assets, through collaborations such as that with the U.S. National Cancer Institute
(&#8220;NCI&#8221;) and other academic groups, as further described below. These developmental assets may be re-evaluated at a future
point depending on market conditions, ongoing data, funding priorities and status.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Invariant Natural Killer
T-cells (iNKT cells) <FONT STYLE="letter-spacing: -0.1pt">Platform</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">iNKT cells
play an important role in anti-tumor immune responses and are a distinct class of T lymphocyte displaying a limited diversity of T-cell
receptors. They recognize lipid antigens on the surface of tumor cells and produce large amounts of cytokines within hours of stimulation
without the need for clonal expansion. Furthermore, iNKT cells activate multiple immune system components, including dendritic cells
(&#8220;DC&#8221;), T-cells and B-cells and stimulate an antigen-specific expansion of these cells. Our operating subsidiary, iOx Therapeutics
Ltd. (&#8220;iOx&#8221;), holds an exclusive license (with the right to sub-license) from the Ludwig Institute for Cancer Research (the
&#8220;Ludwig Institute&#8221;) to use, research, develop and commercialize iNKT cell engagers, for the treatment of various forms of
human disease, including cancer, under the Ludwig Institute&#8217;s intellectual property and know-how.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><FONT STYLE="letter-spacing: -0.1pt">PORT-2
(IMM60)</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">PORT-2 is
an iNKT cell engager formulated in a liposome with a six-member carbon head structure that has been shown to activate both human and
murine iNKT cells, resulting in DC maturation and the priming of Ag-specific T and B cells.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">In animal
models, PORT-2 enhanced the frequency of tumor specific immune responses. iNKT cells are unique lymphocytes defined by their co-expression
of surface markers associated with NK cells along with a T-cell antigen receptor. They recognize amphipathic ligands such as glycolipids
or phospholipids presented in the context of the non-polymorphic, MHC class I-like molecule CD1d. Activated iNKT cells rapidly produce
IFN-gamma and IL-4 and induce DC maturation and IL-12 production.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">In August
2021, we dosed the first patient in the IMP-MEL PORT-2 clinical trial, a Phase 1/2 dose escalation and randomized expansion trial. Prior
to discontinuing the PORT-2 trial, it was expected to enroll up to 88 patients with melanoma or non-small cell lung carcinoma (&#8220;NSCLC&#8221;)
in order to evaluate safety and efficacy. In November 2022, we announced that we had entered into a clinical trial collaboration with
Merck to evaluate PORT-2 in combination with pembrolizumab for patients with NSCLC. Under the terms of the collaboration, Merck supplied
pembrolizumab for our Phase 1/2 trial of PORT-2 in patients with NSCLC and melanoma. The trial was closed in June 2024. The Merck collaboration
terminated in December 2023.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Preliminary
Phase 1 data from the IMP-MEL PORT-2 clinical trial, presented at the Society for Immunotherapy of Cancer in November 2023, suggests
PORT-2 was well tolerated when administered as a monotherapy, with no related severe or serious adverse events. All possibly related
adverse events were mild to moderate and did not limit dosing. Given the favorable safety profile observed in the clinical trials to
date, the clinical protocol for the IMP-MEL PORT-2 clinical trial was amended to include a higher Phase 1 dose level as our near-term
focus was defining the recommended Phase 2 dose.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Prior to
our decision to discontinue further development of our iNKT platform, the combination safety cohort with pembrolizumab was being conducted
in parallel with the ongoing high dose monotherapy cohort. As of November 2023, two patients had received the combination with pembrolizumab,
and no related severe or serious adverse events were reported. The adverse event profile was consistent with pembrolizumab. Previously
reported biomarker data confirmed the mechanism of action (i.e., both activation of the innate and adaptive arms of the immune system).
The following figure illustrates the different lesion responses. Although these are preliminary results, several lesions showed shrinkage,
and the responses in liver metastases were <FONT STYLE="letter-spacing: -0.1pt">encouraging.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><FONT STYLE="letter-spacing: -0.1pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="singleagentactivity.jpg" ALT=""><BR STYLE="clear: both"></P>

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Prior to
our decision to discontinue our iNKT sponsored trial, we were encouraged by the patient data set that we believe supports proof of concept
for using an iNKT engager in cancer treatment. Preliminary Phase 1 data suggests that PORT-2 has a favorable safety and tolerability
profile as a monotherapy at all doses tested to date (as noted above), has demonstrated evidence of single agent activity, and biomarkers
confirm mechanistic potential of PORT-2 to activate both the adaptive and innate immune systems.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The clinical
trial agreement has been transferred from the University of Oxford to us through our iOx subsidiary and the trial was converted to a
program sponsored by iOx.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Prior to
our decision to discontinue the iNKT sponsored trial, the protocol was being amended, given the safety data shown at the highest planned
doses, to escalate patient dosing to include one additional higher dose to identify the recommended Phase 2 dose. We are exploring strategic
alternatives, which may include finding a partner for one or more of our assets, a sale of our company, a merger, restructurings, both
in and out of court, a company wind down, further financing efforts or other strategic action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><FONT STYLE="letter-spacing: -0.1pt">PORT-3
(IMM65)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">PORT-3 is
a poly(lactide-co-glycolide) (&#8220;PLGA&#8221;)-nanoparticle formulation of PORT-2 (IMM60) combined with a NY-ESO-1 peptide vaccine.
Biodegradable PLGA-nanoparticles function as a delivery platform for immunomodulators and tumor antigens to induce a specific anti-tumor
immune response. PLGA has minimal (systemic) toxicity and is used in various drug-carrying platforms as an encapsulating agent. Furthermore,
co-formulating an iNKT engager with a peptide vaccine in a particle has shown to be approximately five times more potent in killing cancer
cells and generating an antigen-specific CD8 T-cell response than giving the two agents individually.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">NY-ESO-1
is a cancer-testis antigen expressed during embryogenesis and in the testis, an immune privileged site. Furthermore, NY-ESO-1 expression
is observed in several advanced cancers: Lung (2-32%), melanoma (40%), bladder (32-35%), prostate (38%), ovarian (30%), esophageal (24-33%),
and gastric cancers (8-12%). Clinical trials have shown the safety and tolerability of Good Manufacturing Practices-grade NY-ESO-1 peptides
in patients with <FONT STYLE="letter-spacing: -0.1pt">cancer.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">PORT-3 is
being evaluated as part of an investigator sponsored study without funding from us. The first patient was dosed in 2021 and patients
continue to enroll in the PRECIOUS Phase 1 trial of PORT-3 in patients with solid tumors. The Phase 1 portion of the trial is expected
to enroll 15 patients. The trial was having difficulty identifying tumors that expressed NY-ESO-1, so the trial protocol was amended
to include all solid tumors regardless of expression to facilitate assessment of safety. This platform is designed to demonstrate proof
of concept. The combination of NY-ESO-1 and IMM-60 is being evaluated to determine its ability to prime and boost an anti-tumor immune
response. Our patent position extends to other known tumor antigens, and, if we resume further development of our iNKT platform, we could
be prepared to rapidly launch other assets into the clinic if we see strong activity of this formulation. Preliminary safety data for
repeat dosing of PORT-3 in the PRECIOUS Phase 1 trial shows a favorable safety profile. The investigators with whom we work with have
continued to explore next generation targeted nanoparticles.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.75pt 0.1in 0 0; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">PORT-4, Nanolipogel (&#8220;NLG&#8221;)
co-formulation <FONT STYLE="letter-spacing: -0.1pt">Platform</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Scientists
are interested in novel ways to deliver multiple signals to the immune system in order to better activate an anti-tumor response. We
have been impressed with a platform from Yale University that allows different types of agents to be packaged together and will concentrate
them in tumors. We have licensed the platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products.
In order to have multiple proprietary agents with known mechanisms of action, we have licensed rights to create DNA aptamers for immune-oncology
targets and the first one developed is a proprietary PD1 aptamer, which has been placed in the NLG formulation. Early testing has shown
the formulation properly modulates PD1 signaling in vitro similar to a PD1 antibody I. In non-clinical, in vivo experiments, the NLG-PD1
performed favorably compared to a mouse PD1 antibody. We have conducted further research with the technology licensed from Yale University
to co-deliver a PD1 blocking signal with a small molecule vascular endothelial growth factor inhibitor.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">As of September
30, 2024, we owned approximately 70% of the outstanding shares of Saugatuck Therapeutics, Ltd., the subsidiary on which the PORT-4 platform
is managed.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">PORT-5, STING Agonist
<FONT STYLE="letter-spacing: -0.1pt">Platform</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Proprietary
immune priming and boosting technology (using a STING agonist delivered in a virus-like particle) has shown proof of concept in animal
models. This platform was developed to offer multiple ways to target immune stimulation towards the cancer, as well as to co-deliver
multiple signals in a single product. The PORT-5 STING platform&#8217;s advantage over chemical intratumoral approaches was potent immune
priming and boosting pathway within a virus-like particle to enable convenient systemic administration and traffic to the correct targets.
This technology would target dendritic cells, which is differentiated from other chemical STING approaches. To that end, Stimunity S.A.
(&#8220;Stimunity&#8221;) received grant funding to study this technology with any COVID-19 vaccine to evaluate if it is possible to
boost the immune response for immunocompromised or elderly patients. During April 2022, the American Association for Cancer Research
showcased PORT-5 preclinical data at a late-breaking session that shows that one or more targeted immunotherapy agents could be packaged
within a virus-like particle to increase potency, while enabling a selective immune activation. Stimunity was unable to raise any outside
funding, and activities were scaled back due to our own liquidity issues.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">In December
2023, we completed a transfer of our equity in Stimunity and the Stimunity Convertible Note to iOx. In connection with that transfer,
the Stimunity Convertible Note was converted into 1,768 Class A shares of Stimunity.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">As of September
30, 2024, we owned approximately 48.9% of the outstanding shares of Stimunity, the subsidiary on which the PORT-5 platform is managed.
We have made the decision not to further fund Stimunity&#8217;s operations and wrote down the remaining balance of our investment of
$1.0 million to nil as of March 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Early-Stage Research and
Development <FONT STYLE="letter-spacing: -0.1pt">Collaborations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We have
also been interested in evaluating and testing new antibody targets in the suppressive tumor microenvironment with the goal to down regulate
or remove MDSC, TAMs, Tregs and other signals that impede the immune response from clearing cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">We continue to collaborate with Dr. Robert Negrin
    and his team at Stanford University in an investigator sponsored trial (&#8220;IST&#8221;) study to evaluate the use of PORT-2 with
    iNKT cell therapies in animals. This work was intended to evaluate if an engager co-administered with expanded or transformed iNKT
    cells can further activate the transplanted and endogenous cells inside the patient. The Stanford collaboration was also expected
    to study the impact iNKT engagers have on driving an adaptive immune response and correcting the suppressive tumor microenvironment.
    This IST remains operational as of the date of this report.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.65pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">We entered into a Cooperative Research and Development
    Agreement (&#8220;CRADA&#8221;) with the NCI. We and NCI planned to advance preclinical and potential clinical development of STING
    agonists and anti-RAGE agents for cancer vaccines. After the acquisition of Tarus Therapeutics, LLC (&#8220;Tarus&#8221;), we amended
    the CRADA to include exploration of the different adenosine compounds. We did not extend the CRADA beyond its current term and made
    a termination payment of $62,500 in June 2024 as required under the contract.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">We have a collaboration with Dr. Carmela de Santos
    at University of Birmingham for the use of iNKT agents to treat sarcomas. Dr. de Santos has tested PORT-2 in human sarcoma cell lines
    and has grant funding to test it in animal models.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">We have a collaboration to study the use of adenosine
    2A and adenosine 2B agents in mesothelioma with Drs. Luciano Mutti from Sbarro Institute for Cancer Research and Molecular Medicine,
    Department of Biology, College of Science and Technology, Temple University and Dr. Steven Gray of St. James Hospital in Dublin.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.8pt"></TD>
    <TD STYLE="width: 16.55pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">There are other collaborations with experts in
    the products areas for which we provide access to our compounds and collaborates on <FONT STYLE="letter-spacing: -0.1pt">studies.</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt/104% Times New Roman, Times, Serif; margin: 3.7pt 0.1in 0 8.65pt; text-align: justify">Three Months Ended September
30, 2024 Compared to the Three Months Ended September 30, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify"><B><A NAME="resultsoperations"></A>Results
of <FONT STYLE="letter-spacing: -0.1pt">Operations</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The following
details major expenses for the three months ended September 30, 2024, compared to the three months ended <FONT STYLE="letter-spacing: -0.2pt">S</FONT>eptember
30, <FONT STYLE="letter-spacing: -0.1pt">2023 (in thousands):</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 10pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Three months ended September 30,</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-weight: bold; text-align: left">Operating expenses</TD>
    <TD STYLE="width: 1%; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 12%; font-weight: bold; text-align: right">(1,604</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">(5,930</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Change in fair value of warrant liability</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(716</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Change in fair value of deferred purchase price payable &ndash; Tarus and deferred
    obligation &ndash; iOx milestone</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(113</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Gain on settlement with Parexel &#8211; iOx CRO</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">946</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Share of loss in associate accounted for using equity method</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(40</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Depreciation expense</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(7</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(15</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Foreign exchange transaction loss</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(5</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(17</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">Interest income, net</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">24</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">43</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Loss before provision for income taxes</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1,362</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(6,072</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">Income tax benefit</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">907</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1,362</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(5,165</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive loss</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Net unrealized loss on investments</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,300</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total comprehensive loss for period</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,362</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,465</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Comprehensive loss attributable to:</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 8.95pt">Owners of the Company</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD>
    <TD STYLE="font-weight: bold; text-align: right">(1,360</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(6,458</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">Non-controlling interest</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(1,362</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,465</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0.7pt 0 0">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify">Results of Operations
for the Three Months Ended September 30, 2024 Compared to the Three Months Ended September 30, <FONT STYLE="letter-spacing: -0.2pt">2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We incurred
a net loss of approximately $1.4 million during the three months ended September 30, 2024 (the &#8220;Fiscal 2025 Quarter&#8221;), compared
to a net loss of approximately $5.2 million during the three months ended September 30, 2023 (the &#8220;Fiscal 2024 Quarter&#8221;),
a decrease in net loss of $3.8 million, quarter-over-<FONT STYLE="letter-spacing: -0.1pt">quarter.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The components
of the change in net loss and total comprehensive loss are as <FONT STYLE="letter-spacing: -0.1pt">follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Operating expenses, which include research and
    development (&#8220;R&amp;D&#8221;) costs and general and administrative (&#8220;G&amp;A&#8221;) expenses, were $1.6 million in the
    Fiscal 2025 Quarter, compared to $5.9 million in the Fiscal 2024 Quarter, a decrease of $4.3 million, which is discussed more fully
    <FONT STYLE="letter-spacing: -0.1pt">below.</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">A net gain of $0.9 million from the settlement
    and release of obligations and liabilities under the Master Services Agreement between iOx and Parexel International (IRL) Limited
    (&#8220;Parexel&#8221;). See &#8220;iOx &#8211; Parexel Master Services Agreement&#8221; section of Note 12 &#8220;Commitments and
    Contingent Liabilities&#8221; for additional discussion regarding this matter included elsewhere in this Report.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 44.8pt; text-indent: -16.2pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">A non-cash loss totaling $0.113 million comprised
    of the change (increase) in the fair value of the deferred obligation - iOx milestone of $0.028 million, and the change (increase)
    in the fair value of the deferred purchase price payable to the former Tarus shareholders of $0.085 million in the Fiscal 2024 Quarter.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0 0.1in 0 44.8pt; text-align: justify; text-indent: 0in">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">A $0.7 million non-cash <FONT STYLE="letter-spacing: -0.1pt">loss
    </FONT>from the change in the fair value of certain warrants accounted for as liabilities issued in connection with</FONT> <FONT STYLE="font-size: 9pt">the
    </FONT><FONT STYLE="font-size: 10pt">Private Placement (defined below) in October 2023.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Additionally, we reflected a marginal income
    tax expense in the Fiscal 2025 Quarter, compared to a net deferred income tax benefit of $0.9 million in the Fiscal 2024 Quarter.
    <FONT STYLE="letter-spacing: -0.1pt">For the Fiscal 2024 Quarter, we recognized a decrease in net deferred tax liability of $0.3
    million to reflect the effect of the change in exchange rates on the liability during the period and the recognition of $0.6 million
    of current period losses in the U.K. </FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 45.35pt; text-indent: -16.55pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Total comprehensive
loss in the Fiscal 2024 Quarter <FONT STYLE="letter-spacing: -0.15pt">includes </FONT>$1.3 million unrealized loss on investments compared
to nil in the Fiscal 2025 Quarter. The difference between net loss and total comprehensive loss in the Fiscal 2024 Quarter was due to
the effect of the unrealized non-cash loss with respect to our investment in Intensity Therapeutics, Inc. (&#8220;Intensity&#8221;).
We recognized a non-cash unrealized loss of $1.3 million in the Fiscal 2024 Quarter, representing the change in the fair value of the
investment in Intensity based on the Nasdaq listed price of the shares during the period.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Operating <FONT STYLE="letter-spacing: -0.1pt">Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Total operating
expenses are comprised of the <FONT STYLE="letter-spacing: -0.1pt">following (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.8pt 0 0.05pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 10pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Three months ended September 30,</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><B>2024</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 8.95pt">Research and development</TD>
    <TD STYLE="width: 1%; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 12%; font-weight: bold; text-align: right"><B>723</B></TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">4,237</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">General and administrative expenses</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><B>881</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,693</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total operating expenses</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><B>$</B></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><B>1,604</B></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,930</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1pt 0.1in 0pt 8.65pt; text-align: justify"><B><I>Research and Development
<FONT STYLE="letter-spacing: -0.2pt">Costs</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">R&amp;D
costs are comprised of the <FONT STYLE="letter-spacing: -0.1pt">following (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.8pt 0 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 10pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Three months ended September 30,</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 8.95pt">Research and development &#8211; Clinical</TD>
    <TD STYLE="width: 1%; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 12%; font-weight: bold; text-align: right">366</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">1,962</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Payroll-related expenses</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">245</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">367</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Consulting fees</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">32</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">247</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Manufacturing costs</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">29</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">968</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Research and development &#8211; CRADA</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">31</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Licensing fees</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">120</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Legal regarding patents&#8217; registration</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">5</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Research and development services and storage</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">46</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">148</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">Share-based compensation expense</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">394</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total research and development costs</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">723</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,237</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">R&amp;D
costs decreased by approximately $3.5 million, or approximately 83%, from approximately $4.2 million in the Fiscal 2024 Quarter to approximately
$0.7 million in the Fiscal 2025 Quarter. The decrease was primarily attributable to the winding down of clinical trial costs (principally
CRO-related), which decreased by approximately $1.6 million, from $2.0 million in the Fiscal 2024 Quarter to $0.4 million in the Fiscal
2025 Quarter, as activities ramped down throughout the period since we made the decision to pause enrollment in our sponsored clinical
trials in the third and fourth quarters of Fiscal 2024. Manufacturing-related costs decreased by $0.9 million, from $1.0 million in the
Fiscal 2024 Quarter to $0.029 million in the Fiscal 2025 Quarter. These decreases reflect the winding down of clinical activity and manufacturing-related
costs resulting from our decision to discontinue our sponsored clinical trial for the iNKT program and pause further patient accrual
to our sponsored adenosine program. R&amp;D non-cash share-based compensation expense decreased from $0.4 million in the Fiscal 2024
Quarter to nil in the Fiscal 2025 Quarter. Payroll-related expenses decreased by $0.1 million, from $0.37 million in the Fiscal 2024
Quarter to $0.24 million in the Fiscal 2025 Quarter, due to the resignation of two employees in January 2024. Additionally, consulting
fees <FONT STYLE="letter-spacing: -0.05pt">decreased by </FONT>approximately $0.2 million from $0.25 million in the Fiscal 2024 Quarter
to $0.03 million in the Fiscal 2025 Quarter, to reflect the decrease in activity period-over-period. Finally, licensing fees decreased
by approximately $0.1 million due to <FONT STYLE="letter-spacing: -0.15pt">licensing </FONT>fees paid <FONT STYLE="letter-spacing: -0.15pt">to
the licensor of certain intellectual property utilized in </FONT>the iNKT <FONT STYLE="letter-spacing: -0.15pt">clinical </FONT>trial
in Fiscal 2024 Quarter compared to nil in Fiscal 2025 Quarter as the iNKT clinical trial was discontinued in the latter half of Fiscal
2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify">General and Administrative
<FONT STYLE="letter-spacing: -0.1pt">Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Key components
of G&amp;A expenses are the <FONT STYLE="letter-spacing: -0.1pt">following (in thousands):</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 11.95pt 0 1.1pt 8.35pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 10pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid"><B>Three months ended September 30,</B></TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>&#160;</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>2024</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>2023</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 11.45pt">Professional fees</TD>
    <TD STYLE="width: 1%; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 12%; font-weight: bold; text-align: right">398</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">762</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11.45pt">Payroll-related expenses</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">134</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">223</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 11.45pt">D&amp;O insurance</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">160</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">175</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11.45pt">Office and general expenses</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">33</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">99</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 11.45pt">Directors&#8217; fees</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">83</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11.45pt">Share-based compensation expense</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">141</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">348</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 11.45pt">Consulting fees</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">15</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 2.5pt">Total general and administrative expenses</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">881</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,693</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">G&amp;A
expenses decreased by approximately $0.8 million, or approximately 48%, from approximately $1.7 million in the Fiscal 2024 Quarter to
approximately $0.9 million in the Fiscal 2025 Quarter. Professional fees decreased by $0.4 million, from $0.8 million in the Fiscal 2024
Quarter to $0.4 million in the Fiscal 2025 Quarter. Payroll-related expenses decreased by $0.1 million from $0.2 million in the Fiscal
2024 Quarter to $0.1 million in the Fiscal 2025 Quarter. The decrease in professional fees and payroll-related expenses is due to the
accrual of the monthly fees and payments for the entire second quarter in the first quarter for a consultant and employee in connection
with the Retention Agreements entered into on July 22, 2024. For further discussion regarding this matter, see &#8220;Retention Agreements
and General Releases&#8221; section of Note 13 &#8220;Related Party Transactions&#8221; included elsewhere in this Report. Additionally,
G&amp;A non-cash share-based compensation expense decreased by $0.2 million due to the continued vesting of stock options, partially
offset by recording all share-based compensation expense as G&amp;A expenses as the result of the discontinuation of the iNKT trial and
the pause of further patient accrual in the adenosine program. Additionally, directors&#8217; fees decreased by $0.1 million in the Fiscal
2025 Quarter, compared to the Fiscal 2024 Quarter, as all directors, except for two directors who resigned in April 2024, waived their
fees in the Fiscal 2025 Quarter.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.8pt 0.1in 0 0; text-align: justify"></P>

<P STYLE="font: bold 10pt/104% Times New Roman, Times, Serif; margin: 3.7pt 0.1in 0 8.65pt; text-align: justify">Six Months Ended September
30, 2024 Compared to the Six Months Ended September 30, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><B>Results of <FONT STYLE="letter-spacing: -0.1pt">Operations</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The following
details major expenses for the six months ended September 30, 2024, compared to the six months ended <FONT STYLE="letter-spacing: -0.2pt">S</FONT>eptember
30, <FONT STYLE="letter-spacing: -0.1pt">2023 (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.8pt 0 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 10pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Six months ended September 30,</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-weight: bold; text-align: left">Operating expenses</TD>
    <TD STYLE="width: 1%; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 12%; font-weight: bold; text-align: right">(4,443</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">(10,927</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Change in fair value of warrant liability</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">426</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Change in fair value of deferred purchase price payable &ndash; Tarus and deferred
    obligation &ndash; iOx milestone</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(1,224</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Gain on settlement with Parexel &ndash; iOx CRO</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">946</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Share of loss in associate accounted for using equity method</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(90</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Foreign exchange transaction (loss) gain</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(7</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Depreciation expense</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(15</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(26</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">Interest income, net</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">69</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">123</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Loss before provision for income taxes</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(3,024</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(12,143</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">Income tax (expense) benefit</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(2</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,052</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">(3,026</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(11,091</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other comprehensive loss</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.65pt">Net unrealized gain on investments</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">469</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total comprehensive loss for period</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,026</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,622</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P></TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Comprehensive loss attributable to:</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: right">&#160;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 8.95pt">Owners of the Company</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD>
    <TD STYLE="font-weight: bold; text-align: right">(3,016</TD>
    <TD STYLE="font-weight: bold; text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(10,608</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">Non-controlling interest</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(10</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total comprehensive loss for period</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,026</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,622</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.7pt 0 0">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify">Results of Operations
for the <FONT STYLE="letter-spacing: -0.2pt">Six </FONT>Months Ended September 30, 2024 Compared to the Six Months Ended September 30,
<FONT STYLE="letter-spacing: -0.2pt">2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We incurred
a net loss of approximately $3.0 million during the six months ended September 30, 2024 (the &#8220;Fiscal 2025 <FONT STYLE="letter-spacing: -0.1pt">Six
Months</FONT>&#8221;), <FONT STYLE="letter-spacing: -0.1pt">compared to net loss of $11.1 million during the six months ended September
30, 2023 (the &#8220;Fiscal 2024 Six Months&#8221;) and total comprehensive loss of approximately $3.0 million and $10.6 million during
the </FONT>Fiscal 2025 Six Months and the Fiscal 2024 Six Months, respectively, a decrease in net loss of $8.1 million and a decrease
in comprehensive loss of $7.6 million, <FONT STYLE="letter-spacing: -0.1pt">period</FONT>-over-period<FONT STYLE="letter-spacing: -0.1pt">.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The components
of the change in net loss and total comprehensive loss are as <FONT STYLE="letter-spacing: -0.1pt">follows:</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Operating expenses, which include R&amp;D and
    G&amp;A expenses, were $4.4 million in the Fiscal 2025 <FONT STYLE="letter-spacing: -0.15pt">Six Months</FONT>, compared to $10.9
    million in the Fiscal 2024 Six Months, a decrease of $6.5 million, which is discussed more fully <FONT STYLE="letter-spacing: -0.1pt">below.</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">A net gain of $0.9 million from the settlement
    and release of obligations and liabilities under the Master Services Agreement between iOx and Parexel. See &#8220;iOx &#8211; Parexel
    Master Services Agreement&#8221; section of Note 12 &#8220;Commitments and Contingent Liabilities&#8221; for additional discussion
    regarding this matter included elsewhere in this Report.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 44.8pt; text-indent: -16.2pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">A $0.4 million non-cash gain from the change
    in the fair value of certain warrants accounted for as liabilities issued in connection with the Private Placement in October 2023.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0.05pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">A non-cash loss totaling $1.2 million comprised
    of the change (increase) in the fair value of the deferred obligation - iOx milestone of $0.45 million, and the change (increase)
    in the fair value of the deferred purchase price payable to the former Tarus shareholders of $0.77 million in the Fiscal 2024 Six
    Months.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Additionally, we reflected a marginal income
    tax expense in the Fiscal 2025 Six Months, compared to a net deferred income tax benefit of $1.1 million <FONT STYLE="letter-spacing: -0.1pt">benefit
    </FONT>in the Fiscal 2024 Six Months. For the Fiscal 2024 Six Months, we recognized a decrease in net deferred tax liability of $0.1
    million to reflect the effect of the change in exchange rates on the liability during the period and the recognition $1.0 million
    of current period losses in the U.K. </FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 44.8pt; text-align: justify; text-indent: -16.2pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Total comprehensive
loss in the Fiscal 2024 Six Months <FONT STYLE="letter-spacing: -0.15pt">includes </FONT>$0.5 million unrealized gain on investments
compared to nil in the Fiscal 2025 Six Months. The difference between net loss and total comprehensive loss in the Fiscal 2024 Six Months
was due to the effect of the unrealized non-cash gain with respect to our investment in Intensity. We recognized a non-cash unrealized
gain of $0.5 million in the Fiscal 2024 Six Months, representing the change in the fair value of the investment in Intensity based on
the Nasdaq listed price of the shares during the period.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.35pt">&#160;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 8.35pt">Operating <FONT STYLE="letter-spacing: -0.1pt">Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0 0"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Total operating
expenses are comprised of the <FONT STYLE="letter-spacing: -0.1pt">following (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.8pt 0 0.05pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 10pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Six months ended September 30,</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD>&#160;</TD>
    <TD COLSPAN="3">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 8.95pt">Research and development</TD>
    <TD STYLE="width: 1%; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 12%; font-weight: bold; text-align: right">2,028</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">7,865</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">General and administrative expenses</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">2,415</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,062</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total operating expenses</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,443</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,927</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1pt 0pt 0pt 8.65pt"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1pt 0pt 0pt 8.65pt"><B><I>Research and Development <FONT STYLE="letter-spacing: -0.2pt">Costs</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1pt 0 0">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">R&amp;D
costs are comprised of the <FONT STYLE="letter-spacing: -0.1pt">following (in thousands):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.8pt 0 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 10pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Six months ended September 30,</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD>
    <TD STYLE="font-size: 11pt">&#160;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 8.95pt">Research and development &#8211; Clinical</TD>
    <TD STYLE="width: 1%; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 12%; font-weight: bold; text-align: right">1,072</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">2,985</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Payroll-related expenses</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">494</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">847</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Consulting fees</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">153</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">460</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Manufacturing costs</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">123</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,715</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Research and development &#8211; CRADA</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">62</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">63</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Licensing fees</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">38</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">232</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Legal regarding patents&#8217; registration</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">28</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">8</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Research and development services and storage</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">58</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">238</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 8.95pt">Share-based compensation expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">817</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 8.95pt">Contractual milestone</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">500</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total research and development costs</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,028</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,865</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">R&amp;D
costs decreased by approximately $5.8 million, or approximately 74%, from approximately $7.9 million in the Fiscal 2024 Six Months to
approximately $2.0 million in the Fiscal 2025 Six Months. The decrease was primarily attributable to the winding down of clinical trial
costs (principally CRO-related), which decreased by approximately $2.0 million, from $3.0 million in the Fiscal 2024 Six Months to $1.0
million in the Fiscal 2025 Six Months, as activities ramped down throughout the period since we made the decision to pause enrollment
in our sponsored clinical trials in the third and fourth quarters of Fiscal 2024. Manufacturing-related costs decreased by $1.6 million,
from $1.7 million in the Fiscal 2024 Six Months to $0.1 million in the Fiscal 2025 Six Months. These decreases reflect the winding down
of clinical activity and manufacturing-related costs resulting from our decision to discontinue our sponsored clinical trial for the
iNKT program and pause further patient accrual to our sponsored adenosine program. R&amp;D non-cash share-based compensation expense
decreased from $0.8 million in the Fiscal 2024 Six Months to nil in the Fiscal 2025 Six Months. Payroll-related expenses decreased by
$0.35 million, from $0.85 million in the Fiscal 2024 Six Months to $0.5 million in the Fiscal 2025 Six Months, due to the resignation
of two employees in January 2024. Additionally, in the Fiscal 2024 Six Months, we incurred a milestone payment of $0.5 million for dosing
our first adenosine patients, a decrease in consulting fees of approximately $0.3 million from $0.5 million in the Fiscal 2024 <FONT STYLE="letter-spacing: -0.05pt">Six
Months </FONT>to $0.2 million in the Fiscal 2025 Six Months, to reflect the decrease in activity period-over-period, and, finally, <FONT STYLE="letter-spacing: -0.15pt">a
decrease of $0.2 million in licensing fees paid to the licensor of certain intellectual property utilized in the iNKT clinical trial
</FONT>prior to discontinuing the study in the latter half of Fiscal 2024.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 3.7pt 0 0 8.35pt">General and Administrative <FONT STYLE="letter-spacing: -0.1pt">Expenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0 0"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 29.1pt">Key components of G&amp;A expenses are the <FONT STYLE="letter-spacing: -0.1pt">following
(in thousands):</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 11.95pt 0 1.1pt 8.35pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 98%; font: 11pt Times New Roman, Times, Serif; margin-left: 8.65pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six months
    ended September <FONT STYLE="letter-spacing: -0.25pt">30,</FONT></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>&#160;</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2024</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>&#160;</B></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>&#160;</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2023</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B>&#160;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD COLSPAN="3">&#160;</TD>
    <TD>&#160;</TD>
    <TD COLSPAN="3">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 11.45pt">Professional fees</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 12%; font-size: 10pt; font-weight: bold; text-align: right">941</TD>
    <TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD>
    <TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,232</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 11.45pt">Payroll-related expenses</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">771</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">447</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 11.45pt">D&amp;O insurance</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">320</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">350</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 11.45pt">Office and general expenses</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">76</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">168</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 11.45pt">Directors&#8217; fees</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">7</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">165</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 11.45pt">Share-based compensation expense</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">285</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">695</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 11.45pt">Consulting fees</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><B>15</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 2.5pt">Total general and administrative
    expenses</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,415</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,062</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.1pt 0 0">&#160;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">G&amp;A
expenses decreased by approximately $0.647 million, or approximately 21%, from approximately $3.062 million in the Fiscal 2024 Six Months
to approximately $2.415 million in the Fiscal 2025 Six Months. Professional fees decreased by $0.3 million, from $1.2 million in the
Fiscal 2024 Six Months to $0.9 million in the Fiscal 2025 Six Months due to decreased accounting and public relations related fees. Payroll-related
expenses increased by $0.4 million from $0.4 million in the Fiscal 2024 Six Months to $0.8 million in the Fiscal 2025 Six Months due
to the amounts associated with retention agreements executed with an employee and a consultant. For further discussion regarding this
matter, see &#8220;Retention Agreements and General Releases&#8221; section of Note 13 &#8220;Related Party Transactions&#8221; included
elsewhere in this Report. Additionally, G&amp;A non-cash share-based compensation expense decreased by $0.4 million due to the continued
vesting of stock options, partially offset by recording all share-based compensation expense as G&amp;A expenses as the result of the
discontinuation of the iNKT trial and the pause of further patient accrual in the adenosine program. Additionally, directors&#8217; fees
decreased by $0.2 million in the Fiscal 2025 Six Months, compared to the Fiscal 2024 Six Months, as all directors, except for two directors
who resigned in April 2024, waived their fees in the Fiscal 2025 Six Months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.8pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><A NAME="liquidity"></A>Liquidity
and Capital <FONT STYLE="letter-spacing: -0.1pt">Resources</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Capital <FONT STYLE="letter-spacing: -0.1pt">Resources</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We filed
the March 2021 Registration Statement with the SEC in order to sell ordinary shares, debt securities, warrants and units in one or more
offerings from time to time, which became effective on March 8, 2021. In connection with the March 2021 Registration Statement, we have
filed with the <FONT STYLE="letter-spacing: -0.2pt">SEC:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">a base prospectus, which covers the offering,
    issuance and sale by us of up to $200 million in the aggregate of the securities identified above from time to time in one or more
    offerings;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">a prospectus supplement, which covers the offer,
    issuance and sale by us in an ATM offering program of up to a maximum aggregate offering price of $50 million of our ordinary shares
    that may be issued and sold from time to time under the Sales Agreement with Cantor Fitzgerald &amp; Co., the sales agent;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">a prospectus supplement dated June 24, 2021,
    for the offer, issuance and sale by us of 57,500 ordinary shares for gross proceeds of <FONT STYLE="letter-spacing: -0.1pt">approximately
    </FONT>$26.5 million in a firm commitment underwritten public offering with Cantor <FONT STYLE="letter-spacing: -0.1pt">Fitzgerald;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0.45pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">a prospectus supplement dated August 19, 2022,
    for the resale of up to $30 million in ordinary shares that we may sell from time to time to Lincoln and an additional 4,726 shares
    that were issued to Lincoln; and</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0.1pt; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">a prospectus supplement dated September 29, 2023
    for the offer, issuance and sale by us in a registered direct public offering through H.C. Wainwright &amp; Co., the placement agent,
    to an institutional and accredited investor of (i) 98,500 of our ordinary shares at a purchase price of $38.00 per share and (ii)
    Pre-Funded Warrants to purchase up to 59,395 of our ordinary shares, at a purchase price of $37.98 per Pre-Funded Warrant), for aggregate
    gross proceeds of approximately $6 million (the &#8220;2023 Equity Financing&#8221;). All Pre-Funded Warrants, which were exercisable
    for one ordinary share at an exercise price of $0.02 per share, were exercised in full on May 29, 2024.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 44.8pt; text-align: justify">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The Sales
Agreement permits us to sell in an ATM program up to $50 million of ordinary shares from time to time. Through September 30, 2024, we raised approximately $4.2 million in gross proceeds through the sale of shares of common shares under the
ATM program. The sales under the prospectus
will be deemed to be made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;).</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">During
Fiscal 2024, we sold 9,331 ordinary shares under the ATM program, generating net proceeds of approximately $0.7 <FONT STYLE="letter-spacing: -0.1pt">million. There were no shares sold under the ATM program during the six months ended September 30, 2024.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The March
2021 Registration Statement expired on March 8, 2024. In order to issue additional shares under our ATM program or the Committed Purchase
Agreement in the future, we would be required to file a new registration statement, which must be declared effective by the SEC prior
to use, and to file a prospectus supplement related to the ATM program or the Committed Purchase Agreement, as the case may be.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Furthermore,
our ATM program and the Committed Purchase Agreement with Lincoln are generally limited based on, among other things, our Nasdaq trading
volume. Under the Baby Shelf Rule, the amount of funds we can raise through primary public offerings of securities in any 12-month period
using a registration statement on Form F-3 is limited to one-third of the aggregate market value of the ordinary shares held by our non-affiliates,
which limitation may change over time based on our stock price, number of ordinary shares outstanding and the percentage of ordinary
shares held by non-affiliates. We are therefore limited by the Baby Shelf Rule as of the filing of this Form 6-K, until such time as
our non-affiliate public float exceeds $75 <FONT STYLE="letter-spacing: -0.1pt">million.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">In connection
with the 2023 Equity Financing, on September 29, 2023, we entered into the Purchase Agreement with an institutional and accredited investor
in connection with the Registered Direct Offering and the concurrent private placement. The Offerings closed on October 3, 2023.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Pursuant
to the Purchase Agreement, in the Registered Direct Offering, we sold (i) 98,500 of our ordinary shares, at a purchase price of $38.00
per share and (ii) Pre-Funded Warrants to purchase up to 59,395 Pre-Funded Warrant Shares. All Pre-Funded Warrants, which were immediately
exercisable for one ordinary share at an exercise price of $0.02 per share, were exercised in full on May 29, 2024.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify"></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">In the Private
Placement, we issued to such institutional and accredited investor unregistered Series A Warrants to purchase up to 157,895 ordinary
shares, unregistered Series B Warrants to purchase up to 157,895 ordinary shares, and unregistered Series C Warrants to purchase up to
157,895 ordinary shares, together exercisable for an aggregate of up to 473,685 Private Warrant Shares. Pursuant to the terms of the
Purchase Agreement, for each ordinary share and Pre-Funded Warrant issued in the Registered Direct Offering, an accompanying Series A
Warrant, Series B Warrant and Series C Warrant were issued to such institutional and accredited investor. Each Series A Warrant is exercisable
for one Private Warrant Share at an exercise price of $38.00 per share, is immediately exercisable and will expire 18 months from the
date of issuance. Each Series B Warrant is exercisable for one Private Warrant Share at an exercise price of $45.20 per share, is immediately
exercisable and will expire three years from the date of issuance. Each Series C Warrant is exercisable for one Private Warrant Share
at an exercise price of $45.20 per share, is immediately exercisable and will expire five years from the date of issuance. The net proceeds
to us from the Offerings were approximately $5.3 million, after deducting placement agent&#8217;s fees and estimated offering <FONT STYLE="letter-spacing: -0.1pt">expenses.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Pursuant
to an engagement letter, dated as of August 26, 2023, between us and H.C. Wainwright &amp; Co., LLC (the &ldquo;Placement Agent&rdquo;),
we paid the Placement Agent a total cash fee equal to 6.0% of the aggregate gross proceeds received in the Offerings, or $0.36 million.
We also agreed to pay the Placement Agent in connection with the Offerings a management fee equal to 1.0% of the aggregate gross proceeds
raised in the Offerings ($0.06 million), $75,000 for non-accountable expenses and $15,950 for clearing fees. In addition, we agreed to
issue to the Placement Agent, or its designees, Placement Agent Warrants to purchase up to 7,896 ordinary shares, which represents 5.0%
of the aggregate number of ordinary shares and Pre-Funded Warrants sold in the Registered Direct Offering. The Placement Agent Warrants
have substantially the same terms as the Private Warrants, except that the Placement Agent Warrants have an exercise price equal to $47.50,
or 125% of the offering price per ordinary share sold in the Registered Direct Offering, and will be exercisable for five years from
the commencement of the sales pursuant to the Offerings.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-style: italic; font-weight: bold; text-align: justify; margin: 0pt 0 0pt 14.95pt">Going Concern</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The accompanying
condensed consolidated interim financial statements for the three and six months ended September 30, 2024 have been prepared on a basis
that assumes that we will continue as a going concern and that contemplates the continuity of operations, the realization of assets and
the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying condensed consolidated
interim financial statements for the three and six months ended September 30, 2024 do not include any adjustments relating to the recoverability
and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&nbsp;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">As of September
30, 2024, we had cash and cash equivalents of approximately $1.8 million and total current liabilities of approximately $0.9 million.
For the six months ended September 30, 2024, we are reporting a net loss of approximately $3.0 million, and cash used in operating activities
of approximately $3.3 million. As of November 25, 2024, we had approximately $1.7 million of cash and cash equivalents on hand.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&nbsp;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">In late
Fiscal 2024, because of continued liquidity constraints, we made the decision to discontinue our iNKT sponsored trial and pause further
patient accrual to our adenosine program. We are exploring strategic alternatives, which may include finding a partner for one or more
of our assets, a sale of our company, a merger, restructurings, both in and out of court, a company wind down, further financing efforts
or other strategic action.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">There can
be no assurance that our evaluation of strategic alternatives will result in any agreements or transactions, or that, if completed, any
agreements or transactions will be successful or on attractive terms. Any potential transaction would be dependent on a number of factors
that may be beyond our control, including, among other things, market conditions, industry trends, the interest of third parties in a
potential transaction with us and the availability of financing to us or third parties in a potential transaction with us on reasonable
terms. The process of reviewing strategic alternatives may require us to incur additional costs and expenses. It could negatively impact
our ability to attract, retain and motivate key employees, and expose us to potential litigation in connection with this process or any
resulting transaction. If we are unable to effectively manage the process, our financial condition and results of operations could be
adversely affected. In addition, any strategic alternative that may be pursued and completed ultimately may not deliver the anticipated
benefits or enhance shareholder value. There can be no guarantee that the process of evaluating strategic alternatives will result in
our company entering into or completing a potential transaction within the anticipated timing or at all. There is no set timetable for
this evaluation and we do not intend to disclose developments with respect to this evaluation unless and until we determine that further
disclosure is appropriate or legally required. As of November 25, 2024, we had approximately $1.7 million of cash and cash equivalents
on hand, which we expect is only sufficient to cover our operating needs through January 2025. These factors raise substantial doubt
about our ability to continue as a going concern within one year after the date of the consolidated statement of financial position.
There were no adjustments made to reflect the effect of this doubt.</P>
<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We have
incurred significant operating losses since inception and expect to continue to incur significant operating losses for the foreseeable
future and may never become profitable. The losses result primarily from our conduct of research and development activities. As previously
discussed, we have discontinued further development of our iNKT sponsored trial and paused further patient accrual to our adenosine program
in order to preserve cash resources. Additionally, during the fourth quarter of Fiscal 2024, we sold our shares in Intensity on Nasdaq.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We historically
have funded our operations principally from proceeds from issuances of equity and debt securities. We will require significant additional
capital to make the investments we need to execute our longer-term business plan. Our ability to successfully raise sufficient funds
through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, future equity issuances would
result in dilution to existing shareholders and any future debt securities may contain covenants that limit our operations or ability
to enter into certain transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify; text-indent: 20.7pt">As
of the date of this filing, we currently anticipate that current cash and cash equivalents is only sufficient to cover our operating
needs through January 2025. These factors raise substantial doubt about our ability to continue as a going concern within one year after
the date of the consolidated statement of financial position.</P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify; text-indent: 20.7pt">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 3.7pt 0.1in 0 8.35pt; text-align: justify">Cash Flows From Operating
<FONT STYLE="letter-spacing: -0.1pt">Activities</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/103% Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify; text-indent: 20.7pt">During
the Fiscal 2025 Six Months, we used cash of $3.25 million to fund operating activities, compared to $7.7 million used during the Fiscal
2024 Six Months. The decrease of $4.5 million period over period is primarily due to our decision to discontinue and pause further patient
accrual in the respective clinical programs in the latter half of Fiscal 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Cash Flows From Investing
<FONT STYLE="letter-spacing: -0.1pt">Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">There were
no cash flows from investing activities during both the Fiscal 2025 Six Months and the Fiscal 2024 Six Months<FONT STYLE="letter-spacing: -0.1pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Cash Flows From Financing
<FONT STYLE="letter-spacing: -0.1pt">Activities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">During the
Fiscal 2025 Six Months, we used net cash of $0.018 million from financing activities. During the Fiscal 2024 Six Months, we generated
cash <FONT STYLE="letter-spacing: -0.25pt">of </FONT>$0.6 million from financing activities <FONT STYLE="letter-spacing: -0.25pt">primarily
attributable to the</FONT> net proceeds from sales under the ATM <FONT STYLE="letter-spacing: -0.1pt">program partially offset by the
repayment of lease liability.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><A NAME="keycontractualobligations"></A>Key
Contractual <FONT STYLE="letter-spacing: -0.1pt">Obligations</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Details
of contractual obligations, commitments and contingent liabilities are provided in Note 12, &#8220;Commitments and Contingent Liabilities,&#8221;
to the unaudited condensed consolidated interim financial statements for the three and six months ended September 30, 2024.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify">Master Services <FONT STYLE="letter-spacing: -0.1pt">Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Effective
March 15, 2022, through iOx, we entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Parexel under which Parexel agreed
to act as clinical service provider (&#8220;CRO&#8221;) pursuant to a work order (&#8220;Work Order&#8221;) effective June 1, 2022. Pursuant
to such Work Order, Parexel planned to operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and NSCLC. The MSA provided
for a five-year term, and the Work Order provided for a term to end upon the completion of the services required. The budget provided
for service fees and pass-through expenses and clinical sites totaling $11.5 million. During Fiscal 2023, we executed two change orders
resulting in a $0.6 million increase in the overall estimated budgeted costs. As a result of our decision to discontinue the development
with respect to this program, on December 20, 2023, we provided Parexel notice of termination of the contract, with a planned termination
date of April 18, 2024. As the ongoing CRO services were wound down, we noticed that expenses incurred under the CRO agreement were higher
than originally budgeted. Parexel agreed to refund $0.552 million to us and release the liability for amounts invoiced and unbilled services
totaling $1.486 million, and we forfeited advanced payments of $1.091 million. As a result, we recognized a net gain on of $0.946 million
as of September 30, 2024. We received the refund from Parexel on October 3, 2024.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Clinical Service <FONT STYLE="letter-spacing: -0.1pt">Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">On March
1, 2023, we, through Tarus, entered into a clinical service agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-
party CRO. The term of the agreement is through the earlier of August 14, 2025, or the completion of provision of services and the payment
of contractual obligations. The budgeted costs for the services to be provided is approximately $12.1 million. Because of our decision
to discontinue and pause further accrual of all clinical studies, we are negotiating a revision to the services required under the change
in circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">iOx (iNKT) <FONT STYLE="letter-spacing: -0.1pt">License</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">On July
1, 2015, iOx entered into a licensing agreement with Ludwig Institute for Cancer Research Ltd. (&#8220;LICR&#8221;), which covers certain
technology, intellectual property and know-how and development with respect to iNKT cell agonists to treat human diseases. Under the
terms of the licensing agreement (&#8220;LICR License&#8221;), LICR granted to iOx an exclusive worldwide license, with the right to
grant sublicenses, under the Licensed Patent and Licensed Technology, each as defined in the LICR License, in each case, to develop,
make, have made, use, sell, offer for sale and import Licensed Products, as defined in the LICR License, subject to certain rights retained
by LICR for academic and research purposes. The LICR License provides for a royalty term of ten years after the first commercial sale,
on a Licensed Product by Licensed Product, country by country basis. Upon the expiration of the applicable royalty term, the license
with respect to such Licensed Product in such country will convert to a non-exclusive, fully paid-up license.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">LICR is
entitled to 15,000 GBP as an annual license fee on each annual anniversary of the effective date of the LICR License until royalties
become duly payable and 15,000 GBP as a patent reimbursement fee until LICR has been fully reimbursed for all patent costs incurred prior
to the LICR <FONT STYLE="letter-spacing: -0.1pt">License.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Additionally,
LICR is entitled to milestone payments totaling up to 20.45 million GBP based upon the first Licensed Product achieving specific clinical,
regulatory and sales-based milestones. LICR is also entitled to milestone payment totaling up to 10.25 million GBP based upon a second
Licensed Product achieving specific clinical, regulatory and sales-based milestones.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Finally,
LICR is entitled to a low-single digit royalty on net sales of Licensed Products that marginally escalates upon sales levels all determined
by territory. LICR is also entitled to a percentage of any sublicensing income that gradually decreases based on the stage of development
of the most advanced Licensed Product that is the subject of the applicable sublicense agreement.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Pursuant
to the terms and conditions of the LICR License, LICR is responsible for managing the preparation, filing, prosecution and maintenance
of all Licensed Patent Rights, as defined in the LICR License. iOx will reimburse LICR for all reasonable patent costs it incurs after
the effective date of the LICR License. Further, the LICR License provides that both parties have the right to termination for material
breach or default in the performance of obligations under the LICR License by the other party and in the event of insolvency of the other
party.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><FONT STYLE="letter-spacing: -0.1pt">Tarus
(adenosine) License</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">On July
1, 2022, we acquired Tarus Therapeutics, Inc. Pursuant to the license agreement entered into by Tarus Therapeutics, Inc. and Impetis
Biosciences Limited (&#8220;Impetis&#8221;) dated October 29, 2019 (&#8220;Impetis License&#8221;), Impetis granted to Tarus an exclusive
sublicensable worldwide license to develop and commercialize the adenosine receptor antagonists for all indications and certain other
assets which were granted upon exercise of a call option on November 5, 2020.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Under the
terms of the Impetis License, Impetis is eligible to receive payments totaling up to $38 million on an Impetis Compound (as defined in
the Impetis License) based upon achievement of certain clinical and commercial milestones. Milestone payments due in the amount of USD
$1 million for achievement of certain regulatory milestones were paid in July 2022 and a $0.5 million milestone was paid upon dosing
the first patient in September 2023.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Additionally,
commencing upon the First Commercial Sale (as defined in the Impetis License) of a Licensed Product (as defined in the Impetis License),
Impetis is entitled to royalties on worldwide net sales that begin in the mid-single digits and escalate through multiple tiers, with
net sales over $1 billion receiving low double digit royalties.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Pursuant
to the terms and conditions of the Impetis License, Tarus has exclusive and full authority to manage all intellectual property (whether
licensed or not) underlying the assets covered by the Impetis License and any other aspects related to exploitation, development and
commercialization thereof at its own cost, and Impetis must provide Tarus reasonable assistance as requested at Tarus&#8217; cost and
expense. Further, the Impetis License provides that both parties have the right to termination for material breach by the other party
and in the event that the other party undergoes certain events such as a voluntary winding-up, a liquidation or entry into receivership.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.7pt 0.1in 0 8.35pt; text-align: justify"><A NAME="offbalancesheetarrangements"></A>Off-balance
Sheet <FONT STYLE="letter-spacing: -0.1pt">Arrangements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">As of September
30, 2024 and March 31, 2024, we did not have any off-balance sheet arrangements, including any relationships with unconsolidated entities
or financial partnership to enhance perceived liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><A NAME="transactions"></A>Transactions
with Related <FONT STYLE="letter-spacing: -0.1pt">Parties</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Significant
related party transactions are detailed in Note 13, &#8220;Related Party Transactions,&#8221; to the unaudited condensed consolidated
interim financial statements for the three and six months ended September 30, 2024 included elsewhere in this Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><A NAME="financialandderivative"></A>Financial
and Derivative <FONT STYLE="letter-spacing: -0.1pt">Instruments</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our financial
instruments recognized in our condensed consolidated interim statements of financial position consist of the <FONT STYLE="letter-spacing: -0.1pt">following:</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Fair value
estimates are made at a specific point in time, based on relevant market information and information about financial instruments. These
estimates are subject to and involve uncertainties and matters of significant judgment; and therefore, these estimates cannot be determined
with precision. Changes in assumptions could significantly affect these estimates.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt">&#160;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The following
table summarizes our financial instruments as of September 30, 2024 and March 31, 2024 (in thousands):</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD STYLE="font-size: 9pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD COLSPAN="11" STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>September
        30, 2024</B></FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Unaudited)</B></FONT></P></TD>
    <TD STYLE="font-size: 9pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#160;</B></FONT></TD>
    <TD COLSPAN="11" STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
    31, 2024</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&#160;</TD>
    <TD STYLE="font-size: 9pt; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amortized</B></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Cost</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">FVTOCI</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">FVTPL</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-size: 9pt; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amortized</B></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Cost</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">FVTOCI</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">FVTPL</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 9pt; font-weight: bold; text-decoration: underline; text-align: left">Financial assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 46%; font-size: 9pt; font-weight: bold; text-align: left">Cash and cash equivalents</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 6%; font-size: 9pt; font-weight: bold; text-align: right">1,764</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 6%; font-size: 9pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 6%; font-size: 9pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="width: 6%; font-size: 9pt; text-align: right">5,028</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="width: 6%; font-size: 9pt; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="width: 6%; font-size: 9pt; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">Prepaid expenses and other current assets</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: right">922</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 9pt">&#160;</TD>
    <TD STYLE="font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; text-align: right">2,667</TD>
    <TD STYLE="font-size: 9pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 9pt">&#160;</TD>
    <TD STYLE="font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-size: 9pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 9pt">&#160;</TD>
    <TD STYLE="font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-size: 9pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 11pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="font-size: 9pt; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="7" STYLE="font-size: 9pt; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>September 30, 2024</B></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Unaudited)</B></P></TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="7" STYLE="font-size: 9pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="font-size: 9pt; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amortized</B></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Cost</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">FVTPL</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="font-size: 9pt; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amortized</B></P>
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Cost</B></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&#160;</B></P></TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">FVTPL</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 9pt; font-weight: bold; text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 9pt; font-weight: bold; text-decoration: underline; text-align: left">Financial liabilities</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font-size: 9pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 10%; font-size: 9pt; font-weight: bold; text-align: right">845</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="width: 10%; font-size: 9pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="width: 10%; font-size: 9pt; text-align: right">2,836</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt">&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="width: 10%; font-size: 9pt; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="width: 1%; font-size: 9pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">Warrant liability</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: right">1,138</TD>
    <TD STYLE="font-size: 9pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 9pt">&#160;</TD>
    <TD STYLE="font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; text-align: right">&#8212;&#160;&#160;</TD>
    <TD STYLE="font-size: 9pt; text-align: left">&#160;</TD>
    <TD STYLE="font-size: 9pt">&#160;</TD>
    <TD STYLE="font-size: 9pt; text-align: left">$</TD>
    <TD STYLE="font-size: 9pt; text-align: right">1,564</TD>
    <TD STYLE="font-size: 9pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23.05pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.05pt">A summary of our risk exposures
as it relates to financial instruments are reflected below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0.4in; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Fair value of Financial
<FONT STYLE="letter-spacing: -0.1pt">Instruments</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 23.05pt">Our financial assets and liabilities
are comprised of cash and cash equivalents, receivables and investments in equities and public entities, accounts payable and accrued
liabilities, lease liability, and warrant liability.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We classify
the fair value of these transactions according to the following fair value hierarchy based on the amount of observable inputs used to
value the instrument:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Level 1 &#8211; Values are based on unadjusted
    quoted prices available in active markets for identical assets or liabilities as of the reporting <FONT STYLE="letter-spacing: -0.1pt">date.</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Level 2 &#8211; Values are based on inputs, including
    quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in
    the marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting date.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Level 3 &#8211; Values are based on prices or
    valuation techniques that are not based on observable market data. Investments are classified as Level 3 financial instrument.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Assessment
of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair
value hierarchy.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Management
has assessed that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts
largely due to the short-term maturities of these instruments.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The following
methods and assumptions were used to estimate their fair <FONT STYLE="letter-spacing: -0.1pt">values:</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><B>Warrant
Liability</B>: The fair value is estimated using a Black-Scholes model and in certain cases, a Monte Carlo simulation (Level <FONT STYLE="letter-spacing: -0.25pt">3).</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><FONT STYLE="letter-spacing: -0.25pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Credit Risk, Liquidity Risk and
Foreign Currency Risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our financial
instruments are exposed to certain financial risks: Credit Risk, Liquidity Risk and Foreign Currency <FONT STYLE="letter-spacing: -0.1pt">Risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Credit <FONT STYLE="letter-spacing: -0.2pt">Risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Credit risk
is the risk of loss associated with a counterparty&#8217;s inability to fulfill its payment obligations. The credit risk is attributable
to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected in our condensed consolidated
interim statements of financial position.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><B>Cash and cash
equivalents:</B> Cash and cash equivalents comprise cash on hand and amounts invested in underlying treasury and money market funds that
are readily convertible to a known amount of cash with three months or less from date of acquisition and are subject to an insignificant
risk of change in value. As of September 30, 2024 and March 31, 2024, cash equivalents was comprised of a money market account with maturities
less than 90 days from the date of purchase. Cash and cash equivalents are held with major international financial institutions and therefore
the risk of loss is minimal.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify">Liquidity <FONT STYLE="letter-spacing: -0.2pt">Risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Liquidity
risk is the risk that we will encounter difficulty in satisfying financial obligations as they become <FONT STYLE="letter-spacing: -0.2pt">due.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our approach
to managing liquidity is to ensure, as far as possible, that we will have sufficient liquidity to meet our liabilities when due, under
both normal and stressed conditions without incurring unacceptable losses or risking harm to our reputation. We hold sufficient cash
and cash equivalents to satisfy current obligations under accounts payable and accruals.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We monitor
our liquidity position regularly to assess whether we have the funds necessary to meet our operating needs and needs for investing in
new <FONT STYLE="letter-spacing: -0.1pt">projects.</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">As a biotech
company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity risks,
including the possibility that additional financing may not be available to us, or that actual drug development expenditures may exceed
those planned. The current uncertainty in global capital markets could have an impact on our future ability to access capital on terms
that are acceptable to us. There can be no assurance that required financing will be available to us.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0.1in 0 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 8.65pt; text-align: justify; text-indent: 0pt"><B><I>Foreign
                                            Currency <FONT STYLE="letter-spacing: -0.2pt">Risk</FONT></I></B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt"><FONT STYLE="letter-spacing: -0.2pt">&#160;</FONT></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">While we
operate in various jurisdictions, substantially all of our transactions are denominated in the U.S. Dollar, except the deferred tax liability
in the U.K. settleable in British pound sterling and the Stimunity Convertible Note receivable settleable in euros.</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0.05pt 0.1in 0 8.35pt; text-align: justify"><A NAME="useofestimates"></A>Use
of Estimates and <FONT STYLE="letter-spacing: -0.1pt">Judgments</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.85pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">The preparation
of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and
assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses.
Actual results may differ from these estimates.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Significant
areas where estimates are made include valuation of financial instruments (including deferred tax assets and liabilities, warrant liabilities,
research and development costs, contingent consideration assumed and measurement
of share-based compensation. Significant areas where critical judgments are applied include
in-process research and development and warrant liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><A NAME="newaccountingstandards"></A>New
Accounting Standards, Interpretations and <FONT STYLE="letter-spacing: -0.1pt">Amendments</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">We are also
unaware of any applicable but not-yet-adopted standards that are expected to materially affect our financial statements for future <FONT STYLE="letter-spacing: -0.1pt">periods.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 3.7pt 0.1in 0 8.35pt; text-align: justify"><A NAME="internalcontrol"></A>Internal
Control Over Financial <FONT STYLE="letter-spacing: -0.1pt">Reporting</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Our management,
including the CEO and CFO, is responsible for establishing and maintaining adequate internal controls over financial reporting (as defined
in Rule 13a-15(f) under the Exchange Act). Our internal control system was designed to provide reasonable assurance to our management
and our Board regarding the reliability of financial reporting and preparation and fair presentation of published financial statements
for external purposes in accordance with IFRS. Internal control over financial reporting includes those policies and procedures that:</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.15pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">pertain to the maintenance of records that in
    reasonable detail accurately and fairly reflect the transactions and dispositions of our <FONT STYLE="letter-spacing: -0.1pt">assets;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">provide reasonable assurance that transactions
    are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and that our receipts and expenditures
    are being made only in accordance with authorizations of our management and directors; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt; letter-spacing: -0.05pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">provide reasonable assurance regarding prevention
    or timely detection of unauthorized acquisition, use or disposition of our assets that have a material effect on the financial statements.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0.1in 0 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">All internal
control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can
provide only reasonable assurance with respect to financial statement preparation and presentation. Because of its inherent limitations,
internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to
future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance
with the policies or procedures may deteriorate.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Management
assessed the effectiveness of our internal control over financial reporting as of September 30, 2024. In making this assessment, it used
the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the
Treadway Commission. Based on the evaluation under these criteria, management identified material weaknesses in our internal controls
over financial reporting and, as a result, management concluded that our internal control over financial reporting was not effective
as of September 30, 2024.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Management
identified the following material weaknesses in our internal control over financial <FONT STYLE="letter-spacing: -0.1pt">reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Management was unable to perform an effective
    risk assessment or monitor internal controls over financial <FONT STYLE="letter-spacing: -0.1pt">reporting;</FONT></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">Management lacks the number of skilled persons
    that it requires given the complexity of the reporting requirements that it has to make, which more specifically include the staff
    and expertise to (i) properly segregate duties and perform oversight of work performed and to perform compensating controls over
    the finance and accounting functions, (ii) establish and perform fair value estimates or subsequently monitor fluctuations in fair
    value estimates, and (iii) apply complex accounting principles, including those relating to business combination accounting, income
    taxes, warrant liabilities and fair value estimates; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.65pt 0.1in 0 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/103% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 28.6pt"></TD>
    <TD STYLE="width: 16.2pt"><FONT STYLE="font-size: 9pt">&#8226;</FONT></TD>
    <TD STYLE="text-align: justify; padding-right: 0.1in"><FONT STYLE="font-size: 10pt">There are insufficient written policies and procedures
    in place to ensure the correct application of accounting and financial reporting with respect to the current requirements of IFRS
    and SEC disclosure requirements, some of which specifically relate to investment accounting and fair value measures, assessment of
    in-process R&amp;D assets, share-based payments, carrying amounts of goodwill and intangible assets and business combination accounting.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.6pt 0.1in 0 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0.1in 0 8.35pt; text-align: justify"><A NAME="publicsecurities"></A>Public
Securities <FONT STYLE="letter-spacing: -0.1pt">Filings</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.9pt 0.1in 0 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">Additional
information, including our annual information in our Annual Report, is filed with the Canadian Securities Administrators at www.sedar.com
and with the SEC at www.edgar.com.</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&nbsp;</P>

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">22</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/104% Times New Roman, Times, Serif; margin: 0 0.1in 0 8.65pt; text-align: justify; text-indent: 20.9pt">&#160;&#160;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>novelpipeline.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 novelpipeline.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %0 D4# 2(  A$! Q$!_\0
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M<T +1110 444F10 M%-+@-@GFEH 6BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM]^<?_Q%:M% &5_8<O\ T%;[\X__ (BC^PY?^@K??G'_ /$5JT4 97]AR_\
M05OOSC_^(H_L.7_H*WWYQ_\ Q%:M% &5_8<O_05OOSC_ /B*/[#E_P"@K??G
M'_\ $5JT4 97]AR_]!6^_./_ .(H_L.7_H*WWYQ__$5JT4 97]AR_P#05OOS
MC_\ B*/[#E_Z"M]^<?\ \16K10!E?V'+_P!!6^_./_XBC^PY?^@K??G'_P#$
M5JT4 97]AR_]!6^_./\ ^(H_L.7_ *"M]^<?_P 16K10!E?V'+_T%;[\X_\
MXBC^PY?^@K??G'_\16K10!E?V'+_ -!6^_./_P"(H_L.7_H*WWYQ_P#Q%:M%
M &5_8<O_ $%;[\X__B*/[#E_Z"M]^<?_ ,16K10!E?V'+_T%;[\X_P#XBC^P
MY?\ H*WWYQ__ !%:M% &5_8<O_05OOSC_P#B*/[#E_Z"M]^<?_Q%:M% &5_8
M<O\ T%;[\X__ (BC^PY?^@K??G'_ /$5JT4 97]AR_\ 05OOSC_^(H_L.7_H
M*WWYQ_\ Q%:M% %6SM6M8RC3RW!)SNE()_059I:* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.: ->BLC_A(H_P#GROO_  '-'_"11_\ /E??^ YH UZ*R/\ A(H_^?*^_P#
M<T?\)%'_ ,^5]_X#F@#7HK(_X2*/_GROO_ <T?\ "11_\^5]_P" YH UZ*R/
M^$BC_P"?*^_\!S1_PD4?_/E??^ YH UZ*R/^$BC_ .?*^_\  <TW_A)HMQ7[
M'?;AV^SF@#9HK(_X2.,_\N5]_P" YH_X2*/_ )\K[_P'- &O161_PD4?_/E?
M?^ YH_X2*/\ Y\K[_P !S0!KT5D?\)%'_P ^5]_X#FC_ (2*/_GROO\ P'-
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M_P"% "P_(N#QSP/05)N%1?OO[J_]]G_"C]]_=7_OL_X4 2[A1N%1?OO[J_\
M?9_PH_??W5_[[/\ A0!+N%&X5%^^_NK_ -]G_"C]]_=7_OL_X4 2[A5:YPUS
M;>N6_P#034G[[^ZO_?9_PJO<-+]JM@57JW\1_NGVH G9=V !\M)Y9ROMS3AY
MO]U?^^C_ (4?OO[J_P#?9_PH 14*C'4=U[5*K?*,]:C_ 'W]U?\ OL_X4?OO
M[J_]]G_"@"7<*-PJ+]]_=7_OL_X4?OO[J_\ ?9_PH EW"C<*B_??W5_[[/\
MA1^^_NK_ -]G_"@"7<*-PJ+]]_=7_OL_X4?OO[J_]]G_  H EW"JK#?<R ?W
M5_F:E_??W5_[[/\ A4*^;]JDRJ_<7^(^I]J )8U*J,9'<\]Z,-W&>?7K2_O?
M[J_]]G_"C]]_=7_OL_X4 17-I'>0RPSHLT$J&-XY!E64C!!'<4^.+R@BHJHB
M+L 7C@=!]*=^^_NK_P!]G_"C]]_=7_OL_P"%  %;(R<BFF,E=IRP)YIW[[^Z
MO_?9_P */WW]U?\ OL_X4 (RMQ@GWP>M(8CU!VMW(IW[[^ZO_?9_PH_??W5_
M[[/^% !\VT#^M2*<*,]:C_??W5_[[/\ A1^^_NK_ -]G_"@"7<*-PJ+]]_=7
M_OL_X4?OO[J_]]G_  H EW"C<*B_??W5_P"^S_A1^^_NK_WV?\* %D(./6N$
M^(W@"/X@>&[>U\SR;F$;X9?[K8[^U=P[2KC**?\ @1_PJ"V$AMHOD7[@_B/^
M%<>*PU'&T9X>NKQ>YM0K5,-5C7HNTHGS2/@!XQA:/R?LF(7+1LL^ &.,L,\C
M.!5M/@Y\18XQ&EVJQ@8V?:QMZY(_SUSS7T?MFQT4?1C_ (4;)>N%_P"^_P#Z
MU?"T^!<LAI&<U_V\?4RXHQTOCC!_]NGS;<?!7X@7R,MQ<1S!OO*]T".P_H/R
MIEI\#_'FG_\ 'M/'#QM_=W6."<D?GS]:^E?WO^R/^!__ %J/WO;'_??_ -:G
M_J)EC?.YSYN_-_P"?]:<8H\G+"W;E/E]OV?_ !BS%FCM6/7)G'7-'_#/OC _
M\L;0_P#;<5]0XD_NK_WT?\*5?,4_=7_OO_ZU<;\.\FD[MS^]?Y'2N,,RM9<O
MW'R[_P ,^>,?^?>T_P"_XI&_9]\7KU@M1_VW%?4NZ7^XO_?9_P *1O,;JB_]
M]G_"DO#O)K[R^_\ X _]<,R_N_<_\SY;_P"&??%K?\LK/_P(%>C_  S^"\_A
M5I;V_N$-](-H6/E4%>L^6W]Q?^^__K4JF1>D:X]=W_UJ]/+>#<JRO$1Q=*+Y
MH[7=_P!#AQG$N88ZDZ$Y))]E8Q?^$8;_ )[ ?A2CPNW_ #\#\JV_,EW?<7_O
MH_X4Y?.(^ZO_ 'V?\*^_4GMV/E5M8P_^$6;_ )^!^5'_  BS?\_ _*MW]]_=
M7_OL_P"%'[[^ZO\ WV?\*?,QF%_PBS?\_ _*C_A%F_Y^!^5;O[[^ZO\ WV?\
M*/WW]U?^^S_A1S,#"_X19O\ GX'Y4?\ "+-_S\#\JW?WW]U?^^S_ (4?OO[J
M_P#?9_PHYF!DV?AN.&99)9/,*G( '%;60*C_ 'W]U?\ OL_X4?OO[J_]]G_"
MD!+FEID>_!W!0>V#FGT %%%% "$[033/,_V3STI[<*3[5X8OPW\16[S7UR;F
M\LKC4IOM.DV=TZR3VIN9'1F=Y0,X\O"J5&WCMB@#W!9MW130TVW;E<;CCD\U
MX$/A_P"+[K6K6^<7-OIL,J&.UDNV^T1VQN7;R@1)MW*A7)8'Y1M!XKK-+\$W
MNAZ+K-M;:8MPEW/?M)#=7LS2R)YCFU$;;SM7!&0""!0!ZB)#_$NW\>*>K;JX
MOP%X!/A=;6Z?5-0N+C["EO-;3W!DB#@[F8 Y(.21UZ8]*[-5"+@4 07_ /QY
MS?[I_E4K3!<^W6HK_P#X\YO]T_RK@?BSI/BG7FTJT\,LMJUK,;^6XDE*(SQX
M\N(X.2&))((P=HR: /1/,/\ =-)YIY^4X%?//B#PSXK\1)<W,.@:YI?FWT#O
M8O=QS%X]LQ:0XN!E@[*-H*@*%^\1BM?P/X%\6Z;XMTS6M8\P)'MBN(UNC)(<
M6RJ&;+[2F\-D 9W'/(YH ]N,X7/%(UQMZJ<]AG%>*6^C_$F#7KVZ5GM[76KD
M3-Y,RR-I\<8<*F'. &41YV@_-DUGM_PMG2H_-@AN'N/-EN+@7!A> AHUPH^;
M=@$'H".O% 'O?V@+]X;?J?\ /^33O._V>^*^?=-\1?$?7;75)]#EO+ZWAE,=
MC)-';;7?RHBXF(?E S/M*9/'/(Q6CJ]E\3;349VLVN;R...()<[81+*"L;NF
M"X"_O-Z[B. .XZ@'N:MN[8IU<K\/+'5K#3=336&G>X?4KB6(SNK?NF?*!=IX
M7!X'&/2NJH **** "BBB@ JK=-MNK7UW-Q_P$U:JK= -<6P/3+?^@F@"5)/]
MD]3_ #I6DVXR,5P6I> +?5/B))JES:3R6,NGB-V6\E1#-O'1 X .W/05R4G@
MOQEI_P ,5T/28DMY9K<M<M]ND%ZTF"2JR,S!<D*,@\ G% 'MJMN&:6J.AK.F
MCV*W2[+E8$$JEMQ#[1N!/?G/-7J "BBB@ HHHH **** "JV[%U*.VQ>?SJS5
M"ZD:&2ZD$?G;(05C!P6(R<?CP* +7G;6P5;\J&F*]4('KFO QX=\;VNFZA;:
MKI=UK,FJW,=\DUC>G&G2.I60,ID4MM 5E53MW&M#X?>%/%^@^+-2NIX;TVS0
M782349599'+(;<G;*V> V?E7% 'MOF^WZTBS!C@#/&:\)N-1^*^DZ''=W6Z5
M8HY);N00PH\8$1(*KO;/[T8ZCY.V:UY--\5>)/ ,L-^NI/,]Y!+#@Q)=-$4!
M;S%5PK+O)^7<#COQB@#U[[1Z+\W3%*)LX^4^_M]:\$N=-^)MQX?_ +/^R3Q_
M*B"$3Q^7Y*NA&)"_F>=P^X$[<<;C6YX/T/Q9>^(+=/$]O=QV"Z=-;3Q+(BVV
M2R^6$*/O+;1R6QSG!H ]?\[C+*5'^U0TX7/%>&Z;HOCKP=X<_L[1-.N1=3K
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M*3RS_P ]&_,?X4 )]ECW9 (.,=:<L*KG&1^-)Y9_YZ-^8_PH\L_\]&_,?X4
M/50N>YIU1>6?^>C?F/\ "CRS_P ]&_,?X4 1W_\ QYS?[I_E4WEKN+8Y-5;Z
M,_8YOWCCY3W'^%6/+/\ ST;\Q_A0 ODKS[]?>E\E=V>?SIOEG_GHWYC_  H\
ML_\ /1OS'^% #A"HZ9_.D:%67!Y'UI/+/_/1OS'^%'EG_GHWYC_"@ ^SITQD
M>E+Y"<\?K2>6?^>C?F/\*/+/_/1OS'^% #T01K@=/K3JB\L_\]&_,?X4>6?^
M>C?F/\* ):*B\L_\]&_,?X4>6?\ GHWYC_"@"6BHO+/_ #T;\Q_A1Y9_YZ-^
M8_PH EJK<_\ 'U:_5O\ T$U+Y9_YZ-^8_P *KSQG[5;?O&ZMW']T^U %GRPW
M7.<TJQA:8(S_ ,]&_,?X4OEG_GHWYC_"@"11M&!2U%Y9_P">C?F/\*/+/_/1
MOS'^% $M%1>6?^>C?F/\*/+/_/1OS'^% $M%1>6?^>C?F/\ "CRS_P ]&_,?
MX4 2T5%Y9_YZ-^8_PH\L_P#/1OS'^% $M5]H:XE!_N#^M/\ +/\ ST;\Q_A4
M 0_:I/WC8VKW'J?:@"?[.FT#G&,=:7R%W9Y/XTGEG_GHWYC_  H\L_\ /1OS
M'^% #O)4XR,XZ4W[.FTC'&",=L&CRS_ST;\Q_A1Y9_YZ-^8_PH 7R1ZGZYI3
M"I[=L=:;Y9_YZ-^8_P */+/_ #T;\Q_A0 [RAP.:0PKS@D'U%)Y9_P">C?F/
M\*/+/_/1OS'^% #EB5<XX!IRC: !4?EG_GHWYC_"CRS_ ,]&_,?X4 2T5%Y9
M_P">C?F/\*/+/_/1OS'^% $M%1>6?^>C?F/\*/+/_/1OS'^% "R G;CUK U;
MPS8^)]'%EJ-NL\#IC!^E;<D9W+^\?KZBJ]HFVVC_ 'CY*CTK&<85%*G)774<
M92IR4XRY6NIY6W[-?AUF)%W?+_P,$_F12?\ #,_AU1D7E]G&#\XY_2O7-A[.
MWY__ %J78_\ ST8?B*^:_P!5LF>OU:)[:SW,DK*O*QY&O[-?AX# O;W_ +Z7
M_"AOV:?#K=;Z^YZ_..:]<\M_[[?G_P#6H\M_[[?F*?\ JODUK?5H?<']N9E_
MS_D>1C]FGP]_S^:@/^!K_A2_\,T^'?\ G\O_ /OM?\*]9'/_ "T8?B*/^VCG
M\JG_ %6R1?\ ,-'[A_V]F5O]XE]YY+_PS3X>_P"?W4/^^U_PI#^S3X>/_+[?
M_P#?:_X5ZZL9Q_K&_2E$1_YZ-^8H_P!5LDZ8:/W#_M[,^E>7WGD:_LS^'/XK
MR_Q[R#_"NM\-_"S1_"MJT.G;TW??D?#.WXUV'E'_ )Z/^8H\G_;;\Q7?A,BR
MW U%6P]",9+JD<M?-,;BH>SK57)=FS';PQ'DGSVR>>@I1X6B//GM^0K7\GG.
M]L_44OEG_GHWYC_"O>N]CRS'_P"$5C_Y[M^0H_X16/\ Y[M^0K8\L_\ /1OS
M'^%'EG_GHWYC_"BX&/\ \(K'_P ]V_(4?\(K'_SW;\A6QY9_YZ-^8_PH\L_\
M]&_,?X47 Q_^$5C_ .>[?D*/^$5B_P">[_D*V/+/_/1OS'^%'EG_ )Z-^8_P
MHN!3T_18+!MXS))_>;M6A4?EG_GHWYC_  H\L_\ /1OS'^%("6BF(I4'+%OK
M3Z "BBB@!&^Z<=>U<<_Q4\,1M=H=84/:N8W4Q29W!RA"C;\Y#@K\F>E=A(2$
M8@9..!7G,?PBMK9H;RSO98]:AOIKZ*^G5IT022O(8A&7 "_O.0I7)7- &M_P
MM3PPLUK$=8027*AXLQR8(W%/F^7Y3N!7#8.0>*GT_P"(&A:E8:AJ%OJ>ZRL&
M*7,SPR(L9#%2,LHR0000,\BN5C^"-L-435+C5)9]2^T)=L_E8B,HF:1LQ[L%
M3NP <XP#FM;5OAHNLZ'?::VK7D(N)[J?,7$1\Z;S2KQY^<+G:#D'KTH Z_0]
M8M=>L5O;&<7%K(?D?!'3@@@@$'/8C-:%<_X'\,_\(?X?BTO[0;D1N[A]A55W
M,3M4$DA1G R2?>N@H K7_P#QYS?[IJEK'B&QT%8'O[N.T2XN4M8C(2-\KG"H
M..IJ[?\ _'G-_NG^5<=\1/AO;_$.6UCO;^ZM+2U64K':':3*X 64M_L@, ,?
MQ'F@"[<?$CP]:C47FU>&&/3P&N7D#*L0+[ <D88;_EXS@T^;XA^'[76+C3)M
M42*]M\B6)T<!<)YA&=NTG;S@'I7&3?!>^UZ:<>)?$KZM%.ZM*+6R%L[JH(2,
MMO8! 69MJJ,MR3D"F0_ <1JLCZY=75]O"2SW"$K)!L6-DV[L!BBX\P?-RV>M
M '>S^/-"MS?JVIQ[[!HTN44,S1-(,H"H!)+ \ "LO_A;'A91/NUV'$,?FM)Y
M<FT#:K8W;<$[64[1SR.*YVX^#-W:WE_>:1XIN]/U34EE2]N9(!,'5VW HNY?
M+90 H().!VK,N_V>UOII99-92!&VC;9V!B( ACBV@F1L+B,'IG)/S&@#T>/Q
MUH;^&[O73J<::39[OM%S(K((BN,A@P!&,CJ.]7+KQ%I^FV[7%SJ%O! $60L\
M@&U21@X)SSD?F*X^;X0VEQX9_L'[=<Q:4VH->RQ ?O)5)R(FDSD@-_$>2 !6
M-_PS_;MI/V2;56O+@296\GLU9S$L"Q1Q-EOF VAB2>2>U 'J?]J6:$C[7"/W
MGD\R@_/C[O7K[=:&U*U4-NNX!A_+.90 '_N]>N<<5X9KW[/^J0W%Q-I]Y%J4
MNHHT,WG0+&EMF1'\Q 7^5AMQE!QCIS6]_P ,^P37CS7&J+(GV:2VC5;3;C<[
M.)F^<[Y1NQN.,@=J /25\4:7]DCN&U"%4D=8T,C;"79]BC!P1EN!GK6T*\?M
M_@*EOJ3WAU?S\S1SB.6S#$LEPLPY9SC[NW@#KDYQ7L"G*@T +1110 55NCBX
MMN<<M_Z":M55NO\ CZM?JW_H)H Y[4/B)H6FZS)I-QJ$D>HQQ^:T"6TKD)_>
MRJ$8_&FP_$GP_<^'TUN+4B^EO*L*7 @E^=SP J[=S9..@-:+>'_^*K&N"<Y%
ME]C$&WMY@?=G\,8]ZY"\^$*7?AFRTMM3DF^S1K&!>1&:W.W.'$6X!7&<AL\$
M4 =9IGB[2M7U"?3[.^%Q>VZ[I(MK!@.G< $CN!T/6MU&W*#7"^%OAW-H'B(Z
MK-JKWK?8_L:[H-K,@*E3(V<,1MQD*#\S9)ZUW,7^K7MQ0 ^BBB@ HHHH ***
M* "JCL$N)G9BJJBDGT'.35NJ<T?F33+EOFC"Y Z9S0!D:-XVT77DE-CJ"3^6
MRJQ.Z,98X7!<#.2" 1G-,_X3G0_LMU>'5H5M;:7R996)55?T (Y/TS7#1_ ^
M2$G&L1,GF;UM38?Z*#LD0OY7F;=Y$F0PV@;1Q5"U_9O2RA> >()+E)%B0FZL
MQ*5V;/G7Y_E<[/O>_M0!Z.OCK1SXE/A\WK?VRBAS;^3(!M.<'=MVXX/.[KQ6
MO_:MIYPA^U0F0D80R@'GIQFN6\6> 9O$VKKJ$6IG3YTBBC53!YJY1W;)&X9!
M#XQ[5S5K^S_9P*"VI/)=A(U^U_9@)-R- =P.XX)\G'7C>>O< ]0?5;2.,.]W
M B%B@<RKC<.HZ]1Z58MYDN$#HP=& 8,IR"#T(KR*/X 6K*SW&H1W#_9A;QQK
M9E(TP@59,"0'?P<L""WM7HO@S06\+Z#9Z4UPUT;6/9YQB$8;))^Z,XZ^M &]
M1110 4444 %%%% !1110 R3L:X7X@?$*W^'^@17#)Y]S( D46<9;'KZ5W,W5
M1ZFO#_C]X7OM4T>PU"SC:9+=29%7GC%>!GN(Q.%P%2MA(WFMCULJH4<1C*=+
M$.T6<Q_PT-XNECEF@T^U:W4\N(7<)[%LXJN/VE/%7>WL?^_)_P#BJXG2/%9T
M2U@@6!#)',[RR."6$;;,@+G!.%(Y'>M:/Q]8_9_*FT]?M +'SEA0E7).)%YP
M2!@8(Q[U_/\ 3SK,ZD4Y8Z4)=4UL^Q^I2RS!4YRBL(I1Z.YTDG[1?B^%8Y'L
M[-(I/N,UNP!^AW4V3]I#Q;#(4DM+%#C/S0LI _[ZK!G^(VG?Z-MLI'>!-A>1
M(\N,IN 4<#(5NGK3V^(.BK?1S1Z=-' N3]F6*(AGS\K%F]!Q@?G73_:V8/;,
M9?<9++\*M\#^)MM^T3XKBV[K2P 8;EW0,,CV^;D5I>'_ -I#5I-2AAU:SM1;
M2,%,EN"-N>Y&:\S\8>)+7Q#?0S6]L;6*.+R_+...I/0^]4= T>X\0:A#9V43
MR22,%S@X4=R3VXS7GT^(L\IXY4Z&(E4C==-'KZ'I/)LLGA'5JT5!V?R_$^O(
M_$EQ(H8;&5AD?+^O6I!XDNA_"G_?/_UZPK*W^RV<$&0WE(J[NYP,5-7]2TN:
M4$ZGQ65S\.J1492BMD]#8_X2:Z_NQ_\ ?)_QH_X2:Z_NQ_\ ?)_QK'HK:R,S
M8_X2:Z_NQ_\ ?)_QH_X2:Z_NQ_\ ?)_QK'HHL@-C_A)KK^['_P!\G_&C_A)K
MK^['_P!\G_&L>BBR V/^$FNO[L?_ 'R?\:/^$FNO[L?_ 'R?\:QZ*+(#8_X2
M:Z_NQ_\ ?)_QI/\ A)[H?P1G\"*R**+(#IM,U_[5,(9U$<C?=9>A]JV17%Z5
M:O<7T04$!2&)QQQ7:"LWN 4M%%( HHHH 3</44GF)_>7\Z0QCJ0/RJ/<F0,+
MSTXH E\Q/[R_G1YB?WE_.H]RD9 4]NE *MT"D>N* )/,3^\OYT>8G]Y?SIH4
M'HJT>7_LK0!#?2+]CF^9?NGO5CS$_O+^=5KY!]CF^5?NGM4V!SPM #_,3^\O
MYT>8G]Y?SIG']U:7R_\ 96@!WF)_>7\Z/,3^\OYTS:/[J_E2?+C.%Q0!)YB?
MWE_.CS$_O+^=,X_NKCZ4C,JXR%Y.!Q0!)YB?WE_.CS$_O+^=1;D[!3]*4,K=
M OY4 2>8G]Y?SH\Q/[R_G4>5YX7CKQ2[1_=6@!_F)_>7\Z/,3^\OYTWR_P#9
M6FJ58X"KGZ4 2>8G]Y?SJM<2+]JM?F'5N_\ LFIAM8X 7-0W"@7%M\J]6_\
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M8NY'9"5; W*2IP<#([5T54M)TFUT2R2TLX5M[=,X1,]2<D\\D^YJ[0!6O_\
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M],AMKF3)6XC!W(Q)(8 G&<DG\30!1;X\>&ECD>1-1A6.86KF2S<;+@YQ ?\
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M'&#DC.2:Z=5"J .@X%9O<!:***0!1110!2O-2%DRAH9I=W(\J,M5?_A((_\
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M_"01_P#/E>_]^#6I10!E_P#"01_\^5[_ -^#1_PD$?\ SY7O_?@UJ44 9?\
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M3_;L7_/E>_\ ?@T?V[%_SY7O_?@UK44 9/\ ;L7_ #Y7O_?@T?V[%_SY7O\
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M0G<!@/[5T_BCXT:;X-U&[LM0LM0D-F(EGN;>(- )9(R\<88D$E@#SC@XSUH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !129Q1N'K0
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MQ_.K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=TF#2H&7S2+>% &]"Y0G!(_O'-7(_#-_)K4$4UPS:/9!_*C9E+R!T9-IP <
M,>370Z7I,NFQF)KQ[F%0JQ*Z %%'8D=:5WR\G3\/N,W3CS<]M?Q^\TZ***9H
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>engagerplatform.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 engagerplatform.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %, C\# 2(  A$! Q$!_\0
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M "(W^-'_  C.F_\ /M_Y$;_&@#3R:,GVK,_X1G3?^?;_ ,B-_C5>;PWIPN(
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M^F*Z;_A&]-SG[-S_ -=&_P :/^$9TS_GV_\ (C?XT :0R!2Y-9G_  C.F?\
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MZT]G/L9_6*/\R^]?YG<AC2Y-<-_;W@3K_;>D_7^T5_\ BZ#X@\##_F-Z2?\
MN(K_ /%U/LY_RB^L4OYU]Z.YR:,FN%_X2+P-_P!!K2?_  8K_P#%T?\ "1>!
MO^@UI/\ X,5_^+I^SGV?W!]8H_SK[T=UDT9-<+_PD7@;_H-:3_X,5_\ BZT+
M!?#FK0F6QGMKR,'EX+K>H]LAJ3A):M/[BHUJ4GRQDK^J.JR:,FL+^QM&V_=0
M9_Z;'_&I/[%T7^[%_P!_S_C4&QLY-&36-_8NB_W8O^_Y_P :/[%T7^[%_P!_
MS_C0!LY-&36-_8NB_P!V+_O^?\:/[%T7^[%_W_/^- &SDT9-8W]BZ+_=B_[_
M )_QH_L71?[L7_?\_P"- &SDT9-8W]BZ+_=B_P"_Y_QH_L31FX"1D_\ 79O\
M: -E2:=5"QTFTT^0M;PF,GK\Q/\ ,U?H **** "BBB@!*\1'@_Q9"S:E=SZI
M+8RZE)]ITRRO93<2VWGR,C99P$P/*^6,KE1SZ5[8TBIU./PIOVB/U/Y&@#PF
M'PKXXNO$%E=DZI!H\,B!(I;V3[2EN;@\%1)L=PN-Q?)V'@[EK>M]%UWPWX:U
MHQ:9JNJ))<W#&%=4E-VT8D_<I"7<[05ZD%3@GO7K'VB/U/Y&C[1'ZG\C0!P_
MA;PWJ5YH_AJXO-2U6QN+"22:>UD.//W%L1299BR)D!2220H)KNX\[>1CFF?:
M(_4_D:/M$?J?R- $<W_'Y;_1OZ5YOJFF^ Y+;4;N^L8X[?\ M=8KF>X=D"W,
M3>:LFXMP QSD?3&*]%FF3[5 V3@!L_*?:O/?%7PALM?L=6@CU?4HA>7)OHX)
M&4P07!!&Y0$W8YZ%C0!)#<?#N"W\J"\TZ."XAA#1_:2%98#F(L,_>!7C/S''
M?%/UN?P)K>HI?ZAJUO\ :9;-EWC4)(%>W).0RJP!&=PPPSP?2JS?!'0+B2ZD
MN;W4IWO)%GNB[(5GE5&178>7QA6( &!Z@TV3X'^'I+5+62YU26V1XIO+:8%7
MDC9RC'Y.HWL,#"XQQ0!@>(M!^'7BB2"=?$-K::=YB)>PP3,!= E B,=P./W2
M@Y! V_PGFL_7=#\"+?:%=0QWR:=JTSEK&/<RW9@S$6E9Y0-H''.20.,5V.L?
M!7P_K2A9GO8T*3+)'&ZA7\V1I&RI0YY=L'M6H?A;X?ET^PL9XI;FULX+BWCB
MF.X;9OOD_+][G@C&* ,/;\-(;-S)J%JL%TOEF9M0F\QPI7@MOW  LO?^)?6N
MKT#Q=X6CTN&#2]4M6LK6+;&$D&$C1<]^< #J?0UC0_"/0X9KF:2?4+VYN4CC
MFN+ADW,J/&Z# 0#K$HZ=,U%>?!O0[R,1I<ZA9KY/DEK>0*2A#@J<H<Y$C?I0
M!HI\7/"S6<5P-3CS(T:K!@^;\[!4RH]\>^"#T-6X/B;X7:S$[ZU9Q#:A9))1
MO&[HN!U/L,XKFH/@3X;M;ZWNHKG4Q-!M\IFE!\L J=H^3./D'&<<FIM+^"?A
MW2?[/6*;4)HK!F>VBFD4B(L26QA!G<22<Y]L4 =KI?B;2M:OIK6RO[>[N(55
MY(X9 Q4-T)QP:V:X;P;\.=)\$ZE/>6$EUOFB6!TD*[-JXP<*@RWRCDY]L#BN
MT^T1^I_(T 2T5%]HC]3^1H^T1^I_(T 0R?\ (0C_ .N9_P#0A7AOB#0/B--?
M:^-/EU.."_CN+2%A=#_1@9KF1)X_FX.T0Q@=<2#^[7N#3)]N1LG'ED9P>N14
MZW"!0,G\C0!X#?:'\3MDD%HU\-E_+J$4TMQGA_,C%N?F^XH"2#J,L*LZ/I/C
MB*\T\O%K*JCH+::24@*3)&96G0R-QM\Q1DMP,C&:]V^T1^I_(T?:(_4_D: )
M:*B^T1^I_(T?:(_4_D: ):*B^T1^I_(T?:(_4_D: ):*B^T1^I_(T?:(_4_D
M: ):K7'_ !]6WU;_ -!J3[1'ZG\C5>:9&N;<C) +9^4^E 'COC;1_B!+XNUQ
M=)%])I=U?VEU;-'<A%C6&*,/&#NR$D=CN '_ "S?UJC/>_%EHY+HVTS7/V>2
M*,0P(HBD:6(\HS88!0X#CG!/'K[Q]HC]3^1H^T1^I_(T >*1ZK\4X[>.6XLY
MO](\UI5@M8GDMRK,(E52_P P8;2Q)X&<"K*W?Q15FO)(69EW.=/C@CVDB7:$
M#%LD%/GSP>!7L7VB/U/Y&C[1'ZG\C0!R'PKN_$]WH=T?%,#0WJW+"+?&J,T6
MU2"0I(X)8?A7:5%]HC]3^1H^T1^I_(T 2T5%]HC]3^1H^T1^I_(T 2T5%]HC
M]3^1H^T1^I_(T 2T5%]HC]3^1H^T1^I_(T 2T5%]HC]3^1H^T1^I_(T <!\<
M/%UUX"^&_BG7[)5>[L;$R0JXX#<@,3Z G]*_-'P;H;_$[7M7NM=U6]EGCA6Z
MFNC-%YCEIHXR2TK*HQYF[KG P!FOU3\1:-9>)+#4=.OXA<6-] ;>6)@?F4@@
M@_@:^,O$?[ FM6VH7B^&O%=H-(N!L^SW\<GF[-P8(S+PP! Z_P!T5]1DV+P^
M'ISA4?+-[/<_/>)LMQN,K4ZF'BYQ6Z3L>12?L\W%]<PG0_$NG7VGND;27<P9
M!%O0LA/&-K #:<CGKVJ%OV;O$D-P8VU+24$<9,TS70$4<P?8(=YP"Y/Y9Y%>
MP:?^Q;\5M*C\NR\=V=K$56/RX9KA!L4812!P0/2IW_8_^+TC%Y/B'"[@,F6N
M+@G:WWOS('%?1+,Z*M_M$?N/D)9)7MIA)7]4?->B^$]-U#2VN]2UC^S?L^JP
M6%VJP%UMXI!(3+NSAL&,@!1W-<YJ45O!J%S%97#7=HDC+#<LNTRIGA\=L^E?
M3,?[ WCI;62W7Q+HZ6\CK(T.)<,R[MK$8QD!C],FFG_@G_XU_P"ABT7'^[+_
M (5W4\TP46W*LG?R/,JY#FDE:&&:_KU/E_YO6CYO6OI__AW_ .-/^AAT7_OF
M7_"C_AW_ .-/^AAT7_OF7_"M?[7R_P#Y^1^XY?\ 5_./^?$OZ^9\P?-ZUW/P
M<\>:I\/?B!HU]83S"*:XC@N[8,=DT3, 01WX/%>S?\.__&G_ $,.B_\ ?,O^
M%>@?"#]A^;PCXEL]<\3ZO;:K)8OYEM9VL3"/=V9F;T]JY,7FV E0E%23;78]
M'+\AS:&)A*5-P5]SZ)9=IQZ4E:?]AW#9.]/S/^%']@W']]/S/^%?F5XO5'[V
MDTDGO8S**T_[!N/[Z?F?\*/[!N/[Z?F?\*-"C,HK3_L&X_OI^9_PH_L&X_OI
M^9_PHT S**T_[!N/[Z?F?\*/[!N/[Z?F?\*- ,RC^=:?]@W']]/S/^%+'H,Y
M;YGC'X'_  I: :_AVZDN+5ED;>8S@-ZBM:J>FVL5G;K%$<[>2?>KE9@%%%%
M!1110 WD>M%-D5S]W:?][--Q-Z)^9H DHJ/$WHGYFC$WHGYF@"2BH\3>B?F:
M,3>B?F: )**@:25)40A,MDYR>U(TTBYSLX]S0!8HJLMQ(V,;"#GG)IPED/\
M<'IR>: )Z*K&>09X3VY/-'GRC.57CT)- %FBJWG2_P!U<>Y-2*TS9P$].IH
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M,CZT@V)=PZ8-/JMOD]8Q^=2_OO1/S-4)7ZDE%1_OO1/S-'[[T3\S0,DHJ/\
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M,LD-O&8SO\_Y2' ?ISD #UK;U35/BGIMMY=LDNH3/YCQSBTC"KY<KA%8;_\
MEH@0DCU[5-?:#XVU+2?#0B>ZAOK:.\GNXYKF1$DEW%H8W,<BGG@#)( ZB@"J
MO@OXC2Z?<A]<O/.CCQ;1I=Q*X)9=^XX(/&[!)X#<8KV/0%NX]'LEOD"WHB7[
M1M;</,P-V#@9&>^!7E$-]\2KQ9C"+BUBC53#-<V$:S3,TD*NKIO( 56E(YY
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M!Y*QM'MV@X^[(X]?F-5)/@IX/FMY()--E>*48E#7L_[T9!PYWY8?*,9SC'%
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MH[JWBFBD2:*10RR(058'N#Z4 1K:A>CN/Q'^%/\ +;_GJ_Z?X5+10!%Y;?\
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M9^U6W[QOO-Z?W3[5<C^Z,U!<?\?5M]6_]!- #_+;_GJ_Z?X4>6W_ #U?]/\
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M0W[5WPLZGQG:_P#CW_Q%?%K?"_P/+KVO65MKK&&R>XA7?<1 W4D9MW46[;\
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M6NM.AU&-I[<-O8D!>%#$ YY.TY^@-7/^$TTF:UU":RN1JCV,?F306.)9,8R
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MIL+'C<68#V[BNTTW]G/X^:/'LT^WO;)"D:8M]455VH,(NT'&!V'TJ3_AGO\
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M$+7_ +_+_C1_PD6E_P#00M?^_P O^-6_L<'_ #QC_P"^!1]C@_YXQ_\ ? H
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M^7_&C_A(M+_Z"%K_ -_E_P :M_8X/^>,?_? H^QP?\\8_P#O@4 5/^$BTO\
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M^\^.VGMXHN=-TQ%U&VMK>&XDNEFV[M\J(RHN.=JR*V3[B@#T/^T-4_Z!0_\
M A:/[0U3_H%#_P "%K%\8_$*P\#P6,E^)IDNIO*5[9 ^WGEB,YQR.F:Y63X]
MV$S0KI^EZA<O*25,B[0T860B1?49B8>M 'HG]H:I_P! H?\ @0M']H:I_P!
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MD3"XN%DE=6"G?G*!!GY?7D4 >H2?#CPM)#Y9\.:848'"_9EQS@GM[#\J36/
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M 2>QIUYXLT?3[>WGNM4L;:"X&Z&2:YC191ZJ2<-QZ4 'VG6?^?&U_P# @_\
MQ-1S7FKQQEC86V!_T\'_ .)JR?$.G;5;[;;['SM?SEVM@X)!SS@D ^AI\]TE
MU9%XCYB-T9#D'F@"C(-2D8.=,LVD7D,TW/!XP=OXU%]COA<1RC2+ .@.&60
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M 9/VK6?^?&U_\"#_ /$T?:M9_P"?&U_\"#_\36M10!D_:M9_Y\;7_P "#_\
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M]JUG_GQM?_ @_P#Q-<W]NN/^>\G_ 'U1]NN/^>\G_?5'*!TGVK6?^?&U_P#
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M&!!Y/6@#VZBO"_#OC;Q3K.C:B]CKMQ=WD>A2W<WVK3%_T*\5AMB4!$W$KO\
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MZ/[)O/\ GUD_+_Z]&@#?[3N_^?F7_OHT?VG=_P#/S+_WT:=_9-Y_SZR?E_\
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M ):*B\D_WF_[Z-'DG^\W_?1H EI:A\D_WF_[Z-'DG^\W_?1H EHP/2HO)/\
M>;_OHT>2?[S?]]&@!FH?\>K_ (?S%6*IWT>VU?+-V_B/J*F\OG&YA_P(T 3T
M5!Y8SC><_P"^:/+_ -MO^^S0!,>E4[/3;>QWK!$D2-(TC(@P"S');ZFIO+_V
MV_[[-+Y)_O-_WT: )J3 /45%Y)_O-_WT:/)/]YO^^C0!-14/DG^\W_?1H\O'
M5V_[[- $U4YK"">\ANG@1YX-PBD9<LF1@X/;(J;R3_>;_OHT>2?[S?\ ?1H
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M^_S_ /Q%:NVC;0!E>?J__/"P_P"_S_\ Q%'GZO\ \\+#_O\ /_\ $5J[:-M
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M?J__ #PL/^_S_P#Q%:NVC;0!E>?J_P#SPL/^_P __P 11Y^K_P#/"P_[_/\
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M8H >^":Y>^^#6E37%XVG7MYHFF7T$%M?:38")8;E(B64$E"ZY#,K;"-P8YH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEHH 3:!V%&!UQS2T4 )1M'I2T4 )COCFC:/2EHH 3:/2EHHH 2C:/2EHH 3
M]**6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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:;3NV>N3C-=S#_JU[TZ,;5 %.H\V)*VQ__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>singleagentactivity.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 singleagentactivity.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &I H@# 2(  A$! Q$!_\0
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M^'^0?ZZ9DND?N?\ F?HI_P -Y?"[_GIKG_@N/_Q5'_#>7PN_YZ:Y_P""X_\
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M?"[_ )Z:Y_X+C_\ %4?\-Y?"[_GIKG_@N/\ \57YT_C1^-'^K6#_ )I?>O\
M(7^NF9=H_<_\S]%O^&\OA=_STUS_ ,%Q_P#BJ/\ AO+X7?\ /37/_!<?_BJ_
M.G\:/QH_U:P?\TOO7^0_]=,R[1^Y_P"9^BW_  WE\+O^>FN?^"X__%4?\-Y?
M"[_GIKG_ (+C_P#%5^=/XT?C1_JU@_YI?>O\@_UTS+M'[G_F?HM_PWE\+O\
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M/YG]S%_J=FO\J^]'P/17WQ_P[S\&_P#0RZS^4?\ A1_P[S\&_P#0RZS^4?\
MA1_K%@/YG]S'_J;FO\J^]'P/17WQ_P .\_!O_0R:S^4?^%'_  [S\&_]#)K/
MY1_X4?ZQ8#^9_<P_U-S7^5?>CX'HK[X_X=Y^#?\ H9=9_*/_  H_X=Y^#?\
MH9-9_*/_  H_UBP'\S^YB_U.S7^5?>CX'HK[X_X=Y^#?^AEUG\H_\*/^'>?@
MW_H9-9_*/_"C_6+ ?S/[F/\ U-S7^5?>CX'HK[X_X=Y^#?\ H9=9_*/_  H_
MX=Y^#?\ H9-9_*/_  H_UBP'\S^YB_U.S7^5?>CX'HK[X_X=Y^#?^AEUG\H_
M\*/^'>?@W_H9-9_*/_"C_6+ ?S/[F/\ U-S7^5?>CX'HK[X_X=Y^#?\ H9=9
M_*/_  H_X=Y^#?\ H9=9_*/_  H_UBP'\S^YB_U.S7^5?>CX'HK[X_X=Y^#?
M^ADUG\H_\*/^'>?@W_H9=9_*/_"C_6+ ?S/[F/\ U-S7^5?>CX'HK[X_X=Y^
M#?\ H9-9_*/_  H_X=Y^#?\ H9=9_*/_  H_UBP'\S^YB_U.S7^5?>CX'HK[
MX_X=Y^#?^ADUG\H_\*/^'>?@W_H9=9_*/_"C_6+ ?S/[F/\ U-S7^5?>CX'H
MK[X_X=Y^#?\ H9-9_*/_  H_X=Y^#?\ H9-9_*/_  H_UBP'\S^YA_J;FO\
M*OO1\#T5]\?\.\_!O_0RZS^4?^%'_#O/P;_T,FL_E'_A1_K%@/YG]S%_J=FO
M\J^]'P/17WQ_P[S\&_\ 0RZS^4?^%'_#O/P;_P!#)K/Y1_X4?ZQ8#^9_<Q_Z
MFYK_ "K[T? ]%??'_#O/P;_T,NL_E'_A1_P[S\&_]#)K/Y1_X4?ZQ8#^9_<Q
M?ZG9K_*OO1\#T5]\?\.\_!O_ $,NL_E'_A1_P[S\&_\ 0R:S^4?^%'^L6 _F
M?W,?^IN:_P J^]'P/17WQ_P[S\&_]#)K/Y1_X4?\.\_!O_0RZS^4?^%'^L6
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M87P:_P"11M/I_2BE^#7_ "*-OW.**_*V]6?O2^&*\CY__P""BG_(J^"_^O\
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M&JOLR&D$1^8Q[E*[L_04[X0^'=4\.:;K^B:GHXL(?[1N9K:]BD0K<Q32,X(
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M:S>+_P#A(/[>^T1L1;K*K["@PV]E!3TPQH ]NM?%&DWBZ<8-3M9QJ2LUD8Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYM_;T_Y
M(S9_]ABW_P#9J^DJ^;?V]/\ DC-G_P!ABW_]FKT,O_WJ'J>-G/\ N%7T_5'I
MOP;_ .12M?I11\&_^12M?I17G5-SU:?P(\!_X**?\BKX+_Z_Y_\ T57R=\$_
M^2O>#?\ L*P?^A5]8_\ !13_ )%7P7_U_P __HJOD[X)_P#)7O!O_85@_P#0
MJ_3,I_Y$\O\ MX_$L_\ ^2ACZP_0_635I9X-*NY+5/,NDB<PIC.Y\':,?6O-
M=)\5>/9-)GDO=%:&\$:[5C@#<\<CGG(W?I7JO7%'E+[C/7!K\T/W".R.1\!Z
MQXFO)K^W\1Z?';M%M,4]N,1N"#GOU_H17R;^WX2?'WAG(Q_Q+),>_P"]-?<2
MQJN<<$]:^'OV_O\ D??#'_8,D_\ 1IKZ3A[_ )&$/1_D>3FO^ZOU1\Q?P_G7
MW-^S/XTM?A_^S VOW\,LMC83W$DJP ,Y&\#@''K7PS_#^=?6G@O#?L*>(5(X
M)G_]&K7VW$--5:-*#V<D?.99)PJRE'I%G=?\-U^!.,Z;K@/<?9D_^+KK?AC^
MU)X:^+'BC^PM&L=1BN_(>XW7<2HFU2 >0Q]:_.+MTKWS]B/'_"\E/_4,N.?Q
M2O+S#(<%AL)4K4^;F2^1W87,ZU6O"FUHV??#:D58 B-2/O R#BD.J*.\7_?U
M:_-C]H34+R'XX>,TCO;J-!?$!4G< ?*O0 ^]>=R:M?[#C4+P'M_I+_XUY]+A
MJ52@JWM5K&^QTSSCDJ<CCUL?KBMU,Q^6'(_WJ=YT_P#SP_\ 'JH^%\_\(]I6
MXY;[)%R3D_<%:M?$[-H^BB^9)D'G3_\ /#_QZCSI_P#GA_X]4]% R#SI_P#G
MA_X]1YT__/#_ ,>J>B@"#SI_^>'_ (]1YT__ #P_\>J>B@"#SI_^>'_CU'G3
M_P#/#_QZIZ* (/.G_P">'_CU'G3_ //#_P >J>B@"#SI_P#GA_X]1YT__/#_
M ,>J>B@"#SI_^>'_ (]1YT__ #P_\>J>B@"#SI_^>'_CU'G3_P#/#_QZIZ*
M(/.G_P">'_CU'G3_ //#_P >J>B@"#SI_P#GA_X]1YT__/#_ ,>J>B@"#SI_
M^>'_ (]1YT__ #P_\>J>B@"#SI_^>'_CU'G3_P#/#_QZIZ* (/.G_P">'_CU
M'G3_ //#_P >J>B@"#SI_P#GA_X]1YT__/#_ ,>J>B@"#SI_^>'_ (]1YT__
M #P_\>J>B@"#SI_^>'_CU'G3_P#/#_QZIZ* (/.G_P">'_CU'G3_ //#_P >
MJ>B@"#SI_P#GA_X]1YT__/#_ ,>J>B@"#SI_^>'_ (]1YT__ #P_\>J>B@"#
MSI_^>'_CU'G3_P#/#_QZIZ* (/.G_P">'_CU'G3_ //#_P >J>B@"#SI_P#G
MA_X]1YT__/#_ ,>J>B@"#SI_^>'_ (]1YT__ #P_\>J>B@"#SI_^>'_CU'G3
M_P#/#_QZIZ* (/.G_P">'_CU'G3_ //#_P >J>B@"#SI_P#GA_X]1YT__/#_
M ,>J>B@"#SI_^>'_ (]1YT__ #P_\>J>B@"#SI_^>'_CU'G3_P#/#_QZIZ*
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M7\/YU]:^"?\ DQ/Q%]9__1JU]SGWP4?\<3YG+_XD_P#"SY(KWW]B/_DN2_\
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M_/):/L4/_/):GHH @^Q0_P#/):/L4/\ SR6IZ* (/L4/_/):/L4/_/):GHH
M@^Q0_P#/):/L4/\ SR6IZ* (/L4/_/):/L4/_/):GHH @^Q0_P#/):/L4/\
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M@";(HR*A\R?_ )Y#_ONCS)_^>0_[[H FR*,BH?,G_P">0_[[H\R?_GD/^^Z
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M "*5K]**\ZIN>K3^!'@/_!13_D5?!?\ U_S_ /HJOD[X)_\ )7O!O_85@_\
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MHQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
MF*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
M )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )MKYM_;S_ .2,
MV?\ V&+?_P!FKZ3KYM_;T_Y(S9_]ABW_ /9J]#+_ />H>IXV<_[A5]/U1Z;\
M&_\ D4K7Z44?!O\ Y%*U^E%>=4W/5I_ CP'_ (**?\BKX+_Z_P"?_P!%5\G?
M!/\ Y*]X-_["L'_H5?6/_!13_D5?!?\ U_S_ /HJOD[X)_\ )7O!O_85@_\
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M4H_X7EXS/_3^W_H"UYR_W3Z5Z)^T1Q\<O&8'3[>W_H"UYU)]PUO@_P#=*?\
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M_P#W!:]9?F=N96^L;]%^1]>_L=_\D?\ B/\ 5O\ TG-?(,/^I3Z5]>_L=_\
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M?$U<+456B[21E5I0K1Y)JZ/B_P#X=_:CD_\ %8V__@$W_P 57KNB?L^7FC_
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MOFG'4\6^!OP'U#X,^%]<TI=:6^GU&8RI=1Q%/*/E[1QDYQP:YO\ X43\7?\
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M27Y'R+'_ *L?2O1?V>/^2X>#?^O\?^@FO.H_]6/I7HO[/)Q\;_!I_P"G\?\
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MSQ_W%_*C[/'_ '%_*I** (_L\?\ <7\J/L\?]Q?RJ2B@"/[/'_<7\J/L\?\
M<7\JDHH C^SQ_P!Q?RH^SQ_W%_*I** (_L\?]Q?RH^SQ_P!Q?RJ2B@"/[/'_
M '%_*C[/'_<7\JDHH C^SQ_W%_*C[/'_ '%_*I** (_L\?\ <7\J/L\?]Q?R
MJ2B@"/[/'_<7\J/L\?\ <7\JDHH C^SQ_P!Q?RH^SQ_W%_*I** (_L\?]Q?R
MH^SQ_P!Q?RJ2B@"/[/'_ '%_*C[/'_<7\JDHH C^SQ_W%_*C[/'_ '%_*I**
M (_L\?\ <7\J/L\?]Q?RJ2B@"/[/'_<7\J/L\?\ <7\JDHH C^SQ_P!Q?RH^
MSQ_W%_*I** (_L\?]Q?RH^SQ_P!Q?RJ2B@"/[/'_ '%_*C[/'_<7\JDHH C^
MSQ_W%_*C[/'_ '%_*I** (_L\?\ <7\J/L\?]Q?RJ2B@"/[/'_<7\J/L\?\
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M^12M?I11\&_^12M?I17S]3<^AI_ CP'_ (**?\BKX+_Z_P"?_P!%5\G?!/\
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MH<?PD<$=^P9C\)AOCJ?XG^9])/X(?X4>I_ ,K_;6J#OY$8ZGH6..,8Q[YQU
MSR3@_MX9_P"%+66>3_:]O_[-6Y\!MQUC5&'*^2G&#W8GKTY!^OT&*POV[_\
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MKV<NQ6,PSE]5Z[GG8NC0K6]LSU[PKI<FB^&]+TZ0J\MI:QV[,GW244 X_*O
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MM<8\N7:'V_DP_.MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK],RG_D3R_[>/Q+/_P#DH8^L/T/UFU#4;;2;*2[O)DM[>)2SR.<  <US5O\
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M82--:KIZPS6AASG+R@-G&/ER3DU]7_:(O^>B_G1Y*?W%_(4W[+'_ '%_[Y%
M#OM$7_/1?SH^T1?\]%_.F_98_P"XO_?(H^RQ_P!Q?^^10 [[1%_ST7\Z/M$7
M_/1?SIOV6/\ N+_WR*/LL?\ <7_OD4 .^T1?\]%_.C[1%_ST7\Z;]EC_ +B_
M]\BC[+'_ '%_[Y% #OM$7_/1?SH^T1?\]%_.F_98_P"XO_?(H^RQ_P!Q?^^1
M0 [[1%_ST7\Z/M$7_/1?SIOV6/\ N+_WR*/LL?\ <7_OD4 .^T1?\]%_.C[1
M%_ST7\Z;]EC_ +B_]\BC[+'_ '%_[Y% #OM$7_/1?SH^T1?\]%_.F_98_P"X
MO_?(H^RQ_P!Q?^^10 [[1%_ST7\Z/M$7_/1?SIOV6/\ N+_WR*/LL?\ <7_O
MD4 .^T1?\]%_.C[1%_ST7\Z;]EC_ +B_]\BC[+'_ '%_[Y% #OM$7_/1?SH^
MT1?\]%_.F_98_P"XO_?(H^RQ_P!Q?^^10 [[1%_ST7\Z/M$7_/1?SIOV6/\
MN+_WR*/LL?\ <7_OD4 .^T1?\]%_.C[1%_ST7\Z;]EC_ +B_]\BC[+'_ '%_
M[Y% #OM$7_/1?SH^T1?\]%_.F_98_P"XO_?(H^RQ_P!Q?^^10 [[1%_ST7\Z
M/M$7_/1?SIOV6/\ N+_WR*/LL?\ <7_OD4 .^T1?\]%_.C[1%_ST7\Z;]EC_
M +B_]\BC[+'_ '%_[Y% #OM$7_/1?SH^T1?\]%_.F_98_P"XO_?(H^RQ_P!Q
M?^^10 [[1%_ST7\Z/M$7_/1?SIOV6/\ N+_WR*/LL?\ <7_OD4 .^T1?\]%_
M.C[1%_ST7\Z;]EC_ +B_]\BC[+'_ '%_[Y% #OM$7_/1?SH^T1?\]%_.F_98
M_P"XO_?(H^RQ_P!Q?^^10 [[1%_ST7\Z/M$7_/1?SIOV6/\ N+_WR*/LL?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M75]/U1Z?\&_^12M?I11\&_\ D4K7Z45\_4W/H:?P(\!_X**?\BKX+_Z_Y_\
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MC[5%_P ]$_.@":BH?M,7_/1/SI1<1GHZG\: ):*A^TQ?\]$_.C[3%_ST3\Z
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M@\9 (KQ!O"VN+_S!-3!_Z\I?_B:Y<JKTU@:5Y)626Y>,ISEB9-19]S>&,_\
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M>>=V!75>2MN8%5%10W"H,#.#VH-C$TC2>1&7;G<5&3WSGK_^J@#$\*^,M/\
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M ,;PWXKT_P 9:9>W.G"1X893 7D3;N8*"2!Z<_I2^(O%MEX7\I;J,L6CW@(
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MIYZ?G5K1?'6C^(+H6]G<N9=C/^]B9 5# 9R0!SD8]B#7">(?%?ACPSK]WO\
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M "KJ"2.%T,;??<@*H..>3VZ=ZQO >NZ9J%Y?6NGZ2VG3>4+ASD,&.?+(!_X
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M .RK\Y]S>C?K1N;^ZWY&E_J[@?/[S3_6_-?Y5_X"?HQ_PWU\,/75_P#P#_\
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MKV!\_O#_ %PS7^5?^ GZ&R?MS?">12IBU,@\_-IZGOD]3ZBI6_;O^%DF[?\
MVNX8;65K($$#.,C=[U^=NYO[K?D:-S?W6_(T?ZO8'S^\/]<,U_E7W'Z(?\-T
M_"8=(-2'TT]?Q[TZ/]N[X50J0B:J@)SA;$ 9_P"^J_.W<W]UOR-&YO[K?D:/
M]7L#Y_>'^N&:_P J_P# 3]$'_;K^%$C,QCU0LQR2; $D]/[WI3D_;M^%,;;D
MCU1&]5L #Z?WO2OSMW-_=;\C1N;^ZWY&C_5[ ^?WA_KAFO\ *O\ P$_1&3]N
MSX42HJ/'JCJIR ]B&Y_%J0?MU?"=>D.ICI_RX+VX'\5?G?N;^ZWY&C<W]UOR
M-'^KV!\_O'_KAFO\J_\  3]$U_;P^%:*%5=650-H5;( 8],;JB_X;F^$NW @
MU)1QTT]>W3O7YX[F_NM^1HW-_=;\C1_J]@?/[Q?ZX9K_ "K_ ,!/T1C_ &[/
MA3$I5(]50$ ';8@<#I_%0W[=GPI=BS1ZHS''S&P4GCI_%7YW;F_NM^1HW-_=
M;\C1_J]@?/[P_P!<,U_E7W'Z'_\ #='PG4@K%J:$< K8+ZY_O>O-/D_;N^%<
MRD.NJN,YPUB"/U;VK\[=S?W6_(T;F_NM^1H_U>P/G]X_]<,U_E7_ ("?H=_P
MW-\)@ !#J0 Z :>O'.?[WK4J_MX_"R, (-60;MV%L@.?^^J_.S<W]UOR-&YO
M[K?D:/\ 5[ ^?WA_KAFO\J_\!/T/_P"&Y_A-S^ZU0YSG-@#G/7^*EC_;K^%,
M+AD35$/)^6P Z]?XN]?G?N;^ZWY&C<W]UOR-'^KV!\_O%_KAFO\ *ON/T0D_
M;J^$\V/,BU20A=H9[ $@>GWJ3_ANGX49),>J'.3SIZ]^O\7T_*OSPW-_=;\C
M1N;^ZWY&C_5[ ^?WA_KAFO\ *ON/T3;]N_X5NK*RZJZLNTJUB""/3[W3FHA^
MW/\ "95*B+4P#G@:>N.1@]_3BOSQW-_=;\C1N;^ZWY&C_5[ ^?WC_P!<,U_E
M7_@)^B:_MW_"M%PJZLHR"=MB!G'3^*O)_P!IO]IWP=\9/A[;:'X?%_\ ;$OX
M;DFZM_+78N0><GGD5\B;F_NM^1J:U3_2H2"W+*N,'J6'%7#(\'0?M8WNO-&5
M3B;,\;!T*D5:7]UGZP?!M?\ BDK;V%%+\&_E\(V^1QC^E%?F#]Y['[G32E%6
M.PUC1;?5K.6&2-2&X.X9_*O-YO@#I%Q,TA4#<<XVBO6'Z?B*5.]"DTK)Z X1
MEJT>1_\ #/>C_P!T?]\T?\,]Z/\ W1_WS7KU%'-+N+V</Y4>0_\ #/>C_P!W
M_P =H_X9[T?^[_X[7KU%'-+N+V5/^5'D/_#/>C_W?_':/^&>]'_N_P#CM>O4
M4<TNX>RI_P J/(?^&>]'_N_^.T?\,]Z/_=_\=KUZBCFEW#V5/^5'D/\ PSWH
M_P#=_P#':/\ AGO1_P"[_P".UZ]11S2[A[*G_*CR'_AGO1_[O_CM'_#/>C_W
M?_':]>HHYI=P]E3_ )4>0_\ #/>C_P!W_P =H_X9[T?^[_X[7KU%'-+N'LJ?
M\J/(?^&>]'_N_P#CM'_#/>C_ -W_ ,=KUZBCFEW#V5/^5'D/_#/>C_W?_':/
M^&>]'_N_^.UZ]11S2[A[*G_*CR'_ (9[T?\ N_\ CM'_  SWH_\ =_\ ':]>
MHHYI=P]E3_E1Y#_PSWH_]W_QVC_AGO1_[O\ X[7KU%'-+N'LJ?\ *CR'_AGO
M1_[O_CM'_#/>C_W?_':]>HHYI=P]E3_E1Y#_ ,,]Z/\ W?\ QVC_ (9[T?\
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MM>O44<TNX>RI_P J/(?^&>]'_N_^.T?\,]Z/_=_\=KUZBCFEW#V5/^5'D/\
MPSWH_P#=_P#':/\ AGO1_P"[_P".UZ]11S2[A[*G_*CR'_AGO1_[O_CM'_#/
M>C_W?_':]>HHYI=P]E3_ )4>0_\ #/>C_P!W_P =H_X9[T?^[_X[7KU%'-+N
M'LJ?\J/(?^&>]'_N_P#CM'_#/>C_ -W_ ,=KUZBCFEW#V5/^5'D/_#/>C_W?
M_':/^&>]'_N_^.UZ]11S2[A[*G_*CR'_ (9[T?\ N_\ CM'_  SWH_\ =_\
M':]>HHYI=P]E3_E1Y#_PSWH_]W_QVC_AGO1_[O\ X[7KU%'-+N'LJ?\ *CR'
M_AGO1_[O_CM'_#/>C_W?_':]>HHYI=P]E3_E1Y#_ ,,]Z/\ W?\ QVC_ (9[
MT?\ N_\ CM>O44<TNX>RI_RH\A_X9[T?^[_X[1_PSWH_]W_QVO7J*.:7</94
M_P"5'D/_  SWH_\ =_\ ':>G[/NCHZMM![_=KUNDI\\ELP]E3_E1D^'_  _#
4H.GK:Q'*CCFBM5^U%0M-C:[/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ptgef-20240930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSaiHmcPtxJFzWZkhv2p8fcmqnyAjf7yOZSO61qDmIX4H -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ptgef="http://portagebiotech.com/20240930" elementFormDefault="qualified" targetNamespace="http://portagebiotech.com/20240930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://portagebiotech.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" id="InterimStatementsOfFinancialPosition">
          <link:definition>00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" id="InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss">
          <link:definition>00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" id="InterimStatementsOfChangesInShareholdersEquity">
          <link:definition>00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" id="InterimStatementsOfCashFlows">
          <link:definition>00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/NatureOfOperations" id="NatureOfOperations">
          <link:definition>00000006 - Disclosure - NATURE OF OPERATIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/GoingConcern" id="GoingConcern">
          <link:definition>00000007 - Disclosure - GOING CONCERN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/BasisOfPresentation" id="BasisOfPresentation">
          <link:definition>00000008 - Disclosure - BASIS OF PRESENTATION</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" id="PrepaidExpensesAndOtherReceivables">
          <link:definition>00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiability" id="WarrantLiability">
          <link:definition>00000011 - Disclosure - WARRANT LIABILITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" id="AccountsPayableAndAccruedLiabilities">
          <link:definition>00000012 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000013 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalStockAndReserves" id="CapitalStockAndReserves">
          <link:definition>00000014 - Disclosure - CAPITAL STOCK AND RESERVES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserve" id="StockOptionReserve">
          <link:definition>00000015 - Disclosure - STOCK OPTION RESERVE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LossPerShare" id="LossPerShare">
          <link:definition>00000016 - Disclosure - LOSS PER SHARE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
          <link:definition>00000017 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000018 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" id="FinancialInstrumentsAndRiskManagement">
          <link:definition>00000019 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalManagement" id="CapitalManagement">
          <link:definition>00000020 - Disclosure - CAPITAL MANAGEMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterest" id="Non-controllingInterest">
          <link:definition>00000021 - Disclosure - NON-CONTROLLING INTEREST</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" id="PrepaidExpensesAndOtherReceivablesTables">
          <link:definition>00000023 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" id="WarrantLiabilityTables">
          <link:definition>00000024 - Disclosure - WARRANT LIABILITY (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" id="AccountsPayableAndAccruedLiabilitiesTables">
          <link:definition>00000025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000026 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalStockAndReservesTables" id="CapitalStockAndReservesTables">
          <link:definition>00000027 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveTables" id="StockOptionReserveTables">
          <link:definition>00000028 - Disclosure - STOCK OPTION RESERVE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LossPerShareTables" id="LossPerShareTables">
          <link:definition>00000029 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" id="FinancialInstrumentsAndRiskManagementTables">
          <link:definition>00000030 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" id="Non-controllingInterestTables">
          <link:definition>00000031 - Disclosure - NON-CONTROLLING INTEREST (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>00000032 - Disclosure - GOING CONCERN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" id="BasisOfPresentationDetailsNarrative">
          <link:definition>00000033 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" id="PrepaidExpensesAndOtherReceivablesDetails">
          <link:definition>00000034 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" id="PrepaidExpensesAndOtherReceivablesDetailsNarrative">
          <link:definition>00000035 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" id="WarrantLiabilityDetails">
          <link:definition>00000036 - Disclosure - WARRANT LIABILITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails1" id="WarrantLiabilityDetails1">
          <link:definition>00000037 - Disclosure - WARRANT LIABILITY (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails2" id="WarrantLiabilityDetails2">
          <link:definition>00000038 - Disclosure -  WARRANT LIABILITY (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails3" id="WarrantLiabilityDetails3">
          <link:definition>00000039 - Disclosure - WARRANT LIABILITY (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" id="WarrantLiabilityDetailsNarrative">
          <link:definition>00000040 - Disclosure - WARRANT LIABILITY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" id="AccountsPayableAndAccruedLiabilitiesDetails">
          <link:definition>00000041 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative" id="AccountsPayableAndAccruedLiabilitiesDetailsNarrative">
          <link:definition>00000042 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
          <link:definition>00000043 - Disclosure - INCOME TAXES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000044 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetails1" id="CapitalStockAndReservesDetails1">
          <link:definition>00000045 - Disclosure - CAPITAL STOCK AND RESERVES (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" id="CapitalStockAndReservesDetailsNarrative">
          <link:definition>00000046 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" id="StockOptionReserveDetails">
          <link:definition>00000047 - Disclosure - STOCK OPTION RESERVE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" id="StockOptionReserveDetails1">
          <link:definition>00000048 - Disclosure - STOCK OPTION RESERVE (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" id="StockOptionReserveDetails2">
          <link:definition>00000049 - Disclosure - STOCK OPTION RESERVE (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" id="StockOptionReserveDetailsNarrative">
          <link:definition>00000050 - Disclosure - STOCK OPTION RESERVE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LossPerShareDetails" id="LossPerShareDetails">
          <link:definition>00000051 - Disclosure - LOSS PER SHARE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/LossPerShareDetails1" id="LossPerShareDetails1">
          <link:definition>00000052 - Disclosure - LOSS PER SHARE (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" id="CommitmentsAndContingentLiabilitiesDetailsNarrative">
          <link:definition>00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000054 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" id="FinancialInstrumentsAndRiskManagementDetails">
          <link:definition>00000055 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" id="CapitalManagementDetailsNarrative">
          <link:definition>00000056 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" id="Non-controllingInterestDetails">
          <link:definition>00000057 - Disclosure - NON-CONTROLLING INTEREST (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ptgef-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <element id="ptgef_StockOptionReserveMember" name="StockOptionReserveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccumulatedOtherComprehensiveLossMember" name="AccumulatedOtherComprehensiveLossMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CountryOfBritishVirginIslandsMember" name="CountryOfBritishVirginIslandsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CountryOfDelawareMember" name="CountryOfDelawareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SaugatuckMember" name="SaugatuckMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ParexelInternationalLimitedMember" name="ParexelInternationalLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PlacementAgentWarrantsMember" name="PlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ClassBWarrantsMember" name="ClassBWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ClassCWarrantsMember" name="ClassCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeriesAWarrantsMember" name="SeriesAWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PlacementAgentWarrantMember" name="PlacementAgentWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ATMMember" name="ATMMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" name="SeriesAWarrantsAndPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PBI2021EquityIncentivePlanMember" name="PBI2021EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RestrictedStockUnitsMember" name="RestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AmortizedCostMember" name="AmortizedCostMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueToOtherComprehensiveIncomeMember" name="FairValueToOtherComprehensiveIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueThroughProfitOrLossMember" name="FairValueThroughProfitOrLossMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiabilityNonCurrent" name="WarrantLiabilityNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CommitmentsAndContingentLiabilities" name="CommitmentsAndContingentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfWarrantsLiability" name="ChangeInFairValueOfWarrantsLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" name="ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainOnSettlementWithParexelIoxCro" name="GainOnSettlementWithParexelIoxCro" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetLoss" name="NetLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetUnrealizedGainOnInvestments" name="NetUnrealizedGainOnInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ComprehensiveLossForPeriod" name="ComprehensiveLossForPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ComprehensiveIncomeAttributableToOwnerOfParent" name="ComprehensiveIncomeAttributableToOwnerOfParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IfrsStatementLineItems" name="IfrsStatementLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_EquityPreSplit" name="EquityPreSplit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ReverseStockSplitValue" name="ReverseStockSplitValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ReverseStockSplitShares" name="ReverseStockSplitShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderAtm" name="SharesIssuedUnderAtm" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedUnderAtmShares" name="SharesIssuedUnderAtmShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedOrAccruedForServices" name="SharesIssuedOrAccruedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedOrAccruedForServicesShares" name="SharesIssuedOrAccruedForServicesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetUnrealizedGainOnInvestment" name="NetUnrealizedGainOnInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrefundedWarrantsExercised" name="PrefundedWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrefundedWarrantsExercisedShares" name="PrefundedWarrantsExercisedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" name="AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" name="AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedForAccruedBonuses" name="SharesIssuedForAccruedBonuses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedForAccruedBonusesShares" name="SharesIssuedForAccruedBonusesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedForRestrictedStockUnitsNet" name="SharesIssuedForRestrictedStockUnitsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesIssuedForRestrictedStockUnitsNetShares" name="SharesIssuedForRestrictedStockUnitsNetShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncreaseDecreaseInShareOfLossInAssociate" name="IncreaseDecreaseInShareOfLossInAssociate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfSharesIssuedForServices" name="FairValueOfSharesIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangesInOperatingWorkingCapitalAbstract" name="ChangesInOperatingWorkingCapitalAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromExerciseOfPrefundedWarrants" name="ProceedsFromExerciseOfPrefundedWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" name="ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RepaymentOfLeaseLiability" name="RepaymentOfLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SupplementalDisclosureOfCashFlowInformationAbstract" name="SupplementalDisclosureOfCashFlowInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashPaidForInterest" name="CashPaidForInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" name="SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RightToUseAssetAcquired" name="RightToUseAssetAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LeaseLiabilityIncurred" name="LeaseLiabilityIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureNatureOfOperationsAbstract" name="DisclosureNatureOfOperationsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NatureOfOperationsExplanatory" name="NatureOfOperationsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureSignificantAccountingPoliciesAbstract" name="DisclosureSignificantAccountingPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" name="DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract" name="DisclosurePrepaidExpensesAndOtherReceivablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory" name="DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureWarrantLiabilityAbstract" name="DisclosureWarrantLiabilityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiabilityTextBlock" name="WarrantLiabilityTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" name="DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" name="AccountsPayableAndAccruedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureCapitalStockAndReservesAbstract" name="DisclosureCapitalStockAndReservesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CapitalStockAndReservesTextBlock" name="CapitalStockAndReservesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" name="DisclosureFinancialInstrumentsAndRiskManagementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" name="DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureCapitalManagementAbstract" name="DisclosureCapitalManagementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" name="DisclosureOfCapitalManagementExplanatoryTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" name="DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" name="DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" name="ScheduleOfWarrantLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" name="AccountsPayableAndAccruedLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" name="ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" name="DisclosureOfFairValueMeasurementOfWarrantsExplanatory" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" name="ScheduleOfTermsStockOptionReserveTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock" name="ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfEarningsPerShareTableTextBlock" name="ScheduleOfEarningsPerShareTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" name="ScheduleOfAntiDilutiveEffectTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" name="ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" name="ScheduleOfNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TotalCurrentLiabilities" name="TotalCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetLossIncome" name="NetLossIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashUsedInOperatingActivities" name="CashUsedInOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PercentageOfOutstandingShares" name="PercentageOfOutstandingShares" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_TaxDeposits" name="TaxDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SecurityDepositOnOfficeLease" name="SecurityDepositOnOfficeLease" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent" name="PrepaidExpensesAndOtherReceivablesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WriteoffOfAdvances" name="WriteoffOfAdvances" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RefundReceivables" name="RefundReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiabilityExercisePrice" name="WarrantLiabilityExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsLiabilityShares" name="WarrantsLiabilityShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsLiabilityFairValue" name="WarrantsLiabilityFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" name="FairValueOfWarrantsAtIssuanceExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrantsShares" name="FairValueOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrantsAmount" name="FairValueOfWarrantsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfWarrantLiability" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfWarrantLiabilityAmount" name="ChangeInFairValueOfWarrantLiabilityAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExercisePriceFairValue" name="ExercisePriceFairValue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharePriceFairvalue" name="SharePriceFairvalue" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OptionLifeShareOptions" name="OptionLifeShareOptions" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OrdinaryNumberOfStockSold" name="OrdinaryNumberOfStockSold" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchasePriceOfPerShare" name="PurchasePriceOfPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseWarrants" name="PurchaseWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OrdinarySharesPurchase" name="OrdinarySharesPurchase" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExercisePriceOfOutstandingWarrant" name="ExercisePriceOfOutstandingWarrant" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AggregateGrossProceeds" name="AggregateGrossProceeds" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ManagementFeePercentage" name="ManagementFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AggregateGrossProceedsIncrease" name="AggregateGrossProceedsIncrease" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PurchaseOfWarrants" name="PurchaseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SaleOfWarrantPercentage" name="SaleOfWarrantPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExercisePriceWarrantPerShare" name="ExercisePriceWarrantPerShare" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetProceedsWarrantLiability" name="NetProceedsWarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_LossOnWarrantLiabilities" name="LossOnWarrantLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OfferingExpenses" name="OfferingExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ChangeInFairValueOfWarrantLiabilities" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantLiabilityBalance" name="WarrantLiabilityBalance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrantPerShare" name="FairValueOfWarrantPerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAmountsAccruedToCro" name="AccountsPayableAndAmountsAccruedToCro" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" name="AccruedBonusesAndOtherPayrollrelatedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedAccountingAndAuditingFees" name="AccruedAccountingAndAuditingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedLegalFees" name="AccruedLegalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedOtherProfessionalFees" name="AccruedOtherProfessionalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OtherAccountsPayable" name="OtherAccountsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccruedClinicalAndRdServices" name="AccruedClinicalAndRdServices" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OtherAccruedExpenses" name="OtherAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilityNet" name="AccountsPayableAndAccruedLiabilityNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_IncomeTaxExpenseContinuingOperation" name="IncomeTaxExpenseContinuingOperation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfOrdinarySharesOutstandingDecrease" name="NumberOfOrdinarySharesOutstandingDecrease" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CashFundDescription" name="CashFundDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfOrdinaryShareIssued" name="NumberOfOrdinaryShareIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfSharesSold" name="NumberOfSharesSold" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PublicFloat" name="PublicFloat" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_FairValueOfWarrants" name="FairValueOfWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_WarrantsPerShare" name="WarrantsPerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_StockOptionReserve" name="StockOptionReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AdjustmentsForSharebasedPayment" name="AdjustmentsForSharebasedPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfOutstandingShareOption" name="NumberOfOutstandingShareOption" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" name="NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" name="NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesReservedForAwardsGranted" name="SharesReservedForAwardsGranted" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesAvailableForFutureAwards" name="SharesAvailableForFutureAwards" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfSharesExercise" name="NumberOfSharesExercise" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" name="SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfSharesGranted" name="NumberOfSharesGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumberOfShareOutstanding" name="NumberOfShareOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DescriptionOfRestrictedStockUnitsExpire" name="DescriptionOfRestrictedStockUnitsExpire" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NumeratorAbstract" name="NumeratorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_DenominatorAbstract" name="DenominatorAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AntidilutiveEffectOnLossPerShare" name="AntidilutiveEffectOnLossPerShare" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_RetainageDeposits" name="RetainageDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_UnbilledContractsReceivables" name="UnbilledContractsReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ForfeitedAdvancedPayments" name="ForfeitedAdvancedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_GainOnLiability" name="GainOnLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities" name="PayablesToParexelInAccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_BudgetedCosts" name="BudgetedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PortagePaidIntensity" name="PortagePaidIntensity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CompensationCommittee" name="CompensationCommittee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_OriginalAnnualTargetsPercentage" name="OriginalAnnualTargetsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedExpenses" name="AccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AnnualFeesdescription" name="AnnualFeesdescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PrepaidExpensesAndOtherReceivable" name="PrepaidExpensesAndOtherReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_AccountsPayableAndAccruedLiabilities" name="AccountsPayableAndAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_PayablesAndAccruedExpense" name="PayablesAndAccruedExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_CurrentAsset" name="CurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareholdersEquity" name="ShareholdersEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_ShareholdersEquityAttributableToOwners" name="ShareholdersEquityAttributableToOwners" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="ptgef_NetLossAttributableToNoncontrollingInterest" name="NetLossAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ptgef-20240930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://portagebiotech.com/role/Cover" xlink:href="ptgef-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:href="ptgef-20240930.xsd#InterimStatementsOfFinancialPosition" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:href="ptgef-20240930.xsd#InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:href="ptgef-20240930.xsd#InterimStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:href="ptgef-20240930.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperations" xlink:href="ptgef-20240930.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoingConcern" xlink:href="ptgef-20240930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentation" xlink:href="ptgef-20240930.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:href="ptgef-20240930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiability" xlink:href="ptgef-20240930.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxes" xlink:href="ptgef-20240930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReserves" xlink:href="ptgef-20240930.xsd#CapitalStockAndReserves" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserve" xlink:href="ptgef-20240930.xsd#StockOptionReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShare" xlink:href="ptgef-20240930.xsd#LossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:href="ptgef-20240930.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:href="ptgef-20240930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:href="ptgef-20240930.xsd#FinancialInstrumentsAndRiskManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalManagement" xlink:href="ptgef-20240930.xsd#CapitalManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterest" xlink:href="ptgef-20240930.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:href="ptgef-20240930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:href="ptgef-20240930.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesTables" xlink:href="ptgef-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReservesTables" xlink:href="ptgef-20240930.xsd#CapitalStockAndReservesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveTables" xlink:href="ptgef-20240930.xsd#StockOptionReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareTables" xlink:href="ptgef-20240930.xsd#LossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:href="ptgef-20240930.xsd#FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:href="ptgef-20240930.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoingConcernDetailsNarrative" xlink:href="ptgef-20240930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ptgef-20240930.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails1" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails2" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails3" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:href="ptgef-20240930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:href="ptgef-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetails1" xlink:href="ptgef-20240930.xsd#CapitalStockAndReservesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" xlink:href="ptgef-20240930.xsd#CapitalStockAndReservesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails" xlink:href="ptgef-20240930.xsd#LossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails1" xlink:href="ptgef-20240930.xsd#LossPerShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="ptgef-20240930.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ptgef-20240930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:href="ptgef-20240930.xsd#FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" xlink:href="ptgef-20240930.xsd#CapitalManagementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:href="ptgef-20240930.xsd#Non-controllingInterestDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:title="00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-fullOtherAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-fullOtherCurrentLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-fullNoncurrentLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentLiabilities" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityNonCurrent" xlink:label="loc_ptgefWarrantLiabilityNonCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentLiabilities" xlink:to="loc_ptgefWarrantLiabilityNonCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullNoncurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:title="00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantsLiability" xlink:label="loc_ptgefChangeInFairValueOfWarrantsLiability" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefChangeInFairValueOfWarrantsLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullDepreciationAndAmortisationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullDepreciationAndAmortisationExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-fullRevenueFromInterest" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullRevenueFromInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetLoss" xlink:label="loc_ptgefNetLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefNetLoss" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefNetLoss" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ComprehensiveLossForPeriod" xlink:label="loc_ptgefComprehensiveLossForPeriod" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefComprehensiveLossForPeriod" xlink:to="loc_ptgefNetLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetUnrealizedGainOnInvestments" xlink:label="loc_ptgefNetUnrealizedGainOnInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefComprehensiveLossForPeriod" xlink:to="loc_ptgefNetUnrealizedGainOnInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ComprehensiveIncomeAttributableToOwnerOfParent" xlink:label="loc_ptgefComprehensiveIncomeAttributableToOwnerOfParent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefComprehensiveIncomeAttributableToOwnerOfParent" xlink:to="loc_ifrs-fullComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ptgefComprehensiveIncomeAttributableToOwnerOfParent" xlink:to="loc_ifrs-fullComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantsLiability" xlink:label="loc_ptgefChangeInFairValueOfWarrantsLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefChangeInFairValueOfWarrantsLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IncreaseDecreaseInShareOfLossInAssociate" xlink:label="loc_ptgefIncreaseDecreaseInShareOfLossInAssociate" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefIncreaseDecreaseInShareOfLossInAssociate" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfSharesIssuedForServices" xlink:label="loc_ptgefFairValueOfSharesIssuedForServices" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ptgefFairValueOfSharesIssuedForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullAdjustmentsForDepreciationAndAmortisationExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="loc_ptgefProceedsFromExerciseOfPrefundedWarrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromExerciseOfPrefundedWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-fullPaymentsForShareIssueCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullPaymentsForShareIssueCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RepaymentOfLeaseLiability" xlink:label="loc_ptgefRepaymentOfLeaseLiability" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ptgefRepaymentOfLeaseLiability" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="00000006 - Disclosure - NATURE OF OPERATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcern" xlink:title="00000007 - Disclosure - GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="00000011 - Disclosure - WARRANT LIABILITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="00000012 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReserves" xlink:title="00000014 - Disclosure - CAPITAL STOCK AND RESERVES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="00000015 - Disclosure - STOCK OPTION RESERVE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="00000016 - Disclosure - LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="00000019 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagement" xlink:title="00000020 - Disclosure - CAPITAL MANAGEMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="00000021 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="00000023 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="00000024 - Disclosure - WARRANT LIABILITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="00000025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesTables" xlink:title="00000027 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="00000028 - Disclosure - STOCK OPTION RESERVE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="00000029 - Disclosure - LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="00000030 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="00000031 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcernDetailsNarrative" xlink:title="00000032 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000033 - Disclosure - BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="00000034 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="loc_ifrs-fullCurrentPrepayments" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:label="loc_ifrs-fullCurrentReceivablesFromSaleOfProperties" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ifrs-fullCurrentReceivablesFromSaleOfProperties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentReceivablesFromRentalOfProperties" xlink:label="loc_ifrs-fullCurrentReceivablesFromRentalOfProperties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ifrs-fullCurrentReceivablesFromRentalOfProperties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="loc_ifrs-fullCurrentAdvancesToSuppliers" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ifrs-fullCurrentAdvancesToSuppliers" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_TaxDeposits" xlink:label="loc_ptgefTaxDeposits" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ptgefTaxDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-fullCurrentPrepaidExpenses" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ifrs-fullCurrentPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SecurityDepositOnOfficeLease" xlink:label="loc_ptgefSecurityDepositOnOfficeLease" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentPrepayments" xlink:to="loc_ptgefSecurityDepositOnOfficeLease" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:title="00000035 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="00000036 - Disclosure - WARRANT LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails1" xlink:title="00000037 - Disclosure - WARRANT LIABILITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails2" xlink:title="00000038 - Disclosure -  WARRANT LIABILITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails3" xlink:title="00000039 - Disclosure - WARRANT LIABILITY (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" xlink:title="00000040 - Disclosure - WARRANT LIABILITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="00000041 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative" xlink:title="00000042 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:title="00000043 - Disclosure - INCOME TAXES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000044 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetails1" xlink:title="00000045 - Disclosure - CAPITAL STOCK AND RESERVES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" xlink:title="00000046 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="00000047 - Disclosure - STOCK OPTION RESERVE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="00000048 - Disclosure - STOCK OPTION RESERVE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="00000049 - Disclosure - STOCK OPTION RESERVE (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="00000050 - Disclosure - STOCK OPTION RESERVE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="00000051 - Disclosure - LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="00000052 - Disclosure - LOSS PER SHARE (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000054 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="00000055 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" xlink:title="00000056 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="00000057 - Disclosure - NON-CONTROLLING INTEREST (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ptgef-20240930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://portagebiotech.com/role/Cover" xlink:href="ptgef-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:href="ptgef-20240930.xsd#InterimStatementsOfFinancialPosition" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:href="ptgef-20240930.xsd#InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:href="ptgef-20240930.xsd#InterimStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:href="ptgef-20240930.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperations" xlink:href="ptgef-20240930.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoingConcern" xlink:href="ptgef-20240930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentation" xlink:href="ptgef-20240930.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:href="ptgef-20240930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiability" xlink:href="ptgef-20240930.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxes" xlink:href="ptgef-20240930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReserves" xlink:href="ptgef-20240930.xsd#CapitalStockAndReserves" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserve" xlink:href="ptgef-20240930.xsd#StockOptionReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShare" xlink:href="ptgef-20240930.xsd#LossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:href="ptgef-20240930.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:href="ptgef-20240930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:href="ptgef-20240930.xsd#FinancialInstrumentsAndRiskManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalManagement" xlink:href="ptgef-20240930.xsd#CapitalManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterest" xlink:href="ptgef-20240930.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:href="ptgef-20240930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:href="ptgef-20240930.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesTables" xlink:href="ptgef-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReservesTables" xlink:href="ptgef-20240930.xsd#CapitalStockAndReservesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveTables" xlink:href="ptgef-20240930.xsd#StockOptionReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareTables" xlink:href="ptgef-20240930.xsd#LossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:href="ptgef-20240930.xsd#FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:href="ptgef-20240930.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoingConcernDetailsNarrative" xlink:href="ptgef-20240930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ptgef-20240930.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails1" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails2" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails3" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:href="ptgef-20240930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:href="ptgef-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetails1" xlink:href="ptgef-20240930.xsd#CapitalStockAndReservesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" xlink:href="ptgef-20240930.xsd#CapitalStockAndReservesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails" xlink:href="ptgef-20240930.xsd#LossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails1" xlink:href="ptgef-20240930.xsd#LossPerShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="ptgef-20240930.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ptgef-20240930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:href="ptgef-20240930.xsd#FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" xlink:href="ptgef-20240930.xsd#CapitalManagementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:href="ptgef-20240930.xsd#Non-controllingInterestDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:title="00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:title="00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullIssuedCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ptgefStockOptionReserveMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccumulatedOtherComprehensiveLossMember" xlink:label="loc_ptgefAccumulatedOtherComprehensiveLossMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ptgefAccumulatedOtherComprehensiveLossMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_EquityPreSplit" xlink:label="loc_ptgefEquityPreSplit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefEquityPreSplit_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ReverseStockSplitValue" xlink:label="loc_ptgefReverseStockSplitValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReverseStockSplitValue_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ReverseStockSplitShares" xlink:label="loc_ptgefReverseStockSplitShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReverseStockSplitShares_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedUnderAtm" xlink:label="loc_ptgefSharesIssuedUnderAtm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtm_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedUnderAtmShares" xlink:label="loc_ptgefSharesIssuedUnderAtmShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtmShares_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-fullShareIssueRelatedCost_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullShareIssueRelatedCost_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="loc_ptgefSharesIssuedOrAccruedForServices_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServices_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="loc_ptgefSharesIssuedOrAccruedForServicesShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServicesShares_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetUnrealizedGainOnInvestment" xlink:label="loc_ptgefNetUnrealizedGainOnInvestment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetUnrealizedGainOnInvestment_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrefundedWarrantsExercised" xlink:label="loc_ptgefPrefundedWarrantsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrefundedWarrantsExercised_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrefundedWarrantsExercisedShares" xlink:label="loc_ptgefPrefundedWarrantsExercisedShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrefundedWarrantsExercisedShares_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:label="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:label="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForAccruedBonuses" xlink:label="loc_ptgefSharesIssuedForAccruedBonuses_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForAccruedBonuses_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForAccruedBonusesShares" xlink:label="loc_ptgefSharesIssuedForAccruedBonusesShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForAccruedBonusesShares_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForRestrictedStockUnitsNet" xlink:label="loc_ptgefSharesIssuedForRestrictedStockUnitsNet_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForRestrictedStockUnitsNet_80" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForRestrictedStockUnitsNetShares" xlink:label="loc_ptgefSharesIssuedForRestrictedStockUnitsNetShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForRestrictedStockUnitsNetShares_80" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss_80" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="00000006 - Disclosure - NATURE OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcern" xlink:title="00000007 - Disclosure - GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="00000011 - Disclosure - WARRANT LIABILITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="00000012 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReserves" xlink:title="00000014 - Disclosure - CAPITAL STOCK AND RESERVES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="00000015 - Disclosure - STOCK OPTION RESERVE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="00000016 - Disclosure - LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="00000019 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagement" xlink:title="00000020 - Disclosure - CAPITAL MANAGEMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="00000021 - Disclosure - NON-CONTROLLING INTEREST" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="00000023 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="00000024 - Disclosure - WARRANT LIABILITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesBWarrantsMember" xlink:label="loc_ptgefSeriesBWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesBWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesCWarrantsMember" xlink:label="loc_ptgefSeriesCWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesCWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementExplanatory_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementExplanatory_50" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="00000025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesTables" xlink:title="00000027 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="00000028 - Disclosure - STOCK OPTION RESERVE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="00000029 - Disclosure - LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="00000030 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="00000031 - Disclosure - NON-CONTROLLING INTEREST (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcernDetailsNarrative" xlink:title="00000032 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000033 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullBottomOfRangeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullTopOfRangeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-fullSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullSegmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-fullSegmentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullSegmentsAxis" xlink:to="loc_ifrs-fullSegmentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-fullSegmentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullSegmentsAxis" xlink:to="loc_ifrs-fullSegmentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CountryOfBritishVirginIslandsMember" xlink:label="loc_ptgefCountryOfBritishVirginIslandsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullSegmentsMember" xlink:to="loc_ptgefCountryOfBritishVirginIslandsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CountryOfDelawareMember" xlink:label="loc_ptgefCountryOfDelawareMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullSegmentsMember" xlink:to="loc_ptgefCountryOfDelawareMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSaugatuckMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PercentageOfOutstandingShares" xlink:label="loc_ptgefPercentageOfOutstandingShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPercentageOfOutstandingShares_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests_80" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="00000034 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:title="00000035 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-fullEntitysTotalForSubsidiariesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" xlink:to="loc_ifrs-fullEntitysTotalForSubsidiariesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-fullEntitysTotalForSubsidiariesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" xlink:to="loc_ifrs-fullEntitysTotalForSubsidiariesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ParexelInternationalLimitedMember" xlink:label="loc_ptgefParexelInternationalLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForSubsidiariesMember" xlink:to="loc_ptgefParexelInternationalLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivablesNoncurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivablesNoncurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WriteoffOfAdvances" xlink:label="loc_ptgefWriteoffOfAdvances_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWriteoffOfAdvances_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RefundReceivables" xlink:label="loc_ptgefRefundReceivables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRefundReceivables_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="00000036 - Disclosure - WARRANT LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ClassBWarrantsMember" xlink:label="loc_ptgefClassBWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefClassBWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ClassCWarrantsMember" xlink:label="loc_ptgefClassCWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefClassCWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityExercisePrice" xlink:label="loc_ptgefWarrantLiabilityExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantLiabilityExercisePrice_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsLiabilityShares" xlink:label="loc_ptgefWarrantsLiabilityShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityShares_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsLiabilityFairValue" xlink:label="loc_ptgefWarrantsLiabilityFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityFairValue_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" xlink:label="loc_ptgefFairValueOfWarrantsAtIssuanceExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsAtIssuanceExercisePrice_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantsShares" xlink:label="loc_ptgefFairValueOfWarrantsShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsShares_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantsAmount" xlink:label="loc_ptgefFairValueOfWarrantsAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsAmount_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantLiability" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiability_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiability_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantLiabilityAmount" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiabilityAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiabilityAmount_110" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails1" xlink:title="00000037 - Disclosure - WARRANT LIABILITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesBWarrantsMember" xlink:label="loc_ptgefSeriesBWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesBWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails2" xlink:title="00000038 - Disclosure -  WARRANT LIABILITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesCWarrantsMember" xlink:label="loc_ptgefSeriesCWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesCWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails3" xlink:title="00000039 - Disclosure - WARRANT LIABILITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" xlink:title="00000040 - Disclosure - WARRANT LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchaseAgreementMember" xlink:label="loc_ptgefPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:to="loc_ptgefPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PreFundedWarrantsMember" xlink:label="loc_ptgefPreFundedWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPreFundedWarrantsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesAWarrantsMember" xlink:label="loc_ptgefSeriesAWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesAWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesBWarrantsMember" xlink:label="loc_ptgefSeriesBWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesBWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesCWarrantsMember" xlink:label="loc_ptgefSeriesCWarrantsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesCWarrantsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantMember" xlink:label="loc_ptgefPlacementAgentWarrantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OrdinaryNumberOfStockSold" xlink:label="loc_ptgefOrdinaryNumberOfStockSold_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOrdinaryNumberOfStockSold_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchasePriceOfPerShare" xlink:label="loc_ptgefPurchasePriceOfPerShare_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchasePriceOfPerShare_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchaseWarrants" xlink:label="loc_ptgefPurchaseWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseWarrants_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OrdinarySharesPurchase" xlink:label="loc_ptgefOrdinarySharesPurchase_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOrdinarySharesPurchase_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceOfOutstandingWarrant" xlink:label="loc_ptgefExercisePriceOfOutstandingWarrant_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceOfOutstandingWarrant_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-fullProceedsFromIssuingShares_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssuingShares_210" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-fullProfessionalFeesExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfessionalFeesExpense_210" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired_210" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AggregateGrossProceeds" xlink:label="loc_ptgefAggregateGrossProceeds_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateGrossProceeds_210" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ManagementFeePercentage" xlink:label="loc_ptgefManagementFeePercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefManagementFeePercentage_210" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AggregateGrossProceedsIncrease" xlink:label="loc_ptgefAggregateGrossProceedsIncrease_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateGrossProceedsIncrease_210" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdministrativeExpense" xlink:label="loc_ifrs-fullAdministrativeExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdministrativeExpense_210" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-fullFeeAndCommissionExpense_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullFeeAndCommissionExpense_210" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchaseOfWarrants" xlink:label="loc_ptgefPurchaseOfWarrants_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseOfWarrants_210" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SaleOfWarrantPercentage" xlink:label="loc_ptgefSaleOfWarrantPercentage_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSaleOfWarrantPercentage_210" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceWarrantPerShare" xlink:label="loc_ptgefExercisePriceWarrantPerShare_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceWarrantPerShare_210" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetProceedsWarrantLiability" xlink:label="loc_ptgefNetProceedsWarrantLiability_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetProceedsWarrantLiability_210" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:label="loc_ifrs-fullIncreaseDecreaseInFairValueMeasurementLiabilities_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseInFairValueMeasurementLiabilities_210" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_LossOnWarrantLiabilities" xlink:label="loc_ptgefLossOnWarrantLiabilities_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnWarrantLiabilities_210" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OfferingExpenses" xlink:label="loc_ptgefOfferingExpenses_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingExpenses_210" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiabilities_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiabilities_210" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityBalance" xlink:label="loc_ptgefWarrantLiabilityBalance_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantLiabilityBalance_210" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePrice" xlink:label="loc_ptgefExercisePrice_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePrice_210" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_210" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantPerShare" xlink:label="loc_ptgefFairValueOfWarrantPerShare_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantPerShare_210" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="00000041 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative" xlink:title="00000042 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:title="00000043 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000044 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetails1" xlink:title="00000045 - Disclosure - CAPITAL STOCK AND RESERVES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesAWarrantsMember" xlink:label="loc_ptgefSeriesAWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesAWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" xlink:title="00000046 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullTopOfRangeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullBottomOfRangeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ATMMember" xlink:label="loc_ptgefATMMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefATMMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" xlink:label="loc_ptgefSeriesAWarrantsAndPreFundedWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesAWarrantsAndPreFundedWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOrdinarySharesOutstandingDecrease" xlink:label="loc_ptgefNumberOfOrdinarySharesOutstandingDecrease_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOrdinarySharesOutstandingDecrease_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CashFundDescription" xlink:label="loc_ptgefCashFundDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCashFundDescription_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOrdinaryShareIssued" xlink:label="loc_ptgefNumberOfOrdinaryShareIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOrdinaryShareIssued_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PublicFloat" xlink:label="loc_ptgefPublicFloat_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPublicFloat_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrants" xlink:label="loc_ptgefFairValueOfWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrants_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsPerShare" xlink:label="loc_ptgefWarrantsPerShare_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsPerShare_90" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="00000047 - Disclosure - STOCK OPTION RESERVE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="00000048 - Disclosure - STOCK OPTION RESERVE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="00000049 - Disclosure - STOCK OPTION RESERVE (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="00000050 - Disclosure - STOCK OPTION RESERVE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember" xlink:label="loc_ifrs-fullAntidilutiveInstrumentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:to="loc_ifrs-fullAntidilutiveInstrumentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember" xlink:label="loc_ifrs-fullAntidilutiveInstrumentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:to="loc_ifrs-fullAntidilutiveInstrumentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember" xlink:label="loc_ifrs-fullRestrictedShareUnitsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAntidilutiveInstrumentsMember" xlink:to="loc_ifrs-fullRestrictedShareUnitsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesReservedForAwardsGranted" xlink:label="loc_ptgefSharesReservedForAwardsGranted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesReservedForAwardsGranted_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesAvailableForFutureAwards" xlink:label="loc_ptgefSharesAvailableForFutureAwards_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesAvailableForFutureAwards_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfSharesExercise" xlink:label="loc_ptgefNumberOfSharesExercise_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesExercise_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:label="loc_ptgefSharesRepurchasedIntoTreasuryEmployeePayrollTaxes_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesRepurchasedIntoTreasuryEmployeePayrollTaxes_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfSharesGranted" xlink:label="loc_ptgefNumberOfSharesGranted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesGranted_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfShareOutstanding" xlink:label="loc_ptgefNumberOfShareOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOutstanding_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DescriptionOfRestrictedStockUnitsExpire" xlink:label="loc_ptgefDescriptionOfRestrictedStockUnitsExpire_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDescriptionOfRestrictedStockUnitsExpire_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment_90" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="00000051 - Disclosure - LOSS PER SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="00000052 - Disclosure - LOSS PER SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-fullWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ifrs-fullWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefStockOptionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefRestrictedStockUnitsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AntidilutiveEffectOnLossPerShare" xlink:label="loc_ptgefAntidilutiveEffectOnLossPerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAntidilutiveEffectOnLossPerShare_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000054 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="00000055 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AmortizedCostMember" xlink:label="loc_ptgefAmortizedCostMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefAmortizedCostMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="loc_ptgefFairValueToOtherComprehensiveIncomeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefFairValueToOtherComprehensiveIncomeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueThroughProfitOrLossMember" xlink:label="loc_ptgefFairValueThroughProfitOrLossMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefFairValueThroughProfitOrLossMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_70" xlink:to="loc_ifrs-fullCashAndCashEquivalents_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrepaidExpensesAndOtherReceivable" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract_70" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivable_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilities_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability" xlink:label="loc_ifrs-fullWarrantLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract_70" xlink:to="loc_ifrs-fullWarrantLiability_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" xlink:title="00000056 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="00000057 - Disclosure - NON-CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSaugatuckMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="loc_ptgefNetLossAttributableToNoncontrollingInterest_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossAttributableToNoncontrollingInterest_70" xlink:type="arc" order="1" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ptgef-20240930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_StockOptionReserveMember" xlink:label="ptgef_StockOptionReserveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserveMember" xlink:to="ptgef_StockOptionReserveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionReserveMember_lbl" xml:lang="en-US">Stock Option Reserve [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccumulatedOtherComprehensiveLossMember" xlink:label="ptgef_AccumulatedOtherComprehensiveLossMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccumulatedOtherComprehensiveLossMember" xlink:to="ptgef_AccumulatedOtherComprehensiveLossMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccumulatedOtherComprehensiveLossMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xml:lang="en-US">Equity attributable to owners of parent [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="ifrs-full_NoncontrollingInterestsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterestsMember" xlink:to="ifrs-full_NoncontrollingInterestsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterestsMember_lbl" xml:lang="en-US">Non-controlling interests [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis" xlink:label="ifrs-full_SegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SegmentsAxis_lbl" xml:lang="en-US">Segments [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CountryOfBritishVirginIslandsMember" xlink:label="ptgef_CountryOfBritishVirginIslandsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CountryOfBritishVirginIslandsMember" xlink:to="ptgef_CountryOfBritishVirginIslandsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CountryOfBritishVirginIslandsMember_lbl" xml:lang="en-US">Country Of British Virgin Islands [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CountryOfDelawareMember" xlink:label="ptgef_CountryOfDelawareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CountryOfDelawareMember" xlink:to="ptgef_CountryOfDelawareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CountryOfDelawareMember_lbl" xml:lang="en-US">Country Of Delaware [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SaugatuckMember" xlink:label="ptgef_SaugatuckMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SaugatuckMember" xlink:to="ptgef_SaugatuckMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SaugatuckMember_lbl" xml:lang="en-US">Saugatuck [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xml:lang="en-US">Subsidiaries [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ParexelInternationalLimitedMember" xlink:label="ptgef_ParexelInternationalLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ParexelInternationalLimitedMember" xlink:to="ptgef_ParexelInternationalLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ParexelInternationalLimitedMember_lbl" xml:lang="en-US">Parexel International Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesBWarrantsMember" xlink:label="ptgef_SeriesBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeriesBWarrantsMember" xlink:to="ptgef_SeriesBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesCWarrantsMember" xlink:label="ptgef_SeriesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeriesCWarrantsMember" xlink:to="ptgef_SeriesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="ptgef_PlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PlacementAgentWarrantsMember" xlink:to="ptgef_PlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ClassBWarrantsMember" xlink:label="ptgef_ClassBWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ClassBWarrantsMember" xlink:to="ptgef_ClassBWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ClassBWarrantsMember_lbl" xml:lang="en-US">Class B Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ClassCWarrantsMember" xlink:label="ptgef_ClassCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ClassCWarrantsMember" xlink:to="ptgef_ClassCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ClassCWarrantsMember_lbl" xml:lang="en-US">Class C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:label="ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis_lbl" xml:lang="en-US">Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchaseAgreementMember" xlink:label="ptgef_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseAgreementMember" xlink:to="ptgef_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PreFundedWarrantsMember" xlink:label="ptgef_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PreFundedWarrantsMember" xlink:to="ptgef_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesAWarrantsMember" xlink:label="ptgef_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeriesAWarrantsMember" xlink:to="ptgef_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantMember" xlink:label="ptgef_PlacementAgentWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PlacementAgentWarrantMember" xlink:to="ptgef_PlacementAgentWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PlacementAgentWarrantMember_lbl" xml:lang="en-US">Placement Agent Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US">Counterparties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ATMMember" xlink:label="ptgef_ATMMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ATMMember" xlink:to="ptgef_ATMMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ATMMember_lbl" xml:lang="en-US">ATM [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" xlink:label="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" xlink:to="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SeriesAWarrantsAndPreFundedWarrantsMember_lbl" xml:lang="en-US">Series A Warrants And Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="ifrs-full_DefinedBenefitPlansAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefinedBenefitPlansAxis_lbl" xml:lang="en-US">Defined benefit plans [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="ptgef_PBI2021EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PBI2021EquityIncentivePlanMember" xlink:to="ptgef_PBI2021EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PBI2021EquityIncentivePlanMember_lbl" xml:lang="en-US">PBI 2021 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xml:lang="en-US">Types of antidilutive instruments [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember" xlink:label="ifrs-full_RestrictedShareUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl" xml:lang="en-US">Restricted share units [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember" xlink:label="ifrs-full_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantsMember" xlink:to="ifrs-full_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantsMember_lbl" xml:lang="en-US">Warrants [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_StockOptionsMember" xlink:label="ptgef_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionsMember" xlink:to="ptgef_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="ptgef_RestrictedStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RestrictedStockUnitsMember" xlink:to="ptgef_RestrictedStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RestrictedStockUnitsMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AmortizedCostMember" xlink:label="ptgef_AmortizedCostMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AmortizedCostMember" xlink:to="ptgef_AmortizedCostMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AmortizedCostMember_lbl" xml:lang="en-US">Amortized Cost [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="ptgef_FairValueToOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:to="ptgef_FairValueToOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueToOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Fair Value To Other Comprehensive Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueThroughProfitOrLossMember" xlink:label="ptgef_FairValueThroughProfitOrLossMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueThroughProfitOrLossMember" xlink:to="ptgef_FairValueThroughProfitOrLossMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueThroughProfitOrLossMember_lbl" xml:lang="en-US">Fair Value Through Profit Or Loss [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right to use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability - current, including interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liability - non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityNonCurrent" xlink:label="ptgef_WarrantLiabilityNonCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiabilityNonCurrent" xlink:to="ptgef_WarrantLiabilityNonCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiabilityNonCurrent_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Capital stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Stock option reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Total equity attributable to owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests" xlink:label="ifrs-full_NoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and equity</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CommitmentsAndContingentLiabilities" xlink:label="ptgef_CommitmentsAndContingentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CommitmentsAndContingentLiabilities" xlink:to="ptgef_CommitmentsAndContingentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CommitmentsAndContingentLiabilities_lbl" xml:lang="en-US">Commitments and Contingent Liabilities (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAbstract" xlink:label="ifrs-full_ProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAbstract_lbl" xml:lang="en-US">Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantsLiability" xlink:label="ptgef_ChangeInFairValueOfWarrantsLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfWarrantsLiability" xlink:to="ptgef_ChangeInFairValueOfWarrantsLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_ChangeInFairValueOfWarrantsLiability_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:to="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_lbl" xml:lang="en-US">Change in fair value of deferred purchase price payable &#150; Tarus and deferred obligation &#150; iOx milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="ptgef_GainOnSettlementWithParexelIoxCro" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnSettlementWithParexelIoxCro" xlink:to="ptgef_GainOnSettlementWithParexelIoxCro_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_GainOnSettlementWithParexelIoxCro_lbl" xml:lang="en-US">Gain on settlement with Parexel &#8211; iOx CRO</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xml:lang="en-US">Share of loss in associate accounted for using equity method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Foreign exchange transaction (loss) gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromInterest_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss before benefit for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income tax benefit (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetLoss" xlink:label="ptgef_NetLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLoss" xlink:to="ptgef_NetLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgef_NetLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetUnrealizedGainOnInvestments" xlink:label="ptgef_NetUnrealizedGainOnInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetUnrealizedGainOnInvestments" xlink:to="ptgef_NetUnrealizedGainOnInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetUnrealizedGainOnInvestments_lbl" xml:lang="en-US">Net unrealized (loss) gain on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ComprehensiveLossForPeriod" xlink:label="ptgef_ComprehensiveLossForPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ComprehensiveLossForPeriod" xlink:to="ptgef_ComprehensiveLossForPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgef_ComprehensiveLossForPeriod_lbl" xml:lang="en-US">Total comprehensive loss for period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="ifrs-full_ProfitLossAttributableToAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToAbstract" xlink:to="ifrs-full_ProfitLossAttributableToAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToAbstract_lbl" xml:lang="en-US">Net loss attributable to:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToAbstract_lbl" xml:lang="en-US">Comprehensive loss attributable to:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_lbl" xml:lang="en-US">Owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ComprehensiveIncomeAttributableToOwnerOfParent" xlink:label="ptgef_ComprehensiveIncomeAttributableToOwnerOfParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ComprehensiveIncomeAttributableToOwnerOfParent" xlink:to="ptgef_ComprehensiveIncomeAttributableToOwnerOfParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ptgef_ComprehensiveIncomeAttributableToOwnerOfParent_lbl" xml:lang="en-US">Total comprehensive loss for period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Loss per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Loss per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:to="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US">Weighted average shares outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="ptgef_IfrsStatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IfrsStatementLineItems" xlink:to="ptgef_IfrsStatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IfrsStatementLineItems_lbl" xml:lang="en-US">IfrsStatementLineItems [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_EquityPreSplit" xlink:label="ptgef_EquityPreSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EquityPreSplit" xlink:to="ptgef_EquityPreSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_EquityPreSplit_lbl" xml:lang="en-US">Balance, April 1, 2023 (Pre-Split)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ReverseStockSplitValue" xlink:label="ptgef_ReverseStockSplitValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ReverseStockSplitValue" xlink:to="ptgef_ReverseStockSplitValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ReverseStockSplitValue_lbl" xml:lang="en-US">Balance, April 1, 2023 (After 1-for-20 reverse stock split)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ReverseStockSplitShares" xlink:label="ptgef_ReverseStockSplitShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ReverseStockSplitShares" xlink:to="ptgef_ReverseStockSplitShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ReverseStockSplitShares_lbl" xml:lang="en-US">After 1-for-20 reverse stock split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedUnderAtm" xlink:label="ptgef_SharesIssuedUnderAtm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderAtm" xlink:to="ptgef_SharesIssuedUnderAtm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderAtm_lbl" xml:lang="en-US">Shares issued under ATM</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedUnderAtmShares" xlink:label="ptgef_SharesIssuedUnderAtmShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedUnderAtmShares" xlink:to="ptgef_SharesIssuedUnderAtmShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedUnderAtmShares_lbl" xml:lang="en-US">Shares issued under ATM, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="ptgef_SharesIssuedOrAccruedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedOrAccruedForServices" xlink:to="ptgef_SharesIssuedOrAccruedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedOrAccruedForServices_lbl" xml:lang="en-US">Shares issued or accrued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="ptgef_SharesIssuedOrAccruedForServicesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedOrAccruedForServicesShares" xlink:to="ptgef_SharesIssuedOrAccruedForServicesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedOrAccruedForServicesShares_lbl" xml:lang="en-US">Shares issued or accrued for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetUnrealizedGainOnInvestment" xlink:label="ptgef_NetUnrealizedGainOnInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetUnrealizedGainOnInvestment" xlink:to="ptgef_NetUnrealizedGainOnInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetUnrealizedGainOnInvestment_lbl" xml:lang="en-US">Net unrealized gain on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrefundedWarrantsExercised" xlink:label="ptgef_PrefundedWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrefundedWarrantsExercised" xlink:to="ptgef_PrefundedWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrefundedWarrantsExercised_lbl" xml:lang="en-US">Pre-Funded warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrefundedWarrantsExercisedShares" xlink:label="ptgef_PrefundedWarrantsExercisedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrefundedWarrantsExercisedShares" xlink:to="ptgef_PrefundedWarrantsExercisedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrefundedWarrantsExercisedShares_lbl" xml:lang="en-US">Pre-Funded warrants exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:label="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:to="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit_lbl" xml:lang="en-US">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:label="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:to="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares_lbl" xml:lang="en-US">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForAccruedBonuses" xlink:label="ptgef_SharesIssuedForAccruedBonuses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedForAccruedBonuses" xlink:to="ptgef_SharesIssuedForAccruedBonuses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedForAccruedBonuses_lbl" xml:lang="en-US">Shares issued for accrued bonuses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForAccruedBonusesShares" xlink:label="ptgef_SharesIssuedForAccruedBonusesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedForAccruedBonusesShares" xlink:to="ptgef_SharesIssuedForAccruedBonusesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedForAccruedBonusesShares_lbl" xml:lang="en-US">Shares issued for accrued bonuses, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForRestrictedStockUnitsNet" xlink:label="ptgef_SharesIssuedForRestrictedStockUnitsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedForRestrictedStockUnitsNet" xlink:to="ptgef_SharesIssuedForRestrictedStockUnitsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedForRestrictedStockUnitsNet_lbl" xml:lang="en-US">Shares issued for restricted stock units, net</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForRestrictedStockUnitsNetShares" xlink:label="ptgef_SharesIssuedForRestrictedStockUnitsNetShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesIssuedForRestrictedStockUnitsNetShares" xlink:to="ptgef_SharesIssuedForRestrictedStockUnitsNetShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesIssuedForRestrictedStockUnitsNetShares_lbl" xml:lang="en-US">Shares issued for restricted stock units, net, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_2_lbl" xml:lang="en-US">Net loss for period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EquityPreSplit" xlink:to="ptgef_EquityPreSplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_EquityPreSplit_2_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_3_lbl" xml:lang="en-US">Net loss for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments for non-cash items:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfWarrantsLiability" xlink:to="ptgef_ChangeInFairValueOfWarrantsLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfWarrantsLiability_2_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnSettlementWithParexelIoxCro" xlink:to="ptgef_GainOnSettlementWithParexelIoxCro_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainOnSettlementWithParexelIoxCro_2_lbl" xml:lang="en-US">Gain on settlement with Parexel &#8211; iOx CRO</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:to="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone_2_lbl" xml:lang="en-US">Change in fair value of deferred purchase price payable &#8211; Tarus and deferred obligation &#8211; iOx milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_lbl" xml:lang="en-US">Decrease in deferred tax liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IncreaseDecreaseInShareOfLossInAssociate" xlink:label="ptgef_IncreaseDecreaseInShareOfLossInAssociate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncreaseDecreaseInShareOfLossInAssociate" xlink:to="ptgef_IncreaseDecreaseInShareOfLossInAssociate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_IncreaseDecreaseInShareOfLossInAssociate_lbl" xml:lang="en-US">Share of loss in associate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfSharesIssuedForServices" xlink:label="ptgef_FairValueOfSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfSharesIssuedForServices" xlink:to="ptgef_FairValueOfSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfSharesIssuedForServices_lbl" xml:lang="en-US">Fair value of shares issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangesInOperatingWorkingCapitalAbstract" xlink:label="ptgef_ChangesInOperatingWorkingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangesInOperatingWorkingCapitalAbstract" xlink:to="ptgef_ChangesInOperatingWorkingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangesInOperatingWorkingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating working capital:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="ptgef_ProceedsFromExerciseOfPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromExerciseOfPrefundedWarrants" xlink:to="ptgef_ProceedsFromExerciseOfPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Proceeds from the&#160;exercise of Pre-Funded Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:label="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:to="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement_lbl" xml:lang="en-US">Proceeds from shares issued under ATM and Committed Purchase Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US">Share issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RepaymentOfLeaseLiability" xlink:label="ptgef_RepaymentOfLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentOfLeaseLiability" xlink:to="ptgef_RepaymentOfLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_RepaymentOfLeaseLiability_lbl" xml:lang="en-US">Repayment of lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Decrease in cash and cash equivalents during the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_3_lbl" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:label="ptgef_SupplementalDisclosureOfCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="ptgef_SupplementalDisclosureOfCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SupplementalDisclosureOfCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CashPaidForInterest" xlink:label="ptgef_CashPaidForInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashPaidForInterest" xlink:to="ptgef_CashPaidForInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashPaidForInterest_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:label="ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:to="ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RightToUseAssetAcquired" xlink:label="ptgef_RightToUseAssetAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RightToUseAssetAcquired" xlink:to="ptgef_RightToUseAssetAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RightToUseAssetAcquired_lbl" xml:lang="en-US">Right to use asset acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_LeaseLiabilityIncurred" xlink:label="ptgef_LeaseLiabilityIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LeaseLiabilityIncurred" xlink:to="ptgef_LeaseLiabilityIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LeaseLiabilityIncurred_lbl" xml:lang="en-US">Lease liability incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureNatureOfOperationsAbstract" xlink:label="ptgef_DisclosureNatureOfOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureNatureOfOperationsAbstract" xlink:to="ptgef_DisclosureNatureOfOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureNatureOfOperationsAbstract_lbl" xml:lang="en-US">Nature Of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NatureOfOperationsExplanatory" xlink:label="ptgef_NatureOfOperationsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NatureOfOperationsExplanatory" xlink:to="ptgef_NatureOfOperationsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NatureOfOperationsExplanatory_lbl" xml:lang="en-US">NATURE OF OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">Notes and other explanatory information [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:to="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xml:lang="en-US">GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:label="ptgef_DisclosureSignificantAccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:to="ptgef_DisclosureSignificantAccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:label="ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory" xlink:label="ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory" xlink:to="ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER RECEIVABLES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="ptgef_DisclosureWarrantLiabilityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureWarrantLiabilityAbstract" xlink:to="ptgef_DisclosureWarrantLiabilityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureWarrantLiabilityAbstract_lbl" xml:lang="en-US">Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityTextBlock" xlink:label="ptgef_WarrantLiabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiabilityTextBlock" xlink:to="ptgef_WarrantLiabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiabilityTextBlock_lbl" xml:lang="en-US">WARRANT LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:label="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract_lbl" xml:lang="en-US">Accounts Payable And Accrued Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" xlink:to="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="ptgef_DisclosureCapitalStockAndReservesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:to="ptgef_DisclosureCapitalStockAndReservesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureCapitalStockAndReservesAbstract_lbl" xml:lang="en-US">Capital Stock And Reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CapitalStockAndReservesTextBlock" xlink:label="ptgef_CapitalStockAndReservesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CapitalStockAndReservesTextBlock" xlink:to="ptgef_CapitalStockAndReservesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CapitalStockAndReservesTextBlock_lbl" xml:lang="en-US">CAPITAL STOCK AND RESERVES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">STOCK OPTION RESERVE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:label="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US">Financial Instruments And Risk Management</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" xlink:label="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" xlink:to="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureCapitalManagementAbstract" xlink:label="ptgef_DisclosureCapitalManagementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureCapitalManagementAbstract" xlink:to="ptgef_DisclosureCapitalManagementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureCapitalManagementAbstract_lbl" xml:lang="en-US">Capital Management</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:label="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:to="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock_lbl" xml:lang="en-US">CAPITAL MANAGEMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:to="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory_lbl" xml:lang="en-US">NON-CONTROLLING INTEREST</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:label="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:to="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:label="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:to="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:to="ptgef_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in the warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Schedule of fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:label="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:to="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_lbl" xml:lang="en-US">Schedule of effective income tax rates</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" xlink:label="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" xlink:to="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory_lbl" xml:lang="en-US">Schedule of fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" xlink:label="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" xlink:to="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock_lbl" xml:lang="en-US">Schedule of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock" xlink:label="ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock" xlink:to="ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of changes in the number of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of weighted average exercise price and the remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfEarningsPerShareTableTextBlock" xlink:label="ptgef_ScheduleOfEarningsPerShareTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfEarningsPerShareTableTextBlock" xlink:to="ptgef_ScheduleOfEarningsPerShareTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfEarningsPerShareTableTextBlock_lbl" xml:lang="en-US">Schedule of basic and diluted EPS calculations</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:label="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:to="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock_lbl" xml:lang="en-US">Schedule of anti-dilutive effect on loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:to="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:to="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ScheduleOfNoncontrollingInterestTableTextBlock_lbl" xml:lang="en-US">Schedule of non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_TotalCurrentLiabilities" xlink:label="ptgef_TotalCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TotalCurrentLiabilities" xlink:to="ptgef_TotalCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TotalCurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetLossIncome" xlink:label="ptgef_NetLossIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossIncome" xlink:to="ptgef_NetLossIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetLossIncome_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CashUsedInOperatingActivities" xlink:label="ptgef_CashUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashUsedInOperatingActivities" xlink:to="ptgef_CashUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand" xlink:label="ifrs-full_CashOnHand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOnHand_lbl" xml:lang="en-US">Cash and cash equivalents on hand</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PercentageOfOutstandingShares" xlink:label="ptgef_PercentageOfOutstandingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PercentageOfOutstandingShares" xlink:to="ptgef_PercentageOfOutstandingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PercentageOfOutstandingShares_lbl" xml:lang="en-US">Percentage of outstanding shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Percentage of ownership subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:to="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_lbl" xml:lang="en-US">Non-controlling interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:label="ifrs-full_CurrentReceivablesFromSaleOfProperties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:to="ifrs-full_CurrentReceivablesFromSaleOfProperties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentReceivablesFromSaleOfProperties_lbl" xml:lang="en-US">Prepaid clinical research costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentReceivablesFromRentalOfProperties" xlink:label="ifrs-full_CurrentReceivablesFromRentalOfProperties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentReceivablesFromRentalOfProperties" xlink:to="ifrs-full_CurrentReceivablesFromRentalOfProperties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentReceivablesFromRentalOfProperties_lbl" xml:lang="en-US">Refund from Parexel</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvancesToSuppliers" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_TaxDeposits" xlink:label="ptgef_TaxDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_TaxDeposits" xlink:to="ptgef_TaxDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_TaxDeposits_lbl" xml:lang="en-US">Tax deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SecurityDepositOnOfficeLease" xlink:label="ptgef_SecurityDepositOnOfficeLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SecurityDepositOnOfficeLease" xlink:to="ptgef_SecurityDepositOnOfficeLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SecurityDepositOnOfficeLease_lbl" xml:lang="en-US">Security deposit on office lease expiring in May 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentPrepayments_lbl" xml:lang="en-US">Total prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xml:lang="en-US">Disclosure of subsidiaries [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent" xlink:label="ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent" xlink:to="ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WriteoffOfAdvances" xlink:label="ptgef_WriteoffOfAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WriteoffOfAdvances" xlink:to="ptgef_WriteoffOfAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WriteoffOfAdvances_lbl" xml:lang="en-US">Write-off of advances</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RefundReceivables" xlink:label="ptgef_RefundReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RefundReceivables" xlink:to="ptgef_RefundReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RefundReceivables_lbl" xml:lang="en-US">Refund receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityExercisePrice" xlink:label="ptgef_WarrantLiabilityExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiabilityExercisePrice" xlink:to="ptgef_WarrantLiabilityExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiabilityExercisePrice_lbl" xml:lang="en-US">Warrants liability exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsLiabilityShares" xlink:label="ptgef_WarrantsLiabilityShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityShares" xlink:to="ptgef_WarrantsLiabilityShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsLiabilityShares_lbl" xml:lang="en-US">Warrants liability, shares at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsLiabilityFairValue" xlink:label="ptgef_WarrantsLiabilityFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityFairValue" xlink:to="ptgef_WarrantsLiabilityFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_WarrantsLiabilityFairValue_lbl" xml:lang="en-US">Warrants liability, fair value at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" xlink:label="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" xlink:to="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrantsAtIssuanceExercisePrice_lbl" xml:lang="en-US">Fair value of warrants at issuance exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantsShares" xlink:label="ptgef_FairValueOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrantsShares" xlink:to="ptgef_FairValueOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrantsShares_lbl" xml:lang="en-US">Fair value of warrants shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantsAmount" xlink:label="ptgef_FairValueOfWarrantsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrantsAmount" xlink:to="ptgef_FairValueOfWarrantsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrantsAmount_lbl" xml:lang="en-US">Fair value of warrants amount</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantLiability" xlink:label="ptgef_ChangeInFairValueOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfWarrantLiability" xlink:to="ptgef_ChangeInFairValueOfWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfWarrantLiability_lbl" xml:lang="en-US">Change in fair value of warrant liability, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantLiabilityAmount" xlink:label="ptgef_ChangeInFairValueOfWarrantLiabilityAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfWarrantLiabilityAmount" xlink:to="ptgef_ChangeInFairValueOfWarrantLiabilityAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfWarrantLiabilityAmount_lbl" xml:lang="en-US">Change in fair value of warrant liability, amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityShares" xlink:to="ptgef_WarrantsLiabilityShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsLiabilityShares_2_lbl" xml:lang="en-US">Warrants liability, shares at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityFairValue" xlink:to="ptgef_WarrantsLiabilityFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_WarrantsLiabilityFairValue_2_lbl" xml:lang="en-US">Warrants liability, fair value at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceFairValue" xlink:label="ptgef_ExercisePriceFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExercisePriceFairValue" xlink:to="ptgef_ExercisePriceFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExercisePriceFairValue_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharePriceFairvalue" xlink:label="ptgef_SharePriceFairvalue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharePriceFairvalue" xlink:to="ptgef_SharePriceFairvalue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharePriceFairvalue_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OptionLifeShareOptions" xlink:label="ptgef_OptionLifeShareOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OptionLifeShareOptions" xlink:to="ptgef_OptionLifeShareOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OptionLifeShareOptions_lbl" xml:lang="en-US">Expected life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:label="ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable_lbl" xml:lang="en-US">Disclosure of transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OrdinaryNumberOfStockSold" xlink:label="ptgef_OrdinaryNumberOfStockSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OrdinaryNumberOfStockSold" xlink:to="ptgef_OrdinaryNumberOfStockSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OrdinaryNumberOfStockSold_lbl" xml:lang="en-US">Number of stock sold</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchasePriceOfPerShare" xlink:label="ptgef_PurchasePriceOfPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchasePriceOfPerShare" xlink:to="ptgef_PurchasePriceOfPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchasePriceOfPerShare_lbl" xml:lang="en-US">Purchase price of per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchaseWarrants" xlink:label="ptgef_PurchaseWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseWarrants" xlink:to="ptgef_PurchaseWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseWarrants_lbl" xml:lang="en-US">Purchase ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OrdinarySharesPurchase" xlink:label="ptgef_OrdinarySharesPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OrdinarySharesPurchase" xlink:to="ptgef_OrdinarySharesPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OrdinarySharesPurchase_lbl" xml:lang="en-US">Ordinary shares purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceOfOutstandingWarrant" xlink:label="ptgef_ExercisePriceOfOutstandingWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExercisePriceOfOutstandingWarrant" xlink:to="ptgef_ExercisePriceOfOutstandingWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_ExercisePriceOfOutstandingWarrant_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Net proceeds warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US">Estimated offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:to="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PercentageOfVotingEquityInterestsAcquired_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AggregateGrossProceeds" xlink:label="ptgef_AggregateGrossProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AggregateGrossProceeds" xlink:to="ptgef_AggregateGrossProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AggregateGrossProceeds_lbl" xml:lang="en-US">Aggregate gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ManagementFeePercentage" xlink:label="ptgef_ManagementFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ManagementFeePercentage" xlink:to="ptgef_ManagementFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ManagementFeePercentage_lbl" xml:lang="en-US">Management fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AggregateGrossProceedsIncrease" xlink:label="ptgef_AggregateGrossProceedsIncrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AggregateGrossProceedsIncrease" xlink:to="ptgef_AggregateGrossProceedsIncrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AggregateGrossProceedsIncrease_lbl" xml:lang="en-US">Aggregate gross proceeds increase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdministrativeExpense" xlink:label="ifrs-full_AdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdministrativeExpense" xlink:to="ifrs-full_AdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdministrativeExpense_lbl" xml:lang="en-US">Non-accountable expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="ifrs-full_FeeAndCommissionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FeeAndCommissionExpense" xlink:to="ifrs-full_FeeAndCommissionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FeeAndCommissionExpense_lbl" xml:lang="en-US">Clearing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchaseOfWarrants" xlink:label="ptgef_PurchaseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PurchaseOfWarrants" xlink:to="ptgef_PurchaseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PurchaseOfWarrants_lbl" xml:lang="en-US">Purchase warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SaleOfWarrantPercentage" xlink:label="ptgef_SaleOfWarrantPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SaleOfWarrantPercentage" xlink:to="ptgef_SaleOfWarrantPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SaleOfWarrantPercentage_lbl" xml:lang="en-US">Sale of warrant percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceWarrantPerShare" xlink:label="ptgef_ExercisePriceWarrantPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExercisePriceWarrantPerShare" xlink:to="ptgef_ExercisePriceWarrantPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExercisePriceWarrantPerShare_lbl" xml:lang="en-US">Exercise price warrant per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetProceedsWarrantLiability" xlink:label="ptgef_NetProceedsWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetProceedsWarrantLiability" xlink:to="ptgef_NetProceedsWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetProceedsWarrantLiability_lbl" xml:lang="en-US">Net proceeds warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:to="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_lbl" xml:lang="en-US">Excess of the fair value of the warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_LossOnWarrantLiabilities" xlink:label="ptgef_LossOnWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_LossOnWarrantLiabilities" xlink:to="ptgef_LossOnWarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_LossOnWarrantLiabilities_lbl" xml:lang="en-US">Loss on warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OfferingExpenses" xlink:label="ptgef_OfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OfferingExpenses" xlink:to="ptgef_OfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OfferingExpenses_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantLiabilities" xlink:label="ptgef_ChangeInFairValueOfWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ChangeInFairValueOfWarrantLiabilities" xlink:to="ptgef_ChangeInFairValueOfWarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ChangeInFairValueOfWarrantLiabilities_lbl" xml:lang="en-US">Gain (loss) in the fair value of the warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityBalance" xlink:label="ptgef_WarrantLiabilityBalance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantLiabilityBalance" xlink:to="ptgef_WarrantLiabilityBalance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantLiabilityBalance_lbl" xml:lang="en-US">Warrant liability balance</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePrice" xlink:label="ptgef_ExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExercisePrice" xlink:to="ptgef_ExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExercisePrice_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_3_lbl" xml:lang="en-US">Total shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantPerShare" xlink:label="ptgef_FairValueOfWarrantPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrantPerShare" xlink:to="ptgef_FairValueOfWarrantPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrantPerShare_lbl" xml:lang="en-US">Fair value of warrant per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAmountsAccruedToCro" xlink:label="ptgef_AccountsPayableAndAmountsAccruedToCro" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAmountsAccruedToCro" xlink:to="ptgef_AccountsPayableAndAmountsAccruedToCro_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAmountsAccruedToCro_lbl" xml:lang="en-US">Accounts payable and amounts accrued to CRO</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" xlink:label="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" xlink:to="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses_lbl" xml:lang="en-US">Accrued bonuses and other payroll-related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedAccountingAndAuditingFees" xlink:label="ptgef_AccruedAccountingAndAuditingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedAccountingAndAuditingFees" xlink:to="ptgef_AccruedAccountingAndAuditingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedAccountingAndAuditingFees_lbl" xml:lang="en-US">Accrued accounting and auditing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedLegalFees" xlink:label="ptgef_AccruedLegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedLegalFees" xlink:to="ptgef_AccruedLegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedLegalFees_lbl" xml:lang="en-US">Accrued legal fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedOtherProfessionalFees" xlink:label="ptgef_AccruedOtherProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedOtherProfessionalFees" xlink:to="ptgef_AccruedOtherProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedOtherProfessionalFees_lbl" xml:lang="en-US">Accrued other professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OtherAccountsPayable" xlink:label="ptgef_OtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OtherAccountsPayable" xlink:to="ptgef_OtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OtherAccountsPayable_lbl" xml:lang="en-US">Other accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedClinicalAndRdServices" xlink:label="ptgef_AccruedClinicalAndRdServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccruedClinicalAndRdServices" xlink:to="ptgef_AccruedClinicalAndRdServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccruedClinicalAndRdServices_lbl" xml:lang="en-US">Accrued clinical and R&amp;D services</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OtherAccruedExpenses" xlink:label="ptgef_OtherAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OtherAccruedExpenses" xlink:to="ptgef_OtherAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_OtherAccruedExpenses_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedLiabilityNet" xlink:label="ptgef_AccountsPayableAndAccruedLiabilityNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilityNet" xlink:to="ptgef_AccountsPayableAndAccruedLiabilityNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilityNet_lbl" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables" xlink:label="ifrs-full_OtherPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughWriteoffFinancialAssets" xlink:label="ifrs-full_DecreaseThroughWriteoffFinancialAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseThroughWriteoffFinancialAssets" xlink:to="ifrs-full_DecreaseThroughWriteoffFinancialAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DecreaseThroughWriteoffFinancialAssets_lbl" xml:lang="en-US">Accounts payable and accrued liabilities write-off</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_2_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IncomeTaxExpenseContinuingOperation" xlink:label="ptgef_IncomeTaxExpenseContinuingOperation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeTaxExpenseContinuingOperation" xlink:to="ptgef_IncomeTaxExpenseContinuingOperation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ptgef_IncomeTaxExpenseContinuingOperation_lbl" xml:lang="en-US">Income tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="ifrs-full_TaxRateEffectOfTaxLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectOfTaxLosses" xlink:to="ifrs-full_TaxRateEffectOfTaxLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxRateEffectOfTaxLosses_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectOfTaxLosses" xlink:to="ifrs-full_TaxRateEffectOfTaxLosses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TaxRateEffectOfTaxLosses_2_lbl" xml:lang="en-US">Tax rate effect of tax losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Expected life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_2_lbl" xml:lang="en-US">Expected dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOrdinarySharesOutstandingDecrease" xlink:label="ptgef_NumberOfOrdinarySharesOutstandingDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOrdinarySharesOutstandingDecrease" xlink:to="ptgef_NumberOfOrdinarySharesOutstandingDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfOrdinarySharesOutstandingDecrease_lbl" xml:lang="en-US">Number of ordinary shares outstanding, decrease</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CashFundDescription" xlink:label="ptgef_CashFundDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CashFundDescription" xlink:to="ptgef_CashFundDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CashFundDescription_lbl" xml:lang="en-US">Cash fund, description</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOrdinaryShareIssued" xlink:label="ptgef_NumberOfOrdinaryShareIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOrdinaryShareIssued" xlink:to="ptgef_NumberOfOrdinaryShareIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfOrdinaryShareIssued_lbl" xml:lang="en-US">Number of ordinary share issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfSharesSold" xlink:label="ptgef_NumberOfSharesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfSharesSold" xlink:to="ptgef_NumberOfSharesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfSharesSold_lbl" xml:lang="en-US">Number of shares sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="ifrs-full_ProceedsFromSalesOfBiologicalAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:to="ifrs-full_ProceedsFromSalesOfBiologicalAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOfBiologicalAssets_lbl" xml:lang="en-US">Net proceeds from sale</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PublicFloat" xlink:label="ptgef_PublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PublicFloat" xlink:to="ptgef_PublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PublicFloat_lbl" xml:lang="en-US">Public float</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrants" xlink:label="ptgef_FairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_FairValueOfWarrants" xlink:to="ptgef_FairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_FairValueOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsPerShare" xlink:label="ptgef_WarrantsPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsPerShare" xlink:to="ptgef_WarrantsPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsPerShare_lbl" xml:lang="en-US">Warrants per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_StockOptionReserve" xlink:label="ptgef_StockOptionReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_StockOptionReserve_lbl" xml:lang="en-US">Balance, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AdjustmentsForSharebasedPayment" xlink:label="ptgef_AdjustmentsForSharebasedPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdjustmentsForSharebasedPayment" xlink:to="ptgef_AdjustmentsForSharebasedPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_AdjustmentsForSharebasedPayment_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_StockOptionReserve_2_lbl" xml:lang="en-US">Balance, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xml:lang="en-US">Disclosure of defined benefit plans [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="ptgef_NumberOfOutstandingShareOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ptgef_NumberOfOutstandingShareOption_lbl" xml:lang="en-US">Balance, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:to="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Expired or forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ptgef_NumberOfOutstandingShareOption_2_lbl" xml:lang="en-US">Balance, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:to="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_lbl" xml:lang="en-US">Exercisable, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_2_lbl" xml:lang="en-US">Weighted average remaining contractual life (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesReservedForAwardsGranted" xlink:label="ptgef_SharesReservedForAwardsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesReservedForAwardsGranted" xlink:to="ptgef_SharesReservedForAwardsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesReservedForAwardsGranted_lbl" xml:lang="en-US">Shares reserved for awards granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesAvailableForFutureAwards" xlink:label="ptgef_SharesAvailableForFutureAwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesAvailableForFutureAwards" xlink:to="ptgef_SharesAvailableForFutureAwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesAvailableForFutureAwards_lbl" xml:lang="en-US">Shares available for future awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfSharesExercise" xlink:label="ptgef_NumberOfSharesExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfSharesExercise" xlink:to="ptgef_NumberOfSharesExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfSharesExercise_lbl" xml:lang="en-US">Number of shares exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:label="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:to="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_lbl" xml:lang="en-US">Shares repurchased into treasury employee payroll taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfSharesGranted" xlink:label="ptgef_NumberOfSharesGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfSharesGranted" xlink:to="ptgef_NumberOfSharesGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfSharesGranted_lbl" xml:lang="en-US">Number of shares granted</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfShareOutstanding" xlink:label="ptgef_NumberOfShareOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfShareOutstanding" xlink:to="ptgef_NumberOfShareOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfShareOutstanding_lbl" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DescriptionOfRestrictedStockUnitsExpire" xlink:label="ptgef_DescriptionOfRestrictedStockUnitsExpire" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DescriptionOfRestrictedStockUnitsExpire" xlink:to="ptgef_DescriptionOfRestrictedStockUnitsExpire_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DescriptionOfRestrictedStockUnitsExpire_lbl" xml:lang="en-US">Description of share expire</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Share based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumeratorAbstract" xlink:label="ptgef_NumeratorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumeratorAbstract" xlink:to="ptgef_NumeratorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumeratorAbstract_lbl" xml:lang="en-US">Numerator</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Net loss attributable to owners of the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DenominatorAbstract" xlink:label="ptgef_DenominatorAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DenominatorAbstract" xlink:to="ptgef_DenominatorAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DenominatorAbstract_lbl" xml:lang="en-US">Denominator</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageShares_2_lbl" xml:lang="en-US">Weighted average number of shares - Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_2_lbl" xml:lang="en-US">Weighted average number of shares - Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_2_lbl" xml:lang="en-US">Basic loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_2_lbl" xml:lang="en-US">Diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AntidilutiveEffectOnLossPerShare" xlink:label="ptgef_AntidilutiveEffectOnLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AntidilutiveEffectOnLossPerShare" xlink:to="ptgef_AntidilutiveEffectOnLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AntidilutiveEffectOnLossPerShare_lbl" xml:lang="en-US">Anti-dilutive effect on loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RetainageDeposits" xlink:label="ptgef_RetainageDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RetainageDeposits" xlink:to="ptgef_RetainageDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RetainageDeposits_lbl" xml:lang="en-US">Release liability amount</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_UnbilledContractsReceivables" xlink:label="ptgef_UnbilledContractsReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_UnbilledContractsReceivables" xlink:to="ptgef_UnbilledContractsReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_UnbilledContractsReceivables_lbl" xml:lang="en-US">Unbilled services</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ForfeitedAdvancedPayments" xlink:label="ptgef_ForfeitedAdvancedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ForfeitedAdvancedPayments" xlink:to="ptgef_ForfeitedAdvancedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ForfeitedAdvancedPayments_lbl" xml:lang="en-US">Forfeited advanced payments</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_GainOnLiability" xlink:label="ptgef_GainOnLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_GainOnLiability" xlink:to="ptgef_GainOnLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_GainOnLiability_lbl" xml:lang="en-US">Gain on liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities" xlink:label="ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities" xlink:to="ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Payables to parexel in accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_BudgetedCosts" xlink:label="ptgef_BudgetedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_BudgetedCosts" xlink:to="ptgef_BudgetedCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_BudgetedCosts_lbl" xml:lang="en-US">Budgeted costs</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PortagePaidIntensity" xlink:label="ptgef_PortagePaidIntensity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PortagePaidIntensity" xlink:to="ptgef_PortagePaidIntensity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PortagePaidIntensity_lbl" xml:lang="en-US">Portage paid intensity</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CompensationCommittee" xlink:label="ptgef_CompensationCommittee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CompensationCommittee" xlink:to="ptgef_CompensationCommittee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CompensationCommittee_lbl" xml:lang="en-US">Compensation committee</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OriginalAnnualTargetsPercentage" xlink:label="ptgef_OriginalAnnualTargetsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OriginalAnnualTargetsPercentage" xlink:to="ptgef_OriginalAnnualTargetsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OriginalAnnualTargetsPercentage_lbl" xml:lang="en-US">Original annual targets percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedExpenses" xlink:label="ptgef_AccountsPayableAndAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedExpenses" xlink:to="ptgef_AccountsPayableAndAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFeeAndCommissionExpense" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFeeAndCommissionExpense" xlink:to="ifrs-full_OtherFeeAndCommissionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFeeAndCommissionExpense_lbl" xml:lang="en-US">Incurred Board fees total</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AnnualFeesdescription" xlink:label="ptgef_AnnualFeesdescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AnnualFeesdescription" xlink:to="ptgef_AnnualFeesdescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AnnualFeesdescription_lbl" xml:lang="en-US">Annual fees description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrepaidExpensesAndOtherReceivable" xlink:label="ptgef_PrepaidExpensesAndOtherReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivable" xlink:to="ptgef_PrepaidExpensesAndOtherReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_PrepaidExpensesAndOtherReceivable_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilities" xlink:to="ptgef_AccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability" xlink:label="ifrs-full_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WarrantLiability_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PayablesAndAccruedExpense" xlink:label="ptgef_PayablesAndAccruedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PayablesAndAccruedExpense" xlink:to="ptgef_PayablesAndAccruedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PayablesAndAccruedExpense_lbl" xml:lang="en-US">Accounts payables and accrued liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_2_lbl" xml:lang="en-US">Lease liability - current</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CurrentAsset" xlink:label="ptgef_CurrentAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentAsset" xlink:to="ptgef_CurrentAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ptgef_CurrentAsset_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ShareholdersEquity" xlink:label="ptgef_ShareholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareholdersEquity" xlink:to="ptgef_ShareholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareholdersEquity_lbl" xml:lang="en-US">Shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ShareholdersEquityAttributableToOwners" xlink:label="ptgef_ShareholdersEquityAttributableToOwners" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ShareholdersEquityAttributableToOwners" xlink:to="ptgef_ShareholdersEquityAttributableToOwners_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ShareholdersEquityAttributableToOwners_lbl" xml:lang="en-US">Shareholders' equity attributable to owners</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NoncontrollingInterests_2_lbl" xml:lang="en-US">Non-controlling interest, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="ptgef_NetLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLossAttributableToNoncontrollingInterest" xlink:to="ptgef_NetLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NoncontrollingInterests_3_lbl" xml:lang="en-US">Non-controlling interest, at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_2_lbl" xml:lang="en-US">Current assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_2_lbl" xml:lang="en-US">Non-current assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_2_lbl" xml:lang="en-US">Current liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_2_lbl" xml:lang="en-US">Non-current liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Equity attributable to owners of parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_2_lbl" xml:lang="en-US">Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_2_lbl" xml:lang="en-US">Equity and liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_2_lbl" xml:lang="en-US">Profit (loss) from operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_2_lbl" xml:lang="en-US">Depreciation and amortisation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_3_lbl" xml:lang="en-US">Profit (loss) before tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xml:lang="en-US">Tax expense (income)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NetLoss" xlink:to="ptgef_NetLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NetLoss_2_lbl" xml:lang="en-US">NetLoss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ComprehensiveLossForPeriod" xlink:to="ptgef_ComprehensiveLossForPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ComprehensiveLossForPeriod_2_lbl" xml:lang="en-US">ComprehensiveLossForPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:to="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToNoncontrollingInterests_2_lbl" xml:lang="en-US">Profit (loss), attributable to non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Comprehensive income from continuing operations, attributable to owners of parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent_2_lbl" xml:lang="en-US">Comprehensive income from discontinued operations, attributable to owners of parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ComprehensiveIncomeAttributableToOwnerOfParent" xlink:to="ptgef_ComprehensiveIncomeAttributableToOwnerOfParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ComprehensiveIncomeAttributableToOwnerOfParent_2_lbl" xml:lang="en-US">ComprehensiveIncomeAttributableToOwnerOfParent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_EquityPreSplit" xlink:to="ptgef_EquityPreSplit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_EquityPreSplit_3_lbl" xml:lang="en-US">EquityPreSplit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_2_lbl" xml:lang="en-US">Share issue related cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_2_lbl" xml:lang="en-US">Adjustments for share-based payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:to="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset_2_lbl" xml:lang="en-US">Increase (decrease) in deferred tax liability (asset)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncreaseDecreaseInShareOfLossInAssociate" xlink:to="ptgef_IncreaseDecreaseInShareOfLossInAssociate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncreaseDecreaseInShareOfLossInAssociate_2_lbl" xml:lang="en-US">IncreaseDecreaseInShareOfLossInAssociate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_2_lbl" xml:lang="en-US">Adjustments for decrease (increase) in other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_2_lbl" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_2_lbl" xml:lang="en-US">Payments for share issue costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_RepaymentOfLeaseLiability" xlink:to="ptgef_RepaymentOfLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_RepaymentOfLeaseLiability_2_lbl" xml:lang="en-US">RepaymentOfLeaseLiability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" xlink:to="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory_2_lbl" xml:lang="en-US">DisclosureOfFairValueMeasurementOfWarrantsExplanatory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:to="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_2_lbl" xml:lang="en-US">Proportion of ownership interests held by non-controlling interests</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepayments_2_lbl" xml:lang="en-US">Current prepayments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent" xlink:to="ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent_2_lbl" xml:lang="en-US">PrepaidExpensesAndOtherReceivablesNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityShares" xlink:to="ptgef_WarrantsLiabilityShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsLiabilityShares_3_lbl" xml:lang="en-US">WarrantsLiabilityShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_WarrantsLiabilityFairValue" xlink:to="ptgef_WarrantsLiabilityFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_WarrantsLiabilityFairValue_3_lbl" xml:lang="en-US">WarrantsLiabilityFairValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_2_lbl" xml:lang="en-US">Exercise price of outstanding share options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_ExercisePriceOfOutstandingWarrant" xlink:to="ptgef_ExercisePriceOfOutstandingWarrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_ExercisePriceOfOutstandingWarrant_2_lbl" xml:lang="en-US">ExercisePriceOfOutstandingWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_OtherAccruedExpenses" xlink:to="ptgef_OtherAccruedExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_OtherAccruedExpenses_2_lbl" xml:lang="en-US">OtherAccruedExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_2_lbl" xml:lang="en-US">Other payables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_IncomeTaxExpenseContinuingOperation" xlink:to="ptgef_IncomeTaxExpenseContinuingOperation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_IncomeTaxExpenseContinuingOperation_2_lbl" xml:lang="en-US">IncomeTaxExpenseContinuingOperation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_StockOptionReserve" xlink:to="ptgef_StockOptionReserve_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_StockOptionReserve_3_lbl" xml:lang="en-US">StockOptionReserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AdjustmentsForSharebasedPayment" xlink:to="ptgef_AdjustmentsForSharebasedPayment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AdjustmentsForSharebasedPayment_2_lbl" xml:lang="en-US">AdjustmentsForSharebasedPayment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_NumberOfOutstandingShareOption" xlink:to="ptgef_NumberOfOutstandingShareOption_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_NumberOfOutstandingShareOption_3_lbl" xml:lang="en-US">NumberOfOutstandingShareOption</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_2_lbl" xml:lang="en-US">Current trade receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_PrepaidExpensesAndOtherReceivable" xlink:to="ptgef_PrepaidExpensesAndOtherReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_PrepaidExpensesAndOtherReceivable_2_lbl" xml:lang="en-US">PrepaidExpensesAndOtherReceivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_AccountsPayableAndAccruedLiabilities" xlink:to="ptgef_AccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_AccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">AccountsPayableAndAccruedLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantLiability" xlink:to="ifrs-full_WarrantLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantLiability_2_lbl" xml:lang="en-US">Warrant liability [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ptgef_CurrentAsset" xlink:to="ptgef_CurrentAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ptgef_CurrentAsset_2_lbl" xml:lang="en-US">CurrentAsset</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ptgef-20240930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://portagebiotech.com/role/Cover" xlink:href="ptgef-20240930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:href="ptgef-20240930.xsd#InterimStatementsOfFinancialPosition" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:href="ptgef-20240930.xsd#InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:href="ptgef-20240930.xsd#InterimStatementsOfChangesInShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:href="ptgef-20240930.xsd#InterimStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/NatureOfOperations" xlink:href="ptgef-20240930.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoingConcern" xlink:href="ptgef-20240930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentation" xlink:href="ptgef-20240930.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:href="ptgef-20240930.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiability" xlink:href="ptgef-20240930.xsd#WarrantLiability" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxes" xlink:href="ptgef-20240930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReserves" xlink:href="ptgef-20240930.xsd#CapitalStockAndReserves" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserve" xlink:href="ptgef-20240930.xsd#StockOptionReserve" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShare" xlink:href="ptgef-20240930.xsd#LossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:href="ptgef-20240930.xsd#CommitmentsAndContingentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:href="ptgef-20240930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:href="ptgef-20240930.xsd#FinancialInstrumentsAndRiskManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalManagement" xlink:href="ptgef-20240930.xsd#CapitalManagement" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterest" xlink:href="ptgef-20240930.xsd#Non-controllingInterest" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:href="ptgef-20240930.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:href="ptgef-20240930.xsd#WarrantLiabilityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesTables" xlink:href="ptgef-20240930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReservesTables" xlink:href="ptgef-20240930.xsd#CapitalStockAndReservesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveTables" xlink:href="ptgef-20240930.xsd#StockOptionReserveTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareTables" xlink:href="ptgef-20240930.xsd#LossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:href="ptgef-20240930.xsd#FinancialInstrumentsAndRiskManagementTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:href="ptgef-20240930.xsd#Non-controllingInterestTables" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/GoingConcernDetailsNarrative" xlink:href="ptgef-20240930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:href="ptgef-20240930.xsd#BasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivablesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:href="ptgef-20240930.xsd#PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails1" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails2" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetails3" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" xlink:href="ptgef-20240930.xsd#WarrantLiabilityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative" xlink:href="ptgef-20240930.xsd#AccountsPayableAndAccruedLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:href="ptgef-20240930.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:href="ptgef-20240930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetails1" xlink:href="ptgef-20240930.xsd#CapitalStockAndReservesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" xlink:href="ptgef-20240930.xsd#CapitalStockAndReservesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:href="ptgef-20240930.xsd#StockOptionReserveDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails" xlink:href="ptgef-20240930.xsd#LossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/LossPerShareDetails1" xlink:href="ptgef-20240930.xsd#LossPerShareDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:href="ptgef-20240930.xsd#CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="ptgef-20240930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:href="ptgef-20240930.xsd#FinancialInstrumentsAndRiskManagementDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" xlink:href="ptgef-20240930.xsd#CapitalManagementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:href="ptgef-20240930.xsd#Non-controllingInterestDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" xlink:title="00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-fullStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-fullAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-fullCurrentAssetsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="loc_ifrs-fullNoncurrentAssetsAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets" xlink:label="loc_ifrs-fullOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-fullEquityAndLiabilitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullCurrentLiabilitiesAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="loc_ifrs-fullOtherCurrentLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullNoncurrentLiabilitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityNonCurrent" xlink:label="loc_ptgefWarrantLiabilityNonCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ptgefWarrantLiabilityNonCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="loc_ifrs-fullNoncurrentLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNoncurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-fullEquityAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="loc_ifrs-fullIssuedCapital" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullIssuedCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves" xlink:label="loc_ifrs-fullOtherReserves" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullOtherReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CommitmentsAndContingentLiabilities" xlink:label="loc_ptgefCommitmentsAndContingentLiabilities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ptgefCommitmentsAndContingentLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:title="00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAbstract" xlink:label="loc_ifrs-fullProfitLossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="loc_ifrs-fullGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="loc_ifrs-fullProfitLossFromOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLossFromOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantsLiability" xlink:label="loc_ptgefChangeInFairValueOfWarrantsLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefChangeInFairValueOfWarrantsLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullDepreciationAndAmortisationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullDepreciationAndAmortisationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullGainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-fullRevenueFromInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullRevenueFromInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetLoss" xlink:label="loc_ptgefNetLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefNetLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetUnrealizedGainOnInvestments" xlink:label="loc_ptgefNetUnrealizedGainOnInvestments" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefNetUnrealizedGainOnInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ComprehensiveLossForPeriod" xlink:label="loc_ptgefComprehensiveLossForPeriod" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAbstract" xlink:to="loc_ptgefComprehensiveLossForPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToAbstract" xlink:label="loc_ifrs-fullProfitLossAttributableToAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToNoncontrollingInterests" xlink:label="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProfitLossAttributableToAbstract" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToAbstract" xlink:label="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ifrs-fullComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ComprehensiveIncomeAttributableToOwnerOfParent" xlink:label="loc_ptgefComprehensiveIncomeAttributableToOwnerOfParent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComprehensiveIncomeAttributableToAbstract" xlink:to="loc_ptgefComprehensiveIncomeAttributableToOwnerOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="loc_ifrs-fullEarningsPerShareAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-fullBasicEarningsLossPerShare" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullBasicEarningsLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-fullDilutedEarningsLossPerShare" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullDilutedEarningsLossPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:label="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullWeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-fullWeightedAverageShares" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullWeightedAverageShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-fullAdjustedWeightedAverageShares" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullAdjustedWeightedAverageShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" xlink:title="00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-fullStatementOfChangesInEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullIssuedCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_StockOptionReserveMember" xlink:label="loc_ptgefStockOptionReserveMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ptgefStockOptionReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccumulatedOtherComprehensiveLossMember" xlink:label="loc_ptgefAccumulatedOtherComprehensiveLossMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ptgefAccumulatedOtherComprehensiveLossMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:label="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityAttributableToOwnersOfParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterestsMember" xlink:label="loc_ifrs-fullNoncontrollingInterestsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullNoncontrollingInterestsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_EquityPreSplit" xlink:label="loc_ptgefEquityPreSplit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefEquityPreSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ReverseStockSplitValue" xlink:label="loc_ptgefReverseStockSplitValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReverseStockSplitValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ReverseStockSplitShares" xlink:label="loc_ptgefReverseStockSplitShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefReverseStockSplitShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedUnderAtm" xlink:label="loc_ptgefSharesIssuedUnderAtm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedUnderAtmShares" xlink:label="loc_ptgefSharesIssuedUnderAtmShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedUnderAtmShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="loc_ifrs-fullShareIssueRelatedCost" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullShareIssueRelatedCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedOrAccruedForServices" xlink:label="loc_ptgefSharesIssuedOrAccruedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedOrAccruedForServicesShares" xlink:label="loc_ptgefSharesIssuedOrAccruedForServicesShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedOrAccruedForServicesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetUnrealizedGainOnInvestment" xlink:label="loc_ptgefNetUnrealizedGainOnInvestment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetUnrealizedGainOnInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrefundedWarrantsExercised" xlink:label="loc_ptgefPrefundedWarrantsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrefundedWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrefundedWarrantsExercisedShares" xlink:label="loc_ptgefPrefundedWarrantsExercisedShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrefundedWarrantsExercisedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:label="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:label="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForAccruedBonuses" xlink:label="loc_ptgefSharesIssuedForAccruedBonuses" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForAccruedBonuses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForAccruedBonusesShares" xlink:label="loc_ptgefSharesIssuedForAccruedBonusesShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForAccruedBonusesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForRestrictedStockUnitsNet" xlink:label="loc_ptgefSharesIssuedForRestrictedStockUnitsNet" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForRestrictedStockUnitsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesIssuedForRestrictedStockUnitsNetShares" xlink:label="loc_ptgefSharesIssuedForRestrictedStockUnitsNetShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesIssuedForRestrictedStockUnitsNetShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_EquityPreSplit" xlink:label="loc_ptgefEquityPreSplit_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefEquityPreSplit_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/InterimStatementsOfCashFlows" xlink:title="00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-fullStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantsLiability" xlink:label="loc_ptgefChangeInFairValueOfWarrantsLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefChangeInFairValueOfWarrantsLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_GainOnSettlementWithParexelIoxCro" xlink:label="loc_ptgefGainOnSettlementWithParexelIoxCro" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefGainOnSettlementWithParexelIoxCro" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:label="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:label="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInDeferredTaxLiabilityAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IncreaseDecreaseInShareOfLossInAssociate" xlink:label="loc_ptgefIncreaseDecreaseInShareOfLossInAssociate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefIncreaseDecreaseInShareOfLossInAssociate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfSharesIssuedForServices" xlink:label="loc_ptgefFairValueOfSharesIssuedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefFairValueOfSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullAdjustmentsForDepreciationAndAmortisationExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangesInOperatingWorkingCapitalAbstract" xlink:label="loc_ptgefChangesInOperatingWorkingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ptgefChangesInOperatingWorkingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefChangesInOperatingWorkingCapitalAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefChangesInOperatingWorkingCapitalAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefChangesInOperatingWorkingCapitalAbstract" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefChangesInOperatingWorkingCapitalAbstract" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ProceedsFromExerciseOfPrefundedWarrants" xlink:label="loc_ptgefProceedsFromExerciseOfPrefundedWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromExerciseOfPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:label="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="loc_ifrs-fullPaymentsForShareIssueCosts" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullPaymentsForShareIssueCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RepaymentOfLeaseLiability" xlink:label="loc_ptgefRepaymentOfLeaseLiability" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ptgefRepaymentOfLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:label="loc_ptgefSupplementalDisclosureOfCashFlowInformationAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefSupplementalDisclosureOfCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CashPaidForInterest" xlink:label="loc_ptgefCashPaidForInterest" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="loc_ptgefCashPaidForInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:label="loc_ptgefSupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ptgefSupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RightToUseAssetAcquired" xlink:label="loc_ptgefRightToUseAssetAcquired" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:to="loc_ptgefRightToUseAssetAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_LeaseLiabilityIncurred" xlink:label="loc_ptgefLeaseLiabilityIncurred" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefSupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract" xlink:to="loc_ptgefLeaseLiabilityIncurred" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/NatureOfOperations" xlink:title="00000006 - Disclosure - NATURE OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureNatureOfOperationsAbstract" xlink:label="loc_ptgefDisclosureNatureOfOperationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NatureOfOperationsExplanatory" xlink:label="loc_ptgefNatureOfOperationsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureNatureOfOperationsAbstract" xlink:to="loc_ptgefNatureOfOperationsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcern" xlink:title="00000007 - Disclosure - GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="loc_ifrs-fullDisclosureOfGoingConcernExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfGoingConcernExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentation" xlink:title="00000008 - Disclosure - BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="loc_ifrs-fullDisclosureOfBasisOfConsolidationExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ptgefDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:label="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory" xlink:label="loc_ptgefDisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ptgefDisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiability" xlink:title="00000011 - Disclosure - WARRANT LIABILITY">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityTextBlock" xlink:label="loc_ptgefWarrantLiabilityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ptgefWarrantLiabilityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities" xlink:title="00000012 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:label="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxes" xlink:title="00000013 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReserves" xlink:title="00000014 - Disclosure - CAPITAL STOCK AND RESERVES">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CapitalStockAndReservesTextBlock" xlink:label="loc_ptgefCapitalStockAndReservesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAndReservesAbstract" xlink:to="loc_ptgefCapitalStockAndReservesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserve" xlink:title="00000015 - Disclosure - STOCK OPTION RESERVE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShare" xlink:title="00000016 - Disclosure - LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-fullEarningsPerShareExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullEarningsPerShareExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" xlink:title="00000017 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactions" xlink:title="00000018 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" xlink:title="00000019 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" xlink:label="loc_ptgefDisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ptgefDisclosureOfFinancialInstrumentsAndRiskManagementExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagement" xlink:title="00000020 - Disclosure - CAPITAL MANAGEMENT">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureCapitalManagementAbstract" xlink:label="loc_ptgefDisclosureCapitalManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock" xlink:label="loc_ptgefDisclosureOfCapitalManagementExplanatoryTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ptgefDisclosureOfCapitalManagementExplanatoryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterest" xlink:title="00000021 - Disclosure - NON-CONTROLLING INTEREST">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfInterestsInOtherEntitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfInterestsInOtherEntitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureSignificantAccountingPoliciesAbstract" xlink:label="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:label="loc_ptgefDescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureSignificantAccountingPoliciesAbstract" xlink:to="loc_ptgefDescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" xlink:title="00000023 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:label="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:label="loc_ptgefDisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ptgefDisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityTables" xlink:title="00000024 - Disclosure - WARRANT LIABILITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesBWarrantsMember" xlink:label="loc_ptgefSeriesBWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesCWarrantsMember" xlink:label="loc_ptgefSeriesCWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfWarrantLiabilityTableTextBlock" xlink:label="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefScheduleOfWarrantLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:title="00000025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:label="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesTables" xlink:title="00000026 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:label="loc_ptgefScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesTables" xlink:title="00000027 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory" xlink:label="loc_ptgefDisclosureOfFairValueMeasurementOfWarrantsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAndReservesAbstract" xlink:to="loc_ptgefDisclosureOfFairValueMeasurementOfWarrantsExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveTables" xlink:title="00000028 - Disclosure - STOCK OPTION RESERVE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock" xlink:label="loc_ptgefScheduleOfTermsStockOptionReserveTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfTermsStockOptionReserveTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock" xlink:label="loc_ptgefScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareTables" xlink:title="00000029 - Disclosure - LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfEarningsPerShareTableTextBlock" xlink:label="loc_ptgefScheduleOfEarningsPerShareTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefScheduleOfEarningsPerShareTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock" xlink:label="loc_ptgefScheduleOfAntiDilutiveEffectTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefScheduleOfAntiDilutiveEffectTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" xlink:title="00000030 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:label="loc_ptgefScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ptgefScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestTables" xlink:title="00000031 - Disclosure - NON-CONTROLLING INTEREST (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:label="loc_ptgefScheduleOfNoncontrollingInterestTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefScheduleOfNoncontrollingInterestTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/GoingConcernDetailsNarrative" xlink:title="00000032 - Disclosure - GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="loc_ifrs-fullCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_TotalCurrentLiabilities" xlink:label="loc_ptgefTotalCurrentLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefTotalCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetLossIncome" xlink:label="loc_ptgefNetLossIncome" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefNetLossIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CashUsedInOperatingActivities" xlink:label="loc_ptgefCashUsedInOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefCashUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand" xlink:label="loc_ifrs-fullCashOnHand" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullCashOnHand" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" xlink:title="00000033 - Disclosure - BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullBottomOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullTopOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis" xlink:label="loc_ifrs-fullSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullSegmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember" xlink:label="loc_ifrs-fullSegmentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSegmentsAxis" xlink:to="loc_ifrs-fullSegmentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CountryOfBritishVirginIslandsMember" xlink:label="loc_ptgefCountryOfBritishVirginIslandsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSegmentsMember" xlink:to="loc_ptgefCountryOfBritishVirginIslandsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CountryOfDelawareMember" xlink:label="loc_ptgefCountryOfDelawareMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSegmentsMember" xlink:to="loc_ptgefCountryOfDelawareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSaugatuckMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PercentageOfOutstandingShares" xlink:label="loc_ptgefPercentageOfOutstandingShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPercentageOfOutstandingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestInSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:label="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProportionOfOwnershipInterestsHeldByNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" xlink:title="00000034 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:label="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentReceivablesFromSaleOfProperties" xlink:label="loc_ifrs-fullCurrentReceivablesFromSaleOfProperties" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentReceivablesFromSaleOfProperties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentReceivablesFromRentalOfProperties" xlink:label="loc_ifrs-fullCurrentReceivablesFromRentalOfProperties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentReceivablesFromRentalOfProperties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="loc_ifrs-fullCurrentAdvancesToSuppliers" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentAdvancesToSuppliers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_TaxDeposits" xlink:label="loc_ptgefTaxDeposits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ptgefTaxDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="loc_ifrs-fullCurrentPrepaidExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentPrepaidExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SecurityDepositOnOfficeLease" xlink:label="loc_ptgefSecurityDepositOnOfficeLease" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ptgefSecurityDepositOnOfficeLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="loc_ifrs-fullCurrentPrepayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentPrepayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative" xlink:title="00000035 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:label="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosurePrepaidExpensesAndOtherReceivablesAbstract" xlink:to="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="loc_ifrs-fullEntitysTotalForSubsidiariesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullSignificantInvestmentsInSubsidiariesAxis" xlink:to="loc_ifrs-fullEntitysTotalForSubsidiariesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ParexelInternationalLimitedMember" xlink:label="loc_ptgefParexelInternationalLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForSubsidiariesMember" xlink:to="loc_ptgefParexelInternationalLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivablesNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivablesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WriteoffOfAdvances" xlink:label="loc_ptgefWriteoffOfAdvances" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWriteoffOfAdvances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RefundReceivables" xlink:label="loc_ptgefRefundReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefRefundReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails" xlink:title="00000036 - Disclosure - WARRANT LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ClassBWarrantsMember" xlink:label="loc_ptgefClassBWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefClassBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ClassCWarrantsMember" xlink:label="loc_ptgefClassCWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefClassCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityExercisePrice" xlink:label="loc_ptgefWarrantLiabilityExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantLiabilityExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsLiabilityShares" xlink:label="loc_ptgefWarrantsLiabilityShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsLiabilityFairValue" xlink:label="loc_ptgefWarrantsLiabilityFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantsAtIssuanceExercisePrice" xlink:label="loc_ptgefFairValueOfWarrantsAtIssuanceExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsAtIssuanceExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantsShares" xlink:label="loc_ptgefFairValueOfWarrantsShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantsAmount" xlink:label="loc_ptgefFairValueOfWarrantsAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantLiability" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantLiabilityAmount" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiabilityAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiabilityAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsLiabilityShares" xlink:label="loc_ptgefWarrantsLiabilityShares_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsLiabilityFairValue" xlink:label="loc_ptgefWarrantsLiabilityFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsLiabilityFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails1" xlink:title="00000037 - Disclosure - WARRANT LIABILITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesBWarrantsMember" xlink:label="loc_ptgefSeriesBWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails2" xlink:title="00000038 - Disclosure -  WARRANT LIABILITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesCWarrantsMember" xlink:label="loc_ptgefSeriesCWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetails3" xlink:title="00000039 - Disclosure - WARRANT LIABILITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OptionLifeShareOptions" xlink:label="loc_ptgefOptionLifeShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOptionLifeShareOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative" xlink:title="00000040 - Disclosure - WARRANT LIABILITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureWarrantLiabilityAbstract" xlink:label="loc_ptgefDisclosureWarrantLiabilityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureWarrantLiabilityAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:label="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis" xlink:to="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchaseAgreementMember" xlink:label="loc_ptgefPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember" xlink:to="loc_ptgefPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PreFundedWarrantsMember" xlink:label="loc_ptgefPreFundedWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesAWarrantsMember" xlink:label="loc_ptgefSeriesAWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesBWarrantsMember" xlink:label="loc_ptgefSeriesBWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesBWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesCWarrantsMember" xlink:label="loc_ptgefSeriesCWarrantsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantMember" xlink:label="loc_ptgefPlacementAgentWarrantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PlacementAgentWarrantsMember" xlink:label="loc_ptgefPlacementAgentWarrantsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OrdinaryNumberOfStockSold" xlink:label="loc_ptgefOrdinaryNumberOfStockSold" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOrdinaryNumberOfStockSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchasePriceOfPerShare" xlink:label="loc_ptgefPurchasePriceOfPerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchasePriceOfPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchaseWarrants" xlink:label="loc_ptgefPurchaseWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OrdinarySharesPurchase" xlink:label="loc_ptgefOrdinarySharesPurchase" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOrdinarySharesPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceOfOutstandingWarrant" xlink:label="loc_ptgefExercisePriceOfOutstandingWarrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceOfOutstandingWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-fullProceedsFromIssuingShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssuingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-fullProfessionalFeesExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfessionalFeesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfVotingEquityInterestsAcquired" xlink:label="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullPercentageOfVotingEquityInterestsAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AggregateGrossProceeds" xlink:label="loc_ptgefAggregateGrossProceeds" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateGrossProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ManagementFeePercentage" xlink:label="loc_ptgefManagementFeePercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefManagementFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AggregateGrossProceedsIncrease" xlink:label="loc_ptgefAggregateGrossProceedsIncrease" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAggregateGrossProceedsIncrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdministrativeExpense" xlink:label="loc_ifrs-fullAdministrativeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FeeAndCommissionExpense" xlink:label="loc_ifrs-fullFeeAndCommissionExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullFeeAndCommissionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PurchaseOfWarrants" xlink:label="loc_ptgefPurchaseOfWarrants" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPurchaseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SaleOfWarrantPercentage" xlink:label="loc_ptgefSaleOfWarrantPercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSaleOfWarrantPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceWarrantPerShare" xlink:label="loc_ptgefExercisePriceWarrantPerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceWarrantPerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetProceedsWarrantLiability" xlink:label="loc_ptgefNetProceedsWarrantLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetProceedsWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:label="loc_ifrs-fullIncreaseDecreaseInFairValueMeasurementLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseInFairValueMeasurementLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_LossOnWarrantLiabilities" xlink:label="loc_ptgefLossOnWarrantLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefLossOnWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OfferingExpenses" xlink:label="loc_ptgefOfferingExpenses" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ChangeInFairValueOfWarrantLiabilities" xlink:label="loc_ptgefChangeInFairValueOfWarrantLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefChangeInFairValueOfWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantLiabilityBalance" xlink:label="loc_ptgefWarrantLiabilityBalance" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantLiabilityBalance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePrice" xlink:label="loc_ptgefExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrantPerShare" xlink:label="loc_ptgefFairValueOfWarrantPerShare" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrantPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails" xlink:title="00000041 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:label="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAmountsAccruedToCro" xlink:label="loc_ptgefAccountsPayableAndAmountsAccruedToCro" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAmountsAccruedToCro" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses" xlink:label="loc_ptgefAccruedBonusesAndOtherPayrollrelatedExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedBonusesAndOtherPayrollrelatedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedAccountingAndAuditingFees" xlink:label="loc_ptgefAccruedAccountingAndAuditingFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedAccountingAndAuditingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedLegalFees" xlink:label="loc_ptgefAccruedLegalFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedOtherProfessionalFees" xlink:label="loc_ptgefAccruedOtherProfessionalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedOtherProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OtherAccountsPayable" xlink:label="loc_ptgefOtherAccountsPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefOtherAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccruedClinicalAndRdServices" xlink:label="loc_ptgefAccruedClinicalAndRdServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccruedClinicalAndRdServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OtherAccruedExpenses" xlink:label="loc_ptgefOtherAccruedExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefOtherAccruedExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedLiabilityNet" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilityNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilityNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative" xlink:title="00000042 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:label="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables" xlink:label="loc_ifrs-fullOtherPayables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ifrs-fullOtherPayables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughWriteoffFinancialAssets" xlink:label="loc_ifrs-fullDecreaseThroughWriteoffFinancialAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureAccountsPayableAndAccruedLiabilitiesAbstract" xlink:to="loc_ifrs-fullDecreaseThroughWriteoffFinancialAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetails" xlink:title="00000043 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IncomeTaxExpenseContinuingOperation" xlink:label="loc_ptgefIncomeTaxExpenseContinuingOperation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefIncomeTaxExpenseContinuingOperation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="loc_ifrs-fullTaxRateEffectOfTaxLosses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullTaxRateEffectOfTaxLosses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000044 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfTaxLosses" xlink:label="loc_ifrs-fullTaxRateEffectOfTaxLosses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullTaxRateEffectOfTaxLosses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetails1" xlink:title="00000045 - Disclosure - CAPITAL STOCK AND RESERVES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAndReservesAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesAWarrantsMember" xlink:label="loc_ptgefSeriesAWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ExercisePriceFairValue" xlink:label="loc_ptgefExercisePriceFairValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefExercisePriceFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharePriceFairvalue" xlink:label="loc_ptgefSharePriceFairvalue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharePriceFairvalue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative" xlink:title="00000046 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureCapitalStockAndReservesAbstract" xlink:label="loc_ptgefDisclosureCapitalStockAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalStockAndReservesAbstract" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullTopOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullBottomOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ATMMember" xlink:label="loc_ptgefATMMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_ptgefATMMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SeriesAWarrantsAndPreFundedWarrantsMember" xlink:label="loc_ptgefSeriesAWarrantsAndPreFundedWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ptgefSeriesAWarrantsAndPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOrdinarySharesOutstandingDecrease" xlink:label="loc_ptgefNumberOfOrdinarySharesOutstandingDecrease" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOrdinarySharesOutstandingDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CashFundDescription" xlink:label="loc_ptgefCashFundDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefCashFundDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOrdinaryShareIssued" xlink:label="loc_ptgefNumberOfOrdinaryShareIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOrdinaryShareIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfSharesSold" xlink:label="loc_ptgefNumberOfSharesSold" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfBiologicalAssets" xlink:label="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromSalesOfBiologicalAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PublicFloat" xlink:label="loc_ptgefPublicFloat" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueOfWarrants" xlink:label="loc_ptgefFairValueOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefFairValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_WarrantsPerShare" xlink:label="loc_ptgefWarrantsPerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefWarrantsPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails" xlink:title="00000047 - Disclosure - STOCK OPTION RESERVE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefStockOptionReserve" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AdjustmentsForSharebasedPayment" xlink:label="loc_ptgefAdjustmentsForSharebasedPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefAdjustmentsForSharebasedPayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_StockOptionReserve" xlink:label="loc_ptgefStockOptionReserve_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefStockOptionReserve_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails1" xlink:title="00000048 - Disclosure - STOCK OPTION RESERVE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:label="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfOutstandingShareOption" xlink:label="loc_ptgefNumberOfOutstandingShareOption_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfOutstandingShareOption_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:label="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOptionsExercisableInSharebasedPaymentsArrangements" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetails2" xlink:title="00000049 - Disclosure - STOCK OPTION RESERVE (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" xlink:title="00000050 - Disclosure - STOCK OPTION RESERVE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis" xlink:label="loc_ifrs-fullDefinedBenefitPlansAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullDefinedBenefitPlansAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember" xlink:label="loc_ifrs-fullDefinedBenefitPlansMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansAxis" xlink:to="loc_ifrs-fullDefinedBenefitPlansMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PBI2021EquityIncentivePlanMember" xlink:label="loc_ptgefPBI2021EquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDefinedBenefitPlansMember" xlink:to="loc_ptgefPBI2021EquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDefinedBenefitPlansTable" xlink:to="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AntidilutiveInstrumentsMember" xlink:label="loc_ifrs-fullAntidilutiveInstrumentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfAntidilutiveInstrumentsAxis" xlink:to="loc_ifrs-fullAntidilutiveInstrumentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember" xlink:label="loc_ifrs-fullRestrictedShareUnitsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAntidilutiveInstrumentsMember" xlink:to="loc_ifrs-fullRestrictedShareUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesReservedForAwardsGranted" xlink:label="loc_ptgefSharesReservedForAwardsGranted" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesReservedForAwardsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesAvailableForFutureAwards" xlink:label="loc_ptgefSharesAvailableForFutureAwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesAvailableForFutureAwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfSharesExercise" xlink:label="loc_ptgefNumberOfSharesExercise" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:label="loc_ptgefSharesRepurchasedIntoTreasuryEmployeePayrollTaxes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefSharesRepurchasedIntoTreasuryEmployeePayrollTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfSharesGranted" xlink:label="loc_ptgefNumberOfSharesGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfSharesGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumberOfShareOutstanding" xlink:label="loc_ptgefNumberOfShareOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNumberOfShareOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DescriptionOfRestrictedStockUnitsExpire" xlink:label="loc_ptgefDescriptionOfRestrictedStockUnitsExpire" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefDescriptionOfRestrictedStockUnitsExpire" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails" xlink:title="00000051 - Disclosure - LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NumeratorAbstract" xlink:label="loc_ptgefNumeratorAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefNumeratorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToOwnersOfParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DenominatorAbstract" xlink:label="loc_ptgefDenominatorAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ptgefDenominatorAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-fullWeightedAverageShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullWeightedAverageShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="loc_ifrs-fullAdjustedWeightedAverageShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullAdjustedWeightedAverageShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="loc_ifrs-fullBasicEarningsLossPerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullBasicEarningsLossPerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="loc_ifrs-fullDilutedEarningsLossPerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullDilutedEarningsLossPerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/LossPerShareDetails1" xlink:title="00000052 - Disclosure - LOSS PER SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember" xlink:label="loc_ifrs-fullWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ifrs-fullWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_StockOptionsMember" xlink:label="loc_ptgefStockOptionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RestrictedStockUnitsMember" xlink:label="loc_ptgefRestrictedStockUnitsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AntidilutiveEffectOnLossPerShare" xlink:label="loc_ptgefAntidilutiveEffectOnLossPerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefAntidilutiveEffectOnLossPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" xlink:title="00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_RetainageDeposits" xlink:label="loc_ptgefRetainageDeposits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefRetainageDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_UnbilledContractsReceivables" xlink:label="loc_ptgefUnbilledContractsReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefUnbilledContractsReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ForfeitedAdvancedPayments" xlink:label="loc_ptgefForfeitedAdvancedPayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefForfeitedAdvancedPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_GainOnLiability" xlink:label="loc_ptgefGainOnLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefGainOnLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities" xlink:label="loc_ptgefPayablesToParexelInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefPayablesToParexelInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="loc_ifrs-fullCurrentTradeReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullCurrentTradeReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_BudgetedCosts" xlink:label="loc_ptgefBudgetedCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefBudgetedCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000054 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PortagePaidIntensity" xlink:label="loc_ptgefPortagePaidIntensity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefPortagePaidIntensity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CompensationCommittee" xlink:label="loc_ptgefCompensationCommittee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefCompensationCommittee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_OriginalAnnualTargetsPercentage" xlink:label="loc_ptgefOriginalAnnualTargetsPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefOriginalAnnualTargetsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedExpenses" xlink:label="loc_ptgefAccountsPayableAndAccruedExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFeeAndCommissionExpense" xlink:label="loc_ifrs-fullOtherFeeAndCommissionExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullOtherFeeAndCommissionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AnnualFeesdescription" xlink:label="loc_ptgefAnnualFeesdescription" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ptgefAnnualFeesdescription" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" xlink:title="00000055 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:label="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureFinancialInstrumentsAndRiskManagementAbstract" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLevelsOfFairValueHierarchyAxis" xlink:to="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AmortizedCostMember" xlink:label="loc_ptgefAmortizedCostMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefAmortizedCostMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueToOtherComprehensiveIncomeMember" xlink:label="loc_ptgefFairValueToOtherComprehensiveIncomeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefFairValueToOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_FairValueThroughProfitOrLossMember" xlink:label="loc_ptgefFairValueThroughProfitOrLossMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAllLevelsOfFairValueHierarchyMember" xlink:to="loc_ptgefFairValueThroughProfitOrLossMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PrepaidExpensesAndOtherReceivable" xlink:label="loc_ptgefPrepaidExpensesAndOtherReceivable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialAssetsAbstract" xlink:to="loc_ptgefPrepaidExpensesAndOtherReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_AccountsPayableAndAccruedLiabilities" xlink:label="loc_ptgefAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ptgefAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability" xlink:label="loc_ifrs-fullWarrantLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfFinancialLiabilitiesAbstract" xlink:to="loc_ifrs-fullWarrantLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/CapitalManagementDetailsNarrative" xlink:title="00000056 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_DisclosureCapitalManagementAbstract" xlink:label="loc_ptgefDisclosureCapitalManagementAbstract" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_PayablesAndAccruedExpense" xlink:label="loc_ptgefPayablesAndAccruedExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ptgefPayablesAndAccruedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_CurrentAsset" xlink:label="loc_ptgefCurrentAsset" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ptgefCurrentAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ShareholdersEquity" xlink:label="loc_ptgefShareholdersEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ptgefShareholdersEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_ShareholdersEquityAttributableToOwners" xlink:label="loc_ptgefShareholdersEquityAttributableToOwners" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefDisclosureCapitalManagementAbstract" xlink:to="loc_ptgefShareholdersEquityAttributableToOwners" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://portagebiotech.com/role/Non-controllingInterestDetails" xlink:title="00000057 - Disclosure - NON-CONTROLLING INTEREST (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:label="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNotesAndOtherExplanatoryInformationAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_IfrsStatementLineItems" xlink:label="loc_ptgefIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ptgefIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_SaugatuckMember" xlink:label="loc_ptgefSaugatuckMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ptgefSaugatuckMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="ptgef-20240930.xsd#ptgef_NetLossAttributableToNoncontrollingInterest" xlink:label="loc_ptgefNetLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ptgefNetLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests" xlink:label="loc_ifrs-fullNoncontrollingInterests_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptgefIfrsStatementLineItems" xlink:to="loc_ifrs-fullNoncontrollingInterests_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887757328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Portage Biotech Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Clarence
Thomas Building<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">P.O.
Box 4649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Road
Town<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tortola<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">VG<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">VG1110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988885814160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Financial Position (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,764<span></span>
</td>
<td class="nump">$ 5,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">2,686<span></span>
</td>
<td class="nump">7,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right to use asset</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="nump">7,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">2,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liability - current, including interest</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liability - non-current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantLiabilityNonCurrent', window );">Warrant liability</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,011<span></span>
</td>
<td class="nump">4,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Capital stock</a></td>
<td class="nump">219,606<span></span>
</td>
<td class="nump">219,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Stock option reserve</a></td>
<td class="nump">24,126<span></span>
</td>
<td class="nump">23,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(242,334)<span></span>
</td>
<td class="num">(239,318)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Total equity attributable to owners of the Company</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="nump">4,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">(703)<span></span>
</td>
<td class="num">(693)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">3,329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="nump">$ 7,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CommitmentsAndContingentLiabilities', window );">Commitments and Contingent Liabilities (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CommitmentsAndContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CommitmentsAndContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988885733104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 723<span></span>
</td>
<td class="nump">$ 4,237<span></span>
</td>
<td class="nump">$ 2,028<span></span>
</td>
<td class="nump">$ 7,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">3,062<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss from operations</a></td>
<td class="num">(1,604)<span></span>
</td>
<td class="num">(5,930)<span></span>
</td>
<td class="num">(4,443)<span></span>
</td>
<td class="num">(10,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfWarrantsLiability', window );">Change in fair value of warrant liability</a></td>
<td class="num">(716)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">426<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone', window );">Change in fair value of deferred purchase price payable &#150; Tarus and deferred obligation &#150; iOx milestone</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementWithParexelIoxCro', window );">Gain on settlement with Parexel &#8211; iOx CRO</a></td>
<td class="nump">946<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of loss in associate accounted for using equity method</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation expense</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange transaction (loss) gain</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income, net</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before benefit for income taxes</a></td>
<td class="num">(1,362)<span></span>
</td>
<td class="num">(6,072)<span></span>
</td>
<td class="num">(3,024)<span></span>
</td>
<td class="num">(12,143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit (expense)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetLoss', window );">Net loss</a></td>
<td class="num">(1,362)<span></span>
</td>
<td class="num">(5,165)<span></span>
</td>
<td class="num">(3,026)<span></span>
</td>
<td class="num">(11,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetUnrealizedGainOnInvestments', window );">Net unrealized (loss) gain on investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,300)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ComprehensiveLossForPeriod', window );">Total comprehensive loss for period</a></td>
<td class="num">(1,362)<span></span>
</td>
<td class="num">(6,465)<span></span>
</td>
<td class="num">(3,026)<span></span>
</td>
<td class="num">(10,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToAbstract', window );"><strong>Net loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="num">(1,360)<span></span>
</td>
<td class="num">(5,158)<span></span>
</td>
<td class="num">(3,016)<span></span>
</td>
<td class="num">(11,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(1,362)<span></span>
</td>
<td class="num">(5,165)<span></span>
</td>
<td class="num">(3,026)<span></span>
</td>
<td class="num">(11,091)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract', window );"><strong>Comprehensive loss attributable to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent', window );">Owners of the Company</a></td>
<td class="num">(1,360)<span></span>
</td>
<td class="num">(6,458)<span></span>
</td>
<td class="num">(3,016)<span></span>
</td>
<td class="num">(10,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent', window );">Non-controlling interest</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ComprehensiveIncomeAttributableToOwnerOfParent', window );">Total comprehensive loss for period</a></td>
<td class="num">$ (1,362)<span></span>
</td>
<td class="num">$ (6,465)<span></span>
</td>
<td class="num">$ (3,026)<span></span>
</td>
<td class="num">$ (10,622)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Loss per share, basic</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (5.80)<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
<td class="num">$ (12.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Loss per share, diluted</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (5.80)<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
<td class="num">$ (12.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The comprehensive income from continuing operations attributable to owners of the parent. [Refer: Comprehensive income from continuing operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The comprehensive income from discontinued operations attributable to owners of the parent. [Refer: Comprehensive income from discontinued operations]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfWarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfWarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ComprehensiveIncomeAttributableToOwnerOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ComprehensiveIncomeAttributableToOwnerOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ComprehensiveLossForPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ComprehensiveLossForPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnSettlementWithParexelIoxCro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnSettlementWithParexelIoxCro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetUnrealizedGainOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetUnrealizedGainOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988862345024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Issued capital [member]</div></th>
<th class="th"><div>Stock Option Reserve [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Retained earnings [member]</div></th>
<th class="th"><div>Equity attributable to owners of parent [member]</div></th>
<th class="th"><div>Non-controlling interests [member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EquityPreSplit', window );">Balance, April 1, 2023 (Pre-Split) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="nump">17,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReverseStockSplitValue', window );">Balance, April 1, 2023 (After 1-for-20 reverse stock split)</a></td>
<td class="nump">$ 218,782<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
<td class="num">(4,325)<span></span>
</td>
<td class="num">(159,616)<span></span>
</td>
<td class="nump">76,045<span></span>
</td>
<td class="num">(650)<span></span>
</td>
<td class="nump">$ 75,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReverseStockSplitShares', window );">After 1-for-20 reverse stock split, shares</a></td>
<td class="nump">880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,512<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,512<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderAtm', window );">Shares issued under ATM</a></td>
<td class="nump">$ 682<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">682<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedUnderAtmShares', window );">Shares issued under ATM, shares</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issuance costs</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServices', window );">Shares issued or accrued for services</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedOrAccruedForServicesShares', window );">Shares issued or accrued for services, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetUnrealizedGainOnInvestment', window );">Net unrealized gain on investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,077)<span></span>
</td>
<td class="num">(11,077)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(11,091)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EquityPreSplit', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="nump">$ 219,494<span></span>
</td>
<td class="nump">22,716<span></span>
</td>
<td class="num">(3,856)<span></span>
</td>
<td class="num">(170,693)<span></span>
</td>
<td class="nump">67,661<span></span>
</td>
<td class="num">(664)<span></span>
</td>
<td class="nump">66,997<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2023</a></td>
<td class="nump">890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EquityPreSplit', window );">Balance, April 1, 2023 (Pre-Split) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2024</a></td>
<td class="nump">19,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReverseStockSplitValue', window );">Balance, April 1, 2023 (After 1-for-20 reverse stock split)</a></td>
<td class="nump">$ 219,499<span></span>
</td>
<td class="nump">23,841<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(239,318)<span></span>
</td>
<td class="nump">4,022<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="nump">3,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ReverseStockSplitShares', window );">After 1-for-20 reverse stock split, shares</a></td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrefundedWarrantsExercised', window );">Pre-Funded warrants exercised</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrefundedWarrantsExercisedShares', window );">Pre-Funded warrants exercised, shares</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit', window );">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares', window );">Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split, shares</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedForAccruedBonuses', window );">Shares issued for accrued bonuses</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedForAccruedBonusesShares', window );">Shares issued for accrued bonuses, shares</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedForRestrictedStockUnitsNet', window );">Shares issued for restricted stock units, net</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesIssuedForRestrictedStockUnitsNetShares', window );">Shares issued for restricted stock units, net, shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,016)<span></span>
</td>
<td class="num">(3,016)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(3,026)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_EquityPreSplit', window );">Ending balance, value at Sep. 30, 2024</a></td>
<td class="nump">$ 219,606<span></span>
</td>
<td class="nump">$ 24,126<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (242,334)<span></span>
</td>
<td class="nump">$ 1,398<span></span>
</td>
<td class="num">$ (703)<span></span>
</td>
<td class="nump">$ 695<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_EquityPreSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_EquityPreSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetUnrealizedGainOnInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetUnrealizedGainOnInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrefundedWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrefundedWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrefundedWarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrefundedWarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ReverseStockSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ReverseStockSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ReverseStockSplitValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ReverseStockSplitValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedForAccruedBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedForAccruedBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedForAccruedBonusesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedForAccruedBonusesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedForRestrictedStockUnitsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedForRestrictedStockUnitsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedForRestrictedStockUnitsNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedForRestrictedStockUnitsNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedOrAccruedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedOrAccruedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedOrAccruedForServicesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedOrAccruedForServicesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderAtm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderAtm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesIssuedUnderAtmShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesIssuedUnderAtmShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886449696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">$ (3,026)<span></span>
</td>
<td class="num">$ (11,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expense</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfWarrantsLiability', window );">Change in fair value of warrant liability</a></td>
<td class="num">(426)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnSettlementWithParexelIoxCro', window );">Gain on settlement with Parexel &#8211; iOx CRO</a></td>
<td class="num">(946)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone', window );">Change in fair value of deferred purchase price payable &#8211; Tarus and deferred obligation &#8211; iOx milestone</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset', window );">Decrease in deferred tax liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,063)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncreaseDecreaseInShareOfLossInAssociate', window );">Share of loss in associate</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfSharesIssuedForServices', window );">Fair value of shares issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangesInOperatingWorkingCapitalAbstract', window );"><strong>Changes in operating working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Other assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(399)<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities', window );">Other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,246)<span></span>
</td>
<td class="num">(7,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromExerciseOfPrefundedWarrants', window );">Proceeds from the&#160;exercise of Pre-Funded Warrants</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement', window );">Proceeds from shares issued under ATM and Committed Purchase Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Share issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RepaymentOfLeaseLiability', window );">Repayment of lease liability</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Decrease in cash and cash equivalents during the period</a></td>
<td class="num">(3,264)<span></span>
</td>
<td class="num">(7,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">10,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">3,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SupplementalDisclosureOfCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashPaidForInterest', window );">Cash paid for interest</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RightToUseAssetAcquired', window );">Right to use asset acquired</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LeaseLiabilityIncurred', window );">Lease liability incurred</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashPaidForInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashPaidForInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfWarrantsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfWarrantsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangesInOperatingWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangesInOperatingWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnSettlementWithParexelIoxCro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnSettlementWithParexelIoxCro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncreaseDecreaseInShareOfLossInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncreaseDecreaseInShareOfLossInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LeaseLiabilityIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LeaseLiabilityIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RepaymentOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RepaymentOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RightToUseAssetAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RightToUseAssetAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SupplementalDisclosureOfCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SupplementalDisclosureOfCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887052992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureNatureOfOperationsAbstract', window );"><strong>Nature Of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NatureOfOperationsExplanatory', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p id="xdx_802_ecustom--NatureOfOperationsExplanatory_zcLRZdXnyXV5" style="margin: 0; font-size: 10pt"><b>NOTE 1. <span id="xdx_823_zDHRMIATIQv">NATURE OF OPERATIONS</span></b></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Portage Biotech Inc. (the &#8220;Company&#8221; or &#8220;Portage&#8221;)
is incorporated in the British Virgin Islands (&#8220;BVI&#8221;) with its registered office located at Clarence Thomas Building, P.O.
Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services Inc. (&#8220;PDS&#8221;), is located at 59 Wilton Road,
Westport, CT, 06880, USA.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company is a foreign private issuer under the Securities
and Exchange Commission (the &#8220;SEC&#8221;) rules. It is also a reporting issuer under the securities legislation of the provinces
of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&#8220;CSE&#8221;) under the symbol
&#8220;PBT.U&#8221;. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;)
under the symbol &#8220;PRTG&#8221;. As the principal market for the Company&#8217;s ordinary shares is Nasdaq, the Company voluntarily
delisted from the CSE on April 23, 2021.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Portage is a clinical-stage immuno-oncology company advancing
treatments the Company believes will be first-in class therapies that target known checkpoint resistance pathways to improve long-term
treatment response and quality of life in patients with invasive cancers. Portage&#8217;s access to next-generation technologies coupled
with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies
that accelerate these medicines through the translational pipeline. After a review of the Company&#8217;s future funding needs for clinical
development of its programs as well as the current capital raising market for biotechnology companies, the Company made the decision to
discontinue the Company sponsored trial for the invariant natural killer T-cell (&#8220;iNKT&#8221;) program and pause further patient
accrual to the Company sponsored adenosine trial for both PORT-6 and PORT-7. The Company is exploring strategic alternatives, which may
include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings, both in and out of court, a
company wind down, further financing efforts or other strategic action.</p>


<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt"><b><i>Reverse Stock Split</i></b></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;)
approved a reverse stock split of its ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024,
the Company&#8217;s ordinary shares began trading on Nasdaq on a split-adjusted basis under the existing trading symbol &#8220;PRTG&#8221;.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The reverse stock split was implemented to increase the
per share trading price of the Company&#8217;s ordinary shares for the purpose of ensuring a share price high enough to comply with the
minimum $1.00 bid price requirement for continued listing on Nasdaq. The Company received notice from Nasdaq on August 30, 2024 informing
the Company that it had regained compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As a result of the reverse stock split,
every twenty (20) pre-split ordinary shares were converted into one (1) post-split ordinary share. Any fractional shares resulting from
the reverse stock split were rounded up to the nearest whole post-split ordinary share. The reverse stock split affected all shareholders
uniformly and did not alter any shareholder&#8217;s percentage interest in the Company&#8217;s ordinary shares, except for adjustments
that may result from the treatment of fractional shares. All outstanding options and warrants entitling their holders to purchase the
Company&#8217;s ordinary shares were adjusted as a result of the reverse stock split, in accordance with the terms of each such security.
In addition, the number of ordinary shares reserved for future issuance pursuant to the Company&#8217;s equity incentive plans were also
appropriately adjusted. The number of authorized ordinary shares was not proportionately reduced because the Company has an unlimited
number of authorized ordinary shares available for issuance, as permitted under the laws of the British Virgin Islands.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">All share and per share information
included in the condensed consolidated interim financial statements have been retroactively adjusted to reflect the impact of the reverse
stock split as if the stock split occurred at the beginning of the periods presented. The shares of ordinary shares authorized remained
at an unlimited number of ordinary shares without par value.</p>
<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>






















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureNatureOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureNatureOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NatureOfOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NatureOfOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887275104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoingConcernExplanatory', window );">GOING CONCERN</a></td>
<td class="text"><p id="xdx_808_eifrs-full--DisclosureOfGoingConcernExplanatory_zhrrssrqEuh8" style="margin: 0; font-size: 10pt"><b>NOTE 2. <span id="xdx_828_zGZQ0eWndc82">GOING CONCERN</span></b></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As of September 30, 2024, the Company had cash and cash
equivalents of approximately $<span id="xdx_90A_eifrs-full--Cash_iI_pn5n6_c20240930_zZB5ujfHhFxb">1.8
</span>million and total current liabilities of approximately $<span id="xdx_906_ecustom--TotalCurrentLiabilities_iI_pn5n6_c20240930_zdtpdfN5W0Dg" title="Total current liabilities">0.9
</span>million. For the six months ended September 30, 2024, the Company is reporting a net loss of approximately $<span id="xdx_907_ecustom--NetLossIncome_pn6n6_c20240401__20240930_ztJx0YCAe7M" title="Net loss">3</span>.0
million, and cash used in operating activities of approximately $<span id="xdx_90D_ecustom--CashUsedInOperatingActivities_pn5n6_c20240401__20240930_zqHk0zQFjwf1" title="Cash used in operating activities">3.3
</span>million. As of November 25, 2024, the Company had approximately $<span id="xdx_901_eifrs-full--CashOnHand_iI_pn5n6_c20241125_zGLAOvpN5gtj" title="Cash and cash equivalents on hand">1.7
</span>million of cash and cash equivalents on hand.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s cash and cash equivalents balance
is decreasing, and the Company did not generate positive cash flows from operations for the six months ended September 30, 2024 and fiscal
year ended March 31, 2024 (&#8220;Fiscal 2024&#8221;).</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">In late Fiscal 2024, because of continued liquidity
constraints, the Company made the decision to discontinue further clinical development of its iNKT sponsored trial and pause further
patient accrual to its sponsored adenosine program for both PORT-6 and PORT-7. The Company is exploring strategic alternatives,
which may include finding a partner for one or more of its assets, a sale of our company, a merger, restructurings, both in and out
of court, company wind down, further financing efforts or other strategic action. These factors raise significant doubt about the
Company&#8217;s ability to continue as a going concern within one year after the date of the condensed consolidated interim
statement of financial position.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company has incurred significant operating losses
since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable.
The losses result primarily from its conduct of research and development activities. As previously discussed, the Company has discontinued
its iNKT sponsored trial and paused further patient accrual to the Company sponsored adenosine program in order to preserve cash resources.
Additionally, during the fourth quarter of Fiscal 2024, the Company sold its shares in Intensity on Nasdaq.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company historically has funded its operations principally
from proceeds from issuances of equity and debt securities. The Company will require significant additional capital to make the investments
it needs to execute its longer-term business plan, beyond the potential proceeds that could be reasonably generated from its &#8220;at-the-market&#8221;
(&#8220;ATM&#8221;) program and Committed Purchase Agreement (as defined below) with Lincoln Park Capital Fund, LLC (&#8220;Lincoln&#8221;)
given the Company&#8217;s current trading volume on Nasdaq. The Company&#8217;s ability to successfully raise sufficient funds through
the sale of debt or equity securities when needed is subject to many risks and uncertainties and, future equity issuances would result
in dilution to existing shareholders and any future debt securities may contain covenants that limit the Company's operations or ability
to enter into certain transactions. See Note 9, &#8220;Capital Stock and Reserves,&#8221; for a further discussion.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">There can be no assurance that the Company&#8217;s evaluation
of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be
successful or on attractive terms. Any potential transaction would be dependent on a number of factors that may be beyond the Company&#8217;s
control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction
with the Company and the availability of financing to the Company or third parties in a potential transaction with the Company on reasonable
terms. The process of reviewing strategic alternatives may require the Company to incur additional costs and expenses. It could negatively
impact the Company&#8217;s ability to attract, retain and motivate key employees, and expose the Company to potential litigation in connection
with this process or any resulting transaction. If the Company is unable to effectively manage the process, the Company&#8217;s financial
condition and results of operations could be adversely affected. In addition, any strategic alternative that may be pursued and completed
ultimately may not deliver the anticipated benefits or enhance shareholder value. There can be no guarantee that the process of evaluating
strategic alternatives will result in the Company entering into or completing a potential transaction within the anticipated timing or
at all. There is no set timetable for this evaluation and the Company does not intend to disclose developments with respect to this evaluation
unless and until the Company determines that further disclosure is appropriate or legally required. As of November 25, 2024, the Company
had approximately $<span id="xdx_901_eifrs-full--CashOnHand_iI_pn5n6_c20241125_zGg95JAYe3f6" title="Cash and cash equivalents on hand">1.7</span> million of cash and cash equivalents on hand, which the Company expects is only sufficient to cover its operating
needs through January 2025. These factors raise substantial doubt about the Company&#8217;s ability to continue as a going concern within
one year after the date of the condensed consolidated interim statement of financial position. There were no adjustments made to reflect
the effect of this doubt.</p>

<p style="margin: 0; font-size: 10pt"><b></b></p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>
















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoingConcernExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoingConcernExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886845072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p id="xdx_80D_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zWrQ2fFpRgRj" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 3. <span id="xdx_82C_zEKCtndpCue">BASIS OF PRESENTATION</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Statement of Compliance and Basis of Presentation</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">These condensed consolidated interim financial statements
have been prepared in accordance with the International Financial Reporting Standards (&#8220;IFRS&#8221;) issued by the International
Accounting Standards Board (&#8220;IASB&#8221;), International Accounting Standards (&#8220;IAS&#8221;) 34 <i>Interim Financial Reporting</i>
and interpretations of the International Financial Reporting Interpretations Committee. These condensed consolidated interim financial
statements do not include all of the information required for full annual financial statements and should be read in conjunction with
the audited consolidated financial statements of the Company for the year ended March 31, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">These condensed consolidated interim financial statements
have been prepared on an historical cost basis except for items disclosed herein at fair value (see Note 14, &#8220;Financial Instruments
and Risk Management&#8221;). In addition, these condensed consolidated interim financial statements have been prepared using the accrual
basis of accounting, except for cash flow information.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company has only one reportable operating segment.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">These condensed consolidated interim financial statements
were approved and authorized for issuance by the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board on November 26<span style="font-size: 10pt"></span>,
2024.</p>

<p style="margin: 0; font-size: 10pt"></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Consolidation</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The consolidated financial statements include the accounts
of the Company and:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td style="text-align: justify">SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td style="text-align: justify">iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company,
through SalvaRx, exchanged certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing <span id="xdx_902_ecustom--PercentageOfOutstandingShares_pip0_dp_c20210901__20210930_z3jGGTP0zKH6" title="Percentage of outstanding shares">17.83</span>%
of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from <span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zkvoRLUhY2me" title="Percentage of ownership subsidiary">60.49</span>%
to <span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_z2LJjqTSDy73" title="Percentage of ownership subsidiary">78.32</span>%. On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. The Company&#8217;s 44% interest in
Stimunity S.A. (&#8220;Stimunity&#8221;) was transferred from Portage to iOx in December 2023 and was increased to 48.9% upon the conversion
of the convertible note to equity;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(c)</td><td style="text-align: justify">Saugatuck, a <span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20240401__20240930__ifrs-full--SegmentsAxis__custom--CountryOfBritishVirginIslandsMember_zM93r3Py7XJ7" title="Percentage of ownership subsidiary">70</span>% owned subsidiary incorporated in the British Virgin Islands;</td></tr></table>

<p style="margin: 0 0 0 0.5in; font-size: 10pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(d)</td><td style="text-align: justify">Tarus Therapeutic Holdings Ltd., a wholly-owned subsidiary incorporated in the British Virgin Islands;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(e)</td><td style="text-align: justify">PDS, a <span id="xdx_904_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20240401__20240930__ifrs-full--SegmentsAxis__custom--CountryOfDelawareMember_zyTeJulxTnie" title="Percentage of ownership subsidiary">100</span>% owned subsidiary incorporated in Delaware, which provides human resources, and other services
to each operating subsidiary via a shared services agreement;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(f)</td><td style="text-align: justify">SalvaRx LLC, a wholly-owned subsidiary through SalvaRx incorporated in Delaware;</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(g)</td><td style="text-align: justify">Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck incorporated in Delaware; and</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(h)</td><td style="text-align: justify">Tarus Therapeutics, LLC (&#8220;Tarus&#8221;), a wholly-owned subsidiary of Portage incorporated in Delaware.</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">All inter-company balances and transactions have been
eliminated in consolidation.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Non-controlling interest in the equity of a subsidiary
is accounted for and reported as a component of shareholders&#8217; equity. As of September 30, 2024 and March 31, 2024, non-controlling
interest represents the <span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4CVFbjn51Ri" title="Non-controlling interest"><span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zaIaAAHFedtl" title="Non-controlling interest">30</span></span>% shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>



<p style="margin: 0; font-size: 10pt; text-align: justify"></p>














<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Functional and Presentation Currency</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s functional and presentation currency
is the U.S. Dollar.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Use of Estimates and Judgments</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The preparation of the condensed consolidated interim
financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application
of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Estimates and underlying assumptions are reviewed on
an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future
periods affected.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Significant areas where estimates are
made include valuation of financial instruments, deferred tax assets and liabilities, warrant liabilities, research and development costs,
contingent consideration assumed and measurement of share-based compensation. Significant areas where critical judgments are applied include
in-process research and development and warrant liabilities.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Reclassifications</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Certain prior year amounts between
accounts payable and accrued liabilities have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>
















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887390912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_805_ecustom--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_z1D0ZVDdE39c" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 4.</b>&#160; <b><span id="xdx_823_zMSJ5cvJNbh6">SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The accounting policies are set out in Note 4 to the
Company&#8217;s audited consolidated financial statements for Fiscal 2024. These policies have been applied consistently to all periods
presented in these condensed consolidated interim financial statements.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zKaYTrbq7im9" style="margin: 0; font-size: 10pt; text-align: justify"><b><span id="xdx_864_zMXSuqmHhCh8">Recent Accounting Pronouncements</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>IFRS Pronouncements Issued</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Impact of Adoption of Significant New IFRS Standards in Fiscal 2025</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>



<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 23.05pt"><b>(a)</b></td><td style="text-align: justify"><b>Amendments to IAS 1: Non-current Liabilities with Covenants</b></td></tr></table>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The amendments to IAS 1, &#8220;Presentation of Financial
Statements,&#8221; clarify how conditions with which an entity must comply within twelve months after the reporting period affect the
classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these
conditions.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The amendments to IFRS 16 and IAS 1 were effective for
annual periods beginning on or after January 1, 2024. The adoption of these amendments did not have a material effect on the Company&#8217;s
annual consolidated financial statements or the condensed consolidated interim financial statements for the three and six months ended
September 30, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 23.05pt"><b>(b)</b></td><td style="text-align: justify"><b>Amendments to IAS 7 and IFRS 7: Supplier Finance</b></td></tr></table>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The amendments to IAS 7 and IFRS 7, &#8220;Statement
of Cash Flows,&#8221; require disclosures to enhance the transparency of supplier finance arrangements and their effects on an entity&#8217;s
liabilities, cash flows and exposure to liquidity risk. The amendments to IAS 7 and IFRS 7 were effective for annual periods beginning
on or after January 1, 2024 (with transitional reliefs in the first year). The adoption of these amendments did not have a material effect
on the Company&#8217;s annual consolidated financial statements or the condensed consolidated interim financial statements for the three
and six months ended September 30, 2024.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0; font-size: 10pt; text-align: justify"><b>New Accounting Standards, Interpretations and Amendments</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Standards issued but not yet effective up to the date
of issuance of the Company&#8217;s condensed consolidated interim financial statements is listed below. This is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes
effective.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Amendments to IAS 21 &#8211; Lack of Exchangeability</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">An entity is impacted by the amendments to IAS 21, &#8220;The
Effects of Changes in Foreign Exchange Rates,&#8221; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The Company is evaluating whether the adoption of the amendments to IAS 21 would have a material effect
on the Company&#8217;s annual consolidated financial statements or its condensed consolidated interim financial statements.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887267088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory', window );">PREPAID EXPENSES AND OTHER RECEIVABLES</a></td>
<td class="text"><p id="xdx_804_ecustom--DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory_zguFcxKP0HM2" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 5. <span id="xdx_822_zSnXhVx0Zcsj">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">At September 30, 2024 and March 31, 2024, prepaid expenses
and other receivables were comprised of the following (in thousands):</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z0jPJYwGU6vd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zpQkJ8fMrDwd" style="display: none">Schedule of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20240930_zzEU0woN1Sx6" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20240331_zdxu0LM7fXZf" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_maCPzKMQ_zzk7XYFBfK4b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left">Prepaid clinical research costs</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,924</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CurrentReceivablesFromRentalOfProperties_iI_maCPzKMQ_zJRDfyKZ9e1e" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Refund from Parexel</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">552</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzKMQ_zku20B74vfyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid insurance</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">249</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">575</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--TaxDeposits_iI_maCPzKMQ_zntCDP3FnKKk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax deposits</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">63</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzKMQ_zRUK8u0x0R9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other prepaid expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">26</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">65</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzKMQ_zLhyFgKfzFP1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">18</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">39</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SecurityDepositOnOfficeLease_iI_pn3n3_maCPzKMQ_zJHqSHVHSNb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Security deposit on office lease expiring in May 2025</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">14</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzKMQ_zYSZF37e1hja" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">922</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,667</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The decrease in prepaid expenses and other receivables
<span style="background-color: white">from $<span id="xdx_906_ecustom--PrepaidExpensesAndOtherReceivablesNoncurrent_iI_pn5n6_c20240331__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_zuLd0xoFWpIa" title="Prepaid expenses and other receivables">2.7</span> million as of March 31, 2024 to $<span id="xdx_904_ecustom--PrepaidExpensesAndOtherReceivablesNoncurrent_iI_pn5n6_c20240930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_zmG51KSG5s5h" title="Prepaid expenses and other receivables">0.9</span> million as of September 30, 2024 </span>is primarily
attributable to periodic amortization of prepaid clinical research costs and insurance premiums and the write-off of $<span id="xdx_905_ecustom--WriteoffOfAdvances_iI_pn5n6_c20240930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_z33LJpUCH5n5" title="Write-off of advances">1.1</span> million of advances
to Parexel <span style="color: #212529; background-color: white">International (IRL) Limited (&#8220;Parexel&#8221;)</span>, partially
offset by a $<span id="xdx_903_ecustom--RefundReceivables_iI_pn5n6_c20240930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_zNn9ilJYcPE2" title="Refund receivables">0.6</span> million refund receivable from Paraxel as of September 30, 2024. Refer to the &#8220;iOx &#8211; Parexel Master Services
Agreement&#8221; section of Note 12, &#8220;Commitments and Contingent Liabilities&#8221; for further discussion regarding this matter.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>



















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988889020672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureWarrantLiabilityAbstract', window );"><strong>Warrant Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantLiabilityTextBlock', window );">WARRANT LIABILITY</a></td>
<td class="text"><p id="xdx_80B_ecustom--WarrantLiabilityTextBlock_zP3234WjSSre" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 6. <span id="xdx_826_zKWV27FunZtf">WARRANT LIABILITY</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On August 15, 2024, the Company effected
a reverse stock split of its ordinary shares at a ratio of 1-for-20. The number of warrants and exercise price information herein have
been retroactively adjusted to reflect the impact of the reverse stock split. See Note 1 &#8220;Nature of Operations&#8221; and Note 9,
&#8220;Capital Stock and Reserves&#8221; for further discussion on the reverse stock split.</p>

<p style="margin: 0pt 0 0pt 26.7pt; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following table summarizes the changes in the warrant
liability during the three and six months ended September 30, 2024:</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zwLAxhHXwtPd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BC_zXWGbAfywazb" style="display: none">Schedule of changes in the warrant
liability</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Warrants</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value Balance</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Warrant liability as of April 1, 2023</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--WarrantLiabilityExercisePrice_iI_pip0_c20230331_zR8JQdLDTJE6" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability exercise price"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_ecustom--WarrantsLiabilityShares_iS_pip0_c20230401__20240331_z2Pq7GJJQzp4" title="Warrants liability, shares at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0669">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20230401__20240331_z4pZHKZA9HW2" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, fair value at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold">Fair value of warrants at issuance on October 3, 2023:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 61%; font-size: 10pt; font-weight: bold; text-align: left">Class B Warrants</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zSmJyE5hKpw1" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price">45.20</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zZN73Kn7CPZf" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares">157,895</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zrfqAQ46ti9k" title="Fair value of warrants amount">3,537</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Class C Warrants</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zznyU7KV5Fqc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price">45.20</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_z0lkrOfzaO8j" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares">157,895</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zlWO6Pqg7OG9" title="Fair value of warrants amount">4,663</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Placement Agent Warrants</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMBu6zY15JVh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price">47.50</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw6ax8GTFgHa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares">7,896</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_znbVJV9Zf6qc" title="Fair value of warrants amount">232</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b><span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20230401__20240331_zvJwJGOMsKQl" title="Change in fair value of warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0691">&#8211;</span></span></b></span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_ziR3u6w2Has9" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount">(6,868</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Warrant liability as of March 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><b style="display: none">&#8211;</b></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20240630_zUGjw8zX5Eoc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at beginning">323,686</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20240630_zZfOIdB69ecb" title="Warrants liability, fair value at beginning">1,564</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--ChangeInFairValueOfWarrantLiability_c20240401__20240630_zDW06zxkz7Cg" title="Change in fair value of warrant liability, shares"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20240630_zDVOnoY49hl4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount">(1,142</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Warrant liability as of June 30, 2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability exercise price">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WarrantsLiabilityShares_iS_pip0_c20240701__20240930_zlmlvAwiTZu" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at beginning">323,686</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"><span id="xdx_903_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240701__20240930_zEk1ELkUSKIh" title="Warrants liability, fair value at beginning">422</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability exercise price">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20240701__20240930_zTjtO1x8Yx34" title="Change in fair value of warrant liability, shares"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240701__20240930_zh6K6ejO8LFc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount">716</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrant liability as of September 30, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><b style="display: none">&#8211;</b></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantsLiabilityShares_iE_pip0_c20240701__20240930_zf2cT80Wi85i" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at ending">323,686</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20240401__20240930_zksU6cTyeeUk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, fair value at ending">1,138</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zD5WVRGnzKJ3" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On September 29, 2023, the Company entered into a securities
purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional and accredited investor in connection with a registered
direct offering (the &#8220;the Registered Direct Offering&#8221;) and a concurrent private placement (the &#8220;Private Placement&#8221;)
and together with the Registered Direct Offering, the &#8220;Offerings&#8221;). The Offerings closed on October 3, 2023.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Pursuant to the Purchase Agreement, in the Registered
Direct Offering, the Company sold (i) <span id="xdx_905_ecustom--OrdinaryNumberOfStockSold_pip0_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember_zpdKRLglN3xd" title="Number of stock sold">98,500</span> shares of the Company&#8217;s ordinary shares at a purchase price of $<span id="xdx_907_ecustom--PurchasePriceOfPerShare_pip0_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember_znPswoVGxSOd" title="Purchase price of per share">38.00</span> per share and
(ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <span id="xdx_90E_ecustom--PurchaseWarrants_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zxUUrqu08mm7" title="Purchase ordinary shares">59,395</span> ordinary shares, at a purchase price of $<span id="xdx_905_ecustom--PurchasePriceOfPerShare_pip0_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zmJvp56kFvsi" title="Purchase price of per share">37.98</span>
per Pre-Funded Warrant. All Pre-Funded Warrants, which were exercisable for one ordinary share at an exercise price of $<span id="xdx_904_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_z3Vq45dso3me" title="Exercise price">0.02</span> per share,
were exercised in full on May 29, 2024.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">In the Private Placement, the Company issued to such
institutional and accredited investor unregistered warrants to purchase up to <span id="xdx_904_ecustom--OrdinarySharesPurchase_pip0_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zVBxxJfTju7e" title="Ordinary shares purchase">157,895</span> ordinary shares (the &#8220;Series A Warrants&#8221;),
unregistered warrants to purchase up to <span id="xdx_909_ecustom--OrdinarySharesPurchase_pip0_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zN9z4HPJKg54" title="Ordinary shares purchase">157,895</span> ordinary shares (the &#8220;Series B Warrants&#8221;), and unregistered warrants to purchase
up to <span id="xdx_909_ecustom--OrdinarySharesPurchase_pip0_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zFDAjV7yrEWa" title="Ordinary shares purchase">157,895</span> ordinary shares (the &#8220;Series C Warrants,&#8221; together with the Series A Warrants and the Series B Warrants, the
&#8220;Private Warrants&#8221;), together exercisable for an aggregate of up to 473,685 ordinary shares (the &#8220;Private Warrant Shares&#8221;).
Pursuant to the terms of the Purchase Agreement, for each ordinary share and Pre-Funded Warrant issued in the Registered Direct Offering,
an accompanying Series A Warrant, Series B Warrant and Series C Warrant were issued to such institutional and accredited investor. Each
Series A Warrant is exercisable for one Private Warrant Share at an exercise price of $<span id="xdx_90E_ecustom--ExercisePriceOfOutstandingWarrant_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zNYddc7uzvB7" title="Exercise price">38.00</span> per share, is immediately exercisable and
will expire 18 months from the date of issuance. Each Series B Warrant is exercisable for one Private Warrant Share at an exercise price
of $<span id="xdx_902_ecustom--ExercisePriceOfOutstandingWarrant_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zkft17r0YC3" title="Exercise price">45.20</span> per share, is immediately exercisable and will expire three years from the date of issuance. Each Series C Warrant is exercisable
for one Private Warrant Share at an exercise price of $<span id="xdx_90D_ecustom--ExercisePriceOfOutstandingWarrant_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zYNNQjPqLqh2" title="Exercise price">45.20</span> per share, is immediately exercisable and will expire five years from the
date of issuance. The net proceeds to the Company from the Offerings were approximately $<span id="xdx_905_eifrs-full--ProceedsFromIssuingShares_pn5n6_c20240401__20240930_zUlWBPmonRe" title="Net proceeds warrants">5.3</span> million, after deducting placement agent&#8217;s
fees and estimated offering expenses of approximately $<span id="xdx_903_eifrs-full--ProfessionalFeesExpense_pn5n6_c20240401__20240930_zhQcuCpYQjQ9" title="Estimated offering expenses">0.7</span> million.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Pursuant to an engagement letter, dated as of August
26, 2023, between the Company and H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;), the Company paid the Placement Agent
a total cash fee equal to <span id="xdx_909_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pip0_dp_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zvIxA30N6SP2" title="Interest rate">6.0</span>% of the aggregate gross proceeds received in the Offerings, or $<span id="xdx_901_ecustom--AggregateGrossProceeds_iI_pn4n6_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zvIahjQjvEdd" title="Aggregate gross proceeds">0.36</span> million. The Company also paid the
Placement Agent in connection with the Offerings a management fee equal to <span id="xdx_908_ecustom--ManagementFeePercentage_iI_pip0_dp_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zPv7Ahyo4DEj" title="Management fee percentage">1.0</span>% of the aggregate gross proceeds raised in the Offerings
($<span id="xdx_903_ecustom--AggregateGrossProceedsIncrease_iI_pn4n6_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zQE0hB2Tpb6b" title="Aggregate gross proceeds increase">0.06</span> million), $<span id="xdx_904_eifrs-full--AdministrativeExpense_pp0p0_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zGtei3LASj6a" title="Non-accountable expenses">75,000</span> for non-accountable expenses and $<span id="xdx_906_eifrs-full--FeeAndCommissionExpense_pp0p0_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_z8Nc31kqmmd5" title="Clearing fees">15,950</span> for clearing fees. In addition, the Company issued to the Placement
Agent, or its designees, warrants to purchase up to <span id="xdx_90D_ecustom--PurchaseOfWarrants_pip0_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zl1DS9IdLlF7" title="Purchase warrants">7,896</span> ordinary shares (the &#8220;Placement Agent Warrants,&#8221; and together with
the Pre-Funded Warrants and the Private Warrants, the &#8220;Warrants&#8221;), which represented <span id="xdx_90B_ecustom--SaleOfWarrantPercentage_iI_pip0_dp_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zs5qq6BDiy42" title="Sale of warrant percentage">5.0</span>% of the aggregate number of ordinary
shares and Pre-Funded Warrants sold in the Registered Direct Offering. The Placement Agent Warrants have substantially the same terms
as the Series B Warrants and the Series C Warrants, except that the Placement Agent Warrants have an exercise price equal to $<span id="xdx_905_ecustom--ExercisePriceWarrantPerShare_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zv3QADJWK9T4" title="Exercise price warrant per share">47.50</span>, or
125% of the offering price per ordinary share sold in the Registered Direct Offering and will be exercisable for five years from the commencement
of the sales pursuant to the Offerings. The Private Warrants, Private Warrant Shares, Placement Agent Warrants and ordinary shares underlying
the Placement Agent Warrants were registered for resale under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)
pursuant to a registration statement on Form F-1 that was declared effective by the SEC on November 7, 2023 (the &#8220;Resale Registration
Statement&#8221;).</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Series B Warrants, the Series C Warrants and the
Placement Agent Warrants include the obligation, in the event of a Fundamental Transaction, as defined in the Series B Warrants, the Series
C Warrants and the Placement Agent Warrants, for the Company or the successor entity to purchase the warrants from the holder at the discretion
of the holder and at the Black-Scholes value, as defined in the warrant agreements. As a result, management concluded that, in line with
IAS 9, &#8220;Financial Instruments&#8221; and IAS 32, &#8220;Financial Instruments: Presentation,&#8221; such warrants will be accounted
for as financial liabilities on the condensed consolidated interim statement of financial position with the changes in fair value recognized
in the condensed consolidated interim statement of operations and other comprehensive income (loss). The Company allocated the net proceeds
of $<span id="xdx_906_ecustom--NetProceedsWarrantLiability_iI_pn5n6_c20240930_z8vpMxqyudA8" title="Net proceeds warrant liability">5.3</span> million for the Registered Direct Offering to the warrant liability and recognized the excess of the fair value of the warrant
liabilities at inception of $<span id="xdx_90C_eifrs-full--IncreaseDecreaseInFairValueMeasurementLiabilities_pn5n6_c20240401__20240930_zR1EVBlH8jd3" title="Excess of the fair value of the warrant liabilities">3.1</span> million as a loss on the Registered Direct Offering of $<span id="xdx_903_ecustom--LossOnWarrantLiabilities_iI_pn5n6_c20240930_z9G45oNC0Ntf" title="Loss on warrant liabilities">2.4</span> million and offering expenses of $<span id="xdx_903_ecustom--OfferingExpenses_iI_pn5n6_c20240930_zG5ZGJiEQa5l" title="Offering expenses">0.7</span> million.
The Company also recorded a loss of $<span id="xdx_904_ecustom--ChangeInFairValueOfWarrantLiabilities_pn5n6_di_c20240701__20240930_zg9yKQjDxfm5" title="Gain (loss) in the fair value of the warrant liabilities">0.7</span> million and a gain of $<span id="xdx_909_ecustom--ChangeInFairValueOfWarrantLiabilities_pn5n6_c20240401__20240930_zHY7z150roQb" title="Gain (loss) in the fair value of the warrant liabilities">0.4</span> million from the change in the fair value of the warrant liabilities
for the three and six months ended September 30, 2024, respectively, resulting in a warrant liability balance of $<span id="xdx_908_ecustom--WarrantLiabilityBalance_iI_pn5n6_c20240930_zcsWGGnhrep4" title="Warrant liability balance">1.1</span> million at September
30, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company filed the Resale Registration Statement to
register for the resale of the Private Warrant Shares and the ordinary shares issuable upon the exercise of the Placement Agent Warrants,
which was declared effective by the SEC on November 7, 2023. Pursuant to the terms of the Purchase Agreement, the Company is obligated
to use its commercially reasonable efforts to keep the Resale Registration Statement effective at all times until such institutional and
accredited investor (and its successors and assigns) no longer owns any Private Warrants or ordinary shares issuable upon exercise thereof.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On May 29, 2024, Armistice Capital Master Fund Ltd. exercised
its Pre-Funded Warrants at an exercise price of $<span id="xdx_908_ecustom--ExercisePrice_c20240528__20240529__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zbLgFRaPDsBj" title="Warrants exercise price">0.02</span> per share increasing the Company&#8217;s total shares outstanding to <span id="xdx_902_eifrs-full--NumberOfSharesOutstanding_iI_pip0_c20240529__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zbvt7TxVkKPc" title="Total shares outstanding">1,048,765</span>.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The accounting for the Series A Warrants and the Pre-Funded
Warrants is detailed below in Note 9, &#8220;Capital Stock and Reserves.&#8221;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Series B Warrants</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">A fair value of
$<span id="xdx_90D_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zkWQFTq02GUe" title="Fair value of warrant per share">22.40</span> per each Series B Warrant was identified at the issue date of October 3, 2023. A fair value of $<span id="xdx_903_ecustom--FairValueOfWarrantPerShare_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zDDzBoB8w0w" title="Fair value of warrant per share">3.05</span> per each warrant has been
identified as of September 30, 2024.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">The inputs associated
with calculating the fair value are reflected below.</span></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEkrm5UZJBGe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BD_zREPodEHY8ti" style="display: none">Schedule of fair value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90D_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zZTmCC7cclRi" title="Exercise price">45.20</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJ19voToTy92" title="Exercise price">45.20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zt6hxDAGNJv9" title="Share price">39.40</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJBVKTZ9m2e5" title="Share price">6.65</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z84uGXOtPsna" title="Expected life">3.01</span> years</b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z4gqsqiIR7S9" title="Expected life">2.01</span> years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zT5LiGEXS3T6" title="Expected volatility">90.4</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zHsOvAIO55m3" title="Expected volatility">159.22</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zoT9D9Wc3gF4" title="Risk free interest rate">4.95</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrBMzoUezxPj" title="Risk free interest rate">3.66</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z04kXw66MSIk" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zP1oUWszKJwc" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0821">&#8211;</span></span></td></tr>
  </table>

<p id="xdx_8A6_zeA6l8wF3ev1" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Series C Warrants</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">A fair value of
$<span id="xdx_909_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zHyusLZVIfCl" title="Fair value of warrant per share">29.60</span> per each Series C Warrant was identified at the issue date of October 3, 2023. A fair value of $<span id="xdx_902_ecustom--FairValueOfWarrantPerShare_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zZgoxflsyTHf" title="Fair value of warrant per share">3.91</span> per each warrant has been
identified as of September 30, 2024.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">The inputs associated
with calculating the fair value are reflected below.</span></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zNo8g7HfVAx" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  WARRANT LIABILITY (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BE_z5i9uOgWjsI7" style="display: none">Schedule of fair value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z3J6gnWUkU4f" title="Exercise price">45.20</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zsCGSLy6od" title="Exercise price">45.20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90F_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4NWSvRDipa5" title="Share price">39.40</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zoSDcNdfzyrc" title="Share price">6.65</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zffuAbj4Gna4" title="Expected life">5.00</span> years</b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zR2vvuZGlCek" title="Expected life">4.01</span> years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_905_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7sKqapVVSzf" title="Expected volatility">100.7</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4bXOJnQUMn4" title="Expected volatility">129.26</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zi1Ht5zQ8sg8" title="Risk free interest rate">4.80</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_903_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zxeevLgY5d83" title="Risk free interest rate">3.58</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zw0kH9IKVOXk" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0849">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zIS5SgmE9Kth" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8211;</span></span></td></tr>
  </table>

<p id="xdx_8AF_z8iBtJ6ERVXi" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Placement Agent Warrants</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">A fair value of
$<span id="xdx_905_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zWHqKMbmVl39" title="Fair value of warrant per share">29.40</span> per each Placement Agent Warrant was identified at the issue date of October 3, 2023. A fair value of $<span id="xdx_906_ecustom--FairValueOfWarrantPerShare_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zFPY4u3vSlUj" title="Fair value of warrant per share">3.86</span> per each warrant has
been identified as of September 30, 2024.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">The inputs associated
with calculating the fair value are reflected below.</span></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNqJsTXTy39d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B6_zizEuT02aYM2" style="display: none">Schedule of fair value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90A_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcEOVuZQcbE9" title="Exercise price">47.60</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHmGOB1v5pgi" title="Exercise price">47.50</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_901_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGzHzT9ujqM8" title="Share price">39.40</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z7MOsQV6Uzx4" title="Share price">6.65</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zAO26TCEDHFe" title="Expected life">4.99</span> years</b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9gSMGkD40b" title="Expected life">4.01</span> years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zFEYBL2WEmq7" title="Expected volatility">100.7</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKmBRjn0xTG7" title="Expected volatility">129.26</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90C_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNXdKGvaccSl" title="Risk free interest rate">4.80</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zo9o1tyDYZMe" title="Risk free interest rate">3.58</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_906_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zfPd7mIQxc12" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0879">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z45tug4uPhn6" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8211;</span></span></td></tr>
  </table>


<p style="margin: 0; font-size: 10pt">&#160;</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureWarrantLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureWarrantLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887710320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract', window );"><strong>Accounts Payable And Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</a></td>
<td class="text"><p id="xdx_80B_ecustom--AccountsPayableAndAccruedLiabilitiesTextBlock_zrKjZ7frTjSj" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 7.&#160; <span id="xdx_826_z5qymSj23Dc8">ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">At September 30, 2024 and March 31, 2024, accounts payable
and accrued liabilities were comprised of the following (in thousands):</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_ztM36cLVhTV3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span><span id="xdx_8BF_zIgoWOD3J5p8" style="display: none">Schedule of accounts payable and accrued liabilities</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20240930_zwsLYUqXcj0b" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20240331_zEoKifOeHuyk" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr id="xdx_409_ecustom--AccountsPayableAndAmountsAccruedToCro_iI_zGrnUPIAEMl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and amounts accrued to CRO</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">49</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,413</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_zU2Hkru1iIgb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued bonuses and other payroll-related expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">371</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">525</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zaFtbYZIToK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued accounting and auditing fees</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">127</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">189</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedLegalFees_iI_zSo5RglA1PIh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued legal fees</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">54</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">194</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedOtherProfessionalFees_iI_z9yIRqvCxyjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued other professional fees</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">33</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">157</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--OtherAccountsPayable_iI_zUfZuBt5BYoc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other accounts payable</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">172</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">136</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedClinicalAndRdServices_iI_zWuKHzGuHyRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued clinical and R&amp;D services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">179</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OtherAccruedExpenses_iI_pn3n3_zbcoTDtytPE" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">36</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">43</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_pn3n3_zO9lOvxYHt3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">845</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,836</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The decrease in <span style="background-color: white">accounts
payable and accrued liabilities from $<span id="xdx_907_eifrs-full--OtherPayables_iI_pn5n6_c20240331_zDMnyuOpAtBj" title="Accounts payable and accrued liabilities">2.8</span> million as of March 31, 2024 to $<span id="xdx_905_eifrs-full--OtherPayables_iI_pn5n6_c20240930_zJSurSXSL56g" title="Accounts payable and accrued liabilities">0.8</span> million as of September 30, 2024 is primarily attributable
to the write-off of $<span id="xdx_907_eifrs-full--DecreaseThroughWriteoffFinancialAssets_pn3n6_c20240401__20240930_zRa7xwbQvYq5" title="Accounts payable and accrued liabilities write-off">1.486</span> million in connection with the settlement with Parexel. </span>Refer to the &#8220;iOx &#8211; Parexel Master
Services Agreement&#8221; section of Note 12, &#8220;Commitments and Contingent Liabilities&#8221; for further discussion regarding this
matter.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887486224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80A_eifrs-full--DisclosureOfIncomeTaxExplanatory_zakDMfsPx0ti" style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b>NOTE 8. <span id="xdx_825_zkwSv8g53iMj">INCOME TAXES</span></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company is a BVI business company. The BVI government
does not, under existing legislation, impose any income or corporate tax on corporations.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">PDS is a U.S. corporation and is subject to U.S. federal,
state and local income taxes, as applicable.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">iOx is subject to U.K. taxes.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following is a reconciliation of the U.S. taxes to
the effective income tax rates for the six months ended September 30, 2024 and 2023 (in thousands, except percentages):</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z9rHamzxYfn7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B2_zGEeeJFpITia" style="display: none">Schedule of effective income tax rates</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20240401__20240930_zHJnklBFtjE9" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20230401__20230930_zMcz3nbMzRJi" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_iN_di_znGvqV0P44Zk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Loss before income taxes</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%">3,024</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">12,143</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncomeTaxExpenseContinuingOperation_iN_di_zLFaFRaXIb27" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income tax benefit</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,052</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_zVO4lrL8mbV1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Effective tax rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">0.10</td><td style="font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">8.66</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s effective tax rates were <span id="xdx_90F_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_c20240401__20240930_zYtaw09zcZ35">0.10</span>% and
<span id="xdx_900_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_c20230401__20230930_zTtntrt8wp5g">8.66</span>% for the six months ended September 30, 2024 and 2023, respectively. The decrease in the effective tax rate was primarily due to
a change in the mix of income and losses in the various tax jurisdiction in which the Company operates.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886751248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND RESERVES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureCapitalStockAndReservesAbstract', window );"><strong>Capital Stock And Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CapitalStockAndReservesTextBlock', window );">CAPITAL STOCK AND RESERVES</a></td>
<td class="text"><p id="xdx_805_ecustom--CapitalStockAndReservesTextBlock_z6hY6CoqtJv7" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 9. <span id="xdx_825_zZF4TiVfWu9k">CAPITAL STOCK AND RESERVES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Authorized ordinary shares<b>: </b>Unlimited number of
Portage ordinary shares without par value.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. The reverse stock split decreased the number of ordinary shares
outstanding as of September 30, 2023, from <span id="xdx_90C_ecustom--NumberOfOrdinarySharesOutstandingDecrease_c20230401__20230930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zDavpgghJ9hc" title="Number of ordinary shares outstanding, decrease">17,808,225</span>
to <span id="xdx_900_ecustom--NumberOfOrdinarySharesOutstandingDecrease_c20230401__20230930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zY7parI27pqc" title="Number of ordinary shares outstanding, decrease">890,412</span>.
All share and per share information included in the condensed consolidated interim financial statements and in the Notes to the
condensed consolidated interim financial statements have been retroactively adjusted to reflect the impact of the reverse stock
split unless otherwise noted. The number of ordinary shares authorized remained at an unlimited number of common shares without par value.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Any fractional shares resulting from the reverse
stock split were rounded up to the nearest whole post-split ordinary share. As a result of this round up provision, the Company
issued an additional 52,254 shares.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0pt 5.6pt 0pt 8.25pt; font-size: 10pt; text-align: justify; text-indent: 18.4pt">Portage filed a shelf registration
statement with the SEC in order to sell ordinary shares, debt securities, warrants and units in one or more offerings from time to time,
which became effective on March 8, 2021 (&#8220;March 2021 Registration Statement&#8221;). In connection with the March 2021 Registration
Statement, Portage has filed with the SEC:</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"></td><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a base prospectus, which covered the offering, issuance and sale by Portage of up
to $200 million in the aggregate of the securities identified above from time to time in one or more offerings;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"></td><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a prospectus supplement, which covered the offer, issuance and sale by Portage in
its ATM offering of up to a maximum aggregate offering price of $50 million of Portage&#8217;s ordinary shares that may be issued and
sold from time to time under a Controlled Equity Offering Sales Agreement, dated February 24, 2021 (the &#8220;Sales Agreement&#8221;),
with Cantor Fitzgerald &amp; Co., the sales agent (&#8220;Cantor Fitzgerald&#8221;);</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"></td><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by
Portage of 57,500 ordinary shares for gross proceeds of approximately $26.5 million in a firm commitment underwritten public offering
with Cantor Fitzgerald;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"></td><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a prospectus supplement dated August 19, 2022, for the resale of up to $30 million
in ordinary shares that Portage may sell from time to time to Lincoln and an additional 4,726 shares that were issued to Lincoln; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 26.7pt"></td><td style="width: 14.4pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify; padding-right: 5.6pt">a prospectus supplement dated September 29, 2023 for the offer, issuance and
                                                                                                             sale by Portage in a registered direct public offering through H.C. Wainwright &amp; Co., the placement agent, to an institutional
                                                                                                             and accredited investor of (i) 98,500 ordinary shares at a purchase price of $38.00 per share; and (ii) Pre-Funded Warrants to
                                                                                                             purchase up to 59,395 ordinary shares, at a purchase price of $37.98 per Pre-Funded Warrant Shares, for aggregate gross proceeds of
                                                                                                             approximately $6 million. All Pre-Funded Warrants, which were exercisable
for one ordinary share at an exercise price of $0.02 per share, were exercised in full on May 29, 2024.</td></tr></table>

<p style="margin: 0pt 5.6pt 0pt 41.1pt; font-size: 10pt; text-align: justify"></p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0pt 5.6pt 0pt 8.25pt; font-size: 10pt; text-align: justify; text-indent: 18.4pt"><span id="xdx_900_ecustom--CashFundDescription_c20240401__20240930_z8Be9MvaAbb2" title="Cash fund, description">The Sales Agreement permits the Company
to sell in an ATM program up to $50 million of ordinary shares from time to time. Through September 30, 2024, the Company raised approximately $4.2 million in gross proceeds through the sale of shares of common shares
under the ATM program. Any sales under the prospectus will be deemed to be
made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act.</span></p>








<p id="xdx_8A8_znBKDu1SwIc1" style="margin: 0; font-size: 10pt; text-align: left">&#160;</p>
























<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On July 6, 2022, the Company entered into a Purchase
Agreement (the &#8220;Committed Purchase Agreement&#8221;) with Lincoln, under which it may require Lincoln to purchase ordinary shares
of the Company having an aggregate value of up to $30 million (the &#8220;Purchase Shares&#8221;) over a period of 36 months. Upon execution
of the Committed Purchase Agreement, the Company issued to Lincoln <span id="xdx_905_ecustom--NumberOfOrdinaryShareIssued_pip0_c20220705__20220706_zuopKK3mm7le" title="Number of ordinary share issued">4,726</span> ordinary shares, representing a 3% commitment fee. Pursuant to
the Committed Purchase Agreement, Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based
on various market criteria and share amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason,
effective upon one business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The
requirement that Lincoln must make a purchase will be suspended based on various criteria such as there not being an effective registration
statement for Lincoln to be able to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing
to be Depository Trust Company eligible, among other things. The Committed Purchase Agreement does not impose any financial or business
covenants on the Company, and there are no limitations on the use of proceeds. The Company may raise capital from other sources in its
sole discretion; provided, however, that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like
securities until the three-year anniversary of the date of the Committed Purchase Agreement, excluding, however, an ATM transaction with
a registered broker-dealer, which includes any sales under the Sales Agreement with Cantor Fitzgerald.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">During the six months ended September 30, 2023, the
Company sold <span id="xdx_90F_ecustom--NumberOfSharesSold_c20230401__20230930__ifrs-full--CounterpartiesAxis__custom--ATMMember_z1hfipEjBD86" title="Number of shares sold">9,331</span>
ordinary shares under the ATM program, generating net proceeds of approximately $<span id="xdx_900_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn5n6_c20230401__20230930__ifrs-full--CounterpartiesAxis__custom--ATMMember_z6UKGwIpC6Kd" title="Net proceeds from sale">0.7</span>
million. There were <span id="xdx_900_ecustom--NumberOfSharesSold_do_c20240401__20240930__ifrs-full--CounterpartiesAxis__custom--ATMMember_zfrdouh2idIb" title="Number of shares sold">no</span> shares sold under the ATM program during the six months ended September 30, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s March 2021 Registration Statement
expired on March 8, 2024. In order to issue additional shares under its ATM program or the Committed Purchase Agreement in the future,
the Company would be required to file a new registration statement, which must be declared effective by the SEC prior to use, and to file
a prospectus supplement related to the ATM program and the Committed Purchase Agreement, as the case may be.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Furthermore, the ATM program and the Committed Purchase
Agreement with Lincoln are generally limited based on, among other things, the Company&#8217;s Nasdaq trading volume. Under General Instruction
I.B.5 to Form F-3 (the &#8220;Baby Shelf Rule&#8221;), the amount of funds the Company can raise through primary public offerings of securities
in any 12-month period using a registration statement on Form F-3 is limited to one-third of the aggregate market value of the ordinary
shares held by the Company&#8217;s non-affiliates, which limitation may change over time based on its stock price, number of ordinary
shares outstanding and the percentage of ordinary shares held by non-affiliates. Accordingly, the Company is limited by the Baby Shelf
Rule as of the filing of this Form 6-K, until such time as its non-affiliate public float exceeds $<span id="xdx_906_ecustom--PublicFloat_iI_pn6n6_c20240930_zHnFS1RHMCUg" title="Public float">75</span> million.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On September 29, 2023, the Company entered into the Purchase
Agreement with an institutional and accredited investor in connection with the Registered Direct Offering and the Private Placement. The
Offerings closed on October 3, 2023.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company filed the Resale Registration Statement to
register for resale the Private Warrant Shares and the ordinary shares issuable upon the exercise of Placement Agent Warrants, which was
declared effective by the SEC on November 7, 2023. Pursuant to the terms of the Purchase Agreement, the Company is obligated to use its
commercially reasonable efforts to keep the Resale Registration Statement effective at all times until such institutional and accredited
investor (and its successors and assigns) no longer owns any Private Warrants or ordinary shares issuable upon exercise thereof.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">If a Fundamental Transaction (as defined in the Warrants)
occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the
Company may exercise and will assume all of the Company&#8217;s obligations under the Warrants with the same effect as if such successor
entity had been named in the Warrants themselves. If holders of ordinary shares are given a choice as to the securities, cash or property
to be received in such a Fundamental Transaction, then the holders of the Warrants shall be given the same choice as to the consideration
they would receive upon any exercise of the Warrants following such a Fundamental Transaction. Additionally, as more fully described in
the Series B Warrants, Series C Warrants and Placement Agent Warrants, in the event of certain Fundamental Transactions, the holders of
the Series B Warrants, Series C Warrants and Placement Agent Warrants will be entitled to receive cash consideration in an amount equal
to the Black-Scholes value of the Series B Warrants, Series C Warrants and Placement Agent Warrants, as the case may be, upon the consummation
of such Fundamental Transaction.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">See Note 6, &#8220;Warrant Liability,&#8221; for a discussion
of the Registered Direct Offering.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Series A Warrants and Pre-Funded Warrants </i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Series A Warrants and the Pre-Funded Warrants are
classified as a component of equity because they are freestanding financial instruments that are legally detachable and separately exercisable
from the ordinary shares with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase
its shares, and permit the holders to receive a fixed number of ordinary shares upon exercise. In addition, the Series A Warrants and
the Pre-Funded Warrants do not provide any guarantee of value or return.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="color: windowtext">On the October 3, 2023
issue date, the calculated fair value of the Series A Warrants and the Pre-Funded Warrants as of March 31, 2024 was $<span id="xdx_90B_ecustom--FairValueOfWarrants_iI_pn3n6_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsAndPreFundedWarrantsMember_zsnz1VqMKrPj" title="Fair value of warrants">2.968</span> million ($<span id="xdx_904_ecustom--WarrantsPerShare_iI_pn3n6_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsAndPreFundedWarrantsMember_zn86iHt8DMVf" title="Warrants per share">0.94</span>
per such warrant). </span>Because the fair value of the warrants accounted for as liabilities exceeded the net proceeds from the Registered
Direct Offering, the proceeds allocated to the Common Shares, the Pre-Funded Warrants and the Series A warrants was zero.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Series A Warrants</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">The inputs associated
with calculating the fair value are reflected below.</span></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_z20IHUyfJbLg" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B4_zspI3QY90L7f" style="display: none">Schedule of fair value</span> </td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 14%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zH37deVPzwX9" title="Exercise price">38.00</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zmDA5IRvLmz4" title="Share price">39.40</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930_zlmOM0oEsudd" title="Expected life">1.50</span> years</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zuPPX2xvmPu3" title="Expected volatility">96.0</span>%</td><td style="font-size: 10pt; font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zQa0R0ELaN2a" title="Risk free interest rate">5.32</span>%</td><td style="font-size: 10pt; font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zflUNZxJi4Bj" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zJYipCh3Scf5" style="margin: 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Nature and Purpose of Reserves</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Stock Option Reserve</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The stock option reserve reflects the reserve of compensation
expense recognized over the vesting period based upon the grant date fair value of the Company&#8217;s equity settled grants calculated
in accordance with IFRS 2, &#8220;Share-based Payment&#8221;. See Note 10, &#8220;Stock Option Reserve,&#8221; below for a further discussion.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CapitalStockAndReservesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CapitalStockAndReservesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalStockAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalStockAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988888073152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">STOCK OPTION RESERVE</a></td>
<td class="text"><p id="xdx_80A_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zD9QWzPtTB1" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 10. <span id="xdx_827_z5B3wAAgASVe">STOCK OPTION RESERVE</span></b></p>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Amended and Restated 2021 Equity Incentive
Plan and Grants of Stock Options and Restricted Stock Units</p>
<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following table provides the activity for the Company&#8217;s
stock option reserve for the six months ended September 30, 2024 and 2023 (in thousands):</p>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_zlDP52wSZwp4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_zXqKGpNgflDk" style="display: none">Schedule of stock options</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><b>2023</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20240930_zcynfXm3Vdud" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period">23,841</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionReserve_iS_pn3n3_c20230401__20230930_za8ZZf6KiUrk" style="width: 10%; font-size: 10pt; text-align: right" title="Balance, beginning of period">21,204</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20240401__20240930_z1JrgPkKhPUa" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share-based compensation expense">285</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20230401__20230930_z0CTjzMn5oVb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share-based compensation expense">1,512</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20240930_ztXuuyhXTpPc" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of period">24,126</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20230401__20230930_z0YKUYL3SMV" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of period">22,716</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zhgDDc5pxfR" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On August 15, 2024, the Company effected
a reverse stock split of its ordinary shares at a ratio of 1-for-20. All share and per share information have been retroactively adjusted
to reflect the impact of the reverse stock split unless otherwise noted. See Note 1 &#8220;Nature of Operations&#8221; and Note 9, &#8220;Capital
Stock and Reserves&#8221; for further discussion on the reverse stock split.</p>
<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As of September 30, 2024, <span id="xdx_903_ecustom--SharesReservedForAwardsGranted_iI_c20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zk9Gf5vWrHg2" title="Shares reserved for awards granted">82,429</span> shares were reserved
for awards previously granted and <span id="xdx_908_ecustom--SharesAvailableForFutureAwards_iI_c20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zBqzzZ9B8jR9" title="Shares available for future awards">59,997</span> shares were available for future awards under the Amended and Restated 2021 Equity Incentive
Plan.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The changes in the number of stock options issued and
outstanding for the six months ended September 30, 2024 and 2023 were as follows:</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock_zhlxz0fEpE59" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zASsIQifpgfg" style="display: none">Schedule of changes in the number of stock options</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zdJTBHDonrOe" style="width: 14%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period">90,281</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z7Bt2VuZdvvb" style="width: 14%; font-size: 10pt; text-align: right" title="Balance, beginning of period">98,171</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Expired or forfeited</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zb6m9yGQ2Do2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited">(25,167</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z4jvdcexEGR6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1047">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z9TE6YjSFTM5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of period">65,114</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjbjLpw8Dipa" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of period">98,171</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Exercisable, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zvcXdnReWvjg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable, end of period">43,723</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zo0jcoERTe0d" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable, end of period">38,461</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z8WxKp5AbF1h" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The table above does not include fully vested
restricted stock units (&#8220;RSUs&#8221;) granted to certain executives in January 2021 and January 2022. In January 2024, the
company issued <span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zadjl6G7IP42" title="Shares issued">308</span>
shares for the exercise of <span id="xdx_902_ecustom--NumberOfSharesExercise_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zF1SrRFGo6n5" title="Number of shares exercise">470</span>
RSUs net of <span id="xdx_909_ecustom--SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zFu4KXD559t2" title="Shares repurchased into treasury employee payroll taxes">162</span>
shares repurchased into treasury to pay for an employee&#8217;s payroll taxes. In September 2024, the company issued <span id="xdx_902_eifrs-full--NumberOfSharesIssued_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zHWgHTQ46Itf" title="Shares issued">882</span>
shares for the exercise of <span id="xdx_90C_ecustom--NumberOfSharesExercise_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zyCbWHWrnIJ5" title="Number of shares exercise">1,152</span>
RSUs net of <span id="xdx_90E_ecustom--SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z4dvcK388up" title="Shares repurchased into treasury employee payroll taxes">270</span>
shares  repurchased into treasury  to pay for an employee&#8217;s payroll taxes. As September 30, 2024, there were <span id="xdx_907_ecustom--NumberOfSharesGranted_pip0_c20240401__20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zznLHxRGwHI8" title="Number of shares granted">17,315</span>
RSUs granted and outstanding of which <span id="xdx_906_ecustom--NumberOfShareOutstanding_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z3sxeMw7LBnc" title="Number of shares outstanding">12,150</span> <span id="xdx_90E_ecustom--DescriptionOfRestrictedStockUnitsExpire_c20240401__20240930_zZGlaE6iKlAh" title="Description of share expire">RSUs
expire in January 2031 and 5,165 expire in January 2032.</span></p>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following is the weighted average exercise price
and the remaining contractual life for outstanding options as of September 30,
2024 and 2023:</p>

<p style="margin: 0; font-size: 10pt; text-indent: 0.3in">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zFxw5TIRItd7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B4_zTv7Hv0vlj5b" style="display: none">Schedule of weighted average exercise price
and the remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br/>2021 Equity Incentive Plan</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIad7SwwqsBi" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price">205.18</td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zGh48cZLymy7" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Weighted average exercise price">210.60</td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life (in years)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOcegh40ODz6" title="Weighted average remaining contractual life (in years)">7.39</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zuR9VcEmIVQj" title="Weighted average remaining contractual life (in years)">8.36</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zfQrITqf0kAf" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The vested options can be exercised at any time in accordance
with the applicable option agreement. The exercise price was greater than the market price for all options outstanding as of September
30, 2024 and March 31, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company recorded approximately $<span id="xdx_905_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20240701__20240930_znWb3L5xML2g" title="Share based compensation expense">0.141</span> million and
$<span id="xdx_900_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20230701__20230930_zZ7Z5Qx3oO59" title="Share based compensation expense">0.743</span> million of share-based compensation expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the three months
ended September 30, 2024 and 2023, respectively. The Company recorded approximately $<span id="xdx_903_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20240401__20240930_z8Gjyqsj9yj" title="Share based compensation expense">0.285</span> million and $<span id="xdx_90A_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20230401__20230930_zAzU6wtcKWx8" title="Share based compensation expense">1.512</span> million of share-based compensation
expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the six months ended September 30, 2024 and 2023, respectively.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887867664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_806_eifrs-full--EarningsPerShareExplanatory_zpLiKB3awY4d" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 11. <span id="xdx_829_zx33HBxwzOHa">LOSS PER SHARE</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">Basic earnings per
share (&#8220;EPS&#8221;) is calculated by dividing the net loss attributable to ordinary equity holders of the Company by the weighted
average number of ordinary shares outstanding during the period.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">&#160;</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">Diluted EPS is calculated
by dividing the net loss attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding
during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential
ordinary shares into ordinary shares. Shares issuable under Pre-Funded Warrants are considered outstanding for this purpose.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">&#160;</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="letter-spacing: -0.1pt">The calculation
of Basic and Diluted EPS reflects the Pre-Funded Warrants as outstanding shares.</span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following table reflects the loss and share data
used in the basic and diluted EPS calculations (in thousands, except per share amounts):</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zXTd7XlTdbZc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B7_zYcLtYyttqYj" style="display: none">Schedule of basic and diluted EPS calculations</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_499_20240701__20240930_zAJGlILzTB61" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20230701__20230930_z7vdwkfL0og" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20240401__20240930_z8AXReKtALwg" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49E_20230401__20230930_zgmBPTleEXE" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2023</td></tr>
  <tr id="xdx_400_ecustom--NumeratorAbstract_iB_zADINWgftxda" style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">Numerator</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to owners of the Company</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240701__20240930_zYHxLZsDXOZ8" title="Net loss attributable to owners of the Company">(1,360</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230701__20230930_zssZdyWUmkh3" title="Net loss attributable to owners of the Company">(5,158</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240401__20240930_zBqeRPFoc1Mj" title="Net loss attributable to owners of the Company">(3,016</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_903_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230401__20230930_z7NAZGiabPOe" title="Net loss attributable to owners of the Company">(11,077</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--DenominatorAbstract_iB_z3zN9tjnO8Gd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">Denominator</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average number of shares &#8211; Basic and Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--WeightedAverageShares_pn3n3_c20240701__20240930_zu8R0HbBwaE5" title="Weighted average number of shares - Basic"><span id="xdx_90C_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240701__20240930_zt0TQCMPITMj" title="Weighted average number of shares - Diluted">1,076</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eifrs-full--WeightedAverageShares_pn3n3_c20230701__20230930_zwRLbr6xxxy5" title="Weighted average number of shares - Basic"><span id="xdx_90B_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230701__20230930_zqmy5lItQT59" title="Weighted average number of shares - Diluted">890</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zwhs1VqvnI4h" title="Weighted average number of shares - Basic"><span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zEvvP0JpaQwk" title="Weighted average number of shares - Basic">1,063</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_908_eifrs-full--WeightedAverageShares_pn3n3_c20230401__20230930_zFwbdmWEq71k" title="Weighted average number of shares - Basic"><span id="xdx_902_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20230930_zNj4OJX6lFad" title="Weighted average number of shares - Diluted">888</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--BasicEarningsLossPerShare_pip0_c20240701__20240930_zzFRLyefpNY" title="Basic loss per share"><span id="xdx_903_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240701__20240930_zwYCQ8ByZGH5" title="Diluted loss per share">(1.26</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_906_eifrs-full--BasicEarningsLossPerShare_pip0_c20230701__20230930_zhj9JnRkGi35" title="Basic loss per share"><span id="xdx_90E_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230701__20230930_zQvzHStWWph2" title="Diluted loss per share">(5.80</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--BasicEarningsLossPerShare_pip0_c20240401__20240930_zFRXdXFQAi2e" title="Basic loss per share"><span id="xdx_901_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240401__20240930_zJxTh14EJkTk" title="Diluted loss per share">(2.84</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eifrs-full--BasicEarningsLossPerShare_pip0_c20230401__20230930_z3P9w4RcoqO9" title="Basic loss per share"><span id="xdx_900_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230401__20230930_zsggS3zYyMub" title="Diluted loss per share">(12.47</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AF_zqob4TeieqF7" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Number of ordinary shares are retroactively adjusted
to reflect the impact of the 1-for-20 reverse stock split on August 15, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The inclusion of the Company&#8217;s share purchase warrants
(other than Pre-Funded Warrants, as described above), stock options and RSUs in the computation of diluted loss per share would have an
anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between basic
loss per share and diluted loss per share for the three and six months ended September 30, 2024 and 2023. The following table reflects
the Company&#8217;s outstanding securities by year that would have an anti-dilutive effect on loss per share and, accordingly, were excluded
from the calculation.</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_ztTT3dH923Ie" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BF_zKm91mX0YDh4" style="display: none">Schedule of anti-dilutive effect on loss per share</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zs2EOIpMcTnk" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zV7L6EwwhOMi" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"><span style="-sec-ix-hidden: xdx2ixbrl1158">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Stock options</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_z2g5zf249sl7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">65,114</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zmmhajLnAo8b" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">98,171</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zIpnXQz6Gysi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">17,315</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zk0cmB2yQvf1" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">18,937</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A5_znGgcpzkWanb" style="margin: 0; font-size: 10pt">&#160;</p>

















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887486224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><p id="xdx_801_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zaSVebmzPC8b" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 12. <span id="xdx_82E_zEWuSuG9kS4l">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>iOx &#8211; Parexel Master Services Agreement</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Effective March 15, 2022, iOx entered into a Master Services
Agreement (the &#8220;MSA&#8221;) with Parexel under which Parexel agreed to act as
a&#160;clinical service provider (&#8220;CRO&#8221;) pursuant to a work order (&#8220;Work Order&#8221;) effective June 1, 2022. Under such Work Order,
Parexel planned to operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer. The MSA provided
for a five-year term, and the Work Order provided for a term to end upon the completion of the services required. The budget provided
for service fees and pass-through expenses and clinical sites totaling $11.5 million. During the year ended March 31, 2023 (&#8220;Fiscal
2023&#8221;), the Company executed two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs. As
a result of the Company&#8217;s decision to discontinue the development with respect to this program, on December 20, 2023, the Company
provided Parexel notice of termination of the contract, with a planned termination date of April 18, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As the ongoing CRO services were wound down, the Company
noticed that expenses incurred under the CRO agreement were higher than originally budgeted. Parexel agreed to refund the Company $<span id="xdx_906_ecustom--RetainageDeposits_iI_pn3n6_c20240930_zdfCaXvFoLOi" title="Release liability amount">0.552</span>
million and release the liability for amounts invoiced and unbilled services totaling $<span id="xdx_90D_ecustom--UnbilledContractsReceivables_iI_pn3n6_c20240930_zwKJ8lUkOHbg" title="Unbilled services">1.486</span> million, and the Company forfeited advanced
payments of $<span id="xdx_90C_ecustom--ForfeitedAdvancedPayments_iI_pn3n6_c20240930_zHjWAsx1jD47" title="Forfeited advanced payments">1.091</span> million. As a result, the Company recognized a net gain of $<span id="xdx_900_ecustom--GainOnLiability_iI_pn3n6_c20240930_zsb7jbSfKln4" title="Gain on liability">0.946</span> million as of September 30, 2024. As of March 31,
2024, the Company reflected $<span id="xdx_906_ecustom--PayablesToParexelInAccountsPayableAndAccruedLiabilities_iI_pn3n6_c20240331_zZ3q2LZu92s1" title="Payables to parexel in accounts payable and accrued liabilities">1.414</span> million of payables to Parexel in accounts payable and accrued liabilities and $<span id="xdx_90A_eifrs-full--CurrentTradeReceivables_iI_pn3n6_c20240331_zCUA7G1aDRAj" title="Prepaid expenses and other receivables">1.277</span> million in prepaid
expenses and other receivables in the consolidated <span style="background-color: white">statement of financial position. </span>The Company
received the refund from Parexel on October 3, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Tarus &#8211; Fortrea Clinical Service Agreement</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On March 1, 2023, Tarus entered into a clinical service
agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier
of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services
to be provided is approximately $<span id="xdx_904_ecustom--BudgetedCosts_pn5n6_c20230228__20230302_z3PBzWsaxNEg" title="Budgeted costs">12.1</span> million. Because of the Company&#8217;s decision to discontinue and pause further accrual of all
clinical studies, the Company is negotiating a revision to the services required under the change in circumstances.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>



<p style="margin: 0; font-size: 10pt; text-align: justify"><b></b></p>













<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988888866000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_80C_eifrs-full--DisclosureOfRelatedPartyExplanatory_z2MlVwRVOZid" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 13. <span id="xdx_827_z6qCF7b6FdH3">RELATED PARTY TRANSACTIONS</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>SalvaRx Acquisition</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Two of the Company&#8217;s directors are also directors
of SalvaRx Group plc, a company which owns approximately 4.1% of the Company&#8217;s issued and outstanding ordinary shares as of September
30, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Investments</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company has entered into related party transactions
and certain services agreements with its investees.&#160;Key management personnel of the Company have also entered into related party
transactions with investees. Key management personnel are those people who have the authority and responsibility for planning, directing
and controlling the activities of the Company, including directors and senior management of the Company.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following subsidiaries and associates are considered
related parties:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td style="text-align: justify"><b>Stimunity</b>. The Chief Executive Officer (&#8220;CEO&#8221;) of Portage is one of three members of
the board of directors of Stimunity. The Company wrote-off its investment in Stimunity to nil in the Fiscal 2024 period.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td style="text-align: justify"><b>iOx</b>. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Portage director resigned
from the iOx board leaving two Portage insiders as directors. The CEO of Portage is also the CEO of iOx, and the management team of Portage
comprises the management team of iOx.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(c)</td><td style="text-align: justify"><b>Saugatuck</b>. The Chairman and CEO of the Company is the sole director of Saugatuck. Saugatuck is
70% owned by the Company and is controlled by Portage.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(d)</td><td style="text-align: justify"><b>Intensity</b>. The CEO of Portage previously served as a part-time officer of Intensity until becoming
a consultant in 2023. Additionally, Intensity provided services (primarily rent) to Portage through April 2023. For the six months ended
September 30, 2023, the Company paid $<span id="xdx_90C_ecustom--PortagePaidIntensity_pn4n6_c20230401__20230930_zsnMSyIT9kWa" title="Portage paid intensity">0.01</span> million. No such services were provided subsequent to April 2023.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt">(e)</td><td style="text-align: justify"><b>Portage Development Services Inc</b>. PDS provides human resources and other services to each operating
subsidiary of Portage through shared services agreements.</td></tr></table>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Transactions between the parent company and its subsidiaries,
which are related parties, have been eliminated in consolidation and are not disclosed in this note.</p>

<p style="margin: 0pt 0 0pt 8.25pt; font-size: 10pt; font-style: italic; font-weight: bold">&#160;</p>

<p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Board Resignations and Appointments</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On April 25, 2024, Mark Simon resigned
all of his positions on the Board of Directors, and on April 26, 2024, Linda Kozick and Dr. Robert Glassman resigned all of their positions
on the Board of Directors. On April 30, 2024, Dr. Jean -Christophe Renondin and Dr. Justin Stebbing were elected to the Board.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>






















<p style="margin: 0; font-size: 10pt; text-align: justify"><span style="background-color: white"><b><i>Bonuses &amp; Board Compensation
Arrangements</i></b></span></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><span style="background-color: white">In December 2022,
the Board approved executive performance bonuses, as recommended by the Compensation Committee, totaling $<span id="xdx_902_ecustom--CompensationCommittee_pn5n6_c20221225__20221231_zLQstJ33N2Q6" title="Compensation committee">0.6</span> million, which is equivalent
to <span id="xdx_906_ecustom--OriginalAnnualTargetsPercentage_pip0_dp_c20221225__20221231_zMkIZECjpry1" title="Original annual targets percentage">73.5</span>% of original annual targets established by the Board in December 2021. The bonuses were approved based upon the original performance
targets established. The Board further approved a payment structure of 25% of approved bonuses, which were paid in January 2023, with
the balance of amounts due payable upon a new financing. The accrued, unpaid amount of approximately $<span id="xdx_90D_ecustom--AccountsPayableAndAccruedExpenses_iI_pn5n6_c20240930_zBBCadOexkY1" title="Accounts payable and accrued expenses"><span id="xdx_903_ecustom--AccountsPayableAndAccruedExpenses_iI_pn5n6_c20240331_zyV0TT2vtQz3" title="Accounts payable and accrued expenses">0.4</span></span> million is included in accounts
payable and accrued liabilities in the condensed consolidated interim statements of financial position as of each of September 30, 2024
and March 31, 2024. </span>No executive performance bonus has been approved by the Compensation Committee or the Board for Fiscal Year
2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Effective January 1, 2022, each non-employee Board
member is entitled to receive cash Board fees of $40,000 per annum, payable quarterly in arrears. Additionally, each non-employee
Board member is entitled to an annual grant of 345 options to purchase Portage ordinary shares, which would vest the first annual
anniversary of the grant date. The Company incurred Board fees totaling nil <span id="xdx_909_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20240701__20240930_zYQHGHEiv2Xh" style="display: none" title="Incurred Board fees total">0</span> and $<span id="xdx_90D_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20230701__20230930_z6mORYUKJgmk" title="Incurred Board fees total">82,500</span> during the three months ended September
30, 2024 and 2023, respectively, and $<span id="xdx_909_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20240401__20240930_zg6GQV4VlG06" title="Incurred Board fees total">7,205</span> and $<span id="xdx_90D_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20230401__20230930_zswv0CoB7D6f" title="Incurred Board fees total">165,000</span> during the six months ended September 30, 2024 and 2023, respectively.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Non-employee Board chairpersons are entitled to an annual
cash fee of $30,000, payable quarterly in arrears. In lieu of a non-executive chairperson, the lead director is entitled to an annual
cash fee of $20,000 per annum paid quarterly in arrears. <span id="xdx_900_ecustom--AnnualFeesdescription_c20240401__20240930_zjbJT72xnatl" title="Annual fees description">Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nominating Committee of the Board is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears.
Members of those committees are entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears. All
non-executive board members waived their right to board fees for the six months ended September 30, 2024, except for the non-executive
board members who resigned in late April 2024.</span></p>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">Retention Agreements and General Releases</p>

<p style="margin: 0pt 0; font-size: 10pt"><b><i>&#160;</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">On July 22, 2024, the Company and Portage
Development Services, Inc. entered into a Retention Agreement and General Release (&#8220;Retention Agreement&#8221;) with each of Allan
Shaw (&#8220;Employee&#8221;) and Joseph Ciavarella (&#8220;Consultant&#8221;). Under the terms of each of the Retention Agreements, Employee&#8217;s
current employment agreement and Consultant&#8217;s current consulting agreement both terminated on July 22, 2024, except with respect
to certain provisions. In return for continuing to provide services to the Company and its affiliates and completing certain Applicable
Retention Events, as defined in the respective Retention Agreements, the Company paid an aggregate $0.2 million (the &#8220;Retention
Amount&#8221;) to Employee and Consultant, in addition to their monthly pay through September 30, 2024.</p>

<p style="margin: 0pt 0; font-size: 10pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company accrued the Retention
Amount, as well as the monthly pay totaling $0.2 million through September 30, 2024, in the condensed consolidated interim financial statements
for the three months ended June 30, 2024, as the material terms of the Retention Agreements were known and agreed upon at June 30, 2024.
In accordance with the terms of the Retention Agreements, the Company paid in full the Retention Amount and issued 14,348 ordinary shares
to the Employee and Consultant in lieu of cash bonuses accrued in Fiscal 2023 totaling $0.1 million by September 30, 2024, the date on
which the Employee&#8217;s employment and the Consultant&#8217;s consulting relationship with the Company and its affiliates ended.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>



















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887038144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory', window );">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</a></td>
<td class="text"><p id="xdx_808_ecustom--DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_zMrid2zf3ou9" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 14. <span id="xdx_821_zH24xjfeYjT1">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s financial instruments recognized
in the Company&#8217;s condensed consolidated interim statements of financial position consist of the following:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Fair value estimates are made at a specific point in
time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties
and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could
significantly affect these estimates.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following table summarizes the Company&#8217;s financial
instruments as of September 30, 2024 and March 31, 2024 (in thousands):</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_zipsfya99PV7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span><span id="xdx_8B9_zasVIPpgU6Pb" style="display: none">Schedule of financial instruments</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zUu1WWqUfH05" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49F_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zGD22lNC0Jyj" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_492_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z6u5FHh8ORl5" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zd0m5ib0Z01l" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49A_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z7D1v6pnwLp2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zk8qvAhQiIs5" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--CashAndCashEquivalents_i01I_zGv0ysjUwoB4" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right">1,764</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right">5,028</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1249">&#8211;</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">&#8211;</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PrepaidExpensesAndOtherReceivable_i01I_zpddYPigyQo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">922</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1253">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,667</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_498_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zLF7FLIsvTo6" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_491_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z4xznnO58W4k" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zbNO4yhYYBr3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zgZQzdvHCrMb" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AccountsPayableAndAccruedLiabilities_i01I_zgWgFVr1Z5Qg" style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">845</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">2,836</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1267">&#8211;</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--WarrantLiability_i01I_za1ckSSwfoH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1269">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,138</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,564</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>






<p id="xdx_8AE_zQcuP6MGdeIb" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">A summary of the Company&#8217;s risk exposures as it
relates to financial instruments are reflected below.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>
<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Fair value of Financial Instruments</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s financial assets and liabilities
are comprised of cash and cash equivalents, receivables and investments in equities and public entities, accounts payable and accrued
liabilities, lease liability, and warrant liability.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company classifies the fair value of these transactions
according to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Level 1 &#8211; Values are based on unadjusted quoted prices available in active markets for identical
assets or liabilities as of the reporting date.</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Level 2 &#8211; Values are based on inputs, including quoted forward prices for commodities, time value
and volatility factors, which can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly
or indirectly observable as of the reporting date.</td></tr></table>

<p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">Level 3 &#8211; Values are based on prices or valuation techniques that are not based on observable market
data. Investments are classified as Level 3 financial instrument.</td></tr></table>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Assessment of the significance of a particular input
to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Management has assessed that the fair values of cash
and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities
of these instruments.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The following methods and assumptions were used to estimate
their fair values:</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>Warrant Liability</b>: The fair value is estimated
using a Black-Scholes model and in certain cases, a Monte Carlo simulation (Level 3) (see Note 6, &#8220;Warrant Liability&#8221;).</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>


<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>




















<p style="margin: 0pt; font-size: 10pt; text-align: justify"><b>Credit Risk, Liquidity Risk and Foreign Currency Risk</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Our financial instruments are exposed to certain financial risks: Credit Risk, Liquidity
Risk and Foreign Currency Risk.</p>
<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Credit Risk</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Credit risk is the risk of loss associated with a counterparty&#8217;s
inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#8217;s condensed consolidated interim statements of financial position.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>Cash and cash equivalents: </b>Cash and cash equivalents
comprise cash on hand and amounts invested in underlying treasury and money market funds that are readily convertible to a known amount
of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. <span style="background-color: white">As
of September 30, 2024 and March 31, 2024, cash equivalents was comprised of a money market account with maturities less than 90 days from
the date of purchase. </span>Cash and cash equivalents are held with major international financial institutions and therefore the risk
of loss is minimal.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Liquidity Risk</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Liquidity risk is the risk that the Company will encounter
difficulty in satisfying financial obligations as they become due.</p>

<p style="margin: 0; font-size: 10pt"><b>&#160;</b></p>



















<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company&#8217;s approach to managing liquidity is
to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed
conditions without incurring unacceptable losses or risking harm to the Company&#8217;s reputation. The Company holds sufficient cash
and cash equivalents to satisfy current obligations under accounts payable and accruals.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company monitors its liquidity position regularly
to assess whether it has the funds necessary to meet its operating needs and needs for investing in new projects.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">As a biotech company at an early stage of development
and without significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional
financing may not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty
in global capital markets could have an impact on the Company&#8217;s future ability to access capital on terms that are acceptable to
the Company. There can be no assurance that required financing will be available to the Company. See Note 9, &#8220;Capital Stock and
Reserves,&#8221; for a discussion of the Company&#8217;s share offering.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>Foreign Currency Risk</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">While the Company operates in various jurisdictions,
substantially all of the Company&#8217;s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K.
settleable in British pound sterling.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988885712464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL MANAGEMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureCapitalManagementAbstract', window );"><strong>Capital Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock', window );">CAPITAL MANAGEMENT</a></td>
<td class="text"><p id="xdx_80A_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zoSDgN6DUI5i" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 15. <span id="xdx_82A_zNYXymQWUoTl">CAPITAL MANAGEMENT</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b>&#160;</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company considers the items included in shareholders&#8217;
equity as capital. The Company had accounts payable and accrued liabilities of approximately $<span id="xdx_902_ecustom--PayablesAndAccruedExpense_iI_pn5n6_c20240930_zn2oiL8OuuH2" title="Accounts payables and accrued liabilities">0.8</span> million and lease liability - current
of $<span id="xdx_909_eifrs-full--CurrentLeaseLiabilities_iI_pn3n6_c20240930_zg1qvRXs3s66" title="Lease liability - current">0.028</span> million as of September 30, 2024 (accounts payable and accrued liabilities of approximately $<span id="xdx_908_ecustom--PayablesAndAccruedExpense_iI_pn5n6_c20240331_zGUvAivGNgra" title="Accounts payables and accrued liabilities">2.8</span> million as of March 31, 2024
and lease liability - current of $<span id="xdx_90E_eifrs-full--CurrentLeaseLiabilities_iI_pn3n6_c20240331_zZVLZwTzbbXa" title="Lease liability - current">0.040</span> million as of March 31, 2024) and current assets of approximately $<span id="xdx_905_ecustom--CurrentAsset_iI_pn5n6_c20240930_zYs3sRCBSb91" title="Current assets">2.7</span> million as of September
30, 2024 (approximately $<span id="xdx_902_ecustom--CurrentAsset_iI_pn5n6_c20240331_zU02m2gRLXIf" title="Current assets">7.7</span> million as of March 31, 2024). The Company&#8217;s objectives when managing capital are to safeguard the
Company&#8217;s ability to continue as a going concern in order to pursue new business opportunities and to maintain a flexible capital
structure, which optimizes the costs of capital at an acceptable risk.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company manages the capital structure and makes adjustments
to it in light of changes in economic conditions and the risk characteristics of the underlying assets.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Nasdaq Listing Rule 5550(b)(1) requires companies listed
on the Nasdaq Capital Market to maintain shareholders&#8217; equity of at least $<span id="xdx_907_ecustom--ShareholdersEquity_iI_pn5n6_c20240930_zr1rzwizPlu3" title="Shareholders' equity">2.5</span> million for continued listing. As of September 30,
2024, shareholders&#8217; equity attributable to the owners of the Company was approximately $<span id="xdx_90F_ecustom--ShareholdersEquityAttributableToOwners_iI_pn5n6_c20240930_zQzidMNFTqq" title="Shareholders' equity attributable to owners">1.4</span> million (approximately $<span id="xdx_904_ecustom--ShareholdersEquityAttributableToOwners_iI_pn6n6_c20240331_zEJj6L0HfXX5" title="Shareholders' equity attributable to owners">4</span>.0 million
as of March 31, 2024). As a result, the Company is not currently in compliance with Nasdaq Listing Rule 5550(b)(1). Accordingly, the Company
expects Nasdaq to notify it of such non-compliance. The Company does not anticipate that the notification will have an immediate effect
on the listing of the Company&#8217;s ordinary shares on the Nasdaq Capital Market. In accordance with the Nasdaq Listing Rules, the Company
expects to have 45 calendar days from the date of the notification to submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1).
If the Company&#8217;s compliance plan is accepted, it may be granted up to 180 calendar days from the date of the initial notification
to evidence compliance. If the compliance plan is not accepted or the Company is otherwise unable to provide evidence of compliance within
Nasdaq&#8217;s allotted timeframe, Nasdaq may take steps to delist the Company&#8217;s ordinary shares. There can be no assurance that
the Company will be able to increase its shareholders&#8217; equity in the future.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company is not subject to any externally imposed
capital requirements and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the
Company&#8217;s approach to capital management during the six months ended September 30, 2024 and 2023.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify">&#160;</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887109856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory', window );">NON-CONTROLLING INTEREST</a></td>
<td class="text"><p id="xdx_80D_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zagSiQPRFyH3" style="margin: 0; font-size: 10pt; text-align: justify"><b>NOTE 16. <span id="xdx_823_zxQw7jhdOjS5">NON-CONTROLLING INTEREST</span></b></p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">The details of non-controlling interest for the six months ended September
30, 2024 and 2023 are as follows (in thousands):</p>

<table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_zYOORpqQXiKk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span><b><span id="xdx_8B0_zJGkj4De6xA2" style="display: none">Schedule of non-controlling interest</span></b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Saugatuck <br/>and subsidiary</b></span></td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2024</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4udUogfx4D6" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">(693</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zes1DKm0cNcg" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net loss attributable to non-controlling interest">(10</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of September 30, 2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zJJ9t8JEgnWf" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(703</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Saugatuck <br/>and subsidiary</b></span></td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font-size: 10pt">Non-controlling interest as of April 1, 2023</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zRW5e9EgMf2i" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(650</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z26eLOAlmNya" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net loss attributable to non-controlling interest">(14</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Non-controlling interest as of September 30, 2023</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zm290RE9uf95" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">(664</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A5_z4SLhKrYuxxb" style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Saugatuck and subsidiary includes Saugatuck and its wholly-owned
subsidiary, Saugatuck Rx LLC.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interests in other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 1<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_1&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988911078416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zKaYTrbq7im9" style="margin: 0; font-size: 10pt; text-align: justify"><b><span id="xdx_864_zMXSuqmHhCh8">Recent Accounting Pronouncements</span></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b><i>IFRS Pronouncements Issued</i></b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Impact of Adoption of Significant New IFRS Standards in Fiscal 2025</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>



<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 23.05pt"><b>(a)</b></td><td style="text-align: justify"><b>Amendments to IAS 1: Non-current Liabilities with Covenants</b></td></tr></table>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The amendments to IAS 1, &#8220;Presentation of Financial
Statements,&#8221; clarify how conditions with which an entity must comply within twelve months after the reporting period affect the
classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these
conditions.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The amendments to IFRS 16 and IAS 1 were effective for
annual periods beginning on or after January 1, 2024. The adoption of these amendments did not have a material effect on the Company&#8217;s
annual consolidated financial statements or the condensed consolidated interim financial statements for the three and six months ended
September 30, 2024.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 23.05pt"><b>(b)</b></td><td style="text-align: justify"><b>Amendments to IAS 7 and IFRS 7: Supplier Finance</b></td></tr></table>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The amendments to IAS 7 and IFRS 7, &#8220;Statement
of Cash Flows,&#8221; require disclosures to enhance the transparency of supplier finance arrangements and their effects on an entity&#8217;s
liabilities, cash flows and exposure to liquidity risk. The amendments to IAS 7 and IFRS 7 were effective for annual periods beginning
on or after January 1, 2024 (with transitional reliefs in the first year). The adoption of these amendments did not have a material effect
on the Company&#8217;s annual consolidated financial statements or the condensed consolidated interim financial statements for the three
and six months ended September 30, 2024.</p>

<p style="margin: 0; font-size: 10pt">&#160;</p>



















<p style="margin: 0; font-size: 10pt; text-align: justify"><b>New Accounting Standards, Interpretations and Amendments</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Standards issued but not yet effective up to the date
of issuance of the Company&#8217;s condensed consolidated interim financial statements is listed below. This is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes
effective.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify"><b>Amendments to IAS 21 &#8211; Lack of Exchangeability</b></p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">An entity is impacted by the amendments to IAS 21, &#8220;The
Effects of Changes in Foreign Exchange Rates,&#8221; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The Company is evaluating whether the adoption of the amendments to IAS 21 would have a material effect
on the Company&#8217;s annual consolidated financial statements or its condensed consolidated interim financial statements.</p>

<p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887867920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock', window );">Schedule of prepaid expenses and other receivables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z0jPJYwGU6vd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zpQkJ8fMrDwd" style="display: none">Schedule of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20240930_zzEU0woN1Sx6" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20240331_zdxu0LM7fXZf" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt; text-align: right">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_maCPzKMQ_zzk7XYFBfK4b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left">Prepaid clinical research costs</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,924</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CurrentReceivablesFromRentalOfProperties_iI_maCPzKMQ_zJRDfyKZ9e1e" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Refund from Parexel</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">552</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0627">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzKMQ_zku20B74vfyl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid insurance</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">249</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">575</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--TaxDeposits_iI_maCPzKMQ_zntCDP3FnKKk" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Tax deposits</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">63</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">64</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzKMQ_zRUK8u0x0R9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other prepaid expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">26</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">65</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzKMQ_zLhyFgKfzFP1" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other receivables</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">18</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">39</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SecurityDepositOnOfficeLease_iI_pn3n3_maCPzKMQ_zJHqSHVHSNb7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Security deposit on office lease expiring in May 2025</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">14</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzKMQ_zYSZF37e1hja" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">922</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,667</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988885633664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfWarrantLiabilityTableTextBlock', window );">Schedule of changes in the warrant liability</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zwLAxhHXwtPd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8BC_zXWGbAfywazb" style="display: none">Schedule of changes in the warrant
liability</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Warrants</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Fair Value Balance</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>In 000&#8217;$</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Warrant liability as of April 1, 2023</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--WarrantLiabilityExercisePrice_iI_pip0_c20230331_zR8JQdLDTJE6" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability exercise price"><span style="-sec-ix-hidden: xdx2ixbrl0667">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_ecustom--WarrantsLiabilityShares_iS_pip0_c20230401__20240331_z2Pq7GJJQzp4" title="Warrants liability, shares at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0669">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20230401__20240331_z4pZHKZA9HW2" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, fair value at beginning"><span style="-sec-ix-hidden: xdx2ixbrl0671">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold">Fair value of warrants at issuance on October 3, 2023:</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 61%; font-size: 10pt; font-weight: bold; text-align: left">Class B Warrants</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zSmJyE5hKpw1" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price">45.20</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zZN73Kn7CPZf" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares">157,895</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zrfqAQ46ti9k" title="Fair value of warrants amount">3,537</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Class C Warrants</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zznyU7KV5Fqc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price">45.20</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_z0lkrOfzaO8j" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares">157,895</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zlWO6Pqg7OG9" title="Fair value of warrants amount">4,663</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Placement Agent Warrants</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMBu6zY15JVh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price">47.50</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw6ax8GTFgHa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares">7,896</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_znbVJV9Zf6qc" title="Fair value of warrants amount">232</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b><span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20230401__20240331_zvJwJGOMsKQl" title="Change in fair value of warrant liability"><span style="-sec-ix-hidden: xdx2ixbrl0691">&#8211;</span></span></b></span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_ziR3u6w2Has9" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount">(6,868</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Warrant liability as of March 31, 2024</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><b style="display: none">&#8211;</b></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20240630_zUGjw8zX5Eoc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at beginning">323,686</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90D_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20240630_zZfOIdB69ecb" title="Warrants liability, fair value at beginning">1,564</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_909_ecustom--ChangeInFairValueOfWarrantLiability_c20240401__20240630_zDW06zxkz7Cg" title="Change in fair value of warrant liability, shares"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20240630_zDVOnoY49hl4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount">(1,142</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Warrant liability as of June 30, 2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability exercise price">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98A_ecustom--WarrantsLiabilityShares_iS_pip0_c20240701__20240930_zlmlvAwiTZu" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at beginning">323,686</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"><span id="xdx_903_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240701__20240930_zEk1ELkUSKIh" title="Warrants liability, fair value at beginning">422</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Change in fair value of warrant liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability exercise price">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20240701__20240930_zTjtO1x8Yx34" title="Change in fair value of warrant liability, shares"><span style="-sec-ix-hidden: xdx2ixbrl0707">&#8211;</span></span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240701__20240930_zh6K6ejO8LFc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount">716</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrant liability as of September 30, 2024</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right"><b style="display: none">&#8211;</b></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_989_ecustom--WarrantsLiabilityShares_iE_pip0_c20240701__20240930_zf2cT80Wi85i" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at ending">323,686</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20240401__20240930_zksU6cTyeeUk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, fair value at ending">1,138</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Schedule of fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEkrm5UZJBGe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BD_zREPodEHY8ti" style="display: none">Schedule of fair value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90D_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zZTmCC7cclRi" title="Exercise price">45.20</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJ19voToTy92" title="Exercise price">45.20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zt6hxDAGNJv9" title="Share price">39.40</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJBVKTZ9m2e5" title="Share price">6.65</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z84uGXOtPsna" title="Expected life">3.01</span> years</b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90A_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z4gqsqiIR7S9" title="Expected life">2.01</span> years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zT5LiGEXS3T6" title="Expected volatility">90.4</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zHsOvAIO55m3" title="Expected volatility">159.22</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zoT9D9Wc3gF4" title="Risk free interest rate">4.95</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrBMzoUezxPj" title="Risk free interest rate">3.66</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z04kXw66MSIk" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0819">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zP1oUWszKJwc" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0821">&#8211;</span></span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Schedule of fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zNo8g7HfVAx" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  WARRANT LIABILITY (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8BE_z5i9uOgWjsI7" style="display: none">Schedule of fair value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z3J6gnWUkU4f" title="Exercise price">45.20</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zsCGSLy6od" title="Exercise price">45.20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90F_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4NWSvRDipa5" title="Share price">39.40</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zoSDcNdfzyrc" title="Share price">6.65</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zffuAbj4Gna4" title="Expected life">5.00</span> years</b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zR2vvuZGlCek" title="Expected life">4.01</span> years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_905_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7sKqapVVSzf" title="Expected volatility">100.7</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4bXOJnQUMn4" title="Expected volatility">129.26</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zi1Ht5zQ8sg8" title="Risk free interest rate">4.80</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_903_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zxeevLgY5d83" title="Risk free interest rate">3.58</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zw0kH9IKVOXk" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0849">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zIS5SgmE9Kth" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0851">&#8211;</span></span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Schedule of fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNqJsTXTy39d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B6_zizEuT02aYM2" style="display: none">Schedule of fair value</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90A_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcEOVuZQcbE9" title="Exercise price">47.60</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHmGOB1v5pgi" title="Exercise price">47.50</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_901_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGzHzT9ujqM8" title="Share price">39.40</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z7MOsQV6Uzx4" title="Share price">6.65</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zAO26TCEDHFe" title="Expected life">4.99</span> years</b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9gSMGkD40b" title="Expected life">4.01</span> years</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zFEYBL2WEmq7" title="Expected volatility">100.7</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKmBRjn0xTG7" title="Expected volatility">129.26</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90C_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNXdKGvaccSl" title="Risk free interest rate">4.80</span>%</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zo9o1tyDYZMe" title="Risk free interest rate">3.58</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_906_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zfPd7mIQxc12" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0879">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z45tug4uPhn6" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl0881">&#8211;</span></span></td></tr>
  </table>


<p style="margin: 0; font-size: 10pt">&#160;</p>















<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS13_g91-99_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887488016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract', window );"><strong>Accounts Payable And Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_ztM36cLVhTV3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span><span id="xdx_8BF_zIgoWOD3J5p8" style="display: none">Schedule of accounts payable and accrued liabilities</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20240930_zwsLYUqXcj0b" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20240331_zEoKifOeHuyk" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr id="xdx_409_ecustom--AccountsPayableAndAmountsAccruedToCro_iI_zGrnUPIAEMl5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and amounts accrued to CRO</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">49</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,413</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_zU2Hkru1iIgb" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued bonuses and other payroll-related expenses</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">371</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">525</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zaFtbYZIToK" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued accounting and auditing fees</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">127</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">189</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--AccruedLegalFees_iI_zSo5RglA1PIh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued legal fees</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">54</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">194</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AccruedOtherProfessionalFees_iI_z9yIRqvCxyjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued other professional fees</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">33</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">157</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--OtherAccountsPayable_iI_zUfZuBt5BYoc" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Other accounts payable</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">172</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">136</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--AccruedClinicalAndRdServices_iI_zWuKHzGuHyRd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Accrued clinical and R&amp;D services</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">179</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--OtherAccruedExpenses_iI_pn3n3_zbcoTDtytPE" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">36</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">43</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_pn3n3_zO9lOvxYHt3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total accounts payable and accrued liabilities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">845</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,836</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988889154416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock', window );">Schedule of effective income tax rates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z9rHamzxYfn7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B2_zGEeeJFpITia" style="display: none">Schedule of effective income tax rates</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20240401__20240930_zHJnklBFtjE9" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20230401__20230930_zMcz3nbMzRJi" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_iN_di_znGvqV0P44Zk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; text-align: left">Loss before income taxes</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%">3,024</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">12,143</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncomeTaxExpenseContinuingOperation_iN_di_zLFaFRaXIb27" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Income tax benefit</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,052</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_zVO4lrL8mbV1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Effective tax rate</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">0.10</td><td style="font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">8.66</td><td style="font-size: 10pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988889088832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND RESERVES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureCapitalStockAndReservesAbstract', window );"><strong>Capital Stock And Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory', window );">Schedule of fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_z20IHUyfJbLg" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B4_zspI3QY90L7f" style="display: none">Schedule of fair value</span> </td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">October 3, 2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 84%; font-size: 10pt; font-weight: bold">Exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 14%; font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zH37deVPzwX9" title="Exercise price">38.00</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold">Share price</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center">$<span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zmDA5IRvLmz4" title="Share price">39.40</span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected life</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930_zlmOM0oEsudd" title="Expected life">1.50</span> years</b></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Expected volatility</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zuPPX2xvmPu3" title="Expected volatility">96.0</span>%</td><td style="font-size: 10pt; font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zQa0R0ELaN2a" title="Risk free interest rate">5.32</span>%</td><td style="font-size: 10pt; font-weight: bold; text-align: center"></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Dividend yield</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center"><span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zflUNZxJi4Bj" title="Expected dividend"><span style="-sec-ix-hidden: xdx2ixbrl1001">&#8211;</span></span></td><td style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalStockAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalStockAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886773696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock', window );">Schedule of stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_zlDP52wSZwp4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BA_zXqKGpNgflDk" style="display: none">Schedule of stock options</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><b>2023</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20240930_zcynfXm3Vdud" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period">23,841</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionReserve_iS_pn3n3_c20230401__20230930_za8ZZf6KiUrk" style="width: 10%; font-size: 10pt; text-align: right" title="Balance, beginning of period">21,204</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20240401__20240930_z1JrgPkKhPUa" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share-based compensation expense">285</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20230401__20230930_z0CTjzMn5oVb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share-based compensation expense">1,512</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20240930_ztXuuyhXTpPc" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of period">24,126</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20230401__20230930_z0YKUYL3SMV" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of period">22,716</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock', window );">Schedule of changes in the number of stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock_zhlxz0fEpE59" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B6_zASsIQifpgfg" style="display: none">Schedule of changes in the number of stock options</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zdJTBHDonrOe" style="width: 14%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period">90,281</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z7Bt2VuZdvvb" style="width: 14%; font-size: 10pt; text-align: right" title="Balance, beginning of period">98,171</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Expired or forfeited</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zb6m9yGQ2Do2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited">(25,167</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z4jvdcexEGR6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1047">&#8211;</span></td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z9TE6YjSFTM5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of period">65,114</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjbjLpw8Dipa" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of period">98,171</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Exercisable, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zvcXdnReWvjg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable, end of period">43,723</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zo0jcoERTe0d" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable, end of period">38,461</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average exercise price and the remaining contractual life</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zFxw5TIRItd7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B4_zTv7Hv0vlj5b" style="display: none">Schedule of weighted average exercise price
and the remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br/>2021 Equity Incentive Plan</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIad7SwwqsBi" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price">205.18</td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zGh48cZLymy7" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Weighted average exercise price">210.60</td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life (in years)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOcegh40ODz6" title="Weighted average remaining contractual life (in years)">7.39</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zuR9VcEmIVQj" title="Weighted average remaining contractual life (in years)">8.36</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886565280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfEarningsPerShareTableTextBlock', window );">Schedule of basic and diluted EPS calculations</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zXTd7XlTdbZc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B7_zYcLtYyttqYj" style="display: none">Schedule of basic and diluted EPS calculations</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_499_20240701__20240930_zAJGlILzTB61" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49C_20230701__20230930_z7vdwkfL0og" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49D_20240401__20240930_z8AXReKtALwg" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49E_20230401__20230930_zgmBPTleEXE" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">2023</td></tr>
  <tr id="xdx_400_ecustom--NumeratorAbstract_iB_zADINWgftxda" style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">Numerator</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td colspan="3" style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss attributable to owners of the Company</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90C_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240701__20240930_zYHxLZsDXOZ8" title="Net loss attributable to owners of the Company">(1,360</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_90A_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230701__20230930_zssZdyWUmkh3" title="Net loss attributable to owners of the Company">(5,158</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240401__20240930_zBqeRPFoc1Mj" title="Net loss attributable to owners of the Company">(3,016</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_903_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230401__20230930_z7NAZGiabPOe" title="Net loss attributable to owners of the Company">(11,077</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--DenominatorAbstract_iB_z3zN9tjnO8Gd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; font-style: italic">Denominator</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Weighted average number of shares &#8211; Basic and Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90B_eifrs-full--WeightedAverageShares_pn3n3_c20240701__20240930_zu8R0HbBwaE5" title="Weighted average number of shares - Basic"><span id="xdx_90C_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240701__20240930_zt0TQCMPITMj" title="Weighted average number of shares - Diluted">1,076</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eifrs-full--WeightedAverageShares_pn3n3_c20230701__20230930_zwRLbr6xxxy5" title="Weighted average number of shares - Basic"><span id="xdx_90B_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230701__20230930_zqmy5lItQT59" title="Weighted average number of shares - Diluted">890</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zwhs1VqvnI4h" title="Weighted average number of shares - Basic"><span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zEvvP0JpaQwk" title="Weighted average number of shares - Basic">1,063</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_908_eifrs-full--WeightedAverageShares_pn3n3_c20230401__20230930_zFwbdmWEq71k" title="Weighted average number of shares - Basic"><span id="xdx_902_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20230930_zNj4OJX6lFad" title="Weighted average number of shares - Diluted">888</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_901_eifrs-full--BasicEarningsLossPerShare_pip0_c20240701__20240930_zzFRLyefpNY" title="Basic loss per share"><span id="xdx_903_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240701__20240930_zwYCQ8ByZGH5" title="Diluted loss per share">(1.26</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_906_eifrs-full--BasicEarningsLossPerShare_pip0_c20230701__20230930_zhj9JnRkGi35" title="Basic loss per share"><span id="xdx_90E_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230701__20230930_zQvzHStWWph2" title="Diluted loss per share">(5.80</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90A_eifrs-full--BasicEarningsLossPerShare_pip0_c20240401__20240930_zFRXdXFQAi2e" title="Basic loss per share"><span id="xdx_901_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240401__20240930_zJxTh14EJkTk" title="Diluted loss per share">(2.84</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eifrs-full--BasicEarningsLossPerShare_pip0_c20230401__20230930_z3P9w4RcoqO9" title="Basic loss per share"><span id="xdx_900_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230401__20230930_zsggS3zYyMub" title="Diluted loss per share">(12.47</span></span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock', window );">Schedule of anti-dilutive effect on loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_ztTT3dH923Ie" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BF_zKm91mX0YDh4" style="display: none">Schedule of anti-dilutive effect on loss per share</span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">As of September 30,</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Warrants</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zs2EOIpMcTnk" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">481,581</td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zV7L6EwwhOMi" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"><span style="-sec-ix-hidden: xdx2ixbrl1158">&#8211;</span></td><td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Stock options</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_z2g5zf249sl7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">65,114</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zmmhajLnAo8b" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">98,171</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zIpnXQz6Gysi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">17,315</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zk0cmB2yQvf1" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">18,937</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfEarningsPerShareTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfEarningsPerShareTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886848752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Financial Instruments And Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock', window );">Schedule of financial instruments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_zipsfya99PV7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span><span id="xdx_8B9_zasVIPpgU6Pb" style="display: none">Schedule of financial instruments</span></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49B_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zUu1WWqUfH05" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_49F_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zGD22lNC0Jyj" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_492_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z6u5FHh8ORl5" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zd0m5ib0Z01l" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49A_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z7D1v6pnwLp2" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_497_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zk8qvAhQiIs5" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--CashAndCashEquivalents_i01I_zGv0ysjUwoB4" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right">1,764</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1246">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right">5,028</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1249">&#8211;</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 6%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">&#8211;</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--PrepaidExpensesAndOtherReceivable_i01I_zpddYPigyQo4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other current assets</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">922</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1253">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1254">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,667</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1256">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0; font-size: 10pt; text-indent: 23.05pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_498_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zLF7FLIsvTo6" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_491_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z4xznnO58W4k" style="font-size: 10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zbNO4yhYYBr3" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_491_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zgZQzdvHCrMb" style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">September 30, 2024 <br/>(Unaudited)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2024</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; text-align: center">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr>
  <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; text-align: right">&#160;</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AccountsPayableAndAccruedLiabilities_i01I_zgWgFVr1Z5Qg" style="vertical-align: bottom; background-color: White">
    <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">845</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">&#8211;</span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">2,836</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1267">&#8211;</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eifrs-full--WarrantLiability_i01I_za1ckSSwfoH9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Warrant liability</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1269">&#8211;</span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">1,138</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">&#8211;</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1,564</td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>






<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886754416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ScheduleOfNoncontrollingInterestTableTextBlock', window );">Schedule of non-controlling interest</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_zYOORpqQXiKk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left"><span><b><span id="xdx_8B0_zJGkj4De6xA2" style="display: none">Schedule of non-controlling interest</span></b></span></td><td style="font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: right">&#160;</td><td style="font-size: 10pt; font-weight: bold; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Saugatuck <br/>and subsidiary</b></span></td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font-size: 10pt; font-weight: bold">Non-controlling interest as of April 1, 2024</td><td style="width: 1%; font-size: 10pt; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4udUogfx4D6" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">(693</td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zes1DKm0cNcg" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net loss attributable to non-controlling interest">(10</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Non-controlling interest as of September 30, 2024</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zJJ9t8JEgnWf" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(703</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr>
  </table>

<p style="margin: 0; font-size: 10pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt">&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Saugatuck <br/>and subsidiary</b></span></td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 87%; font-size: 10pt">Non-controlling interest as of April 1, 2023</td><td style="width: 1%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zRW5e9EgMf2i" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(650</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss attributable to non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z26eLOAlmNya" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net loss attributable to non-controlling interest">(14</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 2.5pt">Non-controlling interest as of September 30, 2023</td><td style="font-size: 10pt; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zm290RE9uf95" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">(664</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ScheduleOfNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ScheduleOfNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887905888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TotalCurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetLossIncome', window );">Net loss</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Cash and cash equivalents on hand</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held by the entity. This does not include demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetLossIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetLossIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TotalCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TotalCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988885720288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">17.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember', window );">Saugatuck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ptgef_CountryOfBritishVirginIslandsMember', window );">Country Of British Virgin Islands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SegmentsAxis=ptgef_CountryOfDelawareMember', window );">Country Of Delaware [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership subsidiary</a></td>
<td class="nump">60.49%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percentage of ownership subsidiary</a></td>
<td class="nump">78.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ptgef_CountryOfBritishVirginIslandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ptgef_CountryOfBritishVirginIslandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SegmentsAxis=ptgef_CountryOfDelawareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SegmentsAxis=ptgef_CountryOfDelawareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886378896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract', window );"><strong>Prepaid Expenses And Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromSaleOfProperties', window );">Prepaid clinical research costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentReceivablesFromRentalOfProperties', window );">Refund from Parexel</a></td>
<td class="nump">552<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAdvancesToSuppliers', window );">Prepaid insurance</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_TaxDeposits', window );">Tax deposits</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Other prepaid expenses</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SecurityDepositOnOfficeLease', window );">Security deposit on office lease expiring in May 2025</a></td>
<td class="nump">14<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Total prepaid expenses and other receivables</a></td>
<td class="nump">$ 922<span></span>
</td>
<td class="nump">$ 2,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current advances made to suppliers before goods or services are received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromRentalOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from rental of properties. [Refer: Receivables from rental of properties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromRentalOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentReceivablesFromSaleOfProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current receivables from sale of properties. [Refer: Receivables from sale of properties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentReceivablesFromSaleOfProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SecurityDepositOnOfficeLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SecurityDepositOnOfficeLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_TaxDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_TaxDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887895504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative) - Parexel International Limited [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WriteoffOfAdvances', window );">Write-off of advances</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RefundReceivables', window );">Refund receivables</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RefundReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RefundReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WriteoffOfAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WriteoffOfAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ptgef_ParexelInternationalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ptgef_ParexelInternationalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988862127792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantLiabilityExercisePrice', window );">Warrants liability exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsLiabilityShares', window );">Warrants liability, shares at beginning</a></td>
<td class="nump">323,686<span></span>
</td>
<td class="nump">323,686<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsLiabilityFairValue', window );">Warrants liability, fair value at beginning</a></td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 1,564<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfWarrantLiabilityAmount', window );">Change in fair value of warrant liability, amount</a></td>
<td class="nump">$ 716<span></span>
</td>
<td class="num">$ (1,142)<span></span>
</td>
<td class="num">$ (6,868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsLiabilityShares', window );">Warrants liability, shares at ending</a></td>
<td class="nump">323,686<span></span>
</td>
<td class="nump">323,686<span></span>
</td>
<td class="nump">323,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsLiabilityFairValue', window );">Warrants liability, fair value at ending</a></td>
<td class="nump">$ 1,138<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 1,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassBWarrantsMember', window );">Class B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAtIssuanceExercisePrice', window );">Fair value of warrants at issuance exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsShares', window );">Fair value of warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAmount', window );">Fair value of warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassCWarrantsMember', window );">Class C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAtIssuanceExercisePrice', window );">Fair value of warrants at issuance exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsShares', window );">Fair value of warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAmount', window );">Fair value of warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAtIssuanceExercisePrice', window );">Fair value of warrants at issuance exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsShares', window );">Fair value of warrants shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantsAmount', window );">Fair value of warrants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfWarrantLiabilityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfWarrantLiabilityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrantsAtIssuanceExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrantsAtIssuanceExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilityExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilityExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsLiabilityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsLiabilityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_ClassCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886893552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details 1) - Series B Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 6.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptions', window );">Expected life</a></td>
<td class="text">3 years 3 days<span></span>
</td>
<td class="text">2 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">90.40%<span></span>
</td>
<td class="nump">159.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">3.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePriceFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePriceFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988862271376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details 2) - Series C Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 6.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptions', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">100.70%<span></span>
</td>
<td class="nump">129.26%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePriceFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePriceFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988889053264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details 3) - Placement Agent Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="nump">$ 47.60<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="nump">$ 6.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OptionLifeShareOptions', window );">Expected life</a></td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
<td class="text">4 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">100.70%<span></span>
</td>
<td class="nump">129.26%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OptionLifeShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OptionLifeShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePriceFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePriceFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988862416480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 29, 2024</div></th>
<th class="th"><div>Sep. 29, 2023</div></th>
<th class="th"><div>Aug. 26, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Net proceeds warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Estimated offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetProceedsWarrantLiability', window );">Net proceeds warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities', window );">Excess of the fair value of the warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_LossOnWarrantLiabilities', window );">Loss on warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ChangeInFairValueOfWarrantLiabilities', window );">Gain (loss) in the fair value of the warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700,000)<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantLiabilityBalance', window );">Warrant liability balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePrice', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Total shares outstanding</a></td>
<td class="nump">1,048,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OrdinarySharesPurchase', window );">Ordinary shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceOfOutstandingWarrant', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.00<span></span>
</td>
<td class="nump">$ 38.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OrdinarySharesPurchase', window );">Ordinary shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceOfOutstandingWarrant', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.20<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantPerShare', window );">Fair value of warrant per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.05<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="nump">$ 22.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OrdinarySharesPurchase', window );">Ordinary shares purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceOfOutstandingWarrant', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.20<span></span>
</td>
<td class="nump">$ 45.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantPerShare', window );">Fair value of warrant per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.91<span></span>
</td>
<td class="nump">3.91<span></span>
</td>
<td class="nump">29.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantMember', window );">Placement Agent Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AggregateGrossProceeds', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ManagementFeePercentage', window );">Management fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AggregateGrossProceedsIncrease', window );">Aggregate gross proceeds increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdministrativeExpense', window );">Non-accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FeeAndCommissionExpense', window );">Clearing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseOfWarrants', window );">Purchase warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SaleOfWarrantPercentage', window );">Sale of warrant percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceWarrantPerShare', window );">Exercise price warrant per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrantPerShare', window );">Fair value of warrant per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.86<span></span>
</td>
<td class="nump">$ 3.86<span></span>
</td>
<td class="nump">$ 29.40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OrdinaryNumberOfStockSold', window );">Number of stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasePriceOfPerShare', window );">Purchase price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_PurchaseAgreementMember', window );">Purchase Agreement [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchasePriceOfPerShare', window );">Purchase price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PurchaseWarrants', window );">Purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity classifies as being administrative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfVotingEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B64<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B64_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfVotingEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AggregateGrossProceedsIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AggregateGrossProceedsIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceOfOutstandingWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceOfOutstandingWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceWarrantPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceWarrantPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrantPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrantPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_LossOnWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_LossOnWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ManagementFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ManagementFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetProceedsWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetProceedsWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OrdinaryNumberOfStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OrdinaryNumberOfStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OrdinarySharesPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OrdinarySharesPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchasePriceOfPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchasePriceOfPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PurchaseWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PurchaseWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SaleOfWarrantPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SaleOfWarrantPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantLiabilityBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantLiabilityBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis=ptgef_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988862144288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract', window );"><strong>Accounts Payable And Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAmountsAccruedToCro', window );">Accounts payable and amounts accrued to CRO</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses', window );">Accrued bonuses and other payroll-related expenses</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedAccountingAndAuditingFees', window );">Accrued accounting and auditing fees</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedLegalFees', window );">Accrued legal fees</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedOtherProfessionalFees', window );">Accrued other professional fees</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherAccountsPayable', window );">Other accounts payable</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccruedClinicalAndRdServices', window );">Accrued clinical and R&amp;D services</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OtherAccruedExpenses', window );">Other</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilityNet', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 845<span></span>
</td>
<td class="nump">$ 2,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAmountsAccruedToCro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAmountsAccruedToCro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedAccountingAndAuditingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedAccountingAndAuditingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedClinicalAndRdServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedClinicalAndRdServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccruedOtherProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccruedOtherProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OtherAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OtherAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988862036896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract', window );"><strong>Accounts Payable And Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughWriteoffFinancialAssets', window );">Accounts payable and accrued liabilities write-off</a></td>
<td class="nump">$ 1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughWriteoffFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in financial assets resulting from write-off. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph IG20B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughWriteoffFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886157808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="nump">$ 1,362<span></span>
</td>
<td class="nump">$ 6,072<span></span>
</td>
<td class="nump">$ 3,024<span></span>
</td>
<td class="nump">$ 12,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IncomeTaxExpenseContinuingOperation', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfTaxLosses', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">8.66%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IncomeTaxExpenseContinuingOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IncomeTaxExpenseContinuingOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988889110416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfTaxLosses', window );">Tax rate effect of tax losses</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">8.66%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988862166416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND RESERVES (Details 1) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ExercisePriceFairValue', window );">Exercise price</a></td>
<td class="nump">$ 38.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharePriceFairvalue', window );">Share price</a></td>
<td class="nump">$ 39.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate</a></td>
<td class="nump">5.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ExercisePriceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ExercisePriceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharePriceFairvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharePriceFairvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886442928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND RESERVES (Details Narrative) - USD ($)<br> $ / shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 06, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CashFundDescription', window );">Cash fund, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Sales Agreement permits the Company
to sell in an ATM program up to $50 million of ordinary shares from time to time. Through September 30, 2024, the Company raised approximately $4.2 million in gross proceeds through the sale of shares of common shares
under the ATM program. Any sales under the prospectus will be deemed to be
made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOrdinaryShareIssued', window );">Number of ordinary share issued</a></td>
<td class="nump">4,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PublicFloat', window );">Public float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsAndPreFundedWarrantsMember', window );">Series A Warrants And Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_WarrantsPerShare', window );">Warrants per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=ptgef_ATMMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesSold', window );">Number of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets', window );">Net proceeds from sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOrdinarySharesOutstandingDecrease', window );">Number of ordinary shares outstanding, decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,808,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOrdinarySharesOutstandingDecrease', window );">Number of ordinary shares outstanding, decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">890,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfBiologicalAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of biological assets. [Refer: Biological assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfBiologicalAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CashFundDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CashFundDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfOrdinaryShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfOrdinaryShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfOrdinarySharesOutstandingDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfOrdinarySharesOutstandingDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_WarrantsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_WarrantsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ptgef_SeriesAWarrantsAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=ptgef_ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=ptgef_ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988889955776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance, beginning of period</a></td>
<td class="nump">$ 23,841<span></span>
</td>
<td class="nump">$ 21,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AdjustmentsForSharebasedPayment', window );">Share-based compensation expense</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_StockOptionReserve', window );">Balance, end of period</a></td>
<td class="nump">$ 24,126<span></span>
</td>
<td class="nump">$ 22,716<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AdjustmentsForSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AdjustmentsForSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_StockOptionReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_StockOptionReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988889615936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 1) - PBI 2021 Equity Incentive Plan [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance, beginning of period</a></td>
<td class="nump">90,281<span></span>
</td>
<td class="nump">98,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement', window );">Expired or forfeited</a></td>
<td class="num">(25,167)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfOutstandingShareOption', window );">Balance, end of period</a></td>
<td class="nump">65,114<span></span>
</td>
<td class="nump">98,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements', window );">Exercisable, end of period</a></td>
<td class="nump">43,723<span></span>
</td>
<td class="nump">38,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfOutstandingShareOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfOutstandingShareOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887906128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember', window );">PBI 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price</a></td>
<td class="nump">$ 205.18<span></span>
</td>
<td class="nump">$ 210.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life (in years)</a></td>
<td class="text">7 years 4 months 20 days<span></span>
</td>
<td class="text">8 years 4 months 9 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988885647088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTION RESERVE (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DescriptionOfRestrictedStockUnitsExpire', window );">Description of share expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">RSUs
expire in January 2031 and 5,165 expire in January 2032.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share based compensation expense</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 743<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted share units [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Shares issued</a></td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesExercise', window );">Number of shares exercise</a></td>
<td class="nump">1,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes', window );">Shares repurchased into treasury employee payroll taxes</a></td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfSharesGranted', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumberOfShareOutstanding', window );">Number of shares outstanding</a></td>
<td class="nump">12,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember', window );">PBI 2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesReservedForAwardsGranted', window );">Shares reserved for awards granted</a></td>
<td class="nump">82,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_SharesAvailableForFutureAwards', window );">Shares available for future awards</a></td>
<td class="nump">59,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DescriptionOfRestrictedStockUnitsExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DescriptionOfRestrictedStockUnitsExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumberOfSharesGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumberOfSharesGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesAvailableForFutureAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesAvailableForFutureAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_SharesReservedForAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_SharesReservedForAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfAntidilutiveInstrumentsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ptgef_PBI2021EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887310496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NumeratorAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Net loss attributable to owners of the Company</a></td>
<td class="num">$ (1,360)<span></span>
</td>
<td class="num">$ (5,158)<span></span>
</td>
<td class="num">$ (3,016)<span></span>
</td>
<td class="num">$ (11,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DenominatorAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares - Basic</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares - Diluted</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">890<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (5.80)<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
<td class="num">$ (12.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share</a></td>
<td class="num">$ (1.26)<span></span>
</td>
<td class="num">$ (5.80)<span></span>
</td>
<td class="num">$ (2.84)<span></span>
</td>
<td class="num">$ (12.47)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886381808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LOSS PER SHARE (Details 1) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShare', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">481,581<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShare', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">65,114<span></span>
</td>
<td class="nump">98,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AntidilutiveEffectOnLossPerShare', window );">Anti-dilutive effect on loss per share</a></td>
<td class="nump">17,315<span></span>
</td>
<td class="nump">18,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AntidilutiveEffectOnLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AntidilutiveEffectOnLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887355936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_RetainageDeposits', window );">Release liability amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_UnbilledContractsReceivables', window );">Unbilled services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ForfeitedAdvancedPayments', window );">Forfeited advanced payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_GainOnLiability', window );">Gain on liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities', window );">Payables to parexel in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Prepaid expenses and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_BudgetedCosts', window );">Budgeted costs</a></td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_BudgetedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_BudgetedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ForfeitedAdvancedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ForfeitedAdvancedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_GainOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_GainOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_RetainageDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_RetainageDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_UnbilledContractsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_UnbilledContractsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988886289056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Notes and other explanatory information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PortagePaidIntensity', window );">Portage paid intensity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CompensationCommittee', window );">Compensation committee</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_OriginalAnnualTargetsPercentage', window );">Original annual targets percentage</a></td>
<td class="nump">73.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFeeAndCommissionExpense', window );">Incurred Board fees total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 82,500<span></span>
</td>
<td class="nump">$ 7,205<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AnnualFeesdescription', window );">Annual fees description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nominating Committee of the Board is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears.
Members of those committees are entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears. All
non-executive board members waived their right to board fees for the six months ended September 30, 2024, except for the non-executive
board members who resigned in late April 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AnnualFeesdescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AnnualFeesdescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CompensationCommittee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CompensationCommittee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_OriginalAnnualTargetsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_OriginalAnnualTargetsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PortagePaidIntensity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PortagePaidIntensity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988862368192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,764<span></span>
</td>
<td class="nump">$ 5,028<span></span>
</td>
<td class="nump">$ 3,445<span></span>
</td>
<td class="nump">$ 10,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember', window );">Amortized Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivable', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">845<span></span>
</td>
<td class="nump">2,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember', window );">Fair Value To Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivable', window );">Prepaid expenses and other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueThroughProfitOrLossMember', window );">Fair Value Through Profit Or Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PrepaidExpensesAndOtherReceivable', window );">Prepaid expenses and other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_AccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">$ 1,138<span></span>
</td>
<td class="nump">$ 1,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_AccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_AccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PrepaidExpensesAndOtherReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PrepaidExpensesAndOtherReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_AmortizedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueToOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueThroughProfitOrLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ptgef_FairValueThroughProfitOrLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988887482304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CAPITAL MANAGEMENT (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_DisclosureCapitalManagementAbstract', window );"><strong>Capital Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_PayablesAndAccruedExpense', window );">Accounts payables and accrued liabilities</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liability - current</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_CurrentAsset', window );">Current assets</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareholdersEquity', window );">Shareholders' equity</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_ShareholdersEquityAttributableToOwners', window );">Shareholders' equity attributable to owners</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_CurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_CurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_DisclosureCapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_DisclosureCapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_PayablesAndAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_PayablesAndAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_ShareholdersEquityAttributableToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_ShareholdersEquityAttributableToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45988889956960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NON-CONTROLLING INTEREST (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at beginning</a></td>
<td class="num">$ (693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at ending</a></td>
<td class="num">(703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember', window );">Saugatuck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at beginning</a></td>
<td class="num">(693)<span></span>
</td>
<td class="num">$ (650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ptgef_NetLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest, at ending</a></td>
<td class="num">$ (703)<span></span>
</td>
<td class="num">$ (664)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptgef_NetLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptgef_NetLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptgef_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ptgef_SaugatuckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=WBD-AIZD0<'CM6HQ2DZ!:>D&M\ 2\GIJI35GDR=D]@V5Y- 7P2I[0-8L*S
MN7D6]!$*O>AP23%8^6[G)+Z?0@M:9 7:#K0LEYREZ;$-6!UJKY"A>[@C,%D%
MT<#6!;5D1'8R=FMM%-?G5_>(7VLS'#X]-#2Q6LXA.^=ZZW*U)[=H[</,<&:J
MK;IW0<-G)M0B#]F1IT9B1N7NEE++7*CNJ\YK]GWM9'#QG4D"(+HT)F#]B1?L
M.OY/H.$U>]2YV=77ZM\POZ>Y "E9J_#N=:AJR7<WU;L7R8KJLG?%I&19];@A
M6,%+&ZCOUTP5H7[1]\?-_Q?,_P-02P,$%     @ Y8%Z64/-4GK?!P  4RD
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MK> KH0P _K^64C]?F #5.<K9_U!+ P04    " #E@7I9K5="Q40)  "32P
M&    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;+V<79.;.!:&_XK*.[6;5,4Q
M" PFV]U5'9N/5$UF4NED]F)J+]18W::"P2/D[LS^^I4P,48(V?2<W9MNL*7G
M",[QD?1*</5<LF_5AE*.OF_SHKJ>;#C?O9O-JG1#MZ1Z6^YH(;YY*-F6<''*
M'F?5CE&RKBMM\QFV+&^V)5DQN;FJ/_O$;J[*/<^S@GYBJ-IOMX3]^9[FY?/U
MQ)[\^.!S]KCA\H/9S=6./-([RK_N/C%Q-CM2UMF6%E56%HC1A^O)K?TN<1Q9
MH2[Q6T:?JY-C)"_EOBR_R9,/Z^N))5M$<YIRB2#BWQ-=TCR7)-&./QKHY&A3
M5CP]_D&/ZHL7%W-/*KHL\W]E:[ZYGBPF:$T?R#[GG\OGA#87-)>\M,RK^B]Z
M;LI:$Y3N*UYNF\JB!=NL./PGWYL;<5(!NP,5<%,!*Q6<(0M.4\%1*KC>0 6W
MJ>"J3?('*LR;"G/50C!0P6LJ>.HUS <J^$T%7ZE@.P,5%DV%1>W=@SMJ7ZX(
M)S=7K'Q&3)86-'E0!T1=6[@P*V3LWG$FOLU$/7ZS+(NUB$2Z1N*H*O-L3;@X
M^5!PRK(MNN/B5(0JKU#Y@)8;4CS2"F4%NML01C=EOJ:L^@<*_]AG_$_TZFM!
M]NM, %ZC*?IZMT*O?GJ-*EFTKO1E4^XK4JRK-^BGSOG5C(MKD2V:I4V[WQ_:
MC0?:_:&J]J*=*=EEG.3H]RW=WE/V;PUH:0;=\3+]AG[=U;^DS[2B[(FBWS\.
MXE9FW&V:[K?[O+Z)O_(-9>*^;D56V<B?NR#_7%:5"1^:\9\I%_E(L"EA158\
M5J8KC\RLQFF$<Y;=[SFYSRGB)2J?"^%3Z>Z=\%O!319BLX5?RF*:E@5G92Z^
M>A0N%U%%*VYL=6)F?BF%O[O59B+FCX&/CX&/:XX[P'E/<E*D] VZW;$L1_8;
MA"WLH%>?&)W>[?*,OQ9W!GTD["URFB]U46HT(CN>=]6.I/1Z(F*@CJW)S=__
M9GO6/W61^@(8TH4H$"<$XD1 G!B(DP YK1-WSC'N''/<T<>LD#]=T>4V$=@D
MR$O"[<#V:K8<ECS=V+YG>5>SI],X,K9@9%"N(&$A)"R"A,60L 0(U@DP]QA@
M;DUWAGK&!U8=N^V?Q9<?Q*'(N/(0U<>ZK/O>A4QDD+ 5)"R$A$60L!@2E@#!
M.@$X/P;@_$4]Z^V#Z/V1/143KBFVQ,3G28PS**KJ 5A5=[FZP#P8FY^D/&PO
M_ 56<MZ\EQFQC2VW6VK5+S5U'3SOE@HUI>QYX-E*GHWZY40R=A5:K*%Y<ZM;
M*.E?I3]W@A;5\81W](1G],3Y._ZC\]'=>*_7[L5":?;2:'_L#QT2%D+"(DA8
M# E+@&"=\/*/X>4;PZN> TZE<B F8F*6(Z8XI)Y&T>_RF.J"RDB\? BW]/L#
MH;FMY(05D+$0B!-=TN@8R%ARQEC'XXNCQQ?G/2ZF\H?)][X0LW]T^^6CSM&+
M7D+S>CG;:&S$? >($P)QHD7OUO>N/0:RE9AM=;P<'+T<O,3+IKXBZ+4B4'QM
M-#FVIX"$A9"P"!(60\(2(%@GHFRKE1FM\S%5AY0<&XKNHN)ZU<_JY0TQ=%%B
MR6QK1.*  H50H*@!>:;KCZ&L)6>L=7U](BG;(_)'R1!)4R8/Q3@4R>9DJ3Z+
M--Q3YZL#Y:79]AC? X%"*%#4@#S#Y<=0QA*SL:[G6TW5-HNJ%WG>U(\T_,ZH
M10T 2,EU!4H+06D1*"T&I250M&Z@M2*J;591?Z%<#$P8)7GV'Q%>CR0KD)AX
M9,43K7B]7J6-KA?H<MK9!Q1H9?<%7==3ADXAE+7H$FLQE+7DC+6NYUMUTS9J
M5[7G<[F()E/*CK*L7&M=_0(%3.]J(- *"A0VH*X\95N^KZA3%Y:+M>44X2P9
M@ 7V@#];L= VJX5AL>XLACR1?$_E6L@=W;U%CC6\%F+KE,' #5RUP]!(@]A7
MQ;R5IMC46<P]]<>H$P=]RPL<]?;W"WJ^Y]GJW=?)@U[O]FM@7A#X W>_%0AM
MLT*HWOUV*>K\[=?H@T%OM 8J$(+20E!:!$J+06D)%*T;9*U,:)MUPO%+[:XV
MX%Z@C TO4;V$IL_K4"HC%"B" L50H 3*==T ;%5+VRQ;7KSFKH^[OL1F!_ZB
MU\V\0-$SI#I(6@A*BT!I,2@M@:)U(ZU53NW@?['X;D,J?4M0V@J4%H+2(E!:
M#$I+H&C=W6VMX(K-@BOP*CSNZ[+U8%N5^7%?4<3.PE5&O2MSX\=L4=,IF$[@
MV ME.*XIZ%I87971X7I#^T13RG'PP-06M[HI-NNF?VVY'O<%O6#1<\\+Y,/A
MU !*"T%I$2@M!J4E4+1NG)WL?+U I1VY;F]&CM!3<%_AQ8NYFA[ =K"";6&]
MH-DQE+7DC+6NWUO1%)M%4SG?BN1R[AH]$\:(W-5/OU.69B(2M$YW>DE?5>/-
M)L?L608"A5"@"&LVVZH.A])*C;:Z[FZ54FQ62HWN-O8D?:W/4X4=L^W1'0GH
M'D]06@1*BT%I"12M&V&M=HO-VNWM>IW)CH/DB)4BTM!^=WS:Y[ $*$7Z!T;2
MIE3[*%!:%D7S^-ISQC?&48\V1HTM&],? 8%64* 0"A1!@6(H4 ( ZH9J*W3C
M,UMA_S^A:DRK?<%\KNZ(,U_%Z+0*JI>#TB)06@Q*2Z!HW5AM]7)\P;[:3ES^
MV$9Q7Q;[:B"Z_/Y8S>KUVE"B-Q0HA )%6+/?5;W^&,I:<L9:U_&M3HW';*_5
M.-Z87C0RM:I1F^V/3B^@&C4H+0*EQ:"T!(K6C;)6H\9CMO?**!.GG&6I?&;Y
MT)?MBXR+8"NH?NP5]%*-^@2BN0EC$@T0*(0"1;B_U]E3TPR0K<1HJ_OX:2L,
M.Q?LQ+W4_::$X_154%4=,#=E]).HD+00E!:!TF)06@)%ZP9<*VL[9EG[PAU;
M9LJ(&1T4: 4%"IV^-#]UK-[CA)<5BW7%;/5Y0CT+#V6/5CMVS-KQ1=NUM,OH
M#5A90=(\O*XIY]I8W:YE;N<8Y_3M3;&+'<=5W=,O:#O!0O6.!N=;Z@J2II0W
M]+2G<_)J ;/ >]EN+KUW- *DK8;>TFQ_=#Z'?;4 [+L%8%\N /MV =#7"\Q.
M7AXD7U?UD;#'K*A03A\$WGKKBR!EAS= '4YXN:O?)W1?<EYNZ\,-)6O*9 'Q
M_4-9\A\G\A5%Q_=PW?P74$L#!!0    ( .6!>EE7TM-3Q08  ,L=   8
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ML4VZQFNU<FP!WI6((<R,:_C!L1'<ZAJA3<AA,,(O_HW5R&% +AEQSAK^6"$
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M!?A>.^ @/[""[4WP^?\!4$L#!!0    ( .6!>EDP)PZ4= <  (L2   8
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M/;Q*T<B]GN#26D]7@Y"SO YW,W@<'L\M9(!D(DY9E 8T@- PSOQ<:.'1.YF
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M1!M.+B)0!]+P.(-:V^6>[@)Y =\4B^<\- =FD2+,741<5@:]AUC<[H2/KOT
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M\I?VL$.)$(FLD%PA&21 )I"(E#H)SS=PP7-:$:4B=W5YVUE2QXK+%(WE?T/
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M- :TGPBA#Q,3H'V Q_\"4$L#!!0    ( .6!>EE1:%8"" D  ,$8   9
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M3'Z;8R:.4\NU3H8-/Z3:&.S9I&0'W*)^+->29G:G$O,<"\5% 1*3J16Z-_/
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MD9+P'$P!O2;;WAX@+/,2MZ*JP.9T82V+0F8(N"2],PH]2<D4GA6I@8<,\%+
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M!X8NGX 7?Z.;Z(G31/S$X-Y3B8[FWA-:[7.R5J6P-C3Y2N)+A8U?(+*% .(
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M]D^/>V'_;&YPU/!?[,"!3A?^,L- )0PMP/N%QBFMOB$#[2?<RS\ 4$L#!!0
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M*P3I+A UX7:%(1/*R%E+O W5-5TCLH+/]QS+[IY#7EM./.?2R2T[Y4&%/*B
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M% [.1?6L9AI%C(<B!OFMMZ&Y!J'4RL0$JOL_8IU/4()7(IXW+E.N% QW7,_
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M9M;+-?VDH+("]'TIZ>;?;ZR!]K=G]!=02P,$%     @ Y8%Z62/D[I)" P
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MX?VY[L;NO^K=X_6)R3TG9B7NR#08S>@V9?<@= LM&CN$MT+32+=B06\H2J-
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M.J%+Q8MHRLM?L*_Z#CP+1#LN:%8'RS/(2%[]HQ^U$ <!DM,?X-8![D<#O#K
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ME;K-(-<!:G_!F'R8Z .:^U'R"U!+ P04    " #E@7I9,R!75!T#  !$"0
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MFT_VN*[>DR7CH=]]I.MI4.(G1W0EC:[D#RFK]#\.<V!TX536#N_"#HF0T.E
M49=6E$!.=L[B_#NJV(%_8*W?6.O_G;4-9T111M7.9; FZ80':>WX8=A_E'QG
M6#2,$G?^!XW(0:O(&96WL!"(0$N%NB04"%W +J&#IPI"/^P.'@EUA\6]@5OH
ML!$Z;!5Z3C<TQS*''466N_2UXMV5#Z[/Y-]Y:H/!P4%5H%C:\UM"QM>EJL^L
M9K2Y(DSLR1C\#J_O%Y=$+&DI@>%"0T._KTM1U&=VW5&\LL?>#5?Z$+7-E;[F
MH# !>G[!N;KOF 6:BU/Z"U!+ P04    " #E@7I9IVGG_N,)  #G;   &0
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M3GTAX'@RK7UF@"X^A-($BJ8K0%F-CMEJ?/##JLEHJA2A+B.41DM:M5+TJEI
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MM78/LGB]O:G38YQE\6J[^23]N4R*!OGKBSC.]@^*#@[W-KOZ/U!+ P04
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M&V6-UG7GE?R30O[WU?A[+2%'N7*=4H$S4W:'>K5NQK'K0?Y+>=G)S5U84:Z
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MD3(:?,195GX]>,'(QDW86AJ<5W>M<*."L@;X7DKLF5:P#KH=G3T"4$L#!!0
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M$"8[P/4UI>+U1"JH/O"8_0]02P,$%     @ Y8%Z67Y\_YG! @  $P<  !D
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M=1:HF\"KEE)-)"O*JKQ@4M7X<IBJ+@Q<!ZC]A#&YG>@#FKX>_@502P,$%
M  @ Y8%Z67+';//[ @  Q D  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN
M>&ULO591;]HP$/XKIVR:6FDC(4!@'40JE&EHZXJ@:Q^J/9CD *M)G-H&RK^?
M[80,JA"M$]M+<K;O^WS?Q1=?=\/XHU@B2GB.HT3TK*64Z85MBV"),1$UEF*B
M5N:,QT2J(5_8(N5(0@.*(]MU',^."4TLOVOFQMSOLI6,:()C#F(5QX1O^QBQ
M3<^J6[N)"5TLI9ZP_6Y*%CA%^2,=<S6R"Y:0QI@(RA+@..]9E_6+04?[&X<[
MBANQ9X-6,F/L40]&8<]R=$ 882 U U&O-0XPBC21"N,IY[2*+35PW]ZQ?S;:
ME989$3A@T3T-Y;)G=2P(<4Y6D9RPS1?,];0T7\ B89ZPR7Q;+0N"E9 LSL$J
M@I@FV9L\YWG8 [C' &X.<%\"FD< C1S0,$*SR(RL*R*)W^5L UQ[*S9MF-P8
MM%)#$_T5IY*K5:IPTI_>W@R^PLWX=G3S'2;#Z7!R-X2S*Y2$1@+<<_@ ;\$&
ML20<1=>6:DL-M(.<OI_1NT?H/;AFB5P*&"8AAH=X6X5:Q.ONXNV[E8133&O0
M<-Z#Z[C-DG@&?PYO5(33*-+7,'R-(WRC.1=3222J@RV_J<61,@4\:!.,_;,L
M:1EILYQ4%^Z%2$F /4M5ID"^1LM_]Z;N.9_*%)^([$!_L]#?K&+W[TV98 AD
MC5Q5O2IL_>N@R0("]>&YJM(5B2"B<X0SFL 6"1?G92FIWJ=ND.!!;(Y361HJ
M"?XR#:TB#:W*\,;]D3Y1=1@^K:C<PB@)U'E0_R<81R2!AVN,9\A+CT(E\6N/
MPHG(#G+@%3GP_D4I>*?4?R*R _WM0G_[=:6 S\@#*A!23@,LTYX1M@VAOF[7
MONNT:O5.UU[OJRIQJSLUK_ Z"+=3A-OY3Y5;O4\[0T(S+UU5)Q"2;6D)5S-U
M7C)]+"'*<F'O78@Q\H7I$X02MDID=M<4LT4K<FENX!?S?=6B9!W%;YJLO[DF
M?$$3 1'.%:53:ZO:XUG/D TD2\VU.V-27>+&7*HV"[EV4.MSQN1NH#<H&C?_
M%U!+ P04    " #E@7I9?( '?@,%  !B'0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6RU65MSXC88?>^OT+@[G=V9;6SY!J3 S!+;4]HF84*R?=CI
M@V($:-:VO)(,R;^O?(G!8%SH:E] MG7.D;XC?Y*EX9:RKWR-L0 O<93PD;86
M(KW6=1ZN<8SX%4UQ(I\L*8N1D)=LI?.48;0H0'&DFX;AZC$BB38>%O=F;#RD
MF8A(@F<,\"R.$7N=X(AN1QK4WFX\D-5:Y#?T\3!%*SS'XBF=,7FEURP+$N.$
M$YH AI<C[1.\#J"; XH:GPG>\KTRR+OR3.G7_&*Z&&E&WB(<X5#D%$C^;? -
MCJ*<2;;C6T6JU9HY<+_\QAX4G9>=>48<W]#H;[(0ZY'6U\ "+U$6B0>Z_1U7
M'7)ROI!&O/@%V[*NZVH@S+B@<066+8A)4OZCERH0>P#)TPXP*X!Y"+!/ *P*
M8!T 7/,$P*X ]KD*3@5PS@6X%: P4R^#543:0P*-AXQN <MK2[:\4-A5H&6
M29*/K+E@\BF1.#&>/][?_ GN9X_3^SOPX,_]A\\^>.]A@4C$P1UB#.76?P"_
M@J>Y!]Z_^P#> 9* QS7-.$H6?*@+V8R<3 \KR4DI:9Z0M, M3<2: S]9X$4+
MWNO&NQUX77:_CH'Y%H.)V4DXQ^D5L(R/P#1,NZ4]-^?#K;;N?)^Z_WWJ03?\
M#Y1(.&Q3;\32JL>35?!9)_BF2\;G @DLLX_X2SZ<RB('7_(B*,K_M(V8DM1N
M)\VSZS5/48A'FDR?'+,-UL:__ Q=X[<VNU22>2K)?)5D@2*RALUV;;/=Q3[V
M, \928O)@2X!7R.& 7Y)"<-M]G:276JO2C*ONYL/\R?^4]FM/.G)ER63TZ]\
M5RP(9/(#SD?H.J"U@GG5-@!4MCU01-88 $X] )S.R,P+Q_,Y?0%"&LN%#D?%
M:)#!D.7645 R.@5CON+9C*$-A_IFW]SC.CW;:M;QCNN8?:=9QV_1<J#9K!1T
M=O%_!M"M ^AV#RW,!2.AD/$KWYXL(4(FRAC'SYBU)LE.PDO?(I5DGDHR7R59
MH(BL87&OMKCW(^;"GDJ;59)Y*LE\E62!(K*&S?W:YOY_IT(.".=9ZW)V4L+=
MO5S4[Q^DHIM.B4M].D/05RD8' M:1K\6;$1U4$=UT!G5NRS/@_7B@LN)!;.0
MM,\L@R-]")W#$'?J71KB<Q1]E8K!L:+=,]IC#(W=UY]QSMAE.,U8N"YF<Y((
M"@3#B&=R)8/C-**O&(,4O3(:14"@%]S^T6<<-=#<:V#I07=S+C7A'$E?J630
M(@E=\X0->Q_A\++!OF(H$>W9I)OJTOE!*9M7L36BT[/@X>),J6B@BJWIG;GS
MSKS,.YH)+N37 4E6K?Z9QS$RH7/TIG2J7FS,6:*^4M% %5O3F-U.!.S\ A[/
M)M-\5P,"_UM&Q"N8)J%<AY$-!K,()>#+[>F5=C?SQ>^8T@T)I6R^4K9 %5O3
M\=VF!+1_Q((;*MV>4,KF*67SE;(%JMB:;N]V(. 96Q#YVJ6@7H E90!M$5MT
M3Y_.\>+8M,W!8?I5M#=0N7B6J*]4-%#%UK1GM[\!NS<X*GO0!I$(/4>X\&>9
MB8SARJ96>]RC2#F#P:!W:(_2[8OS1'VEHH$JMM(>?>\(*,9L51S6<1#2+!'E
M[GU]MSX0_%0<@QW<G\#K&]ARWX/7?GG<MZ,O3Q]O$5N1A(,(+Z64<=63XXZ5
M!WKEA:!I<0#U3(6@<5%<8[3 +*\@GR\I%6\7N4!]K#K^%U!+ P04    " #E
M@7I9^>WAEW8#  !.#0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6RM
M5]N.VC 0_14K756MU"7W %N(M!"J5NIEM73;9T,&$C6Q4]N!]N]K.]F4BT&H
MY87$DSEG?,:#/1YM*?O!,P"!?I4%X6,K$Z*ZLVV^S*#$O$<K(/++BK(2"SED
M:YM7#'"J065A>XX3V27.B16/M.V!Q2-:BR(G\, 0K\L2L]\3*.AV;+G6L^$Q
M7V="&>QX5.$US$$\50],CNR.)<U+(#RG!#%8C:U[]VXV5/[:X5L.6[[SCI22
M!:4_U.!#.K8<-2$H8"D4 Y:/#4RA*!21G,;/EM/J0BK@[OLS^SNM76I98 Y3
M6GS/4Y&-K8&%4ECANA"/=/L>6CVAXEO2@NM?M&U]'0LM:RYHV8+E#,J<-$_\
MJ\W##D#RF %>"_ . <$)@-\"_$LC!"T@N#1"V *T=+O1KA.78('C$:-;Q)2W
M9%,O.OL:+?.5$U4G<\'DUUSB1/SQRWR.'F:/:/[^_G&&7B4@<%[PU^@6/<T3
M].KF-;I!-N(99L!13M 3R05_LV/XFM&:8Y)*X\W>>&0+.4$5QEZVDYDTD_%.
M3,9'GR@1&4<SDD)JP"?G\=$9O"T3TV7'>\[.Q#M+.(>JAWSG#?(<+S#,9WHY
MW#?)^;_HLW^.OI<,ORL57_/Y)_@^UR4P+"@S+6P##<Q0M=G=\0HO86S)W8P#
MVX 5OWSA1LY;4U:O299<DVQV);*]_ ==_H-S[/%G>6H4E'.$A6#YHA9X40 2
M%-$M <8172&1 9K2LL+DMVF1&OY0\ZL#9!/?NG[DC.S-;O8-7J$;#O:]$H.7
M[[C1OM?,%-%U^OW.;2\389>)\&PE)D"HW M/U6)XS5J\)EER3;+9E<CV5B#J
M5B Z6XO?]0$,*<(;N2>L 9&Z7 !3-=B>#+=H@GF^-*U/0QWM%(4LB8/*F1X[
M#88'E9J8B"+_H 0-1(.!N?[ZG?K^?ZM/\J(6QD-LTK]$_['3L7X3T9%^ ]$I
M_8-._^"L?KVRS5Y42=E:LTEHP]+?^_?WO$.E!J^P=[C=&)R\WB XT&H*Z/6"
M$]O-L),[/"NW7<H+! \O$FSP.A9L<#((-@4T"+9W&D1YB*]U9\[1DM9$- U
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M@_TV7KO6W%G9QB$>FTT@6"F;KE,X$,>8S^]$"*+KP4OJGBM]A)%1/494Z2B
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M"#BZ(3[XNWA3"B_4VQOU [N2< K)!6I8Y\BV[&:)GN&_PQL5<AK%9C8T7^,
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M>30E(OO4%K-%8W:EVY&]^8%JV'37\4J3=7MWF,FCPU$$"TEI7;2E))8U4-E
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M!\XH1Q5WR#W.*2MDHVG(@=SC_,$*V>0,Y$#*<9"5,TGWR]]ZGN& VRO8^RM
M@JZ@=4Q(.0ZR<D#,47+I0-IQD+4SO8Z8ZIJ0=YR3K'9^^5''A,SC8._&@)BC
M9PZYQT%V#XRI[VRYD'M<9/>\7CU.=$H7DHZ++)TC?.-TS85\XV)OZD.5\M$<
MY$+B<9'%<[Q2_GI&=R'QN,CB@<L%>B[D@CO[?T@\+^7RD<QU3$@\+K)XCE<U
M!E@=$S*/.YAG=GBA*!<;68F<J[]H5?LZ*]910_J/_?:HX_9;&9N'HO!46U@%
M=98?WD\ZO%OUZ3]02P,$%     @ Y8%Z6?,@BWGI 0  $B(  !H   !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:.T[#0!2%X:U$7@"3^YCP4$)%0XO8
M@!4F#Y'$EF<0R>Z)0A&.14&#YE36V/+U7WVRQIZ_I%U;MMTA;[9]GASWNT->
M-)M2^H<0\G*3]FV^Z?IT.%]9=<.^+>?EL Y]NWQOURGH=#H+P\\9S>/\Y\S)
MZZE/?YG8K5;;97KJEA_[="B_# Z?W?">-RF59O+:#NM4%DTX[JZG<[@<Y.8\
MN9D\ORV:X?E-FE [2"%(ZP<9!%G]((<@KQ\4(2C6#YI!T*Q^T"T$W=8/NH.@
MN_I!]Q!T7S](IBCCE"!IA#6!UH)<"X'7@F +@=B"9 N!V8)H"X':@FP+@=N"
M< N!W()T"X'=@G@+@=Z*>BN!WHIZ*X'>.GK9)M!;46\ET%M1;R706U%O)=!;
M46\ET%M1;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\CT-M&FR4$>AOJ;01Z
M&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z
M^VBSFT!O1[V=0&]'O9U ;T>]G4!O1[V=0&]'O9U [XAZ1P*](^H="?2.J'<D
MT#NBWI% [XAZ1P*]X^AC)8'>$?6.!'I'U#O^I]ZYG'8I7WN^U_C\_Z2ZG.]-
MU\=?EM\G1^Q<< [P"\CC%U!+ P04    " #E@7I9LFA)V-4!  "_(0  $P
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #E@7I9+9V+).X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #E@7I9
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( .6!>ED.=/CCA@,  .4,   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #E@7I9
M\L",/D\%   [&   &               @(')"P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ Y8%Z64/-4GK?!P  4RD  !@
M     ("!3A$  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M .6!>EFM5T+%1 D  )-+   8              " @6,9  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #E@7I95]+34\4&  #+'0  &
M            @('=(@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ Y8%Z6=R1%A5U"0  >Q8  !@              ("!V"D  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( .6!>EG<0 1;* D  !46
M   8              " @8,S  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #E@7I9,"<.E'0'  "+$@  &               @('A/
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ Y8%Z61Y]D%N$
M!@  2A$  !@              ("!BT0  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( .6!>EG73?264P,  (P'   9              "
M@45+  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ Y8%Z
M65%H5@(("0  P1@  !D              ("!STX  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #E@7I9W9S.W$<#  "J!P  &0
M        @($.6   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( .6!>EDXWX7Z; ,  'L'   9              " @8Q;  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ Y8%Z64U:_5&*#0  4B4
M !D              ("!+U\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #E@7I9M2Y-:] %  "O#0  &0              @('P;
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( .6!>EEMX1'E
M504  %X-   9              " @?=R  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ Y8%Z64PCH;2#!0  '0P  !D
M ("!@W@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #E
M@7I9M#9UT+,(  #.%0  &0              @($]?@  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .6!>EF2$%>'T@D  ((9   9
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M970R,RYX;6Q02P$"% ,4    " #E@7I9,F[M4T$$   K$   &0
M    @(&_H0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M .6!>EE\[UJX^ (  +T&   9              " @3>F  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ Y8%Z64O#1_9^ @  = 4  !D
M             ("!9JD  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #E@7I9-MMN"(0"  !H!0  &0              @($;K   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .6!>EGO1B <=0,
M  ()   9              " @=:N  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ Y8%Z62/D[I)" P  H0<  !D              ("!
M@K(  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #E@7I9
MG$P8,/0"  #M!@  &0              @('[M0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( .6!>ED!FF01E0(  $\&   9
M      " @2:Y  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ Y8%Z681#?.KO @  Z@@  !D              ("!\KL  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #E@7I98"A_N!T$  #6&0
M&0              @($8OP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( .6!>EFU[5EE-@,  !0*   9              " @6S#  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ Y8%Z63#N'QNO
M @  Z 8  !D              ("!V<8  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #E@7I9VU<#$5 %   ,)P  &0
M@(&_R0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( .6!
M>EDUPK7U#@,  #,)   9              " @4;/  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ Y8%Z6;<POW41 P  *PD  !D
M         ("!B](  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " #E@7I9,R!75!T#  !$"0  &0              @('3U0  >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .6!>EFG:>?^XPD  .=L
M   9              " @2?9  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ Y8%Z67) M()6 P  A H  !D              ("!0>,
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #E@7I9JIBX
M,I0"  "N!@  &0              @('.Y@  >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( .6!>ED>VBV=^P(  $4*   9
M  " @9GI  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MY8%Z6;4E:QMB @  KP4  !D              ("!R^P  'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " #E@7I9:,_J6BH#  #,"P  &0
M            @(%D[P  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( .6!>EE87E/5T 4  .PA   9              " @<7R  !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ Y8%Z67Y\_YG! @
M$P<  !D              ("!S/@  'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " #E@7I9,3XC3> "  #C!P  &0              @('$
M^P  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( .6!>EER
MQVSS^P(  ,0)   9              " @=O^  !X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ Y8%Z67R !WX#!0  8AT  !D
M     ("!#0(! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .6!>ED($N6FP 0  /XA   9              "
M@<H6 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ Y8%Z
M67I5^*^\ @  S@<  !D              ("!P1L! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " #E@7I9F1/.0PX#  #2"@  &0
M        @(&T'@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( .6!>EG<OVZ(- ,  ,@3   -              "  ?DA 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ Y8%Z69>*NQS     $P(   L
M ( !6"4! %]R96QS+RYR96QS4$L! A0#%     @ Y8%Z69CME5&>!   WR4
M  \              ( !028! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M .6!>EGS((MYZ0$  !(B   :              "  0PK 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .6!>EFR:$G8U0$  +\A   3
M              "  2TM 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !!
- $$ OA$  #,O 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>117</ContextCount>
  <ElementCount>248</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfFinancialPosition</Role>
      <ShortName>Condensed Consolidated Interim Statements of Financial Position (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/InterimStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/NatureOfOperations</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoingConcern</Role>
      <ShortName>GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - WARRANT LIABILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiability</Role>
      <ShortName>WARRANT LIABILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - CAPITAL STOCK AND RESERVES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockAndReserves</Role>
      <ShortName>CAPITAL STOCK AND RESERVES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - STOCK OPTION RESERVE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserve</Role>
      <ShortName>STOCK OPTION RESERVE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShare</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - CAPITAL MANAGEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalManagement</Role>
      <ShortName>CAPITAL MANAGEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - NON-CONTROLLING INTEREST</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterest</Role>
      <ShortName>NON-CONTROLLING INTEREST</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - WARRANT LIABILITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityTables</Role>
      <ShortName>WARRANT LIABILITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiability</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockAndReservesTables</Role>
      <ShortName>CAPITAL STOCK AND RESERVES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockAndReserves</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - STOCK OPTION RESERVE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveTables</Role>
      <ShortName>STOCK OPTION RESERVE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserve</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareTables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - NON-CONTROLLING INTEREST (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterestTables</Role>
      <ShortName>NON-CONTROLLING INTEREST (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Non-controllingInterest</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/GoingConcern</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative</Role>
      <ShortName>BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/BasisOfPresentation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative</Role>
      <ShortName>PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - WARRANT LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails</Role>
      <ShortName>WARRANT LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - WARRANT LIABILITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails1</Role>
      <ShortName>WARRANT LIABILITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure -  WARRANT LIABILITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails2</Role>
      <ShortName>WARRANT LIABILITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - WARRANT LIABILITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetails3</Role>
      <ShortName>WARRANT LIABILITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - WARRANT LIABILITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative</Role>
      <ShortName>WARRANT LIABILITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/WarrantLiabilityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative</Role>
      <ShortName>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/IncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - CAPITAL STOCK AND RESERVES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockAndReservesDetails1</Role>
      <ShortName>CAPITAL STOCK AND RESERVES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockAndReservesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative</Role>
      <ShortName>CAPITAL STOCK AND RESERVES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalStockAndReservesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - STOCK OPTION RESERVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails</Role>
      <ShortName>STOCK OPTION RESERVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - STOCK OPTION RESERVE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails1</Role>
      <ShortName>STOCK OPTION RESERVE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - STOCK OPTION RESERVE (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetails2</Role>
      <ShortName>STOCK OPTION RESERVE (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - STOCK OPTION RESERVE (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/StockOptionReserveDetailsNarrative</Role>
      <ShortName>STOCK OPTION RESERVE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/StockOptionReserveTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareDetails</Role>
      <ShortName>LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShareTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - LOSS PER SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/LossPerShareDetails1</Role>
      <ShortName>LOSS PER SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/LossPerShareTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/CapitalManagementDetailsNarrative</Role>
      <ShortName>CAPITAL MANAGEMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/CapitalManagement</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f6k_112624.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - NON-CONTROLLING INTEREST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://portagebiotech.com/role/Non-controllingInterestDetails</Role>
      <ShortName>NON-CONTROLLING INTEREST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://portagebiotech.com/role/Non-controllingInterestTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="f6k_112624.htm">f6k_112624.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="exh_991.htm">exh_991.htm</File>
    <File>ptgef-20240930.xsd</File>
    <File>ptgef-20240930_cal.xml</File>
    <File>ptgef-20240930_def.xml</File>
    <File>ptgef-20240930_lab.xml</File>
    <File>ptgef-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="17">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="305">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "f6k_112624.htm exh_991.htm": {
   "nsprefix": "ptgef",
   "nsuri": "http://portagebiotech.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "exh_991.htm",
      "f6k_112624.htm"
     ]
    },
    "schema": {
     "local": [
      "ptgef-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ptgef-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptgef-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ptgef-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptgef-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 109,
   "keyCustom": 139,
   "axisStandard": 11,
   "axisCustom": 0,
   "memberStandard": 8,
   "memberCustom": 23,
   "hidden": {
    "total": 124,
    "http://portagebiotech.com/20240930": 76,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 42,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "contextCount": 117,
   "entityCount": 1,
   "segmentCount": 31,
   "elementCount": 389,
   "unitCount": 6,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 305,
    "http://xbrl.sec.gov/dei/2023": 17
   },
   "report": {
    "R1": {
     "role": "http://portagebiotech.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f6k_112624.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "f6k_112624.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition",
     "longName": "00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Financial Position (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
     "longName": "00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
     "longName": "00000004 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "AsOf2023-03-31_ifrs-full_IssuedCapitalMember",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-03-31_ifrs-full_IssuedCapitalMember",
      "name": "ifrs-full:NumberOfSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
     "longName": "00000005 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Interim Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:AdjustmentsForSharebasedPayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://portagebiotech.com/role/NatureOfOperations",
     "longName": "00000006 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:NatureOfOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:NatureOfOperationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://portagebiotech.com/role/GoingConcern",
     "longName": "00000007 - Disclosure - GOING CONCERN",
     "shortName": "GOING CONCERN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfGoingConcernExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfGoingConcernExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://portagebiotech.com/role/BasisOfPresentation",
     "longName": "00000008 - Disclosure - BASIS OF PRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://portagebiotech.com/role/SignificantAccountingPolicies",
     "longName": "00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables",
     "longName": "00000010 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://portagebiotech.com/role/WarrantLiability",
     "longName": "00000011 - Disclosure - WARRANT LIABILITY",
     "shortName": "WARRANT LIABILITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:WarrantLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities",
     "longName": "00000012 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://portagebiotech.com/role/IncomeTaxes",
     "longName": "00000013 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://portagebiotech.com/role/CapitalStockAndReserves",
     "longName": "00000014 - Disclosure - CAPITAL STOCK AND RESERVES",
     "shortName": "CAPITAL STOCK AND RESERVES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:CapitalStockAndReservesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:CapitalStockAndReservesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://portagebiotech.com/role/StockOptionReserve",
     "longName": "00000015 - Disclosure - STOCK OPTION RESERVE",
     "shortName": "STOCK OPTION RESERVE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://portagebiotech.com/role/LossPerShare",
     "longName": "00000016 - Disclosure - LOSS PER SHARE",
     "shortName": "LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities",
     "longName": "00000017 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactions",
     "longName": "00000018 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement",
     "longName": "00000019 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://portagebiotech.com/role/CapitalManagement",
     "longName": "00000020 - Disclosure - CAPITAL MANAGEMENT",
     "shortName": "CAPITAL MANAGEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://portagebiotech.com/role/Non-controllingInterest",
     "longName": "00000021 - Disclosure - NON-CONTROLLING INTEREST",
     "shortName": "NON-CONTROLLING INTEREST",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "00000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables",
     "longName": "00000023 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityTables",
     "longName": "00000024 - Disclosure - WARRANT LIABILITY (Tables)",
     "shortName": "WARRANT LIABILITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables",
     "longName": "00000025 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://portagebiotech.com/role/IncomeTaxesTables",
     "longName": "00000026 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://portagebiotech.com/role/CapitalStockAndReservesTables",
     "longName": "00000027 - Disclosure - CAPITAL STOCK AND RESERVES (Tables)",
     "shortName": "CAPITAL STOCK AND RESERVES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://portagebiotech.com/role/StockOptionReserveTables",
     "longName": "00000028 - Disclosure - STOCK OPTION RESERVE (Tables)",
     "shortName": "STOCK OPTION RESERVE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://portagebiotech.com/role/LossPerShareTables",
     "longName": "00000029 - Disclosure - LOSS PER SHARE (Tables)",
     "shortName": "LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfEarningsPerShareTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfEarningsPerShareTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables",
     "longName": "00000030 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://portagebiotech.com/role/Non-controllingInterestTables",
     "longName": "00000031 - Disclosure - NON-CONTROLLING INTEREST (Tables)",
     "shortName": "NON-CONTROLLING INTEREST (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://portagebiotech.com/role/GoingConcernDetailsNarrative",
     "longName": "00000032 - Disclosure - GOING CONCERN (Details Narrative)",
     "shortName": "GOING CONCERN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ifrs-full:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ifrs-full:Cash",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
     "longName": "00000033 - Disclosure - BASIS OF PRESENTATION (Details Narrative)",
     "shortName": "BASIS OF PRESENTATION (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2021-09-012021-09-30",
      "name": "ptgef:PercentageOfOutstandingShares",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-09-012021-09-30",
      "name": "ptgef:PercentageOfOutstandingShares",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails",
     "longName": "00000034 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
       "ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
       "ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative",
     "longName": "00000035 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)",
     "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30_custom_ParexelInternationalLimitedMember",
      "name": "ptgef:PrepaidExpensesAndOtherReceivablesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_custom_ParexelInternationalLimitedMember",
      "name": "ptgef:PrepaidExpensesAndOtherReceivablesNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails",
     "longName": "00000036 - Disclosure - WARRANT LIABILITY (Details)",
     "shortName": "WARRANT LIABILITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "ptgef:WarrantsLiabilityShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "ptgef:ChangeInFairValueOfWarrantLiabilityAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfWarrantLiabilityTableTextBlock",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails1",
     "longName": "00000037 - Disclosure - WARRANT LIABILITY (Details 1)",
     "shortName": "WARRANT LIABILITY (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2023-10-03_custom_SeriesBWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-10-03_custom_SeriesBWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails2",
     "longName": "00000038 - Disclosure -  WARRANT LIABILITY (Details 2)",
     "shortName": "WARRANT LIABILITY (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2023-10-03_custom_SeriesCWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-10-03_custom_SeriesCWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetails3",
     "longName": "00000039 - Disclosure - WARRANT LIABILITY (Details 3)",
     "shortName": "WARRANT LIABILITY (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-10-03_custom_PlacementAgentWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-10-03_custom_PlacementAgentWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueMeasurementExplanatory",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative",
     "longName": "00000040 - Disclosure - WARRANT LIABILITY (Details Narrative)",
     "shortName": "WARRANT LIABILITY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ptgef:WarrantLiabilityTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails",
     "longName": "00000041 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptgef:AccountsPayableAndAmountsAccruedToCro",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptgef:AccountsPayableAndAmountsAccruedToCro",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative",
     "longName": "00000042 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)",
     "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ifrs-full:OtherPayables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ifrs-full:OtherPayables",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "p",
       "ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetails",
     "longName": "00000043 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:IncomeTaxExpenseContinuingOperation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000044 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:TaxRateEffectOfTaxLosses",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
     "longName": "00000045 - Disclosure - CAPITAL STOCK AND RESERVES (Details 1)",
     "shortName": "CAPITAL STOCK AND RESERVES (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory",
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-10-03_custom_SeriesAWarrantsMember",
      "name": "ptgef:ExercisePriceFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory",
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
     "longName": "00000046 - Disclosure - CAPITAL STOCK AND RESERVES (Details Narrative)",
     "shortName": "CAPITAL STOCK AND RESERVES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:CashFundDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:CashFundDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails",
     "longName": "00000047 - Disclosure - STOCK OPTION RESERVE (Details)",
     "shortName": "STOCK OPTION RESERVE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "ptgef:StockOptionReserve",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "ptgef:StockOptionReserve",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails1",
     "longName": "00000048 - Disclosure - STOCK OPTION RESERVE (Details 1)",
     "shortName": "STOCK OPTION RESERVE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31_custom_PBI2021EquityIncentivePlanMember",
      "name": "ptgef:NumberOfOutstandingShareOption",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_custom_PBI2021EquityIncentivePlanMember",
      "name": "ptgef:NumberOfOutstandingShareOption",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetails2",
     "longName": "00000049 - Disclosure - STOCK OPTION RESERVE (Details 2)",
     "shortName": "STOCK OPTION RESERVE (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "td",
       "tr",
       "table",
       "ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory",
       "ptgef:CapitalStockAndReservesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember",
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
     "longName": "00000050 - Disclosure - STOCK OPTION RESERVE (Details Narrative)",
     "shortName": "STOCK OPTION RESERVE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DescriptionOfRestrictedStockUnitsExpire",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2024-09-30",
      "name": "ptgef:DescriptionOfRestrictedStockUnitsExpire",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://portagebiotech.com/role/LossPerShareDetails",
     "longName": "00000051 - Disclosure - LOSS PER SHARE (Details)",
     "shortName": "LOSS PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2024-07-012024-09-30",
      "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://portagebiotech.com/role/LossPerShareDetails1",
     "longName": "00000052 - Disclosure - LOSS PER SHARE (Details 1)",
     "shortName": "LOSS PER SHARE (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30_ifrs-full_WarrantsMember",
      "name": "ptgef:AntidilutiveEffectOnLossPerShare",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_ifrs-full_WarrantsMember",
      "name": "ptgef:AntidilutiveEffectOnLossPerShare",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock",
       "ifrs-full:EarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
     "longName": "00000053 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptgef:RetainageDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptgef:RetainageDeposits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000054 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2023-04-012023-09-30",
      "name": "ptgef:PortagePaidIntensity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-04-012023-09-30",
      "name": "ptgef:PortagePaidIntensity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
     "longName": "00000055 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)",
     "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30_custom_AmortizedCostMember",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
       "ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://portagebiotech.com/role/CapitalManagementDetailsNarrative",
     "longName": "00000056 - Disclosure - CAPITAL MANAGEMENT (Details Narrative)",
     "shortName": "CAPITAL MANAGEMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptgef:PayablesAndAccruedExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-09-30",
      "name": "ptgef:PayablesAndAccruedExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://portagebiotech.com/role/Non-controllingInterestDetails",
     "longName": "00000057 - Disclosure - NON-CONTROLLING INTEREST (Details)",
     "shortName": "NON-CONTROLLING INTEREST (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31",
      "name": "ifrs-full:NoncontrollingInterests",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_custom_SaugatuckMember",
      "name": "ifrs-full:NoncontrollingInterests",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock",
       "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "exh_991.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ptgef_ATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ATMMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued liabilities",
        "label": "AccountsPayableAndAccruedLiabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccountsPayableAndAccruedLiabilitiesTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAccruedLiabilityNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccountsPayableAndAccruedLiabilityNet",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccountsPayableAndAmountsAccruedToCro": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccountsPayableAndAmountsAccruedToCro",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and amounts accrued to CRO"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedAccountingAndAuditingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccruedAccountingAndAuditingFees",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued accounting and auditing fees"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedBonusesAndOtherPayrollrelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccruedBonusesAndOtherPayrollrelatedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued bonuses and other payroll-related expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedClinicalAndRdServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccruedClinicalAndRdServices",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical and R&amp;D services"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedLegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccruedLegalFees",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued legal fees"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccruedOtherProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccruedOtherProfessionalFees",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued other professional fees"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AccumulatedOtherComprehensiveLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AccumulatedOtherComprehensiveLossMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional round up shares issued for fractional shares in connection with 1-for-20 reverse stock split, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, diluted",
        "verboseLabel": "Weighted average number of shares - Diluted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Adjustments for decrease (increase) in other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued liabilities",
        "label": "Adjustments for increase (decrease) in trade accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for non-cash items:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AdjustmentsForSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AdjustmentsForSharebasedPayment",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "label": "AdjustmentsForSharebasedPayment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_AdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-accountable expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity classifies as being administrative."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r32",
      "r96"
     ]
    },
    "ptgef_AggregateGrossProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AggregateGrossProceeds",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AggregateGrossProceedsIncrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AggregateGrossProceedsIncrease",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate gross proceeds increase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r68"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AmortizedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AmortizedCostMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_AnnualFeesdescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AnnualFeesdescription",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual fees description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ptgef_AntidilutiveEffectOnLossPerShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "AntidilutiveEffectOnLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive effect on loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AntidilutiveInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AntidilutiveInstrumentsMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r69",
      "r89",
      "r91"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share, basic",
        "verboseLabel": "Basic loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r77",
      "r80",
      "r106",
      "r107",
      "r150"
     ]
    },
    "ptgef_BudgetedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "BudgetedCosts",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Budgeted costs"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CapitalStockAndReservesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "CapitalStockAndReservesTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReserves"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL STOCK AND RESERVES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period",
        "periodEndLabel": "Cash and cash equivalents at end of the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r46",
      "r62"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CashFundDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "CashFundDescription",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash fund, description"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashOnHand": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOnHand",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents on hand"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash held by the entity. This does not include demand deposits."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ptgef_CashPaidForInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "CashPaidForInterest",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CashUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "CashUsedInOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      },
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of deferred purchase price payable \u0096 Tarus and deferred obligation \u0096 iOx milestone",
        "negatedLabel": "Change in fair value of deferred purchase price payable \u2013 Tarus and deferred obligation \u2013 iOx milestone"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ChangeInFairValueOfWarrantLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) in the fair value of the warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfWarrantLiabilityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ChangeInFairValueOfWarrantLiabilityAmount",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of warrant liability, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangeInFairValueOfWarrantsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ChangeInFairValueOfWarrantsLiability",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 2.0
      },
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Change in fair value of warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ChangesInOperatingWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ChangesInOperatingWorkingCapitalAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating working capital:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ClassBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ClassBWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ClassCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ClassCWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ptgef_CommitmentsAndContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "CommitmentsAndContingentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingent Liabilities (Note 12)"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CompensationCommittee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "CompensationCommittee",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation committee"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss attributable to:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ComprehensiveIncomeAttributableToOwnerOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ComprehensiveIncomeAttributableToOwnerOfParent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss for period",
        "label": "ComprehensiveIncomeAttributableToOwnerOfParent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ptgef_ComprehensiveIncomeAttributableToOwnerOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Owners of the Company",
        "label": "Comprehensive income from continuing operations, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The comprehensive income from continuing operations attributable to owners of the parent. [Refer: Comprehensive income from continuing operations]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ptgef_ComprehensiveIncomeAttributableToOwnerOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Comprehensive income from discontinued operations, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The comprehensive income from discontinued operations attributable to owners of the parent. [Refer: Comprehensive income from discontinued operations]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ptgef_ComprehensiveLossForPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ComprehensiveLossForPeriod",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss for period",
        "label": "ComprehensiveLossForPeriod"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_CounterpartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ptgef_CountryOfBritishVirginIslandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "CountryOfBritishVirginIslandsMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Of British Virgin Islands [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_CountryOfDelawareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "CountryOfDelawareMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Of Delaware [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAdvancesToSuppliers",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ptgef_CurrentAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "CurrentAsset",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets",
        "label": "CurrentAsset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r58",
      "r105"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagementDetailsNarrative",
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability - current, including interest",
        "verboseLabel": "Lease liability - current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r60",
      "r105"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other receivables",
        "label": "Current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_CurrentReceivablesFromRentalOfProperties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentReceivablesFromRentalOfProperties",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Refund from Parexel"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables from rental of properties. [Refer: Receivables from rental of properties]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_CurrentReceivablesFromSaleOfProperties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentReceivablesFromSaleOfProperties",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid clinical research costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current receivables from sale of properties. [Refer: Receivables from sale of properties]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99"
     ]
    },
    "ifrs-full_DecreaseThroughWriteoffFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DecreaseThroughWriteoffFinancialAssets",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities write-off"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in financial assets resulting from write-off. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ]
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitPlansAxis",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitPlansMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ptgef_DenominatorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DenominatorAbstract",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation expense",
        "label": "Depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r21",
      "r63",
      "r87",
      "r93",
      "r95"
     ]
    },
    "ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ptgef_DescriptionOfRestrictedStockUnitsExpire": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DescriptionOfRestrictedStockUnitsExpire",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of share expire"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share, diluted",
        "verboseLabel": "Diluted loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "ptgef_DisclosureAccountsPayableAndAccruedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureAccountsPayableAndAccruedLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable And Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureCapitalManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureCapitalManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Management"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureCapitalStockAndReservesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureCapitalStockAndReservesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock And Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureFinancialInstrumentsAndRiskManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureFinancialInstrumentsAndRiskManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments And Risk Management"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureNatureOfOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureNatureOfOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature Of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureOfCapitalManagementExplanatoryTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL MANAGEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_DisclosureOfDefinedBenefitPlansTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDefinedBenefitPlansTable",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of defined benefit plans [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to defined benefit plans."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for fair value measurement."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ptgef_DisclosureOfFairValueMeasurementOfWarrantsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureOfFairValueMeasurementOfWarrantsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of fair value",
        "label": "DisclosureOfFairValueMeasurementOfWarrantsExplanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGoingConcernExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGoingConcernExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOING CONCERN"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInterestsInOtherEntitiesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterest"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CONTROLLING INTEREST"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for interests in other entities."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average exercise price and the remaining contractual life"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ptgef_DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND OTHER RECEIVABLES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserve"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK OPTION RESERVE"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r66"
     ]
    },
    "ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ptgef_DisclosurePrepaidExpensesAndOtherReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosurePrepaidExpensesAndOtherReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_DisclosureWarrantLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "DisclosureWarrantLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r128",
      "r129"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER SHARE"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSubsidiariesMember",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r66"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r14",
      "r48",
      "r50",
      "r67",
      "r68",
      "r69"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity attributable to owners of the Company",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ptgef_EquityPreSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "EquityPreSplit",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, April 1, 2023 (Pre-Split)",
        "periodEndLabel": "Ending balance, value",
        "label": "EquityPreSplit"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ExercisePrice",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExercisePriceFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ExercisePriceFairValue",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ptgef_ExercisePriceOfOutstandingWarrant": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ExercisePriceOfOutstandingWarrant",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price",
        "label": "ExercisePriceOfOutstandingWarrant"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ExercisePriceWarrantPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ExercisePriceWarrantPerShare",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price warrant per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "verboseLabel": "Expected dividend"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfSharesIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "FairValueOfSharesIssuedForServices",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of shares issued for services"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfWarrantPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "FairValueOfWarrantPerShare",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant per share"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "FairValueOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfWarrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "FairValueOfWarrantsAmount",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants amount"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfWarrantsAtIssuanceExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "FairValueOfWarrantsAtIssuanceExercisePrice",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants at issuance exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "FairValueOfWarrantsShares",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueThroughProfitOrLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "FairValueThroughProfitOrLossMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Through Profit Or Loss [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_FairValueToOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "FairValueToOtherComprehensiveIncomeMember",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value To Other Comprehensive Income [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clearing fees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to fees and commissions."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ptgef_ForfeitedAdvancedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ForfeitedAdvancedPayments",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited advanced payments"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GainOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "GainOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain on liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_GainOnSettlementWithParexelIoxCro": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "GainOnSettlementWithParexelIoxCro",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 4.0
      },
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on settlement with Parexel \u2013 iOx CRO",
        "label": "Gain on settlement with Parexel \u2013 iOx CRO"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange transaction (loss) gain"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r28"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ptgef_IfrsStatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "IfrsStatementLineItems",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative",
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails",
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/LossPerShareDetails1",
      "http://portagebiotech.com/role/Non-controllingInterestDetails",
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative",
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IfrsStatementLineItems [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_IncomeTaxExpenseContinuingOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "IncomeTaxExpenseContinuingOperation",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit",
        "label": "IncomeTaxExpenseContinuingOperation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ptgef_NetLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax benefit (expense)",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r22",
      "r23",
      "r24",
      "r33",
      "r65",
      "r88"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Decrease in cash and cash equivalents during the period",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in deferred tax liability",
        "label": "Increase (decrease) in deferred tax liability (asset)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess of the fair value of the warrant liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ptgef_IncreaseDecreaseInShareOfLossInAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "IncreaseDecreaseInShareOfLossInAssociate",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share of loss in associate",
        "label": "IncreaseDecreaseInShareOfLossInAssociate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital stock"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ptgef_LeaseLiabilityIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "LeaseLiabilityIncurred",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability incurred"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r68"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r69",
      "r89",
      "r92"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_LossOnWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "LossOnWarrantLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ManagementFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ManagementFeePercentage",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management fee percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NatureOfOperationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NatureOfOperationsExplanatory",
     "presentation": [
      "http://portagebiotech.com/role/NatureOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NetLoss",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ptgef_ComprehensiveLossForPeriod",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "NetLoss"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NetLossAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetLossIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NetLossIncome",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetProceedsWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NetProceedsWarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetUnrealizedGainOnInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NetUnrealizedGainOnInvestment",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net unrealized gain on investments"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NetUnrealizedGainOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NetUnrealizedGainOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ptgef_ComprehensiveLossForPeriod",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net unrealized (loss) gain on investments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition",
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interest",
        "periodStartLabel": "Non-controlling interest, at beginning",
        "periodEndLabel": "Non-controlling interest, at ending"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r52",
      "r56"
     ]
    },
    "ifrs-full_NoncontrollingInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterestsMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interests [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r59",
      "r105"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability - non-current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r61",
      "r105"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and other explanatory information [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfOrdinaryShareIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumberOfOrdinaryShareIssued",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of ordinary share issued"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfOrdinarySharesOutstandingDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumberOfOrdinarySharesOutstandingDecrease",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of ordinary shares outstanding, decrease"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfOutstandingShareOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumberOfOutstandingShareOption",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of period",
        "periodEndLabel": "Balance, end of period",
        "label": "NumberOfOutstandingShareOption"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, end of period"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired or forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfShareOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumberOfShareOutstanding",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfSharesExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumberOfSharesExercise",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares exercise"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumberOfSharesGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumberOfSharesGranted",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Total shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ptgef_NumberOfSharesSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumberOfSharesSold",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares sold"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_NumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "NumeratorAbstract",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "OfferingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OptionLifeShareOptions": {
     "xbrltype": "durationItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "OptionLifeShareOptions",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OrdinaryNumberOfStockSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "OrdinaryNumberOfStockSold",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock sold"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OrdinarySharesPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "OrdinarySharesPurchase",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OriginalAnnualTargetsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "OriginalAnnualTargetsPercentage",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original annual targets percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "OtherAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_OtherAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "OtherAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "OtherAccruedExpenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_OtherFeeAndCommissionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFeeAndCommissionExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred Board fees total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/AccountsPayableAndAccruedLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable and accrued liabilities",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ptgef_PBI2021EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PBI2021EquityIncentivePlanMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2",
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PBI 2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ParexelInternationalLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ParexelInternationalLimitedMember",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parexel International Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PayablesAndAccruedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PayablesAndAccruedExpense",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payables and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PayablesToParexelInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PayablesToParexelInAccountsPayableAndAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables to parexel in accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share issuance costs",
        "label": "Payments for share issue costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ptgef_PercentageOfOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PercentageOfOutstandingShares",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of outstanding shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfVotingEquityInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfVotingEquityInterestsAcquired",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ptgef_PlacementAgentWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PlacementAgentWarrantMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PortagePaidIntensity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PortagePaidIntensity",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portage paid intensity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ptgef_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrefundedWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PrefundedWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrefundedWarrantsExercisedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PrefundedWarrantsExercisedShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Funded warrants exercised, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrepaidExpensesAndOtherReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PrepaidExpensesAndOtherReceivable",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other current assets",
        "label": "PrepaidExpensesAndOtherReceivable"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PrepaidExpensesAndOtherReceivablesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PrepaidExpensesAndOtherReceivablesNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid expenses and other receivables",
        "label": "PrepaidExpensesAndOtherReceivablesNoncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ProceedsFromExerciseOfPrefundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ProceedsFromExerciseOfPrefundedWarrants",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the\u00a0exercise of Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_ProceedsFromSalesOfBiologicalAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromSalesOfBiologicalAssets",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of biological assets. [Refer: Biological assets]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from shares issued under ATM and Committed Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfessionalFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated offering expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows",
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss for period",
        "verboseLabel": "Net loss for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r17",
      "r45",
      "r49",
      "r51",
      "r89",
      "r90",
      "r105",
      "r108"
     ]
    },
    "ifrs-full_ProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss attributable to:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToNoncontrollingInterests",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Profit (loss), attributable to non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r55"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Owners of the Company",
        "verboseLabel": "Net loss attributable to owners of the Company"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ptgef_NetLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails",
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before benefit for income taxes",
        "negatedLabel": "Loss before income taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r95",
      "r96",
      "r113",
      "r114"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r103",
      "r140"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of ownership subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r34",
      "r36",
      "r57"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-controlling interest",
        "label": "Proportion of ownership interests held by non-controlling interests"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ptgef_PublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public float"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PurchaseAgreementMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchaseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PurchaseOfWarrants",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchasePriceOfPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PurchasePriceOfPerShare",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price of per share"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_PurchaseWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "PurchaseWarrants",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase ordinary shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r77",
      "r80",
      "r106",
      "r107",
      "r150"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r77",
      "r80",
      "r106",
      "r107",
      "r150"
     ]
    },
    "ptgef_RefundReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "RefundReceivables",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Refund receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RepaymentOfLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "RepaymentOfLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liability",
        "label": "RepaymentOfLeaseLiability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted share units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing restricted share units."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ptgef_RestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "RestrictedStockUnitsMember",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RetainageDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "RetainageDeposits",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Release liability amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r97"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income, net"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r86",
      "r93",
      "r137"
     ]
    },
    "ptgef_ReverseStockSplitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ReverseStockSplitShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "After 1-for-20 reverse stock split, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ReverseStockSplitValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ReverseStockSplitValue",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance, April 1, 2023 (After 1-for-20 reverse stock split)"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_RightToUseAssetAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "RightToUseAssetAcquired",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right to use asset acquired"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right to use asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r76"
     ]
    },
    "ptgef_SaleOfWarrantPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SaleOfWarrantPercentage",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of warrant percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SaugatuckMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SaugatuckMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/Non-controllingInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Saugatuck [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ScheduleOfAntiDilutiveEffectTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of anti-dilutive effect on loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfEarningsPerShareTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ScheduleOfEarningsPerShareTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of basic and diluted EPS calculations"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of financial instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfNoncontrollingInterestTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ScheduleOfNoncontrollingInterestTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/Non-controllingInterestTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of non-controlling interest"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of effective income tax rates"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of changes in the number of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfTermsStockOptionReserveTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ScheduleOfTermsStockOptionReserveTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ScheduleOfWarrantLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ScheduleOfWarrantLiabilityTableTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of changes in the warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ptgef_SecurityDepositOnOfficeLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SecurityDepositOnOfficeLease",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security deposit on office lease expiring in May 2025"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_SegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsAxis",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r73",
      "r89",
      "r102",
      "r109"
     ]
    },
    "ifrs-full_SegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SegmentsMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r73",
      "r94",
      "r102",
      "r109"
     ]
    },
    "ptgef_SeriesAWarrantsAndPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SeriesAWarrantsAndPreFundedWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants And Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SeriesCWarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative",
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Share issuance costs",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of loss in associate accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ptgef_SharePriceFairvalue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharePriceFairvalue",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ShareholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_ShareholdersEquityAttributableToOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "ShareholdersEquityAttributableToOwners",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/CapitalManagementDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity attributable to owners"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesAvailableForFutureAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesAvailableForFutureAwards",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for future awards"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedForAccruedBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesIssuedForAccruedBonuses",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for accrued bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedForAccruedBonusesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesIssuedForAccruedBonusesShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for accrued bonuses, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedForRestrictedStockUnitsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesIssuedForRestrictedStockUnitsNet",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for restricted stock units, net"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedForRestrictedStockUnitsNetShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesIssuedForRestrictedStockUnitsNetShares",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for restricted stock units, net, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedOrAccruedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesIssuedOrAccruedForServices",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued or accrued for services"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedOrAccruedForServicesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesIssuedOrAccruedForServicesShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued or accrued for services, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderAtm": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesIssuedUnderAtm",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under ATM"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesIssuedUnderAtmShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesIssuedUnderAtmShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued under ATM, shares"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesRepurchasedIntoTreasuryEmployeePayrollTaxes": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesRepurchasedIntoTreasuryEmployeePayrollTaxes",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares repurchased into treasury employee payroll taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SharesReservedForAwardsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SharesReservedForAwardsGranted",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares reserved for awards granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r37",
      "r66"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity",
      "http://portagebiotech.com/role/WarrantLiabilityDetails",
      "http://portagebiotech.com/role/WarrantLiabilityDetails1",
      "http://portagebiotech.com/role/WarrantLiabilityDetails2",
      "http://portagebiotech.com/role/WarrantLiabilityDetails3",
      "http://portagebiotech.com/role/WarrantLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "StockOptionReserve",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of period",
        "periodEndLabel": "Balance, end of period",
        "label": "StockOptionReserve"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "StockOptionReserveMember",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Reserve [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SupplementalDisclosureOfCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SupplementalDisclosureOfCashFlowInformationAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "SupplementalDisclosureOfNoncashInvestingAndFinancingActivitiesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_TaxDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "TaxDeposits",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentPrepayments",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxRateEffectOfTaxLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxRateEffectOfTaxLosses",
     "presentation": [
      "http://portagebiotech.com/role/IncomeTaxesDetails",
      "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective tax rate",
        "verboseLabel": "Tax rate effect of tax losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from tax losses. [Refer: Average effective tax rate; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative",
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r77",
      "r80",
      "r106",
      "r107",
      "r150"
     ]
    },
    "ptgef_TotalCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "TotalCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for transactions that are recognised separately from the acquisition of assets and assumption of liabilities in business combinations. It also represents the standard value for the 'Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination' axis if no other member is used. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ptgef_UnbilledContractsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "UnbilledContractsReceivables",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unbilled services"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant liability",
        "label": "Warrant liability [Default Label]"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ptgef_WarrantLiabilityBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "WarrantLiabilityBalance",
     "crdr": "credit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability balance"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantLiabilityExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "WarrantLiabilityExercisePrice",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants liability exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantLiabilityNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "WarrantLiabilityNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantLiabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "WarrantLiabilityTextBlock",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WARRANT LIABILITY"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsLiabilityFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "WarrantsLiabilityFairValue",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants liability, fair value at beginning",
        "periodEndLabel": "Warrants liability, fair value at ending",
        "label": "WarrantsLiabilityFairValue"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WarrantsLiabilityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "WarrantsLiabilityShares",
     "presentation": [
      "http://portagebiotech.com/role/WarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants liability, shares at beginning",
        "periodEndLabel": "Warrants liability, shares at ending",
        "label": "WarrantsLiabilityShares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://portagebiotech.com/role/LossPerShareDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing warrants."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ptgef_WarrantsPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "WarrantsPerShare",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants per share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://portagebiotech.com/role/CapitalStockAndReservesDetails1",
      "http://portagebiotech.com/role/StockOptionReserveDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected life",
        "label": "Weighted average remaining contractual life (in years)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
      "http://portagebiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, basic",
        "verboseLabel": "Weighted average number of shares - Basic"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract",
     "presentation": [
      "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ptgef_WriteoffOfAdvances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://portagebiotech.com/20240930",
     "localname": "WriteoffOfAdvances",
     "crdr": "debit",
     "presentation": [
      "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Write-off of advances"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://portagebiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "1",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_1&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS13_g91-99_TI",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_l&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG20B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001171843-24-006599-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-24-006599-xbrl.zip
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M5RR"G!G%)TBMF2ZH]@V$?*V $.POT'#IG> ?YOW,V\1N9FRI+' ;)D?NY/[
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MMDO:(YXS%XH@/C%YW6*(TGO/V'-F+4T_9XJZ-?W"?:%()E\%<1$+QUQ:F=Q
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M!;[K-K+C0NF J]TQ.HS_XN^S5'O@X3%<%NS.;(YE#!MK@ C09DQ/9V;+GG:
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M7-N#^:GY0 &PJQJ@C>;@ ;M\P& O)5LD0Y./I3-F:?M#8%=JY#RE*PLB[%/
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MG&V+Y#,G87;Y%6/$,43@DV##FQ7(92FXW0CL">:<=83&LEUFX+[N;XT<H@6
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M!AO"EN+TAI -QD$>DU=W6_OBU1^D9@A[IJI=""=TQ%P111AK<:UB9X/XN4@
M,\H<X?^QG>W7LY,&O"-),L;%-D?5$8EQPN/+0,%_D8$U#*:I8T)/^Y$">OB3
MM60B3C'$>L%.IV,:@?."@XDNHHJIV?LR*!&PD;",.+C;DC:#21A9 S 6)SB
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M X >'12(AF9'FV$;SV]7'8<( \O $!59Z]0G8-YZ& Z;YQ)4E0C\7'>JT&7
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MU37AP/M3,S32H='6E0 ]C&C"%$-X<0Q"9WVT<6L36.F4<Y&P5(8J5+T8A"+
MZ,'R:!RRV9X+R84Y[I.6Y*"'.T4:-X<25ICPP[8!T&6),-Y@S&V" <9(PDZ
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MC3-W00#X',BB2+@OS(]C*;8C^'#3*-(.%)JE$>353).A&6"*JEC?M-$IXO.
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M@PX/VF>L6-JNHN9S%?YO(/_'%GSS$$Y]U:DZKW>;5$30JW')1>1%")5NG^S
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MJ-5DJX4R-QSLA+[>3N#,46TA<W'@%C+)O&_WH6\/\=M#_/803\9#](VP174
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M?)(#:/FF4P!'X^M:'XR"#BZ&B3@P J:CI1\<CT;V!QTD@V4<QNJ^1^ HRP)
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MIE-P(NQH_^>]P[$/"!8\OOM97@:OWZ5IT-@Q:0!UF:JEJ"?DJ2_P@KBOMIG
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M<\LQ\!NP*:TKI[&<"8S(  Q^^R[I91ML=Z=7]M?9=//R836Z&MR,0_NBAT3
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MW-J53,>A G-=_D_OE/\74G *EV^S#^VM.'L[0B);F<Q3V&!4JP^9^0]K71(
MRZ@I[50 +(RS*\T?<E.=^_WT63A"W*P83EK<8#CI$F:2Y_[#22,+@-@>!, Z
MW<<7V'_GDYT*W7E2$1/U0:O<*@EKJZ=6P&Z=*1NU[ORS<O=Y]ZXTA@_90PV3
M2@4-DTIUY_<SN7CY>-'*/1:^ATD=:IA4*O%UPZ1 -G[<W[1N&LUTCW.,LN,?
M)I7MSAN-84VO/?,/UP<=)@5<FWNXOBA\OLFY$7<RPZ2JW7GG*:.,^-FGD2I^
MX3 I.,CL:7H]Z*AE^5T,$C/'/TP*9R2U\P]B[U%J\&O0P?(8S9[-'_XG6/2J
M[#C#%F3ILGNJQJKHC=) K2%*C#<YUN77P=H#E^(6\KWN?-P0?Y?3[/0EL^40
M-C(!*WF^D$U?2!7A14VGK\J?TWGSBOWQJ]&\OV=:M39S?U5JUVS'6&]?HTN7
M4+F//=P]"R5!!Q%Q9KZA_S!G8(+3-GT:D(9@(@.;;-!J)+L-0:UU;W<A$-&=
M)7&&1#BC-V- 1(O$AT1&9P@Z(RD:SCC55;%GT)<<^,F>@2I0'6^H2,!?FC68
MU++-8#UW@GO,\MXZ(SD6AZFZO5B\H5H'H9U"SE?E^Q\ NA:.O_P@52S5 9P!
M-KU8C.T9B\Q:6(PM89$92T9 X4/PBOJ0U9FI8D@\NE[-.F>P6D "XEA9TX!!
M?R@N;)4Q,6-X9<'V8*78XH*D&&_AA^>,JQ*9 (G.EFJ!571A$"OEB<6$ !U@
MJ6+9M:R)\ '!6ZI%"WH!)V-#'2N:\$VVKH.0^54FK:)I"5BC @N-/3=-FV./
M*:7X8L K+4P4[O>*!RP.HESJ@0)E8H 3E>>@S; Q@U:6DM_W;$#R+D"ZH*V1
MX)@^5 P-/J7%&= TP.QV#:=F1XH!P/W[R =\)1.IH %?BUK(UE.\<GY3O,)W
MZ<Z?.WS^6>KPO5<NM$3'JZ78Q3D;E.9\=<+-<L5.OCM_X1KZRTS7/U[>HE3L
MK";@(Z[(L2Z>*1:[?C&BTO6E5&_,.V5L/++AQMMGNA]'_8X#JTK7+VJ3G_#3
M]WXCH0R"0;4%7'97775(LJIV?4,/I>>V\%LO-:8AL/K7D56MZQ<+&(S*K8XD
MU)YK7T!6.ZHA^]/*7#HD$KAJIMSIW_.@D_/^E>5P!SUX>*';-\0/#7$7Z]BO
M &:6N'JC""KZ(DL]C239=<4RZ&35^NW3H*]_\NR/+5G.%[+T,_CY?QA1AP6Y
M'[_LDVST-OI <C/>_U[^0$62F<*&M5"!F<JW@0Z]J;SLO_O#JR@/6SL86M?0
M4I6^J#< ,R478CI*DZ"EV6^QJI6LDO;/(WRY^FR\:M7GYJNK1=9:V Z<(.;$
M=Z(=<X-,PF1B@T2BM-_T+YJW$D_[%C-MFN*\-=$M50$=>57BSIDD D>4MN.(
M)4^ IKWRLZ>'T?LP?90<$9[!"?^W2X[(QI/9P#;2>Z_R6XO\OU^2]5Z2W+8O
MR8);J/PAM%L7"I>\>3M*OEF5E)I,1FW!&XESTO%$,O?]EIS66Y+>]BU9</_E
M;TNOER+;:[E&E!\33X0G R>3&]1IA&A7R7@B[S=8]:"/B:_97G$WQI25D2@O
M&>[I^6U1?Y.;A4M^A>&^X["7GT7O.N2?W0;M^U[?]SJ&>QWMB-RE.F5YL?FQ
ME9^ZE/3RW6%B*_VY'%;O3M.ZPAPO1J&=N.J5IVPM&UQTOH3,,XK&57ZA$H^9
M/\)B$]C5I](3G;O*3:O>N0DIA?<YE4E2:S?),?O(;.#Y2:4VTDV66FBO.G H
M*#<Z>&8W!T=MRL_ "%*OOCMC?%5GC,1:DF+)(35M-WIJ[O/S<[8325'>2%(L
MG>IC-,M*=?VNXRIS_B))L<(CELH=JZ18=?#";@Y>*/HYM?<N)W;94?I;[XC6
M9\?GA5]PTTV'6O+Q8R+7,\-=2),M3U.;3%J)ZS%[-WW?Z#2[U#;"O8/X[T-(
MD5T>>4<J$F@:.;]^#M^:QK%I&J%M?7W>] 5WY<6TQX^>:A_YY&;<&#H%,+JF
ML7"JV[=,\_HY)UVP_!%H&F'^TO2.5/N]:!JA!]^1BE0H^ 4+OUC3./;^H.6E
M&@02'K!+9$Y<7]HDCK,C52GI$4 $SE89#89+K%(:]ZBR!7_(_*+=F G]\>V+
M+7HHNKPH6A5),D71FIM/7RIWA?+L]?+*,?RJOB02(4H4>/M-?!CIJ);)P@ S
MW\A0*ZK8"X'B)I?(1-7HUKI$\CQUO%Z9U5V%OTI-VHF46#OK(8)(6')\#-^*
MUW+[_5),9]>4";7U9<+2[G>3^=6]_O0T'J8.+1-6>"LR4:V-+Y4)JRX158-;
MZQ+9\\*1>&!.O:WX%RH3I?65B05GQT7[F7^^N"N)*6%-R9'<1)M8V/WZLS-,
M9FK7[YWW+] FPCT5F:CVQU?K$RNNL1>U*'5>R'QK%$>K4:36UR@6'!SI5G&:
M:7/*1[.XIEQ(;*)1+.RN#0;WZ?G+[,;H?8%&$>:5R.Y%0=^#1A%ZB;VH1<G4
M><8OE>[K5(KU^K-?=.<?2B_3$43AX\(IA=VRY\<6O4/VU&'E-K"_$/8^405=
M55BSRRC#FEZ]F*Y875A()J@X&L-GK+S0Y!E0TUDJ 1_!/D0"'%@!M&EC2=2Q
M/U')&, J3#)[XMW619F3#*O-DBLAEJ0SY?]7,]O'C V5&[+8*=;LTA/[J<"G
MS1[V/EU\XMC&AR?#PWOH/^XI$^'ON E%>XHUMI:]?]"L/C?8F];066NXN;^?
MSNP6-60G BP0@\W$,[LOE-#O(S[A^PM?PJWP3SPT:8')F,WX>*8/ F9Q^W/2
MM)%T[=2E69Q^#=MQR0H<"S9123O/GJ!/!4&F_4UB/EL&7(%VDK*Z99/./VNT
MS:5]LH,Z"L7\L.AIJ"1PABKJ(G!';T8F:KB[<)EP9:+#-6X.1H"U$513P07<
MF -<I]G+^LQRV!Y$V4Q0#Z(2 *5JPJ1&0+)U%Z*$7Q>B5?MTYWJGD^:OBJET
M7=BD#Q&3/*TAX?"0_1X5DZ/GQ$MUF(G2<B@:_1YQVZ$-U_H>!/[=Q.64AG[_
M*SN:G,Y=UASP_;53ITW=\X\L9PV<1%MS% A4&WB/VM"4/>X)L>[V7"[.>*NP
MNC!05% ,F_VV0'K.ME@5%44ZZLV=\V*"VIKMIJ5JS?KXANO(CM>S%.D%/HHA
MT53/6P4^KU^B!%!R]$D'.%TO;!94RPT]L$LI()E",IXM^ UF.GS)ZY\UV;F\
M(3\MSTS<@I\>\XU<;3H=-F_$K^*G0)^LN3Z.1CP3/\^&(@_&V3\,0"\E?O94
M":B\@/ E]5"'*CL]I4RD>[<3Y,0CA8%LE#_8LV2;SPA6<Y*FQ4>I07;>3V6*
MFI3?(Q\=VUMD3CI=!HCW,<IMZ/A?>HQRV7@RZ1<\^\Y-#N61ZL&>FC >&8V&
M[%M#+BF%WB%YY! ,D5Z3(38,(BTQ1+$03^9WHIR=7 %UY%<09\JI(H?><1H5
M0"C^L<]AX>#/H0-?0O8/"%V+Y>MC^?ENGKN<:?M4+X_T60P&S((TV#!);;FP
M)Q]/)_U&:'X_CT?V/(;QS'N"&Y53L[M)/_F'/Y.1&617SHQD(5Y,^^59'.JY
MM+(I0I,ILMVY?#G@QO/W)U;N11I/&&E*Z45W_E(2/][DU_?9_4&&E):Z\P?^
M[O&U_EPMCJ/-6=QB.&DZ:#AINCN_T6K3AU+M4A\$3@W\'DZZ\^&DR:\;3IKK
MSDO"6T%+%(>&XLQ+.?[AI$"L_9=9A^N]]:[S_6A,LYOAI$5L'SS+INO/M\,"
MN[: ^*KAI" N>Z^5828_8-7[S%;'WFXX::$[K]XG[I[R3P/2?-)?S!S_<-)D
M=_Z:?2X6I$ZK($2AP, DO*\>3IK/+@\G=;)6FOV*,AJ).J&ZDLP#A>H@K^%?
M#1$$FD12EX)GERXF\6^Z;'?.WC\*O=&\52E$>>U#N(Z,-DTMCS:M=>>U)^/>
MN"R^WV>D'[\JS9N;>N>F=MNY9TJW5:;2O.W4;R_AWTRC7BK7&_5.O7:__Y&G
M.\DZI(/-Q5]B\]/F#^R1^2E(S VK@: !=E$GP"L:4QJH I$R0'I'?[&@Q:FZ
MC8; #:MR0RLW-!5G$ 3DQ28C_4 RL(L0B-D08'YBMIPYT?7FOF1/=)V*^M &
M()U?.1V*G/,S%I?@4?!@'BNKQ5AZ74X2951,&(UNQHQ598+C+>W!L95VT]YF
M;*B:P<(YR#&GBOK.$$%I?_@)?]3$']G?$>R;7QNRP"3IO<^9!W)*S8!#.M^*
MQZP#(ZO)],3*&$=G"+!CBZ29IABP0.#(2I^IW]SD$B3W<0P"5 71/#=&; ]S
M1EE^ L\4K# "FTY61BSY&(BJ,VV$(T,E0QXP''Y$I3F3 $_K]GP,DS!9I@_'
M/J-)D((ZBI,5$ /.@>UO,/0;^#D\LP"?-,:*D[HJ";HKD5:SB%O%*:R >GJ$
MGL$/!-U["@LQ?4&@2;%C5M/.]*&J&(,A(WR.\:FFOW&0*=*G'%N5PBW_2L+3
MQ8Q$22+9JU5G."NY&\TII729IOA)VQB]$-$VPT<I;:$T[AD4"]CB2!JK/E48
M;LB"U*1$@9?3# GE*,$'\U?B/&>= G.+0:W3!"N]5\'^"8 6,"_!,"1SB0DP
M!$QJT73MG"D!T9I+!N4CHU5)\I5US,35."+%#8&.AQ4F@J2,"1L1=H&EQB2_
M6S$'MZK*0&4!R_#]JL"9#S+-KTU[[ARSD6Y1JTS?=3P6$ !VA74A&X^!9FN<
M[LLZM.WZ+"H"^(726!4E!HS>TTT=+]'!I8H\4!#W($ <>B<)P%/T+(-9/I6]
M8*50Y&G&L4W90"F&BM*1RC7R!5B2M84B67,(1H>5<JZ !0)PE:29343G/I)0
M%?J&R= 6,?_E4ZOL^']T%E8="%5AK "':<2O)*?EG,L9.^?[%?9Y<J$TFH[W
MM"U(A-0E4Y>8F1-7P[TU2_N%^2\7=*C\^KU$<HN]HA/GV6PJJ)PE9O$QRAW5
MO!\95VO?D0A$.ED6<#A1"&KQXX8,GY#0M6]1A2.I%N'O<O,]F%^KF.RDM8%)
MQ0G:E/ZHF/Z^+D@/[\VKWL!&Q</BWN$X"-MS#71L,"%E"1W)\TPAL)F])5:=
M)\JB:-BW+Q [Q'H08V-V1O1<%#=+ '>UX;ZPOEHRO]DRO^@+[:NWIY+VF7RK
M9IQH^L72YHRU>3C< [>.#O3"!D,X?(">*/J%ZCQ QZ>)L9XF[^.H"IPRD$&,
M @3(2/8!L+0OW%VI_I?PF:9L&1XS7VAKO?Q;[[[_6Y(S-K0OR=JRPX+A,%[8
M9@W(;C"DP4>Z%#,KR9F,^^[[E+L0D,-O;*6%6,V+L"<U+P#Z,*D.A$6XN:.8
M#T1=+G$<D5KFK\ <A)^ G<J[;,%%I*2)!9[^2#5>C6)*<Z( UOKXX(S-)PBU
M(7,/Y ?BC"0U2'0;&X'B*O&TX>&#4)T^2R<74+W!] $_R>6; .)%-6!S[()5
M:WU8D9\OX=K;,Z""JH2L=U26%T+>#X+.RD,I?YEDJ^V2TXBYI0IC5N2]>C>M
M=E-=3\/*"M> <ZR!F5T\\<GS5/ T")>J#KHQN78L_-I.J9[+;>C)"UQ.+)C2
MG#K-<B4B'?1M#R-1?(B(-0_5<:F+=&>!OG>F,D=*RBS:@;,W.5TA@N,$]&G+
M*=)A5</I&0]/H0Z6$E.QC#O3+?!G^$6:LN40L>PL>OL%C\BBFR+FTO[1IK*
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M/5DND?O"(P :.5)IICXQ^,-G"\1JIKLDY^3*%@@@_X_R:U<K68*L*]S^I@X
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M/+$?0+N\(\8\ ATM2LG(!EG2C<4 I+;:-%QT*K[#593*88+O9;$ZC5X:J##
M;%R8:P?/"S@)K#,:& \=:$2=NJ6NP)T5DXH\AUE]IL5NEF:QW&B$8U,YEX&6
MUB6WG9;">*#"NX4-1H^'4.( ]EX#Y)"1!)(2NM&03.'9+AQSZ+)[(HZR'C,Z
MJPM(AG#GWR*Q)R(@BN<S@]O>F"$U&CB!I1#YHQ35@^.K+'2>'Z)G!NT(,O"%
MITBC:-&0XHM^-O]6%E_%>@K^)O!A&AY-9+J :SAFWX 'D@@X+@/%AV026R1Z
M"'4=%'0LVH(HE63D<"H.+EW[ZN"FZC('UEC61FA1TP)AQ#136YLO%_;1QS@L
M_(G4KLUS8#A88C0D(SP:HLF([B"?'!D;Q<6>"JN,<+(@>PO*GV(%2\<F0:I$
M4)D\(VAHR(0@E05=F_I#IAN0:G]G4:X';6]=W9PY'[( C'A8T8=(Q!Z?,A$$
M"KC6WKNA'WZ']TB9)@WZJ/D.59J"!L+O!_M:VBRD^1A)+5$(Q"0G4*50*^,Z
M>3OGB!9P;RWJV5I2A*0J$3T65/L86\G-#XX<'$R/CECE,>F<#]\]7FS#CE<(
M('!0E-#Y<@O6E"5JE66'1"N,$ULYS@LB]]W"+M,'\/W^P2SWY8:T5HJT/ DW
M%ECW2J%%U=XH<NS]$$;0R3#4(2*,:FAAQ^$8T@N59>ETXN@[5C7#ZQ^O6J"+
M:6(79+?P2.5$VY(<)FD,O\>;,D:S@R3^$"Y>OP-* @M4?)G@:<32RUPT)?&&
M)4U=C2=<N/0MK3-!AZ>'(^M?*-9!D_09664C?]>"28S\I7 Q$EHH[Q*EHV*T
M$+4"-)= (1PE*4_%C6!W$'F/-)9M1/"&NJ92%YK4I!T"_02@[H&N^G<&+^YR
M-%3^ (-$W>V@"6OQ2\9:;E'%L@<Z<,Q"?,R?2M(9S2TMG#,2O.14&+&#10R'
M8 AR L#XJP-QE[Q#4M_(Q0WE3B@/[/OQ;.<#@05LYT-.3#R7W=P$'V9QDJ$E
MA.[ /EC&=0Q5.M]L<KY&BE0A+14T_51OOW&\S/3V^2 Z(^>Z+X,N.P?Q4N^0
MGWJ:#X1G,>Z/>HXDP*--$N"S)@$>K5,2X-XC)@$N!.$X6 A=N81$0>-/JH**
M 6U^&$>]6 P2N+12Z?89%'.5@67\57U#JML-?!=&0=0;Y=@8B>14#<%QGKOU
M'@$B,V][5PXH<]J%74+#+):W/@RD/+8L7^%_&* >2NDQ<,P-_!!E1-$]JN+8
MYI@2YTZ"7:E@*RJ 9_+$T<\]9LQU_"@UY\JA$XIPJ@B0)SDL)5T_41$<ST]T
M4)(&]R__=>,D0]"X@#D],!C1.[S+,2!T]?H]D<) X[^ J7^]^G93;V.8!_2X
M"">&VE64@4&@+A^\#;,AHX;0KYDE;]C$%5F"FQ23KW((%Q_!#UTWSLC%S#:J
M&1&6$4;H7=8[1:%%--;ECV$0H0GMT/T)]ZCKB !.)B0W>%+;WLH50KZ')=Z,
M;#7#R'$:P@S(+"Y&ZBG$D"02=4IA @4ZS"5"C/\[ QF# EMC &3FPM'#>^$!
MD&%]LMLY5900C2X\B[@)_3QL%D)3HSL@3[T3>=Q"=F%.*3G9V:%KK8\ G WG
M V*-*.I'9YH13,I,4I/;T!8!Y.1%E=<*VIH?#&,? 8X,[EV88N8?JWJS>1!G
M FK1K+C 0G+D\.$81N0RV.''$MJGAHY1\ Z1K4[#5/2BT$<KNI(8_AJ(%)7&
ME4H2)GR7WMI'0UK=0T@[+FKB+H)G!A(C(GXR0,IW,<@;(\X@@].0MX)HW6>Q
MVY,@$U@9AY_V0>5ACQOQ##T2H50#IJ<6G+ET4M%J?$>:#5"8^&X<67C5[:U=
MY5R\^?)1^1/?-( :$BEBX,4DZ_5 E"2.P4C [YP^7 ?%2*2$^0CTT !?X@T>
M*W<XQO-^P%\N7")9(.)\;@WG8]@#E8AGP5:PF7>LJ!'&!?W1:9TZ>IJGK5,]
M318@]/T'Z_L/YGN0 S#[F.21& QEJ.28A=]0^XW0+@P!@70V&VE^BW<EWH%P
MA;JIPKB@F8X6U_^2<W7B!&+9@]7"DR-Z-&DX5Z"2U^%RH%_P.1*0%9:&KX-I
M6XL.I/ 2 KO"C1!%?!_CUF!PRAED0>H/ ZEHIA!2A1^R X&_0]PB7$>P"!!W
MBL3(:9;A;8/;[<(Q^R&0>\WQ8IAZZ( E)XQC5YF5-!=%A1H/8^^;(Q XDJ0Y
MI6T !I/5'A)ST\/A4HR<]"&;!I"WZW3OD3$/X\)]3]H $QG>8V(H,Q A'.N^
MQ>@Y7[X$>,0;CT*7Z-9"Q[[P;M4-WB4-PO"8,((^41 H>*0C Q\D"UZ-'9QM
MG.!*ZFX FH=V9:413 KOTU@B.=.-B@$' 5R1^8S8,</4>0VDW0!_1,+MJZ@"
MS8X132H[A9 WVUNLD.0=A5FERL4?Z!CY2PG[D&MC(NW?@6+%X5Z#+0 !Y<,;
MHUN+8B<9B6;%=8SP3\2H>0IH! S\802:F(=<73XLO),VV?-!<)"B#)_:T"U>
MJ [YL"H<#5-_@/J*VAZ&^?WP!V#:LWX$<Q=NJD5&X=I@U0NE63XF\=]L'>8U
M,B HZ,ASB&S NTMZ+(#/R6@XW&OF&BKKCX0 $T&&$H^.6X>T2/R+KN00,#].
M'](_CT#=CT*I@/U(RAT5W-.(7(RB#9#.60UE5B6"-?@^O/?U)(0G0._#6 :A
MRSB="K$VVGI0<W&C/BGH*BD(2#R]@Z=[Y+BC^Y7U=B6Z:3F"$4_J1_DUPH '
M-I%(P0[)@@'EW1^"A,#;^US"A<H_-DE?<(GXJ4:OP6)@JHJU]49*G^9  Z)1
M.8BT3$.,48PW#SP4(>U[;)?$?L)\7WAT&(#!0%G7! E!_0FD"8(YIGU.)[(L
MI7[5=?IY2CNEGC+5@O9W<U/7BON\Y\C[W=Q[\QR^EM74YA7O^W"! LWS/:XO
M56 !]@*@1>F95#U,N$NUJP6?T#HA_A;=Q5I\HT-!W\9F''8&\+U6XS^\+*:X
M$:5*<@@?E'&7,'>4#L1<;X0;,$=/Z1S$]9M[8OQ0E==A>TOI4L9O($/,@:3#
M4T:5M:N9-ZJ-WRA?,=/2:0HES)$&U%%Z$:5@HKA&'<L, >_])TKGUEZKK=#
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MHLI9Y0$EO"I.WW_CCRGMII((O#(O,-)O26NJ&O"HMI5/6G##U"';WO)D*OP
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M-X[U#&K.W_QD'0OQURNEYZHG-MU&R[.RJ>!'R,T^E0GEFH0-<Q;<-;;D\D?
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MUA6XU@P\L9U=I[#=L[Q!,6;X)S(T?6]FJ0-T19>MACO8*\:^%(DG_@;^ICX
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MLR14S$K03W._!'.[HO32?D$H*T-0]TMJ>;FHJN8BW0\W(*I))GE%$"IFI0*
M:D:[JZ5JA.L"EZ*23(^Y@(6O@>='/BU:86G>Y.X#<:H>CVI6Z[3ZI&$F%5.R
MJL;.PM_LV:TK)Z!*^\<E4*7F+,"1C2_9WIH8L!K89,(+.H%JV)]$-1PO &JH
M@FFX#\8B1Q;,@":-0W":B\.WX(?#B3UBF$O)E/W$@FC P3#P11>WH7@6G)#]
M'JZOKP$U6/4]QC9K;@1?*^22J?SNQTEJ/J1N+QK)(1!E T]H!$BQX\OV%M7
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M?2P*;UF3NW_EI^"DA]V=/F=Y0=M@4&X12=CG&'D&5K1UGZ]H)2JZ-!7" ^4
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MQ=&*'K'J3)%_TF@0M.VB<Z6MK6BU0I2J^Y_SEIXY,D$3UA8I=EV$?6$S"_;
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MD1 -?-B(85-0#>57+QW;ZB5S,I_Y5?_H3,62<6!<5;!T)UCTBHQ,5S(MXYD
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MG&)0IU$A3-"JF$ZQG)">3]8P-^1 HPQB*:5%EE7T61_P-6 VQ7\$@*PVJ\"
M1M&TJNK6.&A-Y2,W9Y$S0S.7B,\06KKI\N$.IKS"#I0RFK8UN&C@3:=%_H/Q
M>?$!&GU -ASW>!';@<Q/(H]QC!:H=6P(I+P@T?$,6,$ 'ZX+4>"L >-C&V_$
MSF[0(;= 2R=Q=9$/]70\6&7N_J4FFH50UB-B*EA+,Q92V6* =T_EO]Z:F D:
M1]N@R=N??PJ^-;D@FFWI&0SI5/AZ2$K-LZ^#BQS7BS3".#5]2&U#.70,1E^=
MC[2Z.#B+BC0G/CRII;U(L"<2[:JS/&)GT?'^1C5&7V_2YKB;\UX!B7UTN(7$
M;NJ&]PR)?72XA<3>-+9X5_[[LR(F.S;XDI3?P^"#:4W$/TO?LW,Z"GHE..-Z
MW('\:7.]])O0 (3-<0211'8;4>!L%H29RI^"*_8^6-CZM20^7E]'3-RIR^M^
M@U"ZD5?*([,]&Q]KNC<JUIT#01(-E]J?D.B/-/DT+]D"R8EFH?5P.Y H8/LA
M+KB-E+9)A#-*E2<.DM;I")WK$S$SI-FM:^K.S4Z"@?LRE*NHJHJD7S."/[?
MO(R*)*_+[HAK"%] EKMH:]>0J3:^5HO%FC7JJBN]D.W*/CVN9]55C7H>BZES
M3ZIU _MI=\>S3G_"!0B68D/96*?\A=3D"^DB.C0VJ48UY>C\MJ0%>ROFXI?(
MLWANO$LC>DI\41).I0>'"=FT=-*LEVDKZBCXGJ&AJ(N;\128]J4KF78C0^B"
M;/-@5.03]I^R0P4=W[5I$\^VW<0'1)SX3=GTK@VXM0X6P]1Y$+Q9OS]%N+A_
MZ +=B!='S<U0+X LR]GO9.EC2;1)6?#JD%8UU_7A_I@U3FOZ>(1.J,O/#^N^
M(/W*?.!?[(VF2R3=3NG*-*]U4M6N<[OM4R3QT08[0F/7)",S+%UZU^Y8UCRH
MH'-*PH/(NL<KY^S&Z97S11W[UF8QT2K)+-*S1+X%PV0T@FNT0OO;H"3"+4?,
M8QSI>D(-\H1&G),\HHMW=8\V/I]A'6^40;]!GAFHU^R:C- ^PO2MYI[B]@XD
MI718A7N:-8)1A ;3$,<E^'G8/%KN!%O6.-4DYAP5,Q"&1T-8Z !^/'IV$6=P
M>H8B8G9WN*%SAHYNXN@AA43\LUZ+;K \-'I+,D 8<;_XC/@M<7+VMX*-<<2$
MB0]_OHB*":; "6CQM)9.V ?!;\1#P4>\*8L@[62Y-(#2J(5.\LF3%[ BO2=*
MMX[:CE0=DII)A>B6D(8A&-N9L8C'")ZD3$/BK0^T?SKHSO;\%NTCBP?T /(-
M?8I#W_6(P[!9'*LC6/[%.1.LZ."O" AGM-ZUK$"Z.= ZRBU_618=(YVHG^2(
M4W*/^2FZ/B-0F04Q'R@I^V-6>%H=Z>T%]SLMJG*#@/XXSF*)X/,='9%Y4H:B
MU+!>E&3X9X/_L#\@A)UA6E!S'(W9F%I5'$,="H]QZA,]B>";]FYTZ3=$7C5"
M0(6^.*CH@@?#HAXW5L.P:S0FDEUYH/C'((;!0PLL.9"79?%0C2ME*J[Y),O%
M<9KW:>A!-(7J8[-]I">D]MX.$MI=TH!SL;)&-3X8> 8CV&-9VD$X?%Q,2LQ#
M0\<> ^6U\9P0'9:4BHPO7UUP8)-?TDCET-LI%@*+V[0A;*_9S^T/>21.U_%(
MW)_OXP]OJ_L(_6O]K34MJ$@C54^:*\1?Y__6=KLMZMH;I/FN-?GN&,V#RMZ+
MA"[HC&Q $8]J&XM/Z%]DKY;#1%N0MQ*JZ#\FG;^CR7F6D_VH^57,97\]^'H0
MO$,PIPB9_TTET#Z,1W$!!E)%/UPZ,WBTOO:/@Z"D[4QCD_#X%D8T<?PI2KU(
M?' 5^MB8M,'7*IG4&3C>F>=RX%;K+DC?&C*NB]PQJ"O"9KUMV.QAPV:]QQ0V
M._RSA,U6"L[K.V*X+F,];\Q_O0G^^>8C?:LNXWQDNUQ#N+[Y^5>T\R8^](OK
MZ$V,8"W=_>^:7'6[-3$OU\E?6\!D>?#SA>XY!4RPX'O87+9N7WU@7/7.2>,Y
M[9&/D7-'=K!A]DV^/__RU:6U36S^%5MHT??89KK1JF+_*%$<YI)U1%%U.7#1
M=)H2SV(;D?W";'=#'$QIJ@-3?^.R<&/GVL;SG!X?!HV"&[(.X%G">P8O^6!W
MYXWH]C3[.JU$BX?GBNQ/X[E]C!W8[VTJ]GJ*6\4+)?C'*P&#RR2>2?(J61UY
M-L[Q6#\J$S)'OM!?2R&%W#]NCV9XC$%.1N/O3OT@Y2;)^2?.$1>7=_NE2W;C
M:V81[%0UH>3E4@F/++6-V-(-.MVO?JPE0FP(WIFBO<.3:!AK\G_LY3 W8GQ^
M@'_/&>H--;&[?"]<J(K#+W=WZ,K&',C!\[Y9/LA+7'YB52 A^4U6)L-86*!0
MIA*$EYW+K+&\H 4]DRQK>#6(3:@[T=N+P-^* =16U.183B<6-S@8TZEL"S3?
M9],B9TM]Z=2[:@"3*]C.[1JV#Y-&8U6!+)ZYVP^K9!@50U4)Z&/@UY8W?#5_
M#H/W'%(OXBIR<;"U=(4WM.W#!RN@W3!=X3?QL$5IF>_NU%DTPT\0IW#MB42&
M8=6O*[C,GLUC&G>83R%\[5&Y<@4(V8$F$(!7%&I?BI3/&X6[GI(!IZWRY_4\
MM<+$KW+4_B'*7;J1MWY?C@]>7%M]-LY3,+PB3^6RO-=?[NZ<R:^#3V0(N@KS
M-9.A3(G3]G9P2,TIN ONYK-?/C';.3O_%"*T1CQ^"K&#&P.:)I%)MR<I+XQ3
M8P(G,/T__SPD%5J\-')L@1XFJ;,X-B_WS1:=[9$((O&99))B$WRIZ4N]X^A9
M[V1OM*\1*\SLEQ^:'D&Z[OY!@'6T/Q.4\Y(N("<^#&-XYN7>DL"Z),&);(\R
MS[3^S3J*)>8V\8HNN/\(_>YMCHJ_(AY'A=V@(K9NH*9JX);$-?7.6.&?.8E\
M"HF955:OX,+[\L+YIQL\9'>'-_R'KG%:%T@F+*6J%L7@/'UKOQP$[]O;L733
M59R#S;&+W[=&6+H/.1@ )KBR ORAM,F_3'%X[^2*:L#700?3$U")WL']5 A.
M-;-5,^R8(<29J2Z#L6,%JJEF]2[BD+2=) 5%UW#PIG-[7>B?FIO'XS;=N- X
MD])$8$OCZUU+'(B"_GI;*;X1)'Y5O>L*"C^Z+PI?*3^X*,\C3IF',?2+H=2L
M-J+^=&4F2=40$@U9TO16=7'[4#U'4:49(X,XF:K5Z0=TW63ZL02*:1UYELZ[
M!HYJD@=%\GO4N%.>.TRN':K)\Z)\C1^WY>*/]_H<;\+U<=H5W89+((/D*B20
MMT#[C8K3N(H'YI:01:=DBHOE4FU#E$GB)4\N&!)6EPQ?%TE'L+9<$*LEIQ7*
M'7=P6U+>3)I!4K^URYJJ-WTI8SL9N9,7^2R8Q?2TT<5#V7PO]X6XH%<.( F_
M80 Z4-54AV42()ZI"GT_UF,#MLP@(H(Q-,:LK9/0F,/!G-$T[(Z37M#:?87]
M('@;#R*FL1$7-70M(]0R@;6T<).THX3/M,N4'DR2TB._X+.D<1FF#$=&W'!0
MVLW(.',[)].AY1MNIJ WLUZMD88):>8J3=<8<WVW;+' 3 C%Y#J:!",)F(^1
M'H]G\\F43"7:^MT=39SW+(V\\ T-CE?@A!.&/=EZL%<@ GAH ''KX)7;K4^!
MT9+Z MB2"'R)T9L8" +V&  +$07I$J2 WQA\U#D&)*IA;5'CMWG&OQI+3MQY
M$4WB65Y\#_:.#GO'^P'1.Z#$^W-Q0N03NE&5T-%7^!]R3J']5(RCS%=/Z.'=
MG6\HXIA%<WFM+.6N^O!GWF6Q_H32S3WT51Q!IV*D$2LB9G'T'1LLE-^UQ:1G
M+=_D;,AYR9&&YQJ?H_?9%/=TN?6/;R;U3XX*&*NR^T0W@HXW]$IY9]Y$UKL&
M!;1/:2U+U![E@Y=J_F4\*AL&K^3(D&]SG9F45)+<2%'@3&1WO=EYPI7!EB%#
ME&J"^M5^U^M1Y=9%LJ79U32+O$ IHLIJEC<(/G]/TA1PD'%16G>(N/\\[*AQ
M(DJ^0-JF\0]UJ#<AZ?1Q<868,8")I(DY!E1ODD/!)=6>8]LINS<D8LTP154T
M&JDG1/TC-'S)]VPOV8<F.HTYVQ_:ZQA*[[!V\+AZ$W&52FP3ILG*B_Y%@_#>
MI74Q=UI#XRXZ-#^YE+;XQH2#1W5F,EKW$IJ;U:L:<_$P:5P2 S$ ),%RQB'@
M_@Q7&*4UTH-$:P($ :-P&:0V;P1Q*M%GZ;N(E,[-V312ET@5&R3T6Q\J4:TU
MQLA6C-H^\'$XH3^?])-,C2H[CLEDT@V)?BQ)D7#1D]9D[\/]=+IU/STNUO3-
M*[#Q*N9F!<R);%F@2^9#A\R@=:Z<4-E3 8?GBF0^IM N];SE<:B\ IH&8Z/A
MX--U'.KK+V=P8PU2AJ!O/!P&)>QSL"#F? VF)QCU^);#^UZ8Z0*H'P,I.'5B
M9+;#)OI\^<]H,GW]SB8D^NE%"NV 3*468ASF.,[S(5?<2-I:%67C1-TR)D?J
M"CYQ'>?;E3>B>54?ML;FSI.0!-:]C =:UR\9%9_YM[L[7^WOUU,*SQ/4,6SS
MBY[\_,86X,'9!W$<B?_924/V.6=9S1F#]@EC.KZ1OTA6"F=9C)+40*NP_X,4
MK&%"FK]W2&^&@#PHJR)"[ 4UBK/9[(!N8%0<T,V1I 4[ AB(/A(/Q_+(AK@
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M6IM(M,1IL/\T,4L/V[);F=O4K<RF/NY._U?;4OPM=O'?8MC$*?\/4$L#!!0
M   ( .6!>EEL4ADH4Q4  (\# 0 2    <'1G968M,C R-# Y,S N>'-D[5W=
M<]LXDG^_JOL?>'ZYV0?'L9W,3++);M&RG.&-+:HD.<G,RQ1,0A(V%*$ I"WO
M7W\ ^"&2($A0DD]('?,P(P,-L!N_1J/1^/KPS\TJL!XAH0B''T_.7[T^L6#H
M81^%BX\G]]-3>SIPG!/KG__XS_^PV+\/_W5Z:MT@&/COK6OLG3KA'/_=&H$5
M?&]]@B$D(,+D[]9G$,0\!=^@ !)K@%?K $:0921?>F^]?77QYL$Z/=6H]S,,
M?4SN)TY>[S**UO3]V=G3T].K$#^")TR^T5<>7NE5.(U %-.\MM>;U^D_O>)W
MB'IYX5]_#_ZDOVPFZ.L"AK_& Q#ZWA2@WU;>.-K\S\V_O_SY;?EXL?YU[JV^
MA\_VO^:_/+M_3MV?S[]?KYRO;WY+/OF!>DNX A8#(Z0?3[A\J7A/EZ\P69Q=
MO'Y]?O;U[G8JZ$X2PO>; (7?ZLC/W[U[=R9R,U*)<O- @JSJRS.>_0 HS&MF
MN:B!'H4T J%7HO>CO$"1^.U9DEDB1;6D/R>D*"/U886.0N_5 C^>L0Q&?W&9
M$:(YH:?S. @2<IK1\W11>00V.,2K9U'J]/7EZ063(2N4?RXBI]'S&M)ZP5GV
M&<_F=5SP.B[/LY+K: 'G>:DU)A%8P >$(^@MN5[R(F]>O[ODO2N *QA&-YBL
MKN$<Q %KM>\Q"- <0?_$B@!9P(@K&ET##VK5F>DL"$/,5)OUKS2%IZW7B.EN
MGL"2.-;O"0[@C EC\1^L;S5]B).<#3"S$B<6\C^>)#\+56:5^G".0B082'O4
MN77*^T_,168_1<D/9U5BN::80M\-_R%^KPFDK+@0[)8EI.53DN:R'@B\.-BI
MZ):_II)I>M:<^[>S$T:0H!6W44)1J#N_02'K:P@$8TP%0PD,6I1:*%TP:/)J
M!$RA#T,F*O]%<8!\EN=;Z0>WI-3"<RO_II5]U/KI/@2QCUB9O_5@=P3;7?-!
ME#%"[=!WHR4D?/0D<,D 08_088/S"MYB2I5*H%^#EG)<[J,<6UXL-C):@ANK
MQ(Z5\&/]Q#GZ6Z\Z>ZC.8 G"!:1..%T"UKXX\)FW-?P>H^A9J2Q-9;34X\T^
MZI%^W4*A5?S^?UL)![TV[*,-@"YO ORD-A1;"BVDW^Z%-/N6)3[6@ZH+ZHA-
M4P@L&O0$RIIT+0!_YLX8F[P$F++R[(^1/;N?#"WWQG+'PXD]<]S1M(>D"9)/
MF$V,F;I[D*1>6"E%"X9?JC!\<IW1)VO@C@;#R:AO_Z;VOP(4,<LU+@B=P%"7
MH87&KU4TKNRI,^5]8CP93H>CF>@6/2I-J$S1(F3S5P^$D>UY. XCUB?&;$3P
M$$QM5C.)%E+OJDA-G4\CY\89V*.990\&[OUHQCO2V+UU!LZPMV2-F+&>L@;(
M'V[6? S/IPH3Z$'T"!Z"##@-.AWTSE]7T6/=:VP[U];PZW@XF@ZGECVZMMS9
M;\.)-1D.ALYG^^JV![$9Q"^ $-:C;A%X0$'NYDNI6@"=5P'Z8D\FO&O=.O:5
M<^O,_NBQ:,(B-6MT#)YYMV =A:60&/H9#KDMU*+4PNRBBEEJ!J?6V/Z#]Q_1
MJ5CBY'YXG0/9V\;6V10/2<S !N:3IVV"%C"756"<T<"]&UHS^VO?^"V!9K!&
M$0BF$?:^L:XQ8;*3QPP(5:86*&^JH SLL3.S;ZWIS!W\+KH*=_DFGWN(6OP]
MWOSNFG\W12!U\N1T+6#>2IZ= ,0=<]<[PZ2'I D2'CT=0R*B: D8I10M&*3X
MP*T[92,)<\BFO]F3'H"6];'5"D4BWL4,TP"+"0[<>F'YZ*]#J 67%$=@(\R=
M,[L;\O&?&[.!*R9$PX(/UP_]+3!.8,"CF&- HN<9\Z(I\ J1-V6N%F!2J&$R
MO+5GS#$;VY/9']:,>=M3>]!'X5I!RI<<G9!&),[ZT@31;W<@9"5X2H*8'JD6
M?%+\X<89V:.!PQP(9S2=3>ZW/6_B3'^W[NR1_6G($WLT-1R^*G)RL@Y*%U*<
M(7/R>C@T5QUP>.JQ48G]P2I8B.4<2%-05)E:T$@1AI$[.N6#U,2]O>61.V<T
M&S)OKP=H]VAKAZAKI^CKA11J:(F^6C]E]?>K?'L&8F>=PK$S_:#LA12FT O*
M6C\E'^F1[12=+>*HR--"38IC2)':'J"#A6R+H'6@UP)2BGOHAF][?+O&<8LP
MRLE::$GAD6),MT=DG^!N$9UF$BVDY,B(,M#;X[9CQ+<(F3)7"RTI+%(7_>UQ
MZAP&+B)4DZZ%C13S*(>$>U0.%Z\JPM6E@ Z.EU)41#MVU4.\3]2D"&HSB1:,
MVA&4'K7.VSFO80100$=\8A:A;$FSD4(+,REP4MKN:?V4UFKEU?:8==T"6@^=
M#J$6@E*4I':+:(_DX2-?:8OJAKXR<BU4I2B*;NPK_4H/[F' K?3:'<IIP2W%
M6CK"W??J':.>I3ZLRM2"4 K U,0]^\ZY!T;GC2"=ZZ$D!5_4*%GG/4Z[X'31
MB-.%'DY2V*4)J(L>J%V NFP$ZE(/*"D&TX#398_3+CA5?)!6*AW<WD@QEP;<
M>N?B<"MV)8>C2P$M5*40C/Z:7>^;'!CB2K?=J:06Z#N?L^E[^!YKMJ6.7).N
M!5WC29R^3^X*2J7K-1%HP21%8VIAZGO1?NOLY7E>&Y$6<%)<I6FMO9_W'0*^
M2M_3)=:"4XJQZ,#9]\I==U&4ACAUMA9T4N"E?A]%/^+M!=5Y"U::9E-STTMO
M,/>$ZZ(%+KU@V1OY[I%&N/IPV8YP588V#3H=^-Y*H9AF^/KQK/MNL])(5I>A
M!9047:GN-^M'KQV!.5<BHS=BO95B( IH^K%J_Y/B"D=_AX):T$HQ$KV3Y+W!
M[ J]ZOQX/=[:U%H@2Q$6]>GS'M@7V>%;&B([E= "6(K$=-CCVP^K.YU4;PS(
M-)!IX:D,Q=0 UW?4_?9IE[IF"XT6>%(P1KU3^_]EW^/_X0^.3.#<$@^5O.=/
M:WP\H8@_%7.2IBT)?U9#O*YQFCUW\1>3^]5F%60T_!,-+Y4(U*M-E7XYJP(0
M3ZI%>DF%58+7D' OZRSC/JL@0A$O7MQJ;/'O,(4Z.Z3H 7CH*CHK H,7E/F6
MU_\BPC(=[2IL1:U?2.3!]BLO(CCK85T%+W?*%Y+[.O^(+/:'L_)+,^SOZFLT
M'YCDS"I;H?2X3=/[0LG+2+?8$U4U%.%_G6;E3GG2Z?G%Z>7YJPWUMYQV86+;
M#-V8R,KMP$3]PTF:G\\*\.^^[?1%^5VEND]2%3G_P=7W4NNCG5]G:N2EL1)>
M_B].L?W%1G;RUY9D)^VH?0E*Q65;2?$WK?"1OA(EW!%A'?Z20Z%W</7 GV3B
MS-:%2O-\% 1\/\S'$S;/X'V:O^WUGO5UA/V9L$E^G+PC<&(E-BI_".N]CU<
MA4X$5YR2"1D_4&8-8D[]B>!X_?$DJ0XQDD;^;<^+5[&8T,IOTO"H5%D<?7(C
MI!OPC4?DV9U?$68@Z?(S(@M6,PU Z%<DTR,U2ZIK&( G0*!"$BG;".ZG(%Z
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M1&D,_?O0A\2.5OE,NC[/7!CJ&"XCT4AA%!@N2>]68&/+%))'YMS52J&@^S%
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M72^(B'-QQEHDH,WMT:6:H[=$,J:F%D=<4/S$3Q1_XN9SZSJT4AU;S1,&[4>
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M6?*Z"><^4)1NUT*TN4.GM3PJVD7'.PNT&;YJ>?*U/ Y+&>V0O#I# U4M3YT
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MFV]2\25,>]IT0,&$3:UIZCF,>I)R 7U!QZ9:LDTI\9^X/I9_\S]02P,$%
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M2OUUGAFB\,ZGBPC/_3=ROE)U3=_PGU 0QD^<#AV2*:2\'\3HZSL"&-%_7K$
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M.E\^IZ1]"JI3VYPW(NC1<IW^,PM'0HRXB8;W,;(1!<3G =;W4D6";7-+#JW
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MFZ3R;B<H#>SA+"41]DY'4X1C M;2X(F)@QV1GSS@<CG'G[YG9Y3G>(BR"KU
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M,D<(<4B<@4A O!'AXC/8Z;>@),=> V9*7>:DA,6++H;927F(7(XA"N*5C4A
M3!'AXH_V88: ?$?/\15,-F#"+&$5H0PF-U&1D=(!TK[S@HY3-25 1ZF:(ZF
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MOOX1R/^Q8LU-Y<4'6- L;'TQ9JF"XRI,&N"C2DP2Z8!<? U$8:H1IA<HB7#
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M8)3GM&*8\#V2B;JS1&JPG442RP4R*2G!F9JEV;J"!7A_L<X+/*J@8&VRR_]
M>1)[94X9X:I-(^N1-/P*32D8*FV4JS$]/TYE6:8] %^0B]^O(?MW]5SD^\TS
M[?@3_N_D(7HCSMJJJT:B/!!_0&/.#\@?W&'NP+QU2]Z)?A+XPFIF%U2)I@7
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M8[V&I#XH;).'BZ@RHO"1+?IP%([HNLA[.*"Y0#A^BCZHZ Z;=DA%2=P0P"X
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M+S=_WZ/JK:UA3,-VA6)KQJ(%QVRT[=J(GZ;J(3'6$O.8P_-3;BM*/;K99E/
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M,%_CH>$29E<&,1\#GJIP!TF)_)OU&L;58HW_D[P6"@](KN!V.M(!'YHOF71
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MP9#-3>"Z:24$$\C/Y00XJ7F*_R&!II<HE0<03+6#&EAKT(;+SIB,.$G8H7_
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MC$*%! ^V_]$=_@M_W'R$_X]X;?B3_P]02P,$%     @ Y8%Z69ILEX/_-@
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M9)(=OMUS([^7?;UW]/E>_OW>G^@(_L/F/+-\H'O^($8++HEM:_8$QXL@I2*
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MJ?RV"6^7([1Z1%@DLN-VM@A*//4XA8)V3!0RNVR3RE%Y3+EPF,W-UY=0E(Z
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M@)Z[X<@9]8?.?6\XFLVGGP][_W0X^[7WX(R<3P/Z2UT6*! S<'N48G?Z0@=
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M6;KIQOLJ*?IRV@RX/OY9W_JH,+..HR/8'.LK^(*P1Y%9,B+ N88U"5%;*HN
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MWT>%H+\/G>6OL_QUEK_.\F=<ESK+7V?YZRQ_-2Q_QDHV6&0'-%JRH3,'=N;
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M[NQ(!W<YUS,F)S2_HU40")2YDEPN*;.:B5LA'*;R>LOLHPUU/"NP9<IQ! @
M:TNTES+8(-^1.*[KDO1XFQ\E"M$\S:52C]/4Z-NH*G\!4UKD;2C;PUT'J1N6
M_!^2@*0_EW([G,EP[MRS/![G!B(!?!\E+N!^#@&IGOC;DO^9>SKB$QB]8BC
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M# $ OHP*  L              ( !     &5X:%\Y.3$N:'1M4$L! A0#%
M  @ Y8%Z6=/Q)'S!H   &]8$  L              ( !A0P! &5X:%\Y.3(N
M:'1M4$L! A0#%     @ Y8%Z68D184YH"P  938   X              ( !
M;ZT! &8V:U\Q,3(V,C0N:'1M4$L! A0#%     @ Y8%Z66Q2&2A3%0  CP,!
M !(              ( ! [D! '!T9V5F+3(P,C0P.3,P+GAS9%!+ 0(4 Q0
M   ( .6!>ED$1;D0;1   'G0   6              "  8;. 0!P=&=E9BTR
M,#(T,#DS,%]C86PN>&UL4$L! A0#%     @ Y8%Z61NFSR7K'@  MP\" !8
M             ( !)]\! '!T9V5F+3(P,C0P.3,P7V1E9BYX;6Q02P$"% ,4
M    " #E@7I9/><Z$19*  "R$00 %@              @ %&_@$ <'1G968M
M,C R-# Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( .6!>EF:;)>#_S8  )W# P 6
M              "  9!( @!P=&=E9BTR,#(T,#DS,%]P<F4N>&UL4$L%!@
0   (  @ _@$  ,-_ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>f6k_112624_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ptgef="http://portagebiotech.com/20240930"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ptgef-20240930.xsd" xlink:type="simple"/>
    <context id="From2024-04-01to2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_AccumulatedOtherComprehensiveLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_AccumulatedOtherComprehensiveLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_AccumulatedOtherComprehensiveLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_StockOptionReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:StockOptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_AccumulatedOtherComprehensiveLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ptgef:AccumulatedOtherComprehensiveLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_ifrs-full_NoncontrollingInterestsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:NoncontrollingInterestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="From2021-09-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-09-012021-09-30_ifrs-full_BottomOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-09-012021-09-30_ifrs-full_TopOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_CountryOfBritishVirginIslandsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ptgef:CountryOfBritishVirginIslandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_CountryOfDelawareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ptgef:CountryOfDelawareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ParexelInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:ParexelInternationalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_ParexelInternationalLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">ptgef:ParexelInternationalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ClassBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_ClassCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:ClassCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-09-282023-09-29_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="From2023-09-282023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-28</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis">ptgef:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-26_custom_PlacementAgentWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-26</instant>
        </period>
    </context>
    <context id="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-25</startDate>
            <endDate>2023-08-26</endDate>
        </period>
    </context>
    <context id="From2024-05-282024-05-29_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-28</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-29_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-29</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_custom_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_ifrs-full_TopOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_ifrs-full_BottomOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-052022-07-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-07-05</startDate>
            <endDate>2022-07-06</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_ATMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_ATMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">ptgef:ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsAndPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="AsOf2023-10-03_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-03</instant>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_custom_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ptgef:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_ifrs-full_RestrictedShareUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfAntidilutiveInstrumentsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_PBI2021EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ptgef:PBI2021EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_ifrs-full_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_ifrs-full_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_RestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-02-282023-03-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-03-02</endDate>
        </period>
    </context>
    <context id="From2022-12-252022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
        </entity>
        <period>
            <startDate>2022-12-25</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_AmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_FairValueToOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_AmortizedCostMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:AmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_FairValueToOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueToOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ptgef:FairValueThroughProfitOrLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012023-09-30_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_SaugatuckMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095435</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ptgef:SaugatuckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="EURPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="From2024-04-01to2024-09-30" id="Fact000018">6-K</dei:DocumentType>
    <dei:EntityFileNumber contextRef="From2024-04-01to2024-09-30" id="Fact000019">001-40086</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-04-01to2024-09-30" id="Fact000020">Portage Biotech Inc.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="From2024-04-01to2024-09-30" id="Fact000021">Clarence Thomas Building</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-04-01to2024-09-30" id="Fact000022">P.O. Box 4649</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2024-04-01to2024-09-30" id="Fact000023">Road Town</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2024-04-01to2024-09-30" id="Fact000024">Tortola</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2024-04-01to2024-09-30" id="Fact000025">VG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2024-04-01to2024-09-30" id="Fact000026">VG1110</dei:EntityAddressPostalZipCode>
    <dei:AmendmentFlag contextRef="From2024-04-01to2024-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-04-01to2024-09-30" id="Fact000004">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-04-01to2024-09-30" id="Fact000005">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-04-01to2024-09-30" id="Fact000006">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType contextRef="From2024-04-01to2024-09-30" id="Fact000007">6-K</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="From2024-04-01to2024-09-30" id="Fact000008">0001095435</dei:EntityCentralIndexKey>
    <ifrs-full:OtherAssets
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0051"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0072"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0081"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:CommitmentsAndContingentLiabilities
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0117"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfWarrantsLiability
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0141"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfWarrantsLiability
      contextRef="From2023-04-012023-09-30"
      id="xdx2ixbrl0143"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0145"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0151"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2023-04-012023-09-30"
      id="xdx2ixbrl0153"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0157"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0180"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedGainOnInvestments
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0195"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedGainOnInvestments
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-03-31_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ReverseStockSplitValue
      contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplit
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForRestrictedStockUnitsNet
      contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForRestrictedStockUnitsNet
      contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForRestrictedStockUnitsNet
      contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedForRestrictedStockUnitsNet
      contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-012024-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-03-31_custom_StockOptionReserveMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-03-31_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0376"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-03-31_ifrs-full_EquityAttributableToOwnersOfParentMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-03-31_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedGainOnInvestment
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedGainOnInvestment
      contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedGainOnInvestment
      contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:NetUnrealizedGainOnInvestment
      contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfWarrantsLiability
      contextRef="From2023-04-012023-09-30"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2023-04-012023-09-30"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:IncreaseDecreaseInShareOfLossInAssociate
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:FairValueOfSharesIssuedForServices
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="From2023-04-012023-09-30"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromExerciseOfPrefundedWarrants
      contextRef="From2023-04-012023-09-30"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:RightToUseAssetAcquired
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:LeaseLiabilityIncurred
      contextRef="From2024-04-01to2024-09-30"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentReceivablesFromSaleOfProperties
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentReceivablesFromRentalOfProperties
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:SecurityDepositOnOfficeLease
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:WarrantLiabilityExercisePrice
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0667"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ptgef:WarrantsLiabilityShares
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0669"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:WarrantsLiabilityFairValue
      contextRef="AsOf2023-03-31"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfWarrantLiability
      contextRef="From2023-04-012024-03-31"
      id="xdx2ixbrl0691"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-04-012024-06-30"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0707"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember"
      id="xdx2ixbrl0819"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember"
      id="xdx2ixbrl0821"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl0849"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl0851"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember"
      id="xdx2ixbrl0879"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember"
      id="xdx2ixbrl0881"
      unitRef="Pure"
      xsi:nil="true"/>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesAWarrantsMember"
      id="xdx2ixbrl1001"
      unitRef="Pure"
      xsi:nil="true"/>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember"
      id="xdx2ixbrl1047"
      unitRef="Shares"
      xsi:nil="true"/>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2023-09-30_ifrs-full_WarrantsMember"
      id="xdx2ixbrl1158"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-09-30_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1246"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl1247"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1249"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl1250"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2024-09-30_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1253"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl1254"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2024-03-31_custom_FairValueToOtherComprehensiveIncomeMember"
      id="xdx2ixbrl1256"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl1257"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl1265"
      unitRef="USD"
      xsi:nil="true"/>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember"
      id="xdx2ixbrl1267"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2024-09-30_custom_AmortizedCostMember"
      id="xdx2ixbrl1269"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2024-03-31_custom_AmortizedCostMember"
      id="xdx2ixbrl1271"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityRegistrantName contextRef="From2024-04-01to2024-09-30" id="Fact000027">Portage Biotech Inc.</dei:EntityRegistrantName>
    <dei:DocumentPeriodEndDate contextRef="From2024-04-01to2024-09-30" id="Fact000028">2024-09-30</dei:DocumentPeriodEndDate>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000036"
      unitRef="USD">1764000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000037"
      unitRef="USD">5028000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000039"
      unitRef="USD">922000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000040"
      unitRef="USD">2667000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentAssets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000042"
      unitRef="USD">2686000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000043"
      unitRef="USD">7695000</ifrs-full:CurrentAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000048"
      unitRef="USD">20000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000049"
      unitRef="USD">35000</ifrs-full:RightofuseAssets>
    <ifrs-full:OtherAssets
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000052"
      unitRef="USD">49000</ifrs-full:OtherAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000054"
      unitRef="USD">20000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000055"
      unitRef="USD">84000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000057"
      unitRef="USD">2706000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000058"
      unitRef="USD">7779000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000066"
      unitRef="USD">845000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000067"
      unitRef="USD">2836000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000069"
      unitRef="USD">28000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">40000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">3000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">873000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">2879000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">7000</ifrs-full:NoncurrentLeaseLiabilities>
    <ptgef:WarrantLiabilityNonCurrent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">1138000</ptgef:WarrantLiabilityNonCurrent>
    <ptgef:WarrantLiabilityNonCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">1564000</ptgef:WarrantLiabilityNonCurrent>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">1138000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">1571000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">2011000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">4450000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000096"
      unitRef="USD">219606000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">219499000</ifrs-full:IssuedCapital>
    <ifrs-full:OtherReserves
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">24126000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">23841000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000102"
      unitRef="USD">-242334000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">-239318000</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">1398000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">4022000</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">-703000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">-693000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:Equity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000111"
      unitRef="USD">695000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">3329000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000114"
      unitRef="USD">2706000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">7779000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">723000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">4237000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000127"
      unitRef="USD">2028000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">7865000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000130"
      unitRef="USD">881000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">1693000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">2415000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">3062000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">-1604000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000136"
      unitRef="USD">-5930000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">-4443000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">-10927000</ifrs-full:ProfitLossFromOperatingActivities>
    <ptgef:ChangeInFairValueOfWarrantsLiability
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">716000</ptgef:ChangeInFairValueOfWarrantsLiability>
    <ptgef:ChangeInFairValueOfWarrantsLiability
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">-426000</ptgef:ChangeInFairValueOfWarrantsLiability>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000146"
      unitRef="USD">-113000</ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000148"
      unitRef="USD">-1224000</ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">-946000</ptgef:GainOnSettlementWithParexelIoxCro>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">-946000</ptgef:GainOnSettlementWithParexelIoxCro>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">-40000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">-90000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000160"
      unitRef="USD">7000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000161"
      unitRef="USD">15000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000162"
      unitRef="USD">15000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000163"
      unitRef="USD">26000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">-5000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000166"
      unitRef="USD">-17000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000167"
      unitRef="USD">-7000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000168"
      unitRef="USD">1000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:RevenueFromInterest
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">24000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">43000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000172"
      unitRef="USD">69000</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">123000</ifrs-full:RevenueFromInterest>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000175"
      unitRef="USD">-1362000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000176"
      unitRef="USD">-6072000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000177"
      unitRef="USD">-3024000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000178"
      unitRef="USD">-12143000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000181"
      unitRef="USD">-907000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000182"
      unitRef="USD">2000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000183"
      unitRef="USD">-1052000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ptgef:NetLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000185"
      unitRef="USD">-1362000</ptgef:NetLoss>
    <ptgef:NetLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000186"
      unitRef="USD">-5165000</ptgef:NetLoss>
    <ptgef:NetLoss
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000187"
      unitRef="USD">-3026000</ptgef:NetLoss>
    <ptgef:NetLoss
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000188"
      unitRef="USD">-11091000</ptgef:NetLoss>
    <ptgef:NetUnrealizedGainOnInvestments
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000196"
      unitRef="USD">-1300000</ptgef:NetUnrealizedGainOnInvestments>
    <ptgef:NetUnrealizedGainOnInvestments
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000198"
      unitRef="USD">469000</ptgef:NetUnrealizedGainOnInvestments>
    <ptgef:ComprehensiveLossForPeriod
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">-1362000</ptgef:ComprehensiveLossForPeriod>
    <ptgef:ComprehensiveLossForPeriod
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000201"
      unitRef="USD">-6465000</ptgef:ComprehensiveLossForPeriod>
    <ptgef:ComprehensiveLossForPeriod
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000202"
      unitRef="USD">-3026000</ptgef:ComprehensiveLossForPeriod>
    <ptgef:ComprehensiveLossForPeriod
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">-10622000</ptgef:ComprehensiveLossForPeriod>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000210"
      unitRef="USD">-1360000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">-5158000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">-3016000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000213"
      unitRef="USD">-11077000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000215"
      unitRef="USD">-2000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000216"
      unitRef="USD">-7000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000217"
      unitRef="USD">-10000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLossAttributableToNoncontrollingInterests
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">-14000</ifrs-full:ProfitLossAttributableToNoncontrollingInterests>
    <ifrs-full:ProfitLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000220"
      unitRef="USD">-1362000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000221"
      unitRef="USD">-5165000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000222"
      unitRef="USD">-3026000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000223"
      unitRef="USD">-11091000</ifrs-full:ProfitLoss>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">-1360000</ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">-6458000</ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">-3016000</ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">-10608000</ifrs-full:ComprehensiveIncomeFromContinuingOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000235"
      unitRef="USD">-2000</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">-7000</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">-10000</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000238"
      unitRef="USD">-14000</ifrs-full:ComprehensiveIncomeFromDiscontinuedOperationsAttributableToOwnersOfParent>
    <ptgef:ComprehensiveIncomeAttributableToOwnerOfParent
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">-1362000</ptgef:ComprehensiveIncomeAttributableToOwnerOfParent>
    <ptgef:ComprehensiveIncomeAttributableToOwnerOfParent
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000241"
      unitRef="USD">-6465000</ptgef:ComprehensiveIncomeAttributableToOwnerOfParent>
    <ptgef:ComprehensiveIncomeAttributableToOwnerOfParent
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">-3026000</ptgef:ComprehensiveIncomeAttributableToOwnerOfParent>
    <ptgef:ComprehensiveIncomeAttributableToOwnerOfParent
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000243"
      unitRef="USD">-10622000</ptgef:ComprehensiveIncomeAttributableToOwnerOfParent>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000250"
      unitRef="USDPShares">-1.26</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000252"
      unitRef="USDPShares">-1.26</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000254"
      unitRef="USDPShares">-5.80</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact000256"
      unitRef="USDPShares">-5.80</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2024-04-01to2024-09-30"
      decimals="INF"
      id="Fact000258"
      unitRef="USDPShares">-2.84</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2024-04-01to2024-09-30"
      decimals="INF"
      id="Fact000260"
      unitRef="USDPShares">-2.84</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2023-04-012023-09-30"
      decimals="INF"
      id="Fact000262"
      unitRef="USDPShares">-12.47</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2023-04-012023-09-30"
      decimals="INF"
      id="Fact000264"
      unitRef="USDPShares">-12.47</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000271"
      unitRef="Shares">1076000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000273"
      unitRef="Shares">1076000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000275"
      unitRef="Shares">890000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact000277"
      unitRef="Shares">890000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000279"
      unitRef="Shares">1063000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000281"
      unitRef="Shares">1063000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000283"
      unitRef="Shares">888000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000285"
      unitRef="Shares">888000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2024-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000295"
      unitRef="Shares">19784000</ifrs-full:NumberOfSharesOutstanding>
    <ptgef:ReverseStockSplitShares
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000305"
      unitRef="Shares">989000</ptgef:ReverseStockSplitShares>
    <ptgef:ReverseStockSplitValue
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">219499000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">23841000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">-239318000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000301"
      unitRef="USD">4022000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">-693000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">3329000</ptgef:ReverseStockSplitValue>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012024-09-30_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">285000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">285000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">285000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ptgef:PrefundedWarrantsExercisedShares
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000323"
      unitRef="Shares">60000</ptgef:PrefundedWarrantsExercisedShares>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000315"
      unitRef="USD">1000</ptgef:PrefundedWarrantsExercised>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">1000</ptgef:PrefundedWarrantsExercised>
    <ptgef:PrefundedWarrantsExercised
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000321"
      unitRef="USD">1000</ptgef:PrefundedWarrantsExercised>
    <ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000333"
      unitRef="Shares">52000</ptgef:AdditionalRoundUpSharesIssuedForFractionalSharesInConnectionWith1for20ReverseStockSplitShares>
    <ptgef:SharesIssuedForAccruedBonusesShares
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000343"
      unitRef="Shares">14000</ptgef:SharesIssuedForAccruedBonusesShares>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">100000</ptgef:SharesIssuedForAccruedBonuses>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000339"
      unitRef="USD">100000</ptgef:SharesIssuedForAccruedBonuses>
    <ptgef:SharesIssuedForAccruedBonuses
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">100000</ptgef:SharesIssuedForAccruedBonuses>
    <ptgef:SharesIssuedForRestrictedStockUnitsNetShares
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000353"
      unitRef="USD">1000</ptgef:SharesIssuedForRestrictedStockUnitsNetShares>
    <ptgef:SharesIssuedForRestrictedStockUnitsNet
      contextRef="From2024-04-012024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000345"
      unitRef="USD">6000</ptgef:SharesIssuedForRestrictedStockUnitsNet>
    <ptgef:SharesIssuedForRestrictedStockUnitsNet
      contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">6000</ptgef:SharesIssuedForRestrictedStockUnitsNet>
    <ptgef:SharesIssuedForRestrictedStockUnitsNet
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000351"
      unitRef="USD">6000</ptgef:SharesIssuedForRestrictedStockUnitsNet>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-012024-09-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000358"
      unitRef="USD">-3016000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-012024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000359"
      unitRef="USD">-3016000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-012024-09-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000360"
      unitRef="USD">-10000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">-3026000</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000371"
      unitRef="Shares">1116000</ifrs-full:NumberOfSharesOutstanding>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">219606000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-09-30_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000364"
      unitRef="USD">24126000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-09-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000366"
      unitRef="USD">-242334000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000367"
      unitRef="USD">1398000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-09-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">-703000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000369"
      unitRef="USD">695000</ptgef:EquityPreSplit>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2023-03-31_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000381"
      unitRef="Shares">17606000</ifrs-full:NumberOfSharesOutstanding>
    <ptgef:ReverseStockSplitShares
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000391"
      unitRef="Shares">880000</ptgef:ReverseStockSplitShares>
    <ptgef:ReverseStockSplitValue
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000383"
      unitRef="USD">218782000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">21204000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      decimals="-3"
      id="Fact000385"
      unitRef="USD">-4325000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000386"
      unitRef="USD">-159616000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000387"
      unitRef="USD">76045000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000388"
      unitRef="USD">-650000</ptgef:ReverseStockSplitValue>
    <ptgef:ReverseStockSplitValue
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000389"
      unitRef="USD">75395000</ptgef:ReverseStockSplitValue>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012023-09-30_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000394"
      unitRef="USD">1512000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000397"
      unitRef="USD">1512000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">1512000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ptgef:SharesIssuedUnderAtmShares
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000409"
      unitRef="Shares">9000</ptgef:SharesIssuedUnderAtmShares>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">682000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000405"
      unitRef="USD">682000</ptgef:SharesIssuedUnderAtm>
    <ptgef:SharesIssuedUnderAtm
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000407"
      unitRef="USD">682000</ptgef:SharesIssuedUnderAtm>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000411"
      unitRef="USD">20000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000415"
      unitRef="USD">20000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000417"
      unitRef="USD">20000</ifrs-full:ShareIssueRelatedCost>
    <ptgef:SharesIssuedOrAccruedForServicesShares
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000427"
      unitRef="Shares">1000</ptgef:SharesIssuedOrAccruedForServicesShares>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012023-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000419"
      unitRef="USD">50000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000423"
      unitRef="USD">50000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:SharesIssuedOrAccruedForServices
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000425"
      unitRef="USD">50000</ptgef:SharesIssuedOrAccruedForServices>
    <ptgef:NetUnrealizedGainOnInvestment
      contextRef="From2023-04-012023-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      decimals="-3"
      id="Fact000431"
      unitRef="USD">469000</ptgef:NetUnrealizedGainOnInvestment>
    <ptgef:NetUnrealizedGainOnInvestment
      contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">469000</ptgef:NetUnrealizedGainOnInvestment>
    <ptgef:NetUnrealizedGainOnInvestment
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">469000</ptgef:NetUnrealizedGainOnInvestment>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012023-09-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000440"
      unitRef="USD">-11077000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">-11077000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012023-09-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">-14000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000443"
      unitRef="USD">-11091000</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2023-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000453"
      unitRef="Shares">890000</ifrs-full:NumberOfSharesOutstanding>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-09-30_ifrs-full_IssuedCapitalMember"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">219494000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-09-30_custom_StockOptionReserveMember"
      decimals="-3"
      id="Fact000446"
      unitRef="USD">22716000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-09-30_custom_AccumulatedOtherComprehensiveLossMember"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">-3856000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-09-30_ifrs-full_RetainedEarningsMember"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">-170693000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-09-30_ifrs-full_EquityAttributableToOwnersOfParentMember"
      decimals="-3"
      id="Fact000449"
      unitRef="USD">67661000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-09-30_ifrs-full_NoncontrollingInterestsMember"
      decimals="-3"
      id="Fact000450"
      unitRef="USD">-664000</ptgef:EquityPreSplit>
    <ptgef:EquityPreSplit
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000451"
      unitRef="USD">66997000</ptgef:EquityPreSplit>
    <ifrs-full:ProfitLoss
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000458"
      unitRef="USD">-3026000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">-11091000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000464"
      unitRef="USD">285000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">1512000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ptgef:ChangeInFairValueOfWarrantsLiability
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000467"
      unitRef="USD">-426000</ptgef:ChangeInFairValueOfWarrantsLiability>
    <ptgef:GainOnSettlementWithParexelIoxCro
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000470"
      unitRef="USD">-946000</ptgef:GainOnSettlementWithParexelIoxCro>
    <ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000474"
      unitRef="USD">-1224000</ptgef:ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone>
    <ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">1063000</ifrs-full:IncreaseDecreaseInDeferredTaxLiabilityAsset>
    <ptgef:IncreaseDecreaseInShareOfLossInAssociate
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000480"
      unitRef="USD">-90000</ptgef:IncreaseDecreaseInShareOfLossInAssociate>
    <ptgef:FairValueOfSharesIssuedForServices
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000483"
      unitRef="USD">50000</ptgef:FairValueOfSharesIssuedForServices>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000485"
      unitRef="USD">15000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000486"
      unitRef="USD">26000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">1216000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000492"
      unitRef="USD">286000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">38000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">-3000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000497"
      unitRef="USD">-399000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000498"
      unitRef="USD">1224000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000500"
      unitRef="USD">-3000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000503"
      unitRef="USD">-3246000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000504"
      unitRef="USD">-7745000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ptgef:ProceedsFromExerciseOfPrefundedWarrants
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">1000</ptgef:ProceedsFromExerciseOfPrefundedWarrants>
    <ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">682000</ptgef:ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">20000</ifrs-full:PaymentsForShareIssueCosts>
    <ptgef:RepaymentOfLeaseLiability
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000518"
      unitRef="USD">19000</ptgef:RepaymentOfLeaseLiability>
    <ptgef:RepaymentOfLeaseLiability
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">17000</ptgef:RepaymentOfLeaseLiability>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000521"
      unitRef="USD">-18000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000522"
      unitRef="USD">645000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000524"
      unitRef="USD">-3264000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000525"
      unitRef="USD">-7100000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000527"
      unitRef="USD">5028000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000528"
      unitRef="USD">10545000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000530"
      unitRef="USD">1764000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact000531"
      unitRef="USD">3445000</ifrs-full:CashAndCashEquivalents>
    <ptgef:CashPaidForInterest
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000536"
      unitRef="USD">3000</ptgef:CashPaidForInterest>
    <ptgef:CashPaidForInterest
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000537"
      unitRef="USD">13000</ptgef:CashPaidForInterest>
    <ptgef:RightToUseAssetAcquired
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000543"
      unitRef="USD">303000</ptgef:RightToUseAssetAcquired>
    <ptgef:LeaseLiabilityIncurred
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">303000</ptgef:LeaseLiabilityIncurred>
    <ptgef:NatureOfOperationsExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact000548">&lt;p id="xdx_802_ecustom--NatureOfOperationsExplanatory_zcLRZdXnyXV5" style="margin: 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 1. &lt;span id="xdx_823_zDHRMIATIQv"&gt;NATURE OF OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Portage Biotech Inc. (the &#x201c;Company&#x201d; or &#x201c;Portage&#x201d;)
is incorporated in the British Virgin Islands (&#x201c;BVI&#x201d;) with its registered office located at Clarence Thomas Building, P.O.
Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services Inc. (&#x201c;PDS&#x201d;), is located at 59 Wilton Road,
Westport, CT, 06880, USA.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company is a foreign private issuer under the Securities
and Exchange Commission (the &#x201c;SEC&#x201d;) rules. It is also a reporting issuer under the securities legislation of the provinces
of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (&#x201c;CSE&#x201d;) under the symbol
&#x201c;PBT.U&#x201d;. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;)
under the symbol &#x201c;PRTG&#x201d;. As the principal market for the Company&#x2019;s ordinary shares is Nasdaq, the Company voluntarily
delisted from the CSE on April 23, 2021.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Portage is a clinical-stage immuno-oncology company advancing
treatments the Company believes will be first-in class therapies that target known checkpoint resistance pathways to improve long-term
treatment response and quality of life in patients with invasive cancers. Portage&#x2019;s access to next-generation technologies coupled
with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies
that accelerate these medicines through the translational pipeline. After a review of the Company&#x2019;s future funding needs for clinical
development of its programs as well as the current capital raising market for biotechnology companies, the Company made the decision to
discontinue the Company sponsored trial for the invariant natural killer T-cell (&#x201c;iNKT&#x201d;) program and pause further patient
accrual to the Company sponsored adenosine trial for both PORT-6 and PORT-7. The Company is exploring strategic alternatives, which may
include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings, both in and out of court, a
company wind down, further financing efforts or other strategic action.&lt;/p&gt;


&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;)
approved a reverse stock split of its ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024,
the Company&#x2019;s ordinary shares began trading on Nasdaq on a split-adjusted basis under the existing trading symbol &#x201c;PRTG&#x201d;.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The reverse stock split was implemented to increase the
per share trading price of the Company&#x2019;s ordinary shares for the purpose of ensuring a share price high enough to comply with the
minimum $1.00 bid price requirement for continued listing on Nasdaq. The Company received notice from Nasdaq on August 30, 2024 informing
the Company that it had regained compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;As a result of the reverse stock split,
every twenty (20) pre-split ordinary shares were converted into one (1) post-split ordinary share. Any fractional shares resulting from
the reverse stock split were rounded up to the nearest whole post-split ordinary share. The reverse stock split affected all shareholders
uniformly and did not alter any shareholder&#x2019;s percentage interest in the Company&#x2019;s ordinary shares, except for adjustments
that may result from the treatment of fractional shares. All outstanding options and warrants entitling their holders to purchase the
Company&#x2019;s ordinary shares were adjusted as a result of the reverse stock split, in accordance with the terms of each such security.
In addition, the number of ordinary shares reserved for future issuance pursuant to the Company&#x2019;s equity incentive plans were also
appropriately adjusted. The number of authorized ordinary shares was not proportionately reduced because the Company has an unlimited
number of authorized ordinary shares available for issuance, as permitted under the laws of the British Virgin Islands.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;All share and per share information
included in the condensed consolidated interim financial statements have been retroactively adjusted to reflect the impact of the reverse
stock split as if the stock split occurred at the beginning of the periods presented. The shares of ordinary shares authorized remained
at an unlimited number of ordinary shares without par value.&lt;/p&gt;
&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;






















</ptgef:NatureOfOperationsExplanatory>
    <ifrs-full:DisclosureOfGoingConcernExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact000559">&lt;p id="xdx_808_eifrs-full--DisclosureOfGoingConcernExplanatory_zhrrssrqEuh8" style="margin: 0; font-size: 10pt"&gt;&lt;b&gt;NOTE 2. &lt;span id="xdx_828_zGZQ0eWndc82"&gt;GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;As of September 30, 2024, the Company had cash and cash
equivalents of approximately $&lt;span id="xdx_90A_eifrs-full--Cash_iI_pn5n6_c20240930_zZB5ujfHhFxb"&gt;1.8
&lt;/span&gt;million and total current liabilities of approximately $&lt;span id="xdx_906_ecustom--TotalCurrentLiabilities_iI_pn5n6_c20240930_zdtpdfN5W0Dg" title="Total current liabilities"&gt;0.9
&lt;/span&gt;million. For the six months ended September 30, 2024, the Company is reporting a net loss of approximately $&lt;span id="xdx_907_ecustom--NetLossIncome_pn6n6_c20240401__20240930_ztJx0YCAe7M" title="Net loss"&gt;3&lt;/span&gt;.0
million, and cash used in operating activities of approximately $&lt;span id="xdx_90D_ecustom--CashUsedInOperatingActivities_pn5n6_c20240401__20240930_zqHk0zQFjwf1" title="Cash used in operating activities"&gt;3.3
&lt;/span&gt;million. As of November 25, 2024, the Company had approximately $&lt;span id="xdx_901_eifrs-full--CashOnHand_iI_pn5n6_c20241125_zGLAOvpN5gtj" title="Cash and cash equivalents on hand"&gt;1.7
&lt;/span&gt;million of cash and cash equivalents on hand.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company&#x2019;s cash and cash equivalents balance
is decreasing, and the Company did not generate positive cash flows from operations for the six months ended September 30, 2024 and fiscal
year ended March 31, 2024 (&#x201c;Fiscal 2024&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;In late Fiscal 2024, because of continued liquidity
constraints, the Company made the decision to discontinue further clinical development of its iNKT sponsored trial and pause further
patient accrual to its sponsored adenosine program for both PORT-6 and PORT-7. The Company is exploring strategic alternatives,
which may include finding a partner for one or more of its assets, a sale of our company, a merger, restructurings, both in and out
of court, company wind down, further financing efforts or other strategic action. These factors raise significant doubt about the
Company&#x2019;s ability to continue as a going concern within one year after the date of the condensed consolidated interim
statement of financial position.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company has incurred significant operating losses
since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable.
The losses result primarily from its conduct of research and development activities. As previously discussed, the Company has discontinued
its iNKT sponsored trial and paused further patient accrual to the Company sponsored adenosine program in order to preserve cash resources.
Additionally, during the fourth quarter of Fiscal 2024, the Company sold its shares in Intensity on Nasdaq.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company historically has funded its operations principally
from proceeds from issuances of equity and debt securities. The Company will require significant additional capital to make the investments
it needs to execute its longer-term business plan, beyond the potential proceeds that could be reasonably generated from its &#x201c;at-the-market&#x201d;
(&#x201c;ATM&#x201d;) program and Committed Purchase Agreement (as defined below) with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln&#x201d;)
given the Company&#x2019;s current trading volume on Nasdaq. The Company&#x2019;s ability to successfully raise sufficient funds through
the sale of debt or equity securities when needed is subject to many risks and uncertainties and, future equity issuances would result
in dilution to existing shareholders and any future debt securities may contain covenants that limit the Company's operations or ability
to enter into certain transactions. See Note 9, &#x201c;Capital Stock and Reserves,&#x201d; for a further discussion.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;There can be no assurance that the Company&#x2019;s evaluation
of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be
successful or on attractive terms. Any potential transaction would be dependent on a number of factors that may be beyond the Company&#x2019;s
control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction
with the Company and the availability of financing to the Company or third parties in a potential transaction with the Company on reasonable
terms. The process of reviewing strategic alternatives may require the Company to incur additional costs and expenses. It could negatively
impact the Company&#x2019;s ability to attract, retain and motivate key employees, and expose the Company to potential litigation in connection
with this process or any resulting transaction. If the Company is unable to effectively manage the process, the Company&#x2019;s financial
condition and results of operations could be adversely affected. In addition, any strategic alternative that may be pursued and completed
ultimately may not deliver the anticipated benefits or enhance shareholder value. There can be no guarantee that the process of evaluating
strategic alternatives will result in the Company entering into or completing a potential transaction within the anticipated timing or
at all. There is no set timetable for this evaluation and the Company does not intend to disclose developments with respect to this evaluation
unless and until the Company determines that further disclosure is appropriate or legally required. As of November 25, 2024, the Company
had approximately $&lt;span id="xdx_901_eifrs-full--CashOnHand_iI_pn5n6_c20241125_zGg95JAYe3f6" title="Cash and cash equivalents on hand"&gt;1.7&lt;/span&gt; million of cash and cash equivalents on hand, which the Company expects is only sufficient to cover its operating
needs through January 2025. These factors raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within
one year after the date of the condensed consolidated interim statement of financial position. There were no adjustments made to reflect
the effect of this doubt.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
















</ifrs-full:DisclosureOfGoingConcernExplanatory>
    <ifrs-full:Cash
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000560"
      unitRef="USD">1800000</ifrs-full:Cash>
    <ptgef:TotalCurrentLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000562"
      unitRef="USD">900000</ptgef:TotalCurrentLiabilities>
    <ptgef:NetLossIncome
      contextRef="From2024-04-01to2024-09-30"
      decimals="-6"
      id="Fact000564"
      unitRef="USD">3000000</ptgef:NetLossIncome>
    <ptgef:CashUsedInOperatingActivities
      contextRef="From2024-04-01to2024-09-30"
      decimals="-5"
      id="Fact000566"
      unitRef="USD">3300000</ptgef:CashUsedInOperatingActivities>
    <ifrs-full:CashOnHand
      contextRef="AsOf2024-11-25"
      decimals="-5"
      id="Fact000568"
      unitRef="USD">1700000</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand
      contextRef="AsOf2024-11-25"
      decimals="-5"
      id="Fact000570"
      unitRef="USD">1700000</ifrs-full:CashOnHand>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact000578">&lt;p id="xdx_80D_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zWrQ2fFpRgRj" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 3. &lt;span id="xdx_82C_zEKCtndpCue"&gt;BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Statement of Compliance and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;These condensed consolidated interim financial statements
have been prepared in accordance with the International Financial Reporting Standards (&#x201c;IFRS&#x201d;) issued by the International
Accounting Standards Board (&#x201c;IASB&#x201d;), International Accounting Standards (&#x201c;IAS&#x201d;) 34 &lt;i&gt;Interim Financial Reporting&lt;/i&gt;
and interpretations of the International Financial Reporting Interpretations Committee. These condensed consolidated interim financial
statements do not include all of the information required for full annual financial statements and should be read in conjunction with
the audited consolidated financial statements of the Company for the year ended March 31, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;These condensed consolidated interim financial statements
have been prepared on an historical cost basis except for items disclosed herein at fair value (see Note 14, &#x201c;Financial Instruments
and Risk Management&#x201d;). In addition, these condensed consolidated interim financial statements have been prepared using the accrual
basis of accounting, except for cash flow information.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company has only one reportable operating segment.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;These condensed consolidated interim financial statements
were approved and authorized for issuance by the Audit Committee (the &#x201c;Audit Committee&#x201d;) of the Board on November 26&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;,
2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The consolidated financial statements include the accounts
of the Company and:&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(a)&lt;/td&gt;&lt;td style="text-align: justify"&gt;SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(b)&lt;/td&gt;&lt;td style="text-align: justify"&gt;iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company,
through SalvaRx, exchanged certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing &lt;span id="xdx_902_ecustom--PercentageOfOutstandingShares_pip0_dp_c20210901__20210930_z3jGGTP0zKH6" title="Percentage of outstanding shares"&gt;17.83&lt;/span&gt;%
of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from &lt;span id="xdx_901_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zkvoRLUhY2me" title="Percentage of ownership subsidiary"&gt;60.49&lt;/span&gt;%
to &lt;span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_z2LJjqTSDy73" title="Percentage of ownership subsidiary"&gt;78.32&lt;/span&gt;%. On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. The Company&#x2019;s 44% interest in
Stimunity S.A. (&#x201c;Stimunity&#x201d;) was transferred from Portage to iOx in December 2023 and was increased to 48.9% upon the conversion
of the convertible note to equity;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(c)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Saugatuck, a &lt;span id="xdx_90B_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20240401__20240930__ifrs-full--SegmentsAxis__custom--CountryOfBritishVirginIslandsMember_zM93r3Py7XJ7" title="Percentage of ownership subsidiary"&gt;70&lt;/span&gt;% owned subsidiary incorporated in the British Virgin Islands;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 0.5in; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(d)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Tarus Therapeutic Holdings Ltd., a wholly-owned subsidiary incorporated in the British Virgin Islands;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(e)&lt;/td&gt;&lt;td style="text-align: justify"&gt;PDS, a &lt;span id="xdx_904_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pip0_dp_c20240401__20240930__ifrs-full--SegmentsAxis__custom--CountryOfDelawareMember_zyTeJulxTnie" title="Percentage of ownership subsidiary"&gt;100&lt;/span&gt;% owned subsidiary incorporated in Delaware, which provides human resources, and other services
to each operating subsidiary via a shared services agreement;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(f)&lt;/td&gt;&lt;td style="text-align: justify"&gt;SalvaRx LLC, a wholly-owned subsidiary through SalvaRx incorporated in Delaware;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(g)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck incorporated in Delaware; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(h)&lt;/td&gt;&lt;td style="text-align: justify"&gt;Tarus Therapeutics, LLC (&#x201c;Tarus&#x201d;), a wholly-owned subsidiary of Portage incorporated in Delaware.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;All inter-company balances and transactions have been
eliminated in consolidation.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Non-controlling interest in the equity of a subsidiary
is accounted for and reported as a component of shareholders&#x2019; equity. As of September 30, 2024 and March 31, 2024, non-controlling
interest represents the &lt;span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4CVFbjn51Ri" title="Non-controlling interest"&gt;&lt;span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20230401__20240331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zaIaAAHFedtl" title="Non-controlling interest"&gt;30&lt;/span&gt;&lt;/span&gt;% shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;



&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;/p&gt;














&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Functional and Presentation Currency&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company&#x2019;s functional and presentation currency
is the U.S. Dollar.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates and Judgments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The preparation of the condensed consolidated interim
financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application
of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Estimates and underlying assumptions are reviewed on
an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future
periods affected.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Significant areas where estimates are
made include valuation of financial instruments, deferred tax assets and liabilities, warrant liabilities, research and development costs,
contingent consideration assumed and measurement of share-based compensation. Significant areas where critical judgments are applied include
in-process research and development and warrant liabilities.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;Reclassifications&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Certain prior year amounts between
accounts payable and accrued liabilities have been reclassified for consistency with the current year presentation. These reclassifications
had no effect on the reported results of operations.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;
















</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <ptgef:PercentageOfOutstandingShares
      contextRef="From2021-09-012021-09-30"
      decimals="INF"
      id="Fact000580"
      unitRef="Pure">0.1783</ptgef:PercentageOfOutstandingShares>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2021-09-012021-09-30_ifrs-full_BottomOfRangeMember"
      decimals="INF"
      id="Fact000582"
      unitRef="Pure">0.6049</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2021-09-012021-09-30_ifrs-full_TopOfRangeMember"
      decimals="INF"
      id="Fact000584"
      unitRef="Pure">0.7832</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-04-012024-09-30_custom_CountryOfBritishVirginIslandsMember"
      decimals="INF"
      id="Fact000586"
      unitRef="Pure">0.70</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="From2024-04-012024-09-30_custom_CountryOfDelawareMember"
      decimals="INF"
      id="Fact000588"
      unitRef="Pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
      contextRef="From2024-04-012024-09-30_custom_SaugatuckMember"
      decimals="INF"
      id="Fact000590"
      unitRef="Pure">0.30</ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests>
    <ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
      contextRef="From2023-04-012024-03-31_custom_SaugatuckMember"
      decimals="INF"
      id="Fact000592"
      unitRef="Pure">0.30</ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests>
    <ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact000607">&lt;p id="xdx_805_ecustom--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_z1D0ZVDdE39c" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 4.&lt;/b&gt;&#160; &lt;b&gt;&lt;span id="xdx_823_zMSJ5cvJNbh6"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The accounting policies are set out in Note 4 to the
Company&#x2019;s audited consolidated financial statements for Fiscal 2024. These policies have been applied consistently to all periods
presented in these condensed consolidated interim financial statements.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zKaYTrbq7im9" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zMXSuqmHhCh8"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;IFRS Pronouncements Issued&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;Impact of Adoption of Significant New IFRS Standards in Fiscal 2025&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Amendments to IAS 1: Non-current Liabilities with Covenants&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The amendments to IAS 1, &#x201c;Presentation of Financial
Statements,&#x201d; clarify how conditions with which an entity must comply within twelve months after the reporting period affect the
classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these
conditions.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The amendments to IFRS 16 and IAS 1 were effective for
annual periods beginning on or after January 1, 2024. The adoption of these amendments did not have a material effect on the Company&#x2019;s
annual consolidated financial statements or the condensed consolidated interim financial statements for the three and six months ended
September 30, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Amendments to IAS 7 and IFRS 7: Supplier Finance&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The amendments to IAS 7 and IFRS 7, &#x201c;Statement
of Cash Flows,&#x201d; require disclosures to enhance the transparency of supplier finance arrangements and their effects on an entity&#x2019;s
liabilities, cash flows and exposure to liquidity risk. The amendments to IAS 7 and IFRS 7 were effective for annual periods beginning
on or after January 1, 2024 (with transitional reliefs in the first year). The adoption of these amendments did not have a material effect
on the Company&#x2019;s annual consolidated financial statements or the condensed consolidated interim financial statements for the three
and six months ended September 30, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;New Accounting Standards, Interpretations and Amendments&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Standards issued but not yet effective up to the date
of issuance of the Company&#x2019;s condensed consolidated interim financial statements is listed below. This is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes
effective.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;Amendments to IAS 21 &#x2013; Lack of Exchangeability&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;An entity is impacted by the amendments to IAS 21, &#x201c;The
Effects of Changes in Foreign Exchange Rates,&#x201d; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The Company is evaluating whether the adoption of the amendments to IAS 21 would have a material effect
on the Company&#x2019;s annual consolidated financial statements or its condensed consolidated interim financial statements.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact000609">&lt;p id="xdx_845_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zKaYTrbq7im9" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_864_zMXSuqmHhCh8"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;IFRS Pronouncements Issued&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;Impact of Adoption of Significant New IFRS Standards in Fiscal 2025&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Amendments to IAS 1: Non-current Liabilities with Covenants&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The amendments to IAS 1, &#x201c;Presentation of Financial
Statements,&#x201d; clarify how conditions with which an entity must comply within twelve months after the reporting period affect the
classification of a liability. The amendments also aim to improve information an entity provides related to liabilities subject to these
conditions.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The amendments to IFRS 16 and IAS 1 were effective for
annual periods beginning on or after January 1, 2024. The adoption of these amendments did not have a material effect on the Company&#x2019;s
annual consolidated financial statements or the condensed consolidated interim financial statements for the three and six months ended
September 30, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 23.05pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Amendments to IAS 7 and IFRS 7: Supplier Finance&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The amendments to IAS 7 and IFRS 7, &#x201c;Statement
of Cash Flows,&#x201d; require disclosures to enhance the transparency of supplier finance arrangements and their effects on an entity&#x2019;s
liabilities, cash flows and exposure to liquidity risk. The amendments to IAS 7 and IFRS 7 were effective for annual periods beginning
on or after January 1, 2024 (with transitional reliefs in the first year). The adoption of these amendments did not have a material effect
on the Company&#x2019;s annual consolidated financial statements or the condensed consolidated interim financial statements for the three
and six months ended September 30, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;New Accounting Standards, Interpretations and Amendments&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Standards issued but not yet effective up to the date
of issuance of the Company&#x2019;s condensed consolidated interim financial statements is listed below. This is of standards and interpretations
issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt this standard when it becomes
effective.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;Amendments to IAS 21 &#x2013; Lack of Exchangeability&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;An entity is impacted by the amendments to IAS 21, &#x201c;The
Effects of Changes in Foreign Exchange Rates,&#x201d; when it has a transaction or an operation in a foreign currency that is not exchangeable
into another currency at a measurement date for a specified purpose. A currency is exchangeable when there is an ability to obtain the
other currency (with a normal administrative delay), and the transaction would take place through a market or exchange mechanism that
creates enforceable rights and obligations. The amendments to IAS 21 are effective for annual periods beginning on or after January 1,
2025, unless earlier adopted. The Company is evaluating whether the adoption of the amendments to IAS 21 would have a material effect
on the Company&#x2019;s annual consolidated financial statements or its condensed consolidated interim financial statements.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory>
    <ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact000619">&lt;p id="xdx_804_ecustom--DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory_zguFcxKP0HM2" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 5. &lt;span id="xdx_822_zSnXhVx0Zcsj"&gt;PREPAID EXPENSES AND OTHER RECEIVABLES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;At September 30, 2024 and March 31, 2024, prepaid expenses
and other receivables were comprised of the following (in thousands):&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z0jPJYwGU6vd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zpQkJ8fMrDwd" style="display: none"&gt;Schedule of prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20240930_zzEU0woN1Sx6" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20240331_zdxu0LM7fXZf" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024 &lt;br/&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_maCPzKMQ_zzk7XYFBfK4b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid clinical research costs&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,924&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--CurrentReceivablesFromRentalOfProperties_iI_maCPzKMQ_zJRDfyKZ9e1e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Refund from Parexel&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;552&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0627"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzKMQ_zku20B74vfyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;249&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;575&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--TaxDeposits_iI_maCPzKMQ_zntCDP3FnKKk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax deposits&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;63&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzKMQ_zRUK8u0x0R9d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;26&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;65&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzKMQ_zLhyFgKfzFP1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;18&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;39&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--SecurityDepositOnOfficeLease_iI_pn3n3_maCPzKMQ_zJHqSHVHSNb7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Security deposit on office lease expiring in May 2025&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;14&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzKMQ_zYSZF37e1hja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;922&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,667&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The decrease in prepaid expenses and other receivables
&lt;span style="background-color: white"&gt;from $&lt;span id="xdx_906_ecustom--PrepaidExpensesAndOtherReceivablesNoncurrent_iI_pn5n6_c20240331__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_zuLd0xoFWpIa" title="Prepaid expenses and other receivables"&gt;2.7&lt;/span&gt; million as of March 31, 2024 to $&lt;span id="xdx_904_ecustom--PrepaidExpensesAndOtherReceivablesNoncurrent_iI_pn5n6_c20240930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_zmG51KSG5s5h" title="Prepaid expenses and other receivables"&gt;0.9&lt;/span&gt; million as of September 30, 2024 &lt;/span&gt;is primarily
attributable to periodic amortization of prepaid clinical research costs and insurance premiums and the write-off of $&lt;span id="xdx_905_ecustom--WriteoffOfAdvances_iI_pn5n6_c20240930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_z33LJpUCH5n5" title="Write-off of advances"&gt;1.1&lt;/span&gt; million of advances
to Parexel &lt;span style="color: #212529; background-color: white"&gt;International (IRL) Limited (&#x201c;Parexel&#x201d;)&lt;/span&gt;, partially
offset by a $&lt;span id="xdx_903_ecustom--RefundReceivables_iI_pn5n6_c20240930__ifrs-full--SignificantInvestmentsInSubsidiariesAxis__custom--ParexelInternationalLimitedMember_zNn9ilJYcPE2" title="Refund receivables"&gt;0.6&lt;/span&gt; million refund receivable from Paraxel as of September 30, 2024. Refer to the &#x201c;iOx &#x2013; Parexel Master Services
Agreement&#x201d; section of Note 12, &#x201c;Commitments and Contingent Liabilities&#x201d; for further discussion regarding this matter.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















</ptgef:DisclosureOfPrepaidExpensesAndOtherReceivablesExplanatory>
    <ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact000621">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_z0jPJYwGU6vd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zpQkJ8fMrDwd" style="display: none"&gt;Schedule of prepaid expenses and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20240930_zzEU0woN1Sx6" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20240331_zdxu0LM7fXZf" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024 &lt;br/&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_maCPzKMQ_zzk7XYFBfK4b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid clinical research costs&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0623"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,924&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--CurrentReceivablesFromRentalOfProperties_iI_maCPzKMQ_zJRDfyKZ9e1e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Refund from Parexel&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;552&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0627"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPzKMQ_zku20B74vfyl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;249&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;575&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--TaxDeposits_iI_maCPzKMQ_zntCDP3FnKKk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Tax deposits&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;63&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;64&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPzKMQ_zRUK8u0x0R9d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;26&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;65&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPzKMQ_zLhyFgKfzFP1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;18&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;39&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--SecurityDepositOnOfficeLease_iI_pn3n3_maCPzKMQ_zJHqSHVHSNb7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Security deposit on office lease expiring in May 2025&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;14&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPzKMQ_zYSZF37e1hja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total prepaid expenses and other receivables&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;922&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,667&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock>
    <ifrs-full:CurrentReceivablesFromSaleOfProperties
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000624"
      unitRef="USD">1924000</ifrs-full:CurrentReceivablesFromSaleOfProperties>
    <ifrs-full:CurrentReceivablesFromRentalOfProperties
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000626"
      unitRef="USD">552000</ifrs-full:CurrentReceivablesFromRentalOfProperties>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000629"
      unitRef="USD">249000</ifrs-full:CurrentAdvancesToSuppliers>
    <ifrs-full:CurrentAdvancesToSuppliers
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000630"
      unitRef="USD">575000</ifrs-full:CurrentAdvancesToSuppliers>
    <ptgef:TaxDeposits
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000632"
      unitRef="USD">63000</ptgef:TaxDeposits>
    <ptgef:TaxDeposits
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000633"
      unitRef="USD">64000</ptgef:TaxDeposits>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000635"
      unitRef="USD">26000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000636"
      unitRef="USD">65000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000638"
      unitRef="USD">18000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000639"
      unitRef="USD">39000</ifrs-full:OtherCurrentReceivables>
    <ptgef:SecurityDepositOnOfficeLease
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000641"
      unitRef="USD">14000</ptgef:SecurityDepositOnOfficeLease>
    <ifrs-full:CurrentPrepayments
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000644"
      unitRef="USD">922000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">2667000</ifrs-full:CurrentPrepayments>
    <ptgef:PrepaidExpensesAndOtherReceivablesNoncurrent
      contextRef="AsOf2024-03-31_custom_ParexelInternationalLimitedMember"
      decimals="-5"
      id="Fact000647"
      unitRef="USD">2700000</ptgef:PrepaidExpensesAndOtherReceivablesNoncurrent>
    <ptgef:PrepaidExpensesAndOtherReceivablesNoncurrent
      contextRef="AsOf2024-09-30_custom_ParexelInternationalLimitedMember"
      decimals="-5"
      id="Fact000649"
      unitRef="USD">900000</ptgef:PrepaidExpensesAndOtherReceivablesNoncurrent>
    <ptgef:WriteoffOfAdvances
      contextRef="AsOf2024-09-30_custom_ParexelInternationalLimitedMember"
      decimals="-5"
      id="Fact000651"
      unitRef="USD">1100000</ptgef:WriteoffOfAdvances>
    <ptgef:RefundReceivables
      contextRef="AsOf2024-09-30_custom_ParexelInternationalLimitedMember"
      decimals="-5"
      id="Fact000653"
      unitRef="USD">600000</ptgef:RefundReceivables>
    <ptgef:WarrantLiabilityTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact000663">&lt;p id="xdx_80B_ecustom--WarrantLiabilityTextBlock_zP3234WjSSre" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 6. &lt;span id="xdx_826_zKWV27FunZtf"&gt;WARRANT LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On August 15, 2024, the Company effected
a reverse stock split of its ordinary shares at a ratio of 1-for-20. The number of warrants and exercise price information herein have
been retroactively adjusted to reflect the impact of the reverse stock split. See Note 1 &#x201c;Nature of Operations&#x201d; and Note 9,
&#x201c;Capital Stock and Reserves&#x201d; for further discussion on the reverse stock split.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 26.7pt; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The following table summarizes the changes in the warrant
liability during the three and six months ended September 30, 2024:&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zwLAxhHXwtPd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8BC_zXWGbAfywazb" style="display: none"&gt;Schedule of changes in the warrant
liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value Balance&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;In 000&#x2019;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Warrant liability as of April 1, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantLiabilityExercisePrice_iI_pip0_c20230331_zR8JQdLDTJE6" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--WarrantsLiabilityShares_iS_pip0_c20230401__20240331_z2Pq7GJJQzp4" title="Warrants liability, shares at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0669"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20230401__20240331_z4pZHKZA9HW2" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, fair value at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold"&gt;Fair value of warrants at issuance on October 3, 2023:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 61%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Class B Warrants&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zSmJyE5hKpw1" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;45.20&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zZN73Kn7CPZf" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares"&gt;157,895&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zrfqAQ46ti9k" title="Fair value of warrants amount"&gt;3,537&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Class C Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zznyU7KV5Fqc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;45.20&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_z0lkrOfzaO8j" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares"&gt;157,895&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zlWO6Pqg7OG9" title="Fair value of warrants amount"&gt;4,663&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Placement Agent Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMBu6zY15JVh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;47.50&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw6ax8GTFgHa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares"&gt;7,896&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_znbVJV9Zf6qc" title="Fair value of warrants amount"&gt;232&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20230401__20240331_zvJwJGOMsKQl" title="Change in fair value of warrant liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0691"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_ziR3u6w2Has9" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;(6,868&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Warrant liability as of March 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;b style="display: none"&gt;&#x2013;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20240630_zUGjw8zX5Eoc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at beginning"&gt;323,686&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20240630_zZfOIdB69ecb" title="Warrants liability, fair value at beginning"&gt;1,564&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ChangeInFairValueOfWarrantLiability_c20240401__20240630_zDW06zxkz7Cg" title="Change in fair value of warrant liability, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20240630_zDVOnoY49hl4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;(1,142&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Warrant liability as of June 30, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability exercise price"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantsLiabilityShares_iS_pip0_c20240701__20240930_zlmlvAwiTZu" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at beginning"&gt;323,686&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;&lt;span id="xdx_903_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240701__20240930_zEk1ELkUSKIh" title="Warrants liability, fair value at beginning"&gt;422&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability exercise price"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20240701__20240930_zTjtO1x8Yx34" title="Change in fair value of warrant liability, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240701__20240930_zh6K6ejO8LFc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;716&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrant liability as of September 30, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;b style="display: none"&gt;&#x2013;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsLiabilityShares_iE_pip0_c20240701__20240930_zf2cT80Wi85i" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at ending"&gt;323,686&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20240401__20240930_zksU6cTyeeUk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, fair value at ending"&gt;1,138&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zD5WVRGnzKJ3" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On September 29, 2023, the Company entered into a securities
purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an institutional and accredited investor in connection with a registered
direct offering (the &#x201c;the Registered Direct Offering&#x201d;) and a concurrent private placement (the &#x201c;Private Placement&#x201d;)
and together with the Registered Direct Offering, the &#x201c;Offerings&#x201d;). The Offerings closed on October 3, 2023.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Pursuant to the Purchase Agreement, in the Registered
Direct Offering, the Company sold (i) &lt;span id="xdx_905_ecustom--OrdinaryNumberOfStockSold_pip0_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember_zpdKRLglN3xd" title="Number of stock sold"&gt;98,500&lt;/span&gt; shares of the Company&#x2019;s ordinary shares at a purchase price of $&lt;span id="xdx_907_ecustom--PurchasePriceOfPerShare_pip0_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember_znPswoVGxSOd" title="Purchase price of per share"&gt;38.00&lt;/span&gt; per share and
(ii) pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to &lt;span id="xdx_90E_ecustom--PurchaseWarrants_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zxUUrqu08mm7" title="Purchase ordinary shares"&gt;59,395&lt;/span&gt; ordinary shares, at a purchase price of $&lt;span id="xdx_905_ecustom--PurchasePriceOfPerShare_pip0_c20230928__20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zmJvp56kFvsi" title="Purchase price of per share"&gt;37.98&lt;/span&gt;
per Pre-Funded Warrant. All Pre-Funded Warrants, which were exercisable for one ordinary share at an exercise price of $&lt;span id="xdx_904_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pip0_c20230929__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--PurchaseAgreementMember__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_z3Vq45dso3me" title="Exercise price"&gt;0.02&lt;/span&gt; per share,
were exercised in full on May 29, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;In the Private Placement, the Company issued to such
institutional and accredited investor unregistered warrants to purchase up to &lt;span id="xdx_904_ecustom--OrdinarySharesPurchase_pip0_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zVBxxJfTju7e" title="Ordinary shares purchase"&gt;157,895&lt;/span&gt; ordinary shares (the &#x201c;Series A Warrants&#x201d;),
unregistered warrants to purchase up to &lt;span id="xdx_909_ecustom--OrdinarySharesPurchase_pip0_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zN9z4HPJKg54" title="Ordinary shares purchase"&gt;157,895&lt;/span&gt; ordinary shares (the &#x201c;Series B Warrants&#x201d;), and unregistered warrants to purchase
up to &lt;span id="xdx_909_ecustom--OrdinarySharesPurchase_pip0_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zFDAjV7yrEWa" title="Ordinary shares purchase"&gt;157,895&lt;/span&gt; ordinary shares (the &#x201c;Series C Warrants,&#x201d; together with the Series A Warrants and the Series B Warrants, the
&#x201c;Private Warrants&#x201d;), together exercisable for an aggregate of up to 473,685 ordinary shares (the &#x201c;Private Warrant Shares&#x201d;).
Pursuant to the terms of the Purchase Agreement, for each ordinary share and Pre-Funded Warrant issued in the Registered Direct Offering,
an accompanying Series A Warrant, Series B Warrant and Series C Warrant were issued to such institutional and accredited investor. Each
Series A Warrant is exercisable for one Private Warrant Share at an exercise price of $&lt;span id="xdx_90E_ecustom--ExercisePriceOfOutstandingWarrant_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zNYddc7uzvB7" title="Exercise price"&gt;38.00&lt;/span&gt; per share, is immediately exercisable and
will expire 18 months from the date of issuance. Each Series B Warrant is exercisable for one Private Warrant Share at an exercise price
of $&lt;span id="xdx_902_ecustom--ExercisePriceOfOutstandingWarrant_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zkft17r0YC3" title="Exercise price"&gt;45.20&lt;/span&gt; per share, is immediately exercisable and will expire three years from the date of issuance. Each Series C Warrant is exercisable
for one Private Warrant Share at an exercise price of $&lt;span id="xdx_90D_ecustom--ExercisePriceOfOutstandingWarrant_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zYNNQjPqLqh2" title="Exercise price"&gt;45.20&lt;/span&gt; per share, is immediately exercisable and will expire five years from the
date of issuance. The net proceeds to the Company from the Offerings were approximately $&lt;span id="xdx_905_eifrs-full--ProceedsFromIssuingShares_pn5n6_c20240401__20240930_zUlWBPmonRe" title="Net proceeds warrants"&gt;5.3&lt;/span&gt; million, after deducting placement agent&#x2019;s
fees and estimated offering expenses of approximately $&lt;span id="xdx_903_eifrs-full--ProfessionalFeesExpense_pn5n6_c20240401__20240930_zhQcuCpYQjQ9" title="Estimated offering expenses"&gt;0.7&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Pursuant to an engagement letter, dated as of August
26, 2023, between the Company and H.C. Wainwright &amp;amp; Co., LLC (the &#x201c;Placement Agent&#x201d;), the Company paid the Placement Agent
a total cash fee equal to &lt;span id="xdx_909_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pip0_dp_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zvIxA30N6SP2" title="Interest rate"&gt;6.0&lt;/span&gt;% of the aggregate gross proceeds received in the Offerings, or $&lt;span id="xdx_901_ecustom--AggregateGrossProceeds_iI_pn4n6_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zvIahjQjvEdd" title="Aggregate gross proceeds"&gt;0.36&lt;/span&gt; million. The Company also paid the
Placement Agent in connection with the Offerings a management fee equal to &lt;span id="xdx_908_ecustom--ManagementFeePercentage_iI_pip0_dp_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zPv7Ahyo4DEj" title="Management fee percentage"&gt;1.0&lt;/span&gt;% of the aggregate gross proceeds raised in the Offerings
($&lt;span id="xdx_903_ecustom--AggregateGrossProceedsIncrease_iI_pn4n6_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zQE0hB2Tpb6b" title="Aggregate gross proceeds increase"&gt;0.06&lt;/span&gt; million), $&lt;span id="xdx_904_eifrs-full--AdministrativeExpense_pp0p0_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zGtei3LASj6a" title="Non-accountable expenses"&gt;75,000&lt;/span&gt; for non-accountable expenses and $&lt;span id="xdx_906_eifrs-full--FeeAndCommissionExpense_pp0p0_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_z8Nc31kqmmd5" title="Clearing fees"&gt;15,950&lt;/span&gt; for clearing fees. In addition, the Company issued to the Placement
Agent, or its designees, warrants to purchase up to &lt;span id="xdx_90D_ecustom--PurchaseOfWarrants_pip0_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zl1DS9IdLlF7" title="Purchase warrants"&gt;7,896&lt;/span&gt; ordinary shares (the &#x201c;Placement Agent Warrants,&#x201d; and together with
the Pre-Funded Warrants and the Private Warrants, the &#x201c;Warrants&#x201d;), which represented &lt;span id="xdx_90B_ecustom--SaleOfWarrantPercentage_iI_pip0_dp_c20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zs5qq6BDiy42" title="Sale of warrant percentage"&gt;5.0&lt;/span&gt;% of the aggregate number of ordinary
shares and Pre-Funded Warrants sold in the Registered Direct Offering. The Placement Agent Warrants have substantially the same terms
as the Series B Warrants and the Series C Warrants, except that the Placement Agent Warrants have an exercise price equal to $&lt;span id="xdx_905_ecustom--ExercisePriceWarrantPerShare_c20230825__20230826__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantMember_zv3QADJWK9T4" title="Exercise price warrant per share"&gt;47.50&lt;/span&gt;, or
125% of the offering price per ordinary share sold in the Registered Direct Offering and will be exercisable for five years from the commencement
of the sales pursuant to the Offerings. The Private Warrants, Private Warrant Shares, Placement Agent Warrants and ordinary shares underlying
the Placement Agent Warrants were registered for resale under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;)
pursuant to a registration statement on Form F-1 that was declared effective by the SEC on November 7, 2023 (the &#x201c;Resale Registration
Statement&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Series B Warrants, the Series C Warrants and the
Placement Agent Warrants include the obligation, in the event of a Fundamental Transaction, as defined in the Series B Warrants, the Series
C Warrants and the Placement Agent Warrants, for the Company or the successor entity to purchase the warrants from the holder at the discretion
of the holder and at the Black-Scholes value, as defined in the warrant agreements. As a result, management concluded that, in line with
IAS 9, &#x201c;Financial Instruments&#x201d; and IAS 32, &#x201c;Financial Instruments: Presentation,&#x201d; such warrants will be accounted
for as financial liabilities on the condensed consolidated interim statement of financial position with the changes in fair value recognized
in the condensed consolidated interim statement of operations and other comprehensive income (loss). The Company allocated the net proceeds
of $&lt;span id="xdx_906_ecustom--NetProceedsWarrantLiability_iI_pn5n6_c20240930_z8vpMxqyudA8" title="Net proceeds warrant liability"&gt;5.3&lt;/span&gt; million for the Registered Direct Offering to the warrant liability and recognized the excess of the fair value of the warrant
liabilities at inception of $&lt;span id="xdx_90C_eifrs-full--IncreaseDecreaseInFairValueMeasurementLiabilities_pn5n6_c20240401__20240930_zR1EVBlH8jd3" title="Excess of the fair value of the warrant liabilities"&gt;3.1&lt;/span&gt; million as a loss on the Registered Direct Offering of $&lt;span id="xdx_903_ecustom--LossOnWarrantLiabilities_iI_pn5n6_c20240930_z9G45oNC0Ntf" title="Loss on warrant liabilities"&gt;2.4&lt;/span&gt; million and offering expenses of $&lt;span id="xdx_903_ecustom--OfferingExpenses_iI_pn5n6_c20240930_zG5ZGJiEQa5l" title="Offering expenses"&gt;0.7&lt;/span&gt; million.
The Company also recorded a loss of $&lt;span id="xdx_904_ecustom--ChangeInFairValueOfWarrantLiabilities_pn5n6_di_c20240701__20240930_zg9yKQjDxfm5" title="Gain (loss) in the fair value of the warrant liabilities"&gt;0.7&lt;/span&gt; million and a gain of $&lt;span id="xdx_909_ecustom--ChangeInFairValueOfWarrantLiabilities_pn5n6_c20240401__20240930_zHY7z150roQb" title="Gain (loss) in the fair value of the warrant liabilities"&gt;0.4&lt;/span&gt; million from the change in the fair value of the warrant liabilities
for the three and six months ended September 30, 2024, respectively, resulting in a warrant liability balance of $&lt;span id="xdx_908_ecustom--WarrantLiabilityBalance_iI_pn5n6_c20240930_zcsWGGnhrep4" title="Warrant liability balance"&gt;1.1&lt;/span&gt; million at September
30, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company filed the Resale Registration Statement to
register for the resale of the Private Warrant Shares and the ordinary shares issuable upon the exercise of the Placement Agent Warrants,
which was declared effective by the SEC on November 7, 2023. Pursuant to the terms of the Purchase Agreement, the Company is obligated
to use its commercially reasonable efforts to keep the Resale Registration Statement effective at all times until such institutional and
accredited investor (and its successors and assigns) no longer owns any Private Warrants or ordinary shares issuable upon exercise thereof.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On May 29, 2024, Armistice Capital Master Fund Ltd. exercised
its Pre-Funded Warrants at an exercise price of $&lt;span id="xdx_908_ecustom--ExercisePrice_c20240528__20240529__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zbLgFRaPDsBj" title="Warrants exercise price"&gt;0.02&lt;/span&gt; per share increasing the Company&#x2019;s total shares outstanding to &lt;span id="xdx_902_eifrs-full--NumberOfSharesOutstanding_iI_pip0_c20240529__ifrs-full--ClassesOfShareCapitalAxis__custom--PreFundedWarrantsMember_zbvt7TxVkKPc" title="Total shares outstanding"&gt;1,048,765&lt;/span&gt;.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The accounting for the Series A Warrants and the Pre-Funded
Warrants is detailed below in Note 9, &#x201c;Capital Stock and Reserves.&#x201d;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Series B Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;A fair value of
$&lt;span id="xdx_90D_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zkWQFTq02GUe" title="Fair value of warrant per share"&gt;22.40&lt;/span&gt; per each Series B Warrant was identified at the issue date of October 3, 2023. A fair value of $&lt;span id="xdx_903_ecustom--FairValueOfWarrantPerShare_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zDDzBoB8w0w" title="Fair value of warrant per share"&gt;3.05&lt;/span&gt; per each warrant has been
identified as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;The inputs associated
with calculating the fair value are reflected below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEkrm5UZJBGe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BD_zREPodEHY8ti" style="display: none"&gt;Schedule of fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;October 3, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_90D_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zZTmCC7cclRi" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJ19voToTy92" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zt6hxDAGNJv9" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJBVKTZ9m2e5" title="Share price"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z84uGXOtPsna" title="Expected life"&gt;3.01&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z4gqsqiIR7S9" title="Expected life"&gt;2.01&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zT5LiGEXS3T6" title="Expected volatility"&gt;90.4&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zHsOvAIO55m3" title="Expected volatility"&gt;159.22&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zoT9D9Wc3gF4" title="Risk free interest rate"&gt;4.95&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrBMzoUezxPj" title="Risk free interest rate"&gt;3.66&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z04kXw66MSIk" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zP1oUWszKJwc" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zeA6l8wF3ev1" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Series C Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;A fair value of
$&lt;span id="xdx_909_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zHyusLZVIfCl" title="Fair value of warrant per share"&gt;29.60&lt;/span&gt; per each Series C Warrant was identified at the issue date of October 3, 2023. A fair value of $&lt;span id="xdx_902_ecustom--FairValueOfWarrantPerShare_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zZgoxflsyTHf" title="Fair value of warrant per share"&gt;3.91&lt;/span&gt; per each warrant has been
identified as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;The inputs associated
with calculating the fair value are reflected below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zNo8g7HfVAx" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  WARRANT LIABILITY (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BE_z5i9uOgWjsI7" style="display: none"&gt;Schedule of fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;October 3, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z3J6gnWUkU4f" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zsCGSLy6od" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_90F_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4NWSvRDipa5" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zoSDcNdfzyrc" title="Share price"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zffuAbj4Gna4" title="Expected life"&gt;5.00&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zR2vvuZGlCek" title="Expected life"&gt;4.01&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7sKqapVVSzf" title="Expected volatility"&gt;100.7&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4bXOJnQUMn4" title="Expected volatility"&gt;129.26&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zi1Ht5zQ8sg8" title="Risk free interest rate"&gt;4.80&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_903_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zxeevLgY5d83" title="Risk free interest rate"&gt;3.58&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zw0kH9IKVOXk" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zIS5SgmE9Kth" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z8iBtJ6ERVXi" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Placement Agent Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;A fair value of
$&lt;span id="xdx_905_ecustom--FairValueOfWarrantPerShare_iI_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zWHqKMbmVl39" title="Fair value of warrant per share"&gt;29.40&lt;/span&gt; per each Placement Agent Warrant was identified at the issue date of October 3, 2023. A fair value of $&lt;span id="xdx_906_ecustom--FairValueOfWarrantPerShare_iI_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zFPY4u3vSlUj" title="Fair value of warrant per share"&gt;3.86&lt;/span&gt; per each warrant has
been identified as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;The inputs associated
with calculating the fair value are reflected below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNqJsTXTy39d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B6_zizEuT02aYM2" style="display: none"&gt;Schedule of fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;October 3, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_90A_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcEOVuZQcbE9" title="Exercise price"&gt;47.60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHmGOB1v5pgi" title="Exercise price"&gt;47.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_901_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGzHzT9ujqM8" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z7MOsQV6Uzx4" title="Share price"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zAO26TCEDHFe" title="Expected life"&gt;4.99&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9gSMGkD40b" title="Expected life"&gt;4.01&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zFEYBL2WEmq7" title="Expected volatility"&gt;100.7&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKmBRjn0xTG7" title="Expected volatility"&gt;129.26&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNXdKGvaccSl" title="Risk free interest rate"&gt;4.80&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zo9o1tyDYZMe" title="Risk free interest rate"&gt;3.58&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_906_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zfPd7mIQxc12" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0879"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z45tug4uPhn6" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;















</ptgef:WarrantLiabilityTextBlock>
    <ptgef:ScheduleOfWarrantLiabilityTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact000665">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfWarrantLiabilityTableTextBlock_zwLAxhHXwtPd" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8BC_zXWGbAfywazb" style="display: none"&gt;Schedule of changes in the warrant
liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Fair Value Balance&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;In 000&#x2019;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Warrant liability as of April 1, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantLiabilityExercisePrice_iI_pip0_c20230331_zR8JQdLDTJE6" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0667"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_ecustom--WarrantsLiabilityShares_iS_pip0_c20230401__20240331_z2Pq7GJJQzp4" title="Warrants liability, shares at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0669"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20230401__20240331_z4pZHKZA9HW2" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, fair value at beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0671"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold"&gt;Fair value of warrants at issuance on October 3, 2023:&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 61%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Class B Warrants&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zSmJyE5hKpw1" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;45.20&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zZN73Kn7CPZf" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares"&gt;157,895&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassBWarrantsMember_zrfqAQ46ti9k" title="Fair value of warrants amount"&gt;3,537&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Class C Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zznyU7KV5Fqc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;45.20&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_z0lkrOfzaO8j" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares"&gt;157,895&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--ClassCWarrantsMember_zlWO6Pqg7OG9" title="Fair value of warrants amount"&gt;4,663&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Placement Agent Warrants&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FairValueOfWarrantsAtIssuanceExercisePrice_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zMBu6zY15JVh" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants at issuance exercise price"&gt;47.50&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueOfWarrantsShares_pip0_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zw6ax8GTFgHa" style="font-size: 10pt; font-weight: bold; text-align: right" title="Fair value of warrants shares"&gt;7,896&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_ecustom--FairValueOfWarrantsAmount_pn3n3_c20230401__20240331__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_znbVJV9Zf6qc" title="Fair value of warrants amount"&gt;232&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20230401__20240331_zvJwJGOMsKQl" title="Change in fair value of warrant liability"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0691"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20230401__20240331_ziR3u6w2Has9" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;(6,868&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Warrant liability as of March 31, 2024&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;b style="display: none"&gt;&#x2013;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantsLiabilityShares_iS_pip0_c20240401__20240630_zUGjw8zX5Eoc" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at beginning"&gt;323,686&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240401__20240630_zZfOIdB69ecb" title="Warrants liability, fair value at beginning"&gt;1,564&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ChangeInFairValueOfWarrantLiability_c20240401__20240630_zDW06zxkz7Cg" title="Change in fair value of warrant liability, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240401__20240630_zDVOnoY49hl4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;(1,142&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Warrant liability as of June 30, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability exercise price"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WarrantsLiabilityShares_iS_pip0_c20240701__20240930_zlmlvAwiTZu" style="font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at beginning"&gt;323,686&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;&lt;span id="xdx_903_ecustom--WarrantsLiabilityFairValue_iS_pn3n3_c20240701__20240930_zEk1ELkUSKIh" title="Warrants liability, fair value at beginning"&gt;422&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability exercise price"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ChangeInFairValueOfWarrantLiability_c20240701__20240930_zTjtO1x8Yx34" title="Change in fair value of warrant liability, shares"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0707"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ChangeInFairValueOfWarrantLiabilityAmount_pn3n3_c20240701__20240930_zh6K6ejO8LFc" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Change in fair value of warrant liability, amount"&gt;716&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrant liability as of September 30, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;b style="display: none"&gt;&#x2013;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--WarrantsLiabilityShares_iE_pip0_c20240701__20240930_zf2cT80Wi85i" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, shares at ending"&gt;323,686&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WarrantsLiabilityFairValue_iE_pn3n3_c20240401__20240930_zksU6cTyeeUk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Warrants liability, fair value at ending"&gt;1,138&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfWarrantLiabilityTableTextBlock>
    <ptgef:FairValueOfWarrantsAtIssuanceExercisePrice
      contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember"
      decimals="INF"
      id="Fact000673"
      unitRef="USDPShares">45.20</ptgef:FairValueOfWarrantsAtIssuanceExercisePrice>
    <ptgef:FairValueOfWarrantsShares
      contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember"
      decimals="INF"
      id="Fact000675"
      unitRef="Shares">157895</ptgef:FairValueOfWarrantsShares>
    <ptgef:FairValueOfWarrantsAmount
      contextRef="From2023-04-012024-03-31_custom_ClassBWarrantsMember"
      decimals="-3"
      id="Fact000677"
      unitRef="USD">3537000</ptgef:FairValueOfWarrantsAmount>
    <ptgef:FairValueOfWarrantsAtIssuanceExercisePrice
      contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember"
      decimals="INF"
      id="Fact000679"
      unitRef="USDPShares">45.20</ptgef:FairValueOfWarrantsAtIssuanceExercisePrice>
    <ptgef:FairValueOfWarrantsShares
      contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember"
      decimals="INF"
      id="Fact000681"
      unitRef="Shares">157895</ptgef:FairValueOfWarrantsShares>
    <ptgef:FairValueOfWarrantsAmount
      contextRef="From2023-04-012024-03-31_custom_ClassCWarrantsMember"
      decimals="-3"
      id="Fact000683"
      unitRef="USD">4663000</ptgef:FairValueOfWarrantsAmount>
    <ptgef:FairValueOfWarrantsAtIssuanceExercisePrice
      contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000685"
      unitRef="USDPShares">47.50</ptgef:FairValueOfWarrantsAtIssuanceExercisePrice>
    <ptgef:FairValueOfWarrantsShares
      contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000687"
      unitRef="Shares">7896</ptgef:FairValueOfWarrantsShares>
    <ptgef:FairValueOfWarrantsAmount
      contextRef="From2023-04-012024-03-31_custom_PlacementAgentWarrantsMember"
      decimals="-3"
      id="Fact000689"
      unitRef="USD">232000</ptgef:FairValueOfWarrantsAmount>
    <ptgef:ChangeInFairValueOfWarrantLiabilityAmount
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000693"
      unitRef="USD">-6868000</ptgef:ChangeInFairValueOfWarrantLiabilityAmount>
    <ptgef:WarrantsLiabilityShares
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000695"
      unitRef="Shares">323686</ptgef:WarrantsLiabilityShares>
    <ptgef:WarrantsLiabilityFairValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000697"
      unitRef="USD">1564000</ptgef:WarrantsLiabilityFairValue>
    <ptgef:ChangeInFairValueOfWarrantLiabilityAmount
      contextRef="From2024-04-012024-06-30"
      decimals="-3"
      id="Fact000701"
      unitRef="USD">-1142000</ptgef:ChangeInFairValueOfWarrantLiabilityAmount>
    <ptgef:WarrantsLiabilityShares
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000703"
      unitRef="Shares">323686</ptgef:WarrantsLiabilityShares>
    <ptgef:WarrantsLiabilityFairValue
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact000705"
      unitRef="USD">422000</ptgef:WarrantsLiabilityFairValue>
    <ptgef:ChangeInFairValueOfWarrantLiabilityAmount
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000709"
      unitRef="USD">716000</ptgef:ChangeInFairValueOfWarrantLiabilityAmount>
    <ptgef:WarrantsLiabilityShares
      contextRef="AsOf2024-09-30"
      decimals="INF"
      id="Fact000711"
      unitRef="Shares">323686</ptgef:WarrantsLiabilityShares>
    <ptgef:WarrantsLiabilityFairValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000713"
      unitRef="USD">1138000</ptgef:WarrantsLiabilityFairValue>
    <ptgef:OrdinaryNumberOfStockSold
      contextRef="From2023-09-282023-09-29_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000715"
      unitRef="Shares">98500</ptgef:OrdinaryNumberOfStockSold>
    <ptgef:PurchasePriceOfPerShare
      contextRef="From2023-09-282023-09-29_custom_PurchaseAgreementMember"
      decimals="INF"
      id="Fact000717"
      unitRef="USDPShares">38.00</ptgef:PurchasePriceOfPerShare>
    <ptgef:PurchaseWarrants
      contextRef="From2023-09-282023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000719"
      unitRef="Shares">59395</ptgef:PurchaseWarrants>
    <ptgef:PurchasePriceOfPerShare
      contextRef="From2023-09-282023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000721"
      unitRef="USDPShares">37.98</ptgef:PurchasePriceOfPerShare>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="AsOf2023-09-29_custom_PurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000723"
      unitRef="USDPShares">0.02</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ptgef:OrdinarySharesPurchase
      contextRef="From2024-04-012024-09-30_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000733"
      unitRef="Shares">157895</ptgef:OrdinarySharesPurchase>
    <ptgef:OrdinarySharesPurchase
      contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000735"
      unitRef="Shares">157895</ptgef:OrdinarySharesPurchase>
    <ptgef:OrdinarySharesPurchase
      contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000737"
      unitRef="Shares">157895</ptgef:OrdinarySharesPurchase>
    <ptgef:ExercisePriceOfOutstandingWarrant
      contextRef="AsOf2024-09-30_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000739"
      unitRef="USDPShares">38.00</ptgef:ExercisePriceOfOutstandingWarrant>
    <ptgef:ExercisePriceOfOutstandingWarrant
      contextRef="AsOf2024-09-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000741"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceOfOutstandingWarrant>
    <ptgef:ExercisePriceOfOutstandingWarrant
      contextRef="AsOf2024-09-30_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000743"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceOfOutstandingWarrant>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="From2024-04-01to2024-09-30"
      decimals="-5"
      id="Fact000745"
      unitRef="USD">5300000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="From2024-04-01to2024-09-30"
      decimals="-5"
      id="Fact000747"
      unitRef="USD">700000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember"
      decimals="INF"
      id="Fact000749"
      unitRef="Pure">0.060</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ptgef:AggregateGrossProceeds
      contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember"
      decimals="-4"
      id="Fact000751"
      unitRef="USD">360000</ptgef:AggregateGrossProceeds>
    <ptgef:ManagementFeePercentage
      contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember"
      decimals="INF"
      id="Fact000753"
      unitRef="Pure">0.010</ptgef:ManagementFeePercentage>
    <ptgef:AggregateGrossProceedsIncrease
      contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember"
      decimals="-4"
      id="Fact000755"
      unitRef="USD">60000.00</ptgef:AggregateGrossProceedsIncrease>
    <ifrs-full:AdministrativeExpense
      contextRef="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember"
      decimals="0"
      id="Fact000757"
      unitRef="USD">75000</ifrs-full:AdministrativeExpense>
    <ifrs-full:FeeAndCommissionExpense
      contextRef="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember"
      decimals="0"
      id="Fact000759"
      unitRef="USD">15950</ifrs-full:FeeAndCommissionExpense>
    <ptgef:PurchaseOfWarrants
      contextRef="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember"
      decimals="INF"
      id="Fact000761"
      unitRef="Shares">7896</ptgef:PurchaseOfWarrants>
    <ptgef:SaleOfWarrantPercentage
      contextRef="AsOf2023-08-26_custom_PlacementAgentWarrantMember"
      decimals="INF"
      id="Fact000763"
      unitRef="Pure">0.050</ptgef:SaleOfWarrantPercentage>
    <ptgef:ExercisePriceWarrantPerShare
      contextRef="From2023-08-252023-08-26_custom_PlacementAgentWarrantMember"
      decimals="INF"
      id="Fact000765"
      unitRef="USDPShares">47.50</ptgef:ExercisePriceWarrantPerShare>
    <ptgef:NetProceedsWarrantLiability
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000767"
      unitRef="USD">5300000</ptgef:NetProceedsWarrantLiability>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities
      contextRef="From2024-04-01to2024-09-30"
      decimals="-5"
      id="Fact000769"
      unitRef="USD">3100000</ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities>
    <ptgef:LossOnWarrantLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000771"
      unitRef="USD">2400000</ptgef:LossOnWarrantLiabilities>
    <ptgef:OfferingExpenses
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000773"
      unitRef="USD">700000</ptgef:OfferingExpenses>
    <ptgef:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2024-07-012024-09-30"
      decimals="-5"
      id="Fact000775"
      unitRef="USD">-700000</ptgef:ChangeInFairValueOfWarrantLiabilities>
    <ptgef:ChangeInFairValueOfWarrantLiabilities
      contextRef="From2024-04-01to2024-09-30"
      decimals="-5"
      id="Fact000777"
      unitRef="USD">400000</ptgef:ChangeInFairValueOfWarrantLiabilities>
    <ptgef:WarrantLiabilityBalance
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000779"
      unitRef="USD">1100000</ptgef:WarrantLiabilityBalance>
    <ptgef:ExercisePrice
      contextRef="From2024-05-282024-05-29_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000789"
      unitRef="USDPShares">0.02</ptgef:ExercisePrice>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2024-05-29_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact000791"
      unitRef="Shares">1048765</ifrs-full:NumberOfSharesOutstanding>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000793"
      unitRef="USDPShares">22.40</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2024-09-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000795"
      unitRef="USDPShares">3.05</ptgef:FairValueOfWarrantPerShare>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory
      contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember"
      id="Fact000797">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zEkrm5UZJBGe" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BD_zREPodEHY8ti" style="display: none"&gt;Schedule of fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;October 3, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_90D_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zZTmCC7cclRi" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJ19voToTy92" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zt6hxDAGNJv9" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zJBVKTZ9m2e5" title="Share price"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z84uGXOtPsna" title="Expected life"&gt;3.01&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90A_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z4gqsqiIR7S9" title="Expected life"&gt;2.01&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zT5LiGEXS3T6" title="Expected volatility"&gt;90.4&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zHsOvAIO55m3" title="Expected volatility"&gt;159.22&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zoT9D9Wc3gF4" title="Risk free interest rate"&gt;4.95&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_906_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zrBMzoUezxPj" title="Risk free interest rate"&gt;3.66&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_z04kXw66MSIk" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0819"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesBWarrantsMember_zP1oUWszKJwc" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0821"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000799"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2024-09-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000801"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2023-10-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000803"
      unitRef="USDPShares">39.40</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2024-09-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000805"
      unitRef="USDPShares">6.65</ptgef:SharePriceFairvalue>
    <ptgef:OptionLifeShareOptions
      contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember"
      id="Fact000807">P3Y3D</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember"
      id="Fact000809">P2Y3D</ptgef:OptionLifeShareOptions>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000811"
      unitRef="Pure">0.904</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000813"
      unitRef="Pure">1.5922</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000815"
      unitRef="Pure">0.0495</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2024-04-012024-09-30_custom_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact000817"
      unitRef="Pure">0.0366</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000823"
      unitRef="USDPShares">29.60</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2024-09-30_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000825"
      unitRef="USDPShares">3.91</ptgef:FairValueOfWarrantPerShare>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory
      contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember"
      id="Fact000827">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zNo8g7HfVAx" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure -  WARRANT LIABILITY (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8BE_z5i9uOgWjsI7" style="display: none"&gt;Schedule of fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;October 3, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_904_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z3J6gnWUkU4f" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_902_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zsCGSLy6od" title="Exercise price"&gt;45.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_90F_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4NWSvRDipa5" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_904_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zoSDcNdfzyrc" title="Share price"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zffuAbj4Gna4" title="Expected life"&gt;5.00&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_904_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zR2vvuZGlCek" title="Expected life"&gt;4.01&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_905_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z7sKqapVVSzf" title="Expected volatility"&gt;100.7&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_z4bXOJnQUMn4" title="Expected volatility"&gt;129.26&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zi1Ht5zQ8sg8" title="Risk free interest rate"&gt;4.80&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_903_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zxeevLgY5d83" title="Risk free interest rate"&gt;3.58&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zw0kH9IKVOXk" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0849"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_900_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesCWarrantsMember_zIS5SgmE9Kth" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0851"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000829"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2024-09-30_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000831"
      unitRef="USDPShares">45.20</ptgef:ExercisePriceFairValue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2023-10-03_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000833"
      unitRef="USDPShares">39.40</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2024-09-30_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000835"
      unitRef="USDPShares">6.65</ptgef:SharePriceFairvalue>
    <ptgef:OptionLifeShareOptions
      contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember"
      id="Fact000837">P5Y</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember"
      id="Fact000839">P4Y3D</ptgef:OptionLifeShareOptions>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000841"
      unitRef="Pure">1.007</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000843"
      unitRef="Pure">1.2926</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000845"
      unitRef="Pure">0.0480</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2024-04-012024-09-30_custom_SeriesCWarrantsMember"
      decimals="INF"
      id="Fact000847"
      unitRef="Pure">0.0358</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000853"
      unitRef="USDPShares">29.40</ptgef:FairValueOfWarrantPerShare>
    <ptgef:FairValueOfWarrantPerShare
      contextRef="AsOf2024-09-30_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000855"
      unitRef="USDPShares">3.86</ptgef:FairValueOfWarrantPerShare>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory
      contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember"
      id="Fact000857">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_eifrs-full--DisclosureOfFairValueMeasurementExplanatory_hifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNqJsTXTy39d" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - WARRANT LIABILITY (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B6_zizEuT02aYM2" style="display: none"&gt;Schedule of fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;October 3, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_90A_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zcEOVuZQcbE9" title="Exercise price"&gt;47.60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_905_ecustom--ExercisePriceFairValue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zHmGOB1v5pgi" title="Exercise price"&gt;47.50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_901_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zGzHzT9ujqM8" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_903_ecustom--SharePriceFairvalue_iI_pip0_c20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z7MOsQV6Uzx4" title="Share price"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90C_ecustom--OptionLifeShareOptions_dtY_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zAO26TCEDHFe" title="Expected life"&gt;4.99&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90D_ecustom--OptionLifeShareOptions_dtY_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zQ9gSMGkD40b" title="Expected life"&gt;4.01&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_907_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zFEYBL2WEmq7" title="Expected volatility"&gt;100.7&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_903_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zKmBRjn0xTG7" title="Expected volatility"&gt;129.26&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90C_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zNXdKGvaccSl" title="Risk free interest rate"&gt;4.80&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zo9o1tyDYZMe" title="Risk free interest rate"&gt;3.58&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_906_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_zfPd7mIQxc12" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0879"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20240401__20240930__ifrs-full--ClassesOfShareCapitalAxis__custom--PlacementAgentWarrantsMember_z45tug4uPhn6" title="Dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;















</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000859"
      unitRef="USDPShares">47.60</ptgef:ExercisePriceFairValue>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2024-09-30_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000861"
      unitRef="USDPShares">47.50</ptgef:ExercisePriceFairValue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2023-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000863"
      unitRef="USDPShares">39.40</ptgef:SharePriceFairvalue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2024-09-30_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000865"
      unitRef="USDPShares">6.65</ptgef:SharePriceFairvalue>
    <ptgef:OptionLifeShareOptions
      contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember"
      id="Fact000867">P4Y11M26D</ptgef:OptionLifeShareOptions>
    <ptgef:OptionLifeShareOptions
      contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember"
      id="Fact000869">P4Y3D</ptgef:OptionLifeShareOptions>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000871"
      unitRef="Pure">1.007</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000873"
      unitRef="Pure">1.2926</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000875"
      unitRef="Pure">0.0480</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2024-04-012024-09-30_custom_PlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact000877"
      unitRef="Pure">0.0358</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact000889">&lt;p id="xdx_80B_ecustom--AccountsPayableAndAccruedLiabilitiesTextBlock_zrKjZ7frTjSj" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 7.&#160; &lt;span id="xdx_826_z5qymSj23Dc8"&gt;ACCOUNTS PAYABLE AND ACCRUED LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;At September 30, 2024 and March 31, 2024, accounts payable
and accrued liabilities were comprised of the following (in thousands):&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_ztM36cLVhTV3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span&gt;&lt;span id="xdx_8BF_zIgoWOD3J5p8" style="display: none"&gt;Schedule of accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20240930_zwsLYUqXcj0b" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240331_zEoKifOeHuyk" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024 &lt;br/&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccountsPayableAndAmountsAccruedToCro_iI_zGrnUPIAEMl5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable and amounts accrued to CRO&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;49&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,413&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_zU2Hkru1iIgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued bonuses and other payroll-related expenses&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;371&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;525&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zaFtbYZIToK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued accounting and auditing fees&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;127&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;189&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedLegalFees_iI_zSo5RglA1PIh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued legal fees&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;54&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;194&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AccruedOtherProfessionalFees_iI_z9yIRqvCxyjb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued other professional fees&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;157&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--OtherAccountsPayable_iI_zUfZuBt5BYoc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other accounts payable&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;172&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;136&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedClinicalAndRdServices_iI_zWuKHzGuHyRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued clinical and R&amp;amp;D services&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;179&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--OtherAccruedExpenses_iI_pn3n3_zbcoTDtytPE" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;36&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;43&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_pn3n3_zO9lOvxYHt3f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;845&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,836&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The decrease in &lt;span style="background-color: white"&gt;accounts
payable and accrued liabilities from $&lt;span id="xdx_907_eifrs-full--OtherPayables_iI_pn5n6_c20240331_zDMnyuOpAtBj" title="Accounts payable and accrued liabilities"&gt;2.8&lt;/span&gt; million as of March 31, 2024 to $&lt;span id="xdx_905_eifrs-full--OtherPayables_iI_pn5n6_c20240930_zJSurSXSL56g" title="Accounts payable and accrued liabilities"&gt;0.8&lt;/span&gt; million as of September 30, 2024 is primarily attributable
to the write-off of $&lt;span id="xdx_907_eifrs-full--DecreaseThroughWriteoffFinancialAssets_pn3n6_c20240401__20240930_zRa7xwbQvYq5" title="Accounts payable and accrued liabilities write-off"&gt;1.486&lt;/span&gt; million in connection with the settlement with Parexel. &lt;/span&gt;Refer to the &#x201c;iOx &#x2013; Parexel Master
Services Agreement&#x201d; section of Note 12, &#x201c;Commitments and Contingent Liabilities&#x201d; for further discussion regarding this
matter.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

</ptgef:AccountsPayableAndAccruedLiabilitiesTextBlock>
    <ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact000891">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--AccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_ztM36cLVhTV3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span&gt;&lt;span id="xdx_8BF_zIgoWOD3J5p8" style="display: none"&gt;Schedule of accounts payable and accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20240930_zwsLYUqXcj0b" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240331_zEoKifOeHuyk" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024 &lt;br/&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccountsPayableAndAmountsAccruedToCro_iI_zGrnUPIAEMl5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable and amounts accrued to CRO&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;49&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;1,413&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedBonusesAndOtherPayrollrelatedExpenses_iI_zU2Hkru1iIgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued bonuses and other payroll-related expenses&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;371&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;525&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedAccountingAndAuditingFees_iI_zaFtbYZIToK" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued accounting and auditing fees&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;127&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;189&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--AccruedLegalFees_iI_zSo5RglA1PIh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued legal fees&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;54&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;194&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--AccruedOtherProfessionalFees_iI_z9yIRqvCxyjb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued other professional fees&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;33&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;157&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--OtherAccountsPayable_iI_zUfZuBt5BYoc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Other accounts payable&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;172&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;136&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--AccruedClinicalAndRdServices_iI_zWuKHzGuHyRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Accrued clinical and R&amp;amp;D services&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;179&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--OtherAccruedExpenses_iI_pn3n3_zbcoTDtytPE" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"&gt;36&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"&gt;43&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AccountsPayableAndAccruedLiabilityNet_iI_pn3n3_zO9lOvxYHt3f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;845&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;2,836&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:AccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <ptgef:AccountsPayableAndAmountsAccruedToCro
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000893"
      unitRef="USD">49000</ptgef:AccountsPayableAndAmountsAccruedToCro>
    <ptgef:AccountsPayableAndAmountsAccruedToCro
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000894"
      unitRef="USD">1413000</ptgef:AccountsPayableAndAmountsAccruedToCro>
    <ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000896"
      unitRef="USD">371000</ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses>
    <ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000897"
      unitRef="USD">525000</ptgef:AccruedBonusesAndOtherPayrollrelatedExpenses>
    <ptgef:AccruedAccountingAndAuditingFees
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000899"
      unitRef="USD">127000</ptgef:AccruedAccountingAndAuditingFees>
    <ptgef:AccruedAccountingAndAuditingFees
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000900"
      unitRef="USD">189000</ptgef:AccruedAccountingAndAuditingFees>
    <ptgef:AccruedLegalFees
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000902"
      unitRef="USD">54000</ptgef:AccruedLegalFees>
    <ptgef:AccruedLegalFees
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000903"
      unitRef="USD">194000</ptgef:AccruedLegalFees>
    <ptgef:AccruedOtherProfessionalFees
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000905"
      unitRef="USD">33000</ptgef:AccruedOtherProfessionalFees>
    <ptgef:AccruedOtherProfessionalFees
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000906"
      unitRef="USD">157000</ptgef:AccruedOtherProfessionalFees>
    <ptgef:OtherAccountsPayable
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000908"
      unitRef="USD">172000</ptgef:OtherAccountsPayable>
    <ptgef:OtherAccountsPayable
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000909"
      unitRef="USD">136000</ptgef:OtherAccountsPayable>
    <ptgef:AccruedClinicalAndRdServices
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000911"
      unitRef="USD">3000</ptgef:AccruedClinicalAndRdServices>
    <ptgef:AccruedClinicalAndRdServices
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000912"
      unitRef="USD">179000</ptgef:AccruedClinicalAndRdServices>
    <ptgef:OtherAccruedExpenses
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000914"
      unitRef="USD">36000</ptgef:OtherAccruedExpenses>
    <ptgef:OtherAccruedExpenses
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000915"
      unitRef="USD">43000</ptgef:OtherAccruedExpenses>
    <ptgef:AccountsPayableAndAccruedLiabilityNet
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000917"
      unitRef="USD">845000</ptgef:AccountsPayableAndAccruedLiabilityNet>
    <ptgef:AccountsPayableAndAccruedLiabilityNet
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000918"
      unitRef="USD">2836000</ptgef:AccountsPayableAndAccruedLiabilityNet>
    <ifrs-full:OtherPayables
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact000920"
      unitRef="USD">2800000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact000922"
      unitRef="USD">800000</ifrs-full:OtherPayables>
    <ifrs-full:DecreaseThroughWriteoffFinancialAssets
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000924"
      unitRef="USD">1486000</ifrs-full:DecreaseThroughWriteoffFinancialAssets>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact000926">&lt;p id="xdx_80A_eifrs-full--DisclosureOfIncomeTaxExplanatory_zakDMfsPx0ti" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;NOTE 8. &lt;span id="xdx_825_zkwSv8g53iMj"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company is a BVI business company. The BVI government
does not, under existing legislation, impose any income or corporate tax on corporations.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;PDS is a U.S. corporation and is subject to U.S. federal,
state and local income taxes, as applicable.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;iOx is subject to U.K. taxes.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The following is a reconciliation of the U.S. taxes to
the effective income tax rates for the six months ended September 30, 2024 and 2023 (in thousands, except percentages):&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z9rHamzxYfn7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8B2_zGEeeJFpITia" style="display: none"&gt;Schedule of effective income tax rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240401__20240930_zHJnklBFtjE9" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230401__20230930_zMcz3nbMzRJi" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_iN_di_znGvqV0P44Zk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%"&gt;3,024&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;12,143&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IncomeTaxExpenseContinuingOperation_iN_di_zLFaFRaXIb27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Income tax benefit&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,052&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_zVO4lrL8mbV1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Effective tax rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;0.10&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;8.66&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company&#x2019;s effective tax rates were &lt;span id="xdx_90F_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_c20240401__20240930_zYtaw09zcZ35"&gt;0.10&lt;/span&gt;% and
&lt;span id="xdx_900_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_c20230401__20230930_zTtntrt8wp5g"&gt;8.66&lt;/span&gt;% for the six months ended September 30, 2024 and 2023, respectively. The decrease in the effective tax rate was primarily due to
a change in the mix of income and losses in the various tax jurisdiction in which the Company operates.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;















</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact000928">&lt;table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z9rHamzxYfn7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&lt;span id="xdx_8B2_zGEeeJFpITia" style="display: none"&gt;Schedule of effective income tax rates&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240401__20240930_zHJnklBFtjE9" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230401__20230930_zMcz3nbMzRJi" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--ProfitLossBeforeTax_iN_di_znGvqV0P44Zk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; width: 1%"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right; width: 10%"&gt;3,024&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;12,143&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IncomeTaxExpenseContinuingOperation_iN_di_zLFaFRaXIb27" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Income tax benefit&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;3&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,052&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--TaxRateEffectOfTaxLosses_pip0_dp_zVO4lrL8mbV1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Effective tax rate&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;0.10&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;8.66&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000930"
      unitRef="USD">-3024000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000931"
      unitRef="USD">-12143000</ifrs-full:ProfitLossBeforeTax>
    <ptgef:IncomeTaxExpenseContinuingOperation
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact000933"
      unitRef="USD">-3000</ptgef:IncomeTaxExpenseContinuingOperation>
    <ptgef:IncomeTaxExpenseContinuingOperation
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact000934"
      unitRef="USD">-1052000</ptgef:IncomeTaxExpenseContinuingOperation>
    <ifrs-full:TaxRateEffectOfTaxLosses
      contextRef="From2024-04-01to2024-09-30"
      decimals="INF"
      id="Fact000936"
      unitRef="Pure">0.0010</ifrs-full:TaxRateEffectOfTaxLosses>
    <ifrs-full:TaxRateEffectOfTaxLosses
      contextRef="From2023-04-012023-09-30"
      decimals="INF"
      id="Fact000937"
      unitRef="Pure">0.0866</ifrs-full:TaxRateEffectOfTaxLosses>
    <ifrs-full:TaxRateEffectOfTaxLosses
      contextRef="From2024-04-01to2024-09-30"
      decimals="INF"
      id="Fact000938"
      unitRef="Pure">0.0010</ifrs-full:TaxRateEffectOfTaxLosses>
    <ifrs-full:TaxRateEffectOfTaxLosses
      contextRef="From2023-04-012023-09-30"
      decimals="INF"
      id="Fact000939"
      unitRef="Pure">0.0866</ifrs-full:TaxRateEffectOfTaxLosses>
    <ptgef:CapitalStockAndReservesTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact000947">&lt;p id="xdx_805_ecustom--CapitalStockAndReservesTextBlock_z6hY6CoqtJv7" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 9. &lt;span id="xdx_825_zZF4TiVfWu9k"&gt;CAPITAL STOCK AND RESERVES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Authorized ordinary shares&lt;b&gt;: &lt;/b&gt;Unlimited number of
Portage ordinary shares without par value.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On August 15, 2024, the Company effected a reverse
stock split of its ordinary shares at a ratio of 1-for-20. The reverse stock split decreased the number of ordinary shares
outstanding as of September 30, 2023, from &lt;span id="xdx_90C_ecustom--NumberOfOrdinarySharesOutstandingDecrease_c20230401__20230930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zDavpgghJ9hc" title="Number of ordinary shares outstanding, decrease"&gt;17,808,225&lt;/span&gt;
to &lt;span id="xdx_900_ecustom--NumberOfOrdinarySharesOutstandingDecrease_c20230401__20230930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zY7parI27pqc" title="Number of ordinary shares outstanding, decrease"&gt;890,412&lt;/span&gt;.
All share and per share information included in the condensed consolidated interim financial statements and in the Notes to the
condensed consolidated interim financial statements have been retroactively adjusted to reflect the impact of the reverse stock
split unless otherwise noted. The number of ordinary shares authorized remained at an unlimited number of common shares without par value.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Any fractional shares resulting from the reverse
stock split were rounded up to the nearest whole post-split ordinary share. As a result of this round up provision, the Company
issued an additional 52,254 shares.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;


&lt;p style="margin: 0pt 5.6pt 0pt 8.25pt; font-size: 10pt; text-align: justify; text-indent: 18.4pt"&gt;Portage filed a shelf registration
statement with the SEC in order to sell ordinary shares, debt securities, warrants and units in one or more offerings from time to time,
which became effective on March 8, 2021 (&#x201c;March 2021 Registration Statement&#x201d;). In connection with the March 2021 Registration
Statement, Portage has filed with the SEC:&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 26.7pt"&gt;&lt;/td&gt;&lt;td style="width: 14.4pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 5.6pt"&gt;a base prospectus, which covered the offering, issuance and sale by Portage of up
to $200 million in the aggregate of the securities identified above from time to time in one or more offerings;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 26.7pt"&gt;&lt;/td&gt;&lt;td style="width: 14.4pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 5.6pt"&gt;a prospectus supplement, which covered the offer, issuance and sale by Portage in
its ATM offering of up to a maximum aggregate offering price of $50 million of Portage&#x2019;s ordinary shares that may be issued and
sold from time to time under a Controlled Equity Offering Sales Agreement, dated February 24, 2021 (the &#x201c;Sales Agreement&#x201d;),
with Cantor Fitzgerald &amp;amp; Co., the sales agent (&#x201c;Cantor Fitzgerald&#x201d;);&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 26.7pt"&gt;&lt;/td&gt;&lt;td style="width: 14.4pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 5.6pt"&gt;a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by
Portage of 57,500 ordinary shares for gross proceeds of approximately $26.5 million in a firm commitment underwritten public offering
with Cantor Fitzgerald;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 26.7pt"&gt;&lt;/td&gt;&lt;td style="width: 14.4pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 5.6pt"&gt;a prospectus supplement dated August 19, 2022, for the resale of up to $30 million
in ordinary shares that Portage may sell from time to time to Lincoln and an additional 4,726 shares that were issued to Lincoln; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 26.7pt"&gt;&lt;/td&gt;&lt;td style="width: 14.4pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-right: 5.6pt"&gt;a prospectus supplement dated September 29, 2023 for the offer, issuance and
                                                                                                             sale by Portage in a registered direct public offering through H.C. Wainwright &amp;amp; Co., the placement agent, to an institutional
                                                                                                             and accredited investor of (i) 98,500 ordinary shares at a purchase price of $38.00 per share; and (ii) Pre-Funded Warrants to
                                                                                                             purchase up to 59,395 ordinary shares, at a purchase price of $37.98 per Pre-Funded Warrant Shares, for aggregate gross proceeds of
                                                                                                             approximately $6 million. All Pre-Funded Warrants, which were exercisable
for one ordinary share at an exercise price of $0.02 per share, were exercised in full on May 29, 2024.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0pt 5.6pt 0pt 41.1pt; font-size: 10pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 5.6pt 0pt 8.25pt; font-size: 10pt; text-align: justify; text-indent: 18.4pt"&gt;&lt;span id="xdx_900_ecustom--CashFundDescription_c20240401__20240930_z8Be9MvaAbb2" title="Cash fund, description"&gt;The Sales Agreement permits the Company
to sell in an ATM program up to $50 million of ordinary shares from time to time. Through September 30, 2024, the Company raised approximately $4.2 million in gross proceeds through the sale of shares of common shares
under the ATM program. Any sales under the prospectus will be deemed to be
made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act.&lt;/span&gt;&lt;/p&gt;








&lt;p id="xdx_8A8_znBKDu1SwIc1" style="margin: 0; font-size: 10pt; text-align: left"&gt;&#160;&lt;/p&gt;
























&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On July 6, 2022, the Company entered into a Purchase
Agreement (the &#x201c;Committed Purchase Agreement&#x201d;) with Lincoln, under which it may require Lincoln to purchase ordinary shares
of the Company having an aggregate value of up to $30 million (the &#x201c;Purchase Shares&#x201d;) over a period of 36 months. Upon execution
of the Committed Purchase Agreement, the Company issued to Lincoln &lt;span id="xdx_905_ecustom--NumberOfOrdinaryShareIssued_pip0_c20220705__20220706_zuopKK3mm7le" title="Number of ordinary share issued"&gt;4,726&lt;/span&gt; ordinary shares, representing a 3% commitment fee. Pursuant to
the Committed Purchase Agreement, Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based
on various market criteria and share amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason,
effective upon one business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The
requirement that Lincoln must make a purchase will be suspended based on various criteria such as there not being an effective registration
statement for Lincoln to be able to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing
to be Depository Trust Company eligible, among other things. The Committed Purchase Agreement does not impose any financial or business
covenants on the Company, and there are no limitations on the use of proceeds. The Company may raise capital from other sources in its
sole discretion; provided, however, that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like
securities until the three-year anniversary of the date of the Committed Purchase Agreement, excluding, however, an ATM transaction with
a registered broker-dealer, which includes any sales under the Sales Agreement with Cantor Fitzgerald.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;During the six months ended September 30, 2023, the
Company sold &lt;span id="xdx_90F_ecustom--NumberOfSharesSold_c20230401__20230930__ifrs-full--CounterpartiesAxis__custom--ATMMember_z1hfipEjBD86" title="Number of shares sold"&gt;9,331&lt;/span&gt;
ordinary shares under the ATM program, generating net proceeds of approximately $&lt;span id="xdx_900_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn5n6_c20230401__20230930__ifrs-full--CounterpartiesAxis__custom--ATMMember_z6UKGwIpC6Kd" title="Net proceeds from sale"&gt;0.7&lt;/span&gt;
million. There were &lt;span id="xdx_900_ecustom--NumberOfSharesSold_do_c20240401__20240930__ifrs-full--CounterpartiesAxis__custom--ATMMember_zfrdouh2idIb" title="Number of shares sold"&gt;no&lt;/span&gt; shares sold under the ATM program during the six months ended September 30, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company&#x2019;s March 2021 Registration Statement
expired on March 8, 2024. In order to issue additional shares under its ATM program or the Committed Purchase Agreement in the future,
the Company would be required to file a new registration statement, which must be declared effective by the SEC prior to use, and to file
a prospectus supplement related to the ATM program and the Committed Purchase Agreement, as the case may be.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Furthermore, the ATM program and the Committed Purchase
Agreement with Lincoln are generally limited based on, among other things, the Company&#x2019;s Nasdaq trading volume. Under General Instruction
I.B.5 to Form F-3 (the &#x201c;Baby Shelf Rule&#x201d;), the amount of funds the Company can raise through primary public offerings of securities
in any 12-month period using a registration statement on Form F-3 is limited to one-third of the aggregate market value of the ordinary
shares held by the Company&#x2019;s non-affiliates, which limitation may change over time based on its stock price, number of ordinary
shares outstanding and the percentage of ordinary shares held by non-affiliates. Accordingly, the Company is limited by the Baby Shelf
Rule as of the filing of this Form 6-K, until such time as its non-affiliate public float exceeds $&lt;span id="xdx_906_ecustom--PublicFloat_iI_pn6n6_c20240930_zHnFS1RHMCUg" title="Public float"&gt;75&lt;/span&gt; million.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On September 29, 2023, the Company entered into the Purchase
Agreement with an institutional and accredited investor in connection with the Registered Direct Offering and the Private Placement. The
Offerings closed on October 3, 2023.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company filed the Resale Registration Statement to
register for resale the Private Warrant Shares and the ordinary shares issuable upon the exercise of Placement Agent Warrants, which was
declared effective by the SEC on November 7, 2023. Pursuant to the terms of the Purchase Agreement, the Company is obligated to use its
commercially reasonable efforts to keep the Resale Registration Statement effective at all times until such institutional and accredited
investor (and its successors and assigns) no longer owns any Private Warrants or ordinary shares issuable upon exercise thereof.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;If a Fundamental Transaction (as defined in the Warrants)
occurs, then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the
Company may exercise and will assume all of the Company&#x2019;s obligations under the Warrants with the same effect as if such successor
entity had been named in the Warrants themselves. If holders of ordinary shares are given a choice as to the securities, cash or property
to be received in such a Fundamental Transaction, then the holders of the Warrants shall be given the same choice as to the consideration
they would receive upon any exercise of the Warrants following such a Fundamental Transaction. Additionally, as more fully described in
the Series B Warrants, Series C Warrants and Placement Agent Warrants, in the event of certain Fundamental Transactions, the holders of
the Series B Warrants, Series C Warrants and Placement Agent Warrants will be entitled to receive cash consideration in an amount equal
to the Black-Scholes value of the Series B Warrants, Series C Warrants and Placement Agent Warrants, as the case may be, upon the consummation
of such Fundamental Transaction.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;See Note 6, &#x201c;Warrant Liability,&#x201d; for a discussion
of the Registered Direct Offering.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Series A Warrants and Pre-Funded Warrants &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Series A Warrants and the Pre-Funded Warrants are
classified as a component of equity because they are freestanding financial instruments that are legally detachable and separately exercisable
from the ordinary shares with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase
its shares, and permit the holders to receive a fixed number of ordinary shares upon exercise. In addition, the Series A Warrants and
the Pre-Funded Warrants do not provide any guarantee of value or return.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="color: windowtext"&gt;On the October 3, 2023
issue date, the calculated fair value of the Series A Warrants and the Pre-Funded Warrants as of March 31, 2024 was $&lt;span id="xdx_90B_ecustom--FairValueOfWarrants_iI_pn3n6_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsAndPreFundedWarrantsMember_zsnz1VqMKrPj" title="Fair value of warrants"&gt;2.968&lt;/span&gt; million ($&lt;span id="xdx_904_ecustom--WarrantsPerShare_iI_pn3n6_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsAndPreFundedWarrantsMember_zn86iHt8DMVf" title="Warrants per share"&gt;0.94&lt;/span&gt;
per such warrant). &lt;/span&gt;Because the fair value of the warrants accounted for as liabilities exceeded the net proceeds from the Registered
Direct Offering, the proceeds allocated to the Common Shares, the Pre-Funded Warrants and the Series A warrants was zero.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Series A Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;The inputs associated
with calculating the fair value are reflected below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_z20IHUyfJbLg" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B4_zspI3QY90L7f" style="display: none"&gt;Schedule of fair value&lt;/span&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;October 3, 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zH37deVPzwX9" title="Exercise price"&gt;38.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zmDA5IRvLmz4" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_906_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930_zlmOM0oEsudd" title="Expected life"&gt;1.50&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zuPPX2xvmPu3" title="Expected volatility"&gt;96.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zQa0R0ELaN2a" title="Risk free interest rate"&gt;5.32&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zflUNZxJi4Bj" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zJYipCh3Scf5" style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;Nature and Purpose of Reserves&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Option Reserve&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The stock option reserve reflects the reserve of compensation
expense recognized over the vesting period based upon the grant date fair value of the Company&#x2019;s equity settled grants calculated
in accordance with IFRS 2, &#x201c;Share-based Payment&#x201d;. See Note 10, &#x201c;Stock Option Reserve,&#x201d; below for a further discussion.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;



</ptgef:CapitalStockAndReservesTextBlock>
    <ptgef:NumberOfOrdinarySharesOutstandingDecrease
      contextRef="From2023-04-012023-09-30_ifrs-full_TopOfRangeMember"
      decimals="INF"
      id="Fact000949"
      unitRef="Shares">17808225</ptgef:NumberOfOrdinarySharesOutstandingDecrease>
    <ptgef:NumberOfOrdinarySharesOutstandingDecrease
      contextRef="From2023-04-012023-09-30_ifrs-full_BottomOfRangeMember"
      decimals="INF"
      id="Fact000951"
      unitRef="Shares">890412</ptgef:NumberOfOrdinarySharesOutstandingDecrease>
    <ptgef:CashFundDescription contextRef="From2024-04-01to2024-09-30" id="Fact000953">The Sales Agreement permits the Company
to sell in an ATM program up to $50 million of ordinary shares from time to time. Through September 30, 2024, the Company raised approximately $4.2 million in gross proceeds through the sale of shares of common shares
under the ATM program. Any sales under the prospectus will be deemed to be
made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act.</ptgef:CashFundDescription>
    <ptgef:NumberOfOrdinaryShareIssued
      contextRef="From2022-07-052022-07-06"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">4726</ptgef:NumberOfOrdinaryShareIssued>
    <ptgef:NumberOfSharesSold
      contextRef="From2023-04-012023-09-30_custom_ATMMember"
      decimals="INF"
      id="Fact000969"
      unitRef="Shares">9331</ptgef:NumberOfSharesSold>
    <ifrs-full:ProceedsFromSalesOfBiologicalAssets
      contextRef="From2023-04-012023-09-30_custom_ATMMember"
      decimals="-5"
      id="Fact000971"
      unitRef="USD">700000</ifrs-full:ProceedsFromSalesOfBiologicalAssets>
    <ptgef:NumberOfSharesSold
      contextRef="From2024-04-012024-09-30_custom_ATMMember"
      decimals="INF"
      id="Fact000973"
      unitRef="Shares">0</ptgef:NumberOfSharesSold>
    <ptgef:PublicFloat
      contextRef="AsOf2024-09-30"
      decimals="-6"
      id="Fact000975"
      unitRef="USD">75000000</ptgef:PublicFloat>
    <ptgef:FairValueOfWarrants
      contextRef="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember"
      decimals="-3"
      id="Fact000985"
      unitRef="USD">2968000</ptgef:FairValueOfWarrants>
    <ptgef:WarrantsPerShare
      contextRef="AsOf2023-10-03_custom_SeriesAWarrantsAndPreFundedWarrantsMember"
      decimals="-3"
      id="Fact000987"
      unitRef="USDPShares">940000</ptgef:WarrantsPerShare>
    <ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact000989">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--DisclosureOfFairValueMeasurementOfWarrantsExplanatory_z20IHUyfJbLg" style="margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto" summary="xdx: Disclosure - CAPITAL STOCK AND RESERVES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;&lt;span id="xdx_8B4_zspI3QY90L7f" style="display: none"&gt;Schedule of fair value&lt;/span&gt; &lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;October 3, 2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 84%; font-size: 10pt; font-weight: bold"&gt;Exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 14%; font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_90F_ecustom--ExercisePriceFairValue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zH37deVPzwX9" title="Exercise price"&gt;38.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold"&gt;Share price&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;$&lt;span id="xdx_905_ecustom--SharePriceFairvalue_iI_pip0_c20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zmDA5IRvLmz4" title="Share price"&gt;39.40&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_906_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930_zlmOM0oEsudd" title="Expected life"&gt;1.50&lt;/span&gt; years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zuPPX2xvmPu3" title="Expected volatility"&gt;96.0&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_90F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zQa0R0ELaN2a" title="Risk free interest rate"&gt;5.32&lt;/span&gt;%&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&lt;span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pip0_dp_c20231001__20231003__ifrs-full--ClassesOfShareCapitalAxis__custom--SeriesAWarrantsMember_zflUNZxJi4Bj" title="Expected dividend"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1001"&gt;&#x2013;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:DisclosureOfFairValueMeasurementOfWarrantsExplanatory>
    <ptgef:ExercisePriceFairValue
      contextRef="AsOf2023-10-03_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000991"
      unitRef="USDPShares">38.00</ptgef:ExercisePriceFairValue>
    <ptgef:SharePriceFairvalue
      contextRef="AsOf2023-10-03_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000993"
      unitRef="USDPShares">39.40</ptgef:SharePriceFairvalue>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2024-04-01to2024-09-30" id="Fact000995">P1Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000997"
      unitRef="Pure">0.960</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2023-10-012023-10-03_custom_SeriesAWarrantsMember"
      decimals="INF"
      id="Fact000999"
      unitRef="Pure">0.0532</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact001011">&lt;p id="xdx_80A_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zD9QWzPtTB1" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 10. &lt;span id="xdx_827_z5B3wAAgASVe"&gt;STOCK OPTION RESERVE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;Amended and Restated 2021 Equity Incentive
Plan and Grants of Stock Options and Restricted Stock Units&lt;/p&gt;
&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The following table provides the activity for the Company&#x2019;s
stock option reserve for the six months ended September 30, 2024 and 2023 (in thousands):&lt;/p&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_zlDP52wSZwp4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BA_zXqKGpNgflDk" style="display: none"&gt;Schedule of stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20240930_zcynfXm3Vdud" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period"&gt;23,841&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--StockOptionReserve_iS_pn3n3_c20230401__20230930_za8ZZf6KiUrk" style="width: 10%; font-size: 10pt; text-align: right" title="Balance, beginning of period"&gt;21,204&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Share-based compensation expense&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20240401__20240930_z1JrgPkKhPUa" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share-based compensation expense"&gt;285&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20230401__20230930_z0CTjzMn5oVb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share-based compensation expense"&gt;1,512&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20240930_ztXuuyhXTpPc" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of period"&gt;24,126&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20230401__20230930_z0YKUYL3SMV" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of period"&gt;22,716&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zhgDDc5pxfR" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;


&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On August 15, 2024, the Company effected
a reverse stock split of its ordinary shares at a ratio of 1-for-20. All share and per share information have been retroactively adjusted
to reflect the impact of the reverse stock split unless otherwise noted. See Note 1 &#x201c;Nature of Operations&#x201d; and Note 9, &#x201c;Capital
Stock and Reserves&#x201d; for further discussion on the reverse stock split.&lt;/p&gt;
&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;As of September 30, 2024, &lt;span id="xdx_903_ecustom--SharesReservedForAwardsGranted_iI_c20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zk9Gf5vWrHg2" title="Shares reserved for awards granted"&gt;82,429&lt;/span&gt; shares were reserved
for awards previously granted and &lt;span id="xdx_908_ecustom--SharesAvailableForFutureAwards_iI_c20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zBqzzZ9B8jR9" title="Shares available for future awards"&gt;59,997&lt;/span&gt; shares were available for future awards under the Amended and Restated 2021 Equity Incentive
Plan.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The changes in the number of stock options issued and
outstanding for the six months ended September 30, 2024 and 2023 were as follows:&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock_zhlxz0fEpE59" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zASsIQifpgfg" style="display: none"&gt;Schedule of changes in the number of stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zdJTBHDonrOe" style="width: 14%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period"&gt;90,281&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z7Bt2VuZdvvb" style="width: 14%; font-size: 10pt; text-align: right" title="Balance, beginning of period"&gt;98,171&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Expired or forfeited&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zb6m9yGQ2Do2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;(25,167&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z4jvdcexEGR6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z9TE6YjSFTM5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of period"&gt;65,114&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjbjLpw8Dipa" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of period"&gt;98,171&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Exercisable, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zvcXdnReWvjg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable, end of period"&gt;43,723&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zo0jcoERTe0d" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable, end of period"&gt;38,461&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z8WxKp5AbF1h" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The table above does not include fully vested
restricted stock units (&#x201c;RSUs&#x201d;) granted to certain executives in January 2021 and January 2022. In January 2024, the
company issued &lt;span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zadjl6G7IP42" title="Shares issued"&gt;308&lt;/span&gt;
shares for the exercise of &lt;span id="xdx_902_ecustom--NumberOfSharesExercise_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zF1SrRFGo6n5" title="Number of shares exercise"&gt;470&lt;/span&gt;
RSUs net of &lt;span id="xdx_909_ecustom--SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_iI_pip0_c20240131__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zFu4KXD559t2" title="Shares repurchased into treasury employee payroll taxes"&gt;162&lt;/span&gt;
shares repurchased into treasury to pay for an employee&#x2019;s payroll taxes. In September 2024, the company issued &lt;span id="xdx_902_eifrs-full--NumberOfSharesIssued_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zHWgHTQ46Itf" title="Shares issued"&gt;882&lt;/span&gt;
shares for the exercise of &lt;span id="xdx_90C_ecustom--NumberOfSharesExercise_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zyCbWHWrnIJ5" title="Number of shares exercise"&gt;1,152&lt;/span&gt;
RSUs net of &lt;span id="xdx_90E_ecustom--SharesRepurchasedIntoTreasuryEmployeePayrollTaxes_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z4dvcK388up" title="Shares repurchased into treasury employee payroll taxes"&gt;270&lt;/span&gt;
shares  repurchased into treasury  to pay for an employee&#x2019;s payroll taxes. As September 30, 2024, there were &lt;span id="xdx_907_ecustom--NumberOfSharesGranted_pip0_c20240401__20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zznLHxRGwHI8" title="Number of shares granted"&gt;17,315&lt;/span&gt;
RSUs granted and outstanding of which &lt;span id="xdx_906_ecustom--NumberOfShareOutstanding_iI_pip0_c20240930__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z3sxeMw7LBnc" title="Number of shares outstanding"&gt;12,150&lt;/span&gt; &lt;span id="xdx_90E_ecustom--DescriptionOfRestrictedStockUnitsExpire_c20240401__20240930_zZGlaE6iKlAh" title="Description of share expire"&gt;RSUs
expire in January 2031 and 5,165 expire in January 2032.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The following is the weighted average exercise price
and the remaining contractual life for outstanding options as of September 30,
2024 and 2023:&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 0.3in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zFxw5TIRItd7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B4_zTv7Hv0vlj5b" style="display: none"&gt;Schedule of weighted average exercise price
and the remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;PBI Amended and Restated &lt;br/&gt;2021 Equity Incentive Plan&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIad7SwwqsBi" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;205.18&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zGh48cZLymy7" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;210.60&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average remaining contractual life (in years)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOcegh40ODz6" title="Weighted average remaining contractual life (in years)"&gt;7.39&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zuR9VcEmIVQj" title="Weighted average remaining contractual life (in years)"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zfQrITqf0kAf" style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The vested options can be exercised at any time in accordance
with the applicable option agreement. The exercise price was greater than the market price for all options outstanding as of September
30, 2024 and March 31, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company recorded approximately $&lt;span id="xdx_905_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20240701__20240930_znWb3L5xML2g" title="Share based compensation expense"&gt;0.141&lt;/span&gt; million and
$&lt;span id="xdx_900_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20230701__20230930_zZ7Z5Qx3oO59" title="Share based compensation expense"&gt;0.743&lt;/span&gt; million of share-based compensation expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the three months
ended September 30, 2024 and 2023, respectively. The Company recorded approximately $&lt;span id="xdx_903_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20240401__20240930_z8Gjyqsj9yj" title="Share based compensation expense"&gt;0.285&lt;/span&gt; million and $&lt;span id="xdx_90A_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n6_c20230401__20230930_zAzU6wtcKWx8" title="Share based compensation expense"&gt;1.512&lt;/span&gt; million of share-based compensation
expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the six months ended September 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact001013">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--ScheduleOfTermsStockOptionReserveTableTextBlock_zlDP52wSZwp4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BA_zXqKGpNgflDk" style="display: none"&gt;Schedule of stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--StockOptionReserve_iS_pn3n3_c20240401__20240930_zcynfXm3Vdud" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period"&gt;23,841&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--StockOptionReserve_iS_pn3n3_c20230401__20230930_za8ZZf6KiUrk" style="width: 10%; font-size: 10pt; text-align: right" title="Balance, beginning of period"&gt;21,204&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Share-based compensation expense&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20240401__20240930_z1JrgPkKhPUa" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share-based compensation expense"&gt;285&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AdjustmentsForSharebasedPayment_pn3n3_c20230401__20230930_z0CTjzMn5oVb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share-based compensation expense"&gt;1,512&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--StockOptionReserve_iE_pn3n3_c20240401__20240930_ztXuuyhXTpPc" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of period"&gt;24,126&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--StockOptionReserve_iE_pn3n3_c20230401__20230930_z0YKUYL3SMV" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of period"&gt;22,716&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfTermsStockOptionReserveTableTextBlock>
    <ptgef:StockOptionReserve
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001015"
      unitRef="USD">23841000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact001017"
      unitRef="USD">21204000</ptgef:StockOptionReserve>
    <ptgef:AdjustmentsForSharebasedPayment
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact001019"
      unitRef="USD">285000</ptgef:AdjustmentsForSharebasedPayment>
    <ptgef:AdjustmentsForSharebasedPayment
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact001021"
      unitRef="USD">1512000</ptgef:AdjustmentsForSharebasedPayment>
    <ptgef:StockOptionReserve
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001023"
      unitRef="USD">24126000</ptgef:StockOptionReserve>
    <ptgef:StockOptionReserve
      contextRef="AsOf2023-09-30"
      decimals="-3"
      id="Fact001025"
      unitRef="USD">22716000</ptgef:StockOptionReserve>
    <ptgef:SharesReservedForAwardsGranted
      contextRef="AsOf2024-09-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001035"
      unitRef="Shares">82429</ptgef:SharesReservedForAwardsGranted>
    <ptgef:SharesAvailableForFutureAwards
      contextRef="AsOf2024-09-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001037"
      unitRef="Shares">59997</ptgef:SharesAvailableForFutureAwards>
    <ptgef:ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact001039">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_ecustom--ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock_zhlxz0fEpE59" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B6_zASsIQifpgfg" style="display: none"&gt;Schedule of changes in the number of stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; font-size: 10pt; font-weight: bold"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zdJTBHDonrOe" style="width: 14%; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, beginning of period"&gt;90,281&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z7Bt2VuZdvvb" style="width: 14%; font-size: 10pt; text-align: right" title="Balance, beginning of period"&gt;98,171&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Expired or forfeited&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zb6m9yGQ2Do2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"&gt;(25,167&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z4jvdcexEGR6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z9TE6YjSFTM5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Balance, end of period"&gt;65,114&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zjbjLpw8Dipa" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Balance, end of period"&gt;98,171&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Exercisable, end of period&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zvcXdnReWvjg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable, end of period"&gt;43,723&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_pip0_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zo0jcoERTe0d" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable, end of period"&gt;38,461&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfShareBasedCompensationsStockOptionsActivityTableTextBlock>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2024-03-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001041"
      unitRef="Shares">90281</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2023-03-31_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001043"
      unitRef="Shares">98171</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement
      contextRef="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001045"
      unitRef="Shares">-25167</ptgef:NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2024-09-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001049"
      unitRef="Shares">65114</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfOutstandingShareOption
      contextRef="AsOf2023-09-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001051"
      unitRef="Shares">98171</ptgef:NumberOfOutstandingShareOption>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001053"
      unitRef="Shares">43723</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements
      contextRef="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001055"
      unitRef="Shares">38461</ptgef:NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact001057"
      unitRef="Shares">308</ifrs-full:NumberOfSharesIssued>
    <ptgef:NumberOfSharesExercise
      contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact001059"
      unitRef="Shares">470</ptgef:NumberOfSharesExercise>
    <ptgef:SharesRepurchasedIntoTreasuryEmployeePayrollTaxes
      contextRef="AsOf2024-01-31_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact001061"
      unitRef="Shares">162</ptgef:SharesRepurchasedIntoTreasuryEmployeePayrollTaxes>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact001063"
      unitRef="Shares">882</ifrs-full:NumberOfSharesIssued>
    <ptgef:NumberOfSharesExercise
      contextRef="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact001065"
      unitRef="Shares">1152</ptgef:NumberOfSharesExercise>
    <ptgef:SharesRepurchasedIntoTreasuryEmployeePayrollTaxes
      contextRef="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact001067"
      unitRef="Shares">270</ptgef:SharesRepurchasedIntoTreasuryEmployeePayrollTaxes>
    <ptgef:NumberOfSharesGranted
      contextRef="From2024-04-012024-09-30_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact001069"
      unitRef="Shares">17315</ptgef:NumberOfSharesGranted>
    <ptgef:NumberOfShareOutstanding
      contextRef="AsOf2024-09-30_ifrs-full_RestrictedShareUnitsMember"
      decimals="INF"
      id="Fact001071"
      unitRef="Shares">12150</ptgef:NumberOfShareOutstanding>
    <ptgef:DescriptionOfRestrictedStockUnitsExpire contextRef="From2024-04-01to2024-09-30" id="Fact001073">RSUs
expire in January 2031 and 5,165 expire in January 2032.</ptgef:DescriptionOfRestrictedStockUnitsExpire>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact001075">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zFxw5TIRItd7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B4_zTv7Hv0vlj5b" style="display: none"&gt;Schedule of weighted average exercise price
and the remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;PBI Amended and Restated &lt;br/&gt;2021 Equity Incentive Plan&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zIad7SwwqsBi" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"&gt;205.18&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zGh48cZLymy7" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Weighted average exercise price"&gt;210.60&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Weighted average remaining contractual life (in years)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20240401__20240930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zOcegh40ODz6" title="Weighted average remaining contractual life (in years)"&gt;7.39&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20230401__20230930__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zuR9VcEmIVQj" title="Weighted average remaining contractual life (in years)"&gt;8.36&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001077"
      unitRef="USDPShares">205.18</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember"
      decimals="INF"
      id="Fact001079"
      unitRef="USDPShares">210.60</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="From2024-04-012024-09-30_custom_PBI2021EquityIncentivePlanMember"
      id="Fact001081">P7Y4M20D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
      contextRef="From2023-04-012023-09-30_custom_PBI2021EquityIncentivePlanMember"
      id="Fact001083">P8Y4M9D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001085"
      unitRef="USD">141000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact001087"
      unitRef="USD">743000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact001089"
      unitRef="USD">285000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact001091"
      unitRef="USD">1512000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:EarningsPerShareExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact001100">&lt;p id="xdx_806_eifrs-full--EarningsPerShareExplanatory_zpLiKB3awY4d" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 11. &lt;span id="xdx_829_zx33HBxwzOHa"&gt;LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="letter-spacing: -0.1pt"&gt;Basic earnings per
share (&#x201c;EPS&#x201d;) is calculated by dividing the net loss attributable to ordinary equity holders of the Company by the weighted
average number of ordinary shares outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="letter-spacing: -0.1pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="letter-spacing: -0.1pt"&gt;Diluted EPS is calculated
by dividing the net loss attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding
during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential
ordinary shares into ordinary shares. Shares issuable under Pre-Funded Warrants are considered outstanding for this purpose.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="letter-spacing: -0.1pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="letter-spacing: -0.1pt"&gt;The calculation
of Basic and Diluted EPS reflects the Pre-Funded Warrants as outstanding shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The following table reflects the loss and share data
used in the basic and diluted EPS calculations (in thousands, except per share amounts):&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zXTd7XlTdbZc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B7_zYcLtYyttqYj" style="display: none"&gt;Schedule of basic and diluted EPS calculations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20240701__20240930_zAJGlILzTB61" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230701__20230930_z7vdwkfL0og" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20240401__20240930_z8AXReKtALwg" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20230401__20230930_zgmBPTleEXE" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Three Months Ended September 30,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--NumeratorAbstract_iB_zADINWgftxda" style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic"&gt;Numerator&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to owners of the Company&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240701__20240930_zYHxLZsDXOZ8" title="Net loss attributable to owners of the Company"&gt;(1,360&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230701__20230930_zssZdyWUmkh3" title="Net loss attributable to owners of the Company"&gt;(5,158&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240401__20240930_zBqeRPFoc1Mj" title="Net loss attributable to owners of the Company"&gt;(3,016&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230401__20230930_z7NAZGiabPOe" title="Net loss attributable to owners of the Company"&gt;(11,077&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DenominatorAbstract_iB_z3zN9tjnO8Gd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic"&gt;Denominator&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average number of shares &#x2013; Basic and Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--WeightedAverageShares_pn3n3_c20240701__20240930_zu8R0HbBwaE5" title="Weighted average number of shares - Basic"&gt;&lt;span id="xdx_90C_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240701__20240930_zt0TQCMPITMj" title="Weighted average number of shares - Diluted"&gt;1,076&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--WeightedAverageShares_pn3n3_c20230701__20230930_zwRLbr6xxxy5" title="Weighted average number of shares - Basic"&gt;&lt;span id="xdx_90B_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230701__20230930_zqmy5lItQT59" title="Weighted average number of shares - Diluted"&gt;890&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zwhs1VqvnI4h" title="Weighted average number of shares - Basic"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zEvvP0JpaQwk" title="Weighted average number of shares - Basic"&gt;1,063&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--WeightedAverageShares_pn3n3_c20230401__20230930_zFwbdmWEq71k" title="Weighted average number of shares - Basic"&gt;&lt;span id="xdx_902_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20230930_zNj4OJX6lFad" title="Weighted average number of shares - Diluted"&gt;888&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted loss per share&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--BasicEarningsLossPerShare_pip0_c20240701__20240930_zzFRLyefpNY" title="Basic loss per share"&gt;&lt;span id="xdx_903_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240701__20240930_zwYCQ8ByZGH5" title="Diluted loss per share"&gt;(1.26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--BasicEarningsLossPerShare_pip0_c20230701__20230930_zhj9JnRkGi35" title="Basic loss per share"&gt;&lt;span id="xdx_90E_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230701__20230930_zQvzHStWWph2" title="Diluted loss per share"&gt;(5.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--BasicEarningsLossPerShare_pip0_c20240401__20240930_zFRXdXFQAi2e" title="Basic loss per share"&gt;&lt;span id="xdx_901_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240401__20240930_zJxTh14EJkTk" title="Diluted loss per share"&gt;(2.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--BasicEarningsLossPerShare_pip0_c20230401__20230930_z3P9w4RcoqO9" title="Basic loss per share"&gt;&lt;span id="xdx_900_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230401__20230930_zsggS3zYyMub" title="Diluted loss per share"&gt;(12.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zqob4TeieqF7" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Number of ordinary shares are retroactively adjusted
to reflect the impact of the 1-for-20 reverse stock split on August 15, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The inclusion of the Company&#x2019;s share purchase warrants
(other than Pre-Funded Warrants, as described above), stock options and RSUs in the computation of diluted loss per share would have an
anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between basic
loss per share and diluted loss per share for the three and six months ended September 30, 2024 and 2023. The following table reflects
the Company&#x2019;s outstanding securities by year that would have an anti-dilutive effect on loss per share and, accordingly, were excluded
from the calculation.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_ztTT3dH923Ie" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BF_zKm91mX0YDh4" style="display: none"&gt;Schedule of anti-dilutive effect on loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zs2EOIpMcTnk" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zV7L6EwwhOMi" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1158"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Stock options&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_z2g5zf249sl7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;65,114&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zmmhajLnAo8b" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;98,171&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zIpnXQz6Gysi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;17,315&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zk0cmB2yQvf1" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;18,937&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_znGgcpzkWanb" style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

















</ifrs-full:EarningsPerShareExplanatory>
    <ptgef:ScheduleOfEarningsPerShareTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact001102">&lt;table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfEarningsPerShareTableTextBlock_zXTd7XlTdbZc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8B7_zYcLtYyttqYj" style="display: none"&gt;Schedule of basic and diluted EPS calculations&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20240701__20240930_zAJGlILzTB61" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20230701__20230930_z7vdwkfL0og" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20240401__20240930_z8AXReKtALwg" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49E_20230401__20230930_zgmBPTleEXE" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Three Months Ended September 30,&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Six Months Ended September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--NumeratorAbstract_iB_zADINWgftxda" style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic"&gt;Numerator&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Net loss attributable to owners of the Company&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240701__20240930_zYHxLZsDXOZ8" title="Net loss attributable to owners of the Company"&gt;(1,360&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230701__20230930_zssZdyWUmkh3" title="Net loss attributable to owners of the Company"&gt;(5,158&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20240401__20240930_zBqeRPFoc1Mj" title="Net loss attributable to owners of the Company"&gt;(3,016&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_903_eifrs-full--ProfitLossAttributableToOwnersOfParent_pn3n3_c20230401__20230930_z7NAZGiabPOe" title="Net loss attributable to owners of the Company"&gt;(11,077&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DenominatorAbstract_iB_z3zN9tjnO8Gd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; font-style: italic"&gt;Denominator&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Weighted average number of shares &#x2013; Basic and Diluted&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90B_eifrs-full--WeightedAverageShares_pn3n3_c20240701__20240930_zu8R0HbBwaE5" title="Weighted average number of shares - Basic"&gt;&lt;span id="xdx_90C_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20240701__20240930_zt0TQCMPITMj" title="Weighted average number of shares - Diluted"&gt;1,076&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--WeightedAverageShares_pn3n3_c20230701__20230930_zwRLbr6xxxy5" title="Weighted average number of shares - Basic"&gt;&lt;span id="xdx_90B_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230701__20230930_zqmy5lItQT59" title="Weighted average number of shares - Diluted"&gt;890&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zwhs1VqvnI4h" title="Weighted average number of shares - Basic"&gt;&lt;span id="xdx_90F_eifrs-full--WeightedAverageShares_pn3n3_c20240401__20240930_zEvvP0JpaQwk" title="Weighted average number of shares - Basic"&gt;1,063&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--WeightedAverageShares_pn3n3_c20230401__20230930_zFwbdmWEq71k" title="Weighted average number of shares - Basic"&gt;&lt;span id="xdx_902_eifrs-full--AdjustedWeightedAverageShares_pn3n3_c20230401__20230930_zNj4OJX6lFad" title="Weighted average number of shares - Diluted"&gt;888&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Basic and diluted loss per share&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--BasicEarningsLossPerShare_pip0_c20240701__20240930_zzFRLyefpNY" title="Basic loss per share"&gt;&lt;span id="xdx_903_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240701__20240930_zwYCQ8ByZGH5" title="Diluted loss per share"&gt;(1.26&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--BasicEarningsLossPerShare_pip0_c20230701__20230930_zhj9JnRkGi35" title="Basic loss per share"&gt;&lt;span id="xdx_90E_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230701__20230930_zQvzHStWWph2" title="Diluted loss per share"&gt;(5.80&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span id="xdx_90A_eifrs-full--BasicEarningsLossPerShare_pip0_c20240401__20240930_zFRXdXFQAi2e" title="Basic loss per share"&gt;&lt;span id="xdx_901_eifrs-full--DilutedEarningsLossPerShare_pip0_c20240401__20240930_zJxTh14EJkTk" title="Diluted loss per share"&gt;(2.84&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"&gt;&lt;span id="xdx_902_eifrs-full--BasicEarningsLossPerShare_pip0_c20230401__20230930_z3P9w4RcoqO9" title="Basic loss per share"&gt;&lt;span id="xdx_900_eifrs-full--DilutedEarningsLossPerShare_pip0_c20230401__20230930_zsggS3zYyMub" title="Diluted loss per share"&gt;(12.47&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfEarningsPerShareTableTextBlock>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001109"
      unitRef="USD">-1360000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact001111"
      unitRef="USD">-5158000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact001113"
      unitRef="USD">-3016000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact001115"
      unitRef="USD">-11077000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:WeightedAverageShares
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001122"
      unitRef="Shares">1076000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001124"
      unitRef="Shares">1076000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact001126"
      unitRef="Shares">890000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2023-07-012023-09-30"
      decimals="-3"
      id="Fact001128"
      unitRef="Shares">890000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact001130"
      unitRef="Shares">1063000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2024-04-01to2024-09-30"
      decimals="-3"
      id="Fact001132"
      unitRef="Shares">1063000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact001134"
      unitRef="Shares">888000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="From2023-04-012023-09-30"
      decimals="-3"
      id="Fact001136"
      unitRef="Shares">888000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact001138"
      unitRef="USDPShares">-1.26</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact001140"
      unitRef="USDPShares">-1.26</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact001142"
      unitRef="USDPShares">-5.80</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      id="Fact001144"
      unitRef="USDPShares">-5.80</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2024-04-01to2024-09-30"
      decimals="INF"
      id="Fact001146"
      unitRef="USDPShares">-2.84</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2024-04-01to2024-09-30"
      decimals="INF"
      id="Fact001148"
      unitRef="USDPShares">-2.84</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="From2023-04-012023-09-30"
      decimals="INF"
      id="Fact001150"
      unitRef="USDPShares">-12.47</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="From2023-04-012023-09-30"
      decimals="INF"
      id="Fact001152"
      unitRef="USDPShares">-12.47</ifrs-full:DilutedEarningsLossPerShare>
    <ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact001154">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_ztTT3dH923Ie" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LOSS PER SHARE (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span id="xdx_8BF_zKm91mX0YDh4" style="display: none"&gt;Schedule of anti-dilutive effect on loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;As of September 30,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zs2EOIpMcTnk" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;481,581&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--WarrantsMember_zV7L6EwwhOMi" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1158"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Stock options&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_z2g5zf249sl7" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;65,114&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--StockOptionsMember_zmmhajLnAo8b" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;98,171&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Restricted stock units&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zIpnXQz6Gysi" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share"&gt;17,315&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AntidilutiveEffectOnLossPerShare_iI_pip0_c20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--RestrictedStockUnitsMember_zk0cmB2yQvf1" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share"&gt;18,937&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2024-09-30_ifrs-full_WarrantsMember"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">481581</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2024-09-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001160"
      unitRef="Shares">65114</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2023-09-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001162"
      unitRef="Shares">98171</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2024-09-30_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact001164"
      unitRef="Shares">17315</ptgef:AntidilutiveEffectOnLossPerShare>
    <ptgef:AntidilutiveEffectOnLossPerShare
      contextRef="AsOf2023-09-30_custom_RestrictedStockUnitsMember"
      decimals="INF"
      id="Fact001166"
      unitRef="Shares">18937</ptgef:AntidilutiveEffectOnLossPerShare>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact001175">&lt;p id="xdx_801_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zaSVebmzPC8b" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 12. &lt;span id="xdx_82E_zEWuSuG9kS4l"&gt;COMMITMENTS AND CONTINGENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;iOx &#x2013; Parexel Master Services Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Effective March 15, 2022, iOx entered into a Master Services
Agreement (the &#x201c;MSA&#x201d;) with Parexel under which Parexel agreed to act as
a&#160;clinical service provider (&#x201c;CRO&#x201d;) pursuant to a work order (&#x201c;Work Order&#x201d;) effective June 1, 2022. Under such Work Order,
Parexel planned to operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer. The MSA provided
for a five-year term, and the Work Order provided for a term to end upon the completion of the services required. The budget provided
for service fees and pass-through expenses and clinical sites totaling $11.5 million. During the year ended March 31, 2023 (&#x201c;Fiscal
2023&#x201d;), the Company executed two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs. As
a result of the Company&#x2019;s decision to discontinue the development with respect to this program, on December 20, 2023, the Company
provided Parexel notice of termination of the contract, with a planned termination date of April 18, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;As the ongoing CRO services were wound down, the Company
noticed that expenses incurred under the CRO agreement were higher than originally budgeted. Parexel agreed to refund the Company $&lt;span id="xdx_906_ecustom--RetainageDeposits_iI_pn3n6_c20240930_zdfCaXvFoLOi" title="Release liability amount"&gt;0.552&lt;/span&gt;
million and release the liability for amounts invoiced and unbilled services totaling $&lt;span id="xdx_90D_ecustom--UnbilledContractsReceivables_iI_pn3n6_c20240930_zwKJ8lUkOHbg" title="Unbilled services"&gt;1.486&lt;/span&gt; million, and the Company forfeited advanced
payments of $&lt;span id="xdx_90C_ecustom--ForfeitedAdvancedPayments_iI_pn3n6_c20240930_zHjWAsx1jD47" title="Forfeited advanced payments"&gt;1.091&lt;/span&gt; million. As a result, the Company recognized a net gain of $&lt;span id="xdx_900_ecustom--GainOnLiability_iI_pn3n6_c20240930_zsb7jbSfKln4" title="Gain on liability"&gt;0.946&lt;/span&gt; million as of September 30, 2024. As of March 31,
2024, the Company reflected $&lt;span id="xdx_906_ecustom--PayablesToParexelInAccountsPayableAndAccruedLiabilities_iI_pn3n6_c20240331_zZ3q2LZu92s1" title="Payables to parexel in accounts payable and accrued liabilities"&gt;1.414&lt;/span&gt; million of payables to Parexel in accounts payable and accrued liabilities and $&lt;span id="xdx_90A_eifrs-full--CurrentTradeReceivables_iI_pn3n6_c20240331_zCUA7G1aDRAj" title="Prepaid expenses and other receivables"&gt;1.277&lt;/span&gt; million in prepaid
expenses and other receivables in the consolidated &lt;span style="background-color: white"&gt;statement of financial position. &lt;/span&gt;The Company
received the refund from Parexel on October 3, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Tarus &#x2013; Fortrea Clinical Service Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On March 1, 2023, Tarus entered into a clinical service
agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier
of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services
to be provided is approximately $&lt;span id="xdx_904_ecustom--BudgetedCosts_pn5n6_c20230228__20230302_z3PBzWsaxNEg" title="Budgeted costs"&gt;12.1&lt;/span&gt; million. Because of the Company&#x2019;s decision to discontinue and pause further accrual of all
clinical studies, the Company is negotiating a revision to the services required under the change in circumstances.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;













</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ptgef:RetainageDeposits
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001177"
      unitRef="USD">552000</ptgef:RetainageDeposits>
    <ptgef:UnbilledContractsReceivables
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001179"
      unitRef="USD">1486000</ptgef:UnbilledContractsReceivables>
    <ptgef:ForfeitedAdvancedPayments
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001181"
      unitRef="USD">1091000.000</ptgef:ForfeitedAdvancedPayments>
    <ptgef:GainOnLiability
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001183"
      unitRef="USD">946000</ptgef:GainOnLiability>
    <ptgef:PayablesToParexelInAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001185"
      unitRef="USD">1414000</ptgef:PayablesToParexelInAccountsPayableAndAccruedLiabilities>
    <ifrs-full:CurrentTradeReceivables
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001187"
      unitRef="USD">1277000</ifrs-full:CurrentTradeReceivables>
    <ptgef:BudgetedCosts
      contextRef="From2023-02-282023-03-02"
      decimals="-5"
      id="Fact001189"
      unitRef="USD">12100000</ptgef:BudgetedCosts>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact001197">&lt;p id="xdx_80C_eifrs-full--DisclosureOfRelatedPartyExplanatory_z2MlVwRVOZid" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 13. &lt;span id="xdx_827_z6qCF7b6FdH3"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;SalvaRx Acquisition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Two of the Company&#x2019;s directors are also directors
of SalvaRx Group plc, a company which owns approximately 4.1% of the Company&#x2019;s issued and outstanding ordinary shares as of September
30, 2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Investments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company has entered into related party transactions
and certain services agreements with its investees.&#160;Key management personnel of the Company have also entered into related party
transactions with investees. Key management personnel are those people who have the authority and responsibility for planning, directing
and controlling the activities of the Company, including directors and senior management of the Company.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The following subsidiaries and associates are considered
related parties:&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(a)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Stimunity&lt;/b&gt;. The Chief Executive Officer (&#x201c;CEO&#x201d;) of Portage is one of three members of
the board of directors of Stimunity. The Company wrote-off its investment in Stimunity to nil in the Fiscal 2024 period.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(b)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;iOx&lt;/b&gt;. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Portage director resigned
from the iOx board leaving two Portage insiders as directors. The CEO of Portage is also the CEO of iOx, and the management team of Portage
comprises the management team of iOx.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(c)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Saugatuck&lt;/b&gt;. The Chairman and CEO of the Company is the sole director of Saugatuck. Saugatuck is
70% owned by the Company and is controlled by Portage.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(d)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Intensity&lt;/b&gt;. The CEO of Portage previously served as a part-time officer of Intensity until becoming
a consultant in 2023. Additionally, Intensity provided services (primarily rent) to Portage through April 2023. For the six months ended
September 30, 2023, the Company paid $&lt;span id="xdx_90C_ecustom--PortagePaidIntensity_pn4n6_c20230401__20230930_zsnMSyIT9kWa" title="Portage paid intensity"&gt;0.01&lt;/span&gt; million. No such services were provided subsequent to April 2023.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;(e)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;Portage Development Services Inc&lt;/b&gt;. PDS provides human resources and other services to each operating
subsidiary of Portage through shared services agreements.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Transactions between the parent company and its subsidiaries,
which are related parties, have been eliminated in consolidation and are not disclosed in this note.&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 8.25pt; font-size: 10pt; font-style: italic; font-weight: bold"&gt;&#160;&lt;/p&gt;

&lt;p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;Board Resignations and Appointments&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On April 25, 2024, Mark Simon resigned
all of his positions on the Board of Directors, and on April 26, 2024, Linda Kozick and Dr. Robert Glassman resigned all of their positions
on the Board of Directors. On April 30, 2024, Dr. Jean -Christophe Renondin and Dr. Justin Stebbing were elected to the Board.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;






















&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Bonuses &amp;amp; Board Compensation
Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;span style="background-color: white"&gt;In December 2022,
the Board approved executive performance bonuses, as recommended by the Compensation Committee, totaling $&lt;span id="xdx_902_ecustom--CompensationCommittee_pn5n6_c20221225__20221231_zLQstJ33N2Q6" title="Compensation committee"&gt;0.6&lt;/span&gt; million, which is equivalent
to &lt;span id="xdx_906_ecustom--OriginalAnnualTargetsPercentage_pip0_dp_c20221225__20221231_zMkIZECjpry1" title="Original annual targets percentage"&gt;73.5&lt;/span&gt;% of original annual targets established by the Board in December 2021. The bonuses were approved based upon the original performance
targets established. The Board further approved a payment structure of 25% of approved bonuses, which were paid in January 2023, with
the balance of amounts due payable upon a new financing. The accrued, unpaid amount of approximately $&lt;span id="xdx_90D_ecustom--AccountsPayableAndAccruedExpenses_iI_pn5n6_c20240930_zBBCadOexkY1" title="Accounts payable and accrued expenses"&gt;&lt;span id="xdx_903_ecustom--AccountsPayableAndAccruedExpenses_iI_pn5n6_c20240331_zyV0TT2vtQz3" title="Accounts payable and accrued expenses"&gt;0.4&lt;/span&gt;&lt;/span&gt; million is included in accounts
payable and accrued liabilities in the condensed consolidated interim statements of financial position as of each of September 30, 2024
and March 31, 2024. &lt;/span&gt;No executive performance bonus has been approved by the Compensation Committee or the Board for Fiscal Year
2024.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Effective January 1, 2022, each non-employee Board
member is entitled to receive cash Board fees of $40,000 per annum, payable quarterly in arrears. Additionally, each non-employee
Board member is entitled to an annual grant of 345 options to purchase Portage ordinary shares, which would vest the first annual
anniversary of the grant date. The Company incurred Board fees totaling nil &lt;span id="xdx_909_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20240701__20240930_zYQHGHEiv2Xh" style="display: none" title="Incurred Board fees total"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90D_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20230701__20230930_z6mORYUKJgmk" title="Incurred Board fees total"&gt;82,500&lt;/span&gt; during the three months ended September
30, 2024 and 2023, respectively, and $&lt;span id="xdx_909_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20240401__20240930_zg6GQV4VlG06" title="Incurred Board fees total"&gt;7,205&lt;/span&gt; and $&lt;span id="xdx_90D_eifrs-full--OtherFeeAndCommissionExpense_pp0p0_c20230401__20230930_zswv0CoB7D6f" title="Incurred Board fees total"&gt;165,000&lt;/span&gt; during the six months ended September 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Non-employee Board chairpersons are entitled to an annual
cash fee of $30,000, payable quarterly in arrears. In lieu of a non-executive chairperson, the lead director is entitled to an annual
cash fee of $20,000 per annum paid quarterly in arrears. &lt;span id="xdx_900_ecustom--AnnualFeesdescription_c20240401__20240930_zjbJT72xnatl" title="Annual fees description"&gt;Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nominating Committee of the Board is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears.
Members of those committees are entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears. All
non-executive board members waived their right to board fees for the six months ended September 30, 2024, except for the non-executive
board members who resigned in late April 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"&gt;Retention Agreements and General Releases&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;On July 22, 2024, the Company and Portage
Development Services, Inc. entered into a Retention Agreement and General Release (&#x201c;Retention Agreement&#x201d;) with each of Allan
Shaw (&#x201c;Employee&#x201d;) and Joseph Ciavarella (&#x201c;Consultant&#x201d;). Under the terms of each of the Retention Agreements, Employee&#x2019;s
current employment agreement and Consultant&#x2019;s current consulting agreement both terminated on July 22, 2024, except with respect
to certain provisions. In return for continuing to provide services to the Company and its affiliates and completing certain Applicable
Retention Events, as defined in the respective Retention Agreements, the Company paid an aggregate $0.2 million (the &#x201c;Retention
Amount&#x201d;) to Employee and Consultant, in addition to their monthly pay through September 30, 2024.&lt;/p&gt;

&lt;p style="margin: 0pt 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company accrued the Retention
Amount, as well as the monthly pay totaling $0.2 million through September 30, 2024, in the condensed consolidated interim financial statements
for the three months ended June 30, 2024, as the material terms of the Retention Agreements were known and agreed upon at June 30, 2024.
In accordance with the terms of the Retention Agreements, the Company paid in full the Retention Amount and issued 14,348 ordinary shares
to the Employee and Consultant in lieu of cash bonuses accrued in Fiscal 2023 totaling $0.1 million by September 30, 2024, the date on
which the Employee&#x2019;s employment and the Consultant&#x2019;s consulting relationship with the Company and its affiliates ended.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ptgef:PortagePaidIntensity
      contextRef="From2023-04-012023-09-30"
      decimals="-4"
      id="Fact001199"
      unitRef="USD">10000.00</ptgef:PortagePaidIntensity>
    <ptgef:CompensationCommittee
      contextRef="From2022-12-252022-12-31"
      decimals="-5"
      id="Fact001209"
      unitRef="USD">600000</ptgef:CompensationCommittee>
    <ptgef:OriginalAnnualTargetsPercentage
      contextRef="From2022-12-252022-12-31"
      decimals="INF"
      id="Fact001211"
      unitRef="Pure">0.735</ptgef:OriginalAnnualTargetsPercentage>
    <ptgef:AccountsPayableAndAccruedExpenses
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact001213"
      unitRef="USD">400000</ptgef:AccountsPayableAndAccruedExpenses>
    <ptgef:AccountsPayableAndAccruedExpenses
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact001215"
      unitRef="USD">400000</ptgef:AccountsPayableAndAccruedExpenses>
    <ifrs-full:OtherFeeAndCommissionExpense
      contextRef="From2024-07-012024-09-30"
      decimals="0"
      id="Fact001217"
      unitRef="USD">0</ifrs-full:OtherFeeAndCommissionExpense>
    <ifrs-full:OtherFeeAndCommissionExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact001219"
      unitRef="USD">82500</ifrs-full:OtherFeeAndCommissionExpense>
    <ifrs-full:OtherFeeAndCommissionExpense
      contextRef="From2024-04-01to2024-09-30"
      decimals="0"
      id="Fact001221"
      unitRef="USD">7205</ifrs-full:OtherFeeAndCommissionExpense>
    <ifrs-full:OtherFeeAndCommissionExpense
      contextRef="From2023-04-012023-09-30"
      decimals="0"
      id="Fact001223"
      unitRef="USD">165000</ifrs-full:OtherFeeAndCommissionExpense>
    <ptgef:AnnualFeesdescription contextRef="From2024-04-01to2024-09-30" id="Fact001225">Additionally, the chairperson of each of the Audit Committee, Compensation Committee
and Nominating Committee of the Board is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears.
Members of those committees are entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears. All
non-executive board members waived their right to board fees for the six months ended September 30, 2024, except for the non-executive
board members who resigned in late April 2024.</ptgef:AnnualFeesdescription>
    <ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact001234">&lt;p id="xdx_808_ecustom--DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory_zMrid2zf3ou9" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 14. &lt;span id="xdx_821_zH24xjfeYjT1"&gt;FINANCIAL INSTRUMENTS AND RISK MANAGEMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company&#x2019;s financial instruments recognized
in the Company&#x2019;s condensed consolidated interim statements of financial position consist of the following:&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Fair value estimates are made at a specific point in
time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties
and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could
significantly affect these estimates.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The following table summarizes the Company&#x2019;s financial
instruments as of September 30, 2024 and March 31, 2024 (in thousands):&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_zipsfya99PV7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span&gt;&lt;span id="xdx_8B9_zasVIPpgU6Pb" style="display: none"&gt;Schedule of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zUu1WWqUfH05" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zGD22lNC0Jyj" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z6u5FHh8ORl5" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zd0m5ib0Z01l" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z7D1v6pnwLp2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zk8qvAhQiIs5" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024 &lt;br/&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt;Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt;Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--CashAndCashEquivalents_i01I_zGv0ysjUwoB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,764&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1246"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;5,028&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--PrepaidExpensesAndOtherReceivable_i01I_zpddYPigyQo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;922&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1253"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,667&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1256"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zLF7FLIsvTo6" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z4xznnO58W4k" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zbNO4yhYYBr3" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zgZQzdvHCrMb" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024 &lt;br/&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt;Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt;Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--AccountsPayableAndAccruedLiabilities_i01I_zgWgFVr1Z5Qg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;845&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,836&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1267"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--WarrantLiability_i01I_za1ckSSwfoH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,138&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,564&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;






&lt;p id="xdx_8AE_zQcuP6MGdeIb" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;


&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;



















&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;A summary of the Company&#x2019;s risk exposures as it
relates to financial instruments are reflected below.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;
&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company&#x2019;s financial assets and liabilities
are comprised of cash and cash equivalents, receivables and investments in equities and public entities, accounts payable and accrued
liabilities, lease liability, and warrant liability.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company classifies the fair value of these transactions
according to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 1 &#x2013; Values are based on unadjusted quoted prices available in active markets for identical
assets or liabilities as of the reporting date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 2 &#x2013; Values are based on inputs, including quoted forward prices for commodities, time value
and volatility factors, which can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly
or indirectly observable as of the reporting date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0 0 0 41.05pt; font-size: 10pt; text-align: justify; text-indent: -0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 23.05pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Symbol"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Level 3 &#x2013; Values are based on prices or valuation techniques that are not based on observable market
data. Investments are classified as Level 3 financial instrument.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Assessment of the significance of a particular input
to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Management has assessed that the fair values of cash
and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities
of these instruments.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The following methods and assumptions were used to estimate
their fair values:&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;


&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;Warrant Liability&lt;/b&gt;: The fair value is estimated
using a Black-Scholes model and in certain cases, a Monte Carlo simulation (Level 3) (see Note 6, &#x201c;Warrant Liability&#x201d;).&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;


&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;




















&lt;p style="margin: 0pt; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;Credit Risk, Liquidity Risk and Foreign Currency Risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Our financial instruments are exposed to certain financial risks: Credit Risk, Liquidity
Risk and Foreign Currency Risk.&lt;/p&gt;
&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Credit risk is the risk of loss associated with a counterparty&#x2019;s
inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit
risk is limited to the carrying value as reflected in the Company&#x2019;s condensed consolidated interim statements of financial position.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;Cash and cash equivalents: &lt;/b&gt;Cash and cash equivalents
comprise cash on hand and amounts invested in underlying treasury and money market funds that are readily convertible to a known amount
of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. &lt;span style="background-color: white"&gt;As
of September 30, 2024 and March 31, 2024, cash equivalents was comprised of a money market account with maturities less than 90 days from
the date of purchase. &lt;/span&gt;Cash and cash equivalents are held with major international financial institutions and therefore the risk
of loss is minimal.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Liquidity Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Liquidity risk is the risk that the Company will encounter
difficulty in satisfying financial obligations as they become due.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;



















&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company&#x2019;s approach to managing liquidity is
to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed
conditions without incurring unacceptable losses or risking harm to the Company&#x2019;s reputation. The Company holds sufficient cash
and cash equivalents to satisfy current obligations under accounts payable and accruals.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company monitors its liquidity position regularly
to assess whether it has the funds necessary to meet its operating needs and needs for investing in new projects.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;As a biotech company at an early stage of development
and without significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional
financing may not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty
in global capital markets could have an impact on the Company&#x2019;s future ability to access capital on terms that are acceptable to
the Company. There can be no assurance that required financing will be available to the Company. See Note 9, &#x201c;Capital Stock and
Reserves,&#x201d; for a discussion of the Company&#x2019;s share offering.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Foreign Currency Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;While the Company operates in various jurisdictions,
substantially all of the Company&#x2019;s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K.
settleable in British pound sterling.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

</ptgef:DisclosureOfFinancialInstrumentsAndRiskManagementExplanatory>
    <ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact001236">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock_zipsfya99PV7" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span&gt;&lt;span id="xdx_8B9_zasVIPpgU6Pb" style="display: none"&gt;Schedule of financial instruments&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zUu1WWqUfH05" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zGD22lNC0Jyj" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z6u5FHh8ORl5" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zd0m5ib0Z01l" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49A_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_z7D1v6pnwLp2" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zk8qvAhQiIs5" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024 &lt;br/&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt;Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt;Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTOCI&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial assets&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--CashAndCashEquivalents_i01I_zGv0ysjUwoB4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"&gt;1,764&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1246"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;5,028&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1250"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--PrepaidExpensesAndOtherReceivable_i01I_zpddYPigyQo4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Prepaid expenses and other current assets&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;922&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1253"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1254"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;2,667&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1256"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zLF7FLIsvTo6" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240930__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z4xznnO58W4k" style="font-size: 10pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49F_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zbNO4yhYYBr3" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zgZQzdvHCrMb" style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;September 30, 2024 &lt;br/&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;March 31, 2024&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt;Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Amortized &lt;br/&gt;Cost&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;FVTPL&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left"&gt;Financial liabilities&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--AccountsPayableAndAccruedLiabilities_i01I_zgWgFVr1Z5Qg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left"&gt;Accounts payable and accrued liabilities&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;845&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;2,836&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1267"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eifrs-full--WarrantLiability_i01I_za1ckSSwfoH9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;1,138&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;&#x2013;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right"&gt;1,564&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;






</ptgef:ScheduleOfFinancialAssetsAndFinancialLiabilitiesTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-09-30_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact001245"
      unitRef="USD">1764000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2024-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact001248"
      unitRef="USD">5028000</ifrs-full:CashAndCashEquivalents>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2024-09-30_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact001252"
      unitRef="USD">922000</ptgef:PrepaidExpensesAndOtherReceivable>
    <ptgef:PrepaidExpensesAndOtherReceivable
      contextRef="AsOf2024-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact001255"
      unitRef="USD">2667000</ptgef:PrepaidExpensesAndOtherReceivable>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-09-30_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact001264"
      unitRef="USD">845000</ptgef:AccountsPayableAndAccruedLiabilities>
    <ptgef:AccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-03-31_custom_AmortizedCostMember"
      decimals="-3"
      id="Fact001266"
      unitRef="USD">2836000</ptgef:AccountsPayableAndAccruedLiabilities>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2024-09-30_custom_FairValueThroughProfitOrLossMember"
      decimals="-3"
      id="Fact001270"
      unitRef="USD">1138000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability
      contextRef="AsOf2024-03-31_custom_FairValueThroughProfitOrLossMember"
      decimals="-3"
      id="Fact001272"
      unitRef="USD">1564000</ifrs-full:WarrantLiability>
    <ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact001298">&lt;p id="xdx_80A_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zoSDgN6DUI5i" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 15. &lt;span id="xdx_82A_zNYXymQWUoTl"&gt;CAPITAL MANAGEMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company considers the items included in shareholders&#x2019;
equity as capital. The Company had accounts payable and accrued liabilities of approximately $&lt;span id="xdx_902_ecustom--PayablesAndAccruedExpense_iI_pn5n6_c20240930_zn2oiL8OuuH2" title="Accounts payables and accrued liabilities"&gt;0.8&lt;/span&gt; million and lease liability - current
of $&lt;span id="xdx_909_eifrs-full--CurrentLeaseLiabilities_iI_pn3n6_c20240930_zg1qvRXs3s66" title="Lease liability - current"&gt;0.028&lt;/span&gt; million as of September 30, 2024 (accounts payable and accrued liabilities of approximately $&lt;span id="xdx_908_ecustom--PayablesAndAccruedExpense_iI_pn5n6_c20240331_zGUvAivGNgra" title="Accounts payables and accrued liabilities"&gt;2.8&lt;/span&gt; million as of March 31, 2024
and lease liability - current of $&lt;span id="xdx_90E_eifrs-full--CurrentLeaseLiabilities_iI_pn3n6_c20240331_zZVLZwTzbbXa" title="Lease liability - current"&gt;0.040&lt;/span&gt; million as of March 31, 2024) and current assets of approximately $&lt;span id="xdx_905_ecustom--CurrentAsset_iI_pn5n6_c20240930_zYs3sRCBSb91" title="Current assets"&gt;2.7&lt;/span&gt; million as of September
30, 2024 (approximately $&lt;span id="xdx_902_ecustom--CurrentAsset_iI_pn5n6_c20240331_zU02m2gRLXIf" title="Current assets"&gt;7.7&lt;/span&gt; million as of March 31, 2024). The Company&#x2019;s objectives when managing capital are to safeguard the
Company&#x2019;s ability to continue as a going concern in order to pursue new business opportunities and to maintain a flexible capital
structure, which optimizes the costs of capital at an acceptable risk.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company manages the capital structure and makes adjustments
to it in light of changes in economic conditions and the risk characteristics of the underlying assets.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Nasdaq Listing Rule 5550(b)(1) requires companies listed
on the Nasdaq Capital Market to maintain shareholders&#x2019; equity of at least $&lt;span id="xdx_907_ecustom--ShareholdersEquity_iI_pn5n6_c20240930_zr1rzwizPlu3" title="Shareholders' equity"&gt;2.5&lt;/span&gt; million for continued listing. As of September 30,
2024, shareholders&#x2019; equity attributable to the owners of the Company was approximately $&lt;span id="xdx_90F_ecustom--ShareholdersEquityAttributableToOwners_iI_pn5n6_c20240930_zQzidMNFTqq" title="Shareholders' equity attributable to owners"&gt;1.4&lt;/span&gt; million (approximately $&lt;span id="xdx_904_ecustom--ShareholdersEquityAttributableToOwners_iI_pn6n6_c20240331_zEJj6L0HfXX5" title="Shareholders' equity attributable to owners"&gt;4&lt;/span&gt;.0 million
as of March 31, 2024). As a result, the Company is not currently in compliance with Nasdaq Listing Rule 5550(b)(1). Accordingly, the Company
expects Nasdaq to notify it of such non-compliance. The Company does not anticipate that the notification will have an immediate effect
on the listing of the Company&#x2019;s ordinary shares on the Nasdaq Capital Market. In accordance with the Nasdaq Listing Rules, the Company
expects to have 45 calendar days from the date of the notification to submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1).
If the Company&#x2019;s compliance plan is accepted, it may be granted up to 180 calendar days from the date of the initial notification
to evidence compliance. If the compliance plan is not accepted or the Company is otherwise unable to provide evidence of compliance within
Nasdaq&#x2019;s allotted timeframe, Nasdaq may take steps to delist the Company&#x2019;s ordinary shares. There can be no assurance that
the Company will be able to increase its shareholders&#x2019; equity in the future.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;The Company is not subject to any externally imposed
capital requirements and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the
Company&#x2019;s approach to capital management during the six months ended September 30, 2024 and 2023.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify"&gt;&#160;&lt;/p&gt;















</ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock>
    <ptgef:PayablesAndAccruedExpense
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact001300"
      unitRef="USD">800000</ptgef:PayablesAndAccruedExpense>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact001302"
      unitRef="USD">28000.000</ifrs-full:CurrentLeaseLiabilities>
    <ptgef:PayablesAndAccruedExpense
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact001304"
      unitRef="USD">2800000</ptgef:PayablesAndAccruedExpense>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001306"
      unitRef="USD">40000.000</ifrs-full:CurrentLeaseLiabilities>
    <ptgef:CurrentAsset
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact001308"
      unitRef="USD">2700000</ptgef:CurrentAsset>
    <ptgef:CurrentAsset
      contextRef="AsOf2024-03-31"
      decimals="-5"
      id="Fact001310"
      unitRef="USD">7700000</ptgef:CurrentAsset>
    <ptgef:ShareholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact001312"
      unitRef="USD">2500000</ptgef:ShareholdersEquity>
    <ptgef:ShareholdersEquityAttributableToOwners
      contextRef="AsOf2024-09-30"
      decimals="-5"
      id="Fact001314"
      unitRef="USD">1400000</ptgef:ShareholdersEquityAttributableToOwners>
    <ptgef:ShareholdersEquityAttributableToOwners
      contextRef="AsOf2024-03-31"
      decimals="-6"
      id="Fact001316"
      unitRef="USD">4000000</ptgef:ShareholdersEquityAttributableToOwners>
    <ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory contextRef="From2024-04-01to2024-09-30" id="Fact001324">&lt;p id="xdx_80D_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_zagSiQPRFyH3" style="margin: 0; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;NOTE 16. &lt;span id="xdx_823_zxQw7jhdOjS5"&gt;NON-CONTROLLING INTEREST&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;The details of non-controlling interest for the six months ended September
30, 2024 and 2023 are as follows (in thousands):&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_zYOORpqQXiKk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span&gt;&lt;b&gt;&lt;span id="xdx_8B0_zJGkj4De6xA2" style="display: none"&gt;Schedule of non-controlling interest&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Saugatuck &lt;br/&gt;and subsidiary&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; font-size: 10pt; font-weight: bold"&gt;Non-controlling interest as of April 1, 2024&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4udUogfx4D6" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"&gt;(693&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zes1DKm0cNcg" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net loss attributable to non-controlling interest"&gt;(10&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Non-controlling interest as of September 30, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zJJ9t8JEgnWf" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;(703&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Saugatuck &lt;br/&gt;and subsidiary&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; font-size: 10pt"&gt;Non-controlling interest as of April 1, 2023&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zRW5e9EgMf2i" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;(650&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z26eLOAlmNya" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net loss attributable to non-controlling interest"&gt;(14&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Non-controlling interest as of September 30, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zm290RE9uf95" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending"&gt;(664&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z4SLhKrYuxxb" style="margin: 0; font-size: 10pt; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;Saugatuck and subsidiary includes Saugatuck and its wholly-owned
subsidiary, Saugatuck Rx LLC.&lt;/p&gt;

&lt;p style="margin: 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"&gt;&#160;&lt;/p&gt;



</ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory>
    <ptgef:ScheduleOfNoncontrollingInterestTableTextBlock contextRef="From2024-04-01to2024-09-30" id="Fact001326">&lt;table cellpadding="0" cellspacing="0" id="xdx_892_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_zYOORpqQXiKk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&lt;span&gt;&lt;b&gt;&lt;span id="xdx_8B0_zJGkj4De6xA2" style="display: none"&gt;Schedule of non-controlling interest&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Saugatuck &lt;br/&gt;and subsidiary&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; font-size: 10pt; font-weight: bold"&gt;Non-controlling interest as of April 1, 2024&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z4udUogfx4D6" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"&gt;(693&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zes1DKm0cNcg" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net loss attributable to non-controlling interest"&gt;(10&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;Non-controlling interest as of September 30, 2024&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20240401__20240930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zJJ9t8JEgnWf" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"&gt;(703&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin: 0; font-size: 10pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt; padding-left: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Saugatuck &lt;br/&gt;and subsidiary&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 87%; font-size: 10pt"&gt;Non-controlling interest as of April 1, 2023&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zRW5e9EgMf2i" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning"&gt;(650&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1pt"&gt;Net loss attributable to non-controlling interest&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_z26eLOAlmNya" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net loss attributable to non-controlling interest"&gt;(14&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;Non-controlling interest as of September 30, 2023&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230930__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckMember_zm290RE9uf95" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending"&gt;(664&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ptgef:ScheduleOfNoncontrollingInterestTableTextBlock>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2024-03-31_custom_SaugatuckMember"
      decimals="-3"
      id="Fact001328"
      unitRef="USD">-693000</ifrs-full:NoncontrollingInterests>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2024-04-012024-09-30_custom_SaugatuckMember"
      decimals="-3"
      id="Fact001330"
      unitRef="USD">-10000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2024-09-30_custom_SaugatuckMember"
      decimals="-3"
      id="Fact001332"
      unitRef="USD">-703000</ifrs-full:NoncontrollingInterests>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2023-03-31_custom_SaugatuckMember"
      decimals="-3"
      id="Fact001334"
      unitRef="USD">-650000</ifrs-full:NoncontrollingInterests>
    <ptgef:NetLossAttributableToNoncontrollingInterest
      contextRef="From2023-04-012023-09-30_custom_SaugatuckMember"
      decimals="-3"
      id="Fact001336"
      unitRef="USD">-14000</ptgef:NetLossAttributableToNoncontrollingInterest>
    <ifrs-full:NoncontrollingInterests
      contextRef="AsOf2023-09-30_custom_SaugatuckMember"
      decimals="-3"
      id="Fact001338"
      unitRef="USD">-664000</ifrs-full:NoncontrollingInterests>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
